<SEC-DOCUMENT>0001628280-22-027931.txt : 20221103
<SEC-HEADER>0001628280-22-027931.hdr.sgml : 20221103
<ACCEPTANCE-DATETIME>20221103060912
ACCESSION NUMBER:		0001628280-22-027931
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		83
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221103
DATE AS OF CHANGE:		20221103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aurinia Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001600620
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36421
		FILM NUMBER:		221355999

	BUSINESS ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
		BUSINESS PHONE:		250-708-4272

	MAIL ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>auph-20220930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:05323eab-3ae1-47f9-a870-5f1cb7d56826,g:99240d06-396b-484e-9f8c-0586e299f202,d:20b8d43ebbfc4db489a67f7a9d9d59ec--><html xmlns:srt="http://fasb.org/srt/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:auph="http://www.auriniapharma.com/20220930" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>auph-20220930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180L2ZyYWc6MDliZWQ0MjQ0ZjQ3NDIzZGJkZjYxN2FlNzg2YzAzOTcvdGFibGU6OTllYjRiNmM0NTEwNDI3YTgxOWNlODI2YjY2NjE3MWUvdGFibGVyYW5nZTo5OWViNGI2YzQ1MTA0MjdhODE5Y2U4MjZiNjY2MTcxZV8yLTEtMS0xLTY4Nzk1_e2985b45-b58d-4baa-a756-a45ab9bb84f8">false</ix:nonNumeric><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180L2ZyYWc6MDliZWQ0MjQ0ZjQ3NDIzZGJkZjYxN2FlNzg2YzAzOTcvdGFibGU6OTllYjRiNmM0NTEwNDI3YTgxOWNlODI2YjY2NjE3MWUvdGFibGVyYW5nZTo5OWViNGI2YzQ1MTA0MjdhODE5Y2U4MjZiNjY2MTcxZV8zLTEtMS0xLTY4Nzk1_6498d952-52b5-46a6-ad05-09cea9a99a12">2022</ix:nonNumeric><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180L2ZyYWc6MDliZWQ0MjQ0ZjQ3NDIzZGJkZjYxN2FlNzg2YzAzOTcvdGFibGU6OTllYjRiNmM0NTEwNDI3YTgxOWNlODI2YjY2NjE3MWUvdGFibGVyYW5nZTo5OWViNGI2YzQ1MTA0MjdhODE5Y2U4MjZiNjY2MTcxZV80LTEtMS0xLTY4Nzk1_be58425b-b66b-4cbb-aa56-44cb03d85b64">Q3</ix:nonNumeric><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180L2ZyYWc6MDliZWQ0MjQ0ZjQ3NDIzZGJkZjYxN2FlNzg2YzAzOTcvdGFibGU6OTllYjRiNmM0NTEwNDI3YTgxOWNlODI2YjY2NjE3MWUvdGFibGVyYW5nZTo5OWViNGI2YzQ1MTA0MjdhODE5Y2U4MjZiNjY2MTcxZV81LTEtMS0xLTY4Nzk1_79801d84-f635-45fc-862e-9ee6be92fe8a">0001600620</ix:nonNumeric><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180L2ZyYWc6MDliZWQ0MjQ0ZjQ3NDIzZGJkZjYxN2FlNzg2YzAzOTcvdGFibGU6OTllYjRiNmM0NTEwNDI3YTgxOWNlODI2YjY2NjE3MWUvdGFibGVyYW5nZTo5OWViNGI2YzQ1MTA0MjdhODE5Y2U4MjZiNjY2MTcxZV82LTEtMS0xLTY4Nzk1_879fad0b-1367-44e6-a652-4d96e89200ab">12-31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="auph-20220930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4297c0d464e7468e8bf8e0d66421c5a2_I20221102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="iea170fa7b20a4b41b108e493dc1948f2_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i6469b2d1ea454cb388fc81376000b775_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7047233c039c4e5db5ccb689cf181bd9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8e7b1e28ca6475699ad1f3389d65b0f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6eb1901eda7949188f64f0ae3e428eaa_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bad260542ee4aa9ae02bb08274b9038_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4783d7802784076a6f6bfe42837f76c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31e4e566879a474d8c808a4b79ad4910_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id181d42e4a034ee68572be022fef93f4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i436b2d2997234350abf975a031f0ec09_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d4690f8a2eb435883c18b3504cdad69_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5eb0f19f9c074e79a40d0cb3e2ff02f3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic68c4ca008b74f51b6d19d40416666ee_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if36244d95f6d4bd299450825700e832d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i377749222219417c8982b959ba79c8f1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27eec2a9a9cc4f2ba78ceffaf03f0d83_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i835bd94d3b8a46aea93d75b9c3e1b9f5_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i009b59fb6c994af8b5d17ed41e99cf66_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i588bcb33d7f94f32abdfc4d3a91cd187_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i611a8c2b382345d5bee16ff18c8b7de6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic38f683d1d4d4b88a3ddee342ade79d4_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7eb54bdb3b8e4810b83f9db13ac1682e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17263ca8130048c8b999c4d7f9352e2e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11d40396b1dd41869d1b914f4f6d8f92_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41d70372ff754478b1094be19cf13784_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12cec0e7fdf24de3b783ef6f7d90a849_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c9dfc2f3c3741708e7b3da4e03bb444_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfb50debae134f6a85fce4e5f3651cc7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i787c6a58aafe40fb93dba68bac8a5d88_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibaa74b4b308f463fa84d6d3a382b7c6a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i703ab11d0a9946cf8cc57b8243e5db59_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i114549079e764ecab84b77d1ecf6b9e4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b49777eb2204f95acb28165c4ffb245_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02ce71b787ab4ca797b5a9fcbaf61402_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d1cf1ea09434d15b4be325b80931e8c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77fa57c5982e468f985e9bcaf10d6a42_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7443770797b0498c8cdad90152a5c590_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9ee7fe05eee40f48c092e1b88df007a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb29a2f97a214b8e9f797f9687616d27_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib52fb1312906471b8f138a9a0ea36fec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2464b25495094609998bc808c8e1f431_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68fb759408e04e9b9a39503596bd5faa_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb236f49e0c24418ab0220edb3a611e4_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaabe0fca9ec24b28814dfdae4e2dd4d3_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75925341cc3e4f78bacf59fb0684c25d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied2bf63884594bf3a519994bdc8a9be1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6785021da65c4996946ac6e43914d14e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if864e170575941afb3bbe7afabdecd5a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9fdb7f1323043c4ad197d9228b4b4b6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08686fdbde8047d69c05941c654afac6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i533a99201f634a479988a643e020cf8b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16ed573a0bd841e98023564edf9f9c34_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic873b1cf2e4c4bf98cf80aac069abfdf_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84a4831b700f48b1833b184774156aeb_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>auph:segment</xbrli:measure></xbrli:unit><xbrli:context id="ie2b6cee70b84464499f7df7285aed325_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">auph:SpecialtyPharmacyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i92eaeeead41c4c3486efa48480d9b63a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">auph:SpecialtyPharmacyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9fbd2d01b054439a783e60189d0d151_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">auph:SpecialtyPharmacyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:OutsideUnitedStatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id143a176c2d7418fa9b6975ad686ab0a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">auph:SpecialtyPharmacyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:OutsideUnitedStatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5a4159b186c46bdae3c4c7db5a48d91_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">auph:MilestoneAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i248fcdd355b64b138d9e8363df09e99f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:OtuskaPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16cb885c9c784f19a3fb5c186669134a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97636c4925384d11aa8a85148d437f88_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ff9e818dc3248f3a984013c0ec35cb4_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:CashCashEquivalentsAndRestrictedCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45420271e8ea4082b3d52812ce062bcd_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:CashCashEquivalentsAndRestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5b00f6af1a1489ca4e19effbd717dc7_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:CashCashEquivalentsAndRestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id57531e234234b2b9cb0d8e02f891cfd_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:CashCashEquivalentsAndRestrictedCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibabafbb16aec41b1915f48581e656afd_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:USAgencySecurityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f27ddb9f76a467b94259faf2e7e0317_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:USAgencySecurityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc8d7c6306b94e968ff4f645fa32aea3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:USAgencySecurityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idda7e1c04624428eb78cb35510f9fa7f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:USAgencySecurityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a6083a877744937bdaec6596e628a5e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib545381e546241bfb7702079a5b4ae46_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia75ddf3673b0477d801dd590a53168cd_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a88e33246a947da84b61da9acf16369_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64fba90d628a47388702c84b97bf7d7a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa631ff412fa4ce5999335712a18dd4e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4bd4b996a4d4872b3fac48673a43a27_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9f1f2ee39a841c18e4e03be170e2977_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6d26265caac4b03ac1c32ac9b0d215c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieafdf4a188174114bc1155f63c1daa4d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i669c0d32fa12413e948255d28b9891a2_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9a7d157907c4446a83d6762c688bc37_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d9ec18821a143c0b5342802f48f6311_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64661310650543b4a59ec68285dc9734_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i119daddb27794e028c6e80587444d5ad_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i879c4a29d0b4430fa56ad47b590225c2_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c5b7f81c61c4e96ac98e4766d33339a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:YankeeBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9178f49b5784f9aba75be7f38379650_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:YankeeBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb9283d88b424c60b9b3d5353d69a897_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:YankeeBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20cb6a6c7b9e4a5380a7381cd01eeee6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:YankeeBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb5b6a1ae596438681cfbfdf9892f83d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id28bab9c7e1c4295b873580752711af5_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20e1087e0598412981eb9152d79b6b14_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i565005420cf94f52b9804cec98cee107_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:CashCashEquivalentsAndRestrictedCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i615ccd0cba2748fb9fcffb4adcc668be_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:CashCashEquivalentsAndRestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i734f0c5aa1b846b08acb4ccd89a87f39_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:CashCashEquivalentsAndRestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i263f1cbad4dd43fcb51ad6c9abe11101_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:CashCashEquivalentsAndRestrictedCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b5b0fee0d3a410eb5fe646815a1df0d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37d4bff646e04f7f80b9a75717f9fea4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a260d1645884811bafbb0ac61e2190b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64ab53854b6748a49a313e183035fb12_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6ca842beffc422d80be5664771bc026_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4804d6f12b174250ace2bb6d08b12a0e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87306c1797ef420a8944c1b4d0ff89c4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c5de38286e74db18b18df7f49cac2d3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbdc367dda2942d19a94e15c46320342_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if20a77aa2fc04f8a96554bede25f9d7c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7fb0798462249e3a2d60ca4407e0eab_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8af1b2c873d0434eaf8b9108131f9009_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34d4826b176e435f8bd5b0030feb4952_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59210d4302394347a4104d3d57a6934b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf503387569145268e73f2bf99c3cba4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i904ede1b4aeb489099791792b04faf0e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i938ca9c21c994394a2ac416a16c72176_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19c0b5fabb074b7692f8a2ab582c6da6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i477353e441ec446e872a95c69aab7d85_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1d1a617e2e74074ae1e4ccd6de119b5_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0a72a6a58e04c6dbc7123f06753286b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia851cc9f46674b05af88b96945f0cb85_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib711a46ca0504a0f83970696c2b2069c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12201e4c78d14b7fa31409f5abef573b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43c8446460754675965bbc2c13bac604_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:ShortTermCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e7b23d46c544fc184d25711658db577_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:ShortTermCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i694749f08fba4701ba5443abefc101e0_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cb5e9e831f5489cad13f8086d409cfb_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2753c410533a473db311c14ff1da390f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib78726334c604e7abc504057535e595b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i587a5632527b4d8f9fc78a79b55065c0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i762371a552ae4e189fdad22d6c254db5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8ebc008d0bf419399d57a1954b31411_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i015f087f0bfd4fa583200ee0a162bffe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie438ea390b8846d7831dd0900ee639c1_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia783c0184bda40e8a385452883ad9164_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if39e9f1e69324041b0415ecd8d450952_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieafc1263da604de4864e371e83bf3ae9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if15808d1e63744299f8008a22843785a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71d0284de4094b58a61726e34448a7c7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5e1845517044932807f74d13e17f14f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i344a287699e44b6abf65762731d49159_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0122d51e9ce4a43a91c77261f282564_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:VictoriaBritishColumbiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie76075ad5fba4197953b1f9074f707fb_D20220803-20220803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:VictoriaBritishColumbiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-03</xbrli:startDate><xbrli:endDate>2022-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8217ea002f274269ad63c35be20de5d2_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:RockvilleMarylandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="extension_option"><xbrli:measure>auph:extension_option</xbrli:measure></xbrli:unit><xbrli:context id="ifdc02d86fd494bcd9c3bbcefc6567c61_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:RockvilleMarylandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieab7019fc2e44f7281b349abacde0bc3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:RockvilleMarylandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58c5e7c150d14386a0bf23271f8fcc59_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:RockvilleMarylandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2010334e882c4ffd813f86072931dd35_D20211231-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:RockvilleMarylandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-31</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67061bc27f97417eb92caad1115e4f65_I20200312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:RockvilleMarylandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdd4d5c6c4cc486cb6916357de93b010_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="chf"><xbrli:measure>iso4217:CHF</xbrli:measure></xbrli:unit><xbrli:context id="i0218c4022baf4887b278a279993662cb_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf32de36976c4acea4a8d8fcae729345_D20201217-20201217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:OtuskaPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-17</xbrli:startDate><xbrli:endDate>2020-12-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7157bd498212400d9ba95e50a9998561_I20201217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:OtuskaPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cca31f183434cd5ab9525b020f34afc_I20201217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:OtuskaPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91f3a2c3fb9444049582457768137f12_I20201217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:OtuskaPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie85ef3843f6e45c68cf365c48ec7f1a3_I20220915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:OtuskaPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81ca80b01c3949bc93f26e42672ea414_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:OtuskaPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2297b01889a7491d85e8a7f9850e7bfc_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:OtuskaPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6745a5042314bd3ac418f4f36aac11f_D20210817-20210817"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:RiptideBioscienceIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-17</xbrli:startDate><xbrli:endDate>2021-08-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e7f455148c3452faa9d3f2b5d9c272f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:RiptideBioscienceIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00d7e31976534d258d0e07349aba01f3_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i805aaa2562214865ab8c371faa3a53b2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc8095d666774c36bf30723faadf9ce6_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e834a4131b9497aa7197b83f5903f9c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13cbe039556149bf854d1dbc12844c1e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic61229edf4264d52a22130a0c3be9d0a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5279b4da301648499575592309f9f17e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b1a989842e543fabb7e5905343568bb_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e55bb773ff34dceb51b86c13030f998_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">auph:AmendedAndRestatedEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5685017490fa48d98ee11fbfaba4943f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i141c5810302b4f94afd3d50f70c69c68_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="purchase_period"><xbrli:measure>auph:purchase_period</xbrli:measure></xbrli:unit><xbrli:context id="ic9213ee7781c41f3a44fe9ed868b853a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc1689ad65c84b429cf133572117af7a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50399ead67c54ca8bc4d5ef310825018_D20201023-20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-23</xbrli:startDate><xbrli:endDate>2020-10-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i300f179e3ff14347817cbe32101e4854_D20210318-20210318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-18</xbrli:startDate><xbrli:endDate>2021-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93beb22f8ad34d9c947d6dafa4a95334_D20210806-20210806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">auph:PerformanceShareSandRestrictedStockUnitsRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-06</xbrli:startDate><xbrli:endDate>2021-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dac794371204eeea2843a0a01c0643c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b58579e74a9437291aa1de82c974264_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">auph:PerformanceShareSandRestrictedStockUnitsRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c18e125ab214150a60e144497c275d2_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">auph:PerformanceShareSandRestrictedStockUnitsRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccc401454be24c33a5c889e8fc773573_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">auph:PerformanceShareSandRestrictedStockUnitsRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7fef15dae2646efa24f1995243223c6_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41e86bba83634e53a5535985a6f3f748_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i955689f54f8c4df3a7afd2244253bc6d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7ac41ae30d34bb5830b64dd0083e341_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib20172c5476e4c24ba772f206955d222_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa46d448221541eea1922a7412dadd8d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i950b5dba05e8467bb230db400bb54c89_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92f1f72ffef04012bdf6f2e23691fde6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31e34ae4d79d4a16962c6e8ca983e3f6_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84deabd17e064c569d85797d9b5eda83_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3566507c79934103bc6f40ab688f624a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ef75c4fe6024db197c096eb57a144ea_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a603236462942e0951722c7b53081bd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:ILJINMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">auph:MilestonePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i600c866525944e51adcfcdad3efc98eb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:ILJINMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68a01b7c21f844ae96d03ac2032c0e28_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:ILJINMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1901be7a6424fe8a7f80634ccb66032_D20220930-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">auph:NewEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-30</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>auph:employee</xbrli:measure></xbrli:unit><xbrli:context id="i090a7d0df6ad405a8d7fb3f2f1fc2096_D20220930-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">auph:NewEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">auph:ShareBasedPaymentArrangementInducementOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-30</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6baa5e11e43442d0b6c324d3f77c8f48_D20220930-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">auph:NewEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-30</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_____________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGV4dHJlZ2lvbjpmZGQ2ZDhhOGI2ODc0ZjlhOWE3YzBjNWUxNzY4MWI0Ml8yMjg3_b4a89add-b9a3-41af-8f3f-57af906158fc">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_____________________________________________</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGFibGU6MjU0ZmMwNGY2MDlmNGVjZGI1NDEzNmIyZDY1MzVjMTQvdGFibGVyYW5nZToyNTRmYzA0ZjYwOWY0ZWNkYjU0MTM2YjJkNjUzNWMxNF8wLTAtMS0xLTY4Nzk1_eb723448-7bc0-4d51-905c-0ef2d4ce03b1">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGV4dHJlZ2lvbjpmZGQ2ZDhhOGI2ODc0ZjlhOWE3YzBjNWUxNzY4MWI0Ml8yMTI_719a235c-6e6a-460c-9bd6-4796f84ba83d">September 30, 2022</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGFibGU6YmRiMjgyZGU0MjA1NDcyZGJhNmJhMmNkOTcyZDM4MTcvdGFibGVyYW5nZTpiZGIyODJkZTQyMDU0NzJkYmE2YmEyY2Q5NzJkMzgxN18wLTAtMS0xLTY4Nzk1_f31f458d-efb4-46f5-96cb-89670066240d">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from_____________ to ________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGV4dHJlZ2lvbjpmZGQ2ZDhhOGI2ODc0ZjlhOWE3YzBjNWUxNzY4MWI0Ml8yMjg4_2de15a94-08dc-4017-aefe-decdf332b4d2">001-36421</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">__________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGV4dHJlZ2lvbjpmZGQ2ZDhhOGI2ODc0ZjlhOWE3YzBjNWUxNzY4MWI0Ml8yMjg5_1cc75c0e-a778-4df2-8b76-8895f2b2765b">Aurinia Pharmaceuticals Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">__________________________________________</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Alberta, <ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGFibGU6ZDA0ZDk2YzE2MmY2NDNkN2JmYmQ3ZTFmN2NmODkxYTUvdGFibGVyYW5nZTpkMDRkOTZjMTYyZjY0M2Q3YmZiZDdlMWY3Y2Y4OTFhNV8wLTAtMS0xLTY4Nzk1L3RleHRyZWdpb246ZjFhMTY5YzUyNTQ1NDk1Mjg5OTc3YTUwYWFlNGUzMWZfMTM_7a1057bf-fbbc-4e78-88eb-97c9de202e04">Canada</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGFibGU6ZDA0ZDk2YzE2MmY2NDNkN2JmYmQ3ZTFmN2NmODkxYTUvdGFibGVyYW5nZTpkMDRkOTZjMTYyZjY0M2Q3YmZiZDdlMWY3Y2Y4OTFhNV8yLTAtMS0xLTY4Nzk1L3RleHRyZWdpb246OTE3YmVhMTA1ZmIzNDE3YjljYjIwNWU3NzMzODUyOWZfNA_8babe654-5aba-46c8-85ce-28fc2e1178b1">#1203-4464 Markham Street</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGFibGU6ZDA0ZDk2YzE2MmY2NDNkN2JmYmQ3ZTFmN2NmODkxYTUvdGFibGVyYW5nZTpkMDRkOTZjMTYyZjY0M2Q3YmZiZDdlMWY3Y2Y4OTFhNV8yLTAtMS0xLTY4Nzk1L3RleHRyZWdpb246OTE3YmVhMTA1ZmIzNDE3YjljYjIwNWU3NzMzODUyOWZfNw_2383dfee-55c6-4f4f-bf34-b74e93414006">Victoria</ix:nonNumeric>, <ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGFibGU6ZDA0ZDk2YzE2MmY2NDNkN2JmYmQ3ZTFmN2NmODkxYTUvdGFibGVyYW5nZTpkMDRkOTZjMTYyZjY0M2Q3YmZiZDdlMWY3Y2Y4OTFhNV8yLTAtMS0xLTY4Nzk1L3RleHRyZWdpb246OTE3YmVhMTA1ZmIzNDE3YjljYjIwNWU3NzMzODUyOWZfMTE_c7c59036-e001-4433-b081-0337816883ef">British Columbia</ix:nonNumeric> <ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGFibGU6ZDA0ZDk2YzE2MmY2NDNkN2JmYmQ3ZTFmN2NmODkxYTUvdGFibGVyYW5nZTpkMDRkOTZjMTYyZjY0M2Q3YmZiZDdlMWY3Y2Y4OTFhNV8yLTAtMS0xLTY4Nzk1L3RleHRyZWdpb246OTE3YmVhMTA1ZmIzNDE3YjljYjIwNWU3NzMzODUyOWZfMTQ_31482de1-fa2c-4f62-b3ed-da6f9bc66f28">V8Z 7X8</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGFibGU6ZDA0ZDk2YzE2MmY2NDNkN2JmYmQ3ZTFmN2NmODkxYTUvdGFibGVyYW5nZTpkMDRkOTZjMTYyZjY0M2Q3YmZiZDdlMWY3Y2Y4OTFhNV8yLTEtMS0xLTY4Nzk1L3RleHRyZWdpb246MDJiMTQyNmUwMGU1NGU5NTg2ODczOGI2NTk4YTdiNWRfNA_49bdd13d-a67c-43e4-8af5-a8ce7ddc59c7">98-1231763</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGV4dHJlZ2lvbjpmZGQ2ZDhhOGI2ODc0ZjlhOWE3YzBjNWUxNzY4MWI0Ml8yMjkw_e6601714-7760-4f11-9ec7-09302dd62bce">(250)</ix:nonNumeric> <ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGV4dHJlZ2lvbjpmZGQ2ZDhhOGI2ODc0ZjlhOWE3YzBjNWUxNzY4MWI0Ml8yMjkx_f4d7e338-b177-4128-ae17-92f3490f7558">744-2487</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_____________________________________________</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGV4dHJlZ2lvbjpmZGQ2ZDhhOGI2ODc0ZjlhOWE3YzBjNWUxNzY4MWI0Ml8yMjg0_4cbf8dcd-5579-4a69-9d10-21d906403174">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGV4dHJlZ2lvbjpmZGQ2ZDhhOGI2ODc0ZjlhOWE3YzBjNWUxNzY4MWI0Ml8yMjg1_c2538e3d-459d-4ca2-93ab-f208822f6801">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGFibGU6MDc5ZjkxNzA5ODRhNDNjMGJjODM4MWQ5YzkyMDUyOGYvdGFibGVyYW5nZTowNzlmOTE3MDk4NGE0M2MwYmM4MzgxZDljOTIwNTI4Zl8wLTAtMS0xLTY4Nzk1_20bf9d8d-5870-4dd0-bd0e-6ea85b61d288">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGFibGU6MDc5ZjkxNzA5ODRhNDNjMGJjODM4MWQ5YzkyMDUyOGYvdGFibGVyYW5nZTowNzlmOTE3MDk4NGE0M2MwYmM4MzgxZDljOTIwNTI4Zl8yLTQtMS0xLTY4Nzk1_9c8f49e9-afdd-4b18-95dd-d4f114a4598c">&#9744;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGFibGU6MDc5ZjkxNzA5ODRhNDNjMGJjODM4MWQ5YzkyMDUyOGYvdGFibGVyYW5nZTowNzlmOTE3MDk4NGE0M2MwYmM4MzgxZDljOTIwNTI4Zl80LTEtMS0xLTY4Nzk1_95057e11-113e-490c-a05d-9eac8f4f83ee">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGV4dHJlZ2lvbjpmZGQ2ZDhhOGI2ODc0ZjlhOWE3YzBjNWUxNzY4MWI0Ml8yMjg2_75e37ccc-43bd-4c6d-a19d-70484c51d4bf">x</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate the number of shares outstanding of each of the registrant's classes of common shares, as of the latest predictable date. As of November&#160;2, 2022, the registrant had <ix:nonFraction unitRef="shares" contextRef="i4297c0d464e7468e8bf8e0d66421c5a2_I20221102" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGV4dHJlZ2lvbjpmZGQ2ZDhhOGI2ODc0ZjlhOWE3YzBjNWUxNzY4MWI0Ml8xNjQ5MjY3NDQ0MDU1_f6468205-4fc3-4494-b003-89e868e4be54">142,109,703</ix:nonFraction> of common shares outstanding.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.685%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Name of exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGFibGU6MDk1ODE3MTc1OWI4NDUzMDhmNWU1Yzg4NWVmZjgyOGYvdGFibGVyYW5nZTowOTU4MTcxNzU5Yjg0NTMwOGY1ZTVjODg1ZWZmODI4Zl8xLTAtMS0xLTY4Nzk1_2a63b8d9-26b2-4640-9378-33fcf59e3d9c">Common shares, no par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGFibGU6MDk1ODE3MTc1OWI4NDUzMDhmNWU1Yzg4NWVmZjgyOGYvdGFibGVyYW5nZTowOTU4MTcxNzU5Yjg0NTMwOGY1ZTVjODg1ZWZmODI4Zl8xLTEtMS0xLTY4Nzk1_1dab4d97-d4e5-4bc6-b50b-538055a12f73">AUPH</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGFibGU6MDk1ODE3MTc1OWI4NDUzMDhmNWU1Yzg4NWVmZjgyOGYvdGFibGVyYW5nZTowOTU4MTcxNzU5Yjg0NTMwOGY1ZTVjODg1ZWZmODI4Zl8xLTItMS0xLTY4Nzk1_3b77cab3-b6f1-4567-9923-d39fd07d8f5b">The Nasdaq Global Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_10">PART I.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_10">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_10">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_13">Item 1.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_13">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_16">Condensed Consolidated Balance Sheets as of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_16">Se</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_16">ptember</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_16"> 30, 2022 (unaudited) and December 31, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_19">Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) for the three months and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_19">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_19"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_19">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_19"> 30, 2022 and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_19">Sep</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_19">tember</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_19"> 30, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_19">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_22">Condensed Consolidated Statements of Shareholders&#8217; Equity (unaudited) for the three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_22">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_22">  months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_22">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_22"> 30, 2022 and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_22">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_22"> 30, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_22">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_25">Condensed Consolidated Statements of Cash Flows (unaudited) for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_25">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_25"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_25">Se</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_25">ptember</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_25"> 30, 2022 and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_25">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_25"> 30, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_25">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_28">Notes to Unaudited Condensed Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_28">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_94">Item 2.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_94">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_94">18</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_112">Item 3.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_112">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_112">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_115">Item 4.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_115">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_115">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_118">PART II.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_118">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_118">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_121">Item 1.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_121">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_121">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_124">Item 1A.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_124">Risk Factors</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_124">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_127">Item 2.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_127">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_127">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_130">Item 3.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_130">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_130">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_133">Item 4.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_133">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_133">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_136">Item 5.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_136">Other Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_136">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_139">Item 6.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_139">Exhibits</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_139">25</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_142">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i20b8d43ebbfc4db489a67f7a9d9d59ec_142">27</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_13"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements</span></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">(in thousands)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.683%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfNC0yLTEtMS02ODc5NQ_662d350c-0fbb-4659-909c-c2527d99e2e6">86,052</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfNC00LTEtMS02ODc5NQ_06a69c63-6432-4e9c-9536-d01d9baf30f9">231,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfNS0yLTEtMS02ODc5NQ_a3fec716-46b7-4cef-b116-f07e5531f385">290,592</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfNS00LTEtMS02ODc5NQ_b5990155-ebcb-4270-a36a-12d10acdd078">234,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfNi0yLTEtMS02ODc5NQ_ba39803d-6071-400f-99f8-296a7b7076db">41,771</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfNi00LTEtMS02ODc5NQ_eb273425-3ae0-4861-b2dd-b8d24163a253">15,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfNy0yLTEtMS02ODc5NQ_59893fd4-b411-4bb7-9bf5-0dbeb231dd97">25,320</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfNy00LTEtMS02ODc5NQ_24d038ca-1a28-4c91-a23e-2b5f5339da5e">19,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfOC0yLTEtMS02ODc5NQ_13cb65e9-e1f1-45b2-955d-295a21395a1f">12,159</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfOC00LTEtMS02ODc5NQ_8587d2c8-e381-4634-b9ed-28f341d77071">11,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfOS0yLTEtMS03NjE3Mg_c7f76ecc-5ed8-43c6-9ae1-5512e36f8e12">3,808</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfOS00LTEtMS03NjE3Mg_c7caa5b5-f89b-49bf-90b7-4bdd38b6a68f">796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfOS0yLTEtMS02ODc5NQ_9a43d5ac-b820-4857-950d-4ae00a623e34">459,702</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfOS00LTEtMS02ODc5NQ_afb31def-1bdf-462d-a613-aeb1b5227f92">513,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMTMtMi0xLTEtNjg3OTU_40275d7a-1c89-4e5e-9327-c4a4ba14186b">13,049</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMTMtNC0xLTEtNjg3OTU_751f6121-45f6-48c7-866e-321e6aefde44">11,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMTQtMi0xLTEtNjg3OTU_496b733a-abbc-4a67-a9b2-39e62f8fbe75">3,758</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMTQtNC0xLTEtNjg3OTU_ebee8a9e-d2f9-4a26-85ad-156b5baded1f">4,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intellectual property and other intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMTUtMi0xLTEtNjg3OTU_43d45e2f-a508-45ad-a698-c1d817259b93">6,839</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMTUtNC0xLTEtNjg3OTU_c6a6e266-572e-426d-b6d1-151143ad217e">8,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMTYtMi0xLTEtNjg3OTU_a1ce61cf-ab81-4eb0-90cc-de9bb544a6f8">4,945</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMTYtNC0xLTEtNjg3OTU_9b62d272-4c70-489a-aae3-297dbd1d8acc">5,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMTctMi0xLTEtNjg3OTU_4a73fd77-b359-4b6d-b04e-c049e5e59c16">488,293</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMTctNC0xLTEtNjg3OTU_55f5ae56-8698-4452-a2dd-57f61f6d4401">543,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMjEtMi0xLTEtNjg3OTU_90ff1f26-ac8a-46b0-9ef4-66a2f3c55f2f">40,123</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMjEtNC0xLTEtNjg3OTU_7024a41a-97b4-42b2-850d-49071c0db43b">34,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMjItMi0xLTEtNjg3OTU_08be742a-0557-4a50-8ffb-cf8a3d5750b8">724</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMjItNC0xLTEtNjg3OTU_e2571848-5f1e-419e-8643-62e718d08817">4,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMjMtMi0xLTEtNjg3OTU_fb566ef1-9b03-41bc-a911-885211907edc">918</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMjMtNC0xLTEtNjg3OTU_94d9bd6e-301b-46e6-b5df-914e449b3d48">1,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMjQtMi0xLTEtNjg3OTU_a313b7c5-7dcd-424b-b1fa-bfbf3d89dea0">41,765</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMjQtNC0xLTEtNjg3OTU_f853965e-4100-49f9-980e-079c978db5bd">40,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation and other non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMjctMi0xLTEtNjg3OTU_16c1fd81-dbe3-4ae3-9129-c7585ea41b96">15,833</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMjctNC0xLTEtNjg3OTU_056d96f1-34a0-4869-a5de-2b4c93ad5f0c">15,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMjgtMi0xLTEtNjg3OTU_d6e69e7d-a146-45e5-b670-b685a8949a82">7,270</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMjgtNC0xLTEtNjg3OTU_41a42514-6876-4e55-9f77-b392e47002a9">7,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMjktMi0xLTEtNjg3OTU_6992fe4b-ac2a-4624-9564-cece607094cb">64,868</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMjktNC0xLTEtNjg3OTU_09e54f13-885b-454f-b513-9dd1af8ef775">64,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 17)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzAtMi0xLTEtNjg3OTU_a0f8f6a7-b5a2-4063-9c2e-729db481726d"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzAtNC0xLTEtNjg3OTU_6b977572-73cf-457b-bfdf-9e506f21d643"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SHAREHOLDER&#8217;S EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares - <ix:nonFraction unitRef="usdPerShare" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzItMC0xLTEtNjg3OTUvdGV4dHJlZ2lvbjo3NzBjOTRiYjJlMWE0NzNlOWIyNzY4OTEwZTVlZWY5Yl8yMA_22e1a25f-0e51-49c4-b1a6-bf5ac229b7bd"><ix:nonFraction unitRef="usdPerShare" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzItMC0xLTEtNjg3OTUvdGV4dHJlZ2lvbjo3NzBjOTRiYjJlMWE0NzNlOWIyNzY4OTEwZTVlZWY5Yl8yMA_bf763934-c40a-4fdc-8ce7-544fe6b13d0e">no</ix:nonFraction></ix:nonFraction> par value, unlimited shares authorized, <ix:nonFraction unitRef="shares" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzItMC0xLTEtNjg3OTUvdGV4dHJlZ2lvbjo3NzBjOTRiYjJlMWE0NzNlOWIyNzY4OTEwZTVlZWY5Yl82Mw_2f0d46a8-6fb1-4bf7-aa13-5318cf50a72d"><ix:nonFraction unitRef="shares" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzItMC0xLTEtNjg3OTUvdGV4dHJlZ2lvbjo3NzBjOTRiYjJlMWE0NzNlOWIyNzY4OTEwZTVlZWY5Yl82Mw_4a40b82e-36a7-4f09-be91-93dc69d072de">142,110</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzItMC0xLTEtNjg3OTUvdGV4dHJlZ2lvbjo3NzBjOTRiYjJlMWE0NzNlOWIyNzY4OTEwZTVlZWY5Yl83MA_a55f13dd-f09f-4773-805f-f7b174332b4f"><ix:nonFraction unitRef="shares" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzItMC0xLTEtNjg3OTUvdGV4dHJlZ2lvbjo3NzBjOTRiYjJlMWE0NzNlOWIyNzY4OTEwZTVlZWY5Yl83MA_f6af4d5d-016a-42e3-a175-39dcbcfa890e">141,600</ix:nonFraction></ix:nonFraction> shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:CommonStockValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzItMi0xLTEtNjg3OTU_32a101b5-758f-45a3-8419-9dafe1091e00">1,184,020</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:CommonStockValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzItNC0xLTEtNjg3OTU_e95f341d-2eac-48f2-86ce-759f65e2e843">1,177,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzMtMi0xLTEtNjg3OTU_cb8426c0-839e-458a-8a1b-f946183cb4e9">79,188</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzMtNC0xLTEtNjg3OTU_fb2f15bc-bd67-4748-9378-c846a2006dd1">59,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzQtMi0xLTEtNjg3OTU_27e4104f-9332-4733-ac46-f2c4697d588c">1,527</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzQtNC0xLTEtNjg3OTU_c782c557-cab1-446e-86fc-168bc10ebfe0">852</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzUtMi0xLTEtNjg3OTU_8292cbd5-e944-45e7-9512-99098da8e355">838,256</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzUtNC0xLTEtNjg3OTU_f7cf510a-0f05-466e-a77c-d618fc0af3da">756,122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzYtMi0xLTEtNjg3OTU_b5d2e340-525a-44cc-9cc2-e2d33d173388">423,425</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzYtNC0xLTEtNjg3OTU_f4c3a5ab-278b-43f0-87d5-b8b8870b4250">479,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzctMi0xLTEtNjg3OTU_96bea594-120e-4f38-980f-11653735304b">488,293</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzctNC0xLTEtNjg3OTU_43794912-6b75-4fae-801b-4344294116f2">543,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share data)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.683%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6469b2d1ea454cb388fc81376000b775_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfNS0yLTEtMS02ODc5NQ_9e65c100-b232-4d1d-834a-6fd79b0c32c7">25,502</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7047233c039c4e5db5ccb689cf181bd9_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfNS00LTEtMS02ODc5NQ_3ce3b094-5735-4540-b83b-3d75c4884949">14,638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8e7b1e28ca6475699ad1f3389d65b0f_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfNS02LTEtMS02ODc5NQ_de4ccda9-d15d-417b-b86a-b0aa7cce4e61">75,142</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6eb1901eda7949188f64f0ae3e428eaa_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfNS04LTEtMS02ODc5NQ_4810740c-c917-48b1-aa2e-7f261b324763">22,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bad260542ee4aa9ae02bb08274b9038_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfNi0yLTEtMS02ODc5NQ_ca431cb7-132c-4ccd-a7bc-b126f6e329a7">30,277</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4783d7802784076a6f6bfe42837f76c_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfNi00LTEtMS02ODc5NQ_04a3c6f8-bc45-4128-8202-a4a61b0679f1">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31e4e566879a474d8c808a4b79ad4910_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfNi02LTEtMS02ODc5NQ_a7c7a217-3066-4e40-b66f-ef1e0efba75f">30,453</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id181d42e4a034ee68572be022fef93f4_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfNi04LTEtMS02ODc5NQ_6c66b28f-b882-408b-998f-c900bdf4f04a">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfNy0yLTEtMS02ODc5NQ_164a71c7-96a6-44f7-b443-8ef780d46748">55,779</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfNy00LTEtMS02ODc5NQ_c42ff336-8dc9-43a8-913f-faf46f689184">14,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfNy02LTEtMS02ODc5NQ_dd81ac05-7ad8-403c-b13b-cc1403b35b54">105,595</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfNy04LTEtMS02ODc5NQ_1b1f11ce-52d7-4082-9586-10c0d7670257">22,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfOS0yLTEtMS02ODc5NQ_dfb04afb-bdd7-49a5-ad78-4b2930b47cfd">2,447</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930" decimals="-3" name="us-gaap:CostOfRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfOS00LTEtMS02ODc5NQ_5d78ff74-8a50-4d4a-81a4-a9a1bc347d65">254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfOS02LTEtMS02ODc5NQ_6933a87c-61e1-4a89-b069-5199f39a724b">4,302</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:CostOfRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfOS04LTEtMS02ODc5NQ_1502c1a1-40dc-43a4-b233-b12bf76bec77">610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTAtMi0xLTEtNjg3OTU_9f20c9c5-deb4-4e4c-a3b7-3208add48954">52,169</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTAtNC0xLTEtNjg3OTU_f5c760bf-3c08-43ff-b03a-d0117188a5d4">44,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTAtNi0xLTEtNjg3OTU_73733aef-2bc3-4222-a75c-f487b0642b49">148,898</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTAtOC0xLTEtNjg3OTU_933cab8f-2ec2-4b2f-9c9e-763a4556e9f3">128,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTEtMi0xLTEtNjg3OTU_377ab3a5-37b9-41e2-88a4-3b9727e7d827">10,973</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTEtNC0xLTEtNjg3OTU_128d6edf-9194-4569-9b9e-e12dd31bafd1">20,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTEtNi0xLTEtNjg3OTU_d1c8ce1b-0840-417a-be2f-568daf52edd0">35,118</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTEtOC0xLTEtNjg3OTU_116b84af-2c92-47ef-861c-674b49d516a4">39,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTMtMi0xLTEtNjg3OTU_e31948d3-4fc9-4aae-b55f-2f50beb8232b">311</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTMtNC0xLTEtNjg3OTU_8643bddf-4eae-462f-a870-0af5076703ab">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTMtNi0xLTEtNjg3OTU_a45cd1f0-7e20-4a91-b928-d0e40fcbf6ed">647</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTMtOC0xLTEtNjg3OTU_e45f1013-e5e4-45a3-a5fe-01da78d26710">859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of sales and operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTQtMi0xLTEtNjg3OTU_6b81aa24-0c5e-4aea-8965-3110ca879a87">65,278</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTQtNC0xLTEtNjg3OTU_b94eb6f3-95b2-4783-8a9a-3f9ad2081dda">65,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTQtNi0xLTEtNjg3OTU_e9a5871f-1631-4eb3-ad9e-a4cf3a13c48f">188,965</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTQtOC0xLTEtNjg3OTU_53b72284-a70a-46ac-aa87-456625540fb9">170,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTUtMi0xLTEtNjg3OTU_70f5ff8e-a88f-4224-a332-81b944f01629">9,499</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTUtNC0xLTEtNjg3OTU_5d251d21-f1db-4b26-a6a4-0d04f4d73cd4">50,353</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTUtNi0xLTEtNjg3OTU_0ae75d90-6e75-465c-935f-0a3dadec8f21">83,370</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTUtOC0xLTEtNjg3OTU_919ff696-3f67-4070-ac6b-2f6438d566a1">148,030</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTYtMi0xLTEtNjg3OTU_926f56bb-83c0-4caf-9919-264b1681849e">1,464</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTYtNC0xLTEtNjg3OTU_8f7bd871-f702-4101-9543-bacc054d34e4">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTYtNi0xLTEtNjg3OTU_6a0df447-eb65-441b-9fcf-9f54a429d93d">2,209</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTYtOC0xLTEtNjg3OTU_9a8c9b86-22be-4738-aa2c-16e47356cdc5">420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTctMi0xLTEtNjg3OTU_4db5d862-c5d1-47d4-9fb1-bdde710000a8">8,035</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTctNC0xLTEtNjg3OTU_a1cb2137-760d-4087-b792-568ee096d59e">50,247</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTctNi0xLTEtNjg3OTU_8dd833cc-ae0a-4759-867c-f58503553d32">81,161</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTctOC0xLTEtNjg3OTU_70a05b6a-7a82-4e09-a9a4-ff988e1ebc5f">147,610</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTgtMi0xLTEtNjg3OTU_7a0e4cdc-ad8c-48c5-abd5-2b72d0c5ce70">954</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTgtNC0xLTEtNjg3OTU_78e60b59-49fb-4f6a-8960-eec1cb2796d8">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTgtNi0xLTEtNjg3OTU_67818103-59ea-48ff-9499-e72a896784db">973</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTgtOC0xLTEtNjg3OTU_21a7213c-d782-43a3-88e5-9a1e335ad4a1">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTktMi0xLTEtNjg3OTU_c73fa4d2-b2f1-4f6c-96c7-2e75599b0882">8,989</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTktNC0xLTEtNjg3OTU_2fae839c-b95b-444a-84b6-a6af98b12e20">50,255</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTktNi0xLTEtNjg3OTU_9e9b5b58-b094-4198-bfd4-b7dc5a6aab4b">82,134</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTktOC0xLTEtNjg3OTU_d38cd7d1-808f-4cc4-aac9-b23f911b005b">147,644</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on available-for-sale securities, net of tax of <ix:nonFraction unitRef="usd" contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930" decimals="INF" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjEtMC0xLTEtNjg3OTUvdGV4dHJlZ2lvbjpjODJlYTUwNDQzZDI0ZDZmOTkxNjFhYTc1ZTg1ZmRhNl83NQ_8699fd76-fdcf-4a25-94ed-af4ff415ce00"><ix:nonFraction unitRef="usd" contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930" decimals="INF" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjEtMC0xLTEtNjg3OTUvdGV4dHJlZ2lvbjpjODJlYTUwNDQzZDI0ZDZmOTkxNjFhYTc1ZTg1ZmRhNl83NQ_a3bace4b-78ad-454b-b87f-f2d8245c8c3d"><ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="INF" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjEtMC0xLTEtNjg3OTUvdGV4dHJlZ2lvbjpjODJlYTUwNDQzZDI0ZDZmOTkxNjFhYTc1ZTg1ZmRhNl83NQ_c06a3897-48c5-4583-a599-079f5ea26587"><ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="INF" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjEtMC0xLTEtNjg3OTUvdGV4dHJlZ2lvbjpjODJlYTUwNDQzZDI0ZDZmOTkxNjFhYTc1ZTg1ZmRhNl83NQ_f542165e-d5be-40d1-ad4d-d4c69d074b87">nil</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjEtMi0xLTEtNjg3OTU_4f4c0b6f-2c35-4011-afbc-dfad02816ebd">326</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjEtNC0xLTEtNjg3OTU_3e598ad0-b400-447c-a6e8-817029cb40af">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjEtNi0xLTEtNjg3OTU_b5cabf12-abf1-43c3-9d26-2c9fd625ee4d">675</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjEtOC0xLTEtNjg3OTU_ffd69119-5b0f-471b-ba02-c12401e4189b">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjItMi0xLTEtNjg3OTU_6b10f586-6774-48be-83eb-57746a9bd407">8,663</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjItNC0xLTEtNjg3OTU_8e5b2269-3605-4e92-8f9c-eb07d73efdd9">50,257</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjItNi0xLTEtNjg3OTU_50041993-9cee-453a-be31-64041ec63900">82,809</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjItOC0xLTEtNjg3OTU_a7e3f44e-e1f0-4866-bccb-22ff0c6d3d62">147,633</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930" decimals="INF" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjMtMi0xLTEtNjg3OTU_ae38e2c4-7756-406c-8771-fcba4ca02e5f"><ix:nonFraction unitRef="usdPerShare" contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930" decimals="INF" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjMtMi0xLTEtNjg3OTU_daf9800f-993b-4772-bc88-a8a4111d49e1">0.06</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930" decimals="INF" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjMtNC0xLTEtNjg3OTU_dc254853-dc60-4e33-8b3f-4d8fff6e5e85"><ix:nonFraction unitRef="usdPerShare" contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930" decimals="INF" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjMtNC0xLTEtNjg3OTU_fff8f429-aedf-400d-bf81-ee2f2631205d">0.39</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="INF" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjMtNi0xLTEtNjg3OTU_b4968c48-c79b-4a8c-b05a-6bf21069c9ed"><ix:nonFraction unitRef="usdPerShare" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="INF" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjMtNi0xLTEtNjg3OTU_b5a8a608-e110-43a1-88aa-f81c58ffd49b">0.58</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="INF" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjMtOC0xLTEtNjg3OTU_31ffa586-e0ed-48c8-8aaa-ba9f30bfa8d6"><ix:nonFraction unitRef="usdPerShare" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="INF" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjMtOC0xLTEtNjg3OTU_e5084b12-23ad-44fc-97c9-46969cd8e562">1.15</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding used in computation of basic and diluted loss per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjQtMi0xLTEtNjg3OTU_7332c26b-4c28-41c2-a66b-242e73af1578"><ix:nonFraction unitRef="shares" contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjQtMi0xLTEtNjg3OTU_c33d077b-fa58-4487-8c99-79c51376595c">141,856</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjQtNC0xLTEtNjg3OTU_9ac42c5a-ca34-4075-a9aa-d906013a561f"><ix:nonFraction unitRef="shares" contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjQtNC0xLTEtNjg3OTU_d466ad19-a69b-4c0b-b2ce-342866f78249">128,443</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjQtNi0xLTEtNjg3OTU_37a95419-36d0-4d38-adae-31253d4a387d"><ix:nonFraction unitRef="shares" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjQtNi0xLTEtNjg3OTU_c8fedb66-8dc5-4220-98a3-c77d43e50d1b">141,831</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjQtOC0xLTEtNjg3OTU_32e2352f-c254-43ba-94ae-4e53c4979b68"><ix:nonFraction unitRef="shares" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjQtOC0xLTEtNjg3OTU_ce59f9bd-4250-40e5-baa7-145a84bf684d">128,084</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_22"></div><hr style="page-break-after:always"/><div style="min-height:24.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.184%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.346%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.346%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.346%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.346%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.014%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.346%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.238%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.346%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.610%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional<br/>paid in<br/>capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>(Loss) Income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Shareholders'<br/>Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d4690f8a2eb435883c18b3504cdad69_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMi0yLTEtMS02ODc5NQ_a898face-8030-4c5c-86cb-d524e692d2af">141,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d4690f8a2eb435883c18b3504cdad69_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMi00LTEtMS02ODc5NQ_79c62ff9-519c-4d6d-944b-359434aeaed0">1,180,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5eb0f19f9c074e79a40d0cb3e2ff02f3_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMi02LTEtMS02ODc5NQ_3db9be0a-23e4-43fc-9651-39fa8fef7ea3">74,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic68c4ca008b74f51b6d19d40416666ee_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMi04LTEtMS02ODc5NQ_dc494a88-8ccd-4b2e-976a-9f2ee0203fa4">1,853</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if36244d95f6d4bd299450825700e832d_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMi0xMC0xLTEtNjg3OTU_6de3aff4-bec7-453c-8566-4d9659eab1d6">829,267</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i377749222219417c8982b959ba79c8f1_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMi0xMi0xLTEtNjg3OTU_a731e6bc-dea1-404d-ab39-8c709cee4d99">423,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares issued on exercise of stock options and vesting of performance awards and restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i27eec2a9a9cc4f2ba78ceffaf03f0d83_D20220701-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMy0yLTEtMS02ODc5NQ_f7e55753-f923-47b7-b7f5-ceb1e918cc63">218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27eec2a9a9cc4f2ba78ceffaf03f0d83_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMy00LTEtMS02ODc5NQ_956c9ca6-aedd-4e39-95d0-376bc1ea448a">3,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i835bd94d3b8a46aea93d75b9c3e1b9f5_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMy02LTEtMS02ODc5NQ_502d6d60-ea6c-48c1-9564-a5656741826c">3,136</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMy0xMi0xLTEtNjg3OTU_77813bf9-840f-4e5d-b4d8-db91199a2a1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i835bd94d3b8a46aea93d75b9c3e1b9f5_D20220701-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfNS02LTEtMS02ODc5NQ_8f3c317a-1af3-4fdd-98c1-0b7d03e38413">8,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfNS0xMi0xLTEtNjg3OTU_42157d27-24cd-474b-9e3b-051a770c3882">8,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain on available-for-sale securities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i009b59fb6c994af8b5d17ed41e99cf66_D20220701-20220930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfNi04LTEtMS02ODc5NQ_0362e098-1c37-434b-8cbe-43125e6f65c1">326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfNi0xMi0xLTEtNjg3OTU_47ade82e-f3e9-4f5e-9236-5e5c0d371870">326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i588bcb33d7f94f32abdfc4d3a91cd187_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfNy0xMC0xLTEtNjg3OTU_fe0b8e6c-3ddc-4e1f-8a5f-d0036bc7ab26">8,989</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfNy0xMi0xLTEtNjg3OTU_9b611fdd-5dc3-4fa5-b920-dacc6fdaa991">8,989</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Balance at September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i611a8c2b382345d5bee16ff18c8b7de6_I20220930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfOC0yLTEtMS02ODc5NQ_2a283fbc-4f53-43a4-94a6-4e9016d9dfda">142,110</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i611a8c2b382345d5bee16ff18c8b7de6_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfOC00LTEtMS02ODc5NQ_e72b17df-930e-4599-bcc1-8ea91a9c0f2c">1,184,020</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic38f683d1d4d4b88a3ddee342ade79d4_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfOC02LTEtMS02ODc5NQ_812c33c7-b03a-4033-b426-8259af7ccce2">79,188</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7eb54bdb3b8e4810b83f9db13ac1682e_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfOC04LTEtMS02ODc5NQ_52785b08-3b85-4a9a-8fcd-60ac1a78b890">1,527</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17263ca8130048c8b999c4d7f9352e2e_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfOC0xMC0xLTEtNjg3OTU_b25e0e30-5770-479e-85ba-244b54f4e61b">838,256</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfOC0xMi0xLTEtNjg3OTU_0c5c79c7-c3d7-4de0-9434-4d4a0e0581d3">423,425</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional<br/>paid in<br/>capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>(Loss) Income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Shareholders'<br/>Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11d40396b1dd41869d1b914f4f6d8f92_I20210630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTItMi0xLTEtNjg3OTU_0e1af857-d3f1-423c-9e96-984269deedc2">128,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11d40396b1dd41869d1b914f4f6d8f92_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTItNC0xLTEtNjg3OTU_e1fbb94e-f525-4c06-8016-8c44a2d196c8">954,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41d70372ff754478b1094be19cf13784_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTItNi0xLTEtNjg3OTU_6ef07f1c-741c-4cd5-a1ca-57f21fec8a67">51,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12cec0e7fdf24de3b783ef6f7d90a849_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTItOC0xLTEtNjg3OTU_dcbba2c0-9a4e-44de-a819-0f26a4b86f29">792</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9dfc2f3c3741708e7b3da4e03bb444_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTItMTAtMS0xLTY4Nzk1_42a8bdd9-7303-48ef-8e4b-8fcb7314df3d">672,545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfb50debae134f6a85fce4e5f3651cc7_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTItMTItMS0xLTY4Nzk1_5212ad11-6ee2-47a8-bc42-838603fc3e3f">332,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares issued on exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i787c6a58aafe40fb93dba68bac8a5d88_D20210701-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTMtMi0xLTEtNjg3OTU_78d6e3fa-92db-48a3-ad6c-b6952af3e5ab">1,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i787c6a58aafe40fb93dba68bac8a5d88_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTMtNC0xLTEtNjg3OTU_fc192957-fb08-418f-8eb4-fb6759e20b53">12,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibaa74b4b308f463fa84d6d3a382b7c6a_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTMtNi0xLTEtNjg3OTU_6d5bb23c-e318-4ab0-bd31-06c15d6753ff">3,505</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTMtMTItMS0xLTY4Nzk1_430dae3d-6433-4117-ad31-5d95218852e5">9,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i787c6a58aafe40fb93dba68bac8a5d88_D20210701-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTQtMi0xLTEtNjg3OTU_a9edf8df-f430-4188-9958-d6a9160624ad">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i787c6a58aafe40fb93dba68bac8a5d88_D20210701-20210930" decimals="-3" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTQtNC0xLTEtNjg3OTU_775176ff-a02b-4eda-bb93-4fc80d69a56c">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibaa74b4b308f463fa84d6d3a382b7c6a_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTQtNi0xLTEtNjg3OTU_30dd5054-1c16-4ded-8390-63b8bc6b5b1d">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930" decimals="-3" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTQtMTItMS0xLTY4Nzk1_38cef964-60b1-472d-bde2-25fc84024cba">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shared-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa74b4b308f463fa84d6d3a382b7c6a_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTUtNi0xLTEtNjg3OTU_c97aa9f9-5f45-4e84-9557-5b555e919fa4">7,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTUtMTItMS0xLTY4Nzk1_7b961efb-e931-4bf1-a314-e244d91944f9">7,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on available-for-sale securities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i703ab11d0a9946cf8cc57b8243e5db59_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTYtOC0xLTEtNjg3OTU_ef70cf10-9cb9-441c-9960-5afa1de534c1">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTYtMTItMS0xLTY4Nzk1_9ff9de2a-7f50-4ca7-8d15-aa4954b4f732">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i114549079e764ecab84b77d1ecf6b9e4_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTctMTAtMS0xLTY4Nzk1_e358ae8c-2117-4ad7-bf1f-0d3bf7e4478e">50,255</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTctMTItMS0xLTY4Nzk1_0e729ced-4451-4780-807d-74c66a52c207">50,255</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b49777eb2204f95acb28165c4ffb245_I20210930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTgtMi0xLTEtNjg3OTU_b2466e67-10e0-461d-b352-0dbbcf5061e4">129,570</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b49777eb2204f95acb28165c4ffb245_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTgtNC0xLTEtNjg3OTU_1af1afd6-7d20-482f-86d4-23f8299a7905">967,159</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02ce71b787ab4ca797b5a9fcbaf61402_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTgtNi0xLTEtNjg3OTU_87c2ae0d-794f-4e6b-9a83-ee7e66df95ec">54,607</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d1cf1ea09434d15b4be325b80931e8c_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTgtOC0xLTEtNjg3OTU_b8e2b47b-dc54-4cf8-aedc-70fc1dd6a74a">794</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77fa57c5982e468f985e9bcaf10d6a42_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTgtMTAtMS0xLTY4Nzk1_5492085c-376a-49e4-9fc3-7da9efdcf8bf">722,800</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7443770797b0498c8cdad90152a5c590_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTgtMTItMS0xLTY4Nzk1_8c820c97-9ca1-413b-9e6d-b47d235440f1">298,172</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional<br/>paid in<br/>capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>(Loss) Income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Shareholders'<br/>Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if9ee7fe05eee40f48c092e1b88df007a_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjItMi0xLTEtNjg3OTU_cb8428bc-6c82-4fa7-bf24-683868155d8d">141,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9ee7fe05eee40f48c092e1b88df007a_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjItNC0xLTEtNjg3OTU_c912fcd3-b213-483d-8d81-bff366a425ca">1,177,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb29a2f97a214b8e9f797f9687616d27_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjItNi0xLTEtNjg3OTU_cf8e6501-da6d-4eab-b8fc-26bf5e021745">59,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib52fb1312906471b8f138a9a0ea36fec_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjItOC0xLTEtNjg3OTU_53cffa24-b76f-44a1-b900-fd5262d6a9ff">852</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2464b25495094609998bc808c8e1f431_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjItMTAtMS0xLTY4Nzk1_b434fadd-b9b9-4fb1-80a9-183f7f05ddcd">756,122</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjItMTItMS0xLTY4Nzk1_ba9b1549-4e3d-4ed0-a575-1baf5d532ea9">479,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares issued on exercise of stock options and vesting of performance awards and restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i68fb759408e04e9b9a39503596bd5faa_D20220101-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjMtMi0xLTEtNjg3OTU_dde94886-a5bb-4112-a941-cb72149b8f3e">383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68fb759408e04e9b9a39503596bd5faa_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjMtNC0xLTEtNjg3OTU_8ccec8b0-e877-45fb-9e13-076d86e3fb53">5,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb236f49e0c24418ab0220edb3a611e4_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjMtNi0xLTEtNjg3OTU_6fa1e6f4-baea-4168-84c9-8a2cfd007f11">4,542</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjMtMTItMS0xLTY4Nzk1_677d976f-1042-4c6a-9a69-5041f55d8703">522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Issuance of common shares in conjunction with ESPP program</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i68fb759408e04e9b9a39503596bd5faa_D20220101-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjQtMi0xLTEtNjg3OTU_c483bb97-1bf8-47a1-aa5b-2c6b58aa5210">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68fb759408e04e9b9a39503596bd5faa_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjQtNC0xLTEtNjg3OTU_30420317-a0ce-4f96-a063-117bd4ac57a2">1,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb236f49e0c24418ab0220edb3a611e4_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjQtNi0xLTEtNjg3OTU_6e46c3fe-e448-4c42-8484-dce2fc6b3c4d">682</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjQtMTItMS0xLTY4Nzk1_ebaf7db4-fdea-47da-a301-49420b64892b">1,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb236f49e0c24418ab0220edb3a611e4_D20220101-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjUtNi0xLTEtNjg3OTU_47788ec8-d93b-4766-baa0-380d04faba6b">25,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjUtMTItMS0xLTY4Nzk1_0694180e-d1fc-43e0-aa55-41f468d3715b">25,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on available-for-sale securities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaabe0fca9ec24b28814dfdae4e2dd4d3_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjYtOC0xLTEtNjg3OTU_bc881302-defb-4373-82da-776ada61b3d8">675</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjYtMTItMS0xLTY4Nzk1_40ce01ec-0588-4e70-98c9-a242bce7da94">675</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75925341cc3e4f78bacf59fb0684c25d_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjctMTAtMS0xLTY4Nzk1_25b8b42f-153b-4eca-baec-671dbb409753">82,134</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjctMTItMS0xLTY4Nzk1_0406b82d-b8ad-4cc3-9772-263b932e007e">82,134</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i611a8c2b382345d5bee16ff18c8b7de6_I20220930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjgtMi0xLTEtNjg3OTU_bc84aca0-0053-4e43-90a0-8513c77e3f6b">142,110</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i611a8c2b382345d5bee16ff18c8b7de6_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjgtNC0xLTEtNjg3OTU_9392d85e-9733-4ad5-a65d-2e145c33246f">1,184,020</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic38f683d1d4d4b88a3ddee342ade79d4_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjgtNi0xLTEtNjg3OTU_ad3136ac-50f3-4c7a-87e7-da6bf08461e7">79,188</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7eb54bdb3b8e4810b83f9db13ac1682e_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjgtOC0xLTEtNjg3OTU_530bc1ee-dfd1-4b91-a625-74187470ae25">1,527</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17263ca8130048c8b999c4d7f9352e2e_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjgtMTAtMS0xLTY4Nzk1_4e35a265-50d5-436a-84d5-ae8f637ee4b3">838,256</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjgtMTItMS0xLTY4Nzk1_b41c1428-580b-4d8d-831e-43e0edaa7b76">423,425</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional<br/>paid in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>(Loss) Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Shareholders'<br/>Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ied2bf63884594bf3a519994bdc8a9be1_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzItMi0xLTEtNjg3OTU_b3825332-eaf2-41b4-8801-816c27f16a33">126,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied2bf63884594bf3a519994bdc8a9be1_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzItNC0xLTEtNjg3OTU_98eb7918-cf97-4e24-9ce3-0e9b78d6556f">944,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6785021da65c4996946ac6e43914d14e_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzItNi0xLTEtNjg3OTU_a44a19e0-37f2-4d4d-82d4-180b24e52bfe">39,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if864e170575941afb3bbe7afabdecd5a_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzItOC0xLTEtNjg3OTU_d95c27e7-39e8-43c6-b3ca-5b6659d00d74">805</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9fdb7f1323043c4ad197d9228b4b4b6_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzItMTAtMS0xLTY4Nzk1_770ae3c5-7c53-47a3-b455-c0ed81d30c14">575,156</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08686fdbde8047d69c05941c654afac6_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzItMTItMS0xLTY4Nzk1_e4951347-0f48-4bf0-a4e7-6c7fc745e2d2">407,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares issued on exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i533a99201f634a479988a643e020cf8b_D20210101-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzMtMi0xLTEtNjg3OTU_10189998-0c06-42bd-8060-d140d7180350">2,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i533a99201f634a479988a643e020cf8b_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzMtNC0xLTEtNjg3OTU_22b27618-3617-42c5-b6df-1864746cde22">22,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16ed573a0bd841e98023564edf9f9c34_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzMtNi0xLTEtNjg3OTU_0b2d9b9a-cdb9-43d6-91f8-3af81bcc079f">6,745</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzMtMTItMS0xLTY4Nzk1_91f65d2f-870e-44dd-8437-56015afeae27">15,352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i533a99201f634a479988a643e020cf8b_D20210101-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzQtMi0xLTEtNjg3OTU_98fc1a72-7f54-4154-8515-989d951b935f">521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i533a99201f634a479988a643e020cf8b_D20210101-20210930" decimals="-3" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzQtNC0xLTEtNjg3OTU_fa520eaa-95b2-477f-8dd4-1e8906dd8902">734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16ed573a0bd841e98023564edf9f9c34_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzQtNi0xLTEtNjg3OTU_e0c5a1b3-225c-4a1d-be29-6b59d09a4e11">697</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzQtMTItMS0xLTY4Nzk1_79e951df-2157-4a7e-a40e-87a9722cb11b">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shared-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ed573a0bd841e98023564edf9f9c34_D20210101-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzUtNi0xLTEtNjg3OTU_da2527f8-252f-4687-929a-506608ccb25e">22,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzUtMTItMS0xLTY4Nzk1_8ceb0b82-ce7e-4c68-bf56-f188d2630046">22,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain on available-for-sale securities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic873b1cf2e4c4bf98cf80aac069abfdf_D20210101-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzYtOC0xLTEtNjg3OTU_18699567-c755-46d3-bc45-ac5fa63fee49">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzYtMTItMS0xLTY4Nzk1_d3438b1a-61d4-4536-a291-4da6c69ded73">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84a4831b700f48b1833b184774156aeb_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzctMTAtMS0xLTY4Nzk1_3d7ceb99-0913-4a65-a497-b094e454314b">147,644</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzctMTItMS0xLTY4Nzk1_1782ff43-24d4-4241-860d-6185ab8c770a">147,644</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b49777eb2204f95acb28165c4ffb245_I20210930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzgtMi0xLTEtNjg3OTU_98a814a4-8187-4724-b444-9397faf0083b">129,570</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b49777eb2204f95acb28165c4ffb245_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzgtNC0xLTEtNjg3OTU_556f768e-f9fc-46be-924f-7f9f846c1719">967,159</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02ce71b787ab4ca797b5a9fcbaf61402_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzgtNi0xLTEtNjg3OTU_c22c65a8-ceb0-453b-91e2-18fc1f56a5db">54,607</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d1cf1ea09434d15b4be325b80931e8c_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzgtOC0xLTEtNjg3OTU_4a8bdab1-f419-48bb-8193-b80cd55020cd">794</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77fa57c5982e468f985e9bcaf10d6a42_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzgtMTAtMS0xLTY4Nzk1_19ad1ed6-dd35-4128-aa57-58f3aadb8fed">722,800</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7443770797b0498c8cdad90152a5c590_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzgtMTItMS0xLTY4Nzk1_6e80abb3-bf50-428d-a94c-e8605c7094b9">298,172</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:29.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_25"></div><hr style="page-break-after:always"/><div style="min-height:38.25pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:68.006%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfNC0yLTEtMS02ODc5NQ_9e9b5b58-b094-4198-bfd4-b7dc5a6aab4b">82,134</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfNC00LTEtMS02ODc5NQ_e5a51ba3-bbb7-408b-ae56-4b84b30ce5ee">147,644</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfNi0yLTEtMS02ODc5NQ_2bbdc4a1-3849-462b-b4b2-0e73a8e0c0a8">2,487</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfNi00LTEtMS02ODc5NQ_598c8b86-c1c2-4d4d-b1e2-229203dd1543">2,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 46.75pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront license and milestone expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="auph:AcquiredUpfrontLicensePayment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfOC0yLTEtMS02ODc5NQ_72ea9212-8f08-4750-ad11-e61d631d70c8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="auph:AcquiredUpfrontLicensePayment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfOC00LTEtMS02ODc5NQ_4eb2a69f-57f4-4884-8264-eed324b5f639">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfOS0yLTEtMS02ODc5NQ_e03d50bf-ee58-41a3-a490-c46e29de530c">25,398</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfOS00LTEtMS02ODc5NQ_1f5e8134-4edb-41dd-acb8-c09b28ee5a2f">22,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 46.75pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-down of inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMTAtMi0xLTEtNzYzNzU_7a886649-27ef-4086-8255-ddc61d46ad43">2,464</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:InventoryWriteDown" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMTAtNC0xLTEtNzYzNzU_0a5072d2-e212-41a3-bcfe-65d52f6d5852">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMTAtMi0xLTEtNjg3OTU_00273193-17eb-47c0-82e8-48e5cf4e18b7">587</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMTAtNC0xLTEtNjg3OTU_74ea01dc-ea90-4675-bee0-476288d75097">1,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net changes in operating assets and liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMTItMi0xLTEtNjg3OTU_30421dc1-a222-41ac-9a8e-a8b1304895e1">26,356</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMTItNC0xLTEtNjg3OTU_536ecb61-58c1-4a34-903d-b92c23fcdeb8">9,815</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMTMtMi0xLTEtNjg3OTU_4d0a3222-eff1-42e1-93e6-5cdf11b3257f">8,458</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMTMtNC0xLTEtNjg3OTU_4c2ebaae-b68e-4de2-aa5b-b8ab76c1a65b">5,366</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMTQtMi0xLTEtNjg3OTU_90fe5ab1-79e5-48d5-b758-0ce084cbc585">3,461</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMTQtNC0xLTEtNjg3OTU_617f2fd3-928c-4332-979d-4f065894969a">6,541</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 52.75pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMTUtMi0xLTEtNjg3OTU_d1b35d22-2471-4b50-ac6e-826f855ecde4">830</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMTUtNC0xLTEtNjg3OTU_0298ebb2-20d8-4ba1-b08c-efef461fe507">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable, accrued and other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMTYtMi0xLTEtNjg3OTU_24c4dbb5-b0c9-4800-94b9-3ca826d3a558">875</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMTYtNC0xLTEtNjg3OTU_8de71cd8-ba9b-4b78-bfcd-bcb526ae68d9">1,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMTctMi0xLTEtNjg3OTU_fa13faba-ffc4-4896-b1a7-a91d0920d0e6">551</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMTctNC0xLTEtNjg3OTU_b3af62e0-ff66-44a4-adf0-782565436ae4">499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMTgtMi0xLTEtNjg3OTU_4308c792-2a69-4a53-b3e7-b5d45fdcb413">89,979</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMTgtNC0xLTEtNjg3OTU_cc793040-49cc-4f32-96ca-2b689f3bf228">131,770</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows used in investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMjAtMi0xLTEtNjg3OTU_feed88b1-27de-42cf-9f8f-25a6a438dd52">403,184</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMjAtNC0xLTEtNjg3OTU_24e94a65-954f-4932-bd12-3a8d480d3e03">342,831</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMjEtMi0xLTEtNjg3OTU_53a3492e-d886-46fb-8d7f-de77abcf9da3">346,109</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMjEtNC0xLTEtNjg3OTU_8e8912ec-479f-4652-a270-94ca76d40cf3">263,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 33.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront lease payment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsToAcquireLeaseReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMjItMi0xLTEtNjg3OTU_ee15854e-fbf8-4cb8-b037-271fd2bf4e64">381</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquireLeaseReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMjItNC0xLTEtNjg3OTU_769e0faa-e3ad-4536-b51d-00d8df11a188">11,838</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 33.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront license payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsToAcquireOtherInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMjMtMi0xLTEtNjg3OTU_fa752700-75b3-4ea1-a917-7aec767343db">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquireOtherInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMjMtNC0xLTEtNjg3OTU_b1eb9f8a-c896-47e0-b7be-9153695372d2">6,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 33.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMjQtMi0xLTEtNjg3OTU_a7ad90d2-4c70-4f0a-870c-6ba630e160d0">158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMjQtNC0xLTEtNjg3OTU_ddf240ec-1b7f-4835-83bc-fabf2f7307eb">268</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to internal use-software implementation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsForSoftware" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMjUtMi0xLTEtNjg3OTU_78b03456-8a9e-49d9-b45f-ddfed3bdfbab">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsForSoftware" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMjUtNC0xLTEtNjg3OTU_4e1e5ac2-4049-4917-a3ea-53fb8254d168">1,198</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMjctMi0xLTEtNjg3OTU_0472d18e-1903-41dc-bcfb-5b4e885d3423">57,614</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMjctNC0xLTEtNjg3OTU_607cbd72-db9f-4104-a45b-0dc37d9dc757">98,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options and employee share purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMjktMi0xLTEtNjg3OTU_0716ed7c-8658-4442-8916-e425d3cc56b7">1,745</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMjktNC0xLTEtNjg3OTU_b15db537-2d40-408c-a1e6-e02455192474">15,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMzAtMi0xLTEtNjg3OTU_7d5b155c-2cb1-41c5-b01d-f28669dbe178">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMzAtNC0xLTEtNjg3OTU_b9ac990e-8da8-4e83-9669-df8f4fc9f73b">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by financing activities </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMzItMi0xLTEtNjg3OTU_3480d14c-e15f-45ac-9d85-99aede1b2553">1,745</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMzItNC0xLTEtNjg3OTU_78260ae0-bad4-44eb-8add-53ce1a6a0379">15,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMzMtMi0xLTEtNjg3OTU_b74c0b5f-86a2-4f04-8ee2-aa8e97366d60">145,848</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMzMtNC0xLTEtNjg3OTU_9d806e2b-8ae1-4649-b7cb-acab8c414b8d">214,763</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMzQtMi0xLTEtNjg3OTU_b1c6c519-251b-4f56-8a4f-4043905523e8">231,900</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08686fdbde8047d69c05941c654afac6_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMzQtNC0xLTEtNjg3OTU_ffefb36d-6e28-40b5-905d-cc1144600eb6">272,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMzUtMi0xLTEtNjg3OTU_dbb15f7c-ec3b-402a-b9e6-fd014f4cdcc9">86,052</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7443770797b0498c8cdad90152a5c590_I20210930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMzUtNC0xLTEtNjg3OTU_d257afc6-4f5e-43e1-bfd8-00f995efa708">57,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental cash flow information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received for interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromInterestReceived" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMzgtMi0xLTEtNjg3OTU_81632bbd-6eaa-4fef-90aa-4f9a958031ff">1,705</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromInterestReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMzgtNC0xLTEtNjg3OTU_ead4370b-1ab8-452f-9176-23eab2c95913">671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMzktMi0xLTEtNjg3OTU_b22d06cb-e209-4401-b303-75f272f3c961">779</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMzktNC0xLTEtNjg3OTU_e20fba65-088e-40b1-8eab-bd437ce44f25">236</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:CapitalLeaseObligationsIncurred" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfNDAtMi0xLTEtNjg3OTU_a73bc878-9e01-4130-a634-6e2d1bbe6f92">897</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:CapitalLeaseObligationsIncurred" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfNDAtNC0xLTEtNjg3OTU_d8be57ec-b20b-4749-9db2-8d1ab70d32ff">195</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental disclosure of noncash transactions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initial recognition of operating lease right-of-use asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfNDItMi0xLTEtNjg3OTU_07e61505-6c5d-4ad1-9b19-b7571d364b9b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfNDItNC0xLTEtNjg3OTU_1cd60ae4-c663-43bd-81b8-d3c15a71ad0c">419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfNDUtMi0xLTEtNjg3OTU_67f23f59-207f-4427-bcd6-0ec28e0e198e">85,341</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7443770797b0498c8cdad90152a5c590_I20210930" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfNDUtNC0xLTEtNjg3OTU_3422233a-e79f-4a86-9851-20432149e22c">57,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfNDYtMi0xLTEtNjg3OTU_26851756-f81f-4cac-9123-c98d54689fbd">711</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7443770797b0498c8cdad90152a5c590_I20210930" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfNDYtNC0xLTEtNjg3OTU_e86c4a86-41c9-4548-8197-a848a016f862">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfNDctMi0xLTEtNjg3OTU_1723823c-b1cd-497a-a8cc-2b556e2815d5">86,052</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7443770797b0498c8cdad90152a5c590_I20210930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfNDctNC0xLTEtNjg3OTU_00b9d9b0-e2ab-4118-a157-aaf41dcb25b4">57,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:38.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_31"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zMS9mcmFnOjU2ZWFkNGVjZTMzNzQ5MTQ4YzE3MzUyNWE1MzI4ODI3L3RleHRyZWdpb246NTZlYWQ0ZWNlMzM3NDkxNDhjMTczNTI1YTUzMjg4MjdfMTQ1Nw_db3b31e8-a326-4090-b716-e093e6fb536a" continuedAt="i9be0dc449a5244a0a7ef7d5dbe23547c" escape="true">Organization and Description of Business</ix:nonNumeric></span></div><ix:continuation id="i9be0dc449a5244a0a7ef7d5dbe23547c"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurinia Pharmaceuticals Inc. (Aurinia or the Company) is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the Company introduced LUPKYNIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (voclosporin), the first U.S. Food and Drug Administration (FDA) approved oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory activities to support the voclosporin development program as well as our other assets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 17, 2021, the Company announced the addition of two novel assets AUR200 and AUR300. AUR200 and AUR300 are currently undergoing pre-clinical development with projected submission of Investigational New Drug Applications (INDs) to the FDA in 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2022, the European Commission (EC) granted marketing authorization of LUPKYNIS to Otsuka Pharmaceutical Co., Ltd. (Otsuka). </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The centralized marketing authorization is valid in all European (EU) member states as well as in Iceland, Liechtenstein, Norway and Northern Ireland.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurinia's head office is located at #1203-4464 Markham Street, Victoria, British Columbia, Canada and its registered office is located at #201, 17873-106 A Avenue, Edmonton, Alberta. Aurinia also has a U.S. commercial office located at 77 Upper Rock Circle Suite 700, Rockville, Maryland, 20850 United States.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurinia is incorporated pursuant to the Business Corporations Act (Alberta). The Company&#8217;s common shares are traded on the Nasdaq Global Market (Nasdaq) under the symbol AUPH.</span></div></ix:continuation><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_34"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNC9mcmFnOjYyZDEzNWYzOTgxNDRmYmZiOTQ1NGQ1YmRjYWFiMTVjL3RleHRyZWdpb246NjJkMTM1ZjM5ODE0NGZiZmI5NDU0ZDViZGNhYWIxNWNfMjgxNA_d1a6a86c-d195-4422-8363-e2635de46a3d" continuedAt="iff2659a650df4ea5a09c79c4ae7ebc9c" escape="true">Summary of Significant Accounting Policies </ix:nonNumeric></span></div><ix:continuation id="iff2659a650df4ea5a09c79c4ae7ebc9c" continuedAt="i42eca00be7584facb452201fe0363c9b"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNC9mcmFnOjYyZDEzNWYzOTgxNDRmYmZiOTQ1NGQ1YmRjYWFiMTVjL3RleHRyZWdpb246NjJkMTM1ZjM5ODE0NGZiZmI5NDU0ZDViZGNhYWIxNWNfMjgxNQ_4caa8f32-de66-4ec1-9c2c-f98568bd08d3" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of December&#160;31, 2021 was derived from audited annual consolidated financial statements but does not include all annual disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021. The results of operations for the nine months ended September&#160;30, 2022 are not necessarily indicative of the results to be expected for the full year or any other future periods.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aurinia Pharma U.S., Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). All intercompany balances and transactions have been eliminated in consolidation and operate in <ix:nonFraction unitRef="segment" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNC9mcmFnOjYyZDEzNWYzOTgxNDRmYmZiOTQ1NGQ1YmRjYWFiMTVjL3RleHRyZWdpb246NjJkMTM1ZjM5ODE0NGZiZmI5NDU0ZDViZGNhYWIxNWNfMTQ5MQ_50af2f18-3db9-4955-87c9-7eabc98aa3fb">one</ix:nonFraction> segment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements are presented in U.S. dollars which is the Company's functional currency, therefore, there is no currency translation adjustment upon consolidation as the remeasurement of gains or losses are recorded in the condensed consolidated statements of operations. All assets and liabilities denominated in a foreign currency are remeasured into U.S. dollars at the exchange rate on the balance sheet date. Revenues and expenses are remeasured at the average exchange rate during the period. Foreign exchange gains and losses arising on translation or settlement of a foreign currency denominated monetary item are included in the condensed consolidated statements of operations.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i42eca00be7584facb452201fe0363c9b" continuedAt="i6041d4d630fc4189a6d08c7db74bb8bf">The Company is devoting the majority of our operational efforts and financial resources towards the commercialization and post approval commitments of our approved drug, LUPKYNIS. The Company is also expending efforts towards our newly acquired assets AUR200 and AUR300. Taking into consideration the Company's cash, cash equivalents, restricted cash and investments of $<ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-5" name="auph:CashCashEquivalentsAndDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNC9mcmFnOjYyZDEzNWYzOTgxNDRmYmZiOTQ1NGQ1YmRjYWFiMTVjL3RleHRyZWdpb246NjJkMTM1ZjM5ODE0NGZiZmI5NDU0ZDViZGNhYWIxNWNfMjYwMw_10d136df-c3a2-48c3-b024-70e263437060">376.6</ix:nonFraction> million as of September&#160;30, 2022, the Company believes that it has sufficient resources to fund its operations for at least the next few years beyond the date that the unaudited condensed consolidated financial statements are issued.</ix:continuation></span></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_37"></div><ix:continuation id="i6041d4d630fc4189a6d08c7db74bb8bf" continuedAt="i53c4bb15b8fe4030ba6d1607ec52f425"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as described below, the Company's significant accounting policies have not changed from those previously described in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNy9mcmFnOmNmMzVlY2YyZmU1ZjRmNDY5MWZmNTM0YmZkMzFhYjBkL3RleHRyZWdpb246Y2YzNWVjZjJmZTVmNGY0NjkxZmY1MzRiZmQzMWFiMGRfMzU2MQ_24254e40-c0d1-404c-996d-3be0be48c4ae" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Restricted cash consists of the 2021 Employee Share Purchase Plan (2021 ESPP) deposits of $<ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNy9mcmFnOmNmMzVlY2YyZmU1ZjRmNDY5MWZmNTM0YmZkMzFhYjBkL3RleHRyZWdpb246Y2YzNWVjZjJmZTVmNGY0NjkxZmY1MzRiZmQzMWFiMGRfMzM3_7a16d4e0-2cb4-4ca8-99e2-18ecde2ea393">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNy9mcmFnOmNmMzVlY2YyZmU1ZjRmNDY5MWZmNTM0YmZkMzFhYjBkL3RleHRyZWdpb246Y2YzNWVjZjJmZTVmNGY0NjkxZmY1MzRiZmQzMWFiMGRfMzQ0_7f4bc93b-2a77-4867-9b77-9935aacd583d">0.3</ix:nonFraction>&#160;million as of September&#160;30, 2022 and December&#160;31, 2021, respectively.</span></ix:nonNumeric></div><div style="margin-top:12pt;text-align:justify"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNy9mcmFnOmNmMzVlY2YyZmU1ZjRmNDY5MWZmNTM0YmZkMzFhYjBkL3RleHRyZWdpb246Y2YzNWVjZjJmZTVmNGY0NjkxZmY1MzRiZmQzMWFiMGRfMzU2Mw_81da4183-199b-4370-84a2-3da97676ef41" continuedAt="i3641ca9261c44d008e85d39e46488174" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Customers:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company currently has two main customers for U.S. commercial sales of LUPKYNIS and a collaboration partner for sales of LUPKYNIS in the EU, Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine (collectively, the "Otsuka Territories"). Revenues from the two main customers in the U.S. accounted in total of approximately <ix:nonFraction unitRef="number" contextRef="ie2b6cee70b84464499f7df7285aed325_D20220701-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNy9mcmFnOmNmMzVlY2YyZmU1ZjRmNDY5MWZmNTM0YmZkMzFhYjBkL3RleHRyZWdpb246Y2YzNWVjZjJmZTVmNGY0NjkxZmY1MzRiZmQzMWFiMGRfMzU5Ng_96a60ccd-48a8-4143-8aae-5678ab2b58d0">48</ix:nonFraction>% for the three months ended September&#160;30, 2022 and <ix:nonFraction unitRef="number" contextRef="i92eaeeead41c4c3486efa48480d9b63a_D20220101-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNy9mcmFnOmNmMzVlY2YyZmU1ZjRmNDY5MWZmNTM0YmZkMzFhYjBkL3RleHRyZWdpb246Y2YzNWVjZjJmZTVmNGY0NjkxZmY1MzRiZmQzMWFiMGRfNTQ5NzU1ODE3NTA4_fcaa2b79-e53c-48ac-be89-51855e28e114">74</ix:nonFraction>% for the nine months ended September&#160;30, 2022 of the Company's total revenues. Our collaboration partner for sales outside the U.S. accounted for approximately <ix:nonFraction unitRef="number" contextRef="ib9fbd2d01b054439a783e60189d0d151_D20220701-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNy9mcmFnOmNmMzVlY2YyZmU1ZjRmNDY5MWZmNTM0YmZkMzFhYjBkL3RleHRyZWdpb246Y2YzNWVjZjJmZTVmNGY0NjkxZmY1MzRiZmQzMWFiMGRfNTQ5NzU1ODE3ODY4_98c3ffb4-ceba-41c0-9b23-7049f1c53c64">52</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="id143a176c2d7418fa9b6975ad686ab0a_D20220101-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNy9mcmFnOmNmMzVlY2YyZmU1ZjRmNDY5MWZmNTM0YmZkMzFhYjBkL3RleHRyZWdpb246Y2YzNWVjZjJmZTVmNGY0NjkxZmY1MzRiZmQzMWFiMGRfNTQ5NzU1ODE3ODc2_d616c7fb-14c7-4a21-bd5a-406abb8e084a">26</ix:nonFraction>% for the three and nine months ended September&#160;30, 2022 of the Company's total revenues.</span></ix:nonNumeric></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3641ca9261c44d008e85d39e46488174">In late March 2022, we provided a nominal additional discount to both of our two main U.S. customers, applicable for the remainder of the 2022 calendar year, in connection with holding additional amounts of LUPKYNIS on hand due to supply chain concerns. Such discounts, or any future discounts, may result in reduced sales to these customers in subsequent periods and substantial fluctuations in our revenues from period to period. The Company monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances. Global economic conditions and customer specific factors may require the Company to periodically re-evaluate the collectability of its receivables and based on this evaluation the Company could potentially incur credit losses.</ix:continuation> </span></div><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNy9mcmFnOmNmMzVlY2YyZmU1ZjRmNDY5MWZmNTM0YmZkMzFhYjBkL3RleHRyZWdpb246Y2YzNWVjZjJmZTVmNGY0NjkxZmY1MzRiZmQzMWFiMGRfMzI5ODUzNDg5MjgxOA_5bd63648-33d8-40af-bdd1-9e7504fc1655" continuedAt="i72ed8604260b483b949f1ba7ed40b29e" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenues</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States (and territories), the Company sells LUPKYNIS primarily to specialty pharmacies and specialty distributors. These customers subsequently resell the Company's products to health care providers and patients. Revenues from product sales are recognized when the customer obtains control of our product, which typically occurs upon delivery to the customer. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for discounts and allowances: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's estimates of reserves established for variable consideration are calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant judgment is required in estimating variable consideration. In making these estimates, we consider historical data, including patient mix and inventory sold to our customers that has not yet been dispensed. We use a data aggregator and historical claims to estimate variable consideration for inventory sold to our customers, including specialty pharmacies and specialty distributors, that has not yet been dispensed. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjust these estimates, which could have an effect on earnings in the period of adjustment. As of September&#160;30, 2022, we did not have any material adjustments to estimates based on actual results. These specific adjustments are detailed further in our Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the inception of each arrangement that includes development or commercial sales milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i53c4bb15b8fe4030ba6d1607ec52f425" continuedAt="ie172d74b65b440ae80a504f79389a50e"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i72ed8604260b483b949f1ba7ed40b29e">included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment. Any consideration related to sales-based royalties (and sales-based milestones) will be recognized when the related sales occur.</ix:continuation> As of September&#160;30, 2022, we recognized $<ix:nonFraction unitRef="usd" contextRef="ic5a4159b186c46bdae3c4c7db5a48d91_D20220101-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNy9mcmFnOmNmMzVlY2YyZmU1ZjRmNDY5MWZmNTM0YmZkMzFhYjBkL3RleHRyZWdpb246Y2YzNWVjZjJmZTVmNGY0NjkxZmY1MzRiZmQzMWFiMGRfNTQ5NzU1ODIyODEy_8d13aa73-9a06-4eac-8a01-e024c062d4ef">30.0</ix:nonFraction>&#160;million for the regulatory milestone related to the EC marketing authorization of LUPKYNIS.</span></div><div style="margin-top:12pt;text-align:justify"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNy9mcmFnOmNmMzVlY2YyZmU1ZjRmNDY5MWZmNTM0YmZkMzFhYjBkL3RleHRyZWdpb246Y2YzNWVjZjJmZTVmNGY0NjkxZmY1MzRiZmQzMWFiMGRfMzU2NA_59812e18-705c-4a2f-93c7-a006d50c8136" continuedAt="i98ce9ce716e745b9947f8498fbb0d830" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable, net:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accounts receivable are stated at their net realizable value. The Company's accounts receivable represents amounts due to the Company from product sales and from its Otsuka collaboration agreement (Note 12). Milestone payments that have not been invoiced as of the balance sheet date are recorded as unbilled accounts receivable. As of September&#160;30, 2022 and December&#160;31, 2021, accounts receivable, net are $<ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-5" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNy9mcmFnOmNmMzVlY2YyZmU1ZjRmNDY5MWZmNTM0YmZkMzFhYjBkL3RleHRyZWdpb246Y2YzNWVjZjJmZTVmNGY0NjkxZmY1MzRiZmQzMWFiMGRfMTY4MQ_dbc0d206-73ea-4c0c-b7bb-c3b0769a26f1">41.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-5" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNy9mcmFnOmNmMzVlY2YyZmU1ZjRmNDY5MWZmNTM0YmZkMzFhYjBkL3RleHRyZWdpb246Y2YzNWVjZjJmZTVmNGY0NjkxZmY1MzRiZmQzMWFiMGRfMTY4OA_99670b5f-66a3-42f1-8812-9adccdb48d9c">15.4</ix:nonFraction> million. The accounts receivable, net as of September&#160;30, 2022 includes $<ix:nonFraction unitRef="usd" contextRef="i248fcdd355b64b138d9e8363df09e99f_I20220930" decimals="-5" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNy9mcmFnOmNmMzVlY2YyZmU1ZjRmNDY5MWZmNTM0YmZkMzFhYjBkL3RleHRyZWdpb246Y2YzNWVjZjJmZTVmNGY0NjkxZmY1MzRiZmQzMWFiMGRfNjA0NzMxMzk2Nzc1MA_1cee654d-7375-440e-a8fa-a1d47d9679d3">28.8</ix:nonFraction> million due from Otsuka related to the achievement of a regulatory milestone in September 2022, for which payment was received on October 31, 2022. </span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing between the recognition of revenue for product sales and the receipt of payment is not significant. Our standard credit terms range from <ix:nonNumeric contextRef="i16cb885c9c784f19a3fb5c186669134a_D20220101-20220930" name="auph:AccountsReceivableCreditTerm" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNy9mcmFnOmNmMzVlY2YyZmU1ZjRmNDY5MWZmNTM0YmZkMzFhYjBkL3RleHRyZWdpb246Y2YzNWVjZjJmZTVmNGY0NjkxZmY1MzRiZmQzMWFiMGRfMTg0MQ_e0f6bf25-9751-451d-a2da-c886458dc9cc">30</ix:nonNumeric> to <ix:nonNumeric contextRef="i97636c4925384d11aa8a85148d437f88_D20220101-20220930" name="auph:AccountsReceivableCreditTerm" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNy9mcmFnOmNmMzVlY2YyZmU1ZjRmNDY5MWZmNTM0YmZkMzFhYjBkL3RleHRyZWdpb246Y2YzNWVjZjJmZTVmNGY0NjkxZmY1MzRiZmQzMWFiMGRfMTg0Nw_6a60ffd9-3664-4312-a666-ed61ffb31c33">45</ix:nonNumeric> days. We do not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between the transfer of the promised good to the customer and receipt of payment will be one year or less. </span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i98ce9ce716e745b9947f8498fbb0d830">We estimate the allowance for doubtful accounts using the current expected credit loss, or CECL, model. Under the CECL model, the allowance for doubtful accounts reflects the net amount expected to be collected from the account receivables. We evaluate the collectability of these cash flows based on the asset&#8217;s amortized cost, the risk of loss even when that risk is remote, losses over an asset&#8217;s contractual life, and other relevant information available to us. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. The allowance for doubtful accounts was $<ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNy9mcmFnOmNmMzVlY2YyZmU1ZjRmNDY5MWZmNTM0YmZkMzFhYjBkL3RleHRyZWdpb246Y2YzNWVjZjJmZTVmNGY0NjkxZmY1MzRiZmQzMWFiMGRfMjczOQ_305492cf-8b10-41da-bcba-59ee8cf23ebc"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNy9mcmFnOmNmMzVlY2YyZmU1ZjRmNDY5MWZmNTM0YmZkMzFhYjBkL3RleHRyZWdpb246Y2YzNWVjZjJmZTVmNGY0NjkxZmY1MzRiZmQzMWFiMGRfMjczOQ_c69438a3-e2ef-4df3-b2d8-a137088871f7">nil</ix:nonFraction></ix:nonFraction> as of September&#160;30, 2022 and as of December&#160;31, 2021</ix:continuation>.</span></div><div style="margin-top:12pt;text-align:justify"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNy9mcmFnOmNmMzVlY2YyZmU1ZjRmNDY5MWZmNTM0YmZkMzFhYjBkL3RleHRyZWdpb246Y2YzNWVjZjJmZTVmNGY0NjkxZmY1MzRiZmQzMWFiMGRfMzU2NQ_71701bde-6c4f-44f8-8146-f090983a6f91" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Compensation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows ASC Topic 718, Compensation - Stock Compensation (ASC 718), which requires the measurement and recognition of compensation expense, based on estimated fair values, for all share-based awards made to employees and directors. The Company records compensation expense based on the fair value on the grant date using the graded accelerated vesting method for all share-based payments related to stock options, performance awards (PAs), restricted stock units (RSUs) and purchases under the Company's 2021 ESPP. For stock options, forfeitures are estimated based on historical experience at the time of grant and revised in subsequent periods if actual forfeitures differ from those estimates. For RSUs and PAs, forfeitures are accounted for as they occur.</span></ix:nonNumeric></div></ix:continuation><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_40"></div><ix:continuation id="ie172d74b65b440ae80a504f79389a50e"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180MC9mcmFnOjFjZTg3YzQyYmFmYjQ2YmZhMzJlYzVmYTYzZGI0MzY0L3RleHRyZWdpb246MWNlODdjNDJiYWZiNDZiZmEzMmVjNWZhNjNkYjQzNjRfMTQ2MQ_c027534c-3bf8-463c-89e8-727a37690123" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently adopted accounting pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 740): Simplifying the Accounting for Income Taxes, which clarifies and simplifies certain aspects of the accounting for income taxes such as eliminating the exception to the general intraperiod tax allocation principle. The standard is effective for years beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2020. The Company adopted the ASU effective January 1, 2021, with no material impact on the condensed consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, which requires business entities to make annual disclosures about transactions with a government (including government assistance) by analogizing to a grant or contribution accounting model. The required disclosures include the nature of the transaction, the entity's related accounting policy, the financial statement line items affected and the amounts reflected in the current period financial statements, as well as any significant terms and conditions. The guidance is effective for financial statements issued for annual periods beginning after December 15, 2021. The Company adopted the ASU effective January 1, 2022, with no material impact on the condensed consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_43"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RleHRyZWdpb246ZWI2YmU1NzM2MDExNDA3NTg2OTg3Zjc2YzRmMDUwOWFfMzA1NA_08985075-d69b-4e47-91ff-917edcdef018" continuedAt="i389689e3b2a84f2ea8449bf7c798f781" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i389689e3b2a84f2ea8449bf7c798f781" continuedAt="i2671a5e9f5764723aa7a953288bada18"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist primarily of cash and cash equivalents, short-term investments, accounts receivable, accounts payable and accrued liabilities. The carrying value of accounts receivable, accounts payable and accrued liabilities approximate their fair value because of their short-term nature. Estimated fair value of available-for-sale securities are generally based on prices obtained from commercial pricing services.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i2671a5e9f5764723aa7a953288bada18"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8217;s assumptions about how market participants would price assets and liabilities). As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 1 - Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 2 - Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 3 - Unobservable inputs that reflect the reporting entity&#8217;s own assumptions.</span></div><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RleHRyZWdpb246ZWI2YmU1NzM2MDExNDA3NTg2OTg3Zjc2YzRmMDUwOWFfMzA1NQ_4f687540-50c8-4d56-8eae-335fab36b322" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the financial assets (cash, cash equivalents, restricted cash and short-term investments) measured at fair value on a recurring basis:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ff9e818dc3248f3a984013c0ec35cb4_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfMy0yLTEtMS02ODc5NQ_0f58a6a8-e9e9-429a-aa29-637c80e7ba2c">86,052</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45420271e8ea4082b3d52812ce062bcd_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfMy00LTEtMS02ODc5NQ_35f2d719-f00b-4580-836a-bed530bac936">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5b00f6af1a1489ca4e19effbd717dc7_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfMy02LTEtMS02ODc5NQ_f6912df7-c7b7-45b8-8d6a-b558024cdfbb">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id57531e234234b2b9cb0d8e02f891cfd_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfMy04LTEtMS02ODc5NQ_1fd7da1e-5ddd-4efc-bb55-a86846f4ffb8">86,052</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency security</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibabafbb16aec41b1915f48581e656afd_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfNC0yLTEtMS02ODc5NQ_13c04e29-a57b-497c-9cb8-2719aa54c08a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f27ddb9f76a467b94259faf2e7e0317_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfNC00LTEtMS02ODc5NQ_89cac281-f637-4451-bfa2-c0ab79444141">4,904</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8d7c6306b94e968ff4f645fa32aea3_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfNC02LTEtMS02ODc5NQ_27d4de28-2cfa-4350-9cb4-034d91f6eb60">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idda7e1c04624428eb78cb35510f9fa7f_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfNC04LTEtMS02ODc5NQ_f2f30ae7-f227-4d1c-b2d2-34505b65ee1d">4,904</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a6083a877744937bdaec6596e628a5e_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfNS0yLTEtMS02ODc5NQ_3dc4d6c9-40bd-4ff0-8539-bffc73f98f7a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib545381e546241bfb7702079a5b4ae46_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfNS00LTEtMS02ODc5NQ_e31a10ac-d6e8-4db3-9970-89b1796d3832">98,068</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia75ddf3673b0477d801dd590a53168cd_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfNS02LTEtMS02ODc5NQ_f543e973-f658-4cd5-b208-b555dd24ddb1">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a88e33246a947da84b61da9acf16369_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfNS04LTEtMS02ODc5NQ_8487c157-3d10-48fb-98e6-d50c4d3756a0">98,068</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64fba90d628a47388702c84b97bf7d7a_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfNi0yLTEtMS02ODc5NQ_918ecd8b-7aa0-48cc-9553-eb81d8bdbdd4">112,633</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa631ff412fa4ce5999335712a18dd4e_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfNi00LTEtMS02ODc5NQ_6cc77c21-200b-45f0-b28b-062c97f8080d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4bd4b996a4d4872b3fac48673a43a27_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfNi02LTEtMS02ODc5NQ_70bea9e4-3d7d-428d-9805-f88de570bc8a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9f1f2ee39a841c18e4e03be170e2977_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfNi04LTEtMS02ODc5NQ_a7dc80df-e5c8-4055-8e9b-b10793e8d540">112,633</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6d26265caac4b03ac1c32ac9b0d215c_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfNy0yLTEtMS02ODc5NQ_e7be56ae-b592-4c21-b4db-b0f66b8011db">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieafdf4a188174114bc1155f63c1daa4d_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfNy00LTEtMS02ODc5NQ_7a7dade0-a3cc-44e9-803a-f16cd9805969">26,704</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i669c0d32fa12413e948255d28b9891a2_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfNy02LTEtMS02ODc5NQ_23311e05-fa7e-409b-8d96-9edb4d5bc170">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a7d157907c4446a83d6762c688bc37_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfNy04LTEtMS02ODc5NQ_60301726-6033-453f-ac78-3db82bb672e3">26,704</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bond</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d9ec18821a143c0b5342802f48f6311_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfOC0yLTEtMS02ODc5NQ_f04f8a1b-06a8-4567-8fe3-5cbb4998a35e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64661310650543b4a59ec68285dc9734_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfOC00LTEtMS02ODc5NQ_d1e4a774-6ef4-4de4-8d86-c6e40fcd9f8f">44,553</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i119daddb27794e028c6e80587444d5ad_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfOC02LTEtMS02ODc5NQ_618838dd-f137-4b56-9e27-b43f86bee238">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i879c4a29d0b4430fa56ad47b590225c2_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfOC04LTEtMS02ODc5NQ_9b1aa131-159b-4344-aa31-de4bc8905a32">44,553</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yankee bond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c5b7f81c61c4e96ac98e4766d33339a_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfOS0yLTEtMS02ODc5NQ_3162cad1-d375-45f1-9bb4-12d9102b0fa6">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9178f49b5784f9aba75be7f38379650_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfOS00LTEtMS02ODc5NQ_85fb6444-a11d-41af-983a-63192cc8cee6">3,730</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb9283d88b424c60b9b3d5353d69a897_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfOS02LTEtMS02ODc5NQ_713e2211-180e-427c-bccc-9a621363ce5a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20cb6a6c7b9e4a5380a7381cd01eeee6_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfOS04LTEtMS02ODc5NQ_e3957fc1-06db-44e0-ba2a-8e97f7ab840f">3,730</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5b6a1ae596438681cfbfdf9892f83d_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfMTAtMi0xLTEtNjg3OTU_a6687f8a-df76-42a0-8b76-95a0127c2707">198,685</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id28bab9c7e1c4295b873580752711af5_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfMTAtNC0xLTEtNjg3OTU_cf4d65dc-a9b9-4cfb-9c5b-095e832631e2">177,959</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e1087e0598412981eb9152d79b6b14_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfMTAtNi0xLTEtNjg3OTU_82bc9610-4a27-492c-9d64-b2fcc3f06c11">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfMTAtOC0xLTEtNjg3OTU_ab8fc484-1320-4b5a-aeaa-18cc1c125635">376,644</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i565005420cf94f52b9804cec98cee107_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfMy0yLTEtMS02ODc5NQ_1da3ebaf-d65d-4761-82e0-a969812f3c96">231,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i615ccd0cba2748fb9fcffb4adcc668be_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfMy00LTEtMS02ODc5NQ_bc5d9569-72cd-4c08-ba9f-4cf55fedcb20">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i734f0c5aa1b846b08acb4ccd89a87f39_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfMy02LTEtMS02ODc5NQ_9f53e8a0-0c92-4e8f-bb79-888846adca74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i263f1cbad4dd43fcb51ad6c9abe11101_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfMy04LTEtMS02ODc5NQ_e040f6d8-a34b-44a0-888f-59f5312ac468">231,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b5b0fee0d3a410eb5fe646815a1df0d_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfNC0yLTEtMS02ODc5NQ_ce7d2fc1-8f2c-486e-bfc4-0327812a1ee9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37d4bff646e04f7f80b9a75717f9fea4_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfNC00LTEtMS02ODc5NQ_dbfd7c18-517a-411f-a5b2-03fe77de7b1b">3,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a260d1645884811bafbb0ac61e2190b_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfNC02LTEtMS02ODc5NQ_823df57a-f73f-4d33-9eab-4bac48419769">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64ab53854b6748a49a313e183035fb12_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfNC04LTEtMS02ODc5NQ_942c4a9a-42e8-4bd1-9e89-6893c7891c2d">3,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6ca842beffc422d80be5664771bc026_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfNS0yLTEtMS02ODc5NQ_fa25dab5-d465-4cb8-8261-1480494f8535">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4804d6f12b174250ace2bb6d08b12a0e_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfNS00LTEtMS02ODc5NQ_55f4450f-69d9-4034-b5b8-d156fee80e8d">21,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87306c1797ef420a8944c1b4d0ff89c4_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfNS02LTEtMS02ODc5NQ_7f076051-86d7-4c13-b943-fbc61dedc865">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c5de38286e74db18b18df7f49cac2d3_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfNS04LTEtMS02ODc5NQ_1eb3da97-d273-415b-afe5-1a50df6525c1">21,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbdc367dda2942d19a94e15c46320342_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfNi0yLTEtMS02ODc5NQ_a4e3750c-1a4a-4c4a-a67b-fd00882246fa">206,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if20a77aa2fc04f8a96554bede25f9d7c_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfNi00LTEtMS02ODc5NQ_656b7ace-ef5d-49c3-9748-0ec1c4198d4f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7fb0798462249e3a2d60ca4407e0eab_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfNi02LTEtMS02ODc5NQ_f65052b6-faa8-48a5-bfe2-9b8774b38666">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8af1b2c873d0434eaf8b9108131f9009_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfNi04LTEtMS02ODc5NQ_48c7015d-35df-4d44-8a19-056043ee5542">206,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d4826b176e435f8bd5b0030feb4952_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfNy0yLTEtMS02ODc5NQ_02e5b54e-9708-474f-ad1c-1adc032f77e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59210d4302394347a4104d3d57a6934b_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfNy00LTEtMS02ODc5NQ_d1a643eb-9f6c-4cb7-bc3f-4cb774ffd556">2,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf503387569145268e73f2bf99c3cba4_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfNy02LTEtMS02ODc5NQ_1dfaacd5-97ea-4de5-b692-9ba0604c74d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i904ede1b4aeb489099791792b04faf0e_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfNy04LTEtMS02ODc5NQ_934e28aa-7604-4138-81ce-6cf38c1c0278">2,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i938ca9c21c994394a2ac416a16c72176_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfOC0yLTEtMS02ODc5NQ_539f0880-1737-489e-8571-b0e46bc2f259">438,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19c0b5fabb074b7692f8a2ab582c6da6_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfOC00LTEtMS02ODc5NQ_889a28db-b709-4bc4-b8e6-81936370381c">27,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i477353e441ec446e872a95c69aab7d85_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfOC02LTEtMS02ODc5NQ_8b14add2-c433-4f66-b7ab-cc0610a7db73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfOC04LTEtMS02ODc5NQ_00c64c1a-8a25-4a6f-80d1-e2a7aee3081d">466,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Level 1 instruments include cash, cash equivalents, restricted cash and commercial paper that are valued using quoted market prices. We estimate the fair values of our investments in corporate debt securities, government and government related securities and certificates of deposits by taking into consideration valuations obtained from third-party pricing services. The fair value of our short-term investments classified within Level 2 is based upon observable inputs that may include benchmark yield curves, reported trades, issuer spreads, benchmark securities and reference data including market research publications. At September&#160;30, 2022, and December&#160;31, 2021, the weighted average remaining contractual maturities of our Level 1 and 2 investments were approximately for <ix:nonNumeric contextRef="if1d1a617e2e74074ae1e4ccd6de119b5_D20220101-20220930" name="us-gaap:DerivativeAverageRemainingMaturity1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RleHRyZWdpb246ZWI2YmU1NzM2MDExNDA3NTg2OTg3Zjc2YzRmMDUwOWFfMjE5OTAyMzI1ODc0Mg_0e3ee853-fe6b-4045-af9e-afc7cc5ed9db"><ix:nonNumeric contextRef="ib0a72a6a58e04c6dbc7123f06753286b_D20220101-20220930" name="us-gaap:DerivativeAverageRemainingMaturity1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RleHRyZWdpb246ZWI2YmU1NzM2MDExNDA3NTg2OTg3Zjc2YzRmMDUwOWFfMjE5OTAyMzI1ODc0Mg_1132c95e-fa13-4e45-ac18-1534489b700e">7</ix:nonNumeric></ix:nonNumeric> months and <ix:nonNumeric contextRef="ia851cc9f46674b05af88b96945f0cb85_D20210101-20211231" name="us-gaap:DerivativeAverageRemainingMaturity1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RleHRyZWdpb246ZWI2YmU1NzM2MDExNDA3NTg2OTg3Zjc2YzRmMDUwOWFfNTQ5NzU1ODE3Mjkx_43f50693-824b-4035-bc78-318ee7e808ce"><ix:nonNumeric contextRef="ib711a46ca0504a0f83970696c2b2069c_D20210101-20211231" name="us-gaap:DerivativeAverageRemainingMaturity1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RleHRyZWdpb246ZWI2YmU1NzM2MDExNDA3NTg2OTg3Zjc2YzRmMDUwOWFfNTQ5NzU1ODE3Mjkx_e525f9c3-8960-4bb2-8156-5ad275892543">8</ix:nonNumeric></ix:nonNumeric> months, respectively. These investments have an overall rating of A-1, or higher, by Moody&#8217;s, Standard &amp; Poor&#8217;s and Fitch.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No credit loss allowance was recorded as of September&#160;30, 2022, as we do not believe the unrealized loss is a result of a credit loss due to the nature of our investments. We also considered the current and expected future economic and market conditions and determined that the estimate of credit losses was not significantly impacted.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 4, &#8220;Cash, Cash Equivalents, Restricted Cash and Short-Term Investments,&#8221; for the carrying amount and related unrealized gains (losses) by type of investment.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RleHRyZWdpb246M2I2NmFlYjhmZDQxNDIxMmJiYjRkN2Q3NTQ3NTRiYjJfMTMwNw_896c34bc-d3fd-4575-be9c-dcf465a8cb51" continuedAt="i57a08bea5ebc4f4d902f1b52f1f61f0a" escape="true">Cash, Cash Equivalents, Restricted Cash and Short-Term Investments</ix:nonNumeric></span></div><ix:continuation id="i57a08bea5ebc4f4d902f1b52f1f61f0a" continuedAt="i008915d73d2d4b02a181f87ab526e292"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022 and December&#160;31, 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-5" name="auph:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RleHRyZWdpb246M2I2NmFlYjhmZDQxNDIxMmJiYjRkN2Q3NTQ3NTRiYjJfMTA4_b282e28c-6aad-43a0-9b00-cea734aaab7e">376.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-5" name="auph:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RleHRyZWdpb246M2I2NmFlYjhmZDQxNDIxMmJiYjRkN2Q3NTQ3NTRiYjJfMTE1_9bb8aa69-57bb-4f9b-a7fc-956e0515be96">466.1</ix:nonFraction> million, respectively of cash, cash equivalents, restricted cash and short-term investments summarized below. As of September&#160;30, 2022, $<ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RleHRyZWdpb246M2I2NmFlYjhmZDQxNDIxMmJiYjRkN2Q3NTQ3NTRiYjJfMzcz_5e6f8d7e-b0ee-4aae-9137-6cfd953185ee">376.6</ix:nonFraction> million were available-for-sale debt securities which are carried at fair market value. As of December&#160;31, 2021, $<ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RleHRyZWdpb246M2I2NmFlYjhmZDQxNDIxMmJiYjRkN2Q3NTQ3NTRiYjJfNDY1_01672470-c976-41d3-8460-d971e982a33b">446.9</ix:nonFraction> million were classified as available-for-sale and $<ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RleHRyZWdpb246M2I2NmFlYjhmZDQxNDIxMmJiYjRkN2Q3NTQ3NTRiYjJfNTEw_0f084000-198d-47e0-963c-4455deaed013">19.2</ix:nonFraction> million were held-to-maturity. </span></div><div style="text-align:justify"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:MarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RleHRyZWdpb246M2I2NmFlYjhmZDQxNDIxMmJiYjRkN2Q3NTQ3NTRiYjJfMTMwNg_5251ef9e-0071-478b-b5f6-64f2fc2891ce" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.660%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id57531e234234b2b9cb0d8e02f891cfd_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMi0yLTEtMS02ODc5NQ_292380e1-2a0b-4b54-a167-d5d554ec7b4d">86,052</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id57531e234234b2b9cb0d8e02f891cfd_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMi00LTEtMS02ODc5NQ_fdf4a2cf-f4fe-4883-a8b3-f5d11a69c18b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id57531e234234b2b9cb0d8e02f891cfd_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMi02LTEtMS02ODc5NQ_e9284e29-627c-4b38-b5b4-ecda05fce5da">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id57531e234234b2b9cb0d8e02f891cfd_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMi04LTEtMS02ODc5NQ_e7e8b5a1-e30b-46f5-8d6e-796692d9e606">86,052</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency security</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12201e4c78d14b7fa31409f5abef573b_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMy0yLTEtMS02ODc5NQ_3d78ac5a-b748-40b3-be54-fb6aa0fd5673">4,900</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12201e4c78d14b7fa31409f5abef573b_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMy00LTEtMS02ODc5NQ_6009cb0e-ee76-4512-a214-0d6d6e3f1f9b">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12201e4c78d14b7fa31409f5abef573b_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMy02LTEtMS02ODc5NQ_b7156f0c-ed55-4c9f-b8ce-ee5c62f4c450">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12201e4c78d14b7fa31409f5abef573b_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMy04LTEtMS02ODc5NQ_95ccb73f-a2b3-4eb7-9ff1-b5300d16d98e">4,904</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bond</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43c8446460754675965bbc2c13bac604_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfNC0yLTEtMS02ODc5NQ_155c3f9e-6d16-4436-8c23-3c4cb701bf3b">98,448</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43c8446460754675965bbc2c13bac604_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfNC00LTEtMS02ODc5NQ_f2df411a-329c-4b29-af03-ca8ca2bdfa3f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i43c8446460754675965bbc2c13bac604_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfNC02LTEtMS02ODc5NQ_4cfd8961-74ea-4471-9c3f-5141b7a484bf">380</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43c8446460754675965bbc2c13bac604_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfNC04LTEtMS02ODc5NQ_8200aec7-5e42-44a5-a802-fab1f394e0dd">98,068</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9f1f2ee39a841c18e4e03be170e2977_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfNS0yLTEtMS02ODc5NQ_057b2520-e009-42df-a96b-6f161b8095c1">112,833</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9f1f2ee39a841c18e4e03be170e2977_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfNS00LTEtMS02ODc5NQ_8db69ca7-f7ee-4d26-8381-d16936cef70b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9f1f2ee39a841c18e4e03be170e2977_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfNS02LTEtMS02ODc5NQ_0ff6fd58-6471-48a7-976c-948240f2f6cc">200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9f1f2ee39a841c18e4e03be170e2977_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfNS04LTEtMS02ODc5NQ_aeb3c0c2-47ff-4b6e-9ad0-9fa4d3a43bd7">112,633</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a7d157907c4446a83d6762c688bc37_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfNi0yLTEtMS02ODc5NQ_c8a388e3-f323-4c5f-9f2e-4481a5111076">26,721</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a7d157907c4446a83d6762c688bc37_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfNi00LTEtMS02ODc5NQ_5a10dd7b-e5f4-40f6-b3e2-062bc2b38f1f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9a7d157907c4446a83d6762c688bc37_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfNi02LTEtMS02ODc5NQ_dc08edf0-dc07-41b3-a082-782f75b7dd04">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a7d157907c4446a83d6762c688bc37_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfNi04LTEtMS02ODc5NQ_6688f986-1a6d-4f2a-b004-6546fe683683">26,704</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i879c4a29d0b4430fa56ad47b590225c2_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfNy0yLTEtMS02ODc5NQ_e93b5f19-fa0e-45fb-be64-f0609e935958">44,670</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i879c4a29d0b4430fa56ad47b590225c2_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfNy00LTEtMS02ODc5NQ_e6024505-6829-42e1-b97d-cba8e94b0ad7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i879c4a29d0b4430fa56ad47b590225c2_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfNy02LTEtMS02ODc5NQ_6ef3e60b-2ecc-497e-b5bd-1d6cd414b512">117</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i879c4a29d0b4430fa56ad47b590225c2_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfNy04LTEtMS02ODc5NQ_5b9d3e61-4404-4b2b-a26d-fe8024ee28dd">44,553</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yankee bond</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20cb6a6c7b9e4a5380a7381cd01eeee6_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfOC0yLTEtMS02ODc5NQ_f74cbc3e-e80e-48b2-a6f7-c24eae84cdb1">3,742</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20cb6a6c7b9e4a5380a7381cd01eeee6_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfOC00LTEtMS02ODc5NQ_1c99b2c0-ee6a-4e2c-9f1a-fa1beca708a0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20cb6a6c7b9e4a5380a7381cd01eeee6_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfOC02LTEtMS02ODc5NQ_f5dcefa6-5cd2-4447-adde-0ec440b638e9">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20cb6a6c7b9e4a5380a7381cd01eeee6_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfOC04LTEtMS02ODc5NQ_7b16b480-e8b0-4fd3-ac8d-8462b77c1d08">3,730</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash and short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfOS0yLTEtMS02ODc5NQ_e9e1b46d-7af4-4891-a5b8-1ea71033832b">377,366</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfOS00LTEtMS02ODc5NQ_c44f819e-e063-4ef2-bbb3-f9d94d09a593">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfOS02LTEtMS02ODc5NQ_21b8d7da-51c2-4cde-8ee0-ad375ff46e27">726</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfOS04LTEtMS02ODc5NQ_ad2365d4-7121-402e-bb7f-a2d3729fe70d">376,644</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i263f1cbad4dd43fcb51ad6c9abe11101_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTUtMi0xLTEtNjg3OTU_3160bbe2-e915-4d71-bd5e-bb073ef2db01">231,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i263f1cbad4dd43fcb51ad6c9abe11101_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTUtNC0xLTEtNjg3OTU_c4af9328-203d-4d08-a9c2-57493cbe7294">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i263f1cbad4dd43fcb51ad6c9abe11101_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTUtNi0xLTEtNjg3OTU_d36fa762-9d74-4708-80ae-7d5356ef2b3a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i263f1cbad4dd43fcb51ad6c9abe11101_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTUtOC0xLTEtNjg3OTU_42789cfc-a373-4a72-b49b-432dd3ec5440">231,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64ab53854b6748a49a313e183035fb12_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTYtMi0xLTEtNjg3OTU_2cdd382c-f619-45a2-8037-c0a6b29f2cf6">3,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64ab53854b6748a49a313e183035fb12_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTYtNC0xLTEtNjg3OTU_304c4be7-16d3-4818-a5b5-be415f493fa4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64ab53854b6748a49a313e183035fb12_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTYtNi0xLTEtNjg3OTU_dab8ce03-2a52-4a13-ab6d-60b1dd87bca1">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64ab53854b6748a49a313e183035fb12_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTYtOC0xLTEtNjg3OTU_a8f30e72-702d-4a79-992c-dc0b20892842">3,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bond</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e7b23d46c544fc184d25711658db577_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTctMi0xLTEtNjg3OTU_d517519b-a15e-406b-a732-cf0962901419">2,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e7b23d46c544fc184d25711658db577_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTctNC0xLTEtNjg3OTU_78e30e68-b8de-45f4-af31-8a5dafc8d579">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e7b23d46c544fc184d25711658db577_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTctNi0xLTEtNjg3OTU_7e3246bc-dee0-48ea-8015-66a3c1995b91">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e7b23d46c544fc184d25711658db577_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTctOC0xLTEtNjg3OTU_10538dd6-ef3f-4610-aaec-9e946b38a0fd">2,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8af1b2c873d0434eaf8b9108131f9009_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTgtMi0xLTEtNjg3OTU_80286073-e2ca-4d27-9e63-d59721a7fbc1">206,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8af1b2c873d0434eaf8b9108131f9009_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTgtNC0xLTEtNjg3OTU_37cd595b-dda7-4a6b-b4ba-116fd25c51d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8af1b2c873d0434eaf8b9108131f9009_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTgtNi0xLTEtNjg3OTU_afcfaa68-d614-46c4-a3f9-22408ed1b3e3">40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8af1b2c873d0434eaf8b9108131f9009_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTgtOC0xLTEtNjg3OTU_60b2e566-0e3f-4d41-943b-168e77caa70e">206,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i904ede1b4aeb489099791792b04faf0e_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTktMi0xLTEtNjg3OTU_b31385c0-c4b8-49a5-883f-bc58446406a6">2,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i904ede1b4aeb489099791792b04faf0e_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTktNC0xLTEtNjg3OTU_fc6041de-c124-4a40-8e9b-ba8661720b21">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i904ede1b4aeb489099791792b04faf0e_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTktNi0xLTEtNjg3OTU_e9bddc5a-e208-4774-bb9b-f58dd64d7a45">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i904ede1b4aeb489099791792b04faf0e_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTktOC0xLTEtNjg3OTU_49ea8984-c1f6-44a7-94ae-bf0bdffd7b87">2,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMjItMi0xLTEtNjg3OTU_6687bdf2-2fb9-41ac-87f9-1c6e26f53498">446,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMjItNC0xLTEtNjg3OTU_935476cc-9a1d-4a71-9f64-855f4dd9d7c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMjItNi0xLTEtNjg3OTU_6bcdf914-cdfc-4a11-80f2-bfc0b7c35d66">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMjItOC0xLTEtNjg3OTU_cb69bee1-79c1-4757-9e5e-002fa5e29bb6">446,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total held to maturity securities at amortized cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMjMtOC0xLTEtNjg3OTU_34089a43-d35e-475e-a4c0-c9f56a7e820f">19,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash and short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="auph:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMjQtOC0xLTEtNjg3OTU_21b7fa22-00b5-4f89-a44b-7d0f3508228b">466,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022 and December&#160;31, 2021, accrued interest receivable from the investments were $<ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-5" name="us-gaap:InterestReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RleHRyZWdpb246M2I2NmFlYjhmZDQxNDIxMmJiYjRkN2Q3NTQ3NTRiYjJfNjEx_9d5a7087-0cf3-402f-a925-1c6d51015b47">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-5" name="us-gaap:InterestReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RleHRyZWdpb246M2I2NmFlYjhmZDQxNDIxMmJiYjRkN2Q3NTQ3NTRiYjJfNjE4_21fc23e6-5b08-49f0-a154-bb8dd7139507">0.1</ix:nonFraction> million, respectively. During the three and nine months ended September&#160;30, 2022, the Company had $<ix:nonFraction unitRef="usd" contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RleHRyZWdpb246M2I2NmFlYjhmZDQxNDIxMmJiYjRkN2Q3NTQ3NTRiYjJfNTQ5NzU1ODE3MjE2_73ee6758-7b6e-447c-bf3c-de96fba404ac">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RleHRyZWdpb246M2I2NmFlYjhmZDQxNDIxMmJiYjRkN2Q3NTQ3NTRiYjJfNzAx_c27bd659-e4b4-42d6-a805-f33ba0a4e5ce">0.7</ix:nonFraction> million unrealized gains and losses on available-for-sale securities, net of tax, respectively, which are included as a component of comprehensive loss on the consolidated statements of operations. Currently, the Company does not intend to sell investments that are in an unrealized loss position, and it is unlikely we will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. We have determined that the gross unrealized losses on our investments at September&#160;30, 2022, were temporary in nature. Realized gains or losses were immaterial during the three and nine months ended September&#160;30, 2022 and 2021.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i008915d73d2d4b02a181f87ab526e292">The Company's short-term investments as of September&#160;30, 2022 mature at various dates through June 2023.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_52"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181Mi9mcmFnOjU2OTY2MzQ4ZGVmZDRmY2U4ZjdiOWRjZDdkZWNkMWE5L3RleHRyZWdpb246NTY5NjYzNDhkZWZkNGZjZThmN2I5ZGNkN2RlY2QxYTlfMTEzNw_5d4d993a-0e60-455b-9ecf-b9f665433822" continuedAt="i40f11319ffbc405aa628ae11db35bdf2" escape="true">Inventories, net</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i40f11319ffbc405aa628ae11db35bdf2" continuedAt="iaf4e1677698a49bd928e554e5c5fbabc">Inventories are valued under a standard costing methodology on a first-in, first-out basis and are stated at the lower of cost or net realizable value. The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs. Capitalized costs of inventories for LUPKYNIS mainly include third party manufacturing costs, transportation, storage, insurance, and allocated internal labor. </ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iaf4e1677698a49bd928e554e5c5fbabc"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses recoverability of inventory each reporting period to determine any write-down to net realizable value resulting from excess or obsolete inventories. As of September&#160;30, 2022, we have recorded reserves of finished goods inventories of approximately $<ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-5" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181Mi9mcmFnOjU2OTY2MzQ4ZGVmZDRmY2U4ZjdiOWRjZDdkZWNkMWE5L3RleHRyZWdpb246NTY5NjYzNDhkZWZkNGZjZThmN2I5ZGNkN2RlY2QxYTlfNTQ5NzU1ODE1Nzgz_3fc43d79-9600-433d-9694-aa9baf313b9d">2.7</ix:nonFraction> million which were primarily related to process validation batches used for FDA approval.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181Mi9mcmFnOjU2OTY2MzQ4ZGVmZDRmY2U4ZjdiOWRjZDdkZWNkMWE5L3RleHRyZWdpb246NTY5NjYzNDhkZWZkNGZjZThmN2I5ZGNkN2RlY2QxYTlfMTEzOA_2a9a15b5-bb3a-4b79-8c16-517d9ea852fd" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory, net are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181Mi9mcmFnOjU2OTY2MzQ4ZGVmZDRmY2U4ZjdiOWRjZDdkZWNkMWE5L3RhYmxlOjcxMjkyNjYwMzQ4YzQyODZhYmY3MzI0MTRlYTg0YjNlL3RhYmxlcmFuZ2U6NzEyOTI2NjAzNDhjNDI4NmFiZjczMjQxNGVhODRiM2VfMS0yLTEtMS02ODc5NQ_e4b86337-11f2-441b-b3f6-9baba78df695">2,217</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181Mi9mcmFnOjU2OTY2MzQ4ZGVmZDRmY2U4ZjdiOWRjZDdkZWNkMWE5L3RhYmxlOjcxMjkyNjYwMzQ4YzQyODZhYmY3MzI0MTRlYTg0YjNlL3RhYmxlcmFuZ2U6NzEyOTI2NjAzNDhjNDI4NmFiZjczMjQxNGVhODRiM2VfMS00LTEtMS02ODc5NQ_4e6c673f-dc72-413e-a6fd-d66de0aa627f">2,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181Mi9mcmFnOjU2OTY2MzQ4ZGVmZDRmY2U4ZjdiOWRjZDdkZWNkMWE5L3RhYmxlOjcxMjkyNjYwMzQ4YzQyODZhYmY3MzI0MTRlYTg0YjNlL3RhYmxlcmFuZ2U6NzEyOTI2NjAzNDhjNDI4NmFiZjczMjQxNGVhODRiM2VfMi0yLTEtMS02ODc5NQ_31704ada-2a3b-482c-857d-0a60e82dce22">20,150</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181Mi9mcmFnOjU2OTY2MzQ4ZGVmZDRmY2U4ZjdiOWRjZDdkZWNkMWE5L3RhYmxlOjcxMjkyNjYwMzQ4YzQyODZhYmY3MzI0MTRlYTg0YjNlL3RhYmxlcmFuZ2U6NzEyOTI2NjAzNDhjNDI4NmFiZjczMjQxNGVhODRiM2VfMi00LTEtMS02ODc5NQ_8a3af0c2-889b-44af-a728-0eb1c8c46b36">12,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181Mi9mcmFnOjU2OTY2MzQ4ZGVmZDRmY2U4ZjdiOWRjZDdkZWNkMWE5L3RhYmxlOjcxMjkyNjYwMzQ4YzQyODZhYmY3MzI0MTRlYTg0YjNlL3RhYmxlcmFuZ2U6NzEyOTI2NjAzNDhjNDI4NmFiZjczMjQxNGVhODRiM2VfMy0yLTEtMS02ODc5NQ_30fe7b80-8827-4d77-ac15-861edef0b965">2,953</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181Mi9mcmFnOjU2OTY2MzQ4ZGVmZDRmY2U4ZjdiOWRjZDdkZWNkMWE5L3RhYmxlOjcxMjkyNjYwMzQ4YzQyODZhYmY3MzI0MTRlYTg0YjNlL3RhYmxlcmFuZ2U6NzEyOTI2NjAzNDhjNDI4NmFiZjczMjQxNGVhODRiM2VfMy00LTEtMS02ODc5NQ_1c36d2ac-5729-4e33-882a-513fbe66ab8b">4,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181Mi9mcmFnOjU2OTY2MzQ4ZGVmZDRmY2U4ZjdiOWRjZDdkZWNkMWE5L3RhYmxlOjcxMjkyNjYwMzQ4YzQyODZhYmY3MzI0MTRlYTg0YjNlL3RhYmxlcmFuZ2U6NzEyOTI2NjAzNDhjNDI4NmFiZjczMjQxNGVhODRiM2VfNC0yLTEtMS02ODc5NQ_3a7b3d95-4cce-4e61-a522-ce80a8702d67">25,320</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181Mi9mcmFnOjU2OTY2MzQ4ZGVmZDRmY2U4ZjdiOWRjZDdkZWNkMWE5L3RhYmxlOjcxMjkyNjYwMzQ4YzQyODZhYmY3MzI0MTRlYTg0YjNlL3RhYmxlcmFuZ2U6NzEyOTI2NjAzNDhjNDI4NmFiZjczMjQxNGVhODRiM2VfNC00LTEtMS02ODc5NQ_5c692dce-f250-4e68-bbf4-59ff63f06a37">19,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_55"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="auph:PrepaidExpensesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181NS9mcmFnOmJiMmEzNjE0M2Q2MzQ1YTBiYmNlNTNmNjgxMmUwNzkxL3RleHRyZWdpb246YmIyYTM2MTQzZDYzNDVhMGJiY2U1M2Y2ODEyZTA3OTFfMTA4_ce07956f-bf6b-4374-b794-277dcdc327fc" continuedAt="i51936b2851a747229737b3893aa5e006" escape="true">Prepaid Expenses</ix:nonNumeric></span></div><ix:continuation id="i51936b2851a747229737b3893aa5e006"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181NS9mcmFnOmJiMmEzNjE0M2Q2MzQ1YTBiYmNlNTNmNjgxMmUwNzkxL3RleHRyZWdpb246YmIyYTM2MTQzZDYzNDVhMGJiY2U1M2Y2ODEyZTA3OTFfMTA3_3f468894-31ee-4161-a959-90345fb7dc29" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses are as follows:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="auph:PrepaidAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181NS9mcmFnOmJiMmEzNjE0M2Q2MzQ1YTBiYmNlNTNmNjgxMmUwNzkxL3RhYmxlOmVkYTQ2NmYxNDMwMTQ0OTQ5MGY5OWJlYTE0YWM3NDVkL3RhYmxlcmFuZ2U6ZWRhNDY2ZjE0MzAxNDQ5NDkwZjk5YmVhMTRhYzc0NWRfMi0yLTEtMS02ODc5NQ_22498e45-b99b-4cbd-82bf-4809c895ea0e">5,725</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="auph:PrepaidAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181NS9mcmFnOmJiMmEzNjE0M2Q2MzQ1YTBiYmNlNTNmNjgxMmUwNzkxL3RhYmxlOmVkYTQ2NmYxNDMwMTQ0OTQ5MGY5OWJlYTE0YWM3NDVkL3RhYmxlcmFuZ2U6ZWRhNDY2ZjE0MzAxNDQ5NDkwZjk5YmVhMTRhYzc0NWRfMi00LTEtMS02ODc5NQ_feac2aa8-ab73-494c-91ed-eb316511ebdd">5,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:DepositsAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181NS9mcmFnOmJiMmEzNjE0M2Q2MzQ1YTBiYmNlNTNmNjgxMmUwNzkxL3RhYmxlOmVkYTQ2NmYxNDMwMTQ0OTQ5MGY5OWJlYTE0YWM3NDVkL3RhYmxlcmFuZ2U6ZWRhNDY2ZjE0MzAxNDQ5NDkwZjk5YmVhMTRhYzc0NWRfMy0yLTEtMS02ODc5NQ_8f6c97c1-04b4-441b-86a6-d20b5c0785a4">3,582</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:DepositsAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181NS9mcmFnOmJiMmEzNjE0M2Q2MzQ1YTBiYmNlNTNmNjgxMmUwNzkxL3RhYmxlOmVkYTQ2NmYxNDMwMTQ0OTQ5MGY5OWJlYTE0YWM3NDVkL3RhYmxlcmFuZ2U6ZWRhNDY2ZjE0MzAxNDQ5NDkwZjk5YmVhMTRhYzc0NWRfMy00LTEtMS02ODc5NQ_7fae2a7b-f87a-4c27-8ee5-a89f9f5303ca">4,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:PrepaidInsurance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181NS9mcmFnOmJiMmEzNjE0M2Q2MzQ1YTBiYmNlNTNmNjgxMmUwNzkxL3RhYmxlOmVkYTQ2NmYxNDMwMTQ0OTQ5MGY5OWJlYTE0YWM3NDVkL3RhYmxlcmFuZ2U6ZWRhNDY2ZjE0MzAxNDQ5NDkwZjk5YmVhMTRhYzc0NWRfNC0yLTEtMS02ODc5NQ_3a7e27b5-25b1-42df-9313-956afd7bfc3d">2,852</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:PrepaidInsurance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181NS9mcmFnOmJiMmEzNjE0M2Q2MzQ1YTBiYmNlNTNmNjgxMmUwNzkxL3RhYmxlOmVkYTQ2NmYxNDMwMTQ0OTQ5MGY5OWJlYTE0YWM3NDVkL3RhYmxlcmFuZ2U6ZWRhNDY2ZjE0MzAxNDQ5NDkwZjk5YmVhMTRhYzc0NWRfNC00LTEtMS02ODc5NQ_20724876-45cd-4083-b72a-60129a0d82e5">1,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181NS9mcmFnOmJiMmEzNjE0M2Q2MzQ1YTBiYmNlNTNmNjgxMmUwNzkxL3RhYmxlOmVkYTQ2NmYxNDMwMTQ0OTQ5MGY5OWJlYTE0YWM3NDVkL3RhYmxlcmFuZ2U6ZWRhNDY2ZjE0MzAxNDQ5NDkwZjk5YmVhMTRhYzc0NWRfNi0yLTEtMS02ODc5NQ_04b46fe0-295c-478b-b55d-7caa14236198">12,159</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181NS9mcmFnOmJiMmEzNjE0M2Q2MzQ1YTBiYmNlNTNmNjgxMmUwNzkxL3RhYmxlOmVkYTQ2NmYxNDMwMTQ0OTQ5MGY5OWJlYTE0YWM3NDVkL3RhYmxlcmFuZ2U6ZWRhNDY2ZjE0MzAxNDQ5NDkwZjk5YmVhMTRhYzc0NWRfNi00LTEtMS02ODc5NQ_c49b98e9-1439-488b-a5a0-4c9af051d83e">11,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_58"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RleHRyZWdpb246Y2I2NGE2MTQwYTlkNDViOGI5ZGM2MTc2NTU3YTBmN2ZfMjgz_08cc33bd-e485-4ec1-afcc-206e086d99bc" continuedAt="i12e65af42ebf4d6884da4b0943a96de2" escape="true">Intangible Assets</ix:nonNumeric></span></div><ix:continuation id="i12e65af42ebf4d6884da4b0943a96de2"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RleHRyZWdpb246Y2I2NGE2MTQwYTlkNDViOGI5ZGM2MTc2NTU3YTBmN2ZfMjg0_3fd534f3-7788-40ea-bd34-cc8ab8d1af3a" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of intangible assets, net of accumulated amortization. </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i694749f08fba4701ba5443abefc101e0_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmQ4ZDFmZGFjYzJjNTQwZjU5YWI5MGNkZTMzYjE2MWZkL3RhYmxlcmFuZ2U6ZDhkMWZkYWNjMmM1NDBmNTlhYjkwY2RlMzNiMTYxZmRfMi0yLTEtMS02ODc5NQ_3f9c4b7d-a49d-4680-86f9-3fca5964cfe8">1,473</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i694749f08fba4701ba5443abefc101e0_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmQ4ZDFmZGFjYzJjNTQwZjU5YWI5MGNkZTMzYjE2MWZkL3RhYmxlcmFuZ2U6ZDhkMWZkYWNjMmM1NDBmNTlhYjkwY2RlMzNiMTYxZmRfMi00LTEtMS02ODc5NQ_85faf7c7-a47b-429c-8cbb-346e647d0506">1,249</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i694749f08fba4701ba5443abefc101e0_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmQ4ZDFmZGFjYzJjNTQwZjU5YWI5MGNkZTMzYjE2MWZkL3RhYmxlcmFuZ2U6ZDhkMWZkYWNjMmM1NDBmNTlhYjkwY2RlMzNiMTYxZmRfMi02LTEtMS02ODc5NQ_d5fd3868-9bc6-4592-acb4-84d3425c36e5">224</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intellectual property and reacquired rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cb5e9e831f5489cad13f8086d409cfb_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmQ4ZDFmZGFjYzJjNTQwZjU5YWI5MGNkZTMzYjE2MWZkL3RhYmxlcmFuZ2U6ZDhkMWZkYWNjMmM1NDBmNTlhYjkwY2RlMzNiMTYxZmRfMy0yLTEtMS02ODc5NQ_f15f0895-921f-491e-b06e-211cd4fef072">15,126</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cb5e9e831f5489cad13f8086d409cfb_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmQ4ZDFmZGFjYzJjNTQwZjU5YWI5MGNkZTMzYjE2MWZkL3RhYmxlcmFuZ2U6ZDhkMWZkYWNjMmM1NDBmNTlhYjkwY2RlMzNiMTYxZmRfMy00LTEtMS02ODc5NQ_12fa4cb0-7802-4245-86d8-632c4c61ea11">9,580</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cb5e9e831f5489cad13f8086d409cfb_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmQ4ZDFmZGFjYzJjNTQwZjU5YWI5MGNkZTMzYjE2MWZkL3RhYmxlcmFuZ2U6ZDhkMWZkYWNjMmM1NDBmNTlhYjkwY2RlMzNiMTYxZmRfMy02LTEtMS02ODc5NQ_ba5e17f5-a221-4f70-a410-77c1525c9e88">5,546</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software implementation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2753c410533a473db311c14ff1da390f_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmQ4ZDFmZGFjYzJjNTQwZjU5YWI5MGNkZTMzYjE2MWZkL3RhYmxlcmFuZ2U6ZDhkMWZkYWNjMmM1NDBmNTlhYjkwY2RlMzNiMTYxZmRfNC0yLTEtMS02ODc5NQ_ca8af901-d722-4f04-8fea-decc205c1ed2">2,873</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2753c410533a473db311c14ff1da390f_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmQ4ZDFmZGFjYzJjNTQwZjU5YWI5MGNkZTMzYjE2MWZkL3RhYmxlcmFuZ2U6ZDhkMWZkYWNjMmM1NDBmNTlhYjkwY2RlMzNiMTYxZmRfNC00LTEtMS02ODc5NQ_e6b0aee1-56bb-4969-aeaf-82b400fc065a">1,804</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2753c410533a473db311c14ff1da390f_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmQ4ZDFmZGFjYzJjNTQwZjU5YWI5MGNkZTMzYjE2MWZkL3RhYmxlcmFuZ2U6ZDhkMWZkYWNjMmM1NDBmNTlhYjkwY2RlMzNiMTYxZmRfNC02LTEtMS02ODc5NQ_f199ab17-edf8-41ac-a225-9c48d9878222">1,069</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmQ4ZDFmZGFjYzJjNTQwZjU5YWI5MGNkZTMzYjE2MWZkL3RhYmxlcmFuZ2U6ZDhkMWZkYWNjMmM1NDBmNTlhYjkwY2RlMzNiMTYxZmRfNS0yLTEtMS02ODc5NQ_717535fe-7141-42b1-b2d4-1cecd1a5805d">19,472</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmQ4ZDFmZGFjYzJjNTQwZjU5YWI5MGNkZTMzYjE2MWZkL3RhYmxlcmFuZ2U6ZDhkMWZkYWNjMmM1NDBmNTlhYjkwY2RlMzNiMTYxZmRfNS00LTEtMS02ODc5NQ_0f28b44f-2b09-4afd-86c4-268a82f3b9a5">12,633</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmQ4ZDFmZGFjYzJjNTQwZjU5YWI5MGNkZTMzYjE2MWZkL3RhYmxlcmFuZ2U6ZDhkMWZkYWNjMmM1NDBmNTlhYjkwY2RlMzNiMTYxZmRfNS02LTEtMS02ODc5NQ_2730ee3c-3e43-43ed-95e7-456eb0089aef">6,839</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib78726334c604e7abc504057535e595b_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmRhN2UzZGM1ZDg5NDQ2OWFiMzAwYzVkZjc2MDU4N2NiL3RhYmxlcmFuZ2U6ZGE3ZTNkYzVkODk0NDY5YWIzMDBjNWRmNzYwNTg3Y2JfMi0yLTEtMS02ODc5NQ_f048f570-32b0-4c17-950b-2bba73b2ca5f">1,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib78726334c604e7abc504057535e595b_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmRhN2UzZGM1ZDg5NDQ2OWFiMzAwYzVkZjc2MDU4N2NiL3RhYmxlcmFuZ2U6ZGE3ZTNkYzVkODk0NDY5YWIzMDBjNWRmNzYwNTg3Y2JfMi00LTEtMS02ODc5NQ_b35546f6-1ada-4411-8c66-e01f361dedc5">1,176</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib78726334c604e7abc504057535e595b_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmRhN2UzZGM1ZDg5NDQ2OWFiMzAwYzVkZjc2MDU4N2NiL3RhYmxlcmFuZ2U6ZGE3ZTNkYzVkODk0NDY5YWIzMDBjNWRmNzYwNTg3Y2JfMi02LTEtMS02ODc5NQ_81b3ac90-3e27-47d8-b84a-ecc6a97bcb94">295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intellectual property and reacquired rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587a5632527b4d8f9fc78a79b55065c0_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmRhN2UzZGM1ZDg5NDQ2OWFiMzAwYzVkZjc2MDU4N2NiL3RhYmxlcmFuZ2U6ZGE3ZTNkYzVkODk0NDY5YWIzMDBjNWRmNzYwNTg3Y2JfMy0yLTEtMS02ODc5NQ_21160a41-1416-46ee-98a9-241e7b276670">15,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i587a5632527b4d8f9fc78a79b55065c0_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmRhN2UzZGM1ZDg5NDQ2OWFiMzAwYzVkZjc2MDU4N2NiL3RhYmxlcmFuZ2U6ZGE3ZTNkYzVkODk0NDY5YWIzMDBjNWRmNzYwNTg3Y2JfMy00LTEtMS02ODc5NQ_a0a51aa0-1920-4366-9a85-ffc29bec23aa">8,804</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587a5632527b4d8f9fc78a79b55065c0_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmRhN2UzZGM1ZDg5NDQ2OWFiMzAwYzVkZjc2MDU4N2NiL3RhYmxlcmFuZ2U6ZGE3ZTNkYzVkODk0NDY5YWIzMDBjNWRmNzYwNTg3Y2JfMy02LTEtMS02ODc5NQ_cd5aed9e-3e9e-4a6b-98b8-2ad1459adb54">6,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software implementation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i762371a552ae4e189fdad22d6c254db5_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmRhN2UzZGM1ZDg5NDQ2OWFiMzAwYzVkZjc2MDU4N2NiL3RhYmxlcmFuZ2U6ZGE3ZTNkYzVkODk0NDY5YWIzMDBjNWRmNzYwNTg3Y2JfNC0yLTEtMS02ODc5NQ_219a56f4-5381-444a-86c7-88db614f77f0">2,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i762371a552ae4e189fdad22d6c254db5_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmRhN2UzZGM1ZDg5NDQ2OWFiMzAwYzVkZjc2MDU4N2NiL3RhYmxlcmFuZ2U6ZGE3ZTNkYzVkODk0NDY5YWIzMDBjNWRmNzYwNTg3Y2JfNC00LTEtMS02ODc5NQ_45044935-9898-4836-81ca-d9ed4958e3ed">1,086</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i762371a552ae4e189fdad22d6c254db5_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmRhN2UzZGM1ZDg5NDQ2OWFiMzAwYzVkZjc2MDU4N2NiL3RhYmxlcmFuZ2U6ZGE3ZTNkYzVkODk0NDY5YWIzMDBjNWRmNzYwNTg3Y2JfNC02LTEtMS02ODc5NQ_ae9ee208-5679-4936-9784-6e80ac617475">1,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmRhN2UzZGM1ZDg5NDQ2OWFiMzAwYzVkZjc2MDU4N2NiL3RhYmxlcmFuZ2U6ZGE3ZTNkYzVkODk0NDY5YWIzMDBjNWRmNzYwNTg3Y2JfNS0yLTEtMS02ODc5NQ_e7f1a310-adc6-46b2-b836-8ba52454f1e1">19,470</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmRhN2UzZGM1ZDg5NDQ2OWFiMzAwYzVkZjc2MDU4N2NiL3RhYmxlcmFuZ2U6ZGE3ZTNkYzVkODk0NDY5YWIzMDBjNWRmNzYwNTg3Y2JfNS00LTEtMS02ODc5NQ_f67669d8-1252-47f5-829d-bce3e6f3e0a9">11,066</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmRhN2UzZGM1ZDg5NDQ2OWFiMzAwYzVkZjc2MDU4N2NiL3RhYmxlcmFuZ2U6ZGE3ZTNkYzVkODk0NDY5YWIzMDBjNWRmNzYwNTg3Y2JfNS02LTEtMS02ODc5NQ_fbb396bf-b673-44e6-84cd-294b8b1565b7">8,404</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for the three months ended September&#160;30, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RleHRyZWdpb246Y2I2NGE2MTQwYTlkNDViOGI5ZGM2MTc2NTU3YTBmN2ZfMTk2_630c461a-6744-4e2e-b086-0b2f4dd9b9db"><ix:nonFraction unitRef="usd" contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RleHRyZWdpb246Y2I2NGE2MTQwYTlkNDViOGI5ZGM2MTc2NTU3YTBmN2ZfMTk2_7c38ddcf-41d2-40a9-9833-97bc14e2202c">0.5</ix:nonFraction></ix:nonFraction> million for both periods and for the nine months ended September&#160;30, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RleHRyZWdpb246Y2I2NGE2MTQwYTlkNDViOGI5ZGM2MTc2NTU3YTBmN2ZfMjU5_05092861-082a-4e8c-84d1-297232da3a62"><ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RleHRyZWdpb246Y2I2NGE2MTQwYTlkNDViOGI5ZGM2MTc2NTU3YTBmN2ZfMjU5_ff1c458b-c487-4b10-ae22-41edf4777654">1.6</ix:nonFraction></ix:nonFraction> million for both periods.</span></div></ix:continuation><div style="margin-top:2pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182MS9mcmFnOmIwYTY5ZGVmZmJiODRkZmFhZjFiNDc3NmM0YTc4Yjk1L3RleHRyZWdpb246YjBhNjlkZWZmYmI4NGRmYWFmMWI0Nzc2YzRhNzhiOTVfODE_7846d576-4958-435f-a51a-32fa3ed1b2d3" continuedAt="i16b01509bcd84d8daaccc55af60a13b8" escape="true">Property and Equipment, net</ix:nonNumeric></span></div><ix:continuation id="i16b01509bcd84d8daaccc55af60a13b8"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182MS9mcmFnOmIwYTY5ZGVmZmJiODRkZmFhZjFiNDc3NmM0YTc4Yjk1L3RleHRyZWdpb246YjBhNjlkZWZmYmI4NGRmYWFmMWI0Nzc2YzRhNzhiOTVfODI_bdc50715-10b2-4bc9-b700-e0ede4cbc6b3" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net are as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8ebc008d0bf419399d57a1954b31411_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182MS9mcmFnOmIwYTY5ZGVmZmJiODRkZmFhZjFiNDc3NmM0YTc4Yjk1L3RhYmxlOjMwYmVkOGNmZjg1ODRmOGZiOTlhYjViZDkwZmRhNmEzL3RhYmxlcmFuZ2U6MzBiZWQ4Y2ZmODU4NGY4ZmI5OWFiNWJkOTBmZGE2YTNfMS0yLTEtMS02ODc5NQ_1b33c370-a9ef-42f2-a394-220084b54074">217</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015f087f0bfd4fa583200ee0a162bffe_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182MS9mcmFnOmIwYTY5ZGVmZmJiODRkZmFhZjFiNDc3NmM0YTc4Yjk1L3RhYmxlOjMwYmVkOGNmZjg1ODRmOGZiOTlhYjViZDkwZmRhNmEzL3RhYmxlcmFuZ2U6MzBiZWQ4Y2ZmODU4NGY4ZmI5OWFiNWJkOTBmZGE2YTNfMS00LTEtMS02ODc5NQ_427360e6-e034-4583-85bd-b72b99120805">393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie438ea390b8846d7831dd0900ee639c1_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182MS9mcmFnOmIwYTY5ZGVmZmJiODRkZmFhZjFiNDc3NmM0YTc4Yjk1L3RhYmxlOjMwYmVkOGNmZjg1ODRmOGZiOTlhYjViZDkwZmRhNmEzL3RhYmxlcmFuZ2U6MzBiZWQ4Y2ZmODU4NGY4ZmI5OWFiNWJkOTBmZGE2YTNfMi0yLTEtMS02ODc5NQ_ef48536e-8c58-45e2-ad2c-38c53f765e95">2,978</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia783c0184bda40e8a385452883ad9164_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182MS9mcmFnOmIwYTY5ZGVmZmJiODRkZmFhZjFiNDc3NmM0YTc4Yjk1L3RhYmxlOjMwYmVkOGNmZjg1ODRmOGZiOTlhYjViZDkwZmRhNmEzL3RhYmxlcmFuZ2U6MzBiZWQ4Y2ZmODU4NGY4ZmI5OWFiNWJkOTBmZGE2YTNfMi00LTEtMS02ODc5NQ_4eef1e40-a7ce-4aee-aa0b-f21fbf6e3afb">2,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if39e9f1e69324041b0415ecd8d450952_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182MS9mcmFnOmIwYTY5ZGVmZmJiODRkZmFhZjFiNDc3NmM0YTc4Yjk1L3RhYmxlOjMwYmVkOGNmZjg1ODRmOGZiOTlhYjViZDkwZmRhNmEzL3RhYmxlcmFuZ2U6MzBiZWQ4Y2ZmODU4NGY4ZmI5OWFiNWJkOTBmZGE2YTNfMy0yLTEtMS02ODc5NQ_9919cc9f-425c-4842-8b6b-047ee6903bb6">645</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieafc1263da604de4864e371e83bf3ae9_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182MS9mcmFnOmIwYTY5ZGVmZmJiODRkZmFhZjFiNDc3NmM0YTc4Yjk1L3RhYmxlOjMwYmVkOGNmZjg1ODRmOGZiOTlhYjViZDkwZmRhNmEzL3RhYmxlcmFuZ2U6MzBiZWQ4Y2ZmODU4NGY4ZmI5OWFiNWJkOTBmZGE2YTNfMy00LTEtMS02ODc5NQ_2deb5c2a-4280-44d8-841c-5349c61f1be2">645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if15808d1e63744299f8008a22843785a_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182MS9mcmFnOmIwYTY5ZGVmZmJiODRkZmFhZjFiNDc3NmM0YTc4Yjk1L3RhYmxlOjMwYmVkOGNmZjg1ODRmOGZiOTlhYjViZDkwZmRhNmEzL3RhYmxlcmFuZ2U6MzBiZWQ4Y2ZmODU4NGY4ZmI5OWFiNWJkOTBmZGE2YTNfNC0yLTEtMS02ODc5NQ_fe914c6d-693b-4ac1-862f-dfc7ebdaf7ae">976</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71d0284de4094b58a61726e34448a7c7_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182MS9mcmFnOmIwYTY5ZGVmZmJiODRkZmFhZjFiNDc3NmM0YTc4Yjk1L3RhYmxlOjMwYmVkOGNmZjg1ODRmOGZiOTlhYjViZDkwZmRhNmEzL3RhYmxlcmFuZ2U6MzBiZWQ4Y2ZmODU4NGY4ZmI5OWFiNWJkOTBmZGE2YTNfNC00LTEtMS02ODc5NQ_43f95113-4ce0-4fc4-b4a1-e7cc0b904172">976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5e1845517044932807f74d13e17f14f_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182MS9mcmFnOmIwYTY5ZGVmZmJiODRkZmFhZjFiNDc3NmM0YTc4Yjk1L3RhYmxlOjMwYmVkOGNmZjg1ODRmOGZiOTlhYjViZDkwZmRhNmEzL3RhYmxlcmFuZ2U6MzBiZWQ4Y2ZmODU4NGY4ZmI5OWFiNWJkOTBmZGE2YTNfNS0yLTEtMS02ODc5NQ_67353fe9-88c6-4082-aaa3-daa6ab1ec6db">251</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i344a287699e44b6abf65762731d49159_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182MS9mcmFnOmIwYTY5ZGVmZmJiODRkZmFhZjFiNDc3NmM0YTc4Yjk1L3RhYmxlOjMwYmVkOGNmZjg1ODRmOGZiOTlhYjViZDkwZmRhNmEzL3RhYmxlcmFuZ2U6MzBiZWQ4Y2ZmODU4NGY4ZmI5OWFiNWJkOTBmZGE2YTNfNS00LTEtMS02ODc5NQ_78535d9d-803e-4c74-b7a9-45175e61fa78">262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182MS9mcmFnOmIwYTY5ZGVmZmJiODRkZmFhZjFiNDc3NmM0YTc4Yjk1L3RhYmxlOjMwYmVkOGNmZjg1ODRmOGZiOTlhYjViZDkwZmRhNmEzL3RhYmxlcmFuZ2U6MzBiZWQ4Y2ZmODU4NGY4ZmI5OWFiNWJkOTBmZGE2YTNfNi0yLTEtMS02ODc5NQ_76eb6285-2148-4329-9275-34f4b93ab2d0">5,067</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182MS9mcmFnOmIwYTY5ZGVmZmJiODRkZmFhZjFiNDc3NmM0YTc4Yjk1L3RhYmxlOjMwYmVkOGNmZjg1ODRmOGZiOTlhYjViZDkwZmRhNmEzL3RhYmxlcmFuZ2U6MzBiZWQ4Y2ZmODU4NGY4ZmI5OWFiNWJkOTBmZGE2YTNfNi00LTEtMS02ODc5NQ_d82d2596-6c51-4445-9cec-24b4b2084721">5,254</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182MS9mcmFnOmIwYTY5ZGVmZmJiODRkZmFhZjFiNDc3NmM0YTc4Yjk1L3RhYmxlOjMwYmVkOGNmZjg1ODRmOGZiOTlhYjViZDkwZmRhNmEzL3RhYmxlcmFuZ2U6MzBiZWQ4Y2ZmODU4NGY4ZmI5OWFiNWJkOTBmZGE2YTNfNy0yLTEtMS02ODc5NQ_119568d9-d383-4be5-afe8-5d0df0d29156">1,309</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182MS9mcmFnOmIwYTY5ZGVmZmJiODRkZmFhZjFiNDc3NmM0YTc4Yjk1L3RhYmxlOjMwYmVkOGNmZjg1ODRmOGZiOTlhYjViZDkwZmRhNmEzL3RhYmxlcmFuZ2U6MzBiZWQ4Y2ZmODU4NGY4ZmI5OWFiNWJkOTBmZGE2YTNfNy00LTEtMS02ODc5NQ_67850c58-56b4-4b85-83a0-05aa213547ce">836</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182MS9mcmFnOmIwYTY5ZGVmZmJiODRkZmFhZjFiNDc3NmM0YTc4Yjk1L3RhYmxlOjMwYmVkOGNmZjg1ODRmOGZiOTlhYjViZDkwZmRhNmEzL3RhYmxlcmFuZ2U6MzBiZWQ4Y2ZmODU4NGY4ZmI5OWFiNWJkOTBmZGE2YTNfOC0yLTEtMS02ODc5NQ_482fd5bd-2a92-4e4b-851f-6cb424aac17d">3,758</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182MS9mcmFnOmIwYTY5ZGVmZmJiODRkZmFhZjFiNDc3NmM0YTc4Yjk1L3RhYmxlOjMwYmVkOGNmZjg1ODRmOGZiOTlhYjViZDkwZmRhNmEzL3RhYmxlcmFuZ2U6MzBiZWQ4Y2ZmODU4NGY4ZmI5OWFiNWJkOTBmZGE2YTNfOC00LTEtMS02ODc5NQ_1a5c222c-a76a-4883-aefb-78b7ed89dde3">4,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_64"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfNTA4NQ_2f5ae9bc-eb13-4f2d-8774-754418f3b68b" continuedAt="iba3a2f473437447ea9e3b52fc47b3776" escape="true">Lease Obligations</ix:nonNumeric></span></div><ix:continuation id="iba3a2f473437447ea9e3b52fc47b3776" continuedAt="i42d02151ab154167ae2c003572368f32"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has the following lease obligations:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Victoria, British Columbia</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During August 2020, the Company signed a lease for commercial office space in Victoria, British Columbia for a new corporate headquarters that was expected to commence in April 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2020, the Company entered into <ix:nonNumeric contextRef="ib0122d51e9ce4a43a91c77261f282564_I20201231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfMzI5ODUzNDg5OTUxMw_4cabe27d-e635-4110-b23c-d6443a41a297">18-month</ix:nonNumeric> facility and furniture leases for its existing corporate head office located in Victoria, British Columbia. The lease terms commenced on January 1, 2021 with an end date of August 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 3, 2022, we provided notice of termination for the lease of the intended new corporate headquarters space in Victoria on the basis that the landlord's work was not completed by the time required under the lease. As a result of the termination, the company expensed $<ix:nonFraction unitRef="usd" contextRef="ie76075ad5fba4197953b1f9074f707fb_D20220803-20220803" decimals="-5" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfNjA0NzMxMzk2NzIzNg_906873e4-1c70-47c3-ab43-a8b39db26846">0.3</ix:nonFraction>&#160;million of CIP cost that was related to the new corporate headquarters.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2022, the fixed lease term ended for Aurinia's existing corporate headquarters and the Company exercised its right to enter into a month to month lease, of which expenses are incurred in SG&amp;A.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rockville, Maryland</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During March 2020, the Company entered into a lease for its U.S. commercial office in Rockville, Maryland for a total of <ix:nonFraction unitRef="sqft" contextRef="i8217ea002f274269ad63c35be20de5d2_I20200331" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfMTQ4MA_88508329-924f-4e77-ad96-39a7406aa1e3">30,531</ix:nonFraction> square feet of office space. The lease has a remaining term of approximately <ix:nonNumeric contextRef="i8217ea002f274269ad63c35be20de5d2_I20200331" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfMTU2MA_b6b8ad8e-3b87-4871-8f4c-adc761c8af82">9</ix:nonNumeric> years and has an option to extend for <ix:nonFraction unitRef="extension_option" contextRef="i8217ea002f274269ad63c35be20de5d2_I20200331" decimals="INF" name="auph:LesseeOperatingLeaseNumberOfExtensionOptions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfMTU5NQ_561546a4-afeb-4d87-bc22-3615c47e68cb">two</ix:nonFraction> <ix:nonNumeric contextRef="i8217ea002f274269ad63c35be20de5d2_I20200331" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfNTA4Mw_3c52e5d6-5ce0-43bb-a01f-ea07ad290ec0">five-year</ix:nonNumeric> periods after the initial term of <ix:nonNumeric contextRef="i8217ea002f274269ad63c35be20de5d2_I20200331" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfMTY0MA_f7428842-4528-40eb-ad9f-cc7e3e076d6c">11</ix:nonNumeric> years has elapsed and has an option to terminate after <ix:nonNumeric contextRef="ifdc02d86fd494bcd9c3bbcefc6567c61_D20200301-20200331" name="auph:LesseeOperatingLeaseLeaseTerminationTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfMTY5Mg_6f7f160a-2190-4f54-8e08-de2d0e8498af">seven years</ix:nonNumeric>. As of September&#160;30, 2022, the Company had a right-of-use asset of $<ix:nonFraction unitRef="usd" contextRef="ieab7019fc2e44f7281b349abacde0bc3_I20220930" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfMTc0Ng_d2671925-1487-4ff5-bf01-db3d6b779bef">4.9</ix:nonFraction> million and lease liability of $<ix:nonFraction unitRef="usd" contextRef="ieab7019fc2e44f7281b349abacde0bc3_I20220930" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfMTc3Mg_94d72b14-c86a-420c-b159-9ecc62e1494e">8.2</ix:nonFraction> million included in the condensed consolidated balance sheets. As of December&#160;31, 2021, the Company had a right of use asset of $<ix:nonFraction unitRef="usd" contextRef="i58c5e7c150d14386a0bf23271f8fcc59_I20211231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfMTg4MA_25844fc8-9946-4a5b-90f4-25464cd906f3">5.2</ix:nonFraction> million and lease liability of $<ix:nonFraction unitRef="usd" contextRef="i58c5e7c150d14386a0bf23271f8fcc59_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfMTkwNg_987efbb4-2bd8-4807-9e43-06be09b5bc3e">8.6</ix:nonFraction> million included in the condensed consolidated balance sheets. The Company recorded leasehold improvement incentives in the amount of $<ix:nonFraction unitRef="usd" contextRef="i2010334e882c4ffd813f86072931dd35_D20211231-20211231" decimals="-5" sign="-" name="us-gaap:PaymentsForProceedsFromTenantAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfMjAzNQ_aca3994c-e5f6-4525-a610-32bce41787d2">2.3</ix:nonFraction>&#160;million as additions to the lease liability. The lease term commenced on March 12, 2020. When measuring the lease liability, the Company discounted lease payments using its incremental borrowing rate at March 12, 2020. The incremental borrowing rate applied to the lease liability on March 12, 2020 was <ix:nonFraction unitRef="number" contextRef="i67061bc27f97417eb92caad1115e4f65_I20200312" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfMjMzMw_2ec5a935-1045-4fe0-bdb4-000b6facaa16">5.2</ix:nonFraction>% based on the financial position of the Company, geographical region and term of lease.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Edmonton, Alberta</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Company has a short term lease in Edmonton, Alberta in which expenses are recognized in SG&amp;A. The lease is not material to the Company's financial position.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i42d02151ab154167ae2c003572368f32" continuedAt="i03237d62b0da410ba047ca8d15556238"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs variable lease costs under the existing Victoria and Rockville leases. These costs include operation and maintenance costs included in SG&amp;A and are expensed as incurred. The variable lease costs are not material to the Company's financial position.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating lease costs for the three and nine months ended September&#160;30, 2022 and September&#160;30, 2021 are $<ix:nonFraction unitRef="usd" contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfMjk5Ng_1d9cb948-776c-4a31-aeee-e4e5b6f28756"><ix:nonFraction unitRef="usd" contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfMjk5Ng_279a15c6-4d14-4cd8-b01a-ec64afb8d289">0.2</ix:nonFraction></ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfMzAwMw_52c9d97d-90c7-40b9-9292-9449df0374f3"><ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfMzAwMw_c8123bca-09f7-454b-b966-64414fd5ec05">0.8</ix:nonFraction></ix:nonFraction>&#160;million for both periods respectively.</span></div><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfNTA4NA_55f75ea0-1acd-440a-a090-c3a360c928fd" escape="true"><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the weighted-average remaining lease term and discount rate as of September&#160;30, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term (years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RhYmxlOjcwMzc0Y2JhYWUwMzQ2ZWJiZDQ1YjZiMmRiZGFlZjQwL3RhYmxlcmFuZ2U6NzAzNzRjYmFhZTAzNDZlYmJkNDViNmIyZGJkYWVmNDBfMi0yLTEtMS02ODc5NQ_2abb25dd-d984-4e6a-a3e7-22ab2806a4a8">8.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RhYmxlOjcwMzc0Y2JhYWUwMzQ2ZWJiZDQ1YjZiMmRiZGFlZjQwL3RhYmxlcmFuZ2U6NzAzNzRjYmFhZTAzNDZlYmJkNDViNmIyZGJkYWVmNDBfMi00LTEtMS02ODc5NQ_fbb8c3ad-87bf-43c4-b74a-f5cd1a412990">5.22</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfNTA4MA_10be816a-a992-4413-be64-fb3627824bb4" escape="true"><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of operating lease liabilities payments for the next five years and thereafter:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Lease Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RhYmxlOjU1ZjYwNzA1YWMzYjRkNzk5ZjFkNTFmMWI0Y2YxYmYyL3RhYmxlcmFuZ2U6NTVmNjA3MDVhYzNiNGQ3OTlmMWQ1MWYxYjRjZjFiZjJfMS0yLTEtMS02ODc5NQ_36eb41db-451d-4917-8d02-80f35182f9f4">263</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RhYmxlOjU1ZjYwNzA1YWMzYjRkNzk5ZjFkNTFmMWI0Y2YxYmYyL3RhYmxlcmFuZ2U6NTVmNjA3MDVhYzNiNGQ3OTlmMWQ1MWYxYjRjZjFiZjJfMi0yLTEtMS02ODc5NQ_c84a48f1-86fb-49fe-b927-554e5dbab94f">1,061</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RhYmxlOjU1ZjYwNzA1YWMzYjRkNzk5ZjFkNTFmMWI0Y2YxYmYyL3RhYmxlcmFuZ2U6NTVmNjA3MDVhYzNiNGQ3OTlmMWQ1MWYxYjRjZjFiZjJfMy0yLTEtMS02ODc5NQ_befec823-b04e-4fbf-986f-36929b733447">1,085</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RhYmxlOjU1ZjYwNzA1YWMzYjRkNzk5ZjFkNTFmMWI0Y2YxYmYyL3RhYmxlcmFuZ2U6NTVmNjA3MDVhYzNiNGQ3OTlmMWQ1MWYxYjRjZjFiZjJfNC0yLTEtMS02ODc5NQ_b55e9fa1-3451-47aa-b325-8c9482b7f33b">1,110</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RhYmxlOjU1ZjYwNzA1YWMzYjRkNzk5ZjFkNTFmMWI0Y2YxYmYyL3RhYmxlcmFuZ2U6NTVmNjA3MDVhYzNiNGQ3OTlmMWQ1MWYxYjRjZjFiZjJfNS0yLTEtMS02ODc5NQ_3b71b346-cc45-4535-8f63-547b5d3c3b75">1,135</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="auph:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RhYmxlOjU1ZjYwNzA1YWMzYjRkNzk5ZjFkNTFmMWI0Y2YxYmYyL3RhYmxlcmFuZ2U6NTVmNjA3MDVhYzNiNGQ3OTlmMWQ1MWYxYjRjZjFiZjJfNi0yLTEtMS02ODc5NQ_774094d1-bf82-43fb-81be-33796d9f215a">5,638</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RhYmxlOjU1ZjYwNzA1YWMzYjRkNzk5ZjFkNTFmMWI0Y2YxYmYyL3RhYmxlcmFuZ2U6NTVmNjA3MDVhYzNiNGQ3OTlmMWQ1MWYxYjRjZjFiZjJfNy0yLTEtMS02ODc5NQ_932dfafa-0ef4-49aa-8553-137ca1c9c0b0">10,292</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: lease imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RhYmxlOjU1ZjYwNzA1YWMzYjRkNzk5ZjFkNTFmMWI0Y2YxYmYyL3RhYmxlcmFuZ2U6NTVmNjA3MDVhYzNiNGQ3OTlmMWQ1MWYxYjRjZjFiZjJfOC0yLTEtMS02ODc5NQ_644c9f15-8b33-4141-8f21-fd193de19dd3">2,104</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RhYmxlOjU1ZjYwNzA1YWMzYjRkNzk5ZjFkNTFmMWI0Y2YxYmYyL3RhYmxlcmFuZ2U6NTVmNjA3MDVhYzNiNGQ3OTlmMWQ1MWYxYjRjZjFiZjJfOS0yLTEtMS02ODc5NQ_e229ccb5-16d7-42c1-b3b6-eb3554c6ab5d">8,188</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 15, 2020, the Company entered into a collaborative agreement with Lonza to build a dedicated manufacturing facility within Lonza&#8217;s existing small molecule facility in Visp, Switzerland. The dedicated facility (also referred to as "monoplant") will be equipped with state-of-the-art manufacturing equipment to provide cost and production efficiency for the manufacture of voclosporin, while expanding existing capacity and providing supply security to meet future commercial demand.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following U.S. regulatory approval of LUPKYNIS in January 2021, the Company has commenced a capital expenditure payment program for the monoplant totaling approximately CHF <ix:nonFraction unitRef="chf" contextRef="ibdd4d5c6c4cc486cb6916357de93b010_D20210101-20210131" decimals="-5" name="us-gaap:PaymentsForCapitalImprovements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfMzkyOA_f6b1cf3f-4d6d-4b5e-a66e-d841c50de924">21.0</ix:nonFraction>&#160;million. The first capital expenditure payment was made in February 2021 of $<ix:nonFraction unitRef="usd" contextRef="i0218c4022baf4887b278a279993662cb_D20210201-20210228" decimals="-5" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfMzk5OQ_06129fa9-bc5e-43f5-8829-a6b8553cfd48">11.8</ix:nonFraction>&#160;million (CHF <ix:nonFraction unitRef="chf" contextRef="i0218c4022baf4887b278a279993662cb_D20210201-20210228" decimals="-5" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfNDAwNw_e48e55dc-90d3-4584-b116-a55315708e0a">10.5</ix:nonFraction>&#160;million) and was treated as an upfront lease payment and recorded under other non-current assets on the condensed consolidated balance sheets. The second payment is not due until the facility fulfills the required operational qualifications which is estimated to be during the first half of 2023. Upon completion of the monoplant, the Company will have the right to maintain sole dedicated use of the monoplant by paying a quarterly fixed facility fee. The Company expects to account for the arrangement as a finance lease under ASC 842. The present value of the minimum lease payments total approximately $<ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfNDYwOA_8e8d7f34-66dc-4e15-b621-759741b35ad9">73.0</ix:nonFraction>&#160;million, beginning April 2023 and expiring in 2030, and are not included in the above table.</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i03237d62b0da410ba047ca8d15556238">The Company has entered into an equipment and facility finance lease for a backup manufacturing encapsulation site in Beinheim, France that has not yet commenced and is therefore, not included in the above table. As part of the agreement, the Company expects to make payments of approximately $<ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="auph:LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfNDk2OQ_740a985d-4af0-4974-90e2-0cde0b4b4545">0.9</ix:nonFraction>&#160;million prior to lease commencement and the future value of minimum lease payments will total approximately $<ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="auph:LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfNTA3Mg_bff0ebad-e2eb-48d9-8554-e6bb032c79fc">0.1</ix:nonFraction>&#160;million.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182Ny9mcmFnOmU4MWNhODY5MzI5YjQ4N2ZiZDUxZDNkZmZiZTNmOGRhL3RleHRyZWdpb246ZTgxY2E4NjkzMjliNDg3ZmJkNTFkM2RmZmJlM2Y4ZGFfMTA1_0daf5d1c-ffa0-45f3-8bc2-405327be7ea4" continuedAt="ic297959ea077426b8136bfbf0ee36aa4" escape="true">Accounts Payable and Accrued Liabilities</ix:nonNumeric></span></div><ix:continuation id="ic297959ea077426b8136bfbf0ee36aa4"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182Ny9mcmFnOmU4MWNhODY5MzI5YjQ4N2ZiZDUxZDNkZmZiZTNmOGRhL3RleHRyZWdpb246ZTgxY2E4NjkzMjliNDg3ZmJkNTFkM2RmZmJlM2Y4ZGFfMTA2_189e39b2-7737-43e9-9fe3-d1c5e5802b3f" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee accruals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182Ny9mcmFnOmU4MWNhODY5MzI5YjQ4N2ZiZDUxZDNkZmZiZTNmOGRhL3RhYmxlOjY1NTgxMjdmODk0NDQwYjdiYTE3NWExOWExOTQzNTg0L3RhYmxlcmFuZ2U6NjU1ODEyN2Y4OTQ0NDBiN2JhMTc1YTE5YTE5NDM1ODRfMi0yLTEtMS02ODc5NQ_31531be6-fa35-40a2-b287-2d7afc179bfa">16,511</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182Ny9mcmFnOmU4MWNhODY5MzI5YjQ4N2ZiZDUxZDNkZmZiZTNmOGRhL3RhYmxlOjY1NTgxMjdmODk0NDQwYjdiYTE3NWExOWExOTQzNTg0L3RhYmxlcmFuZ2U6NjU1ODEyN2Y4OTQ0NDBiN2JhMTc1YTE5YTE5NDM1ODRfMi00LTEtMS02ODc5NQ_b2e3ea0a-66fd-4154-af8e-75a82439697b">18,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial accruals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="auph:CommercialRelatedAccrualsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182Ny9mcmFnOmU4MWNhODY5MzI5YjQ4N2ZiZDUxZDNkZmZiZTNmOGRhL3RhYmxlOjY1NTgxMjdmODk0NDQwYjdiYTE3NWExOWExOTQzNTg0L3RhYmxlcmFuZ2U6NjU1ODEyN2Y4OTQ0NDBiN2JhMTc1YTE5YTE5NDM1ODRfMy0yLTEtMS02ODc5NQ_dc277bda-003b-49f0-b05b-fa7633cd7426">9,140</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="auph:CommercialRelatedAccrualsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182Ny9mcmFnOmU4MWNhODY5MzI5YjQ4N2ZiZDUxZDNkZmZiZTNmOGRhL3RhYmxlOjY1NTgxMjdmODk0NDQwYjdiYTE3NWExOWExOTQzNTg0L3RhYmxlcmFuZ2U6NjU1ODEyN2Y4OTQ0NDBiN2JhMTc1YTE5YTE5NDM1ODRfMy00LTEtMS02ODc5NQ_afaeacdb-6d2d-47f8-a6c4-87fd54a30f8e">5,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued R&amp;D projects</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="auph:AccruedResearchCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182Ny9mcmFnOmU4MWNhODY5MzI5YjQ4N2ZiZDUxZDNkZmZiZTNmOGRhL3RhYmxlOjY1NTgxMjdmODk0NDQwYjdiYTE3NWExOWExOTQzNTg0L3RhYmxlcmFuZ2U6NjU1ODEyN2Y4OTQ0NDBiN2JhMTc1YTE5YTE5NDM1ODRfNC0yLTEtMS02ODc5NQ_cac803de-4033-4ce3-8cd8-e43bd34f9238">8,995</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="auph:AccruedResearchCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182Ny9mcmFnOmU4MWNhODY5MzI5YjQ4N2ZiZDUxZDNkZmZiZTNmOGRhL3RhYmxlOjY1NTgxMjdmODk0NDQwYjdiYTE3NWExOWExOTQzNTg0L3RhYmxlcmFuZ2U6NjU1ODEyN2Y4OTQ0NDBiN2JhMTc1YTE5YTE5NDM1ODRfNC00LTEtMS02ODc5NQ_d8cde40a-aee1-435a-962c-b8a2ac33caed">6,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182Ny9mcmFnOmU4MWNhODY5MzI5YjQ4N2ZiZDUxZDNkZmZiZTNmOGRhL3RhYmxlOjY1NTgxMjdmODk0NDQwYjdiYTE3NWExOWExOTQzNTg0L3RhYmxlcmFuZ2U6NjU1ODEyN2Y4OTQ0NDBiN2JhMTc1YTE5YTE5NDM1ODRfNS0yLTEtMS02ODc5NQ_8e9e14eb-f3a1-48fb-aa03-2679b4bff5ce">5,411</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182Ny9mcmFnOmU4MWNhODY5MzI5YjQ4N2ZiZDUxZDNkZmZiZTNmOGRhL3RhYmxlOjY1NTgxMjdmODk0NDQwYjdiYTE3NWExOWExOTQzNTg0L3RhYmxlcmFuZ2U6NjU1ODEyN2Y4OTQ0NDBiN2JhMTc1YTE5YTE5NDM1ODRfNS00LTEtMS02ODc5NQ_0c02072d-6059-4d5f-bbd0-f0997f1c9142">3,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:TaxesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182Ny9mcmFnOmU4MWNhODY5MzI5YjQ4N2ZiZDUxZDNkZmZiZTNmOGRhL3RhYmxlOjY1NTgxMjdmODk0NDQwYjdiYTE3NWExOWExOTQzNTg0L3RhYmxlcmFuZ2U6NjU1ODEyN2Y4OTQ0NDBiN2JhMTc1YTE5YTE5NDM1ODRfNi0yLTEtMS02ODc5NQ_b845daf9-5710-4969-9c11-8de1cfcce787">66</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:TaxesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182Ny9mcmFnOmU4MWNhODY5MzI5YjQ4N2ZiZDUxZDNkZmZiZTNmOGRhL3RhYmxlOjY1NTgxMjdmODk0NDQwYjdiYTE3NWExOWExOTQzNTg0L3RhYmxlcmFuZ2U6NjU1ODEyN2Y4OTQ0NDBiN2JhMTc1YTE5YTE5NDM1ODRfNi00LTEtMS02ODc5NQ_ee1f5f28-90d0-4f79-912a-92998602a50c">814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182Ny9mcmFnOmU4MWNhODY5MzI5YjQ4N2ZiZDUxZDNkZmZiZTNmOGRhL3RhYmxlOjY1NTgxMjdmODk0NDQwYjdiYTE3NWExOWExOTQzNTg0L3RhYmxlcmFuZ2U6NjU1ODEyN2Y4OTQ0NDBiN2JhMTc1YTE5YTE5NDM1ODRfNy0yLTEtMS02ODc5NQ_e417ebb8-b16f-41a1-b813-e86877459264">40,123</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182Ny9mcmFnOmU4MWNhODY5MzI5YjQ4N2ZiZDUxZDNkZmZiZTNmOGRhL3RhYmxlOjY1NTgxMjdmODk0NDQwYjdiYTE3NWExOWExOTQzNTg0L3RhYmxlcmFuZ2U6NjU1ODEyN2Y4OTQ0NDBiN2JhMTc1YTE5YTE5NDM1ODRfNy00LTEtMS02ODc5NQ_d5d747f4-5c3d-4707-8b50-658dee628c98">34,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div><span><br/></span></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_70"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183MC9mcmFnOjUwNTdmMzM4NTZkMTRjMzViNTE1N2M3NTQ4ZDU3NzU0L3RleHRyZWdpb246NTA1N2YzMzg1NmQxNGMzNWI1MTU3Yzc1NDhkNTc3NTRfNjA4_3df413ab-5913-4c3d-80ac-13c0b5af3e83" continuedAt="i1aca50fa2c084db18fbde72984001838" escape="true">Deferred Compensation and Other Non-current Liabilities</ix:nonNumeric></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1aca50fa2c084db18fbde72984001838">The Company recorded other non-current liabilities of $<ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183MC9mcmFnOjUwNTdmMzM4NTZkMTRjMzViNTE1N2M3NTQ4ZDU3NzU0L3RleHRyZWdpb246NTA1N2YzMzg1NmQxNGMzNWI1MTU3Yzc1NDhkNTc3NTRfMTE2_662589bf-7438-4f45-9f38-be6a0dcaaac6">15.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183MC9mcmFnOjUwNTdmMzM4NTZkMTRjMzViNTE1N2M3NTQ4ZDU3NzU0L3RleHRyZWdpb246NTA1N2YzMzg1NmQxNGMzNWI1MTU3Yzc1NDhkNTc3NTRfMTIz_b4c79447-6a4c-48f1-9506-3f9673f192d0">16.0</ix:nonFraction> million as of September&#160;30, 2022 and December&#160;31, 2021, respectively. The balance as of September&#160;30, 2022 and December&#160;31, 2021 primarily included deferred compensation arrangements whereby certain executive officers as of March 8, 2012 were provided with future potential employee benefit obligations for remaining with the Company, for a certain period of time. These obligations were also contingent on the occurrence of uncertain future events. Other non-current liabilities also include milestone payments deemed probable to be paid in the future.</ix:continuation></span></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_73"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183My9mcmFnOjU1ZDc2NmJjNDc3ZjRhZjk4YjlmMjk3ZWFkM2RkMjM2L3RleHRyZWdpb246NTVkNzY2YmM0NzdmNGFmOThiOWYyOTdlYWQzZGQyMzZfMzAwNw_269ca0bc-d293-4540-a3ab-be14ab1a5448" continuedAt="ie9943a2e092b478eadc33f4727e1f3c7" escape="true">License and Collaboration Agreements</ix:nonNumeric></span></div><ix:continuation id="ie9943a2e092b478eadc33f4727e1f3c7"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Otsuka Contract</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 17, 2020, the Company entered into a collaboration and license agreement with Otsuka for the development and commercialization of oral LUPKYNIS in the Otsuka Territories.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the agreement, the Company received an upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="ibf32de36976c4acea4a8d8fcae729345_D20201217-20201217" decimals="-5" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183My9mcmFnOjU1ZDc2NmJjNDc3ZjRhZjk4YjlmMjk3ZWFkM2RkMjM2L3RleHRyZWdpb246NTVkNzY2YmM0NzdmNGFmOThiOWYyOTdlYWQzZGQyMzZfNDg0_13c16ae0-f594-4db4-bc2e-a88e152eef87">50.0</ix:nonFraction>&#160;million for the license agreement and has the potential to receive up to $<ix:nonFraction unitRef="usd" contextRef="i7157bd498212400d9ba95e50a9998561_I20201217" decimals="-5" name="auph:ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183My9mcmFnOjU1ZDc2NmJjNDc3ZjRhZjk4YjlmMjk3ZWFkM2RkMjM2L3RleHRyZWdpb246NTVkNzY2YmM0NzdmNGFmOThiOWYyOTdlYWQzZGQyMzZfNTUy_70f10401-63b8-495e-af6c-9d7c2a66c216">50.0</ix:nonFraction>&#160;million in regulatory related milestones. The Company will provide semi-finished product of LUPKYNIS to Otsuka on a cost-plus basis, and will receive tiered royalties on future sales ranging from <ix:nonFraction unitRef="number" contextRef="i8cca31f183434cd5ab9525b020f34afc_I20201217" decimals="INF" name="auph:ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183My9mcmFnOjU1ZDc2NmJjNDc3ZjRhZjk4YjlmMjk3ZWFkM2RkMjM2L3RleHRyZWdpb246NTVkNzY2YmM0NzdmNGFmOThiOWYyOTdlYWQzZGQyMzZfNjU2_9cdd850f-2d81-4f8d-a8b9-090835d12a47">10</ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="i91f3a2c3fb9444049582457768137f12_I20201217" decimals="INF" name="auph:ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183My9mcmFnOjU1ZDc2NmJjNDc3ZjRhZjk4YjlmMjk3ZWFkM2RkMjM2L3RleHRyZWdpb246NTVkNzY2YmM0NzdmNGFmOThiOWYyOTdlYWQzZGQyMzZfNjYy_7533e1ff-0546-4bb5-8640-1bb7fb8729b9">20</ix:nonFraction> percent (dependent on territory and achievement of sale thresholds) on net product sales by Otsuka, along with additional milestone payments based on the attainment of certain annual sales. In addition, certain collaboration services are to be provided to Otsuka on agreed upon rates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In furtherance of the collaboration and license agreement with Otsuka mentioned above, on August 1, 2022, the Company entered into a commercial supply agreement with Otsuka, formalizing the terms to supply semi-finished goods of LUPKYNIS to Otsuka in the Otsuka Territories, including capacity sharing of the monoplant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2022, the European Commission (EC) granted marketing authorization of LUPKYNIS. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The centralized marketing authorization is valid in all EU member states as well as in Iceland, Liechtenstein, Norway and Northern Ireland.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The approval triggered a $<ix:nonFraction unitRef="usd" contextRef="ie85ef3843f6e45c68cf365c48ec7f1a3_I20220915" decimals="-5" name="auph:ResearchAndDevelopmentArrangementContractToPerformMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183My9mcmFnOjU1ZDc2NmJjNDc3ZjRhZjk4YjlmMjk3ZWFkM2RkMjM2L3RleHRyZWdpb246NTVkNzY2YmM0NzdmNGFmOThiOWYyOTdlYWQzZGQyMzZfNzU5Mg_3e5bbcce-d2c1-4df9-94cc-5606b95397c7">30.0</ix:nonFraction>&#160;million milestone to the Company, which was recognized as collaboration revenue in the three and nine months period ended September&#160;30, 2022 and was subsequently received on October 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September&#160;30, 2022, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i81ca80b01c3949bc93f26e42672ea414_D20220701-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183My9mcmFnOjU1ZDc2NmJjNDc3ZjRhZjk4YjlmMjk3ZWFkM2RkMjM2L3RleHRyZWdpb246NTVkNzY2YmM0NzdmNGFmOThiOWYyOTdlYWQzZGQyMzZfNjA0NzMxMzk2MjA3Ng_9f45fc79-9d09-4036-a460-e3036d2e51bf">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2297b01889a7491d85e8a7f9850e7bfc_D20220101-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183My9mcmFnOjU1ZDc2NmJjNDc3ZjRhZjk4YjlmMjk3ZWFkM2RkMjM2L3RleHRyZWdpb246NTVkNzY2YmM0NzdmNGFmOThiOWYyOTdlYWQzZGQyMzZfODc5NjA5MzAzNDEzNA_f88c884f-2460-4e39-8142-d957072d26d3">0.4</ix:nonFraction> million, respectively, of collaboration service revenue from Otsuka. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Riptide License</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 17, 2021, AUR300 (M2 macrophage modulation via CD206 binding) was secured through a global licensing and research agreement with Riptide Bioscience, Inc. (Riptide), a private company. As part of the agreement, in 2021 the Company paid Riptide an upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="ia6745a5042314bd3ac418f4f36aac11f_D20210817-20210817" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183My9mcmFnOjU1ZDc2NmJjNDc3ZjRhZjk4YjlmMjk3ZWFkM2RkMjM2L3RleHRyZWdpb246NTVkNzY2YmM0NzdmNGFmOThiOWYyOTdlYWQzZGQyMzZfMjU4Mg_6b44f803-3e47-4b08-b5bc-9fa9a3f6763d">6.0</ix:nonFraction>&#160;million which was expensed as research and development on the condensed consolidated statements of operations. During the first quarter of 2022, Aurinia paid $<ix:nonFraction unitRef="usd" contextRef="i7e7f455148c3452faa9d3f2b5d9c272f_D20220101-20220331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183My9mcmFnOjU1ZDc2NmJjNDc3ZjRhZjk4YjlmMjk3ZWFkM2RkMjM2L3RleHRyZWdpb246NTVkNzY2YmM0NzdmNGFmOThiOWYyOTdlYWQzZGQyMzZfMjczNQ_dbb7603c-408a-4533-9454-2faa532654eb">4.0</ix:nonFraction>&#160;million for the achievement of a one-time milestone. Additional payments are due upon certain development, clinical and regulatory milestones, and royalties will be payable upon commercialization.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RleHRyZWdpb246ODQ4N2ZlZmEwNzdmNDdmMzliYzMwNjRkYTA1ZjE5ZDJfNjEz_a89df5f4-5759-478e-bf5e-4a316385e950" continuedAt="i09433315b10e49a188a417c6405ebaab" escape="true">Net Loss per Common Share</ix:nonNumeric></span></div><ix:continuation id="i09433315b10e49a188a417c6405ebaab"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share. <ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RleHRyZWdpb246ODQ4N2ZlZmEwNzdmNDdmMzliYzMwNjRkYTA1ZjE5ZDJfNjE0_d6b94c93-4e7e-4e8c-a0a3-fbec4a0b5005" continuedAt="i087ab346fbd24e129bc063346d4f006d" escape="true">The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows:</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><ix:continuation id="i087ab346fbd24e129bc063346d4f006d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.683%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfMi0yLTEtMS02ODc5NQ_c73fa4d2-b2f1-4f6c-96c7-2e75599b0882">8,989</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfMi00LTEtMS02ODc5NQ_2fae839c-b95b-444a-84b6-a6af98b12e20">50,255</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfMi02LTEtMS02ODc5NQ_b1df6359-2567-40fb-80aa-bdf327e8d662">82,134</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfMi04LTEtMS02ODc5NQ_8e151243-12ca-443e-9333-2b7dd5992450">147,644</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfMy0yLTEtMS02ODc5NQ_2f6f4577-4aae-498f-bc00-db2290c5958c"><ix:nonFraction unitRef="shares" contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfMy0yLTEtMS02ODc5NQ_8de6666d-c0cc-4c47-9325-47629ca2234f">141,856</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfMy00LTEtMS02ODc5NQ_4ac79ce8-694a-4ae4-9a02-65d155ae1c8c"><ix:nonFraction unitRef="shares" contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfMy00LTEtMS02ODc5NQ_c8bf3ac4-84c1-4291-a588-bcce36602e4d">128,443</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfMy02LTEtMS02ODc5NQ_37a95419-36d0-4d38-adae-31253d4a387d"><ix:nonFraction unitRef="shares" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfMy02LTEtMS02ODc5NQ_c8fedb66-8dc5-4220-98a3-c77d43e50d1b">141,831</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfMy04LTEtMS02ODc5NQ_32e2352f-c254-43ba-94ae-4e53c4979b68"><ix:nonFraction unitRef="shares" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfMy04LTEtMS02ODc5NQ_ce59f9bd-4250-40e5-baa7-145a84bf684d">128,084</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share (expressed in $ per share)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfNC0yLTEtMS02ODc5NQ_b7599d8e-c50e-4a95-a92e-d7c623250ed7"><ix:nonFraction unitRef="usdPerShare" contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfNC0yLTEtMS02ODc5NQ_e6a46748-e86b-40eb-828c-108ede09c663">0.06</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfNC00LTEtMS02ODc5NQ_4fce060b-700a-419b-8641-047039f2aeaa"><ix:nonFraction unitRef="usdPerShare" contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfNC00LTEtMS02ODc5NQ_e4f4c6c0-8b7b-407c-aae6-bfccf6800823">0.39</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfNC02LTEtMS02ODc5NS90ZXh0cmVnaW9uOjQ2M2I1YTViM2JjNjQ2NzBhNGJkNTgyYTc1YjdiOWRlXzQ_a1f5937a-b012-468b-9e86-4e5a1d1d1bf6"><ix:nonFraction unitRef="usdPerShare" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfNC02LTEtMS02ODc5NS90ZXh0cmVnaW9uOjQ2M2I1YTViM2JjNjQ2NzBhNGJkNTgyYTc1YjdiOWRlXzQ_ecea9620-3dde-456d-a067-e863ad066b8a">0.58</ix:nonFraction></ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfNC04LTEtMS02ODc5NS90ZXh0cmVnaW9uOmVmYjA4ZmFmYmZmODRlOWY4MmY5M2I1MDJiNzM2YmMzXzQ_ac7df738-dd03-492e-b4b2-0f8f821c250c"><ix:nonFraction unitRef="usdPerShare" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfNC04LTEtMS02ODc5NS90ZXh0cmVnaW9uOmVmYjA4ZmFmYmZmODRlOWY4MmY5M2I1MDJiNzM2YmMzXzQ_fa406006-2a74-469b-ab4e-23069c25d9a1">1.15</ix:nonFraction></ix:nonFraction>)</span></div></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RleHRyZWdpb246ODQ4N2ZlZmEwNzdmNDdmMzliYzMwNjRkYTA1ZjE5ZDJfNjEy_21f2f967-5b7a-40e5-a702-9f2f4040aaf8" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not include the securities in the following table in the computation of the net loss per common share because the effect would have been anti-dilutive during each period:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00d7e31976534d258d0e07349aba01f3_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOjlhYTAzNjE0MGE5NzQ4OTg4Y2EwMWQyYWMxMDkxMTQxL3RhYmxlcmFuZ2U6OWFhMDM2MTQwYTk3NDg5ODhjYTAxZDJhYzEwOTExNDFfMi0yLTEtMS02ODc5NQ_35b4d04f-3399-449a-a435-332dcf2f6432">14,299</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i805aaa2562214865ab8c371faa3a53b2_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOjlhYTAzNjE0MGE5NzQ4OTg4Y2EwMWQyYWMxMDkxMTQxL3RhYmxlcmFuZ2U6OWFhMDM2MTQwYTk3NDg5ODhjYTAxZDJhYzEwOTExNDFfMi00LTEtMS02ODc5NQ_c9f6ceaf-bf51-4f37-bccb-5081bf49561f">12,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested performance awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icc8095d666774c36bf30723faadf9ce6_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOjlhYTAzNjE0MGE5NzQ4OTg4Y2EwMWQyYWMxMDkxMTQxL3RhYmxlcmFuZ2U6OWFhMDM2MTQwYTk3NDg5ODhjYTAxZDJhYzEwOTExNDFfMy0yLTEtMS02ODc5NQ_4fb58457-8b03-4b4c-be16-211b93125a44">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2e834a4131b9497aa7197b83f5903f9c_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOjlhYTAzNjE0MGE5NzQ4OTg4Y2EwMWQyYWMxMDkxMTQxL3RhYmxlcmFuZ2U6OWFhMDM2MTQwYTk3NDg5ODhjYTAxZDJhYzEwOTExNDFfMy00LTEtMS02ODc5NQ_7698d05f-8f30-4dce-8440-e8a491427374">857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i13cbe039556149bf854d1dbc12844c1e_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOjlhYTAzNjE0MGE5NzQ4OTg4Y2EwMWQyYWMxMDkxMTQxL3RhYmxlcmFuZ2U6OWFhMDM2MTQwYTk3NDg5ODhjYTAxZDJhYzEwOTExNDFfNC0yLTEtMS02ODc5NQ_c153ee83-406f-4d35-9f1b-3823b543f965">2,098</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic61229edf4264d52a22130a0c3be9d0a_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOjlhYTAzNjE0MGE5NzQ4OTg4Y2EwMWQyYWMxMDkxMTQxL3RhYmxlcmFuZ2U6OWFhMDM2MTQwYTk3NDg5ODhjYTAxZDJhYzEwOTExNDFfNC00LTEtMS02ODc5NQ_9cd5ba7d-9b7c-478c-a1a3-814ce8409a94">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5279b4da301648499575592309f9f17e_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOjlhYTAzNjE0MGE5NzQ4OTg4Y2EwMWQyYWMxMDkxMTQxL3RhYmxlcmFuZ2U6OWFhMDM2MTQwYTk3NDg5ODhjYTAxZDJhYzEwOTExNDFfNS0yLTEtMS02ODc5NQ_a119d7cc-9dcf-4291-b57b-961d106c9b69">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b1a989842e543fabb7e5905343568bb_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOjlhYTAzNjE0MGE5NzQ4OTg4Y2EwMWQyYWMxMDkxMTQxL3RhYmxlcmFuZ2U6OWFhMDM2MTQwYTk3NDg5ODhjYTAxZDJhYzEwOTExNDFfNS00LTEtMS02ODc5NQ_450e58ad-d4db-4267-a64a-a98d86b5765b">1,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOjlhYTAzNjE0MGE5NzQ4OTg4Y2EwMWQyYWMxMDkxMTQxL3RhYmxlcmFuZ2U6OWFhMDM2MTQwYTk3NDg5ODhjYTAxZDJhYzEwOTExNDFfNi0yLTEtMS02ODc5NQ_e81c354e-40f3-4b22-91f5-424465bdca7b">16,397</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOjlhYTAzNjE0MGE5NzQ4OTg4Y2EwMWQyYWMxMDkxMTQxL3RhYmxlcmFuZ2U6OWFhMDM2MTQwYTk3NDg5ODhjYTAxZDJhYzEwOTExNDFfNi00LTEtMS02ODc5NQ_34032153-94c3-4f49-ad5f-92cb0e524df8">14,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_79"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfNTc4Nw_5136c0db-83ce-4041-b9a2-450f4984cba0" continuedAt="i4c422029e6aa4789957607b313d5b71b" escape="true">Share-based Compensation</ix:nonNumeric></span></div><ix:continuation id="i4c422029e6aa4789957607b313d5b71b" continuedAt="i02f45acd69954ecf898279d21e0d4cb9"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Amended and Restated Equity Incentive Plan (the Plan), which was adopted and approved by the Company's shareholders in June 2021, allows for an issuance of up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="i2e55bb773ff34dceb51b86c13030f998_D20210601-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfMjIy_b866e602-4f8a-4d50-89ce-8f0ff4a8c309">23.8</ix:nonFraction> million shares (inclusive of then outstanding awards) and provides for grants of stock options, performance awards, and restricted stock units (RSUs) that may be settled in cash and common shares. Also in June 2021, the Company's shareholders adopted and approved the Company's 2021 ESPP, which allows for the issuance of up to <ix:nonFraction unitRef="shares" contextRef="i5685017490fa48d98ee11fbfaba4943f_I20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfNTYy_b739828a-4710-4c19-8064-3787c823299e">2.5</ix:nonFraction> million shares. The 2021 ESPP is intended to qualify as an &#8220;employee stock purchase plan&#8221; under Section 423 of the Internal Revenue Code (the Code) but also permits the Company to include the employees, including non-United States employees, in offerings not intended to qualify under Section 423. The purpose of the 2021 ESPP is to provide eligible employees with opportunities to purchase the Company&#8217;s common shares at a discounted price.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2022, the Company modified the 2021 ESPP for the current and future offerings. The new ESPP terms shortened the plan from <ix:nonFraction unitRef="purchase_period" contextRef="i141c5810302b4f94afd3d50f70c69c68_D20210101-20211231" decimals="INF" name="auph:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfMTE1Mg_7278e8f8-4702-4f20-9b47-c8524be54565">four</ix:nonFraction> (4) purchases over a <ix:nonNumeric contextRef="i141c5810302b4f94afd3d50f70c69c68_D20210101-20211231" name="auph:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfNTc4OA_f517359d-fe07-41ab-b75a-08c53e3f1d16">24</ix:nonNumeric> month Offering Period to <ix:nonFraction unitRef="purchase_period" contextRef="ic9213ee7781c41f3a44fe9ed868b853a_D20220401-20220630" decimals="INF" name="auph:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfMTIwNA_133f152e-4884-4658-a796-a84ffaf5af0f">two</ix:nonFraction> (2) purchases over a <ix:nonNumeric contextRef="ic9213ee7781c41f3a44fe9ed868b853a_D20220401-20220630" name="auph:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfNTc5Mg_b5c2c45e-83c5-40c6-b4b5-0a1dd9ebfa4d">12</ix:nonNumeric> month offering period. Additionally, the ESPP now contains a rollover mechanism; that is, if the stock price on the purchase date is less than the offering price (as that is determined under the 2021 ESPP), that offering is then canceled and any participants are rolled into the new <ix:nonNumeric contextRef="ic9213ee7781c41f3a44fe9ed868b853a_D20220401-20220630" name="auph:ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfNTc4Mw_8891bb6c-80a3-4a05-9da6-0feb6c804b92">12</ix:nonNumeric> month offering period at the lower price.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As a result of the modification, $<ix:nonFraction unitRef="usd" contextRef="idc1689ad65c84b429cf133572117af7a_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfMTU5Mw_3612dbd1-bda4-4673-a83e-b57047263298">475</ix:nonFraction>&#160;thousand of incremental expense was added to the estimated expense for the November 2022 and May 2023 purchase dates (to be amortized over the new <ix:nonNumeric contextRef="idc1689ad65c84b429cf133572117af7a_D20220101-20220930" name="auph:ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfNTc4OQ_a4eead4e-9ce3-4f6f-a674-0fb9ae5dd3cd">12</ix:nonNumeric> month offering period). Additionally, the originally scheduled purchase date in November 2023 is no longer planned given the new <ix:nonNumeric contextRef="idc1689ad65c84b429cf133572117af7a_D20220101-20220930" name="auph:ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfNTc4NA_08db3686-61c0-457d-9f6c-bc4ecb7cb171">12</ix:nonNumeric> month offering period; therefore, the modification also resulted in a &#8220;repurchase for no consideration&#8221; under ASC 718. The Company recognized an additional $<ix:nonFraction unitRef="usd" contextRef="idc1689ad65c84b429cf133572117af7a_D20220101-20220930" decimals="-3" name="auph:ShareBasedPaymentArrangementUnamortizedExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfMjAyNQ_2d2700c0-bda7-4967-9c2b-567b25e89243">651</ix:nonFraction>&#160;thousand of unamortized expense for the cancelled November 2023 purchase, which was recorded during the second quarter of 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to stock options, performance awards and RSUs granted under the Plan, the Company has granted certain stock options and RSUs as inducements material to new employees entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The inducements were granted outside of the Plan during 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i02f45acd69954ecf898279d21e0d4cb9" continuedAt="ibc824445236f48cab5b06fc452e8552d"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plan requires the exercise price of each option not to be less than the closing market price of the Company&#8217;s common shares on the day immediately prior to the date of grant. The board of directors approves the vesting criteria and periods at its discretion. The options issued under the plan are accounted for as equity-settled share-based payments. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used the Black-Scholes option pricing model to estimate the fair value of the options granted. The Company considers historical volatility of its common shares in estimating its future stock price volatility. The risk-free interest rate for the expected life of the options was based on the yield available on government benchmark bonds with an approximate equivalent remaining term at the time of the grant. The expected life is based upon the contractual term, taking into account expected employee exercise and expected post-vesting employment termination behavior. </span></div><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfNTc5Mw_d2712560-228b-46fc-84ba-e31a07c7be72" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted average assumptions were used to estimate the fair value of the options granted during the nine months ended September&#160;30, 2022 and September&#160;30, 2021:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annualized volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmU5ZDk0M2U2ODViMTRlMDc5ODUyOGQ0ZDYwNDIwN2QwL3RhYmxlcmFuZ2U6ZTlkOTQzZTY4NWIxNGUwNzk4NTI4ZDRkNjA0MjA3ZDBfMS0yLTEtMS02ODc5NQ_9c5eb342-a00e-4a03-a7bd-45334bbaf031">70</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmU5ZDk0M2U2ODViMTRlMDc5ODUyOGQ0ZDYwNDIwN2QwL3RhYmxlcmFuZ2U6ZTlkOTQzZTY4NWIxNGUwNzk4NTI4ZDRkNjA0MjA3ZDBfMS00LTEtMS02ODc5NQ_8f34046a-fcbd-4787-a409-b945674c9495">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmU5ZDk0M2U2ODViMTRlMDc5ODUyOGQ0ZDYwNDIwN2QwL3RhYmxlcmFuZ2U6ZTlkOTQzZTY4NWIxNGUwNzk4NTI4ZDRkNjA0MjA3ZDBfMi0yLTEtMS02ODc5NQ_5f5b2a4b-9321-4038-9f31-a01ef46ca99c">2.01</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmU5ZDk0M2U2ODViMTRlMDc5ODUyOGQ0ZDYwNDIwN2QwL3RhYmxlcmFuZ2U6ZTlkOTQzZTY4NWIxNGUwNzk4NTI4ZDRkNjA0MjA3ZDBfMi00LTEtMS02ODc5NQ_756667ba-6706-4e99-8564-707b42b0aaa0">0.38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of options in years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmU5ZDk0M2U2ODViMTRlMDc5ODUyOGQ0ZDYwNDIwN2QwL3RhYmxlcmFuZ2U6ZTlkOTQzZTY4NWIxNGUwNzk4NTI4ZDRkNjA0MjA3ZDBfMy0yLTEtMS02ODc5NQ_8628180a-a62d-44d6-905c-0ca8d3d3d448">5.0</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmU5ZDk0M2U2ODViMTRlMDc5ODUyOGQ0ZDYwNDIwN2QwL3RhYmxlcmFuZ2U6ZTlkOTQzZTY4NWIxNGUwNzk4NTI4ZDRkNjA0MjA3ZDBfMy00LTEtMS02ODc5NQ_840b1ae5-9cf9-40b6-9001-d4df1fc72ab2">4.0</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated forfeiture rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="4" name="auph:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmU5ZDk0M2U2ODViMTRlMDc5ODUyOGQ0ZDYwNDIwN2QwL3RhYmxlcmFuZ2U6ZTlkOTQzZTY4NWIxNGUwNzk4NTI4ZDRkNjA0MjA3ZDBfNC0yLTEtMS02ODc5NQ_cf9bcd7c-380c-48f0-ae6d-11f739b3af2f">12.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="4" name="auph:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmU5ZDk0M2U2ODViMTRlMDc5ODUyOGQ0ZDYwNDIwN2QwL3RhYmxlcmFuZ2U6ZTlkOTQzZTY4NWIxNGUwNzk4NTI4ZDRkNjA0MjA3ZDBfNC00LTEtMS02ODc5NQ_53039eb5-ba15-4702-a736-5eab31af9213">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmU5ZDk0M2U2ODViMTRlMDc5ODUyOGQ0ZDYwNDIwN2QwL3RhYmxlcmFuZ2U6ZTlkOTQzZTY4NWIxNGUwNzk4NTI4ZDRkNjA0MjA3ZDBfNS0yLTEtMS02ODc5NQ_b7d4a8a8-1074-4d1e-8743-34b1976688be">0.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmU5ZDk0M2U2ODViMTRlMDc5ODUyOGQ0ZDYwNDIwN2QwL3RhYmxlcmFuZ2U6ZTlkOTQzZTY4NWIxNGUwNzk4NTI4ZDRkNjA0MjA3ZDBfNS00LTEtMS02ODc5NQ_9f4ec4d6-12b9-4573-bad1-a345344c6402">0.0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value per common share option</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmU5ZDk0M2U2ODViMTRlMDc5ODUyOGQ0ZDYwNDIwN2QwL3RhYmxlcmFuZ2U6ZTlkOTQzZTY4NWIxNGUwNzk4NTI4ZDRkNjA0MjA3ZDBfNi0yLTEtMS02ODc5NQ_e2d15d61-65ab-4638-b6e0-210136495cd9">6.60</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmU5ZDk0M2U2ODViMTRlMDc5ODUyOGQ0ZDYwNDIwN2QwL3RhYmxlcmFuZ2U6ZTlkOTQzZTY4NWIxNGUwNzk4NTI4ZDRkNjA0MjA3ZDBfNi00LTEtMS02ODc5NQ_3d0c34d9-af9c-4665-8bd8-dd94fd346adb">6.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfNTc4NQ_ea6d8a2c-d452-4ea2-965c-4d81304591c7" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the option award activity for the nine months ended September&#160;30, 2022:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of shares (in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price $</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjdjMTA5YjA2Njc5MTQ5NTVhMmFjMzA2OTVjZDQ3ZDVlL3RhYmxlcmFuZ2U6N2MxMDliMDY2NzkxNDk1NWEyYWMzMDY5NWNkNDdkNWVfMi0yLTEtMS02ODc5NQ_81f48d5a-b424-425d-8078-43937686ba79">12,074</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjdjMTA5YjA2Njc5MTQ5NTVhMmFjMzA2OTVjZDQ3ZDVlL3RhYmxlcmFuZ2U6N2MxMDliMDY2NzkxNDk1NWEyYWMzMDY5NWNkNDdkNWVfMi00LTEtMS02ODc5NQ_7c0477b0-8f1c-4662-bcd8-2c69e8868011">12.84</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjdjMTA5YjA2Njc5MTQ5NTVhMmFjMzA2OTVjZDQ3ZDVlL3RhYmxlcmFuZ2U6N2MxMDliMDY2NzkxNDk1NWEyYWMzMDY5NWNkNDdkNWVfMy0yLTEtMS02ODc5NQ_65622d42-c9fd-450a-83fe-7da3a425d771">3,809</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjdjMTA5YjA2Njc5MTQ5NTVhMmFjMzA2OTVjZDQ3ZDVlL3RhYmxlcmFuZ2U6N2MxMDliMDY2NzkxNDk1NWEyYWMzMDY5NWNkNDdkNWVfMy00LTEtMS02ODc5NQ_ce3785ee-cca1-4810-9db9-44da4d2d0970">11.25</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjdjMTA5YjA2Njc5MTQ5NTVhMmFjMzA2OTVjZDQ3ZDVlL3RhYmxlcmFuZ2U6N2MxMDliMDY2NzkxNDk1NWEyYWMzMDY5NWNkNDdkNWVfNC0yLTEtMS02ODc5NQ_21a01c79-c0b4-440f-88d7-6651f0ab6ab4">77</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjdjMTA5YjA2Njc5MTQ5NTVhMmFjMzA2OTVjZDQ3ZDVlL3RhYmxlcmFuZ2U6N2MxMDliMDY2NzkxNDk1NWEyYWMzMDY5NWNkNDdkNWVfNC00LTEtMS02ODc5NQ_e5fd7bd9-5235-41be-b0f9-2f84b43277cf">6.47</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjdjMTA5YjA2Njc5MTQ5NTVhMmFjMzA2OTVjZDQ3ZDVlL3RhYmxlcmFuZ2U6N2MxMDliMDY2NzkxNDk1NWEyYWMzMDY5NWNkNDdkNWVfNS0yLTEtMS02ODc5NQ_3e09209b-da7f-4e2f-91f2-2399078f2932">1,507</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjdjMTA5YjA2Njc5MTQ5NTVhMmFjMzA2OTVjZDQ3ZDVlL3RhYmxlcmFuZ2U6N2MxMDliMDY2NzkxNDk1NWEyYWMzMDY5NWNkNDdkNWVfNS00LTEtMS02ODc5NQ_e4ef5fac-40f6-4a33-b924-c3165f0acfa9">14.63</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjdjMTA5YjA2Njc5MTQ5NTVhMmFjMzA2OTVjZDQ3ZDVlL3RhYmxlcmFuZ2U6N2MxMDliMDY2NzkxNDk1NWEyYWMzMDY5NWNkNDdkNWVfNi0yLTEtMS02ODc5NQ_8b2f687e-0d89-43b1-9694-c28452d5dad6">14,299</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjdjMTA5YjA2Njc5MTQ5NTVhMmFjMzA2OTVjZDQ3ZDVlL3RhYmxlcmFuZ2U6N2MxMDliMDY2NzkxNDk1NWEyYWMzMDY5NWNkNDdkNWVfNi00LTEtMS02ODc5NQ_6a09d391-39d2-4e3c-baae-9aa1017da235">12.26</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Awards and Restricted Stock Units</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 23, 2020, the Company issued <ix:nonFraction unitRef="shares" contextRef="i50399ead67c54ca8bc4d5ef310825018_D20201023-20201023" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfMzk2MQ_a7570dad-7a4d-4534-af79-32da5bea7221">439,000</ix:nonFraction> PAs to executive management of the Company whose vesting was contingent upon meeting specific performance metrics based on the results for the year ended December 31, 2021. Each PA which vested entitled the participant to receive common shares on the basis of the performance metrics set. On March 18, 2021 performance metrics were set and formally communicated. Therefore, March 18, 2021 was the grant date and the fair value on the grant date was $<ix:nonFraction unitRef="usdPerShare" contextRef="i300f179e3ff14347817cbe32101e4854_D20210318-20210318" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfNDQxMw_0cf7b650-7fe1-4352-ab6f-2108aa8ad0bf">13.56</ix:nonFraction>. The PAs vested in 2022 and the participant was required to achieve at least one of the performance metrics to obtain the portion of the award associated with the metric.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2021, the Company granted approximately <ix:nonFraction unitRef="shares" contextRef="i93beb22f8ad34d9c947d6dafa4a95334_D20210806-20210806" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfNDYxNA_6748dda3-df4b-4ed8-9341-3a1502471f4f">619,000</ix:nonFraction> PAs and RSUs. The grant date for the PAs and RSUs was August 6, 2021 and the fair value on the grant date was $<ix:nonFraction unitRef="usdPerShare" contextRef="i93beb22f8ad34d9c947d6dafa4a95334_D20210806-20210806" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfNDcyNw_70b31072-1d4b-497e-b0b1-2dd9ab0752b8">14.42</ix:nonFraction> as this was the date performance measures were set and communicated to employees. The PAs vested on the employee's first anniversary of the grant date and the employee was required to achieve at least one of the performance metrics to obtain the portion of the award associated with the metric. The RSUs had no performance metrics and vested on the <ix:nonNumeric contextRef="i6dac794371204eeea2843a0a01c0643c_D20220101-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfNTA3MA_a10b57f9-e830-4717-b810-7b9b456d9b98">one year</ix:nonNumeric> anniversary of the grant.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the 2022, the Company has granted RSUs and intends to grant RSUs throughout the year under the Plan, as well as inducements for certain new hires as discussed above. The RSUs are fair valued based on the market price of our common shares on the date of the grant.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ibc824445236f48cab5b06fc452e8552d"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfNTc5MQ_53a2bcf5-e92d-42dd-97b9-66cfb2c0db87" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the PA and RSU activity for the nine months ended September&#160;30, 2022:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of shares (in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price $</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b58579e74a9437291aa1de82c974264_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjNhMzdlNTlkNDg4YjQ4ZmRiNzkzNmE5MDdiMDJiMjBiL3RhYmxlcmFuZ2U6M2EzN2U1OWQ0ODhiNDhmZGI3OTM2YTkwN2IwMmIyMGJfMi0yLTEtMS02ODc5NQ_6fa2ad18-fd92-48db-b7f1-028f023836ba">347</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2b58579e74a9437291aa1de82c974264_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjNhMzdlNTlkNDg4YjQ4ZmRiNzkzNmE5MDdiMDJiMjBiL3RhYmxlcmFuZ2U6M2EzN2U1OWQ0ODhiNDhmZGI3OTM2YTkwN2IwMmIyMGJfMi00LTEtMS02ODc5NQ_5e860032-9a0e-4b1f-814f-a88849c7f8f9">13.33</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3c18e125ab214150a60e144497c275d2_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjNhMzdlNTlkNDg4YjQ4ZmRiNzkzNmE5MDdiMDJiMjBiL3RhYmxlcmFuZ2U6M2EzN2U1OWQ0ODhiNDhmZGI3OTM2YTkwN2IwMmIyMGJfMy0yLTEtMS02ODc5NQ_48aa4325-bbcc-40d8-bb35-c8d54d3d3c86">2,311</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3c18e125ab214150a60e144497c275d2_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjNhMzdlNTlkNDg4YjQ4ZmRiNzkzNmE5MDdiMDJiMjBiL3RhYmxlcmFuZ2U6M2EzN2U1OWQ0ODhiNDhmZGI3OTM2YTkwN2IwMmIyMGJfMy00LTEtMS02ODc5NQ_a29b8d04-4700-4eda-a4ff-7b93d8440e60">11.26</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3c18e125ab214150a60e144497c275d2_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjNhMzdlNTlkNDg4YjQ4ZmRiNzkzNmE5MDdiMDJiMjBiL3RhYmxlcmFuZ2U6M2EzN2U1OWQ0ODhiNDhmZGI3OTM2YTkwN2IwMmIyMGJfNC0yLTEtMS02ODc5NQ_f791e65e-45bd-4f30-bdcc-115ac0d4c31d">305</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3c18e125ab214150a60e144497c275d2_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjNhMzdlNTlkNDg4YjQ4ZmRiNzkzNmE5MDdiMDJiMjBiL3RhYmxlcmFuZ2U6M2EzN2U1OWQ0ODhiNDhmZGI3OTM2YTkwN2IwMmIyMGJfNC00LTEtMS02ODc5NQ_ab4daf32-a54e-4475-b534-fcaddeb7e490">14.17</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3c18e125ab214150a60e144497c275d2_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjNhMzdlNTlkNDg4YjQ4ZmRiNzkzNmE5MDdiMDJiMjBiL3RhYmxlcmFuZ2U6M2EzN2U1OWQ0ODhiNDhmZGI3OTM2YTkwN2IwMmIyMGJfNS0yLTEtMS02ODc5NQ_ac058427-ba1c-45f4-b28c-cd4592ada0b5">255</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3c18e125ab214150a60e144497c275d2_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjNhMzdlNTlkNDg4YjQ4ZmRiNzkzNmE5MDdiMDJiMjBiL3RhYmxlcmFuZ2U6M2EzN2U1OWQ0ODhiNDhmZGI3OTM2YTkwN2IwMmIyMGJfNS00LTEtMS02ODc5NQ_c3e8e264-3559-4eb9-a7ac-e7ac5280b339">12.39</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iccc401454be24c33a5c889e8fc773573_I20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjNhMzdlNTlkNDg4YjQ4ZmRiNzkzNmE5MDdiMDJiMjBiL3RhYmxlcmFuZ2U6M2EzN2U1OWQ0ODhiNDhmZGI3OTM2YTkwN2IwMmIyMGJfNi0yLTEtMS02ODc5NQ_8892e87e-3c56-438e-b7d0-2caeecd3be4a">2,098</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iccc401454be24c33a5c889e8fc773573_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjNhMzdlNTlkNDg4YjQ4ZmRiNzkzNmE5MDdiMDJiMjBiL3RhYmxlcmFuZ2U6M2EzN2U1OWQ0ODhiNDhmZGI3OTM2YTkwN2IwMmIyMGJfNi00LTEtMS02ODc5NQ_b2f1bccb-7d8e-4f03-ab22-1d476402cdd3">11.04</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Expense</span></div><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfNTc4Ng_6a782ad5-b363-4f74-bb35-40cbbd92aa10" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized share-based compensation expense for the three and nine month periods ended September&#160;30, 2022 and September&#160;30, 2021 as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.683%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7fef15dae2646efa24f1995243223c6_D20220701-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmE1NTE3MjI0NGUzMjRkZmM5NzlhMzRjNDhhMWIxZjRmL3RhYmxlcmFuZ2U6YTU1MTcyMjQ0ZTMyNGRmYzk3OWEzNGM0OGExYjFmNGZfMi0yLTEtMS02ODc5NQ_4c72b30e-332f-49cc-bc91-aae936927f88">1,489</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41e86bba83634e53a5535985a6f3f748_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmE1NTE3MjI0NGUzMjRkZmM5NzlhMzRjNDhhMWIxZjRmL3RhYmxlcmFuZ2U6YTU1MTcyMjQ0ZTMyNGRmYzk3OWEzNGM0OGExYjFmNGZfMi00LTEtMS02ODc5NQ_a99195d9-6ee3-4afe-8049-762ad897728b">1,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i955689f54f8c4df3a7afd2244253bc6d_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmE1NTE3MjI0NGUzMjRkZmM5NzlhMzRjNDhhMWIxZjRmL3RhYmxlcmFuZ2U6YTU1MTcyMjQ0ZTMyNGRmYzk3OWEzNGM0OGExYjFmNGZfMi02LTEtMS02ODc5NQ_5f861c07-1e0a-454f-bdd2-f0cfe01c6c78">3,531</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7ac41ae30d34bb5830b64dd0083e341_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmE1NTE3MjI0NGUzMjRkZmM5NzlhMzRjNDhhMWIxZjRmL3RhYmxlcmFuZ2U6YTU1MTcyMjQ0ZTMyNGRmYzk3OWEzNGM0OGExYjFmNGZfMi04LTEtMS02ODc5NQ_d645e456-f9d6-494c-9be0-6b7103963c5b">3,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib20172c5476e4c24ba772f206955d222_D20220701-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmE1NTE3MjI0NGUzMjRkZmM5NzlhMzRjNDhhMWIxZjRmL3RhYmxlcmFuZ2U6YTU1MTcyMjQ0ZTMyNGRmYzk3OWEzNGM0OGExYjFmNGZfMy0yLTEtMS02ODc5NQ_259e0b5c-b88f-4247-bba5-1ca9813c86de">6,625</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa46d448221541eea1922a7412dadd8d_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmE1NTE3MjI0NGUzMjRkZmM5NzlhMzRjNDhhMWIxZjRmL3RhYmxlcmFuZ2U6YTU1MTcyMjQ0ZTMyNGRmYzk3OWEzNGM0OGExYjFmNGZfMy00LTEtMS02ODc5NQ_5ad26f0f-ab50-46b7-80f6-b039bba3d2d1">6,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950b5dba05e8467bb230db400bb54c89_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmE1NTE3MjI0NGUzMjRkZmM5NzlhMzRjNDhhMWIxZjRmL3RhYmxlcmFuZ2U6YTU1MTcyMjQ0ZTMyNGRmYzk3OWEzNGM0OGExYjFmNGZfMy02LTEtMS02ODc5NQ_f6c62b59-4eb1-4ba0-97d5-c622e5c511c7">21,480</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92f1f72ffef04012bdf6f2e23691fde6_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmE1NTE3MjI0NGUzMjRkZmM5NzlhMzRjNDhhMWIxZjRmL3RhYmxlcmFuZ2U6YTU1MTcyMjQ0ZTMyNGRmYzk3OWEzNGM0OGExYjFmNGZfMy04LTEtMS02ODc5NQ_0c053a3b-6df4-409b-a84e-fced33243b05">19,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized under inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31e34ae4d79d4a16962c6e8ca983e3f6_D20220701-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmE1NTE3MjI0NGUzMjRkZmM5NzlhMzRjNDhhMWIxZjRmL3RhYmxlcmFuZ2U6YTU1MTcyMjQ0ZTMyNGRmYzk3OWEzNGM0OGExYjFmNGZfNC0yLTEtMS02ODc5NQ_2b235d5a-5fd5-457d-9e9a-0f9584b83bb5">206</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84deabd17e064c569d85797d9b5eda83_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmE1NTE3MjI0NGUzMjRkZmM5NzlhMzRjNDhhMWIxZjRmL3RhYmxlcmFuZ2U6YTU1MTcyMjQ0ZTMyNGRmYzk3OWEzNGM0OGExYjFmNGZfNC00LTEtMS02ODc5NQ_e6fcb77d-4983-41b0-bcd9-5ecced913e2b">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3566507c79934103bc6f40ab688f624a_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmE1NTE3MjI0NGUzMjRkZmM5NzlhMzRjNDhhMWIxZjRmL3RhYmxlcmFuZ2U6YTU1MTcyMjQ0ZTMyNGRmYzk3OWEzNGM0OGExYjFmNGZfNC02LTEtMS02ODc5NQ_b8128654-120c-4bd7-a9cb-2bcf0da5698a">387</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ef75c4fe6024db197c096eb57a144ea_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmE1NTE3MjI0NGUzMjRkZmM5NzlhMzRjNDhhMWIxZjRmL3RhYmxlcmFuZ2U6YTU1MTcyMjQ0ZTMyNGRmYzk3OWEzNGM0OGExYjFmNGZfNC04LTEtMS02ODc5NQ_57183706-0cee-433a-9aae-9c556f8fbe18">276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmE1NTE3MjI0NGUzMjRkZmM5NzlhMzRjNDhhMWIxZjRmL3RhYmxlcmFuZ2U6YTU1MTcyMjQ0ZTMyNGRmYzk3OWEzNGM0OGExYjFmNGZfNS0yLTEtMS02ODc5NQ_9d8ba67d-de9a-468c-814d-f74540b93ab1">8,320</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmE1NTE3MjI0NGUzMjRkZmM5NzlhMzRjNDhhMWIxZjRmL3RhYmxlcmFuZ2U6YTU1MTcyMjQ0ZTMyNGRmYzk3OWEzNGM0OGExYjFmNGZfNS00LTEtMS02ODc5NQ_ec7359b4-1d06-4e0e-9a76-efdba30ae05e">7,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmE1NTE3MjI0NGUzMjRkZmM5NzlhMzRjNDhhMWIxZjRmL3RhYmxlcmFuZ2U6YTU1MTcyMjQ0ZTMyNGRmYzk3OWEzNGM0OGExYjFmNGZfNS02LTEtMS02ODc5NQ_1a3eda00-d1ca-4dfb-a339-cdcb6dd61e97">25,398</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmE1NTE3MjI0NGUzMjRkZmM5NzlhMzRjNDhhMWIxZjRmL3RhYmxlcmFuZ2U6YTU1MTcyMjQ0ZTMyNGRmYzk3OWEzNGM0OGExYjFmNGZfNS04LTEtMS02ODc5NQ_9bfa44ed-27b7-4766-87fd-b32e65026f82">22,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of September&#160;30, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfNTYwNA_ff3635ed-62c3-4f90-b853-d34a99933b4e">33.6</ix:nonFraction>&#160;million of unrecognized share-based compensation expense related to unvested awards granted which is expected to be recognized over a weighted-average period of approximately <ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfNTc3NA_02099802-d2fb-45bc-8064-db3ab612c6fe">1.4</ix:nonNumeric> years.</span></div></ix:continuation><div style="margin-top:7pt;text-align:justify"><span><br/></span></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_82"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY184Mi9mcmFnOjMxOTEwNWVjOTFlODQwOWNiOGU3NDQ0ZGZhM2ZmNjk5L3RleHRyZWdpb246MzE5MTA1ZWM5MWU4NDA5Y2I4ZTc0NDRkZmEzZmY2OTlfMTAyMQ_59f70ea8-8865-41af-8b56-d67226ce24ee" continuedAt="ia23e8281c47b4adcb5f806fbb0e794b5" escape="true">Income Taxes</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ia23e8281c47b4adcb5f806fbb0e794b5"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rates for the three and nine months ended September&#160;30, 2022 and September&#160;30, 2021 differed from the federal statutory rate applied to losses before income taxes primarily as a result of the mix of income, losses and valuation allowances. The Company recognized an income tax expense of approximately $<ix:nonFraction unitRef="usd" contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY184Mi9mcmFnOjMxOTEwNWVjOTFlODQwOWNiOGU3NDQ0ZGZhM2ZmNjk5L3RleHRyZWdpb246MzE5MTA1ZWM5MWU4NDA5Y2I4ZTc0NDRkZmEzZmY2OTlfNTQ5NzU1ODE1MDYx_16822bc4-41cd-419a-b116-2bb4a8e21b70"><ix:nonFraction unitRef="usd" contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY184Mi9mcmFnOjMxOTEwNWVjOTFlODQwOWNiOGU3NDQ0ZGZhM2ZmNjk5L3RleHRyZWdpb246MzE5MTA1ZWM5MWU4NDA5Y2I4ZTc0NDRkZmEzZmY2OTlfNTQ5NzU1ODE1MDYx_c5fea533-9251-4506-90c4-79cddabf16e8">1.0</ix:nonFraction></ix:nonFraction> million for the three and nine months ended September&#160;30, 2022. The Company recognized an income tax expense of approximately $<ix:nonFraction unitRef="usd" contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY184Mi9mcmFnOjMxOTEwNWVjOTFlODQwOWNiOGU3NDQ0ZGZhM2ZmNjk5L3RleHRyZWdpb246MzE5MTA1ZWM5MWU4NDA5Y2I4ZTc0NDRkZmEzZmY2OTlfNTQ5NzU1ODE1MTM3_95bfe8fb-7a15-4267-a190-62384ee2953d">8</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY184Mi9mcmFnOjMxOTEwNWVjOTFlODQwOWNiOGU3NDQ0ZGZhM2ZmNjk5L3RleHRyZWdpb246MzE5MTA1ZWM5MWU4NDA5Y2I4ZTc0NDRkZmEzZmY2OTlfNTQ5NzU1ODE1MTQz_722f454f-d1c2-4f29-9d7e-43db4be8a975">34</ix:nonFraction> thousand for the three and nine months ended September&#160;30, 2021, respectively. The expense recognized for these periods is a result of income in certain jurisdictions and withholding taxes on foreign income. The Company currently has tax expense in certain jurisdictions that are not offset by tax benefits. The increase from prior periods was due to withholding taxes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Uncertain Tax Positions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was under examination by the Canadian Revenue Agency for years 2017 and 2018. In March 2022, the Company was notified by the Canadian Revenue Agency that the examination is now complete and there were no findings and as a result, there is no additional tax expense or benefit recognized in regards to the audit. There are no outstanding tax audits ongoing at September&#160;30, 2022.</span></div></ix:continuation><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_85"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY184NS9mcmFnOjcwNWQ0OTNjZWM2OTRjMmQ4OTMxOTk1OTBhMTVhNDI5L3RleHRyZWdpb246NzA1ZDQ5M2NlYzY5NGMyZDg5MzE5OTU5MGExNWE0MjlfNDM4_c1ede05f-460a-414e-9d58-1316c07de90a" continuedAt="ia08562dfafb3428ba73fc83ba53195de" escape="true">Related Party Transactions</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia08562dfafb3428ba73fc83ba53195de">ILJIN SNT Co., Ltd (ILJIN) was considered to be a related party due to their equity ownership of over 5% as per their public filing. The outstanding related party amount payable to ILJIN was the result of a settlement completed on September 20, 2013 between ILJIN and the Company. During 2021, Aurinia paid ILJIN $<ix:nonFraction unitRef="usd" contextRef="i6a603236462942e0951722c7b53081bd_D20210101-20211231" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY184NS9mcmFnOjcwNWQ0OTNjZWM2OTRjMmQ4OTMxOTk1OTBhMTVhNDI5L3RleHRyZWdpb246NzA1ZDQ5M2NlYzY5NGMyZDg5MzE5OTU5MGExNWE0MjlfMzQ1_a043d8ab-3b30-4742-b920-d7bc15c2cb17">6.0</ix:nonFraction>&#160;million upon achievement of specific milestones. The amount payable to ILJIN is <ix:nonFraction unitRef="usd" contextRef="i600c866525944e51adcfcdad3efc98eb_I20211231" decimals="INF" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY184NS9mcmFnOjcwNWQ0OTNjZWM2OTRjMmQ4OTMxOTk1OTBhMTVhNDI5L3RleHRyZWdpb246NzA1ZDQ5M2NlYzY5NGMyZDg5MzE5OTU5MGExNWE0MjlfNDIw_aa3c34c3-9beb-45c7-8ead-42932dd63dc5"><ix:nonFraction unitRef="usd" contextRef="i68a01b7c21f844ae96d03ac2032c0e28_I20220930" decimals="INF" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY184NS9mcmFnOjcwNWQ0OTNjZWM2OTRjMmQ4OTMxOTk1OTBhMTVhNDI5L3RleHRyZWdpb246NzA1ZDQ5M2NlYzY5NGMyZDg5MzE5OTU5MGExNWE0MjlfNDIw_fd775a7f-91a1-4e55-9e3e-27815a4de38e">nil</ix:nonFraction></ix:nonFraction> as of September&#160;30, 2022 and December&#160;31, 2021.</ix:continuation></span></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_88"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY184OC9mcmFnOmMzZWEwMWNlNzU1NzRmMmFiNDQ3NGNiODY4NTY5NTQ5L3RleHRyZWdpb246YzNlYTAxY2U3NTU3NGYyYWI0NDc0Y2I4Njg1Njk1NDlfMTIwMg_866fc7cf-3632-4fc5-8298-00ae4d4c4f2f" continuedAt="ic605646119d34cfabd1f7750c8647cff" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic605646119d34cfabd1f7750c8647cff" continuedAt="i61cdb0eb64f64c1883ba4f71af89e6da">The Company may, from time to time, be subject to claims and legal proceedings brought against it in the normal course of business. Such matters are subject to many uncertainties. Management believes the ultimate resolution of such contingencies </ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i61cdb0eb64f64c1883ba4f71af89e6da"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will not have a material adverse effect on the consolidated financial position of the Company. The Company's material commitments and contingencies have not changed in any material manner from those previously described in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021 and the quarterly report for the quarter ended September&#160;30, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Funding Commitments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into agreements with contract research organizations, contract manufacturing organizations and other third parties for services to be provided to the Company. Generally, these agreements provide for termination upon notice, with specified amounts due upon termination based on the timing of termination and the terms of the agreement. The actual amounts and timing of payments under these agreements are uncertain and contingent upon the initiation and completion of services to be provided to the Company.</span></div></ix:continuation><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_91"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY185MS9mcmFnOmY4ZGFlZTY3MmRhOTQ5OTQ4MWMyNzIyMTQzNmNlZTAwL3RleHRyZWdpb246ZjhkYWVlNjcyZGE5NDk5NDgxYzI3MjIxNDM2Y2VlMDBfMTUyMQ_397ef8a4-0d0b-4c4e-8ea9-4ed163dda99a" continuedAt="i08fb55d146874b16b98f674409d4ab4f" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="i08fb55d146874b16b98f674409d4ab4f"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Compensation Committee granted <ix:nonFraction unitRef="employee" contextRef="ie1901be7a6424fe8a7f80634ccb66032_D20220930-20220930" decimals="INF" name="auph:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNewEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY185MS9mcmFnOmY4ZGFlZTY3MmRhOTQ5OTQ4MWMyNzIyMTQzNmNlZTAwL3RleHRyZWdpb246ZjhkYWVlNjcyZGE5NDk5NDgxYzI3MjIxNDM2Y2VlMDBfNjc_2fa4a765-16ff-416d-b4a0-f17ed71c6a53">4</ix:nonFraction> new employees an aggregate of <ix:nonFraction unitRef="shares" contextRef="i090a7d0df6ad405a8d7fb3f2f1fc2096_D20220930-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY185MS9mcmFnOmY4ZGFlZTY3MmRhOTQ5OTQ4MWMyNzIyMTQzNmNlZTAwL3RleHRyZWdpb246ZjhkYWVlNjcyZGE5NDk5NDgxYzI3MjIxNDM2Y2VlMDBfMTAw_abb6c555-7eb2-49ff-ad5c-7d8d846d00e0">20,800</ix:nonFraction> inducement stock options and an aggregate of <ix:nonFraction unitRef="shares" contextRef="i6baa5e11e43442d0b6c324d3f77c8f48_D20220930-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY185MS9mcmFnOmY4ZGFlZTY3MmRhOTQ5OTQ4MWMyNzIyMTQzNmNlZTAwL3RleHRyZWdpb246ZjhkYWVlNjcyZGE5NDk5NDgxYzI3MjIxNDM2Y2VlMDBfMTQ4_3cde9f86-4e0d-41b5-864f-f724cfb3a87e">12,500</ix:nonFraction> inducement RSUs. The options have a per share exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i090a7d0df6ad405a8d7fb3f2f1fc2096_D20220930-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY185MS9mcmFnOmY4ZGFlZTY3MmRhOTQ5OTQ4MWMyNzIyMTQzNmNlZTAwL3RleHRyZWdpb246ZjhkYWVlNjcyZGE5NDk5NDgxYzI3MjIxNDM2Y2VlMDBfMjE1_6b4d61c9-d4c7-40cc-a787-bbf183798010">7.52</ix:nonFraction>,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the closing price of Aurinia's common stock on September 30</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 2022. The stock options and RSUs have a grant date of October 3, 2022. The stock options and RSUs were granted as inducements material to the new employees entering employment with Aurinia in accordance with Nasdaq Listing Rule 5635(c)(4).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 17, 2022, Aurinia mutually agreed with Robert Huizinga, PhD RN, CNeph(C), Executive Vice President, Research and Neil Solomons, M.D.,  Chief Medical Officer, to cease their employment with Aurinia, each effective October 31, 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurnia has entered into separation agreements with Dr. Huizinga and Dr. Solomons which will supersede and replace all the severance arrangements between Aurinia and Dr. Huizinga and Dr. Solomons, set forth in their respective employment agreements with Aurinia, dated October 1, 2018 and September 12, 2012, respectively (together, as amended, the Employment Agreements). The terms of the separation agreements are expected to be consistent with the terms of the Employment Agreements, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included in this Quarterly Report. The information in this discussion contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Exchange Act, which are subject to the &#8220;safe harbor&#8221; created by those sections, as well as &#8220;forward-looking information&#8221; as defined in applicable Canadian securities laws. Forward-looking statements are based on our management&#8217;s beliefs and assumptions and on information currently available to our management. These forward-looking statements include, but are not limited to, statements concerning our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans; objectives of management; the key potential benefits of LUPKYNIS; our belief that we have sufficient financial resources to fund our current plans for at least the next few years; and our potential to receive certain payments and royalties under our agreement with Otsuka; and that an IND is expected to be submitted for AUR200 and AUR300 in 2023. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;predict,&#8221; &#8220;propose,&#8221; &#8220;intend,&#8221; &#8220;continue,&#8221; &#8220;potential,&#8221; &#8220;possible,&#8221; &#8220;foreseeable,&#8221; &#8220;likely,&#8221; &#8220;unforeseen&#8221; and similar expressions intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance, time frames or achievements to be materially different from any future results, performance, time frames or achievements expressed or implied by the forward-looking statements. We have made numerous assumptions about the forward-looking statements and information contained herein, including among other things, assumptions about: the accuracy of reported data from third party studies and reports; that our IP rights are valid and do not infringe the IP rights of third parties; our assumptions relating to the capital required to fund operations for the next few years; the assumption that our current good relationships with our suppliers, service providers and other third parties will be maintained; assumptions relating to the burn rate of our cash for operations; assumptions relating to the capital required to fund operations for the next few years; assumptions relating to the progress of our pre-clinical activities that our third party service providers will comply with their contractual obligations. Even though management believes that the assumptions made, and the expectations represented by such statements or information are reasonable, there can be no assurance that the forward-looking information will prove to be accurate. We discuss many of these risks, uncertainties and other factors in greater detail under the heading &#8220;Risk Factors&#8221; in Part I, Item 1A of our 2021 Annual Report on Form 10-K, as filed with the U.S. Securities and Exchange Commission on February 28, 2022 and with applicable Canadian securities regulatory authorities. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this filing. You should read this discussion completely and with the understanding that our actual future results may be materially different from what we expect. We hereby qualify our forward-looking statements by our cautionary statements. Except as required by law, we assume no obligation to update our forward-looking statements publicly, or to update the reasons that actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.</span></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_97"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Aurinia is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, we introduced LUPKYNIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active LN. We continue to conduct pre-clinical, clinical, and regulatory activities to support the LUPKYNIS development program as well as our other assets. We engaged with Otsuka as a collaboration partner for development and commercialization of LUPKYNIS in the Otsuka Territories.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LUPKYNIS is an orally administered CNI immunosuppressant that has been demonstrated to improve near and long-term outcomes in LN when used in combination with mycophenolate mofetil (MMF) (although MMF is not currently approved as such) and steroids. By inhibiting calcineurin, LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. LUPKYNIS also potentially stabilizes podocytes, which can protect against proteinuria. Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. The mechanism of action of LUPKYNIS has been validated with certain earlier generation CNIs for the prevention of rejection in patients undergoing solid organ transplants and in several autoimmune indications, including uveitis, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">keratoconjunctivitis sicca, psoriasis, rheumatoid arthritis, and for LN in Japan. We believe that LUPKYNIS possesses pharmacologic properties with the potential to demonstrate best-in-class differentiation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Aurinia announced during the fourth quarter of 2021 the initiation of ENLIGHT-LN, a U.S. based prospective, observational registry of adult patients with LN treated with LUPKYNIS. The registry is intended to support the interests of patients, clinicians, regulatory bodies, payers and industry by obtaining longitudinal data on LUPKYNIS. During the first quarter of 2022, we began actively enrolling patients.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 17, 2021, the Company announced the addition of two novel assets AUR200 and AUR300. AUR200 and AUR300 are currently undergoing pre-clinical development with projected submission of Investigational New Drug Applications (INDs) to the FDA in 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2022, the EC granted marketing authorization of LUPKYNIS. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The centralized marketing authorization is valid in all EU member states as well as in Iceland, Liechtenstein, Norway and Northern Ireland.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The approval triggered a $<ix:nonFraction unitRef="usd" contextRef="ie85ef3843f6e45c68cf365c48ec7f1a3_I20220915" decimals="-5" name="auph:ResearchAndDevelopmentArrangementContractToPerformMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY185Ny9mcmFnOjZmYTcyOTY2N2EzZTRkYjRiYzg4YTE1MDM1YmUzYjU4L3RleHRyZWdpb246NmZhNzI5NjY3YTNlNGRiNGJjODhhMTUwMzViZTNiNThfNTQ5NzU1ODE3MjU0_3e5bbcce-d2c1-4df9-94cc-5606b95397c7">30.0</ix:nonFraction>&#160;million milestone payment to the Company, which was recognized as collaboration revenue in the three and nine months period ended September&#160;30, 2022. We continue to progress with regulatory approval with Otsuka on the other Otsuka Territories.</span></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_100"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as described below, there have been no material changes to the Company&#8217;s critical accounting policies and significant judgments and estimates as described in our Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenues</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States (and territories), the Company sells LUPKYNIS primarily to specialty pharmacies and specialty distributors. These customers subsequently resell the Company's products to health care providers and patients. Revenues from product sales are recognized when the customer obtains control of our product, which typically occurs upon delivery to the customer. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for discounts and allowances: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's estimates of reserves established for variable consideration are calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant judgment is required in estimating variable consideration. In making these estimates, we consider historical data, including patient mix and inventory sold to our customers that has not yet been dispensed. We use a data aggregator and historical claims to estimate variable consideration for inventory sold to our customers, including specialty pharmacies and specialty distributors, that has not yet been dispensed. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjust these estimates, which could have an effect on earnings in the period of adjustment. As of September 30, 2022, we did not have any material adjustments to estimates based on actual results. These specific adjustments are detailed further in our Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the inception of each arrangement that includes development or commercial sales milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment. Any consideration related to sales-based </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">royalties (and sales-based milestones) will be recognized when the related sales occur. As of September&#160;30, 2022, we recognized $30.0&#160;million for the regulatory milestone related to the EC marketing authorization of LUPKYNIS.</span></div><div style="margin-top:12pt"><span><br/></span></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_103"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Three and Nine Months ended September&#160;30, 2022 compared to Three and Nine Months ended September&#160;30, 2021</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth our results of operations for the three and nine months ended September&#160;30, 2022 and September&#160;30, 2021.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.970%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,502</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">75,142</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30,277</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30,453</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">55,779</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,667&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,112&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">105,595</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,201</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,394&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,447</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,302</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">52,169</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">148,898</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,973</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,093)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35,118</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,872)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(311)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(366)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">647</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of sales and operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">65,278</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,020&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">188,965</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,231&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,734&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,499)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,353)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,854&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(83,370)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148,030)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,464</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,358&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,209</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,789&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,035)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,247)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,212&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(81,161)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147,610)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,449&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">954</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">973</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,989)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,255)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,266&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(82,134)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147,644)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,510&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net revenue was $55.8 million and $14.7 million for the three months ended September&#160;30, 2022 and September&#160;30, 2021, respectively. Total revenue was $105.6 million and $22.2 million for the nine months ended September&#160;30, 2022 and September&#160;30, 2021, respectively. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The increase in both periods is primarily due to the recognition of a $30.0 million regulatory milestone from Otsuka following the EC marketing authorization of LUPKYNIS in September 2022, coupled with an increase in product sales to our two main customers for LUPKYNIS driven predominantly by further penetration in the lupus nephritis market.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Sales</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales were $2.4&#160;million and $0.3&#160;million for the three months ended September&#160;30, 2022 and September&#160;30, 2021, respectively. Cost of sales were $4.3 million and $0.6 million for the nine months ended September&#160;30, 2022 and September&#160;30, 2021, respectively. The increase for both periods was primarily due to an increase in product related revenue, coupled with an increase in our safety stock inventory reserves.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin for the three months ended September&#160;30, 2022 and September&#160;30, 2021 was approximately 96% and 98% respectively. Gross margin for the nine months ended September&#160;30, 2022 and September&#160;30, 2021 was approximately 96% and 97% respectively. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses increased to $52.2&#160;million for the three months ended September&#160;30, 2022 compared to $44.6&#160;million for the three months ended September&#160;30, 2021. For the nine months ended September&#160;30, 2022 and September&#160;30, 2021, SG&amp;A expenses were $148.9 million and $128.8 million, respectively. SG&amp;A expenses consisted of the following:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.771%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, incentive pay and employee benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,422</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,981&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">62,487</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,723&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees and services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,920</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44,487</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,625</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,480</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other corporate costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,093</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,091</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Travel, trade shows and sponsorships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,109</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,353</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">52,169</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,645&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">148,898</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,772&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary drivers for the increase in SG&amp;A expense for the three and nine months ended September&#160;30, 2022 as compared to the same periods ended September&#160;30, 2021 were an increase in professional fees and services related to corporate legal matters, and travel and sponsorships to support the commercialization of LUPKYNIS. For the nine months ended September&#160;30, 2022, salaries, incentive pay and employee benefits also increased due to employee related expenses such as increased headcount, promotions and inflation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses were $11.0&#160;million and $20.1&#160;million for the three months ended September&#160;30, 2022 and September&#160;30, 2021, respectively. For the nine months ended September&#160;30, 2022 and September&#160;30, 2021, R&amp;D expenses were $35.1 million and $40.0 million, respectively. R&amp;D expenses consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.315%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.162%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract research organizations (CRO) and developmental expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,075</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,873&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,460</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,579&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical supply and distribution</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,077</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,173</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, incentive pay and employee benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,159</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,429</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,489</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,531</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">173</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">525</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,973</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,066&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35,118</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,990&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary driver for the decrease for the three and nine months ended September&#160;30, 2022 as compared to the same periods ended September&#160;30, 2021 were due to the upfront license and accrued milestone expense for AUR300 from the periods ended September&#160;30, 2021 offset year to date by additional developmental expenses related to AUR200 and AUR300 for the periods ended  September&#160;30, 2022. In accordance with U.S. GAAP, AUR300 was recorded as an asset acquisition during the period ended September 30, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income was $1.5 million and $0.1 million  for the three months ended September&#160;30, 2022 and September&#160;30, 2021, respectively. Interest income was $2.2 million and $0.4 million for the nine months ended September&#160;30, 2022 and September&#160;30, 2021, respectively. The increase in both periods is due to higher yields on our investments as a result of increasing interest rates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, we had cash, cash equivalents and restricted cash and investments of $376.6 million compared to cash, cash equivalents and restricted cash and investments of $466.1 million at December&#160;31, 2021. The decrease in cash, cash equivalents and restricted cash and investments is primarily related to the continued investment in commercialization activities, advancement of our pipeline and a payment for the achievement of a one-time milestone, partially offset by an increase in cash receipts from sales of LUPKYNIS. Cash, cash equivalents and restricted cash and investments are primarily held in U.S. dollars. As of September&#160;30, 2022 and December&#160;31, 2021, we had working capital of $417.9 million and $472.7 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are devoting the majority of our operational efforts and financial resources towards the commercialization and post approval commitments of our approved drug, LUPKYNIS. We are also expending efforts towards the development of our AUR200 and AUR300 assets. Taking into consideration the cash and cash equivalents and investments as of September&#160;30, 2022, we believe that our cash position is sufficient to fund our current plans which include funding commercial activities, including our FDA related post approval commitments, manufacturing and packaging commercial drug supply, funding our supporting commercial infrastructure, advancing our R&amp;D programs and funding our working capital obligations for at least the next few years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flow Summary</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the nine months ended September&#160;30, 2022 and September&#160;30, 2021:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(89,979)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131,770)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(57,614)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98,383)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,745</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(145,848)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(214,763)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net cash used in operating activities was $90.0 million for the nine months ended September&#160;30, 2022 compared to $131.8 million for the nine months ended September&#160;30, 2021. Net cash used in both periods was primarily related to the continued investment in commercialization activities, payments made for our ongoing post approval obligations, advancement of our pipeline, and inventory purchases partially offset by cash receipts from sales of LUPKYNIS. The decrease in net cash is primarily due to an increase in cash receipts from sales of LUPKYNIS.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities during the nine months ended September&#160;30, 2022 was $57.6 million compared to cash used in investing activities of $98.4 million during the nine months ended September&#160;30, 2021. The decrease was primarily related to the timing of purchases of investments offset by proceeds of maturities of investments and a nonrecurring upfront lease and license payment made during the nine months ended 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities during the nine months ended September&#160;30, 2022 was $1.7 million compared to cash provided by financing activities of $15.4 million during the nine months ended September&#160;30, 2021. The decrease was primarily due to less proceeds from the exercise of stock options.</span></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_109"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off&#8209;Balance Sheet Arrangements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the periods presented, we did not have, nor do we currently have, any off&#8209;balance sheet arrangements as such term is defined in Item 303(a)(4)(ii) of Regulation S-K under the Securities Act.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes outside the ordinary course of business to our contractual obligations and commitments as described in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risks</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our activities can expose us to market risks which include interest rate risk, foreign currency risk, inflation risk and credit risk. Risk management is carried out by management under policies approved by our Board of Directors, with oversight provided by the Audit Committee of our Board of Directors. Our overall risk management program seeks to minimize adverse effects on our financial performance.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and financial liabilities with variable interest rates expose us to cash flow interest rate risk. We manage our interest rate risk by maximizing the interest income earned on excess funds while maintaining the liquidity necessary to conduct</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operations on a day-to-day basis. As of September&#160;30, 2022, our investment portfolio includes cash, cash equivalents, restricted cash and investments of $376.6 million that earn interest at market rates. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. Our investments held during the year were comprised of highly rated instruments such as certificates of deposits, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities. As of September&#160;30, 2022, these instruments have a maturity of less than a year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, a hypothetical decrease of 100 basis points on the interest rates of our investments would result in $2.9 million less interest in our portfolio.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, accounts payable and accrued liabilities bear no interest. We do not believe that the results of operations or cash flows would be affected to any significant degree by a sudden change in market interest rates relative to our investment portfolio.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to financial risk related to the fluctuation of foreign currency exchange rates. Foreign currency risk for the Company is the risk variations in exchange rates between the U.S. dollar and foreign currencies, primarily with the Canadian dollar, Swiss Franc and Great British Pound, which could affect our operating and financial results. The majority of our cash is held in U.S. dollars and a Canadian denominated bank account. As of September&#160;30, 2022, a 10% increase of the Canadian dollar would have increased the net loss by $0.1 million assuming all other variables remained constant. An assumed 10% weakening of the Canadian dollar would have had an equal but opposite effect to the amounts shown above, on the basis all other variables remain constant. There were no other foreign currency fluctuations that would have had a material impact on our financial condition or results of operations as of September&#160;30, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inflation Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation has increased during the periods covered by this Quarterly Report and is expected to continue to increase for the near future. Inflation generally affects us by increasing our cost of labor, commercial support, manufacturing and clinical trial expenditures. In addition, due to the increasing interest rates and market volatility, our investment portfolio may have higher yields with short-term maturities of nine months or less which could in turn increase the risk of realized losses on our investments if we were to sell before maturity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our exposure to credit risk generally consists of cash and cash equivalents, investments and accounts receivable. We place our cash and cash equivalents with highly rated financial institutions and invest the excess cash in highly rated investments. Our investment policy limits investments to certain types of debt and money market instruments issued by institutions primarily with investment grade credit ratings and places restriction on maturities and concentrations by asset class and issuer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to credit risk in connection with our accounts receivable due from our two customers and our collaboration partner which accounted for 99% of our net trade accounts receivable balances as of September&#160;30, 2022. We monitor economic conditions, the creditworthiness of our customers and government regulations and funding, both domestically and abroad. We regularly communicate with our customers regarding the status of receivable balances. During the quarter ended September&#160;30, 2022, we did not recognize any allowance for doubtful accounts receivable related to credit risk for our customers.</span></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_115"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of&#160;September&#160;30, 2022, have concluded that, based on such evaluation, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the SEC, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the quarter ended September&#160;30, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_121"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no material developments to report in respect of the litigation described in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021 or the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2022.</span></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_124"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Item 1A of our Annual Report on Form 10-K for the year ended December&#160;31, 2021 we identified important factors that could affect our financial performance and could cause our actual results for future periods to differ materially from our anticipated results or other expectations, including those expressed in any forward-looking statements made in this Quarterly Report. There has been no material change in our risk factors subsequent to the filing of our prior reports referenced above except as mentioned below. However, the risks described in our reports are not the only risks we face. Additional risks and uncertainties that we currently deem to be immaterial or not currently known to us, as well as other risks reported from time to time in our reports to the SEC, also could cause our actual results to differ materially from our anticipated results or other expectations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the ongoing armed conflict in Ukraine, the U.S. government, numerous state governments, the EU and other countries in which we conduct business have imposed a wide range of economic sanctions that restrict commerce and business dealings with Russia, certain regions of Ukraine and certain entities. This conflict may also precipitate or amplify the other risks described herein and in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, Part I. Item A. Risk Factors including risks relating to cyber security, global economic conditions and supply chains which could adversely affect our business, operations and financial condition and results.</span></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_127"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_130"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_133"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_136"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_139"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are filed as part of this report:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.521%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1600620/000162828021003060/exhibit31articlesofamalgam.htm">Articles of Amalgamation, as amended, as currently in effect (filed as Exhibit 3.1 to the Company's Annual Report on Form 10-K with the SEC on February 24, 2021 and incorporated herein by reference)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1600620/000162828021007736/exhibit32amendedandrestate.htm">Amended and Restated By-Law No. 2 amended as of April 23, 2021 (filed as Exhibit 3.2 to the Company's Current Report on Form 8-K filed with the SEC on April 27, 2021 and incorporated herein by reference)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">+#</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1600620/000162828022020820/exhibit1022employeeagreeme.htm">Employment Agreement between Aurinia Pharma U.S. Inc., and Volker Knappertz, M.D., dated July 11, 2022</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">+#</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1600620/000162828022020820/exhibit1023employmentagree.htm">Employment Agreement between Aurinia Pharma U.S. Inc., and Scott Habig dated June 27, 2022</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">+#*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1024separationagree.htm">Separation Agreement between Aurinia Pharma U.S. Inc. and Max Colao dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1024separationagree.htm">August 12,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1024separationagree.htm"> 2022</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">+#*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1025separationagree.htm">Separation Agreement between Aurinia Pharmaceuticals Inc. and Neil Solomons dated October 20, 2022</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">+#*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1026separationagree.htm">Separation Agreement between Aurinia Pharmaceuticals Inc. and Rob Huizinga dated October 20, 2022</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.46</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">#</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1600620/000162828022020820/exhibit1046commercialsuppl.htm">Supply Agreement by and between Aurinia Pharmaceuticals Inc. and Otsuka Pharmaceutical Co. Ltd. dated August 1, 2022</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="auph-2022q3exx311.htm">Certification of Principal Executive Officer pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="auph-2022q3exx312.htm">Certification of Principal Financial Officer pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="auph-2022q3exx321.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="auph-2022q3exx322.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.521%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith. Exhibits 32.1 and 32.2 are being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall such exhibit be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise specifically stated in such filing.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicates a management contract of compensatory plan.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K because they are not material and are the type that Aurinia treats as private or confidential.</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="i20b8d43ebbfc4db489a67f7a9d9d59ec_142"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.930%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AURINIA PHARMACEUTICALS INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Peter Greenleaf</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Peter Greenleaf</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer, Director<br/>(Principal Executive Officer)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Joseph Miller</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Joseph Miller</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer<br/>(Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.24
<SEQUENCE>2
<FILENAME>exhibit1024separationagree.htm
<DESCRIPTION>EX-10.24
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i554c0dd1d53f451795f75808b5ba71c6_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.24</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CONFIDENTIAL SEPARATION AGREEMENT, <br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">GENERAL RELEASE AND COVENANT NOT TO SUE</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This is a Confidential Separation Agreement, General Release and Covenant Not to Sue (&#8220;Agreement&#8221;) between Aurinia Pharma U.S., Inc. (&#8220;Aurinia&#8221;), on the one hand, and Max Colao (&#8220;Mr.&#160;Colao&#8221;), on the other hand.  Aurinia and Mr.&#160;Colao shall collectively be referred to herein as the &#8220;Parties&#8221;.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, Mr.&#160;Colao had been an employee of Aurinia&#59; and</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, Mr.&#160;Colao&#8217;s employment with Aurinia ended on or about July 22, 2022&#59; and</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Parties desire to amicably end their employment relationship and wish to formalize their agreement regarding the termination of their relationship&#59; and</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Parties desire to document the terms of their separation, with the Parties agreeing that Aurinia admits no wrongdoing, fault, or liability whatsoever, and that nothing herein shall be construed or interpreted as an admission of any wrongdoing, fault or liability of Aurinia&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW THEREFORE, in consideration of the mutual promises, covenants, and conditions set forth herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, the Parties agree as follows&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Payments by Aurinia&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Provided Mr.&#160;Colao has complied and continues to comply with his obligations as set forth in this Agreement, Aurinia shall make the following payments&#58;  </font></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Severance Payment&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  A one-time, lump sum payment in the gross amount of Four Hundred, Eighty-Eight Thousand, Eight Hundred, Thirty-Five Dollars and Zero Cents ($488,835.00), payable to Mr.&#160;Colao, less income tax withholding and other standard payroll deductions. </font></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">2022 Performance Bonus Payment&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  A one-time, lump sum payment in the gross amount of Two hundred, Forty-Four Thousand, Four Hundred, Seventeen Dollars and Fifty Cents ($244,417.50), payable to Mr.&#160;Colao, less income tax withholding and other standard payroll deductions.  This payment will be made within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;redacted&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the earlier of (i) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;redacted&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, or (ii) the date that such 2022 performance bonuses are generally otherwise paid to Aurinia&#8217;s executive officers for objectives met in calendar year 2022.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">COBRA Payments&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Assuming Mr.&#160;Colao&#8217;s proper election of and eligibility for COBRA coverage, Aurinia shall pay on his behalf the premium costs for COBRA continuation coverage for medical benefits, for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;redacted&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#160; It is understood and agreed that any period during which Aurinia reimburses Mr.&#160;Colao&#8217;s COBRA premium costs pursuant to the preceding sentence shall count toward the COBRA period to which Mr.&#160;Colao shall be entitled by law.&#160; Such payments will be made directly by Aurinia to Aurinia&#8217;s third-party administrator of COBRA.&#160; To receive this benefit, Mr.&#160;Colao must elect to continue his current health coverage under COBRA by completing and signing the necessary forms, which have been or will be mailed to him directly and returning them in a timely fashion.&#160; This benefit is subject to the applicable terms and conditions of the benefit plan(s) in effect during the period of time in which the benefit(s) is provided and nothing herein shall affect Aurinia&#8217; ability to modify, terminate or otherwise change any benefit plan it has in effect at any given time, to the extent permitted by law, and such changes shall be effective immediately, including any changes to the employee </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Certain identified information has been excluded from this exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">share of the premium.&#160; Mr.&#160;Colao will be responsible for paying the total cost of continuing insurance coverage under COBRA before and after the payments made by Aurinia and all such payments must be mailed directly to the third-party administrator of COBRA.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Taxes&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Mr.&#160;Colao agrees that he shall be solely and entirely responsible for the payment and discharge of all federal, state and local taxes, if any, which may at any time be found to be due upon or as a result of the payments or benefits described herein (though Aurinia shall withhold for all employer obligations for taxes, including for FICA, Medicare, FUTA, SUTA or similar obligations on an employer) and agrees to indemnify and hold harmless Aurinia against any claim or liability for any such taxes as described above and any related penalties and&#47;or interest, in the event any such taxes, penalties and&#47;or interest be assessed by the United States Internal Revenue Service and&#47;or any other state or local taxing authority.  Mr.&#160;Colao also agrees to cooperate with Aurinia in the event of a tax audit involving the payments under this Agreement.  Mr.&#160;Colao agrees to cooperate fully with the designation and payments set forth above and complete any paperwork necessary as a condition for Aurinia&#8217;s payments pursuant to this Agreement, including, but not limited to, completion of any tax forms (such as a W-4 and&#47;or W-9) or other forms necessary for legal compliance or at the request of Aurinia, either before or after such payments.  Aurinia may issue any tax forms and make reports of any such payments or benefits, within its sole discretion and as it deems necessary and&#47;or appropriate.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">No Further Benefits&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Mr.&#160;Colao expressly admits, agrees, and acknowledges that the benefits described in this Agreement are not benefits to which he is otherwise entitled, and that he receives none of the benefits in this Agreement unless he signs this Agreement and does not revoke it, pursuant to the revocation provision below.  Mr.&#160;Colao further expressly admits, agrees and acknowledges that he is not entitled to any other or further compensation, remuneration, commissions, bonuses, benefits, reimbursement, vacation&#47;PTO pay, payments, options, stock, or other equity issue of or from Aurinia.  Nothing in this Agreement affects any vested benefits Mr.&#160;Colao has under any retirement plan or any deferred compensation plan.  Any remaining continuation and&#47;or conversion rights to health or other insurance benefits, if any, will be as provided by the terms and conditions of those plans and applicable law.  For purposes of any 401(k) plan or other retirement plans, the payments described herein do not constitute salary and wages to which existing employee contribution elections and&#47;or employer match, if any, apply.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">General Release of Aurinia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Mr.&#160;Colao agrees to and hereby does, for himself and for each of his family members, heirs, representatives, executors, administrators and assigns, and each person or entity acting by or through any of them, forever and irrevocably fully release and discharge Aurinia and the Releasees (as defined below), of and from any and all grievances, disputes, liens, suits, judgments, proceedings, charges, lawsuits, claims, awards, demands, debts, defenses, actions or causes of action, rights, obligations, damages, and liabilities whatsoever which he now has, has had, or may have, whether the same be known or unknown, suspected or unsuspected, at law, in equity, or mixed, in any way arising out of or relating in any way to any matter, act, occurrence, omission, practice, conduct, policy, event, or transaction which occurred or allegedly occurred on or before the date this Agreement is signed by Mr.&#160;Colao.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">This is a General Release. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">By signing this Agreement, Mr.&#160;Colao is agreeing to forego all claims or potential claims against Aurinia and the Releasees.  Mr.&#160;Colao agrees that this release will extinguish all claims which have arisen at any time up to the time he signs this Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Mr.&#160;Colao expressly acknowledges that this General Release includes, but is not limited to, any claims arising out of or relating in any way to his employment with Aurinia, the ending of his employment with Aurinia, and all issues raised or which could have been raised in any litigation against Aurinia and&#47;or the Releasees.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Notwithstanding anything in this Agreement to the contrary, this Agreement will not waive (a) any rights expressly provided for in this Agreement or (b) any rights that, as a matter of law, cannot be waived.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If any claim is not subject to release, to the extent permitted by law, Mr.&#160;Colao waives any right or ability to be a class or collective action representative or to otherwise participate in any putative or certified class, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">collective or multi-party action or proceeding and to collect or receive any money from Aurinia based on such a claim in which Mr.&#160;Colao or any other Releasee identified in this Agreement is a party.  Mr.&#160;Colao agrees to this General Release knowingly and voluntarily.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Further Description of General Release&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Mr.&#160;Colao expressly acknowledges that his General Release of Aurinia and the Releasees includes, but is not limited to, any claims constituting or based on tort, contract, implied contract, defamation, libel, slander, intentional infliction of emotional distress, wrongful or abusive discharge, negligence, interference with contract or employment, assault and battery, personal injury, whistle-blowing, implied covenant of good faith and fair dealing, fraud, stock fraud, equity, any short-term or long-term disability benefits plan, intellectual property, spoliation of evidence, statute or common law, severance pay, equity compensation and&#47;or fringe benefits, attorneys&#8217; fees, vacation pay, bonus, sales commissions, debts, accounts, compensatory damages, punitive or exemplary damages, expense reimbursement, or liquidated damages, arbitration claims, claims under any local, state or federal law, wage and hour law, wage collection law or labor relations law, and any claims of discrimination or harassment on the basis of age, race, sex, religion, disability, pregnancy, sexual orientation, national origin, ancestry, citizenship, retaliation or any other claim under any federal, state or local employment-related, human rights, civil rights, or employment discrimination statute, rule, regulation or ordinance, including, but not limited to, the following&#58; the Civil Rights Acts of 1964 and 1991, as amended&#59; Section 1981 of the Civil Rights Act of 1866&#59; the Equal Pay Act of 1963&#59; the Family and Medical Leave Act&#59; the Age Discrimination In Employment Act (ADEA)&#59; the Americans With Disabilities Act&#59; the Rehabilitation Act of 1973&#59; the Employee Retirement Income Security Act&#59; the Consolidated Omnibus Budget Reconciliation Act of 1985&#59; The Worker Adjustment and Retraining Notification Act&#59; The&#160;False Claims Act&#59; The Sarbanes-Oxley Act of 2002&#59; the Fair Labor Standards Act of 1993&#59; the Lilly Ledbetter Fair Pay Act of 2009, as amended&#59; the Occupational Safety and Health Act&#59; the Maryland Fair Employment Practices Act (MD State Govt. Code Sec. 20-601 et seq.)&#59; the Maryland Wage Payment and Collection Act&#59; the Maryland Wage and Hour Law&#59; and any other claim under any law, regulation, or ordinance prohibiting employment discrimination or relating to employment.  By signing this Agreement, Mr.&#160;Colao agrees that he has not suffered any injuries or occupational diseases relating to or arising out of his employment with Aurinia which would be compensable under the state workers&#8217; compensation act and that he has received all salary and wages (including any commissions or overtime pay for all hours worked, as applicable) and leave to which he was entitled as an employee of Aurinia and that he is not aware of any facts or evidence of any discrimination or retaliation by Aurinia.  Further, by signing this Agreement, Mr.&#160;Colao also expressly acknowledges and represents that he is not currently aware of any facts or circumstances constituting a violation of the Family and Medical Leave Act of 1993 or the Fair Labor Standards Act, or any similar state law.  Mr.&#160;Colao specifically acknowledges that he releases and waives any claim for any attorneys&#8217; fees, costs and expenses, including any attorneys&#8217; liens for fees.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Release of Unknown Claims by Mr.&#160;Colao&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Mr.&#160;Colao understands and agrees that the claims released herein by him are intended to and do include any and all claims of every nature and kind whatsoever, known or unknown, suspected or unsuspected, which he has or may have against any person or entity he released above and he expressly consents that this Agreement shall be given full force and effect according to each and all of its expressed terms and provisions, including as well those relating to unknown and unspecified claims, charges, demands, suits, actions, causes of action and debts, if any, and those relating to any other claims, charges, demands, suits, actions, causes of action and debts hereinabove specified.  Mr.&#160;Colao acknowledges that he is aware that he may hereafter discover claims or facts in addition to, or different from, those which he now knows or believes to exist with respect to the subject matter covered by this Agreement and which, if known or suspected at the time of executing this Agreement, may have materially affected this Agreement or his decision to enter into it.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nevertheless, he hereby waives any rights, claims or causes of action that might arise as a result of such different or additional claims or facts. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Agreement Not to File Actions&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Mr.&#160;Colao agrees not to file, join in or prosecute further any lawsuits against Aurinia and&#47;or any of the Releasees, concerning any matter in any way arising out of or relating in any way to any matter, act, occurrence, omission, practice, conduct, policy, event, or transaction which occurred or allegedly occurred on or before the date this Agreement is signed by Mr.&#160;Colao.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">By signing this Agreement, Mr.&#160;Colao agrees not to sue Aurinia and&#47;or any of the Releasees for anything which has been released pursuant to this Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Nothing in this Agreement prohibits or prevents Mr.&#160;Colao from filing a charge with or participating, testifying, or assisting in any investigation, hearing, whistleblower proceeding, or other proceeding before any federal, state, or local government agency (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> EEOC, NLRB, SEC, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">etc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), nor does anything in this Agreement preclude, prohibit, or otherwise limit, in any way, his rights and abilities to contact, communicate with, report matters to, or otherwise participate in any whistleblower program administered by any such agencies.  However, to the maximum extent permitted by law, Mr.&#160;Colao agrees that if such an administrative claim is made, Mr.&#160;Colao shall not be entitled to recover any additional monetary relief or other individual remedies.  Nothing in this Agreement will interfere with the right of Mr.&#160;Colao to challenge the enforceability of the release of claims in this Agreement under the Age Discrimination in Employment Act or to enforce the terms of this Agreement.  Mr.&#160;Colao represents and warrants that he does not presently have on file any claim, charge, grievance, or complaint against Aurinia or any of the Releasees in or with any administrative, state, federal, or governmental entity, agency, board, or court or before any other tribunal, panel or arbitrators, public or private, based upon any actions or omissions by Aurinia or any of the Releasees occurring prior to his execution of this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Releasees&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Without limiting the generality of the General Release, Mr.&#160;Colao specifically acknowledges and agrees that he is knowingly and voluntarily releasing each and all of the following persons, companies, and entities from any and all claims he has or may have&#58;  Aurinia Pharma U.S., Inc., and any and all past, present, and&#47;or future parent, subsidiary, affiliate, related business entity, employee benefit plan or fund, or any insurers, and its and their respective past, present, and&#47;or future officers, Board members, directors, personnel, employees, managers, partners, administrators, associates, agents, predecessors, successors, purchasers, attorneys, assigns, members, and representatives and any person or entity acting by or through any of them, as well as any co-employer or professional employer organization (collectively known herein as &#8220;Releasees&#8221;).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Testimony by Subpoena</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Mr.&#160;Colao further agrees that in the event that he is required by subpoena to provide testimony to any person or entity who has filed or who seeks to file or prosecute any grievance, claim, charge, complaint or lawsuit against Aurinia or any Releasee, he will provide written notice of such subpoena to Aurinia within 48 hours of receipt of such subpoena.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">No Admission of Liability&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Mr.&#160;Colao expressly acknowledges and agrees that this Agreement is not an admission of liability under any federal, state, or local statute, regulation, or ordinance, or breach of any contract, duty or obligation owed by Aurinia to Mr.&#160;Colao and is not otherwise an admission by Aurinia, and that Aurinia does not admit but denies any violation of his legal rights.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Not a Prevailing Party&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Mr.&#160;Colao agrees that he shall not be regarded as the prevailing party for any purpose, including, but not limited to, determining responsibility for or entitlement to attorneys&#8217; fees or costs, under any statute or otherwise.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Duty to Cooperate&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Mr.&#160;Colao agrees that, in the event Aurinia is or becomes a party or witness to any actual or threatened legal proceeding regarding any matter that arose, concerns or occurred during the term of his employment with Aurinia, he shall make himself reasonably available to and cooperate with Aurinia and its counsel in such proceedings, without further payment or compensation.  Mr.&#160;Colao further agrees to answer any practical administration questions which may arise and to make himself reasonably available to assist Aurinia in its transition following his employment and to cooperate with any other reasonable request by Aurinia which may require his services after the ending of his employment.  The Parties agree that, for the purpose of this Paragraph, the transition period shall be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;redacted&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">following the Effective Date of this Agreement.  Mr.&#160;Colao will not seek or be entitled to any additional compensation for such assistance or cooperation.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">No Future Employment&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Mr.&#160;Colao specifically acknowledges that his employment with the Company is irrevocably severed and his signing of this Agreement shall have the legal effect of forever surrendering, waiving and withdrawing any request or claim he has made, may have made, or could make for continuing employment with Aurinia beyond the last day of employment.  Mr.&#160;Colao acknowledges that because of circumstances unique to him including, but not limited to, irreconcilable differences with Aurinia, he is not qualified to hold any position with Aurinia or any of the Releasees, now or in the future, and, therefore, shall not apply in the future for or hold employment with Aurinia or any of the Releasees.  In the event that Mr.&#160;Colao should unknowingly seek&#47;obtain employment with Aurinia or any of the Releasees, he will, immediately upon obtaining knowledge of his breach of this Paragraph, remedy said breach by either withdrawing such application and&#47;or resigning his employment and that failure to do so shall subject him to immediate termination without notice or cause as a remedy for breach of this Agreement.  Mr.&#160;Colao agrees that this is a negotiated, non-retaliatory settlement term.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Agreement is Confidential&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Except as otherwise stated in this Paragraph, Mr.&#160;Colao specifically agrees to keep the existence and terms of this Agreement, the circumstances giving rise to its execution, the negotiations leading thereto and all matters relating to the allegations raised or which could have been raised in any litigation completely confidential and secret.  He expressly covenants not to display, publish, disseminate, or disclose any such information to any person or entity, except to his attorneys, tax advisor, accountant, spouse, or if necessary to comply with a court order or to enforce the terms of this Agreement.  Mr.&#160;Colao will instruct such person(s) to keep the information confidential pursuant to his obligations under this Paragraph and he agrees that any unauthorized disclosure by any such persons to any other person, entity or organization shall constitute a breach of this Paragraph by Mr.&#160;Colao.  Mr.&#160;Colao may respond to unsolicited inquiries concerning his employment separation with Aurinia by stating only that his &#8220;employment ended amicably with Aurinia,&#8221; and may provide general information about his position and duties while at Aurinia.  Mr.&#160;Colao agrees not to disparage or defame, or otherwise communicate any negative information about Aurinia and&#47;or the Releasees in any such response.  Mr.&#160;Colao warrants and represents that prior to his execution of this Agreement, he did not disclose, directly or indirectly, any of the terms or promises of this Agreement or the payments offered him to any person, including other current or former employees of Aurinia, other than his attorneys, tax advisor, accountant and spouse.  If required by a valid court-issued subpoena, Mr.&#160;Colao may produce a copy of this Agreement provided that he gives written notice of such subpoena to Aurinia within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;redacted&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of receipt of such subpoena and allows Aurinia a reasonable opportunity to move for a protective order or to otherwise quash the subpoena.  Mr.&#160;Colao may also discuss the terms of his separation with official law enforcement, if required to do so pursuant to a subpoena, provided he gives notification to Aurinia within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;redacted&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of being requested to provide such information.  Nothing in this Agreement prohibits or limits Aurinia&#8217;s right to reveal the existence, terms, and conditions of this Agreement within its organization, to its attorneys, to its financial advisors and accountants or as otherwise judged appropriate by Aurinia, and to fulfill reporting obligations under applicable laws and requirements.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Confidential Information&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Mr.&#160;Colao agrees that all information and know-how, regardless of whether in writing, of a private, secret or confidential nature concerning Aurinia&#8217;s business or financial affairs (collectively, &#8220;Proprietary Information&#8221;) is and shall be the exclusive property of Aurinia and that he will not use or disclose to any person or entity or aid others in obtaining or using any such information.  By way of illustration, but not limitation, Proprietary Information may include inventions, products, processes, methods, techniques, formulas, compositions, compounds, projects, developments, plans, research data, financial data, personnel data, computer programs, computer software or code, information about actual or prospective customers, supplier lists and any other confidential business information.  Mr.&#160;Colao will not disclose, at any time, any Proprietary Information to others outside Aurinia or use the same for any unauthorized purposes without prior written approval by an officer of Aurinia unless and until such Proprietary Information has become public knowledge without fault by Mr.&#160;Colao.  Accordingly, Mr.&#160;Colao agrees to keep confidential any trade secret, business or Proprietary Information which Mr.&#160;Colao acquired during his employment with Aurinia, including, but not limited to, any Aurinia marketing, technology, customer, or sales information, plans, or strategies.  This is intended to cover any information of a nature not normally disclosed by Aurinia to the general public.  If required by a valid court-issued subpoena, Mr.&#160;Colao may disclose Proprietary Information provided that he gives written notice of such subpoena to Aurinia within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;redacted&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of receipt of such subpoena.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Return of Property&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Mr.&#160;Colao agrees that within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;redacted&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the Effective Date, he will return to Aurinia any and all property of Aurinia, including, but not limited to, any files and any documents prepared for or by Aurinia, whether or not prepared for or by Mr.&#160;Colao&#59; computers&#59; iPhones or similar devices&#59; cellular phones&#59; credit cards&#59; files, books, binders, manuals, and other printed material&#59; computer disks and software&#59; files&#59; and all other tangible and intangible property belonging to Aurinia and obtained by Mr.&#160;Colao in connection with his employment with Aurinia, including all copies of such property, in any form, electronic or otherwise.  Mr.&#160;Colao agrees that no payment or any other benefit under this Agreement shall be made or given by Aurinia until and unless Mr.&#160;Colao has returned all property of Aurinia as required by this Paragraph.  Mr.&#160;Colao also affirms that Aurinia is not in possession of any of his personal property.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Non-Disparagement&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Mr.&#160;Colao agrees that he will not communicate or make or cause, directly or indirectly, any other person or entity to communicate or make any adverse, derogatory, libelous, slanderous, defamatory or disparaging remarks, statements or communications about Aurinia or any of the Releasees, including the personal and&#47;or business reputations, practices, products, services or conduct of Aurinia or any of the Releasees.  For instance, and without limitation, Mr.&#160;Colao shall not post on any social media or disclose in any other format or manner any issues, concerns or problems regarding any Aurinia business or service or disparage any Releasee on any such internet website or posting.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Breach of Agreement&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Mr.&#160;Colao expressly agrees that a breach of any of the promises and covenants contained or referenced in this Agreement, including the filing of a lawsuit against Aurinia, shall be considered a material breach of the terms of this Agreement, and shall entitle Aurinia to recover from Mr.&#160;Colao any monies paid to him under this Agreement and Aurinia will have no further obligations to pay Mr.&#160;Colao any further compensation, as well as any and all remedies available at law and costs and reasonable attorneys&#8217; fees incurred in enforcing any provision of or any right contained in this Agreement.  However, nothing in this Agreement will interfere with his right to challenge the enforceability of the foregoing release of claims under the Age Discrimination In Employment Act, and Mr.&#160;Colao shall not be required to tender back the payments made to him under this Agreement nor be liable for the costs and attorneys&#8217; fees that Aurinia and&#47;or the Releasees incur in connection with a challenge by Mr.&#160;Colao of the foregoing release of claims pursuant to the Age Discrimination In Employment Act.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">No Transfer or Assignment&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Mr.&#160;Colao represents and warrants that no person had or has or claims any interest in the claims referred to anywhere in this Agreement.  He also represents and warrants that he has the sole right and exclusive authority to execute this Agreement and that he has the sole right to receive the consideration paid therefore.  He also represents and warrants that he has not heretofore assigned or transferred, or purported to assign or transfer, to any person or entity, any claim against Aurinia or any of the Releasees or portion thereof or interest therein, and will not assign or otherwise transfer, any claim or demand relating to any matter covered by this Agreement or the consideration to be paid pursuant thereto.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Entire Agreement and Enforcement&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Parties agree that this Agreement shall be binding upon the assigns, heirs, executors, and administrators of Mr.&#160;Colao and shall inure to the benefit of the officers, directors, employees, agents, parents, affiliates, predecessors, successors, purchasers, assigns, and representatives of Aurinia, including Aurinia and the Releasees.  This Agreement supersedes all prior agreements between the Parties, and this Agreement constitutes the entire agreement between the Parties and all previous discussions, promises, representations, and understandings relating to the topics herein discussed are hereby merged into this Agreement.  The Parties agree that there are no additional promises or terms among the Parties other than those contained or referred to herein.  Notwithstanding the above, any other any invention, confidentiality, non-competition, and&#47;or non-solicitation agreements&#47;provisions between Mr.&#160;Colao and Aurinia are hereby incorporated in this Agreement and remain enforceable notwithstanding this Agreement.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Amendment and Notice&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  This Agreement may not be modified, waived or amended except in writing signed by each of the Parties wherein specific reference is made to this Agreement.  Notification to Aurinia under this Agreement shall be via both written letter to counsel for Aurinia, Larry R. Seegull, Esq., Jackson Lewis P.C., 2800 Quarry Lake Drive, Suite 200, Baltimore, Maryland 21209, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;redacted&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and electronic mail to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;redacted&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">No Waiver&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Parties recognize, acknowledge and agree that the failure by Aurinia to enforce any term of this Agreement shall not constitute a waiver of any rights or deprive Aurinia of the right to insist thereafter upon strict adherence to that or any other term of this Agreement, nor shall a waiver of any breach of this Agreement constitute a waiver of any preceding or succeeding breach.  No waiver of a right under any provision of this Agreement shall be binding on Aurinia unless made in writing and signed by Aurinia.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Governing Law&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The validity and construction of this Agreement or of any of its terms or provisions shall be determined under the laws of the State of Maryland, regardless of any principles of conflicts of laws or choice of laws of any jurisdiction.  Accordingly, Mr.&#160;Colao waives any right he may have to assert the applicability of another state&#8217;s law or to contest the application of the law of the State of Maryland.  The exclusive jurisdiction and venue of any lawsuit arising under this Agreement shall be the State and Federal Courts in the State of Maryland having proper jurisdiction, and Mr.&#160;Colao hereby irrevocably agrees, acknowledges and submits to the exclusive jurisdiction and venue of such court for the purposes of any such lawsuit arising under this Agreement.  Whenever in this Agreement the context may so require, the masculine gender shall be deemed to refer to and include the feminine and neuter, and the singular to refer to and include the plural, and vice versa.  This Agreement has been freely negotiated by both Parties and therefore the language of all parts of this Agreement shall in all cases be construed as a whole, according to its fair meaning, and not strictly for or against any of the Parties, notwithstanding any statutory or common law provisions which would suggest otherwise.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Reformation and Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;  Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law.  If, however, any of the provisions contained in this Agreement is declared illegal, unenforceable, or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ineffective in a legal forum of competent jurisdiction, Mr.&#160;Colao agrees that such provision shall be modified and reformed, if possible, in order to achieve, to the extent possible, the intentions of the Parties, and, if necessary, such provision shall be deemed severable, such that all other provisions contained in this Agreement shall remain valid and binding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#59; provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that if any portion of the General Release is held to be invalid or unenforceable, then the entire Agreement, including any obligation for Aurinia to provide any payment or benefits hereunder, shall be voidable at the option of Aurinia.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Consultation with Attorney&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Mr.&#160;Colao is advised to consult an attorney regarding the terms of this Agreement before signing it, and states that he has consulted with his attorney regarding this Agreement, and had a full and fair opportunity to consult with any personal, family or professional advisors of his choosing regarding this Agreement, and that in executing this Agreement he has not relied upon any representations or statements by Aurinia or any of its respective agents, representatives, employees, or attorneys regarding the subject matter, basis, or effect of this Agreement.  The Parties specifically agree and acknowledge that no court or agency must specifically approve this Agreement or its terms and conditions, including the release of any claims herein, for it to become effective.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">27.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Offer Period and Effective Date&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Pursuant to the Older Workers Benefit Protection Act, Mr.&#160;Colao acknowledges and represents that he waives his claims identified above herein knowingly and voluntarily and in exchange for consideration of value.  Mr.&#160;Colao acknowledges and represents that he understands that he has twenty-one (21) days from his receipt of this Agreement to consider his decision to sign it.  Mr.&#160;Colao acknowledges and understands that he may revoke this Agreement within seven (7) days following his execution of this Agreement.  Revocation shall be made by delivering written notice of revocation to Larry Seegull, Esq. and must be received no later than the final day of the revocation period.  Revocation by Mr.&#160;Colao under this paragraph shall be via electronic mail to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;redacted&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and&#47;or written letter to Larry Seegull, Esq., Jackson Lewis P.C., 2800 Quarry Lake Drive, Suite 200, Baltimore, Maryland 21209, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;redacted&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement shall not become effective or enforceable until the revocation period has expired and the Agreement has been timely returned to Aurinia, and no monies shall be paid to Mr.&#160;Colao if he exercises his right to revocation.  Accordingly, the Effective Date of this Agreement shall be the eighth day following his signing of this Agreement, provided he has not revoked the Agreement previously and has timely returned the signed Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">28.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Tax Code Compliance&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement is intended to comply with, or otherwise be exempt from, Section 409A of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) and any regulations and Treasury guidance promulgated thereunder.  The immediately preceding sentence, however, shall not be construed as a guarantee by Aurinia of any particular tax effect to Mr.&#160;Colao under this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Full Defense&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  This Agreement may be pled as a full and complete defense to, and may be used as a basis for an injunction against, any action, suit or other proceeding that may be prosecuted, instituted or attempted by or on behalf of Mr.&#160;Colao in breach hereof.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Counterparts, Facsimile and PDF Signature&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  This Agreement may be executed in counterparts, each of which will be deemed an original, but both of which together will constitute one and the same instrument.  A facsimile, electronic, PDF or email copy of the signature of any signatory on this Agreement shall be deemed the equivalent of an original thereof.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Headings&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The headings and other captions in this Agreement are for convenience and reference only and shall not be used in interpreting, construing or enforcing any of the provisions of this Agreement or to define or limit the scope of any Paragraph of this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">MR. COLAO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">REPRESENTS THAT HE HAS READ THIS AGREEMENT, THAT BASED THEREON, HE UNDERSTANDS ALL OF ITS TERMS, AND THAT HE ENTERS INTO THIS AGREEMENT VOLUNTARILY AND WITH FULL KNOWLEDGE OF ITS EFFECT.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">August 11, 2022&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">&#47;s&#47; Max Colao</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Date&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Max Colao</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">August 12, 2022&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">&#47;s&#47; Max Donley</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Date&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Aurinia Pharma U.S., Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.25
<SEQUENCE>3
<FILENAME>exhibit1025separationagree.htm
<DESCRIPTION>EX-10.25
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ifeb3ef3875e84f45af8b31e614972c16_1"></div><div style="min-height:78.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.25</font></div><div><img alt="image_0.jpg" src="image_0.jpg" style="height:38px;margin-bottom:5pt;vertical-align:text-bottom;width:136px"></div></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-top:2pt"><font style="color:#2e74b5;font-family:'Calibri Light',sans-serif;font-size:13pt;font-weight:400;line-height:100%">PERSONAL AND CONFIDENTIAL</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">October 20, 2022</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Neil Solomons</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;redacted&#93;</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dear Neil&#58;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Re&#58; End of Employment with Aurinia Pharmaceuticals Inc. (the &#8220;Company&#8221;)</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Further to our recent discussions, as you are aware, the Company wished for you to begin to report to Volker Knappertz, Executive Vice President, Research and Development, pursuant to your current terms and conditions of employment (including with respect to compensation and benefits). We do not view this as a fundamental change to the terms and conditions of your employment and, in any event, as set out in your employment agreement with the Company dated September 12, 2012 (the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Employment Agreement&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), you are required to report to such other person that the Board may otherwise determine from time to time. However, we understand that this is not an arrangement you wish to accept, and that you wish to end your employment.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As such, this letter confirms that you and the Company have mutually agreed that your employment with the Company will come to an end, effective October 31, 2022 (the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;End Date&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This letter also sets forth details regarding the end of your employment and makes a without prejudice severance offer in exchange for a full and final Release in favour of the Company. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">GENERAL</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Working Notice and Statutory Payments</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">From now until the End Date (the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Working Notice Period&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), you will be expected to perform your assigned duties and responsibilities to the best of your ability, and you will continue to receive your usual compensation and benefits, less applicable deductions, and withholdings. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Following the End Date, the balance of all outstanding wages, including any accrued and unused vacation pay, will be paid to you in a lump sum. Your accrued and unused vacation entitlements will be paid out on October 31, 2022, and are as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accrued (unused) vacation &#61; 240 hours ($52,873.97 CAD) (provided no vacation is taken between now and the End Date)</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Grandfathered vacation &#61; 779.52 hours ($194,725.98 CAD)</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">These amounts are subject to the usual deductions, and you will be paid these amounts regardless of whether you accept the without prejudice severance offer detailed below.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Note that, in the event that you are terminated for just cause or resign from your employment prior to the end of the Working Notice Period, all payments and benefits will cease, and you will not receive any further compensation or pay in lieu, except as may be minimally required pursuant to the British Columbia </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Employment Standards Act</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Record of Employment</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain identified information has been excluded from this exhibit because it both (i) is not material and (ii)</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">would be competitively harmful if publicly disclosed.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:78.48pt;width:100%"><div style="margin-bottom:0.12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">After the end of the Working Notice Period, your Record of Employment will be submitted electronically to Service Canada, which you will be able to access online on the Service Canada website. We encourage you to visit the Service Canada website at&#58; https&#58;&#47;&#47;www.canada.ca&#47;en&#47;services&#47;benefits&#47;ei.html to familiarize yourself with the available Employment Insurance (EI) application process and support services offered by the Canadian Government.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Outstanding Business Expenses</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">After the end of the Working Notice Period, outstanding unreimbursed business expenses will be paid within the Company&#8217;s normal policies for expense reimbursement following submission of the expense report.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Return of Company Property</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">On or before the End Date, please return to the Company all its property, including, but not limited to, building access card, laptop, iPad, passwords, computer usernames, voicemail code, phone cards, company credit card, keys, internal policies, and other confidential business information and documents, and any other property belonging to the Company. Please also destroy or delete all tangible or electronic copies of any such property after returning it to the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality and Other Continuing Obligations</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">We wish to remind you that, despite the cessation of your employment with the Company, you continue to be bound by&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Confidentiality Agreement and Assignment of Inventions attached as Schedule C to the Employment Agreement&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">All restrictive covenants contained in the Employment Agreement, including paragraph 23 (Restrictive Covenant) of the Employment Agreement&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">All fiduciary duties that arise from your employment.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company expects you to comply with these obligations, which survive the cessation of your employment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Benefits</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subject to provider approval and the terms and conditions of the applicable plans, the Company will maintain your Medical, Dental, and Vision benefits until the earlier of&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;       the date you obtain replacement benefits&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;       twelve (12) months from the End Date,</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">after which time you will be responsible for obtaining your own replacement benefits. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Coverage for your Short Term &#38; Long-Term Disability, Life Insurance, AD&#38;D, Group Retirement Savings Plan, and all other benefits other than Medical, Dental, and Vision benefits, will terminate as of the End Date, October 31, 2022, and you will be responsible for obtaining your own replacement benefits. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">There may be conversion options available to you through Sun Life that are subject to strict time limitations (e.g., within 31 days of your coverage termination date)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:78.48pt;width:100%"><div style="margin-bottom:0.12pt;text-align:justify"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Please call Sun Life Client Services at 800-247-6875 if you want to exercise conversion options or if you have any questions or require further information about this coverage.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Please contact Manulife at gromail&#64;manulife.com or 888-727-7766 for details regarding transferring your Group Retirement Savings Plan (RRSP) and your Non-registered Savings Plan (NRSP) or any other plans you hold for your retirement savings.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Stock Options</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any unvested options that you received under the Company&#8217;s Equity Incentive Plan will be cancelled on the End Date, October 31, 2022.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You have the right to exercise your vested options for a period of 90 days post termination, after which time your vested options will be cancelled. Please direct any inquiries regarding stock options to securities&#64;auriniapharma.com</font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">WITHOUT PREJUDICE SEVERANCE OFFER</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As the Company did not wish to terminate your employment, and your employment is coming to an end only by mutual agreement, the Company has no legal obligation to provide you with any termination notice entitlements under statute, contract, or otherwise. However, on the condition that you&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Remain with the Company and continue to perform all of your assigned duties and responsibilities to the best of your ability until the end of the Working Notice Period&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Resign any directorship or office held in the Company, or any subsidiary or affiliated companies of the Company,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">effective as of the End Date&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sign the attached Release on or after the End Date (i.e., after the end of the Working Notice Period), and return it to us within two (2) business days after the End Date&#59; and </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Keep the terms of the offer confidential,</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">he Company is prepared to offer you a severance package on the following terms, in full and final satisfaction of all claims you may have against the Company and any affiliated company&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a)&#160;&#160;&#160;&#160;The Company will pay to you a lump-sum payment of $899,688.00 CAD, less applicable statutory deductions and withholdings, which represents eighteen (18) months of your Base</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Salary (the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Severance Payment&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), which will be paid on January 15, 2023, per your request&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b)&#160;&#160;&#160;&#160;The Company will pay to you a lump-sum payment of $299,896.00 CAD, less applicable statutory deductions and withholdings, representing a target bonus payment equal to 50% of your Base Salary, which will be paid on March 15, 2023&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">c)&#160;&#160;&#160;&#160;The Company will provide you with a 12-month career transition services package through Lee Hecht Harrison (LHH), which can be activated commencing on November 1, 2022 through to October 31, 2023.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For clarity, you will not be entitled to receive the severance package set out above if you terminate your employment for any reason, including if you resign, or if you have been terminated for just cause, prior to the end of the Working Notice Period.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As mentioned above, this without prejudice severance offer is made in full and final satisfaction of all claims you may have against the Company and its related entities. Accordingly, it is a condition of this offer that you sign the attached Release on or after the End Date (i.e., after the end of the Working Notice Period), and that you keep the terms of the offer confidential.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:78.48pt;width:100%"><div style="margin-bottom:0.12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You may wish to obtain legal advice with respect to this offer.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If you wish to accept this offer, please sign and return a copy of this letter to us by no later than October 31, 2022. As set out above, you must sign and return the signed Release to us within two (2) business days </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">after the End Date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If you have any questions, please feel free to contact me. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Yours truly,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Aurinia Pharmaceuticals Inc. </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Per&#58;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47;_</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Max Donley</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">_________________________                                                 </font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Max Donley&#160;&#160;&#160;&#160;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executive VP, Operations &#38; Strategy</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:78.48pt;width:100%"><div style="margin-bottom:0.12pt;text-align:justify"><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ACKNOWLEDGEMENT AND ACCEPTANCE </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">I have read and understand the terms of this letter and the enclosed Release and confirm that I voluntarily accept the terms offered above in full and final satisfaction of all claims which I might have against Aurinia Pharmaceuticals Inc. and its related entities, including but not limited to those relating to or arising out of my employment with Aurinia Pharmaceuticals Inc. or the cessation of my employment. I acknowledge that I have been given the opportunity to obtain independent legal advice with respect to this offer, and that I am accepting it freely, voluntarily, and without duress.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accepted&#58; _</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Neil Solomons</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">____________               Date&#58; _</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">October 20, 2022</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_____________________</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;&#160;&#160;&#160;Neil Solomons </font></div><div style="margin-bottom:10pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:78.48pt;width:100%"><div style="margin-bottom:0.12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">RELEASE</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Neil Solomons </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Employee</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">for the consideration set out in the attached letter dated October 20, 2022 (the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Letter&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), and for other good and valuable consideration, does, to the fullest extent permitted by law, forever release and forever discharge</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Aurinia Pharmaceuticals Inc. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Aurinia Pharma U.S. Inc., </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">together with their affiliates, subsidiaries, directors, officers, employees, agents, owners and shareholders (collectively the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Company&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) from any and all manners of actions, causes of actions, suits, contracts, claims, complaints, damages, costs and expenses of any nature or kind whatsoever known or unknown whether in law (including the common law) or in equity or pursuant to statute, which, as against the Company, the Employee has ever had or now has by reason of or arising out of any cause, matter or thing whatsoever occurring or existing up to the date of execution of this Release and, without limiting the generality of the foregoing, any matter, cause, or thing relating to or arising out of the Employee&#8217;s employment with the Company, the Employee&#8217;s contract of employment with the Company, or the cessation of Employee&#8217;s employment with the Company, and any other claim for damages, notice, payment in lieu of notice, wrongful dismissal, severance pay, loss of benefits including life insurance and long term and short term disability insurance, pension issues, bonus (pro-rated or otherwise), profit sharing, stock distribution, stock options or stock purchase rights, overtime pay, commissions, vacation pay, earned time off, or any claims under the British Columbia </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Employment Standards Act</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or the British Columbia </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Human Rights Code</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Employee acknowledges that, upon receipt of the payments set out in the Letter, he&#47;she will have received all payments and amounts owing to him&#47;her under the British Columbia </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Employment Standards Act</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and that, to the fullest extent permitted by law, the payments made to him&#47;her in the Letter are in full and final satisfaction of any further entitlements he&#47;she may have pursuant to the British Columbia </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Employment Standards Act</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Employee acknowledges that he&#47;she has not be subjected to any form of discrimination or prohibited action whatsoever and hereby represents and warrants that he&#47;she has not commenced any complaint and undertakes not to commence any complaint under the British Columbia </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Human Rights Code</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Workers Compensation Act</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Employee acknowledges and agrees that the consideration set out in the Letter includes full compensation and consideration for loss of employment benefits and that all of his&#47;her employment benefits will cease as set out in the Letter. The Employee fully accepts sole responsibility to replace those benefits that he&#47;she wishes to continue and to exercise conversion privileges where applicable with respect to benefits at his&#47;her own cost. In the event that the Employee becomes disabled, he&#47;she covenants not to sue the Company for insurance or other benefits, or for loss of benefits. The Employee hereby releases the Company from any and further obligations or liabilities arising from his&#47;her employment benefits and the loss of such benefits.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Employee covenants and undertakes not to defame, disparage or demean the Company, or any of its affiliates, subsidiaries, employees, officers, directors or agents, or any of its products or services, to any third party, in any manner whatsoever, including through social media.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Release is binding upon and enures to the benefit of the Employee&#8217;s heirs, executors, administrators, assigns, committees and trustees.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Release is binding upon and enures to the benefit of the Company&#8217;s affiliates, subsidiaries, directors, officers, employees, agents, predecessors, successors, assigns, liquidators, receivers, receiver managers, trustees, owners and shareholders.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the event withholdings have not been deducted which should have been deducted, the Employee shall indemnify and save harmless the Company from any resulting liabilities, obligations, and costs regarding any claims which Canada Revenue Agency or Employment Insurance Commission may make upon the Company pursuant to the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Income Tax Act</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (Canada), </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Employment Insurance Act</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (Canada), and&#47;or the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Canada Pension Plan</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, as such legislation or plans may be amended from time to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:78.48pt;width:100%"><div style="margin-bottom:0.12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">time, with respect to any payments made or benefits provided to or on behalf of the Employee or in respect of any Canada Pension Plan or Employment Insurance benefits or contributions.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Employee acknowledges that the facts in respect of which this Release is made may prove to be other than or different from the facts in that connection now known or believed by the Employee to be true.  The Employee accepts and assumes the risk of the facts being different and agrees that this Release shall be in all respects enforceable and not subject to termination, rescission, or variation by discovery of any differences in facts.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Employee agrees not to make claim or take proceedings (including, but not limited to, any cross-claims, counter-claims, third party claims, actions or applications) against any other person or corporation that might claim contribution or indemnity under the provisions of any statute or otherwise against the Company.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Employee agrees to keep the terms of the Letter and this Release strictly confidential and will not disclose any information with respect to the Letter or this Release to anyone with the exception of his&#47;her spouse and his&#47;her legal or financial advisors, unless compelled to do so by law or court order. </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Employee acknowledges that this Release has been executed voluntarily after having had the opportunity to receive legal advice.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Release is given voluntarily for the purposes of making a full and final settlement of all of the Employee&#8217;s claims whatsoever arising against the Company. This Release and the Letter are not to be construed or considered as an admission of liability by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the event that any paragraph or portion thereof of this Release shall be invalid or unenforceable, for any reason whatsoever, then such invalid or unenforceable paragraph or portion shall be severed from the remainder of this Release, provided that it does not render the remainder of the Release unenforceable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Employee understands and agrees that this Release and the Letter contains the entire agreement between the Company and the Employee and that the terms of this Release are contractual and not recitals.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Release shall be governed by the laws of the Province of British Columbia, Canada and the Employee hereby submits to the exclusive jurisdiction of the courts and tribunals of that province, as applicable.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executed copies of this Release may be exchanged by facsimile or electronically via PDF format. Each facsimile or PDF copy so executed and exchanged will be deemed an original.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dated at  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Victoria</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (city), the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">20th</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> day of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">October</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> , 20</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">22</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.519%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">&#47;s&#47; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%;text-decoration:underline">Neil Solomons</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Neil Solomons </font></div></td></tr></table></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:78.48pt;width:100%"><div style="margin-bottom:0.12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:-49.5pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.26
<SEQUENCE>4
<FILENAME>exhibit1026separationagree.htm
<DESCRIPTION>EX-10.26
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i0d43b1ff5a9540f2b36db56cca355c27_1"></div><div style="min-height:78.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.26</font></div><div><img alt="image_01.jpg" src="image_01.jpg" style="height:38px;margin-bottom:5pt;vertical-align:text-bottom;width:136px"></div></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-top:2pt"><font style="color:#2e74b5;font-family:'Calibri Light',sans-serif;font-size:13pt;font-weight:400;line-height:100%">PERSONAL AND CONFIDENTIAL</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">October 20, 2022</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Robert B. Huizinga </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;redacted&#93;</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dear Rob&#58;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Re&#58; End of Employment with Aurinia Pharmaceuticals Inc. (the &#8220;Company&#8221;)</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Further to our recent discussions, as you are aware, the Company wished for you to assume the role of Senior Vice President, Medical Affairs, pursuant to your current terms and conditions of employment (including with respect to compensation and benefits). We view the position of Senior Vice President, Medical Affairs, as comparable to your current role of Executive Vice President, Research, and, in any event, as set out in your employment agreement with the Company dated October 1, 2018 (the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Employment Agreement&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), the Company may vary or add to your position, duties and functions from time to time. However, we understand that this is not an arrangement you wish to accept, and that you wish to end your employment.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As such, this letter confirms that you and the Company have mutually agreed that your employment with the Company will come to an end, effective October 31, 2022 (the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;End Date&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This letter also sets forth details regarding the end of your employment and makes a without prejudice severance offer in exchange for a full and final Release in favour of the Company. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">GENERAL</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Working Notice and Statutory Payments</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">From now until the End Date (the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Working Notice Period&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), you will be expected to perform your assigned duties and responsibilities to the best of your ability, and you will continue to receive your usual compensation and benefits, less applicable deductions and withholdings. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Following the End Date, the balance of all outstanding wages, including any accrued and unused vacation pay, will be paid to you in a lump sum. Your accrued and unused vacation entitlements will be paid out on October 31, 2022, and are as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accrued (unused) vacation &#61; 149.83 hours ($41,643.62 CAD) (provided no vacation is taken between now and the End Date)</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Grandfathered vacation &#61; 770.54 hours ($163,633.52 CAD)</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">These amounts are subject to the usual deductions, and you will be paid these amounts regardless of whether you accept the without prejudice severance offer detailed below.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Note that, in the event that you are terminated for just cause or resign from your employment prior to the end of the Working Notice Period, all payments and benefits will cease and you will not receive any further compensation or pay in lieu, except as may be minimally required pursuant to the British Columbia </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Employment Standards Act</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Record of Employment</font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain identified information has been excluded from this exhibit because it both (i) is not material and (ii)</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:78.48pt;width:100%"><div style="margin-bottom:0.12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">After the end of the Working Notice Period, your Record of Employment will be submitted electronically to Service Canada, which you will be able to access online on the Service Canada website. We encourage you to visit the Service Canada website at&#58; https&#58;&#47;&#47;www.canada.ca&#47;en&#47;services&#47;benefits&#47;ei.html to familiarize yourself with the available Employment Insurance (EI) application process and support services offered by the Canadian Government.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Outstanding Business Expenses</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">After the end of the Working Notice Period, outstanding unreimbursed business expenses will be paid within the Company&#8217;s normal policies for expense reimbursement following submission of the expense report.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Return of Company Property</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">On or before the End Date, please return to the Company all its property, including, but not limited to, building access card, laptop, iPad, passwords, computer usernames, voicemail code, phone cards, company credit card, keys, internal policies, and other confidential business information and documents, and any other property belonging to the Company. Please also destroy or delete all tangible or electronic copies of any such property after returning it to the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality and Other Continuing Obligations</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">We wish to remind you that, despite the cessation of your employment with the Company, you continue to be bound by&#58;  </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Confidentiality and Work Product Ownership Agreement attached as Schedule B to the Employment Agreement&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">All restrictive covenants contained in the Employment Agreement, including paragraph 24 (Restrictive Covenant) of the Employment Agreement&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">All fiduciary duties that arise from your employment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company expects you to comply with these obligations, which survive the cessation of your employment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Benefits</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subject to provider approval and the terms and conditions of the applicable plans, the Company will maintain your Medical, Dental, and Vision benefits until the earlier of&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;       the date you obtain replacement benefits&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;       twelve (12) months from the End Date,</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">after which time you will be responsible for obtaining your own replacement benefits. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Coverage for your Short Term &#38; Long-Term Disability, Life Insurance, AD&#38;D, Group Retirement Savings Plan, and all other benefits other than Medical, Dental, and Vision benefits, will terminate as of the End Date, October 31, 2022, and you will be responsible for obtaining your own replacement benefits. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">There may be conversion options available to you through Sun Life that are subject to strict time limitations (e.g., within 31 days of your coverage termination date)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:78.48pt;width:100%"><div style="margin-bottom:0.12pt;text-align:justify"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Please call Sun Life Client Services at 800-247-6875 if you want to exercise conversion options or if you have any questions or require further information about this coverage.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Please contact Manulife at gromail&#64;manulife.com or 888-727-7766 for details regarding transferring your Group Retirement Savings Plan (RRSP) and your Non-registered Savings Plan (NRSP) or any other plans you hold for your retirement savings.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Stock Options</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any unvested options that you received under the Company&#8217;s Equity Incentive Plan will be cancelled on the End Date, October 31, 2022.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You have the right to exercise your vested options for a period of 90 days post termination, after which time your vested options will be cancelled. Please direct any inquiries regarding stock options to securities&#64;auriniapharma.com.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">WITHOUT PREJUDICE SEVERANCE OFFER</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As the Company did not wish to terminate your employment, and your employment is coming to an end only by mutual agreement, the Company has no legal obligation to provide you with any termination notice entitlements under statute, contract, or otherwise. However, on the condition that you&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Remain with the Company and continue to perform all of your assigned duties and responsibilities to the best of your ability until the end of the Working Notice Period&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Resign any directorship or office held in the Company, or any subsidiary or affiliated companies of the Company, effective as of the End Date&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sign the attached Release on or after the End Date (i.e., after the end of the Working Notice Period), and return it to us within two (2) business days after the End Date&#59; and </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Keep the terms of the offer confidential,</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the Company is prepared to offer you a severance package on the following terms, in full and final satisfaction of all claims you may have against the Company and any affiliated company&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a)&#160;&#160;&#160;&#160;The Company will pay to you a lump-sum payment of $740,921.94 CAD, less applicable statutory deductions and withholdings, which represents eighteen (18) months of your annualized Base</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Salary (the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Severance Payment&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), which will be paid on January 15, 2023, per your request&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b)&#160;&#160;&#160;&#160;The Company will pay to you a lump-sum payment of $246,974.00 CAD, less applicable statutory deductions and withholdings, representing a target bonus payment equal to 50% of your Base Salary, which</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">will be paid on March 15, 2023&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">c)&#160;&#160;&#160;&#160;You will continue to be eligible to receive the Retention Incentive set out at Section 8 of the Employment Agreement&#59; and </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">d)&#160;&#160;&#160;&#160;The Company will provide you with a 12-month career transition services package through Lee Hecht Harrison (LHH), which can be activated commencing on November 1, 2022 through to October 31, 2023.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For clarity, you will not be entitled to receive the severance package set out above if you terminate your employment for any reason, including if you resign, or if you have been terminated for just cause, prior to the end of the Working Notice Period.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As mentioned above, this without prejudice severance offer is made in full and final satisfaction of all claims you may have against the Company and its related entities. Accordingly, it is a condition of this </font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:78.48pt;width:100%"><div style="margin-bottom:0.12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">offer that you sign the attached Release on or after the End Date (i.e., after the end of the Working Notice Period), and that you keep the terms of the offer confidential.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You may wish to obtain legal advice with respect to this offer.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If you wish to accept this offer, please sign and return a copy of this letter to us by no later than October 31, 2022. As set out above, you must sign and return the signed Release to us within two (2) business days </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">after the End Date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If you have any questions, please feel free to contact me. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Yours truly,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Aurinia Pharmaceuticals Inc. </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Per&#58;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Max Donley</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">_________________</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Max Donley&#160;&#160;&#160;&#160;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executive VP, Operations &#38; Strategy</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ACKNOWLEDGEMENT AND ACCEPTANCE </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">I have read and understand the terms of this letter and the enclosed Release and confirm that I voluntarily accept the terms offered above in full and final satisfaction of all claims which I might have against Aurinia Pharmaceuticals Inc. and its related entities, including but not limited to those relating to or arising out of my employment with Aurinia Pharmaceuticals Inc. or the cessation of my employment. I acknowledge that I have been given the opportunity to obtain independent legal advice with respect to this offer, and that I am accepting it freely, voluntarily, and without duress.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accepted&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> _&#47;s&#47; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Robert B. Huizinga</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_______________               Date&#58; _</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">October 20, 2022</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_______________</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;&#160;&#160;&#160;Robert B. Huizinga </font></div><div style="margin-bottom:10pt;text-align:center"><font><br></font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:78.48pt;width:100%"><div style="margin-bottom:0.12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">RELEASE</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Robert B. Huizinga </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Employee</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">for the consideration set out in the attached letter dated October 20, 2022 (the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Letter&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), and for other good and valuable consideration, does, to the fullest extent permitted by law, forever release and forever discharge</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Aurinia Pharmaceuticals Inc. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Aurinia Pharma U.S. Inc., </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">together with their affiliates, subsidiaries, directors, officers, employees, agents, owners and shareholders (collectively the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Company&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) from any and all manners of actions, causes of actions, suits, contracts, claims, complaints, damages, costs and expenses of any nature or kind whatsoever known or unknown whether in law (including the common law) or in equity or pursuant to statute, which, as against the Company, the Employee has ever had or now has by reason of or arising out of any cause, matter or thing whatsoever occurring or existing up to the date of execution of this Release and, without limiting the generality of the foregoing, any matter, cause, or thing relating to or arising out of the Employee&#8217;s employment with the Company, the Employee&#8217;s contract of employment with the Company, or the cessation of Employee&#8217;s employment with the Company, and any other claim for damages, notice, payment in lieu of notice, wrongful dismissal, severance pay, loss of benefits including life insurance and long term and short term disability insurance, pension issues, bonus (pro-rated or otherwise), profit sharing, stock distribution, stock options or stock purchase rights, overtime pay, commissions, vacation pay, earned time off, or any claims under the British Columbia </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Employment Standards Act</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or the British Columbia </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Human Rights Code</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Employee acknowledges that, upon receipt of the payments set out in the Letter, he&#47;she will have received all payments and amounts owing to him&#47;her under the British Columbia </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Employment Standards Act</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and that, to the fullest extent permitted by law, the payments made to him&#47;her in the Letter are in full and final satisfaction of any further entitlements he&#47;she may have pursuant to the British Columbia </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Employment Standards Act</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Employee acknowledges that he&#47;she has not be subjected to any form of discrimination or prohibited action whatsoever and hereby represents and warrants that he&#47;she has not commenced any complaint and undertakes not to commence any complaint under the British Columbia </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Human Rights Code</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Workers Compensation Act</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Employee acknowledges and agrees that the consideration set out in the Letter includes full compensation and consideration for loss of employment benefits and that all of his&#47;her employment benefits will cease as set out in the Letter. The Employee fully accepts sole responsibility to replace those benefits that he&#47;she wishes to continue and to exercise conversion privileges where applicable with respect to benefits at his&#47;her own cost. In the event that the Employee becomes disabled, he&#47;she covenants not to sue the Company for insurance or other benefits, or for loss of benefits. The Employee hereby releases the Company from any and further obligations or liabilities arising from his&#47;her employment benefits and the loss of such benefits.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Employee covenants and undertakes not to defame, disparage or demean the Company, or any of its affiliates, subsidiaries, employees, officers, directors or agents, or any of its products or services, to any third party, in any manner whatsoever, including through social media.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Release is binding upon and enures to the benefit of the Employee&#8217;s heirs, executors, administrators, assigns, committees and trustees.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Release is binding upon and enures to the benefit of the Company&#8217;s affiliates, subsidiaries, directors, officers, employees, agents, predecessors, successors, assigns, liquidators, receivers, receiver managers, trustees, owners and shareholders.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the event withholdings have not been deducted which should have been deducted, the Employee shall indemnify and save harmless the Company from any resulting liabilities, obligations, and costs regarding any claims which Canada Revenue Agency or Employment Insurance Commission may make upon the Company pursuant to the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Income Tax Act</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (Canada), </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Employment Insurance Act</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (Canada), and&#47;or the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Canada Pension Plan</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, as such legislation or plans may be amended from time to </font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:78.48pt;width:100%"><div style="margin-bottom:0.12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">time, with respect to any payments made or benefits provided to or on behalf of the Employee or in respect of any Canada Pension Plan or Employment Insurance benefits or contributions.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Employee acknowledges that the facts in respect of which this Release is made may prove to be other than or different from the facts in that connection now known or believed by the Employee to be true.  The Employee accepts and assumes the risk of the facts being different and agrees that this Release shall be in all respects enforceable and not subject to termination, rescission, or variation by discovery of any differences in facts.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Employee agrees not to make claim or take proceedings (including, but not limited to, any cross-claims, counter-claims, third party claims, actions or applications) against any other person or corporation that might claim contribution or indemnity under the provisions of any statute or otherwise against the Company.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Employee agrees to keep the terms of the Letter and this Release strictly confidential and will not disclose any information with respect to the Letter or this Release to anyone with the exception of his&#47;her spouse and his&#47;her legal or financial advisors, unless compelled to do so by law or court order. </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Employee acknowledges that this Release has been executed voluntarily after having had the opportunity to receive legal advice.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Release is given voluntarily for the purposes of making a full and final settlement of all of the Employee&#8217;s claims whatsoever arising against the Company. This Release and the Letter are not to be construed or considered as an admission of liability by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the event that any paragraph or portion thereof of this Release shall be invalid or unenforceable, for any reason whatsoever, then such invalid or unenforceable paragraph or portion shall be severed from the remainder of this Release, provided that it does not render the remainder of the Release unenforceable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Employee understands and agrees that this Release and the Letter contains the entire agreement between the Company and the Employee and that the terms of this Release are contractual and not recitals.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Release shall be governed by the laws of the Province of British Columbia, Canada and the Employee hereby submits to the exclusive jurisdiction of the courts and tribunals of that province, as applicable.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executed copies of this Release may be exchanged by facsimile or electronically via PDF format. Each facsimile or PDF copy so executed and exchanged will be deemed an original.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dated at </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Victoria    </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (city), the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">20th </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> day of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">October</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, 20</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">22</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.519%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">&#47;s&#47; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%;text-decoration:underline">Robert B. Huizinga</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Robert B. Huizinga </font></div></td></tr></table></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:78.48pt;width:100%"><div style="margin-bottom:0.12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:-49.5pt"><font><br></font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>auph-2022q3exx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i3724e68c89f547e59541904bfe2d04c0_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE RULES 13a-14(a) AND 15d-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Peter Greenleaf, certify that&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10-Q of Aurinia Pharmaceuticals Inc.&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.988%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.088%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Peter Greenleaf</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Peter Greenleaf</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>auph-2022q3exx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i5f017ebe754644daad60b6b0c17809b9_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULES 13a-14(a) AND 15d-14(a),</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Joseph Miller, certify that&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10-Q of Aurinia Pharmaceuticals Inc..&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Joseph Miller</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Joseph Miller</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>auph-2022q3exx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="id46d850982b247ab949a2cf9f3491d25_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Aurinia Pharmaceuticals Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending September&#160;30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Peter Greenleaf, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that&#58;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.247%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Peter Greenleaf</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Peter Greenleaf</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>auph-2022q3exx322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i081a6a3c4f3d421994134ee1475892fb_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Aurinia Pharmaceuticals Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending September&#160;30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Joseph Miller, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that&#58;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Joseph Miller</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Joseph Miller</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>auph-20220930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:05323eab-3ae1-47f9-a870-5f1cb7d56826,g:99240d06-396b-484e-9f8c-0586e299f202-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:auph="http://www.auriniapharma.com/20220930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.auriniapharma.com/20220930">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="auph-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="auph-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="auph-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="auph-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="COVER" roleURI="http://www.auriniapharma.com/role/COVER">
        <link:definition>0000001 - Document - COVER</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical" roleURI="http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical">
        <link:definition>0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" roleURI="http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY">
        <link:definition>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandDescriptionofBusiness" roleURI="http://www.auriniapharma.com/role/OrganizationandDescriptionofBusiness">
        <link:definition>0000008 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.auriniapharma.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.auriniapharma.com/role/FairValueMeasurements">
        <link:definition>0000010 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsRestrictedCashandShortTermInvestments" roleURI="http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestments">
        <link:definition>0000011 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Short-Term Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventoriesnet" roleURI="http://www.auriniapharma.com/role/Inventoriesnet">
        <link:definition>0000012 - Disclosure - Inventories, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpenses" roleURI="http://www.auriniapharma.com/role/PrepaidExpenses">
        <link:definition>0000013 - Disclosure - Prepaid Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssets" roleURI="http://www.auriniapharma.com/role/IntangibleAssets">
        <link:definition>0000014 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnet" roleURI="http://www.auriniapharma.com/role/PropertyandEquipmentnet">
        <link:definition>0000015 - Disclosure - Property and Equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseObligations" roleURI="http://www.auriniapharma.com/role/LeaseObligations">
        <link:definition>0000016 - Disclosure - Lease Obligations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedLiabilities" roleURI="http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilities">
        <link:definition>0000017 - Disclosure - Accounts Payable and Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DeferredCompensationandOtherNoncurrentLiabilities" roleURI="http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilities">
        <link:definition>0000018 - Disclosure - Deferred Compensation and Other Non-current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreement" roleURI="http://www.auriniapharma.com/role/LicenseandCollaborationAgreement">
        <link:definition>0000019 - Disclosure - License and Collaboration Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperCommonShare" roleURI="http://www.auriniapharma.com/role/NetLossperCommonShare">
        <link:definition>0000020 - Disclosure - Net Loss per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensation" roleURI="http://www.auriniapharma.com/role/SharebasedCompensation">
        <link:definition>0000021 - Disclosure - Share-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.auriniapharma.com/role/IncomeTaxes">
        <link:definition>0000022 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.auriniapharma.com/role/RelatedPartyTransactions">
        <link:definition>0000023 - Disclosure - Related-Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingencies" roleURI="http://www.auriniapharma.com/role/CommitmentandContingencies">
        <link:definition>0000024 - Disclosure - Commitment and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.auriniapharma.com/role/SubsequentEvents">
        <link:definition>0000025 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000026 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.auriniapharma.com/role/FairValueMeasurementsTables">
        <link:definition>0000027 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsRestrictedCashandShortTermInvestmentsTables" roleURI="http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsTables">
        <link:definition>0000028 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Short-Term Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesnetTables" roleURI="http://www.auriniapharma.com/role/InventoriesnetTables">
        <link:definition>0000029 - Disclosure - Inventories, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesTables" roleURI="http://www.auriniapharma.com/role/PrepaidExpensesTables">
        <link:definition>0000030 - Disclosure - Prepaid Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsTables" roleURI="http://www.auriniapharma.com/role/IntangibleAssetsTables">
        <link:definition>0000031 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnetTables" roleURI="http://www.auriniapharma.com/role/PropertyandEquipmentnetTables">
        <link:definition>0000032 - Disclosure - Property and Equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseObligationsTables" roleURI="http://www.auriniapharma.com/role/LeaseObligationsTables">
        <link:definition>0000033 - Disclosure - Lease Obligations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedLiabilitiesTables" roleURI="http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesTables">
        <link:definition>0000034 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperCommonShareTables" roleURI="http://www.auriniapharma.com/role/NetLossperCommonShareTables">
        <link:definition>0000035 - Disclosure - Net Loss per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationTables" roleURI="http://www.auriniapharma.com/role/SharebasedCompensationTables">
        <link:definition>0000036 - Disclosure - Share-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>0000037 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" roleURI="http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails">
        <link:definition>0000038 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsRestrictedCashandShortTermInvestmentsNarrativeDetails" roleURI="http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsNarrativeDetails">
        <link:definition>0000039 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Short-Term Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails" roleURI="http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails">
        <link:definition>0000040 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Short-Term Investments - Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesnetDetails" roleURI="http://www.auriniapharma.com/role/InventoriesnetDetails">
        <link:definition>0000041 - Disclosure - Inventories, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesDetails" roleURI="http://www.auriniapharma.com/role/PrepaidExpensesDetails">
        <link:definition>0000042 - Disclosure - Prepaid Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsScheduleofIntangibleAssetsDetails" roleURI="http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails">
        <link:definition>0000043 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNarrativeDetails" roleURI="http://www.auriniapharma.com/role/IntangibleAssetsNarrativeDetails">
        <link:definition>0000044 - Disclosure - Intangible Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnetDetails" roleURI="http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails">
        <link:definition>0000045 - Disclosure - Property and Equipment, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseObligationsNarrativeDetails" roleURI="http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails">
        <link:definition>0000046 - Disclosure - Lease Obligations - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails" roleURI="http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails">
        <link:definition>0000047 - Disclosure - Lease Obligations - Summary of Components of Leasing Costs and Rent (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" roleURI="http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails">
        <link:definition>0000048 - Disclosure - Lease Obligations - Schedule of Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1" roleURI="http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1">
        <link:definition>0000048 - Disclosure - Lease Obligations - Schedule of Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedLiabilitiesDetails" roleURI="http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails">
        <link:definition>0000049 - Disclosure - Accounts Payable and Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DeferredCompensationandOtherNoncurrentLiabilitiesDetails" roleURI="http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilitiesDetails">
        <link:definition>0000050 - Disclosure - Deferred Compensation and Other Non-current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreementDetails" roleURI="http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails">
        <link:definition>0000051 - Disclosure - License and Collaboration Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails" roleURI="http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails">
        <link:definition>0000052 - Disclosure - Net Loss per Common Share - Schedule of Earnings Per Share, Basic and Diluted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperCommonShareAntiDilutiveSecuritiesDetails" roleURI="http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails">
        <link:definition>0000053 - Disclosure - Net Loss per Common Share - Anti-Dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationNarrativeDetails" roleURI="http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails">
        <link:definition>0000054 - Disclosure - Share-based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationWeightedAverageAssumptionsDetails" roleURI="http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails">
        <link:definition>0000055 - Disclosure - Share-Based Compensation - Weighted Average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationStockOptionActivityDetails" roleURI="http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails">
        <link:definition>0000056 - Disclosure - Share-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails" roleURI="http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails">
        <link:definition>0000057 - Disclosure - Share-Based Compensation - Performance Awards and Restricted Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails" roleURI="http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails">
        <link:definition>0000058 - Disclosure - Share-Based Compensation - Allocated Share-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.auriniapharma.com/role/IncomeTaxesDetails">
        <link:definition>0000059 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails">
        <link:definition>0000060 - Disclosure - Related-Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.auriniapharma.com/role/SubsequentEventsDetails">
        <link:definition>0000061 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="auph_LesseeOperatingLeaseLeaseTerminationTerm" abstract="false" name="LesseeOperatingLeaseLeaseTerminationTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="auph_OtuskaPharmaceuticalCoLtdMember" abstract="true" name="OtuskaPharmaceuticalCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="auph_OutsideUnitedStatesMember" abstract="true" name="OutsideUnitedStatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="auph_PerformanceShareSandRestrictedStockUnitsRSUsMember" abstract="true" name="PerformanceShareSandRestrictedStockUnitsRSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="auph_AmendedAndRestatedEquityIncentivePlanMember" abstract="true" name="AmendedAndRestatedEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="auph_YankeeBondMember" abstract="true" name="YankeeBondMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="auph_AccruedResearchCurrent" abstract="false" name="AccruedResearchCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNewEmployees" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNewEmployees" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="auph_SpecialtyPharmacyOneMember" abstract="true" name="SpecialtyPharmacyOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="auph_VictoriaBritishColumbiaMember" abstract="true" name="VictoriaBritishColumbiaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="auph_AccountsReceivableCreditTerm" abstract="false" name="AccountsReceivableCreditTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="auph_ShareBasedPaymentArrangementInducementOptionMember" abstract="true" name="ShareBasedPaymentArrangementInducementOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="auph_CommercialRelatedAccrualsCurrent" abstract="false" name="CommercialRelatedAccrualsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="auph_CashCashEquivalentsAndDebtSecuritiesCurrent" abstract="false" name="CashCashEquivalentsAndDebtSecuritiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="auph_NewEmployeesMember" abstract="true" name="NewEmployeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="auph_MilestoneAchievementMember" abstract="true" name="MilestoneAchievementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="auph_MilestonePaymentMember" abstract="true" name="MilestonePaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="auph_RockvilleMarylandMember" abstract="true" name="RockvilleMarylandMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="auph_CashCashEquivalentsAndRestrictedCashMember" abstract="true" name="CashCashEquivalentsAndRestrictedCashMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="auph_USAgencySecurityMember" abstract="true" name="USAgencySecurityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="auph_AcquiredUpfrontLicensePayment" abstract="false" name="AcquiredUpfrontLicensePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="auph_ShareBasedPaymentArrangementUnamortizedExpense" abstract="false" name="ShareBasedPaymentArrangementUnamortizedExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="auph_LesseeOperatingLeaseNumberOfExtensionOptions" abstract="false" name="LesseeOperatingLeaseNumberOfExtensionOptions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="auph_ResearchAndDevelopmentArrangementContractToPerformMilestonePayments" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="auph_ILJINMember" abstract="true" name="ILJINMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="auph_RiptideBioscienceIncMember" abstract="true" name="RiptideBioscienceIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="auph_PrepaidAssetsCurrent" abstract="false" name="PrepaidAssetsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="auph_ShortTermCorporateDebtSecuritiesMember" abstract="true" name="ShortTermCorporateDebtSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="auph_PrepaidExpensesTextBlock" abstract="false" name="PrepaidExpensesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>auph-20220930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:05323eab-3ae1-47f9-a870-5f1cb7d56826,g:99240d06-396b-484e-9f8c-0586e299f202-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="auph-20220930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ae742a0d-b79d-48f8-9fee-c15ab873c1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c8db360a-558e-42d8-a623-da573d1424ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ae742a0d-b79d-48f8-9fee-c15ab873c1b0" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c8db360a-558e-42d8-a623-da573d1424ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_16f8bc62-1c91-426f-a8f1-6cfbf0a2967a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ae742a0d-b79d-48f8-9fee-c15ab873c1b0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_16f8bc62-1c91-426f-a8f1-6cfbf0a2967a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_bbc1362d-2984-4eb4-8205-9cbcf003469e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ae742a0d-b79d-48f8-9fee-c15ab873c1b0" xlink:to="loc_us-gaap_AssetsCurrent_bbc1362d-2984-4eb4-8205-9cbcf003469e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9b8e19cc-45a3-47b9-a04c-58799b9aaddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ae742a0d-b79d-48f8-9fee-c15ab873c1b0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9b8e19cc-45a3-47b9-a04c-58799b9aaddf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8171709d-cc66-4654-8ee4-331bbe46de45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ae742a0d-b79d-48f8-9fee-c15ab873c1b0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8171709d-cc66-4654-8ee4-331bbe46de45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0d48a853-d8c7-42c4-928a-701c06412e91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_52e18caf-f93c-4684-b74a-e99ce849b07f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0d48a853-d8c7-42c4-928a-701c06412e91" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_52e18caf-f93c-4684-b74a-e99ce849b07f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_66bcda20-f1a8-4321-9105-a6354621bff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0d48a853-d8c7-42c4-928a-701c06412e91" xlink:to="loc_us-gaap_LiabilitiesCurrent_66bcda20-f1a8-4321-9105-a6354621bff0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_97bb3214-1a13-46ae-80c2-4b81460a25fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0d48a853-d8c7-42c4-928a-701c06412e91" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_97bb3214-1a13-46ae-80c2-4b81460a25fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_aee219fc-a66d-4e31-873a-1b19b33abeba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e952c092-f90a-4de3-8988-609774267689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_aee219fc-a66d-4e31-873a-1b19b33abeba" xlink:to="loc_us-gaap_Liabilities_e952c092-f90a-4de3-8988-609774267689" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_59f2381f-b6a4-46c1-a824-f175343ccc66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_aee219fc-a66d-4e31-873a-1b19b33abeba" xlink:to="loc_us-gaap_CommitmentsAndContingencies_59f2381f-b6a4-46c1-a824-f175343ccc66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_169bb96c-014a-4944-abbb-1b3b9933939c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_aee219fc-a66d-4e31-873a-1b19b33abeba" xlink:to="loc_us-gaap_StockholdersEquity_169bb96c-014a-4944-abbb-1b3b9933939c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e59bfe72-2918-45a0-aab0-47d68f98b552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_6ca512ed-19ea-4cfa-ad12-0ff48ae7b787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e59bfe72-2918-45a0-aab0-47d68f98b552" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_6ca512ed-19ea-4cfa-ad12-0ff48ae7b787" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e0f96929-e3bf-4127-8c28-3b2133278afd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e59bfe72-2918-45a0-aab0-47d68f98b552" xlink:to="loc_us-gaap_InventoryNet_e0f96929-e3bf-4127-8c28-3b2133278afd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesCurrent_b6eb8b6b-f242-4bdf-bceb-bb7c8b9af599" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e59bfe72-2918-45a0-aab0-47d68f98b552" xlink:to="loc_us-gaap_DebtSecuritiesCurrent_b6eb8b6b-f242-4bdf-bceb-bb7c8b9af599" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_9402c011-a4f1-4b96-8d4f-39b31d8cc25e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e59bfe72-2918-45a0-aab0-47d68f98b552" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_9402c011-a4f1-4b96-8d4f-39b31d8cc25e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dcd3c252-8ec2-47a3-8145-f9746bc091cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e59bfe72-2918-45a0-aab0-47d68f98b552" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dcd3c252-8ec2-47a3-8145-f9746bc091cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_f25c3bd8-40a0-4ae0-9e57-5bfeab985977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e59bfe72-2918-45a0-aab0-47d68f98b552" xlink:to="loc_us-gaap_OtherAssetsCurrent_f25c3bd8-40a0-4ae0-9e57-5bfeab985977" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fa400289-aea4-4f8b-9c56-92ce3c5adadd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_a32c63e2-1f62-4259-982c-ea87a2dc4365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fa400289-aea4-4f8b-9c56-92ce3c5adadd" xlink:to="loc_us-gaap_CommonStockValueOutstanding_a32c63e2-1f62-4259-982c-ea87a2dc4365" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_7243e85e-49a1-477f-b59b-c78b6dfdcc01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fa400289-aea4-4f8b-9c56-92ce3c5adadd" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_7243e85e-49a1-477f-b59b-c78b6dfdcc01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8f2dbcda-5d3e-471c-9e8f-c5f72870a075" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fa400289-aea4-4f8b-9c56-92ce3c5adadd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8f2dbcda-5d3e-471c-9e8f-c5f72870a075" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8bccdb07-0bf7-4e41-a0f9-5bf07c198f26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fa400289-aea4-4f8b-9c56-92ce3c5adadd" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8bccdb07-0bf7-4e41-a0f9-5bf07c198f26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9cd2130a-afc7-4d57-892b-e2f159d564e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c8161f6a-db7b-41b8-b927-d8b0a50a3317" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9cd2130a-afc7-4d57-892b-e2f159d564e6" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c8161f6a-db7b-41b8-b927-d8b0a50a3317" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2dd591cf-f2da-464f-8873-6e2fe55af316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9cd2130a-afc7-4d57-892b-e2f159d564e6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2dd591cf-f2da-464f-8873-6e2fe55af316" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_c5b92879-7a2d-45ba-907c-d07f6568e7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9cd2130a-afc7-4d57-892b-e2f159d564e6" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_c5b92879-7a2d-45ba-907c-d07f6568e7c0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="auph-20220930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_817869a2-c726-4a70-9612-5ef1da729945" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_43254a1b-d89e-4d25-a13a-4827912a821e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_817869a2-c726-4a70-9612-5ef1da729945" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_43254a1b-d89e-4d25-a13a-4827912a821e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_29e71ce2-09ed-4b87-b381-bb1869778179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_817869a2-c726-4a70-9612-5ef1da729945" xlink:to="loc_us-gaap_NetIncomeLoss_29e71ce2-09ed-4b87-b381-bb1869778179" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7917ea75-3cd5-48ce-8ec2-e776ce4f181a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_fe8d402a-8e25-4b94-983d-6d67b7773370" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_7917ea75-3cd5-48ce-8ec2-e776ce4f181a" xlink:to="loc_us-gaap_CostsAndExpenses_fe8d402a-8e25-4b94-983d-6d67b7773370" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ef93dc0d-0827-4191-9ae6-f653a8e60807" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_7917ea75-3cd5-48ce-8ec2-e776ce4f181a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ef93dc0d-0827-4191-9ae6-f653a8e60807" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a3acf517-9c15-4b0d-a2fd-14c81df405dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_9721e3b0-a268-4c97-8f8c-bdc1024f8ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a3acf517-9c15-4b0d-a2fd-14c81df405dc" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_9721e3b0-a268-4c97-8f8c-bdc1024f8ec8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c1e30d86-641a-49e9-8585-a3599683382e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a3acf517-9c15-4b0d-a2fd-14c81df405dc" xlink:to="loc_us-gaap_OperatingIncomeLoss_c1e30d86-641a-49e9-8585-a3599683382e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_86e363d2-cbbd-47d3-89e3-962145a352e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_b55dc36b-1bc6-4462-bcb1-b641c94bac0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_86e363d2-cbbd-47d3-89e3-962145a352e9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_b55dc36b-1bc6-4462-bcb1-b641c94bac0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_deaaf997-3330-4350-af19-47cf85b1b526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_86e363d2-cbbd-47d3-89e3-962145a352e9" xlink:to="loc_us-gaap_CostOfRevenue_deaaf997-3330-4350-af19-47cf85b1b526" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_9cd28ccb-6c74-436a-ab4d-8cec6c2d5c73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_86e363d2-cbbd-47d3-89e3-962145a352e9" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_9cd28ccb-6c74-436a-ab4d-8cec6c2d5c73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_16ff7697-fb91-4e08-92c1-2d42c459b957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_86e363d2-cbbd-47d3-89e3-962145a352e9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_16ff7697-fb91-4e08-92c1-2d42c459b957" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_eb9a65e3-999b-4b53-8588-c58f375b3ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_51818c1f-8e56-44d7-837e-8c30c2e391d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_eb9a65e3-999b-4b53-8588-c58f375b3ec2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_51818c1f-8e56-44d7-837e-8c30c2e391d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c3b88b74-d808-44a6-bbce-01f539342a52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_eb9a65e3-999b-4b53-8588-c58f375b3ec2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c3b88b74-d808-44a6-bbce-01f539342a52" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="auph-20220930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_702bc8b4-979c-4361-9be4-678358ff3557" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_17f0d82e-3223-4df7-b9bc-d0ca49f134a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_702bc8b4-979c-4361-9be4-678358ff3557" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_17f0d82e-3223-4df7-b9bc-d0ca49f134a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d944e4c3-8606-4389-a52c-50bd3d823898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_702bc8b4-979c-4361-9be4-678358ff3557" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d944e4c3-8606-4389-a52c-50bd3d823898" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_17cafc97-ec1b-4b3c-931a-ab65fe2437b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_702bc8b4-979c-4361-9be4-678358ff3557" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_17cafc97-ec1b-4b3c-931a-ab65fe2437b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6ef09159-ddb0-441c-93a3-a755b74a8638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_de8b2111-e8d4-4096-8073-e415927736c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6ef09159-ddb0-441c-93a3-a755b74a8638" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_de8b2111-e8d4-4096-8073-e415927736c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_6e7a77cd-663a-464e-add5-f1d7c589edb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6ef09159-ddb0-441c-93a3-a755b74a8638" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_6e7a77cd-663a-464e-add5-f1d7c589edb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_c8bdcac4-395c-4278-8d01-5abfd7034267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6ef09159-ddb0-441c-93a3-a755b74a8638" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_c8bdcac4-395c-4278-8d01-5abfd7034267" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_432e71c4-6dda-40da-8d7b-df880ab6180a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6ef09159-ddb0-441c-93a3-a755b74a8638" xlink:to="loc_us-gaap_Depreciation_432e71c4-6dda-40da-8d7b-df880ab6180a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_0e92263c-1c1a-4a9d-ab8d-1b7b22dc856a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6ef09159-ddb0-441c-93a3-a755b74a8638" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_0e92263c-1c1a-4a9d-ab8d-1b7b22dc856a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fc332982-5467-48f4-8a82-2bcedc073130" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6ef09159-ddb0-441c-93a3-a755b74a8638" xlink:to="loc_us-gaap_NetIncomeLoss_fc332982-5467-48f4-8a82-2bcedc073130" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_9ac31d8b-a0df-4199-8650-8265d78508fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6ef09159-ddb0-441c-93a3-a755b74a8638" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_9ac31d8b-a0df-4199-8650-8265d78508fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_b1aa8e3b-fedf-4818-bcb5-6b388603aff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6ef09159-ddb0-441c-93a3-a755b74a8638" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_b1aa8e3b-fedf-4818-bcb5-6b388603aff7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3cc17a11-30e7-488f-b28d-39e532595538" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6ef09159-ddb0-441c-93a3-a755b74a8638" xlink:to="loc_us-gaap_ShareBasedCompensation_3cc17a11-30e7-488f-b28d-39e532595538" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_e7ccc5fe-3319-4ebb-8963-0b207727e443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6ef09159-ddb0-441c-93a3-a755b74a8638" xlink:to="loc_us-gaap_InventoryWriteDown_e7ccc5fe-3319-4ebb-8963-0b207727e443" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_AcquiredUpfrontLicensePayment_7fbfa482-66da-493e-a089-280d857db752" xlink:href="auph-20220930.xsd#auph_AcquiredUpfrontLicensePayment"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6ef09159-ddb0-441c-93a3-a755b74a8638" xlink:to="loc_auph_AcquiredUpfrontLicensePayment_7fbfa482-66da-493e-a089-280d857db752" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_97dd5a27-55c7-4d55-870f-c0008b0fa5fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6ef09159-ddb0-441c-93a3-a755b74a8638" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_97dd5a27-55c7-4d55-870f-c0008b0fa5fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4c381b60-b24c-4cea-8878-4027c1765f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_b9fe6b37-9be2-45af-9f93-e5b6c73a500f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4c381b60-b24c-4cea-8878-4027c1765f2e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_b9fe6b37-9be2-45af-9f93-e5b6c73a500f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fedc6533-fbef-42f7-b68c-9a51b9d980c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4c381b60-b24c-4cea-8878-4027c1765f2e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fedc6533-fbef-42f7-b68c-9a51b9d980c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a23e468e-37d4-4ab7-8145-26453b170380" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_4c08c777-941e-4ebc-81c4-0401798d10a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a23e468e-37d4-4ab7-8145-26453b170380" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_4c08c777-941e-4ebc-81c4-0401798d10a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_e0ef8e8f-1ecb-49c2-85d7-dabea8d6d57e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a23e468e-37d4-4ab7-8145-26453b170380" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_e0ef8e8f-1ecb-49c2-85d7-dabea8d6d57e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_75544aaa-9702-43da-bb51-5cd624a0d1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_5a33e20c-c7e0-40a6-bb64-f4ed88cdd43b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_75544aaa-9702-43da-bb51-5cd624a0d1d4" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_5a33e20c-c7e0-40a6-bb64-f4ed88cdd43b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLeaseReceivables_5a9ec07f-5bb2-407f-adfb-e22fa826db9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireLeaseReceivables"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_75544aaa-9702-43da-bb51-5cd624a0d1d4" xlink:to="loc_us-gaap_PaymentsToAcquireLeaseReceivables_5a9ec07f-5bb2-407f-adfb-e22fa826db9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForSoftware_029ac73a-12f1-4c1a-bb78-44d5f4e4f8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForSoftware"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_75544aaa-9702-43da-bb51-5cd624a0d1d4" xlink:to="loc_us-gaap_PaymentsForSoftware_029ac73a-12f1-4c1a-bb78-44d5f4e4f8c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_2ddb6c77-e531-4999-a954-db4c8cf3e90a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_75544aaa-9702-43da-bb51-5cd624a0d1d4" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_2ddb6c77-e531-4999-a954-db4c8cf3e90a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_46bb5972-f8c2-4e94-8017-9db89052ad8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_75544aaa-9702-43da-bb51-5cd624a0d1d4" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_46bb5972-f8c2-4e94-8017-9db89052ad8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_cf41b523-32d1-40d7-b28a-580e1a9112e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_75544aaa-9702-43da-bb51-5cd624a0d1d4" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_cf41b523-32d1-40d7-b28a-580e1a9112e4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments_8e92cc06-cc18-4268-9e5c-b270b2dfae04" xlink:href="auph-20220930.xsd#auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent_610ca2b8-97f1-48d5-b111-858d097ead0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments_8e92cc06-cc18-4268-9e5c-b270b2dfae04" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent_610ca2b8-97f1-48d5-b111-858d097ead0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_2c6a96b2-0893-4911-8af2-afb44c2cc428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments_8e92cc06-cc18-4268-9e5c-b270b2dfae04" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_2c6a96b2-0893-4911-8af2-afb44c2cc428" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_cd00f6ea-c20b-4e02-8f60-776e37343293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_4d3d8e9a-f72f-4356-8ec5-aa121b831d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_cd00f6ea-c20b-4e02-8f60-776e37343293" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_4d3d8e9a-f72f-4356-8ec5-aa121b831d6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_18978e59-d54f-46b8-8d9b-b139197acc13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_cd00f6ea-c20b-4e02-8f60-776e37343293" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_18978e59-d54f-46b8-8d9b-b139197acc13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_ff3a23d6-fe2b-4dd0-9f32-e591aad2e5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_cd00f6ea-c20b-4e02-8f60-776e37343293" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_ff3a23d6-fe2b-4dd0-9f32-e591aad2e5f2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/InventoriesnetDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#InventoriesnetDetails"/>
  <link:calculationLink xlink:role="http://www.auriniapharma.com/role/InventoriesnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d4f03a2f-7478-409c-82a2-6e4583728a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_3e97de8d-ee22-410b-8168-ec87fc566442" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_d4f03a2f-7478-409c-82a2-6e4583728a8e" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_3e97de8d-ee22-410b-8168-ec87fc566442" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_e3c27efd-44d8-4072-b12a-fe3eaa327103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_d4f03a2f-7478-409c-82a2-6e4583728a8e" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_e3c27efd-44d8-4072-b12a-fe3eaa327103" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_53c18c0b-ced5-4455-995f-e71639b57849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_d4f03a2f-7478-409c-82a2-6e4583728a8e" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_53c18c0b-ced5-4455-995f-e71639b57849" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/PrepaidExpensesDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#PrepaidExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.auriniapharma.com/role/PrepaidExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_e8bee8f6-01c1-4739-9c53-facf96b7a5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_cc72c154-bced-416a-913b-9b3ee386de1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_e8bee8f6-01c1-4739-9c53-facf96b7a5e6" xlink:to="loc_us-gaap_PrepaidInsurance_cc72c154-bced-416a-913b-9b3ee386de1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsCurrent_5082b6aa-af93-417f-9057-4c7052b348a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_e8bee8f6-01c1-4739-9c53-facf96b7a5e6" xlink:to="loc_us-gaap_DepositsAssetsCurrent_5082b6aa-af93-417f-9057-4c7052b348a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_PrepaidAssetsCurrent_601bdf9b-295f-4490-ac01-3cb204bff753" xlink:href="auph-20220930.xsd#auph_PrepaidAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_e8bee8f6-01c1-4739-9c53-facf96b7a5e6" xlink:to="loc_auph_PrepaidAssetsCurrent_601bdf9b-295f-4490-ac01-3cb204bff753" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c85a1705-c638-4397-84f0-1badedf8fc25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3f450760-642d-4f33-9f82-927b5b2a2678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c85a1705-c638-4397-84f0-1badedf8fc25" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3f450760-642d-4f33-9f82-927b5b2a2678" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9e2d3f7f-bd88-47a3-b342-07c52a489104" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c85a1705-c638-4397-84f0-1badedf8fc25" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9e2d3f7f-bd88-47a3-b342-07c52a489104" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#PropertyandEquipmentnetDetails"/>
  <link:calculationLink xlink:role="http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f4c3eca4-bbb5-45e8-a87e-2e2baf7b7d36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_34f678f5-e2da-4ce2-9e9f-e0a7eb032d47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_f4c3eca4-bbb5-45e8-a87e-2e2baf7b7d36" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_34f678f5-e2da-4ce2-9e9f-e0a7eb032d47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_bf26461d-f59a-49ec-bd9f-4515d036c8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_f4c3eca4-bbb5-45e8-a87e-2e2baf7b7d36" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_bf26461d-f59a-49ec-bd9f-4515d036c8c2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d49562a1-bb8a-43ff-ad74-c6b4406d5340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_eb4872e8-093c-48c3-b4d8-5faa42ff7b49" xlink:href="auph-20220930.xsd#auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d49562a1-bb8a-43ff-ad74-c6b4406d5340" xlink:to="loc_auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_eb4872e8-093c-48c3-b4d8-5faa42ff7b49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9f51fc6a-1720-415d-b243-b3c3db6eafbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d49562a1-bb8a-43ff-ad74-c6b4406d5340" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9f51fc6a-1720-415d-b243-b3c3db6eafbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2a4fbf4f-fc0f-4cd2-b7d6-eeb636e7e6d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d49562a1-bb8a-43ff-ad74-c6b4406d5340" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2a4fbf4f-fc0f-4cd2-b7d6-eeb636e7e6d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bfde38ce-8f8a-4835-9361-60a9a4b4d660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d49562a1-bb8a-43ff-ad74-c6b4406d5340" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bfde38ce-8f8a-4835-9361-60a9a4b4d660" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_183d6443-2977-4f74-ab7a-0360301bc3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d49562a1-bb8a-43ff-ad74-c6b4406d5340" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_183d6443-2977-4f74-ab7a-0360301bc3ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5554fc77-349c-45e1-a9e2-17f6bd819c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d49562a1-bb8a-43ff-ad74-c6b4406d5340" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5554fc77-349c-45e1-a9e2-17f6bd819c0d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="auph-20220930.xsd#LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f75bc575-9748-430f-9679-54239e8643e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4f855b87-3e98-4069-bc6d-06fb43979226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f75bc575-9748-430f-9679-54239e8643e4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4f855b87-3e98-4069-bc6d-06fb43979226" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_08ca7c3d-7960-491f-80ce-cfa3b310b3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f75bc575-9748-430f-9679-54239e8643e4" xlink:to="loc_us-gaap_OperatingLeaseLiability_08ca7c3d-7960-491f-80ce-cfa3b310b3c4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#AccountsPayableandAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_a3fa3ece-8a53-4f86-a934-41cfb0b72122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_CommercialRelatedAccrualsCurrent_de04916c-3655-4d1a-a5f3-f955c4f2dff9" xlink:href="auph-20220930.xsd#auph_CommercialRelatedAccrualsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_a3fa3ece-8a53-4f86-a934-41cfb0b72122" xlink:to="loc_auph_CommercialRelatedAccrualsCurrent_de04916c-3655-4d1a-a5f3-f955c4f2dff9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_dd6fd7cf-facd-4897-ab15-e0be29881b15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_a3fa3ece-8a53-4f86-a934-41cfb0b72122" xlink:to="loc_us-gaap_TaxesPayableCurrent_dd6fd7cf-facd-4897-ab15-e0be29881b15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_AccruedResearchCurrent_c70cb714-a29c-4efe-a392-015fca4fc1ea" xlink:href="auph-20220930.xsd#auph_AccruedResearchCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_a3fa3ece-8a53-4f86-a934-41cfb0b72122" xlink:to="loc_auph_AccruedResearchCurrent_c70cb714-a29c-4efe-a392-015fca4fc1ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_58f51d15-16b1-4d37-bf91-e0af0e0a8d96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_a3fa3ece-8a53-4f86-a934-41cfb0b72122" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_58f51d15-16b1-4d37-bf91-e0af0e0a8d96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2ddb6285-9961-4cfa-95fc-ed5ba7ab3105" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_a3fa3ece-8a53-4f86-a934-41cfb0b72122" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2ddb6285-9961-4cfa-95fc-ed5ba7ab3105" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails"/>
  <link:calculationLink xlink:role="http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9e012c46-7025-40a6-90ec-891f41360654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_aec8f211-16e1-4da7-9fc3-76b0a7f39529" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_9e012c46-7025-40a6-90ec-891f41360654" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_aec8f211-16e1-4da7-9fc3-76b0a7f39529" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_696ad4d0-0ab8-4ae2-b99c-7a0d7330de21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_9e012c46-7025-40a6-90ec-891f41360654" xlink:to="loc_us-gaap_NetIncomeLoss_696ad4d0-0ab8-4ae2-b99c-7a0d7330de21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_5fd316c8-506d-49df-b5b8-e745c14dc6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b7fe7968-db4f-465b-b8c5-0b33d07d1e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_5fd316c8-506d-49df-b5b8-e745c14dc6e4" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b7fe7968-db4f-465b-b8c5-0b33d07d1e7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6a949b90-9274-4455-9c4c-66b33d50953c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_5fd316c8-506d-49df-b5b8-e745c14dc6e4" xlink:to="loc_us-gaap_NetIncomeLoss_6a949b90-9274-4455-9c4c-66b33d50953c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ccf83e95-5975-47bb-817d-0eb9c392de05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_5fd316c8-506d-49df-b5b8-e745c14dc6e4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ccf83e95-5975-47bb-817d-0eb9c392de05" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>auph-20220930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:05323eab-3ae1-47f9-a870-5f1cb7d56826,g:99240d06-396b-484e-9f8c-0586e299f202-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="auph-20220930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended" id="i09fd6c6ebde049e9a8a232dce9a3b62b_CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9db917f2-91fd-4780-a7b7-1e89dda98bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_acfd923b-67af-436b-bb25-bcf583bae229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9db917f2-91fd-4780-a7b7-1e89dda98bc2" xlink:to="loc_us-gaap_RevenuesAbstract_acfd923b-67af-436b-bb25-bcf583bae229" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2a64f894-bb9a-4829-bbff-e1ed6ef8b8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_acfd923b-67af-436b-bb25-bcf583bae229" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2a64f894-bb9a-4829-bbff-e1ed6ef8b8c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_327d0e97-4865-43af-a6be-a38557d37105" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9db917f2-91fd-4780-a7b7-1e89dda98bc2" xlink:to="loc_us-gaap_OperatingExpensesAbstract_327d0e97-4865-43af-a6be-a38557d37105" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_ce9d84c0-9ae0-4d3c-80d1-51be4e0edd88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_327d0e97-4865-43af-a6be-a38557d37105" xlink:to="loc_us-gaap_CostOfRevenue_ce9d84c0-9ae0-4d3c-80d1-51be4e0edd88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_63cd6c4f-1220-4984-b36c-e0fe95811103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_327d0e97-4865-43af-a6be-a38557d37105" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_63cd6c4f-1220-4984-b36c-e0fe95811103" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f5918434-a384-4cdc-aa41-c94bb301e1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_327d0e97-4865-43af-a6be-a38557d37105" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f5918434-a384-4cdc-aa41-c94bb301e1e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_5932e93c-878c-4a4a-bb14-7441a79001a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_327d0e97-4865-43af-a6be-a38557d37105" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_5932e93c-878c-4a4a-bb14-7441a79001a9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_17d442e2-4ae3-4fb7-bfff-ccf2e9a6d864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_327d0e97-4865-43af-a6be-a38557d37105" xlink:to="loc_us-gaap_CostsAndExpenses_17d442e2-4ae3-4fb7-bfff-ccf2e9a6d864" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c62a5133-58ee-47fd-a0a1-b9e033ea11fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9db917f2-91fd-4780-a7b7-1e89dda98bc2" xlink:to="loc_us-gaap_OperatingIncomeLoss_c62a5133-58ee-47fd-a0a1-b9e033ea11fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_0652e27a-c0c2-4b46-8e49-335c8a27365a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9db917f2-91fd-4780-a7b7-1e89dda98bc2" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_0652e27a-c0c2-4b46-8e49-335c8a27365a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6b7cf79d-dc46-4bcc-ad37-3c9bfa187ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9db917f2-91fd-4780-a7b7-1e89dda98bc2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6b7cf79d-dc46-4bcc-ad37-3c9bfa187ed7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_22dac452-2c7a-4589-b66b-278875c87789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9db917f2-91fd-4780-a7b7-1e89dda98bc2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_22dac452-2c7a-4589-b66b-278875c87789" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8d3c30f5-9721-4f08-89ce-e83acc121712" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9db917f2-91fd-4780-a7b7-1e89dda98bc2" xlink:to="loc_us-gaap_NetIncomeLoss_8d3c30f5-9721-4f08-89ce-e83acc121712" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5bafdba0-af47-49af-bcf0-8aa5233b5b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9db917f2-91fd-4780-a7b7-1e89dda98bc2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5bafdba0-af47-49af-bcf0-8aa5233b5b9d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_b9f35cef-1330-4bdc-8a7d-6eb7c883c621" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5bafdba0-af47-49af-bcf0-8aa5233b5b9d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_b9f35cef-1330-4bdc-8a7d-6eb7c883c621" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_1a2070ab-f381-44c8-be6b-6bc549dceae7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9db917f2-91fd-4780-a7b7-1e89dda98bc2" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_1a2070ab-f381-44c8-be6b-6bc549dceae7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_4111a5b7-6e71-4ed6-972d-8951f4f481d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9db917f2-91fd-4780-a7b7-1e89dda98bc2" xlink:to="loc_us-gaap_EarningsPerShareBasic_4111a5b7-6e71-4ed6-972d-8951f4f481d6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1558927b-a85b-462f-8edc-0ac90df4f828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9db917f2-91fd-4780-a7b7-1e89dda98bc2" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1558927b-a85b-462f-8edc-0ac90df4f828" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_98c5825d-5096-4553-b8ad-df1505bc0568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9db917f2-91fd-4780-a7b7-1e89dda98bc2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_98c5825d-5096-4553-b8ad-df1505bc0568" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ac3dc0f8-e3f8-47ca-a69b-0cf90cb82bda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9db917f2-91fd-4780-a7b7-1e89dda98bc2" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ac3dc0f8-e3f8-47ca-a69b-0cf90cb82bda" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e78be07f-ccf2-4838-9d82-a9433cd5393d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_9db917f2-91fd-4780-a7b7-1e89dda98bc2" xlink:to="loc_us-gaap_StatementTable_e78be07f-ccf2-4838-9d82-a9433cd5393d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_434f56b9-7e96-429d-a3db-5fcb9152ac6d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e78be07f-ccf2-4838-9d82-a9433cd5393d" xlink:to="loc_srt_ProductOrServiceAxis_434f56b9-7e96-429d-a3db-5fcb9152ac6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_434f56b9-7e96-429d-a3db-5fcb9152ac6d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_434f56b9-7e96-429d-a3db-5fcb9152ac6d" xlink:to="loc_srt_ProductsAndServicesDomain_434f56b9-7e96-429d-a3db-5fcb9152ac6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_11db1404-dea5-45fd-9d1c-ebb40bcf5568" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_434f56b9-7e96-429d-a3db-5fcb9152ac6d" xlink:to="loc_srt_ProductsAndServicesDomain_11db1404-dea5-45fd-9d1c-ebb40bcf5568" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_bccea20d-1361-416d-abe2-c767816f9aab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_11db1404-dea5-45fd-9d1c-ebb40bcf5568" xlink:to="loc_us-gaap_ProductMember_bccea20d-1361-416d-abe2-c767816f9aab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_c08ff704-21d7-43d2-a933-5396af16e85f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_11db1404-dea5-45fd-9d1c-ebb40bcf5568" xlink:to="loc_us-gaap_LicenseMember_c08ff704-21d7-43d2-a933-5396af16e85f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" xlink:type="simple" xlink:href="auph-20220930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" xlink:type="extended" id="i36e19176791e4fd2b034fd7da247657a_CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_49e8f2ce-72c9-41e6-83ec-02497de14e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4522719d-28b8-4c48-b935-9c05740fbfea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49e8f2ce-72c9-41e6-83ec-02497de14e5c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4522719d-28b8-4c48-b935-9c05740fbfea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_db0618dd-d114-468a-99a4-298ca83c3276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4522719d-28b8-4c48-b935-9c05740fbfea" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_db0618dd-d114-468a-99a4-298ca83c3276" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_76c774f4-5331-4c2f-b12a-007926cb140f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4522719d-28b8-4c48-b935-9c05740fbfea" xlink:to="loc_us-gaap_StockholdersEquity_76c774f4-5331-4c2f-b12a-007926cb140f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_50045edd-9d9e-4b2f-a22e-7facc886c8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4522719d-28b8-4c48-b935-9c05740fbfea" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_50045edd-9d9e-4b2f-a22e-7facc886c8b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f8e8cf73-82d3-4467-8d33-fb53bf99decb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4522719d-28b8-4c48-b935-9c05740fbfea" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f8e8cf73-82d3-4467-8d33-fb53bf99decb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_39a34695-297f-44fa-acf6-04f629fbcc94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4522719d-28b8-4c48-b935-9c05740fbfea" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_39a34695-297f-44fa-acf6-04f629fbcc94" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_ec9e898e-5b9c-4c8f-8c39-02c95076999f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4522719d-28b8-4c48-b935-9c05740fbfea" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_ec9e898e-5b9c-4c8f-8c39-02c95076999f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_41caf01a-287d-470f-b24b-c0abb602c6b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4522719d-28b8-4c48-b935-9c05740fbfea" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_41caf01a-287d-470f-b24b-c0abb602c6b5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_1cfb04a1-dc54-41bb-a64e-82cf931db02b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4522719d-28b8-4c48-b935-9c05740fbfea" xlink:to="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_1cfb04a1-dc54-41bb-a64e-82cf931db02b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_162112c1-f0e5-45cf-b11b-32561a77f33c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4522719d-28b8-4c48-b935-9c05740fbfea" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_162112c1-f0e5-45cf-b11b-32561a77f33c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_fe4daf12-802e-4ad2-a294-6c8c2cfe99b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4522719d-28b8-4c48-b935-9c05740fbfea" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_fe4daf12-802e-4ad2-a294-6c8c2cfe99b3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1b79ab45-0f71-4c4d-ada4-c4f1d7132670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4522719d-28b8-4c48-b935-9c05740fbfea" xlink:to="loc_us-gaap_NetIncomeLoss_1b79ab45-0f71-4c4d-ada4-c4f1d7132670" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_068c4da2-34b8-4b34-89bf-350d1a72724d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_57b55eea-9134-45f4-947a-deabf8234802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_78bf16c7-d5ae-46e5-9ea4-15cca9ec67b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_49e8f2ce-72c9-41e6-83ec-02497de14e5c" xlink:to="loc_us-gaap_StatementTable_78bf16c7-d5ae-46e5-9ea4-15cca9ec67b2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_849c22f7-3efd-4627-8005-f64fa342aaa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_78bf16c7-d5ae-46e5-9ea4-15cca9ec67b2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_849c22f7-3efd-4627-8005-f64fa342aaa0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_849c22f7-3efd-4627-8005-f64fa342aaa0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_849c22f7-3efd-4627-8005-f64fa342aaa0" xlink:to="loc_us-gaap_EquityComponentDomain_849c22f7-3efd-4627-8005-f64fa342aaa0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d5526451-ae00-4906-9ad8-002c4879f05a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_849c22f7-3efd-4627-8005-f64fa342aaa0" xlink:to="loc_us-gaap_EquityComponentDomain_d5526451-ae00-4906-9ad8-002c4879f05a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a8e27a21-4b5e-4c93-a13a-b7ba9f22df0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d5526451-ae00-4906-9ad8-002c4879f05a" xlink:to="loc_us-gaap_CommonStockMember_a8e27a21-4b5e-4c93-a13a-b7ba9f22df0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4873dfee-9f5f-4b84-963a-b1aa662e4747" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d5526451-ae00-4906-9ad8-002c4879f05a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4873dfee-9f5f-4b84-963a-b1aa662e4747" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2820e52a-50a4-42a8-8ac4-ed82a9a15af3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d5526451-ae00-4906-9ad8-002c4879f05a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2820e52a-50a4-42a8-8ac4-ed82a9a15af3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_937620fb-ee5e-4dba-928c-edd8eec904c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d5526451-ae00-4906-9ad8-002c4879f05a" xlink:to="loc_us-gaap_RetainedEarningsMember_937620fb-ee5e-4dba-928c-edd8eec904c8" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="id5a86fbafa804911baacfbc3643d5618_SummaryofSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_390ed9eb-eaff-403d-9644-e35b4dac104b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_e965a585-6f84-4e39-99fa-0db1d7394399" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_390ed9eb-eaff-403d-9644-e35b4dac104b" xlink:to="loc_us-gaap_NumberOfOperatingSegments_e965a585-6f84-4e39-99fa-0db1d7394399" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_CashCashEquivalentsAndDebtSecuritiesCurrent_c09836c8-0b9b-4595-869f-e7062f462193" xlink:href="auph-20220930.xsd#auph_CashCashEquivalentsAndDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_390ed9eb-eaff-403d-9644-e35b4dac104b" xlink:to="loc_auph_CashCashEquivalentsAndDebtSecuritiesCurrent_c09836c8-0b9b-4595-869f-e7062f462193" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_9380668b-e153-49aa-9490-948cc938244c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_390ed9eb-eaff-403d-9644-e35b4dac104b" xlink:to="loc_us-gaap_RestrictedCash_9380668b-e153-49aa-9490-948cc938244c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_d6acef76-795f-4a29-8afd-47c077e1114d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_390ed9eb-eaff-403d-9644-e35b4dac104b" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_d6acef76-795f-4a29-8afd-47c077e1114d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d0024453-0124-4b74-aef2-a9ac1d5e62d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_390ed9eb-eaff-403d-9644-e35b4dac104b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d0024453-0124-4b74-aef2-a9ac1d5e62d3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_9dce3246-3e6f-4856-a1c3-ece588fe396f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_390ed9eb-eaff-403d-9644-e35b4dac104b" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_9dce3246-3e6f-4856-a1c3-ece588fe396f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_AccountsReceivableCreditTerm_d8f9d584-2db7-41fe-bed2-54eaadeb44d1" xlink:href="auph-20220930.xsd#auph_AccountsReceivableCreditTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_390ed9eb-eaff-403d-9644-e35b4dac104b" xlink:to="loc_auph_AccountsReceivableCreditTerm_d8f9d584-2db7-41fe-bed2-54eaadeb44d1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_41c64b39-8876-4e44-88fa-e41fa140b25f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_390ed9eb-eaff-403d-9644-e35b4dac104b" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_41c64b39-8876-4e44-88fa-e41fa140b25f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_AcquiredUpfrontLicensePayment_880d4b68-ab8b-4aad-afe2-3ce200337610" xlink:href="auph-20220930.xsd#auph_AcquiredUpfrontLicensePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_390ed9eb-eaff-403d-9644-e35b4dac104b" xlink:to="loc_auph_AcquiredUpfrontLicensePayment_880d4b68-ab8b-4aad-afe2-3ce200337610" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_19a285cc-57f2-47df-b2f5-5d864f06c549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_390ed9eb-eaff-403d-9644-e35b4dac104b" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_19a285cc-57f2-47df-b2f5-5d864f06c549" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1e596b79-7b5c-4e5a-970c-bfd04862d202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_390ed9eb-eaff-403d-9644-e35b4dac104b" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1e596b79-7b5c-4e5a-970c-bfd04862d202" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_02864f94-e3f7-4893-b822-55e615218f01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1e596b79-7b5c-4e5a-970c-bfd04862d202" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_02864f94-e3f7-4893-b822-55e615218f01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_02864f94-e3f7-4893-b822-55e615218f01_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_02864f94-e3f7-4893-b822-55e615218f01" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_02864f94-e3f7-4893-b822-55e615218f01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_b9f78e8d-f95b-4b17-a31b-71db9deec676" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_02864f94-e3f7-4893-b822-55e615218f01" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_b9f78e8d-f95b-4b17-a31b-71db9deec676" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_a6575359-87fe-44a1-b5e3-6aef90bb49b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_b9f78e8d-f95b-4b17-a31b-71db9deec676" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_a6575359-87fe-44a1-b5e3-6aef90bb49b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3fa4e998-0da9-414c-8af2-18254449f829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1e596b79-7b5c-4e5a-970c-bfd04862d202" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3fa4e998-0da9-414c-8af2-18254449f829" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3fa4e998-0da9-414c-8af2-18254449f829_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3fa4e998-0da9-414c-8af2-18254449f829" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3fa4e998-0da9-414c-8af2-18254449f829_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ae84e254-3e01-470d-a18b-d16c84246af2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3fa4e998-0da9-414c-8af2-18254449f829" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ae84e254-3e01-470d-a18b-d16c84246af2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_7a200275-4f52-4dea-833a-a8400a5ce5c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ae84e254-3e01-470d-a18b-d16c84246af2" xlink:to="loc_us-gaap_SalesRevenueNetMember_7a200275-4f52-4dea-833a-a8400a5ce5c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_4ae7b7f9-3771-4f38-a2f0-c259190de12b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1e596b79-7b5c-4e5a-970c-bfd04862d202" xlink:to="loc_srt_MajorCustomersAxis_4ae7b7f9-3771-4f38-a2f0-c259190de12b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_4ae7b7f9-3771-4f38-a2f0-c259190de12b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_4ae7b7f9-3771-4f38-a2f0-c259190de12b" xlink:to="loc_srt_NameOfMajorCustomerDomain_4ae7b7f9-3771-4f38-a2f0-c259190de12b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_fda99c08-36ab-4f04-8b15-d3b206e69c02" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_4ae7b7f9-3771-4f38-a2f0-c259190de12b" xlink:to="loc_srt_NameOfMajorCustomerDomain_fda99c08-36ab-4f04-8b15-d3b206e69c02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_SpecialtyPharmacyOneMember_f4bed16f-812a-4355-904a-b61995c7824e" xlink:href="auph-20220930.xsd#auph_SpecialtyPharmacyOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_fda99c08-36ab-4f04-8b15-d3b206e69c02" xlink:to="loc_auph_SpecialtyPharmacyOneMember_f4bed16f-812a-4355-904a-b61995c7824e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c612800f-acf7-4762-ac64-5b9e02b83f63" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1e596b79-7b5c-4e5a-970c-bfd04862d202" xlink:to="loc_srt_RangeAxis_c612800f-acf7-4762-ac64-5b9e02b83f63" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c612800f-acf7-4762-ac64-5b9e02b83f63_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c612800f-acf7-4762-ac64-5b9e02b83f63" xlink:to="loc_srt_RangeMember_c612800f-acf7-4762-ac64-5b9e02b83f63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c31536a8-52a0-4b7a-950c-7f6597ecc2f4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c612800f-acf7-4762-ac64-5b9e02b83f63" xlink:to="loc_srt_RangeMember_c31536a8-52a0-4b7a-950c-7f6597ecc2f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_eec6ea0e-a280-464e-a5f2-44029d60484c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c31536a8-52a0-4b7a-950c-7f6597ecc2f4" xlink:to="loc_srt_MinimumMember_eec6ea0e-a280-464e-a5f2-44029d60484c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_386531a1-95a6-47c6-bac1-22a9c888ee09" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c31536a8-52a0-4b7a-950c-7f6597ecc2f4" xlink:to="loc_srt_MaximumMember_386531a1-95a6-47c6-bac1-22a9c888ee09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ad5ab528-073e-4f02-8a56-6771e574960b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1e596b79-7b5c-4e5a-970c-bfd04862d202" xlink:to="loc_srt_StatementGeographicalAxis_ad5ab528-073e-4f02-8a56-6771e574960b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ad5ab528-073e-4f02-8a56-6771e574960b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_ad5ab528-073e-4f02-8a56-6771e574960b" xlink:to="loc_srt_SegmentGeographicalDomain_ad5ab528-073e-4f02-8a56-6771e574960b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7ae61164-2a33-44e6-89d8-78c3b587e617" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_ad5ab528-073e-4f02-8a56-6771e574960b" xlink:to="loc_srt_SegmentGeographicalDomain_7ae61164-2a33-44e6-89d8-78c3b587e617" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_2ba2309f-b9fa-4158-8fba-95f084c9b6eb" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7ae61164-2a33-44e6-89d8-78c3b587e617" xlink:to="loc_country_US_2ba2309f-b9fa-4158-8fba-95f084c9b6eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_OutsideUnitedStatesMember_52f6d92f-fcfe-472b-a443-4053c4aa0c87" xlink:href="auph-20220930.xsd#auph_OutsideUnitedStatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7ae61164-2a33-44e6-89d8-78c3b587e617" xlink:to="loc_auph_OutsideUnitedStatesMember_52f6d92f-fcfe-472b-a443-4053c4aa0c87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1e07db2d-70fd-47be-bce2-082e68d2b2af" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1e596b79-7b5c-4e5a-970c-bfd04862d202" xlink:to="loc_srt_ProductOrServiceAxis_1e07db2d-70fd-47be-bce2-082e68d2b2af" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1e07db2d-70fd-47be-bce2-082e68d2b2af_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1e07db2d-70fd-47be-bce2-082e68d2b2af" xlink:to="loc_srt_ProductsAndServicesDomain_1e07db2d-70fd-47be-bce2-082e68d2b2af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cf22ef01-9936-4145-8878-dc0eef6aa481" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1e07db2d-70fd-47be-bce2-082e68d2b2af" xlink:to="loc_srt_ProductsAndServicesDomain_cf22ef01-9936-4145-8878-dc0eef6aa481" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_MilestoneAchievementMember_8ff05424-070c-4380-829b-a77b154ec473" xlink:href="auph-20220930.xsd#auph_MilestoneAchievementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cf22ef01-9936-4145-8878-dc0eef6aa481" xlink:to="loc_auph_MilestoneAchievementMember_8ff05424-070c-4380-829b-a77b154ec473" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_90b4aa32-a532-4044-b6a2-427a1c6848c5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1e596b79-7b5c-4e5a-970c-bfd04862d202" xlink:to="loc_srt_CounterpartyNameAxis_90b4aa32-a532-4044-b6a2-427a1c6848c5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90b4aa32-a532-4044-b6a2-427a1c6848c5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_90b4aa32-a532-4044-b6a2-427a1c6848c5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90b4aa32-a532-4044-b6a2-427a1c6848c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b503fca2-09ac-441d-8327-596abd4e1073" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_90b4aa32-a532-4044-b6a2-427a1c6848c5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b503fca2-09ac-441d-8327-596abd4e1073" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_OtuskaPharmaceuticalCoLtdMember_7ecd2682-5a7e-4626-9254-6742e10aaf82" xlink:href="auph-20220930.xsd#auph_OtuskaPharmaceuticalCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b503fca2-09ac-441d-8327-596abd4e1073" xlink:to="loc_auph_OtuskaPharmaceuticalCoLtdMember_7ecd2682-5a7e-4626-9254-6742e10aaf82" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended" id="if70c21093c22448c9887c6af5acdab70_FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e8b8160c-1dbd-49b7-b1fa-5e7e493a0c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_e7698262-b7c6-4b7f-a2ea-2447c54ee1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e8b8160c-1dbd-49b7-b1fa-5e7e493a0c3d" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_e7698262-b7c6-4b7f-a2ea-2447c54ee1ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2ad0da58-d285-4527-a613-3a29f605bf0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_e7698262-b7c6-4b7f-a2ea-2447c54ee1ff" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_2ad0da58-d285-4527-a613-3a29f605bf0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAverageRemainingMaturity1_cc8b0a60-c36c-4b48-ad04-cbd263c966c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAverageRemainingMaturity1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e8b8160c-1dbd-49b7-b1fa-5e7e493a0c3d" xlink:to="loc_us-gaap_DerivativeAverageRemainingMaturity1_cc8b0a60-c36c-4b48-ad04-cbd263c966c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_54e16137-407c-4e3d-bd03-19bbe631a5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e8b8160c-1dbd-49b7-b1fa-5e7e493a0c3d" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_54e16137-407c-4e3d-bd03-19bbe631a5a9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cae3d3a5-9609-4e44-b63c-62059d6a7b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_54e16137-407c-4e3d-bd03-19bbe631a5a9" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cae3d3a5-9609-4e44-b63c-62059d6a7b2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cae3d3a5-9609-4e44-b63c-62059d6a7b2f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cae3d3a5-9609-4e44-b63c-62059d6a7b2f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cae3d3a5-9609-4e44-b63c-62059d6a7b2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_164df746-9130-46b0-ba7f-3143138e59cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cae3d3a5-9609-4e44-b63c-62059d6a7b2f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_164df746-9130-46b0-ba7f-3143138e59cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_edff2fe0-ed96-4e42-bc48-17ab70953a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_164df746-9130-46b0-ba7f-3143138e59cd" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_edff2fe0-ed96-4e42-bc48-17ab70953a1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_722ba192-0821-4194-a580-97e8c0e742c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_164df746-9130-46b0-ba7f-3143138e59cd" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_722ba192-0821-4194-a580-97e8c0e742c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_db9d24b9-3648-4d4e-af78-0a18526d9edc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_164df746-9130-46b0-ba7f-3143138e59cd" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_db9d24b9-3648-4d4e-af78-0a18526d9edc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_49f10987-68a3-4156-905c-0c10d82c2b51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_54e16137-407c-4e3d-bd03-19bbe631a5a9" xlink:to="loc_us-gaap_FinancialInstrumentAxis_49f10987-68a3-4156-905c-0c10d82c2b51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_49f10987-68a3-4156-905c-0c10d82c2b51_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_49f10987-68a3-4156-905c-0c10d82c2b51" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_49f10987-68a3-4156-905c-0c10d82c2b51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82f41609-afe9-47e5-8325-4a66274a2884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_49f10987-68a3-4156-905c-0c10d82c2b51" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82f41609-afe9-47e5-8325-4a66274a2884" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_CashCashEquivalentsAndRestrictedCashMember_2379e385-7a57-46a2-ab2d-3e9a98c10dcf" xlink:href="auph-20220930.xsd#auph_CashCashEquivalentsAndRestrictedCashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82f41609-afe9-47e5-8325-4a66274a2884" xlink:to="loc_auph_CashCashEquivalentsAndRestrictedCashMember_2379e385-7a57-46a2-ab2d-3e9a98c10dcf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_USAgencySecurityMember_36d51964-37be-4b05-a601-d4030365af83" xlink:href="auph-20220930.xsd#auph_USAgencySecurityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82f41609-afe9-47e5-8325-4a66274a2884" xlink:to="loc_auph_USAgencySecurityMember_36d51964-37be-4b05-a601-d4030365af83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_0b3b3f1c-8438-4b9d-8a0c-85eaa60f3da5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82f41609-afe9-47e5-8325-4a66274a2884" xlink:to="loc_us-gaap_CertificatesOfDepositMember_0b3b3f1c-8438-4b9d-8a0c-85eaa60f3da5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_b944f875-7887-44f7-b37b-e187f19ff31d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82f41609-afe9-47e5-8325-4a66274a2884" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_b944f875-7887-44f7-b37b-e187f19ff31d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_4d7cf9fc-9fd7-49cd-a8b5-ee4c6c1b3910" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82f41609-afe9-47e5-8325-4a66274a2884" xlink:to="loc_us-gaap_CommercialPaperMember_4d7cf9fc-9fd7-49cd-a8b5-ee4c6c1b3910" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_c16d9167-b304-4762-af73-7466a73a7a41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82f41609-afe9-47e5-8325-4a66274a2884" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_c16d9167-b304-4762-af73-7466a73a7a41" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBondSecuritiesMember_42763879-1d8d-4721-a864-ab9a733424ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82f41609-afe9-47e5-8325-4a66274a2884" xlink:to="loc_us-gaap_USTreasuryBondSecuritiesMember_42763879-1d8d-4721-a864-ab9a733424ae" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_YankeeBondMember_f220c02d-1c5d-4913-9db8-a1ec4957e295" xlink:href="auph-20220930.xsd#auph_YankeeBondMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82f41609-afe9-47e5-8325-4a66274a2884" xlink:to="loc_auph_YankeeBondMember_f220c02d-1c5d-4913-9db8-a1ec4957e295" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails" xlink:type="extended" id="ic3b70ece47aa4c64bd39774cadcf1f5b_CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_45c55731-2447-4353-bc5e-a4e37176e5b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_309e2e1f-e6d2-49c3-b477-43bfc3e29aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_45c55731-2447-4353-bc5e-a4e37176e5b8" xlink:to="loc_us-gaap_HeldToMaturitySecurities_309e2e1f-e6d2-49c3-b477-43bfc3e29aa0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_590718db-f402-42e6-9927-cf764dd5e351" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_45c55731-2447-4353-bc5e-a4e37176e5b8" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_590718db-f402-42e6-9927-cf764dd5e351" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_4adc92e9-cb1f-4d5a-a392-96206645f82a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_45c55731-2447-4353-bc5e-a4e37176e5b8" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_4adc92e9-cb1f-4d5a-a392-96206645f82a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_77288f13-52bd-4ddd-98f4-73cd56aa580e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_45c55731-2447-4353-bc5e-a4e37176e5b8" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_77288f13-52bd-4ddd-98f4-73cd56aa580e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent_c35b8b18-4791-415d-8d44-a255282ba8af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_45c55731-2447-4353-bc5e-a4e37176e5b8" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent_c35b8b18-4791-415d-8d44-a255282ba8af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments_d8a3a43c-862b-4479-84a9-36347b36b072" xlink:href="auph-20220930.xsd#auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_45c55731-2447-4353-bc5e-a4e37176e5b8" xlink:to="loc_auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments_d8a3a43c-862b-4479-84a9-36347b36b072" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable_c65c60ce-b652-4db1-8a51-aa9f73026aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_45c55731-2447-4353-bc5e-a4e37176e5b8" xlink:to="loc_us-gaap_MarketableSecuritiesTable_c65c60ce-b652-4db1-8a51-aa9f73026aeb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0cad72cf-6098-4ac4-8e67-4315f0ab2354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MarketableSecuritiesTable_c65c60ce-b652-4db1-8a51-aa9f73026aeb" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0cad72cf-6098-4ac4-8e67-4315f0ab2354" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0cad72cf-6098-4ac4-8e67-4315f0ab2354_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0cad72cf-6098-4ac4-8e67-4315f0ab2354" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0cad72cf-6098-4ac4-8e67-4315f0ab2354_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_22e859fa-f0b6-4585-af18-c80de4e9d513" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0cad72cf-6098-4ac4-8e67-4315f0ab2354" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_22e859fa-f0b6-4585-af18-c80de4e9d513" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_CashCashEquivalentsAndRestrictedCashMember_7d14e646-96cc-4c8a-b513-a6e772281b19" xlink:href="auph-20220930.xsd#auph_CashCashEquivalentsAndRestrictedCashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_22e859fa-f0b6-4585-af18-c80de4e9d513" xlink:to="loc_auph_CashCashEquivalentsAndRestrictedCashMember_7d14e646-96cc-4c8a-b513-a6e772281b19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_6252df43-33f1-4ea6-8a99-2a3e9c60b64c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_22e859fa-f0b6-4585-af18-c80de4e9d513" xlink:to="loc_us-gaap_CertificatesOfDepositMember_6252df43-33f1-4ea6-8a99-2a3e9c60b64c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ShortTermCorporateDebtSecuritiesMember_c57ad559-eceb-4a98-b779-8ddb36cca303" xlink:href="auph-20220930.xsd#auph_ShortTermCorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_22e859fa-f0b6-4585-af18-c80de4e9d513" xlink:to="loc_auph_ShortTermCorporateDebtSecuritiesMember_c57ad559-eceb-4a98-b779-8ddb36cca303" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_8c807e6f-9381-49b9-8d38-622ac143fb6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_22e859fa-f0b6-4585-af18-c80de4e9d513" xlink:to="loc_us-gaap_CommercialPaperMember_8c807e6f-9381-49b9-8d38-622ac143fb6a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_fc2e542f-d5cf-447a-963f-ebc513a68dce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_22e859fa-f0b6-4585-af18-c80de4e9d513" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_fc2e542f-d5cf-447a-963f-ebc513a68dce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBondSecuritiesMember_d090df08-b82b-4542-b2f5-4100a7aaf100" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_22e859fa-f0b6-4585-af18-c80de4e9d513" xlink:to="loc_us-gaap_USTreasuryBondSecuritiesMember_d090df08-b82b-4542-b2f5-4100a7aaf100" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_YankeeBondMember_60888c53-d8de-4d4a-98db-21e5f975b2d6" xlink:href="auph-20220930.xsd#auph_YankeeBondMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_22e859fa-f0b6-4585-af18-c80de4e9d513" xlink:to="loc_auph_YankeeBondMember_60888c53-d8de-4d4a-98db-21e5f975b2d6" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended" id="i3e1c1865acd84c23ac5c33df9fe64515_IntangibleAssetsScheduleofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4ebcfc16-2991-4d37-865f-0ec9c53b4a29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_40716b6f-cc55-4e1a-a854-659c7670de2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4ebcfc16-2991-4d37-865f-0ec9c53b4a29" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_40716b6f-cc55-4e1a-a854-659c7670de2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bb88f03a-8e17-4d67-9336-2ae55ee83131" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4ebcfc16-2991-4d37-865f-0ec9c53b4a29" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bb88f03a-8e17-4d67-9336-2ae55ee83131" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ce937958-10c9-4b3b-af1b-3b570e7b5145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4ebcfc16-2991-4d37-865f-0ec9c53b4a29" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ce937958-10c9-4b3b-af1b-3b570e7b5145" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_985fb18b-cb78-4739-9cec-0b1facdcba6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4ebcfc16-2991-4d37-865f-0ec9c53b4a29" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_985fb18b-cb78-4739-9cec-0b1facdcba6a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eac598ae-2a0d-4dda-ad25-a62026453ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_985fb18b-cb78-4739-9cec-0b1facdcba6a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eac598ae-2a0d-4dda-ad25-a62026453ebb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eac598ae-2a0d-4dda-ad25-a62026453ebb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eac598ae-2a0d-4dda-ad25-a62026453ebb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eac598ae-2a0d-4dda-ad25-a62026453ebb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7fbd94f1-cf9d-44e8-888e-9a60b1d0a709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eac598ae-2a0d-4dda-ad25-a62026453ebb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7fbd94f1-cf9d-44e8-888e-9a60b1d0a709" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_9422de61-a54c-42e6-a57f-c6df1db1425d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7fbd94f1-cf9d-44e8-888e-9a60b1d0a709" xlink:to="loc_us-gaap_PatentsMember_9422de61-a54c-42e6-a57f-c6df1db1425d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntellectualPropertyMember_fc06c37d-eb01-411b-b93a-c52186c63616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntellectualPropertyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7fbd94f1-cf9d-44e8-888e-9a60b1d0a709" xlink:to="loc_us-gaap_IntellectualPropertyMember_fc06c37d-eb01-411b-b93a-c52186c63616" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_7b3fa0b9-8fa4-4f42-9a47-b2153330eb62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7fbd94f1-cf9d-44e8-888e-9a60b1d0a709" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_7b3fa0b9-8fa4-4f42-9a47-b2153330eb62" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#PropertyandEquipmentnetDetails"/>
  <link:definitionLink xlink:role="http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails" xlink:type="extended" id="ifb1cfe28da4b4ad19b4c55118cc8574d_PropertyandEquipmentnetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2819a6d8-d782-4a62-82f4-0ba243800095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_5bc2c6e4-fa20-4429-bead-f9b1f46a22f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2819a6d8-d782-4a62-82f4-0ba243800095" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_5bc2c6e4-fa20-4429-bead-f9b1f46a22f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0a1ada70-318b-450f-bbfd-7f4ad39020b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2819a6d8-d782-4a62-82f4-0ba243800095" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0a1ada70-318b-450f-bbfd-7f4ad39020b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7608eb10-9044-4e33-bc12-a7f3cf9f2773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2819a6d8-d782-4a62-82f4-0ba243800095" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7608eb10-9044-4e33-bc12-a7f3cf9f2773" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_90afd21a-7a94-4acc-b530-985083933399" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2819a6d8-d782-4a62-82f4-0ba243800095" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_90afd21a-7a94-4acc-b530-985083933399" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6bf71091-1c09-44ef-8a75-de45385ec976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_90afd21a-7a94-4acc-b530-985083933399" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6bf71091-1c09-44ef-8a75-de45385ec976" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6bf71091-1c09-44ef-8a75-de45385ec976_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6bf71091-1c09-44ef-8a75-de45385ec976" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6bf71091-1c09-44ef-8a75-de45385ec976_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f8464cf-4fd8-4b3a-80ba-1da5698c2bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6bf71091-1c09-44ef-8a75-de45385ec976" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f8464cf-4fd8-4b3a-80ba-1da5698c2bd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_028c3cb8-1a27-437d-864f-4c0075a06265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f8464cf-4fd8-4b3a-80ba-1da5698c2bd7" xlink:to="loc_us-gaap_ConstructionInProgressMember_028c3cb8-1a27-437d-864f-4c0075a06265" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_4ade8ae8-4e3c-458d-b7df-dd680f485e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f8464cf-4fd8-4b3a-80ba-1da5698c2bd7" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_4ade8ae8-4e3c-458d-b7df-dd680f485e7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_991f353b-5172-4f49-9bd0-c332c83d55ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f8464cf-4fd8-4b3a-80ba-1da5698c2bd7" xlink:to="loc_us-gaap_OfficeEquipmentMember_991f353b-5172-4f49-9bd0-c332c83d55ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_dddace0b-b37c-49c8-b1b4-666cbcf2914c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f8464cf-4fd8-4b3a-80ba-1da5698c2bd7" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_dddace0b-b37c-49c8-b1b4-666cbcf2914c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_40bcd1f8-8d47-4829-affa-0b703eabd5a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f8464cf-4fd8-4b3a-80ba-1da5698c2bd7" xlink:to="loc_us-gaap_ComputerEquipmentMember_40bcd1f8-8d47-4829-affa-0b703eabd5a6" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#LeaseObligationsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" xlink:type="extended" id="ib81adbf94d1045c581bc662c93abff2b_LeaseObligationsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ff107ab-d6a5-45b2-b58f-22b806245596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_1e5fab73-3a26-4a54-a3c0-564ae385a673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ff107ab-d6a5-45b2-b58f-22b806245596" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_1e5fab73-3a26-4a54-a3c0-564ae385a673" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_546f88c3-226f-44c0-be2e-510613a27395" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ff107ab-d6a5-45b2-b58f-22b806245596" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_546f88c3-226f-44c0-be2e-510613a27395" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_1a7278e5-747d-41b8-9694-9155a703e384" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ff107ab-d6a5-45b2-b58f-22b806245596" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_1a7278e5-747d-41b8-9694-9155a703e384" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_f0eee7a0-ca07-4d74-b864-918790dfe337" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ff107ab-d6a5-45b2-b58f-22b806245596" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_f0eee7a0-ca07-4d74-b864-918790dfe337" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_LesseeOperatingLeaseNumberOfExtensionOptions_3e195e80-59d1-4b38-8500-47d17b8fda1f" xlink:href="auph-20220930.xsd#auph_LesseeOperatingLeaseNumberOfExtensionOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ff107ab-d6a5-45b2-b58f-22b806245596" xlink:to="loc_auph_LesseeOperatingLeaseNumberOfExtensionOptions_3e195e80-59d1-4b38-8500-47d17b8fda1f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_63a6d795-91f7-49af-807d-759861f7de17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ff107ab-d6a5-45b2-b58f-22b806245596" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_63a6d795-91f7-49af-807d-759861f7de17" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_LesseeOperatingLeaseLeaseTerminationTerm_399c57f9-79e6-41a6-af8e-3b0283452c2a" xlink:href="auph-20220930.xsd#auph_LesseeOperatingLeaseLeaseTerminationTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ff107ab-d6a5-45b2-b58f-22b806245596" xlink:to="loc_auph_LesseeOperatingLeaseLeaseTerminationTerm_399c57f9-79e6-41a6-af8e-3b0283452c2a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_aafdcce9-8605-4f79-9381-567fff2bca33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ff107ab-d6a5-45b2-b58f-22b806245596" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_aafdcce9-8605-4f79-9381-567fff2bca33" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_54e5663c-9732-4b0b-8578-a5ed4cdebb98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ff107ab-d6a5-45b2-b58f-22b806245596" xlink:to="loc_us-gaap_OperatingLeaseLiability_54e5663c-9732-4b0b-8578-a5ed4cdebb98" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_047c8b85-6f80-45d7-a1cb-655ee4a50a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ff107ab-d6a5-45b2-b58f-22b806245596" xlink:to="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_047c8b85-6f80-45d7-a1cb-655ee4a50a1e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_021e3015-2e75-4c8a-ae36-fb1d450393e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ff107ab-d6a5-45b2-b58f-22b806245596" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_021e3015-2e75-4c8a-ae36-fb1d450393e4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_bdbac142-3b43-487c-bb6f-60c91b280169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ff107ab-d6a5-45b2-b58f-22b806245596" xlink:to="loc_us-gaap_OperatingLeaseCost_bdbac142-3b43-487c-bb6f-60c91b280169" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCapitalImprovements_ce6ccb2b-28df-4910-9e02-edd689de0f57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForCapitalImprovements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ff107ab-d6a5-45b2-b58f-22b806245596" xlink:to="loc_us-gaap_PaymentsForCapitalImprovements_ce6ccb2b-28df-4910-9e02-edd689de0f57" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_ba4427d1-6b94-4feb-8bdc-fede06ee166e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ff107ab-d6a5-45b2-b58f-22b806245596" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_ba4427d1-6b94-4feb-8bdc-fede06ee166e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease_d53104e9-7148-47e1-a4ea-35296513c7f1" xlink:href="auph-20220930.xsd#auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ff107ab-d6a5-45b2-b58f-22b806245596" xlink:to="loc_auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease_d53104e9-7148-47e1-a4ea-35296513c7f1" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid_9ada4fea-7b06-4f24-8f6f-347032b63c4b" xlink:href="auph-20220930.xsd#auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ff107ab-d6a5-45b2-b58f-22b806245596" xlink:to="loc_auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid_9ada4fea-7b06-4f24-8f6f-347032b63c4b" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_cdc82de8-5b92-4414-826e-82c7c38442ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ff107ab-d6a5-45b2-b58f-22b806245596" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_cdc82de8-5b92-4414-826e-82c7c38442ad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_bb6b0118-a653-4493-8598-7abffa94e0c6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_cdc82de8-5b92-4414-826e-82c7c38442ad" xlink:to="loc_srt_StatementGeographicalAxis_bb6b0118-a653-4493-8598-7abffa94e0c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_bb6b0118-a653-4493-8598-7abffa94e0c6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_bb6b0118-a653-4493-8598-7abffa94e0c6" xlink:to="loc_srt_SegmentGeographicalDomain_bb6b0118-a653-4493-8598-7abffa94e0c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_18552065-5880-4e9d-aa28-ae9ed8677483" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_bb6b0118-a653-4493-8598-7abffa94e0c6" xlink:to="loc_srt_SegmentGeographicalDomain_18552065-5880-4e9d-aa28-ae9ed8677483" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_VictoriaBritishColumbiaMember_3e37d73d-34d0-4a88-ad98-04e21e0579ba" xlink:href="auph-20220930.xsd#auph_VictoriaBritishColumbiaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_18552065-5880-4e9d-aa28-ae9ed8677483" xlink:to="loc_auph_VictoriaBritishColumbiaMember_3e37d73d-34d0-4a88-ad98-04e21e0579ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_RockvilleMarylandMember_8eb45e8c-560e-4987-9b10-3ca2c7db00f2" xlink:href="auph-20220930.xsd#auph_RockvilleMarylandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_18552065-5880-4e9d-aa28-ae9ed8677483" xlink:to="loc_auph_RockvilleMarylandMember_8eb45e8c-560e-4987-9b10-3ca2c7db00f2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#LicenseandCollaborationAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" xlink:type="extended" id="ib27fd66e21ec4b1d8ef1ff49cab32f27_LicenseandCollaborationAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ab45cd25-feff-4fc7-b8aa-f8655cb7a7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_6b396efb-86d8-40d2-b86c-a484a7065869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ab45cd25-feff-4fc7-b8aa-f8655cb7a7b5" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_6b396efb-86d8-40d2-b86c-a484a7065869" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount_95b769c7-ef50-4315-b1e2-7e3a1f20d6c5" xlink:href="auph-20220930.xsd#auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ab45cd25-feff-4fc7-b8aa-f8655cb7a7b5" xlink:to="loc_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount_95b769c7-ef50-4315-b1e2-7e3a1f20d6c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent_e0003e90-695c-4a62-a096-95505a880e30" xlink:href="auph-20220930.xsd#auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ab45cd25-feff-4fc7-b8aa-f8655cb7a7b5" xlink:to="loc_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent_e0003e90-695c-4a62-a096-95505a880e30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ResearchAndDevelopmentArrangementContractToPerformMilestonePayments_cf27fc57-743e-4459-98ec-f94f86e8a0f0" xlink:href="auph-20220930.xsd#auph_ResearchAndDevelopmentArrangementContractToPerformMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ab45cd25-feff-4fc7-b8aa-f8655cb7a7b5" xlink:to="loc_auph_ResearchAndDevelopmentArrangementContractToPerformMilestonePayments_cf27fc57-743e-4459-98ec-f94f86e8a0f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9416f5dd-c4a5-4827-b105-a7d8406a6e74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ab45cd25-feff-4fc7-b8aa-f8655cb7a7b5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9416f5dd-c4a5-4827-b105-a7d8406a6e74" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_ae50bf2f-cc43-4246-96b0-6c1ede7292cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ab45cd25-feff-4fc7-b8aa-f8655cb7a7b5" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_ae50bf2f-cc43-4246-96b0-6c1ede7292cf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_69373b1f-cb78-4a9f-bdd6-74516c05f0d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ab45cd25-feff-4fc7-b8aa-f8655cb7a7b5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_69373b1f-cb78-4a9f-bdd6-74516c05f0d9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_ff6e02f7-e5da-4f25-8eba-7f0f53342c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ab45cd25-feff-4fc7-b8aa-f8655cb7a7b5" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_ff6e02f7-e5da-4f25-8eba-7f0f53342c2c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_63845c31-6e07-4f56-b5f3-85361ab6a012" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_ff6e02f7-e5da-4f25-8eba-7f0f53342c2c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_63845c31-6e07-4f56-b5f3-85361ab6a012" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_63845c31-6e07-4f56-b5f3-85361ab6a012_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_63845c31-6e07-4f56-b5f3-85361ab6a012" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_63845c31-6e07-4f56-b5f3-85361ab6a012_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8c47d957-a91f-4e11-9103-dedc70faa9ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_63845c31-6e07-4f56-b5f3-85361ab6a012" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8c47d957-a91f-4e11-9103-dedc70faa9ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_9a02d7ba-28c3-4814-86ed-886667781e83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8c47d957-a91f-4e11-9103-dedc70faa9ba" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_9a02d7ba-28c3-4814-86ed-886667781e83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_bffb4414-e35f-4c25-b70e-60d24bd2ae06" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_ff6e02f7-e5da-4f25-8eba-7f0f53342c2c" xlink:to="loc_srt_CounterpartyNameAxis_bffb4414-e35f-4c25-b70e-60d24bd2ae06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bffb4414-e35f-4c25-b70e-60d24bd2ae06_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_bffb4414-e35f-4c25-b70e-60d24bd2ae06" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bffb4414-e35f-4c25-b70e-60d24bd2ae06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c7f6c0a-1e55-417a-bae4-96c59cd126d7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_bffb4414-e35f-4c25-b70e-60d24bd2ae06" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c7f6c0a-1e55-417a-bae4-96c59cd126d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_OtuskaPharmaceuticalCoLtdMember_211fb543-4dec-4f78-8cdc-9de4bbe2cc4a" xlink:href="auph-20220930.xsd#auph_OtuskaPharmaceuticalCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c7f6c0a-1e55-417a-bae4-96c59cd126d7" xlink:to="loc_auph_OtuskaPharmaceuticalCoLtdMember_211fb543-4dec-4f78-8cdc-9de4bbe2cc4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_RiptideBioscienceIncMember_ccd2cbd3-c96d-43bc-98e8-8764b453ed2d" xlink:href="auph-20220930.xsd#auph_RiptideBioscienceIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c7f6c0a-1e55-417a-bae4-96c59cd126d7" xlink:to="loc_auph_RiptideBioscienceIncMember_ccd2cbd3-c96d-43bc-98e8-8764b453ed2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e9293ceb-e6e2-4ba4-a419-195a8d309066" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_ff6e02f7-e5da-4f25-8eba-7f0f53342c2c" xlink:to="loc_srt_RangeAxis_e9293ceb-e6e2-4ba4-a419-195a8d309066" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e9293ceb-e6e2-4ba4-a419-195a8d309066_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e9293ceb-e6e2-4ba4-a419-195a8d309066" xlink:to="loc_srt_RangeMember_e9293ceb-e6e2-4ba4-a419-195a8d309066_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3cba41b4-1dcf-4bb7-b3fa-d862ddcebf04" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e9293ceb-e6e2-4ba4-a419-195a8d309066" xlink:to="loc_srt_RangeMember_3cba41b4-1dcf-4bb7-b3fa-d862ddcebf04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d6584826-750f-4621-8dbd-fd550248ccc9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3cba41b4-1dcf-4bb7-b3fa-d862ddcebf04" xlink:to="loc_srt_MinimumMember_d6584826-750f-4621-8dbd-fd550248ccc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0e03dcc4-a1a4-4c15-a5c1-2529fb96b44a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3cba41b4-1dcf-4bb7-b3fa-d862ddcebf04" xlink:to="loc_srt_MaximumMember_0e03dcc4-a1a4-4c15-a5c1-2529fb96b44a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_13f719ec-2730-4b03-a824-22ccf72fa944" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_ff6e02f7-e5da-4f25-8eba-7f0f53342c2c" xlink:to="loc_srt_ProductOrServiceAxis_13f719ec-2730-4b03-a824-22ccf72fa944" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_13f719ec-2730-4b03-a824-22ccf72fa944_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_13f719ec-2730-4b03-a824-22ccf72fa944" xlink:to="loc_srt_ProductsAndServicesDomain_13f719ec-2730-4b03-a824-22ccf72fa944_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1c52c380-dca0-40eb-b557-483be6b659d4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_13f719ec-2730-4b03-a824-22ccf72fa944" xlink:to="loc_srt_ProductsAndServicesDomain_1c52c380-dca0-40eb-b557-483be6b659d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_09825403-7b66-4b99-9eab-952d7cab6315" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1c52c380-dca0-40eb-b557-483be6b659d4" xlink:to="loc_us-gaap_ProductMember_09825403-7b66-4b99-9eab-952d7cab6315" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_e90bf5b4-a53c-41b6-8e60-9231d26e7153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1c52c380-dca0-40eb-b557-483be6b659d4" xlink:to="loc_us-gaap_ServiceMember_e90bf5b4-a53c-41b6-8e60-9231d26e7153" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#NetLossperCommonShareAntiDilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails" xlink:type="extended" id="i8c95f798e388474493b2491cbe94b31a_NetLossperCommonShareAntiDilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4ff89b45-9a6c-466f-a84a-54c7e8b297cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ac8180ce-8a4c-4493-b441-38d4a0972f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4ff89b45-9a6c-466f-a84a-54c7e8b297cf" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ac8180ce-8a4c-4493-b441-38d4a0972f8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ee5974f1-0b63-48a5-bb53-8be754d7a236" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4ff89b45-9a6c-466f-a84a-54c7e8b297cf" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ee5974f1-0b63-48a5-bb53-8be754d7a236" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_736b4420-5050-4ec0-86ba-f1c59886c117" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ee5974f1-0b63-48a5-bb53-8be754d7a236" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_736b4420-5050-4ec0-86ba-f1c59886c117" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_736b4420-5050-4ec0-86ba-f1c59886c117_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_736b4420-5050-4ec0-86ba-f1c59886c117" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_736b4420-5050-4ec0-86ba-f1c59886c117_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_752accdf-9b5d-46ef-851d-ef49d6102343" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_736b4420-5050-4ec0-86ba-f1c59886c117" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_752accdf-9b5d-46ef-851d-ef49d6102343" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d1cf3257-d8c6-4bf6-87ad-b66fb9b756a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_752accdf-9b5d-46ef-851d-ef49d6102343" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d1cf3257-d8c6-4bf6-87ad-b66fb9b756a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_604c3020-df61-4b57-9fc7-96a7c04605ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_752accdf-9b5d-46ef-851d-ef49d6102343" xlink:to="loc_us-gaap_PerformanceSharesMember_604c3020-df61-4b57-9fc7-96a7c04605ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1d7159cc-8202-42cf-9fc6-944e55aca3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_752accdf-9b5d-46ef-851d-ef49d6102343" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1d7159cc-8202-42cf-9fc6-944e55aca3c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_3891de19-6ae9-4bbf-98d3-0c9ee6daed6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_752accdf-9b5d-46ef-851d-ef49d6102343" xlink:to="loc_us-gaap_WarrantMember_3891de19-6ae9-4bbf-98d3-0c9ee6daed6c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#SharebasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" xlink:type="extended" id="ia58f2e433f2342cea12141edeea256d7_SharebasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_210381bc-1e45-48ed-88bf-c8015ef37d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_79856e54-c213-4928-af33-aa85b089ac64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_210381bc-1e45-48ed-88bf-c8015ef37d8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_79856e54-c213-4928-af33-aa85b089ac64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_91c65629-3143-4607-9e24-b45292cd7c12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_210381bc-1e45-48ed-88bf-c8015ef37d8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_91c65629-3143-4607-9e24-b45292cd7c12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_8bf97207-86cb-4c87-b6e7-2fd1bd7a4058" xlink:href="auph-20220930.xsd#auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_210381bc-1e45-48ed-88bf-c8015ef37d8f" xlink:to="loc_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_8bf97207-86cb-4c87-b6e7-2fd1bd7a4058" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_074b812d-cc2c-4bd2-b41a-9314e6f853c3" xlink:href="auph-20220930.xsd#auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_210381bc-1e45-48ed-88bf-c8015ef37d8f" xlink:to="loc_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_074b812d-cc2c-4bd2-b41a-9314e6f853c3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod_86b3f0da-0b1c-43cf-a212-8347efc304ee" xlink:href="auph-20220930.xsd#auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_210381bc-1e45-48ed-88bf-c8015ef37d8f" xlink:to="loc_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod_86b3f0da-0b1c-43cf-a212-8347efc304ee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4c083d4e-a07e-4290-8566-4ecf821ace2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_210381bc-1e45-48ed-88bf-c8015ef37d8f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4c083d4e-a07e-4290-8566-4ecf821ace2b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ShareBasedPaymentArrangementUnamortizedExpense_c3766796-8a35-4b6b-8ea6-bd0bef155f96" xlink:href="auph-20220930.xsd#auph_ShareBasedPaymentArrangementUnamortizedExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_210381bc-1e45-48ed-88bf-c8015ef37d8f" xlink:to="loc_auph_ShareBasedPaymentArrangementUnamortizedExpense_c3766796-8a35-4b6b-8ea6-bd0bef155f96" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_fae8b579-fb8c-4372-a3d0-727726f8687f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_210381bc-1e45-48ed-88bf-c8015ef37d8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_fae8b579-fb8c-4372-a3d0-727726f8687f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a7511f42-16cc-4b1c-9ff9-f763baf80812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_210381bc-1e45-48ed-88bf-c8015ef37d8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a7511f42-16cc-4b1c-9ff9-f763baf80812" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e61395d3-4599-47d4-a3c2-5380b3da174f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_210381bc-1e45-48ed-88bf-c8015ef37d8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e61395d3-4599-47d4-a3c2-5380b3da174f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_295f0fdc-f70b-4d50-8b44-e09dabbb943f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_210381bc-1e45-48ed-88bf-c8015ef37d8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_295f0fdc-f70b-4d50-8b44-e09dabbb943f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ac44a4c2-4036-4496-ba88-4ca54b302665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_210381bc-1e45-48ed-88bf-c8015ef37d8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ac44a4c2-4036-4496-ba88-4ca54b302665" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_25ba2474-b471-446c-b7de-c2d844c12c91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_210381bc-1e45-48ed-88bf-c8015ef37d8f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_25ba2474-b471-446c-b7de-c2d844c12c91" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0213f65c-9799-46ae-b1c1-16462948ef2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_210381bc-1e45-48ed-88bf-c8015ef37d8f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0213f65c-9799-46ae-b1c1-16462948ef2c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17cfa0f3-7c94-481e-9dac-a790c06b1376" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_210381bc-1e45-48ed-88bf-c8015ef37d8f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17cfa0f3-7c94-481e-9dac-a790c06b1376" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_898fc9ab-0a57-4e52-abfb-b6ef2e6bf324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17cfa0f3-7c94-481e-9dac-a790c06b1376" xlink:to="loc_us-gaap_PlanNameAxis_898fc9ab-0a57-4e52-abfb-b6ef2e6bf324" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_898fc9ab-0a57-4e52-abfb-b6ef2e6bf324_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_898fc9ab-0a57-4e52-abfb-b6ef2e6bf324" xlink:to="loc_us-gaap_PlanNameDomain_898fc9ab-0a57-4e52-abfb-b6ef2e6bf324_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d23cb24b-18e2-4055-a67d-d1b83305134a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_898fc9ab-0a57-4e52-abfb-b6ef2e6bf324" xlink:to="loc_us-gaap_PlanNameDomain_d23cb24b-18e2-4055-a67d-d1b83305134a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_AmendedAndRestatedEquityIncentivePlanMember_014f3825-0ffd-4276-94de-f7b721df69da" xlink:href="auph-20220930.xsd#auph_AmendedAndRestatedEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d23cb24b-18e2-4055-a67d-d1b83305134a" xlink:to="loc_auph_AmendedAndRestatedEquityIncentivePlanMember_014f3825-0ffd-4276-94de-f7b721df69da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c91f8968-78d7-41b6-9625-c2f5d44e0034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17cfa0f3-7c94-481e-9dac-a790c06b1376" xlink:to="loc_us-gaap_AwardTypeAxis_c91f8968-78d7-41b6-9625-c2f5d44e0034" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c91f8968-78d7-41b6-9625-c2f5d44e0034_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c91f8968-78d7-41b6-9625-c2f5d44e0034" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c91f8968-78d7-41b6-9625-c2f5d44e0034_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_162430f6-c168-46be-aacc-36a9d9979d66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c91f8968-78d7-41b6-9625-c2f5d44e0034" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_162430f6-c168-46be-aacc-36a9d9979d66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_ecdedfca-06a2-4fc0-965e-d5e5600ccc02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_162430f6-c168-46be-aacc-36a9d9979d66" xlink:to="loc_us-gaap_EmployeeStockMember_ecdedfca-06a2-4fc0-965e-d5e5600ccc02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_2528057d-b5ae-44a2-af75-aef1d1ba90ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_162430f6-c168-46be-aacc-36a9d9979d66" xlink:to="loc_us-gaap_PerformanceSharesMember_2528057d-b5ae-44a2-af75-aef1d1ba90ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_PerformanceShareSandRestrictedStockUnitsRSUsMember_1c55613c-b129-4c54-8351-abdb134b827d" xlink:href="auph-20220930.xsd#auph_PerformanceShareSandRestrictedStockUnitsRSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_162430f6-c168-46be-aacc-36a9d9979d66" xlink:to="loc_auph_PerformanceShareSandRestrictedStockUnitsRSUsMember_1c55613c-b129-4c54-8351-abdb134b827d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d048bc3b-cfeb-4374-9357-07dd18cd167e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_162430f6-c168-46be-aacc-36a9d9979d66" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d048bc3b-cfeb-4374-9357-07dd18cd167e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_3025acf7-ba54-4390-9310-ef2f1d4fd6d0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17cfa0f3-7c94-481e-9dac-a790c06b1376" xlink:to="loc_srt_TitleOfIndividualAxis_3025acf7-ba54-4390-9310-ef2f1d4fd6d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3025acf7-ba54-4390-9310-ef2f1d4fd6d0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_3025acf7-ba54-4390-9310-ef2f1d4fd6d0" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3025acf7-ba54-4390-9310-ef2f1d4fd6d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_99ebf775-5404-488f-99b5-0ca5d40d25a8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_3025acf7-ba54-4390-9310-ef2f1d4fd6d0" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_99ebf775-5404-488f-99b5-0ca5d40d25a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficerMember_084c8cce-c99b-4003-92b8-7731117241ec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_99ebf775-5404-488f-99b5-0ca5d40d25a8" xlink:to="loc_srt_OfficerMember_084c8cce-c99b-4003-92b8-7731117241ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_af9208d8-019b-4258-a1c5-f4fbea364127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17cfa0f3-7c94-481e-9dac-a790c06b1376" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_af9208d8-019b-4258-a1c5-f4fbea364127" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_af9208d8-019b-4258-a1c5-f4fbea364127_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_af9208d8-019b-4258-a1c5-f4fbea364127" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_af9208d8-019b-4258-a1c5-f4fbea364127_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63339b48-993d-4e8c-8313-829f9fddc8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_af9208d8-019b-4258-a1c5-f4fbea364127" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63339b48-993d-4e8c-8313-829f9fddc8fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_69eea806-0989-493f-9823-48d536f4289e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63339b48-993d-4e8c-8313-829f9fddc8fe" xlink:to="loc_us-gaap_EmployeeStockMember_69eea806-0989-493f-9823-48d536f4289e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails" xlink:type="extended" id="id43172bc21214943a77bec53a0966539_ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf12a7f5-9948-46fa-b373-c6b26447d915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_6ce5015c-d01f-4101-9b56-3af1fe8385d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf12a7f5-9948-46fa-b373-c6b26447d915" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_6ce5015c-d01f-4101-9b56-3af1fe8385d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5672969a-bfdc-4fea-88d1-ef83ed2b6bda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_6ce5015c-d01f-4101-9b56-3af1fe8385d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5672969a-bfdc-4fea-88d1-ef83ed2b6bda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b123a1f3-7faf-44b3-aa68-afa2adb5acce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_6ce5015c-d01f-4101-9b56-3af1fe8385d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b123a1f3-7faf-44b3-aa68-afa2adb5acce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2c7adc74-6c73-48c2-8774-c5a85b3462a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_6ce5015c-d01f-4101-9b56-3af1fe8385d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2c7adc74-6c73-48c2-8774-c5a85b3462a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_84a47f36-6cb5-41d6-be03-c0d460f3987c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_6ce5015c-d01f-4101-9b56-3af1fe8385d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_84a47f36-6cb5-41d6-be03-c0d460f3987c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c1e9b119-363e-4b82-ade5-4d77fcb850ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b134edce-1f5c-4362-83d5-33e2ec4be27f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf12a7f5-9948-46fa-b373-c6b26447d915" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b134edce-1f5c-4362-83d5-33e2ec4be27f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6a8ead5b-6448-48a8-8a36-a41f39c8337e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b134edce-1f5c-4362-83d5-33e2ec4be27f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6a8ead5b-6448-48a8-8a36-a41f39c8337e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0b1cdd2-11b1-4e17-ae1f-238725347541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b134edce-1f5c-4362-83d5-33e2ec4be27f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0b1cdd2-11b1-4e17-ae1f-238725347541" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_fa2a255e-3d15-43de-8761-1396ccbfbb71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b134edce-1f5c-4362-83d5-33e2ec4be27f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_fa2a255e-3d15-43de-8761-1396ccbfbb71" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fec1fc9b-4396-4860-827f-e27792b10443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b134edce-1f5c-4362-83d5-33e2ec4be27f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fec1fc9b-4396-4860-827f-e27792b10443" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cda9b518-89fe-4d83-aeb7-fd66966f1818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e2adbf68-0eb9-4db8-8a35-b3fcd16f39ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf12a7f5-9948-46fa-b373-c6b26447d915" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e2adbf68-0eb9-4db8-8a35-b3fcd16f39ae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8f9c844e-d846-4782-b31f-f15022e78f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e2adbf68-0eb9-4db8-8a35-b3fcd16f39ae" xlink:to="loc_us-gaap_AwardTypeAxis_8f9c844e-d846-4782-b31f-f15022e78f4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f9c844e-d846-4782-b31f-f15022e78f4f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8f9c844e-d846-4782-b31f-f15022e78f4f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f9c844e-d846-4782-b31f-f15022e78f4f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56c4e608-9191-4834-8d17-ea9ad2381fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8f9c844e-d846-4782-b31f-f15022e78f4f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56c4e608-9191-4834-8d17-ea9ad2381fd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_PerformanceShareSandRestrictedStockUnitsRSUsMember_8fc5e396-6542-4662-8e27-92e7b99044c5" xlink:href="auph-20220930.xsd#auph_PerformanceShareSandRestrictedStockUnitsRSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56c4e608-9191-4834-8d17-ea9ad2381fd4" xlink:to="loc_auph_PerformanceShareSandRestrictedStockUnitsRSUsMember_8fc5e396-6542-4662-8e27-92e7b99044c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_b1d50b64-a791-4ef9-9e60-82febd619543" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e2adbf68-0eb9-4db8-8a35-b3fcd16f39ae" xlink:to="loc_srt_TitleOfIndividualAxis_b1d50b64-a791-4ef9-9e60-82febd619543" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b1d50b64-a791-4ef9-9e60-82febd619543_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_b1d50b64-a791-4ef9-9e60-82febd619543" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b1d50b64-a791-4ef9-9e60-82febd619543_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_302d8f2c-0b1b-421f-9e34-f21dcb7704e4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_b1d50b64-a791-4ef9-9e60-82febd619543" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_302d8f2c-0b1b-421f-9e34-f21dcb7704e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficerMember_e1345ca0-86d7-47a2-b68e-9910a739abb4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_302d8f2c-0b1b-421f-9e34-f21dcb7704e4" xlink:to="loc_srt_OfficerMember_e1345ca0-86d7-47a2-b68e-9910a739abb4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails" xlink:type="extended" id="ife4c08d5fbdd4e99a917001d46d885d3_ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_545c9588-a845-44ec-8315-6f49bf9fee94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5b728db2-ea2d-41c9-8611-795256963849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_545c9588-a845-44ec-8315-6f49bf9fee94" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5b728db2-ea2d-41c9-8611-795256963849" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a91a964-455a-44c2-858e-17e0c09300bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_545c9588-a845-44ec-8315-6f49bf9fee94" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a91a964-455a-44c2-858e-17e0c09300bb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d54668a5-ba13-43c1-ad6c-e33b4a5a5546" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a91a964-455a-44c2-858e-17e0c09300bb" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d54668a5-ba13-43c1-ad6c-e33b4a5a5546" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d54668a5-ba13-43c1-ad6c-e33b4a5a5546_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d54668a5-ba13-43c1-ad6c-e33b4a5a5546" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d54668a5-ba13-43c1-ad6c-e33b4a5a5546_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8cf5112c-4bb8-4a17-a00d-633f06e5827b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d54668a5-ba13-43c1-ad6c-e33b4a5a5546" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8cf5112c-4bb8-4a17-a00d-633f06e5827b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9710b071-c50e-4327-b108-b11f2d0f467c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8cf5112c-4bb8-4a17-a00d-633f06e5827b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9710b071-c50e-4327-b108-b11f2d0f467c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_841f423e-0eab-49bd-98e2-2666ab2bf5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8cf5112c-4bb8-4a17-a00d-633f06e5827b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_841f423e-0eab-49bd-98e2-2666ab2bf5b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_6bd9c3ee-3a95-4e65-839b-27963c18c919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8cf5112c-4bb8-4a17-a00d-633f06e5827b" xlink:to="loc_us-gaap_InventoriesMember_6bd9c3ee-3a95-4e65-839b-27963c18c919" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" id="iae11f50b2ebe42a0a42e23aeb153badd_RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_3111eaf7-1fd2-4326-87e7-22cf14a97774" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_e5a61dd5-b23d-4df1-ad82-c55953ea4db4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_3111eaf7-1fd2-4326-87e7-22cf14a97774" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_e5a61dd5-b23d-4df1-ad82-c55953ea4db4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_0680f1ac-c26b-46e0-afc4-c9736ea19fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_3111eaf7-1fd2-4326-87e7-22cf14a97774" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_0680f1ac-c26b-46e0-afc4-c9736ea19fa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4694ece6-9058-46ee-8682-8470082c23f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_3111eaf7-1fd2-4326-87e7-22cf14a97774" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4694ece6-9058-46ee-8682-8470082c23f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_c4126f28-b9a6-4352-8167-432eb1dcf468" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4694ece6-9058-46ee-8682-8470082c23f3" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_c4126f28-b9a6-4352-8167-432eb1dcf468" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_c4126f28-b9a6-4352-8167-432eb1dcf468_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_c4126f28-b9a6-4352-8167-432eb1dcf468" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_c4126f28-b9a6-4352-8167-432eb1dcf468_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_6a4bd4b5-5583-4eeb-9fc9-489cd9bc275d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_c4126f28-b9a6-4352-8167-432eb1dcf468" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_6a4bd4b5-5583-4eeb-9fc9-489cd9bc275d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_MilestonePaymentMember_1a195e6c-ba25-40f5-b750-3c2ae1ed7116" xlink:href="auph-20220930.xsd#auph_MilestonePaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_6a4bd4b5-5583-4eeb-9fc9-489cd9bc275d" xlink:to="loc_auph_MilestonePaymentMember_1a195e6c-ba25-40f5-b750-3c2ae1ed7116" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_69ebbadb-7aba-4f14-aca2-7b416ec44758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4694ece6-9058-46ee-8682-8470082c23f3" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_69ebbadb-7aba-4f14-aca2-7b416ec44758" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_69ebbadb-7aba-4f14-aca2-7b416ec44758_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_69ebbadb-7aba-4f14-aca2-7b416ec44758" xlink:to="loc_us-gaap_RelatedPartyDomain_69ebbadb-7aba-4f14-aca2-7b416ec44758_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_63a942c1-f931-4637-aa5e-2b246be7eb13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_69ebbadb-7aba-4f14-aca2-7b416ec44758" xlink:to="loc_us-gaap_RelatedPartyDomain_63a942c1-f931-4637-aa5e-2b246be7eb13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_cba11231-6846-4571-b2cc-e9c03f1ca346" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_63a942c1-f931-4637-aa5e-2b246be7eb13" xlink:to="loc_srt_AffiliatedEntityMember_cba11231-6846-4571-b2cc-e9c03f1ca346" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_2dad3a02-ad4d-4c92-83bd-6e95878f8061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4694ece6-9058-46ee-8682-8470082c23f3" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_2dad3a02-ad4d-4c92-83bd-6e95878f8061" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2dad3a02-ad4d-4c92-83bd-6e95878f8061_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2dad3a02-ad4d-4c92-83bd-6e95878f8061" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2dad3a02-ad4d-4c92-83bd-6e95878f8061_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f989a0ac-ec6d-4a4c-8ce4-0837a3cea50a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2dad3a02-ad4d-4c92-83bd-6e95878f8061" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f989a0ac-ec6d-4a4c-8ce4-0837a3cea50a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_cc749583-68e4-4028-913a-e22df04cbbbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f989a0ac-ec6d-4a4c-8ce4-0837a3cea50a" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_cc749583-68e4-4028-913a-e22df04cbbbc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_54a44b12-3e17-4da1-bd71-01664886ea64" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4694ece6-9058-46ee-8682-8470082c23f3" xlink:to="loc_srt_CounterpartyNameAxis_54a44b12-3e17-4da1-bd71-01664886ea64" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_54a44b12-3e17-4da1-bd71-01664886ea64_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_54a44b12-3e17-4da1-bd71-01664886ea64" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_54a44b12-3e17-4da1-bd71-01664886ea64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c34f27fa-5f0c-49ee-b573-b695f9c0f5e3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_54a44b12-3e17-4da1-bd71-01664886ea64" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c34f27fa-5f0c-49ee-b573-b695f9c0f5e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ILJINMember_97546d40-da65-484d-8d08-d0672d5516c8" xlink:href="auph-20220930.xsd#auph_ILJINMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c34f27fa-5f0c-49ee-b573-b695f9c0f5e3" xlink:to="loc_auph_ILJINMember_97546d40-da65-484d-8d08-d0672d5516c8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.auriniapharma.com/role/SubsequentEventsDetails" xlink:type="extended" id="i210e8946094d4fe6a87da5fff47c0a09_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_93ad8da6-25bd-4a40-bc60-00abfa027261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNewEmployees_575e4fab-7dcb-4f0d-9ae7-522468d70dad" xlink:href="auph-20220930.xsd#auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNewEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_93ad8da6-25bd-4a40-bc60-00abfa027261" xlink:to="loc_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNewEmployees_575e4fab-7dcb-4f0d-9ae7-522468d70dad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f4a75f40-7ebf-4151-aced-d59aa75b052f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_93ad8da6-25bd-4a40-bc60-00abfa027261" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f4a75f40-7ebf-4151-aced-d59aa75b052f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_74f29c41-4f3f-4f30-a3fd-4ed3a682698e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_93ad8da6-25bd-4a40-bc60-00abfa027261" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_74f29c41-4f3f-4f30-a3fd-4ed3a682698e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_93192e79-6148-4e93-b3cc-816b80a10baf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_93ad8da6-25bd-4a40-bc60-00abfa027261" xlink:to="loc_us-gaap_SubsequentEventTable_93192e79-6148-4e93-b3cc-816b80a10baf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_9f033c81-e84b-415c-a0fb-baf8643f0523" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_93192e79-6148-4e93-b3cc-816b80a10baf" xlink:to="loc_srt_TitleOfIndividualAxis_9f033c81-e84b-415c-a0fb-baf8643f0523" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9f033c81-e84b-415c-a0fb-baf8643f0523_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_9f033c81-e84b-415c-a0fb-baf8643f0523" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9f033c81-e84b-415c-a0fb-baf8643f0523_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_93f88697-f5f6-4cb1-b2c5-272a323f7235" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_9f033c81-e84b-415c-a0fb-baf8643f0523" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_93f88697-f5f6-4cb1-b2c5-272a323f7235" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_NewEmployeesMember_98a52a33-d578-4ded-ba43-2298c29830cb" xlink:href="auph-20220930.xsd#auph_NewEmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_93f88697-f5f6-4cb1-b2c5-272a323f7235" xlink:to="loc_auph_NewEmployeesMember_98a52a33-d578-4ded-ba43-2298c29830cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_37ea861b-6862-46ff-8667-6d28352e3784" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_93192e79-6148-4e93-b3cc-816b80a10baf" xlink:to="loc_us-gaap_AwardTypeAxis_37ea861b-6862-46ff-8667-6d28352e3784" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_37ea861b-6862-46ff-8667-6d28352e3784_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_37ea861b-6862-46ff-8667-6d28352e3784" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_37ea861b-6862-46ff-8667-6d28352e3784_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89b93056-380d-4380-bb29-977e11a423a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_37ea861b-6862-46ff-8667-6d28352e3784" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89b93056-380d-4380-bb29-977e11a423a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ShareBasedPaymentArrangementInducementOptionMember_6c8ae793-7164-476c-bbd8-3f73838f13d3" xlink:href="auph-20220930.xsd#auph_ShareBasedPaymentArrangementInducementOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89b93056-380d-4380-bb29-977e11a423a8" xlink:to="loc_auph_ShareBasedPaymentArrangementInducementOptionMember_6c8ae793-7164-476c-bbd8-3f73838f13d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c7f816a9-3563-4407-9ca1-f405431ff2e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89b93056-380d-4380-bb29-977e11a423a8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c7f816a9-3563-4407-9ca1-f405431ff2e7" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>auph-20220930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:05323eab-3ae1-47f9-a870-5f1cb7d56826,g:99240d06-396b-484e-9f8c-0586e299f202-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5d7a8303-8766-499d-b029-2198f0406359_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d079119b-d7e4-4de0-8ec3-bb635c39500d_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_1a816a17-c437-45ab-b1a5-3ea8f44ca5d8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payments received</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_96c8a7c3-47df-4863-a148-e6372d8dcf6c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent_70a0224f-1e78-407e-babf-c7ac145344e6_verboseLabel_en-US" xlink:label="lab_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered royalty percentages on future sales</link:label>
    <link:label id="lab_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent_label_en-US" xlink:label="lab_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Tiered Royalty, Percent</link:label>
    <link:label id="lab_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent_documentation_en-US" xlink:label="lab_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Tiered Royalty, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent" xlink:href="auph-20220930.xsd#auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent" xlink:to="lab_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_37da32b6-fa10-48cb-be80-2e934708d984_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of property (in sqft)</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_c09e22fb-235f-440a-a6f8-b15d09823bf0_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_1426deb2-d012-4a5a-a8c3-e985b4031492_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on available-for-sale securities, net of tax of nil</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_37afb55b-da58-4808-b921-374ec8f40084_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromInterestReceived_80df8210-5459-4a33-9044-f7730c34d038_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromInterestReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received for interest</link:label>
    <link:label id="lab_us-gaap_ProceedsFromInterestReceived_label_en-US" xlink:label="lab_us-gaap_ProceedsFromInterestReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Interest Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInterestReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromInterestReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromInterestReceived" xlink:to="lab_us-gaap_ProceedsFromInterestReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_3580f223-ee66-4de5-9e56-642362325513_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows used in investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d67a3b45-f554-4696-bc30-d260956007a4_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_8f3ec834-f267-43e8-af37-c7d915c0d13d_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_55db68a6-cf6a-4ca9-b7df-910791ba033e_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_31bbbc21-816f-4939-b500-0570f22a877a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued on exercise of stock options and vesting of performance awards and restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_345badaa-9225-4bbd-aca2-e92b0677e8d0_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_06633e68-6cd1-4f72-a992-0b44dbf2ea0c_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental borrowing rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_681b9f70-ac4c-4d23-81c9-3a196d0e9e8d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate - operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_e6d8a933-c6c8-44ae-a4a5-9042db110f5d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod_8d4fe96c-c09a-4ab8-ad7c-0cddd20a09bb_terseLabel_en-US" xlink:label="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering period</link:label>
    <link:label id="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod_label_en-US" xlink:label="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Consecutive Offering Period</link:label>
    <link:label id="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod_documentation_en-US" xlink:label="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Consecutive Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod" xlink:href="auph-20220930.xsd#auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod" xlink:to="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_b5eadc84-eb4f-41a5-8aa7-02d77de2bd6d_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_CommercialRelatedAccrualsCurrent_d8ff1538-54ad-429c-8a29-5ea4de641821_terseLabel_en-US" xlink:label="lab_auph_CommercialRelatedAccrualsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial accruals</link:label>
    <link:label id="lab_auph_CommercialRelatedAccrualsCurrent_label_en-US" xlink:label="lab_auph_CommercialRelatedAccrualsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Related Accruals, Current</link:label>
    <link:label id="lab_auph_CommercialRelatedAccrualsCurrent_documentation_en-US" xlink:label="lab_auph_CommercialRelatedAccrualsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Related Accruals, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_CommercialRelatedAccrualsCurrent" xlink:href="auph-20220930.xsd#auph_CommercialRelatedAccrualsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_CommercialRelatedAccrualsCurrent" xlink:to="lab_auph_CommercialRelatedAccrualsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_18c3fb31-6747-40c9-82b0-d324c19d5125_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_b0990aba-32a0-4420-b301-6f4eb100cd5f_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_5c83fab7-f66b-4f5b-b5a2-de463b00ff91_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_e446f9a4-59e3-4b99-a9d7-21be33767ac0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_8c38a3de-5982-4d23-9310-9450dd93e62d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annualized volatility(as percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_408db823-8c6e-43cf-91ad-3035a3a32587_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6cd7d4ff-9f4a-44eb-9eb4-d566dc60fff3_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_2943bd61-69ec-4655-9f9f-1539df2fe91d_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_cbf5f9ee-6411-4f08-aede-a93d62422815_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_5db496d0-ae2e-4823-a034-4de92bad072b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_4920448d-6105-4267-90f6-b5ed061a0576_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Obligations</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_beb6c4ba-1278-4dc0-8a3d-b8520808d4b1_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_73c15a47-fe47-4895-bae0-4cf53f7f3fcb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_cb6eaab0-160d-4b26-9106-f90635985339_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4793d50c-268e-409c-92f8-d2db34265a44_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_e3f5b371-bf84-468d-a21f-43e1076274b4_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_b079f219-e050-46a5-9dfa-7c67b39610c9_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_e1c82d79-5823-4051-a563-9f6497ee372b_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_f7d02804-012a-4f14-974d-b54ca7f2ce4f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_5e592b21-888d-4323-b745-d5ae4b653216_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares - no par value, unlimited shares authorized, 142,110 and 141,600 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_e9b6038b-9393-4d14-83c0-9023a6c30646_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_ed18c8f8-fc9c-4a85-a059-1069a4881035_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_e5e0eb9a-b38a-420a-a6f1-23b654b9530f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_0bc59ea0-7565-4428-91dc-25365ef4ac17_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_49b4b2b0-3ba4-4a34-8957-87ad06f40d0d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_7fcf59ff-c5e5-4c49-848c-869a2d9deb14_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_9cd2e09c-e073-4e32-95a6-23f1d9109815_terseLabel_en-US" xlink:label="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase period</link:label>
    <link:label id="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_label_en-US" xlink:label="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</link:label>
    <link:label id="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_documentation_en-US" xlink:label="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:href="auph-20220930.xsd#auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:to="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_9ee0397f-adca-49cf-b9b9-90a300656d99_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f7012a4b-43dd-4ccc-8c47-ca3d17e02300_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromTenantAllowance_1ab14d8b-301a-4489-bb66-a785c432f82e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from tenant improvements</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromTenantAllowance_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Tenant Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:to="lab_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_951d0c48-3f40-4ba5-9368-c4fa70a34cc1_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_3d3a0e65-efda-47fe-bcf3-8e450a456c51_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_c4d42229-cd57-437f-b733-6ed5bc690701_terseLabel_en-US" xlink:label="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of purchase periods</link:label>
    <link:label id="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_label_en-US" xlink:label="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Purchase Periods</link:label>
    <link:label id="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_documentation_en-US" xlink:label="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Purchase Periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" xlink:href="auph-20220930.xsd#auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" xlink:to="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7a2bb8f6-910f-4912-844d-d079557b6618_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term - operating leases (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb664644-3177-4110-bbc6-fbe57b8d3dd2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_4f7f600f-e120-41e3-b710-728473761487_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_bef72871-a982-4f69-93f9-d42968d2443a_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ed38dc8e-4774-415b-a612-3ed5a12cfbf6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_af7504b5-44c1-4aa2-b479-9bee1535b052_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoriesMember_6a22ca1e-5cba-4e63-bbfb-8919334f81c9_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized under inventories</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_label_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember" xlink:to="lab_us-gaap_InventoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_e7da2df1-7c72-4bdf-b0ca-1219b7b6b7ba_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_5a814169-8642-4613-a83f-dad2416faa90_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_ResearchAndDevelopmentArrangementContractToPerformMilestonePayments_ea6b3439-483b-48d3-a19d-f7c76a736591_terseLabel_en-US" xlink:label="lab_auph_ResearchAndDevelopmentArrangementContractToPerformMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Triggered milestone, payments</link:label>
    <link:label id="lab_auph_ResearchAndDevelopmentArrangementContractToPerformMilestonePayments_label_en-US" xlink:label="lab_auph_ResearchAndDevelopmentArrangementContractToPerformMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform, Milestone Payments</link:label>
    <link:label id="lab_auph_ResearchAndDevelopmentArrangementContractToPerformMilestonePayments_documentation_en-US" xlink:label="lab_auph_ResearchAndDevelopmentArrangementContractToPerformMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform, Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ResearchAndDevelopmentArrangementContractToPerformMilestonePayments" xlink:href="auph-20220930.xsd#auph_ResearchAndDevelopmentArrangementContractToPerformMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_ResearchAndDevelopmentArrangementContractToPerformMilestonePayments" xlink:to="lab_auph_ResearchAndDevelopmentArrangementContractToPerformMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_665851d9-99c6-464d-8c1b-4d962af17e52_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price $</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_24aa4088-a1c1-4a85-91d1-64a2968d0d41_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_0416d0c5-54c5-4df2-bcc5-5d3939e79afe_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNewEmployees_3fda367b-7fd4-4b14-9ed3-a6a94837d67b_terseLabel_en-US" xlink:label="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNewEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of new employees</link:label>
    <link:label id="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNewEmployees_label_en-US" xlink:label="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNewEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number of New Employees</link:label>
    <link:label id="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNewEmployees_documentation_en-US" xlink:label="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNewEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number of New Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNewEmployees" xlink:href="auph-20220930.xsd#auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNewEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNewEmployees" xlink:to="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNewEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_6e01a208-1f88-4936-9961-37b354332974_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_1bcbe17c-22a2-4f0c-baa2-4ba7611988f4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a85367bb-0c50-4b9e-a8ee-1b5f4d1ad990_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_de26d1fe-af7f-4218-8129-f2477e18aa66_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Weighted average exercise price - Beginning of Period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6d33fbf1-87bc-4d98-b1aa-c91d7ede2bbe_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Weighted average exercise price - End of Period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_b926d083-95fe-4849-8377-6641de59a683_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5a2bc1c5-741c-4675-b413-fc04f8c229a9_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows used in operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_97e94c0a-ef52-44a1-8126-c256f81384a5_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_50cfd7da-b77a-44a1-884f-7e2d61b88499_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of non-current assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a8811ae7-286f-4e9e-b594-408c411bce3d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease_89b0aabb-a009-4df7-af99-3eaad62d3089_terseLabel_en-US" xlink:label="lab_auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected payments prior to commencement of lease</link:label>
    <link:label id="lab_auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease_label_en-US" xlink:label="lab_auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Payments Prior To Commencement Of Lease</link:label>
    <link:label id="lab_auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease_documentation_en-US" xlink:label="lab_auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Payments Prior To Commencement Of Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease" xlink:href="auph-20220930.xsd#auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease" xlink:to="lab_auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_9d97a045-1107-4110-891b-b3ea6b994a34_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_d821d356-5ab5-4cfe-95e9-10b998b8a136_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_486dd28d-dbbd-4a2e-b6fa-7471bdd66baf_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Shareholder</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_83c1536b-0ebf-4680-94f7-6d5875cf6f17_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_38ec6529-722f-4ce6-8d2f-9ab596d974a5_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_28f6518c-cb37-44ae-af7b-d3dc5b0477df_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_48c080a5-1fb0-4e8c-a02c-f4c214966638_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_ecf623c5-b9b4-411a-b4f4-3471a1efb050_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_e7329ee7-5375-432e-93f3-332ed169fee1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on available-for-sale securities, tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_08c2e73c-7372-4d98-8cd8-8d743c23afc4_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested performance awards</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_72b3a679-2439-449a-b38b-3197b287516f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a235fe19-b3b6-48af-a524-6006bf328318_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_bdfcd458-458b-484d-9122-d503dcace6d8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_d1bc0d11-577e-4aa8-a07d-34aeebbd61bc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_46754ff5-34ac-499b-9709-8410537bdf97_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee accruals</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c6f4b484-2243-4401-84d2-5fae448f5aa7_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_MilestonePaymentMember_3cc54397-8cca-472f-801c-d273dea4886e_terseLabel_en-US" xlink:label="lab_auph_MilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment</link:label>
    <link:label id="lab_auph_MilestonePaymentMember_label_en-US" xlink:label="lab_auph_MilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment [Member]</link:label>
    <link:label id="lab_auph_MilestonePaymentMember_documentation_en-US" xlink:label="lab_auph_MilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_MilestonePaymentMember" xlink:href="auph-20220930.xsd#auph_MilestonePaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_MilestonePaymentMember" xlink:to="lab_auph_MilestonePaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_2cd13e9d-cab8-4836-bda8-f3c52e9fbf02_totalLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecurities" xlink:to="lab_us-gaap_HeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAverageRemainingMaturity1_cc59171e-39a4-4c95-add0-1cf2a1660275_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAverageRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, average remaining maturity</link:label>
    <link:label id="lab_us-gaap_DerivativeAverageRemainingMaturity1_label_en-US" xlink:label="lab_us-gaap_DerivativeAverageRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Average Remaining Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAverageRemainingMaturity1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAverageRemainingMaturity1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAverageRemainingMaturity1" xlink:to="lab_us-gaap_DerivativeAverageRemainingMaturity1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_57276c0a-baaa-43a0-af77-d55ceb2e349e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_fb23d849-8dae-4637-b207-cdb77bba379f_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_05a3e551-4142-4321-903b-afd4fc22c6c8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_be2a13a2-2394-4d65-b8f6-c633834ad703_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_e669bafc-6e1f-4229-927b-7e3a16da3abb_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eb52b897-642d-4aa2-9f7e-192b414b7d46_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5393e9de-d71c-4533-8ead-9f9c2c2a3f13_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized share-based compensation expense weighted average recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount_10e17946-c243-4f28-8214-ebfb9ad119da_terseLabel_en-US" xlink:label="lab_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential regulatory milestone revenue</link:label>
    <link:label id="lab_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount_label_en-US" xlink:label="lab_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Performance Obligation, Potential Revenue Amount</link:label>
    <link:label id="lab_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount_documentation_en-US" xlink:label="lab_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Performance Obligation, Potential Revenue Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount" xlink:href="auph-20220930.xsd#auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount" xlink:to="lab_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_cd4c76d4-d898-4c57-ab87-9c1bbd446b5c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_45344561-7845-4893-a698-06d8edbf6aad_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_ae8a3291-db19-4af6-a7f9-d62d6aa967be_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront license payment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_cbb4cf0a-c025-4772-b6c6-71a8e72953ee_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods inventories</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_cac9ed0e-ca2d-4019-8184-e42d4a94ea08_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_a75ee652-e049-422b-aeeb-69292756d7a0_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_9c0c9bea-ada8-46a0-8a9b-d36755696baa_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ad11fdb0-0105-4c8b-9935-9f006cfee087_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_c6b7475e-1cb9-4659-8c8b-dd2ea2c999d9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentsMember_7232cc8b-2a32-4334-90d2-2b4e1fe116d5_terseLabel_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents</link:label>
    <link:label id="lab_us-gaap_PatentsMember_label_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_e7701401-e89d-426f-b686-c8c733a14e4b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_4c4a54f3-ffe0-4a45-8c7c-0e22cd80174a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_d92f2b2b-722e-4a7b-be66-8a95d9c631a7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_faea1762-6d82-47e1-861c-c0566040a629_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_4bdff064-a633-42d1-b02c-ea8a8d281c32_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_29a37013-df19-4fa5-a45c-c36f6c5bd9e5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value ($ per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_ae8f910d-5fbf-4b47-8619-8f11a664a2cb_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_9813d59e-a281-44fa-84c0-521a5891ce68_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory write-down</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_SpecialtyPharmacyOneMember_2f5e4d67-13bc-4031-a024-ddfca36536b2_terseLabel_en-US" xlink:label="lab_auph_SpecialtyPharmacyOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specialty Pharmacy One</link:label>
    <link:label id="lab_auph_SpecialtyPharmacyOneMember_label_en-US" xlink:label="lab_auph_SpecialtyPharmacyOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specialty Pharmacy One [Member]</link:label>
    <link:label id="lab_auph_SpecialtyPharmacyOneMember_documentation_en-US" xlink:label="lab_auph_SpecialtyPharmacyOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specialty Pharmacy One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_SpecialtyPharmacyOneMember" xlink:href="auph-20220930.xsd#auph_SpecialtyPharmacyOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_SpecialtyPharmacyOneMember" xlink:to="lab_auph_SpecialtyPharmacyOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_4e3ae930-916e-43e9-b9c5-1891488070cc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_9f850dc8-260d-4efa-94b9-391d25cca679_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_da74248a-1fcc-4853-a945-fb12c6c78233_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_38552123-d8a8-4ed6-87c0-27398f5718de_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_ILJINMember_e5d0e0cd-696b-4a31-92f8-7c741680697f_terseLabel_en-US" xlink:label="lab_auph_ILJINMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ILJIN</link:label>
    <link:label id="lab_auph_ILJINMember_label_en-US" xlink:label="lab_auph_ILJINMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ILJIN [Member]</link:label>
    <link:label id="lab_auph_ILJINMember_documentation_en-US" xlink:label="lab_auph_ILJINMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ILJIN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ILJINMember" xlink:href="auph-20220930.xsd#auph_ILJINMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_ILJINMember" xlink:to="lab_auph_ILJINMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_b2501147-9563-49bf-878a-74d19f0a8322_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_5ab8d8bb-60ba-407a-8a78-980bddc5dfd0_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesLineItems_b683f1ed-3d3f-4f90-ba43-e24af4e1a826_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems" xlink:to="lab_us-gaap_MarketableSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_1b5f8783-1509-4847-8d42-07f3535a95b9_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_141ce57e-7bb0-4c89-8cf7-5cd81ab1a639_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_3b6f3d45-9293-4113-bec0-070c72bdef46_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_25413796-3de5-491a-bc54-25e92766fa1f_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_4065d7a9-2828-4e33-b846-14cb62188faf_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8351eb2a-28b1-4cdc-9b53-6b4ea667f5f0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_ShareBasedPaymentArrangementInducementOptionMember_a3ed9e3a-d1d0-4852-91e2-ce2afbfc77c1_terseLabel_en-US" xlink:label="lab_auph_ShareBasedPaymentArrangementInducementOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Stock Option</link:label>
    <link:label id="lab_auph_ShareBasedPaymentArrangementInducementOptionMember_label_en-US" xlink:label="lab_auph_ShareBasedPaymentArrangementInducementOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Inducement Option [Member]</link:label>
    <link:label id="lab_auph_ShareBasedPaymentArrangementInducementOptionMember_documentation_en-US" xlink:label="lab_auph_ShareBasedPaymentArrangementInducementOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Inducement Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ShareBasedPaymentArrangementInducementOptionMember" xlink:href="auph-20220930.xsd#auph_ShareBasedPaymentArrangementInducementOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_ShareBasedPaymentArrangementInducementOptionMember" xlink:to="lab_auph_ShareBasedPaymentArrangementInducementOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_MilestoneAchievementMember_e22e7011-1aa4-4b6d-8011-6aac769fd014_terseLabel_en-US" xlink:label="lab_auph_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Achievement</link:label>
    <link:label id="lab_auph_MilestoneAchievementMember_label_en-US" xlink:label="lab_auph_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Achievement [Member]</link:label>
    <link:label id="lab_auph_MilestoneAchievementMember_documentation_en-US" xlink:label="lab_auph_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Achievement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_MilestoneAchievementMember" xlink:href="auph-20220930.xsd#auph_MilestoneAchievementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_MilestoneAchievementMember" xlink:to="lab_auph_MilestoneAchievementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_decea29c-e214-467c-b6e7-eea6d0bb3c47_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk (as percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_2e7b4141-6750-455f-a7a1-9e3d472ea60d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_dad01af6-abc6-43f9-808b-c5f84a7210c6_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Short-Term Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_23397d65-0540-4037-8ab4-501a4f4f7a87_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_f8b36fbd-123e-4d66-9345-90270791ee41_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_eff98c6b-ce73-482d-aff5-ad54775d70ab_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to related parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_95e4fd4e-fee5-4fbc-b0d5-e7cb2834a836_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_557a550e-f8c5-4419-ad54-6bea97c8fc3d_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_92894dd9-9fce-4436-a8be-5ea9be02125c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic loss per share ($ per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_87d2ba72-03bc-4a1f-a9ea-738fe6aa9d0d_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic loss per share ($ per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_dc318581-e41f-4050-a246-42b1c8052779_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_6a6a4f0b-483f-4aea-ae34-1c3ba52c8a55_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_ebd5a724-c4de-45f8-af47-77bd1fb443bb_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_88306c37-74c7-423d-bab3-3a63912c2263_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_1e46a948-ba16-4a72-a40e-f142b7b1f53b_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_30c9d7fd-235c-4970-a560-9a3f8930899d_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_351f6945-fa0f-4f90-ae33-916a3aa216ac_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_ed47f8d8-679a-468a-8768-7ac8e294dda9_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_89162e13-fa86-4d89-8044-a505170eb690_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance share forfeited, Weighted average exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_OtuskaPharmaceuticalCoLtdMember_168f4048-40a6-42ca-aa56-7f572e73ef25_terseLabel_en-US" xlink:label="lab_auph_OtuskaPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Otuska</link:label>
    <link:label id="lab_auph_OtuskaPharmaceuticalCoLtdMember_label_en-US" xlink:label="lab_auph_OtuskaPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Otuska Pharmaceutical Co., Ltd. [Member]</link:label>
    <link:label id="lab_auph_OtuskaPharmaceuticalCoLtdMember_documentation_en-US" xlink:label="lab_auph_OtuskaPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Otuska Pharmaceutical Co., Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_OtuskaPharmaceuticalCoLtdMember" xlink:href="auph-20220930.xsd#auph_OtuskaPharmaceuticalCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_OtuskaPharmaceuticalCoLtdMember" xlink:to="lab_auph_OtuskaPharmaceuticalCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_c43824ec-4bf1-48a5-8ac6-39d12d589185_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_174409df-3ca0-48b9-8fd6-e796938b963d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_9173aa93-bf8a-43ad-a2cf-c38dbd15e961_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e6cc95d3-9d98-4316-9ec3-84cf3b85fc07_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6fb09e3a-7ddf-4255-ae20-62cda4ac7f3b_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net changes in operating assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_1dbc618a-5f88-4961-acff-f9a2bb4b9668_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2e17a7cc-559e-4bc4-9055-0f1b1700a80d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_fd367e75-faf5-4afe-8817-531399ba963f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_c0f1afa0-acae-46be-b950-1b83321a0e03_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_LesseeOperatingLeaseNumberOfExtensionOptions_41f8c20d-8975-4d95-bbf0-c6f3dff07a1b_terseLabel_en-US" xlink:label="lab_auph_LesseeOperatingLeaseNumberOfExtensionOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of extension options</link:label>
    <link:label id="lab_auph_LesseeOperatingLeaseNumberOfExtensionOptions_label_en-US" xlink:label="lab_auph_LesseeOperatingLeaseNumberOfExtensionOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number of Extension Options</link:label>
    <link:label id="lab_auph_LesseeOperatingLeaseNumberOfExtensionOptions_documentation_en-US" xlink:label="lab_auph_LesseeOperatingLeaseNumberOfExtensionOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number of Extension Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_LesseeOperatingLeaseNumberOfExtensionOptions" xlink:href="auph-20220930.xsd#auph_LesseeOperatingLeaseNumberOfExtensionOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_LesseeOperatingLeaseNumberOfExtensionOptions" xlink:to="lab_auph_LesseeOperatingLeaseNumberOfExtensionOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_a06e99dc-94c0-4fef-a781-3be57d00d557_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesCurrent_3da87304-3295-4bef-b303-d1976d74a39b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesCurrent" xlink:to="lab_us-gaap_DebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7f8f34ef-d8f3-4448-9e37-a76e4d1a80a5_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance shares vested, Weighted average grant date fair value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_f3bd1cc7-f78d-4005-bd43-511584c757c9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease extension term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_51350b1c-2b11-49d1-bdd2-d7f289afc488_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_NewEmployeesMember_35bf9b14-ed06-4cb0-9fd1-269d2f2f4cba_terseLabel_en-US" xlink:label="lab_auph_NewEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Employees</link:label>
    <link:label id="lab_auph_NewEmployeesMember_label_en-US" xlink:label="lab_auph_NewEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Employees [Member]</link:label>
    <link:label id="lab_auph_NewEmployeesMember_documentation_en-US" xlink:label="lab_auph_NewEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_NewEmployeesMember" xlink:href="auph-20220930.xsd#auph_NewEmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_NewEmployeesMember" xlink:to="lab_auph_NewEmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments_7091161e-dbb5-4e28-8229-9129aea61811_terseLabel_en-US" xlink:label="lab_auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents, restricted cash and short-term investments</link:label>
    <link:label id="lab_auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments_86240427-edd3-4209-bba2-19a739b09cc4_totalLabel_en-US" xlink:label="lab_auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents, restricted cash and short-term investments</link:label>
    <link:label id="lab_auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Short Term Investments</link:label>
    <link:label id="lab_auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments_documentation_en-US" xlink:label="lab_auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Short Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments" xlink:href="auph-20220930.xsd#auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments" xlink:to="lab_auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_614c5662-2ddc-4fc2-a0a0-4e9b25040aec_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_bacc0e8a-6b29-45c1-81ad-62c71a4eb690_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_811819db-ca7b-4f39-8f80-ab3588ef881f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_1cba44ff-a026-4592-b951-0eae113e9f03_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_85da31bf-0b64-46b9-9df8-7d343559a4d3_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_db5bf12b-994d-422a-8573-772b19d95470_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_9cf8bbb6-5683-4b8b-b434-c3d83b72ea06_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_dba03e92-8a39-4ad2-b44e-596f348aaf7e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_df753f06-2559-48b5-ad0b-0e40f5eb67c1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_dcc799f0-9d2a-4549-9605-d9dc658ec66f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_d1823bc6-349e-46f7-937d-7a3cea7fa6a8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related-Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_LesseeOperatingLeaseLeaseTerminationTerm_6f5a2d83-26d2-4f81-84f5-95684f7abfc5_terseLabel_en-US" xlink:label="lab_auph_LesseeOperatingLeaseLeaseTerminationTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease termination option term</link:label>
    <link:label id="lab_auph_LesseeOperatingLeaseLeaseTerminationTerm_label_en-US" xlink:label="lab_auph_LesseeOperatingLeaseLeaseTerminationTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Termination Term</link:label>
    <link:label id="lab_auph_LesseeOperatingLeaseLeaseTerminationTerm_documentation_en-US" xlink:label="lab_auph_LesseeOperatingLeaseLeaseTerminationTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Termination Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_LesseeOperatingLeaseLeaseTerminationTerm" xlink:href="auph-20220930.xsd#auph_LesseeOperatingLeaseLeaseTerminationTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_LesseeOperatingLeaseLeaseTerminationTerm" xlink:to="lab_auph_LesseeOperatingLeaseLeaseTerminationTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_3330b421-fdf2-4f0b-969e-9b4c95d2ba25_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_04b50715-21c9-4fc7-8299-a3d9882c78af_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_8cb3599f-8aec-46a0-8756-023325f234db_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_2b4a91b6-adb9-4177-b55f-6d94d7dda5bb_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditure payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForCapitalImprovements_d15669d6-bbee-4002-a47a-9a2218fcda78_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForCapitalImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for capital improvements</link:label>
    <link:label id="lab_us-gaap_PaymentsForCapitalImprovements_label_en-US" xlink:label="lab_us-gaap_PaymentsForCapitalImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Capital Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCapitalImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForCapitalImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForCapitalImprovements" xlink:to="lab_us-gaap_PaymentsForCapitalImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_987bcc2f-7256-4e41-bec3-d483dc6e5ede_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding - Beginning of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fba0cead-009e-4a9b-a8f7-96b8012b860c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding - End of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_f88bf2cd-8c28-4245-a67e-a7e4d0091b86_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Value</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_f1ca56ae-00d6-4bc6-88eb-ca1336c8267d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_c6959eb5-364d-44ff-bee1-a94ac21c1a15_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenue, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_fa23a3af-528a-4f52-b584-fb98f83fcabc_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_5c0de1d0-5642-4716-a833-f4b5d2e0333e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_94d1b8b0-f8c2-4b51-a41e-b11d5652cc23_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury bill</link:label>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Bill Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f0509860-b949-4c79-b7d3-69d2ae9476da_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent_d1d3fcbe-9b46-4522-836f-d71d6a82619e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total held to maturity securities at amortized cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent" xlink:to="lab_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_AmendedAndRestatedEquityIncentivePlanMember_5d8238bf-2141-4826-bec3-37244148e475_terseLabel_en-US" xlink:label="lab_auph_AmendedAndRestatedEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated Equity Incentive Plan</link:label>
    <link:label id="lab_auph_AmendedAndRestatedEquityIncentivePlanMember_label_en-US" xlink:label="lab_auph_AmendedAndRestatedEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_auph_AmendedAndRestatedEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_auph_AmendedAndRestatedEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_AmendedAndRestatedEquityIncentivePlanMember" xlink:href="auph-20220930.xsd#auph_AmendedAndRestatedEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_AmendedAndRestatedEquityIncentivePlanMember" xlink:to="lab_auph_AmendedAndRestatedEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsSummationsAbstract_41481f3e-058c-4a01-9ac3-5ee6f3852aef_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsSummationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets</link:label>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsSummationsAbstract_label_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsSummationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Flow Elements, Summations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsSummationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalCashFlowElementsSummationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsSummationsAbstract" xlink:to="lab_us-gaap_AdditionalCashFlowElementsSummationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_0136ca12-2181-412f-b8a5-8af34b8f292d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront license fee</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_fc80f4d4-48b6-4583-baec-74e76424075a_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_aaab8563-4814-437a-8abf-71585acca33a_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_c6181877-55e4-4d62-8759-a83f776a0e8d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_1e9eb6b3-020a-4688-a34c-08a3571b53d0_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_d9ae6576-91ec-47ce-b30c-791caccc4a9f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9a44ecbc-c21a-4038-a4e6-ec121233547a_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently adopted accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c1d782e3-e356-4a34-ba09-ed93a55126f8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b9817d2e-a37b-432a-827f-5ca337b70f63_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_67574545-cd42-42d3-9309-7ef8623666db_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_c816f56d-a299-4479-a25f-16fc57715c25_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Revenue</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_5ee375e1-19cd-42c2-ba24-cd9fc7da642c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5677eaa0-69c9-4f99-9074-bafdc3760ba8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c8bc6d9d-d2be-4970-a5ae-b2ba505ac37d_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryBondSecuritiesMember_6a66f2e8-55f1-4255-9627-ced0c3215905_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury bond</link:label>
    <link:label id="lab_us-gaap_USTreasuryBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryBondSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_59fda49f-c810-4c45-89a7-bd9d04f856bb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_5f6fc028-98c9-4d28-bb5d-f45016e64538_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_df153347-e467-4172-a4f9-b712f092d236_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_e477e327-2274-4531-83d1-92599c79363c_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8679bedb-6090-457b-bea1-c4d3e865e41f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_354635e0-9f61-4b03-b474-f8b60db16cc3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_RiptideBioscienceIncMember_a07aa0fb-eff4-4357-8a9e-9eb5a32893f9_terseLabel_en-US" xlink:label="lab_auph_RiptideBioscienceIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Riptide Bioscience, Inc.</link:label>
    <link:label id="lab_auph_RiptideBioscienceIncMember_label_en-US" xlink:label="lab_auph_RiptideBioscienceIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Riptide Bioscience, Inc. [Member]</link:label>
    <link:label id="lab_auph_RiptideBioscienceIncMember_documentation_en-US" xlink:label="lab_auph_RiptideBioscienceIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Riptide Bioscience, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_RiptideBioscienceIncMember" xlink:href="auph-20220930.xsd#auph_RiptideBioscienceIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_RiptideBioscienceIncMember" xlink:to="lab_auph_RiptideBioscienceIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_d010ceee-5847-4f59-a20f-71101d26a861_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_0641d14c-fa7f-48f2-aa20-a5a732b3aa08_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_f2de10ce-b5f6-4aa6-bb16-4170954f029e_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_PrepaidAssetsCurrent_5ef87f7e-fd11-4629-9d9d-fac804acec80_terseLabel_en-US" xlink:label="lab_auph_PrepaidAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid assets</link:label>
    <link:label id="lab_auph_PrepaidAssetsCurrent_label_en-US" xlink:label="lab_auph_PrepaidAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Assets, Current</link:label>
    <link:label id="lab_auph_PrepaidAssetsCurrent_documentation_en-US" xlink:label="lab_auph_PrepaidAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_PrepaidAssetsCurrent" xlink:href="auph-20220930.xsd#auph_PrepaidAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_PrepaidAssetsCurrent" xlink:to="lab_auph_PrepaidAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1e703925-a08b-4fb0-a2d0-66751ef498f7_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding used in computation of diluted loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b077f4e4-4e72-40cf-bbd6-85add90465ad_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_6bdac25b-cccd-4e09-85b4-bd1ded255938_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventories, net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ac3e5757-dcb5-40cf-abfe-cddd17072c8f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life of options in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_d055ee3e-81e4-46da-841f-aa865a9eae9b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4a60a003-35d8-4eb4-99cd-ed11c63f0db3_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5885446b-9abc-4273-bdb8-743a801a3137_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted, weighted average exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_48b3c246-8e8e-4171-90e9-3a40d12afc2f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance shares awards, weighted average grant date fair value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_b7eec0fd-e52b-43dd-9f62-57b25e2f77d1_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_40c9232b-760e-484f-8947-240945210130_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_f4d8eb34-c244-4c16-bbfa-e06b75e9d9f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ad4d999b-063f-49ae-bd2e-76a836400a56_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1fa618e6-bb6c-44e9-8abd-a91e88088c83_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_194c45d5-5e2b-4993-b347-aef801ba77b3_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8776389b-106b-4f2f-8765-230ed92befc0_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ad529155-ca4d-48f9-91af-db016e4ce9c1_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_c4a74e2a-a2f3-4f07-9dc6-70c59d251792_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_84dcc896-56d8-4960-949b-d6340c01e749_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options and employee share purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_2b564789-c8e7-45a7-b4c0-26e581d785cb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_cccbaf64-1c7d-4a7b-aef1-e48bcf1c4965_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_99f307fd-efdd-4d7c-a6e1-67bd1ac6b12d_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Terms</link:label>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_label_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Terms [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAgreementTermsMember" xlink:to="lab_us-gaap_LicenseAgreementTermsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_OutsideUnitedStatesMember_57945e89-ce7b-429b-8ef8-afba7ab96e60_terseLabel_en-US" xlink:label="lab_auph_OutsideUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside United States</link:label>
    <link:label id="lab_auph_OutsideUnitedStatesMember_label_en-US" xlink:label="lab_auph_OutsideUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside United States [Member]</link:label>
    <link:label id="lab_auph_OutsideUnitedStatesMember_documentation_en-US" xlink:label="lab_auph_OutsideUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside United States</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_OutsideUnitedStatesMember" xlink:href="auph-20220930.xsd#auph_OutsideUnitedStatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_OutsideUnitedStatesMember" xlink:to="lab_auph_OutsideUnitedStatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_04030588-7049-4916-b6f9-e0c57382784a_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_dfd417a9-2be9-41dc-9d31-1816c13c1284_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_b4686878-3127-4bc8-bffb-74928590bc5f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_a58a3dc7-58e5-46ad-8ed0-0844a5d1dcba_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_PrepaidExpensesTextBlock_1947f851-5257-4c8f-91ef-0ece27481193_terseLabel_en-US" xlink:label="lab_auph_PrepaidExpensesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses</link:label>
    <link:label id="lab_auph_PrepaidExpensesTextBlock_label_en-US" xlink:label="lab_auph_PrepaidExpensesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses [Text Block]</link:label>
    <link:label id="lab_auph_PrepaidExpensesTextBlock_documentation_en-US" xlink:label="lab_auph_PrepaidExpensesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_PrepaidExpensesTextBlock" xlink:href="auph-20220930.xsd#auph_PrepaidExpensesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_PrepaidExpensesTextBlock" xlink:to="lab_auph_PrepaidExpensesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c0f1addc-657a-4a3c-aad4-6483c8316a72_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_11c3a01a-7412-4268-9704-cbe806d92f50_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common shares in conjunction with ESPP program</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_8ffef4df-7d1a-464d-90da-8da2115ab16c_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireLeaseReceivables_f1e93cf4-0926-43b2-8c57-a29b02542421_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireLeaseReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront lease payment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireLeaseReceivables_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireLeaseReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Lease Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLeaseReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireLeaseReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireLeaseReceivables" xlink:to="lab_us-gaap_PaymentsToAcquireLeaseReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_d649bf25-6069-4482-a9c6-cd2b5fc8feca_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_ea4258f7-fb9a-4c64-a240-6c5f5bf6af12_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_25864eba-32c4-4afc-8ace-14e04616fb30_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_4e42f968-2361-4863-9fe1-eb5d59bba521_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_AccruedResearchCurrent_1e3df4df-7d84-45c5-b38d-4ec11ff7ed42_terseLabel_en-US" xlink:label="lab_auph_AccruedResearchCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued R&amp;D projects</link:label>
    <link:label id="lab_auph_AccruedResearchCurrent_label_en-US" xlink:label="lab_auph_AccruedResearchCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research, Current</link:label>
    <link:label id="lab_auph_AccruedResearchCurrent_documentation_en-US" xlink:label="lab_auph_AccruedResearchCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_AccruedResearchCurrent" xlink:href="auph-20220930.xsd#auph_AccruedResearchCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_AccruedResearchCurrent" xlink:to="lab_auph_AccruedResearchCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_2679a6e3-5bf7-472b-9afc-77ef83e131e3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_78a69d08-f4e7-42ce-a58e-6d33270262bf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3c2811e8-5b7a-45ad-9e66-a2b58beb39b0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common shares in conjunction with ESPP program (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_b657d727-6a50-405f-85fe-21f91ed64e56_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2783d398-164c-4e0e-a9c7-bad4af7c33b0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_24d52a25-eb6e-480f-98b4-2de1df253303_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_99db4e03-bdd8-48f9-9b49-019c3eeb9213_terseLabel_en-US" xlink:label="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of warrants</link:label>
    <link:label id="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_label_en-US" xlink:label="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_c354c525-a69f-46bc-8e83-59ee4b76186e_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_5c185732-dd7b-4881-834d-e79261742494_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares (in thousands)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_fd9adbb3-44fa-489a-8662-e430b9007522_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_57d64e1e-825d-4fe5-a666-af2f562bc278_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_805cd4a7-119d-468b-a2f7-ea3ac0ee7da0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3a858a60-496b-4e5b-a954-06c8aedf6bd2_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsIncurred_fe47cf3c-d2a4-40b1-b39f-adbfee51e9a4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsIncurred" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsIncurred_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Obligation Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLeaseObligationsIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsIncurred" xlink:to="lab_us-gaap_CapitalLeaseObligationsIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_beae2ee7-aac2-4444-a2fe-bef7abff6fbf_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_cfa50acc-604d-4a06-908d-c5c6368ca97f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_c69256d3-c86f-43d3-ac3e-54560b05b0d3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_2b525098-145a-4b1e-8051-ee9761bf3c28_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_a1bfbbb9-a8f1-4d4b-bf44-b7f81e9c2d4d_terseLabel_en-US" xlink:label="lab_auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, After Year Four</link:label>
    <link:label id="lab_auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="auph-20220930.xsd#auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_78e20ef5-5aba-43fc-9460-3a3eb404d355_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued on exercise of stock options and vesting of performance awards and restricted stock units</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4b2e2101-0ca2-40bc-9600-4104cc6ae358_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares forfeited/canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d2d4de7e-9fd9-41a9-9344-45211549a620_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance shares forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_749dc431-7de9-41c9-a533-74ed413c29f0_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_67f40e27-3f08-4fd5-a852-3ca63d9ad2a6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_b6dc5691-a990-4b34-a74e-f8e57bee8d4e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_9fcacd68-cb05-4c4e-aeeb-13427c4a713b_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e6937c84-9339-42d0-a366-dc4ddb1401bf_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_e57b17eb-0d84-40cb-9f77-8ce4991dd1d6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_710edc62-aa4d-419a-86c5-44e285dca538_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_dec1519e-d9c6-4248-9cd4-6393572adb48_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_72eaea9d-71ea-4893-b221-b28f46693c2c_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_046f3d5f-6047-46ef-a2aa-5eb66385a1fc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ce5503d2-73c8-4a4b-804b-0d53c4d6316e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_564ad276-8b2c-4e5b-9e1c-be84f3fafe13_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_4cc91c4b-7d2d-4e8d-9fd1-5bdcc7c09e62_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_7a7c12ff-f396-4052-89cb-0f804e809cb1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired intellectual property and other intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_7cf1d8ba-3d63-4554-a6a0-2bd9f04e6987_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_4051229a-a7f7-4702-9884-1b395cf7092b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_3b9edb09-7381-46a6-b01b-5a3e072cc4d2_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_ac72d7a4-2fe9-4736-9d26-7945a8c572a2_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal-use software implementation costs</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_label_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_367286ac-2cf8-466c-bcb1-c9624735bb43_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares (in thousands)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepositsAssetsCurrent_8da4ed78-1e8a-487b-955f-7d5078545a96_terseLabel_en-US" xlink:label="lab_us-gaap_DepositsAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid deposits</link:label>
    <link:label id="lab_us-gaap_DepositsAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DepositsAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssetsCurrent" xlink:to="lab_us-gaap_DepositsAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_e69b1967-de24-4b61-9d67-27f8b2bb428a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_04b8ff52-6322-4214-bb69-c8536a9644c4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Performance Shares Activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_1086d8c2-c6f2-4fbb-8cba-9be1da261c38_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_665901bf-319c-49b6-9307-35a512b59ca3_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_d14eeb62-3573-4b20-ab96-e8aff3caa6f6_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Description of Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_aa40dde5-997b-4a8f-a3c4-92a132acc940_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost of sales and operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_c2bfadb7-1185-4181-b2e8-45e984b57e40_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_78c20765-d652-4d2d-b43f-c772ec866530_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_ed22e9ca-bf7c-4323-aeec-4c28ad15a1a4_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_316cd68d-e0d5-44fd-a4f2-4101baddb1a5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OfficerMember_201e18cd-5765-4f5c-b861-b8643c5133e2_terseLabel_en-US" xlink:label="lab_srt_OfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Officer</link:label>
    <link:label id="lab_srt_OfficerMember_label_en-US" xlink:label="lab_srt_OfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficerMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OfficerMember" xlink:to="lab_srt_OfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_06ec631c-be1f-4559-a523-471a3108cbaa_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum finance lease liability payments due</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock_e4a6f2d8-8384-4218-a87e-c3be40099f83_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation and Other Non-current Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Noncurrent [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_CashCashEquivalentsAndRestrictedCashMember_aad64045-01b5-4d01-bc86-42c8da220e85_terseLabel_en-US" xlink:label="lab_auph_CashCashEquivalentsAndRestrictedCashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_auph_CashCashEquivalentsAndRestrictedCashMember_label_en-US" xlink:label="lab_auph_CashCashEquivalentsAndRestrictedCashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Restricted Cash [Member]</link:label>
    <link:label id="lab_auph_CashCashEquivalentsAndRestrictedCashMember_documentation_en-US" xlink:label="lab_auph_CashCashEquivalentsAndRestrictedCashMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Restricted Cash Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_CashCashEquivalentsAndRestrictedCashMember" xlink:href="auph-20220930.xsd#auph_CashCashEquivalentsAndRestrictedCashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_CashCashEquivalentsAndRestrictedCashMember" xlink:to="lab_auph_CashCashEquivalentsAndRestrictedCashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_620637de-b38e-404c-a1a3-300eee3ee754_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_ef194817-dd4b-4877-8357-8831747e0a3c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_9720e3eb-09e4-4b89-864f-29bb8fe8986f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_a4b37141-3144-4696-8ab5-52ac4c1111e9_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_6603904b-8a02-445c-9944-17991b6082e8_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_b0ca8557-c7ef-49cb-b67d-3eeffd889141_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_664eb80e-13c2-483a-8be7-df0458870184_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding used in computation of basic loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0e4db3fc-3d94-4c96-9545-5dc2882776b0_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHAREHOLDER&#8217;S EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_cfd685d4-0d83-4c3c-a445-e5bc439d3032_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_b8c70172-a938-4b4b-a57d-d39314684053_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_0fe67871-2f49-4c0b-aa0a-f7b1638b3e10_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 17)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_05f2c1f0-436d-49e7-9e96-e44325e0f7fc_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50385a99-3667-42b2-92a7-f6f18960be86_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d3d21409-022e-48eb-9ab6-f3615973c5eb_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_YankeeBondMember_6c4a7b5f-c916-437e-bad3-618685a40505_terseLabel_en-US" xlink:label="lab_auph_YankeeBondMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Yankee bond</link:label>
    <link:label id="lab_auph_YankeeBondMember_label_en-US" xlink:label="lab_auph_YankeeBondMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Yankee Bond [Member]</link:label>
    <link:label id="lab_auph_YankeeBondMember_documentation_en-US" xlink:label="lab_auph_YankeeBondMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Yankee Bond</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_YankeeBondMember" xlink:href="auph-20220930.xsd#auph_YankeeBondMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_YankeeBondMember" xlink:to="lab_auph_YankeeBondMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_eaabdee1-acaa-4c6d-b9ac-3e6c517b3d59_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and collaboration revenue</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_52fad19d-b0fe-4d71-ac41-52e3aabe9325_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_ShortTermCorporateDebtSecuritiesMember_a0dab6e4-8f2e-48d5-b75c-3cc1cf37482b_terseLabel_en-US" xlink:label="lab_auph_ShortTermCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bond</link:label>
    <link:label id="lab_auph_ShortTermCorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_auph_ShortTermCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Corporate Debt Securities [Member]</link:label>
    <link:label id="lab_auph_ShortTermCorporateDebtSecuritiesMember_documentation_en-US" xlink:label="lab_auph_ShortTermCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Corporate Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ShortTermCorporateDebtSecuritiesMember" xlink:href="auph-20220930.xsd#auph_ShortTermCorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_ShortTermCorporateDebtSecuritiesMember" xlink:to="lab_auph_ShortTermCorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_ShareBasedPaymentArrangementUnamortizedExpense_e179fe98-2389-489a-aadd-90e76e5fcca5_terseLabel_en-US" xlink:label="lab_auph_ShareBasedPaymentArrangementUnamortizedExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized expense</link:label>
    <link:label id="lab_auph_ShareBasedPaymentArrangementUnamortizedExpense_label_en-US" xlink:label="lab_auph_ShareBasedPaymentArrangementUnamortizedExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Unamortized Expense</link:label>
    <link:label id="lab_auph_ShareBasedPaymentArrangementUnamortizedExpense_documentation_en-US" xlink:label="lab_auph_ShareBasedPaymentArrangementUnamortizedExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Unamortized Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ShareBasedPaymentArrangementUnamortizedExpense" xlink:href="auph-20220930.xsd#auph_ShareBasedPaymentArrangementUnamortizedExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_ShareBasedPaymentArrangementUnamortizedExpense" xlink:to="lab_auph_ShareBasedPaymentArrangementUnamortizedExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_52b7d273-5d21-43b1-962d-4ed72bb98868_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_3c0158a8-4eca-4106-9540-81c4150f9645_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_dece4472-8655-4dbc-bb3b-a32be1ab3e9f_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue, net</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_abf45b42-54d2-458a-b76f-320c3b309a1e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_61326826-451e-403a-a313-6ca5faac435b_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bond</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_8a7dc792-8bab-4237-b97d-50142867b32a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_c0aeee9b-b65f-48a6-9cbc-970b80277d81_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_919376d4-4a91-47d2-8529-e16fbffc9ece_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_499c287e-ec09-4bf6-82a9-608a1d9c0738_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_e56dbfea-0aaa-4396-aa98-324cfb1978ba_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_3dade670-1555-4c80-8182-10266e303076_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocation of Share-Based Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_2c9d8ad5-7115-4c9e-87b1-69164fcc91aa_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_58b29432-7c64-4469-a6ed-b3ae709b9765_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_24a6bf03-4658-4e64-a9b8-ce8475f80a40_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Collaboration Agreement</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_CashCashEquivalentsAndDebtSecuritiesCurrent_82a34cdc-4270-48f0-8457-8366ff688e9b_terseLabel_en-US" xlink:label="lab_auph_CashCashEquivalentsAndDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and investments</link:label>
    <link:label id="lab_auph_CashCashEquivalentsAndDebtSecuritiesCurrent_label_en-US" xlink:label="lab_auph_CashCashEquivalentsAndDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Debt Securities, Current</link:label>
    <link:label id="lab_auph_CashCashEquivalentsAndDebtSecuritiesCurrent_documentation_en-US" xlink:label="lab_auph_CashCashEquivalentsAndDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Debt Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_CashCashEquivalentsAndDebtSecuritiesCurrent" xlink:href="auph-20220930.xsd#auph_CashCashEquivalentsAndDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_CashCashEquivalentsAndDebtSecuritiesCurrent" xlink:to="lab_auph_CashCashEquivalentsAndDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6016e543-49fe-4154-82c6-514aed7c6fa5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate (as percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_229e5b0a-523c-4abc-a720-ee7a3e8936f9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_RockvilleMarylandMember_34284cf4-cc84-490b-8b4b-0615119c487f_terseLabel_en-US" xlink:label="lab_auph_RockvilleMarylandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rockville, Maryland</link:label>
    <link:label id="lab_auph_RockvilleMarylandMember_label_en-US" xlink:label="lab_auph_RockvilleMarylandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rockville, Maryland [Member]</link:label>
    <link:label id="lab_auph_RockvilleMarylandMember_documentation_en-US" xlink:label="lab_auph_RockvilleMarylandMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rockville, Maryland</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_RockvilleMarylandMember" xlink:href="auph-20220930.xsd#auph_RockvilleMarylandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_RockvilleMarylandMember" xlink:to="lab_auph_RockvilleMarylandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_96bd7a38-cc81-4334-ae45-256f1ad10a3d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivable_8c0d9f71-3d2a-4971-b3c0-a394d73ab8f2_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivable_label_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivable" xlink:to="lab_us-gaap_InterestReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_f075555b-e3ac-44be-9cc9-29a9588fd7a1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_7aa562ac-e08e-4de8-a63d-4f7a5b8a3d88_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_e3e9d7bb-aea7-46a1-8ff2-fb43e0d56ec1_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_b03a6c07-dbc0-4062-9b66-3ade5fc66e25_terseLabel_en-US" xlink:label="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated forfeiture rate (as percent)</link:label>
    <link:label id="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_label_en-US" xlink:label="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate</link:label>
    <link:label id="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_documentation_en-US" xlink:label="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:href="auph-20220930.xsd#auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:to="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_7e72dc34-069f-48f5-8dd8-3f439487de35_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f71a897f-789e-4caf-88d3-0f29ec66394b_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: lease imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_a291d10a-8d59-4486-97fb-a341d47d12e7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_b90f074a-c1ed-499a-9e73-7f59b7e3b79f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted loss per share ($ per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_aed3e866-19e6-4b95-aaeb-3082dbb71f55_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted loss per share ($ per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_b6ab2d6c-7a4e-40f0-950c-668eb5ad0b35_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b7fef652-9e9f-4295-a8e8-61eac6d99b9b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a9ccdf5a-5fb4-441f-8ee9-75b34757cf82_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shared-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_95f774bc-94c2-4b82-8f7b-f30653dade9e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_ee4cdfeb-afe0-4931-8edd-063f025b4131_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_33af09fa-b064-4998-a751-74aa9cb92902_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_79eaf5e4-7874-4f15-afdd-7682d253d340_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntellectualPropertyMember_6e15ff3e-9d8f-40b2-8889-c27fbf5191d3_terseLabel_en-US" xlink:label="lab_us-gaap_IntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired intellectual property and reacquired rights</link:label>
    <link:label id="lab_us-gaap_IntellectualPropertyMember_label_en-US" xlink:label="lab_us-gaap_IntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual Property [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntellectualPropertyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntellectualPropertyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntellectualPropertyMember" xlink:to="lab_us-gaap_IntellectualPropertyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_d1e274b2-83a4-4c2c-9dde-21b4117727bc_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTable_8aa1c4b8-8740-45ba-b934-88059bea1100_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table]</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTable" xlink:to="lab_us-gaap_MarketableSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent_ea4a2100-cdfd-4c5c-bc7a-ee80662ee437_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6ce277b6-2577-4fe6-ac88-dbdf4d7234ce_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_14a8989e-1f02-4e55-a903-e3ba5cff18aa_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_234ae83a-8242-411a-9696-44d7d26ae912_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_9ac4610e-0fe9-49a8-96fa-238f2bc47adf_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_VictoriaBritishColumbiaMember_94ae7404-7824-4da4-a402-02c4e0e777cf_terseLabel_en-US" xlink:label="lab_auph_VictoriaBritishColumbiaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Victoria, British Columbia</link:label>
    <link:label id="lab_auph_VictoriaBritishColumbiaMember_label_en-US" xlink:label="lab_auph_VictoriaBritishColumbiaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Victoria, British Columbia [Member]</link:label>
    <link:label id="lab_auph_VictoriaBritishColumbiaMember_documentation_en-US" xlink:label="lab_auph_VictoriaBritishColumbiaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Victoria, British Columbia</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_VictoriaBritishColumbiaMember" xlink:href="auph-20220930.xsd#auph_VictoriaBritishColumbiaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_VictoriaBritishColumbiaMember" xlink:to="lab_auph_VictoriaBritishColumbiaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_1a4c48c7-e1be-49bd-9fa1-f8985c8c3188_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_b3344c9c-3020-46ce-b0ea-ab34babcfbc1_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to related party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_be5af45f-ddca-4204-9219-2e0f888c1161_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_c7be912e-bbf6-486c-971f-be97eff20a36_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_c40164fe-40c7-4cc1-9405-c4a864e7be89_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e6df7dea-106b-4eec-b9c4-5772b8c5163b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance shares vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_af5894de-ddb5-4675-ad3d-c9b57ae219f3_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance shares vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_f799403f-13ed-4a73-bb75-ddec36945568_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e4f1808e-29f9-4c5f-8293-ce0fe4903605_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_AcquiredUpfrontLicensePayment_f0238794-0d09-42fc-8f3c-66e1ccbe6a88_terseLabel_en-US" xlink:label="lab_auph_AcquiredUpfrontLicensePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront license and milestone expense</link:label>
    <link:label id="lab_auph_AcquiredUpfrontLicensePayment_label_en-US" xlink:label="lab_auph_AcquiredUpfrontLicensePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Upfront License Payment</link:label>
    <link:label id="lab_auph_AcquiredUpfrontLicensePayment_documentation_en-US" xlink:label="lab_auph_AcquiredUpfrontLicensePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Upfront License Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_AcquiredUpfrontLicensePayment" xlink:href="auph-20220930.xsd#auph_AcquiredUpfrontLicensePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_AcquiredUpfrontLicensePayment" xlink:to="lab_auph_AcquiredUpfrontLicensePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1e5ec997-073d-442f-b16b-2ec44dc79dcc_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_7828d370-1b56-40a4-8242-778b25ec70ac_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_4b4aa19b-3496-4079-a75d-848adba2207d_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_25853ff7-22b3-4307-8dfb-4705b4a924bc_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_269e07bf-4d1b-4eeb-bc91-3766e652486c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price $</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_feaaebcf-8518-4f1b-b084-fbf59fbaada0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cf6fc943-5d83-40fe-8e8b-1fe1bc7c1e6d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_dc25c09f-1290-4c1c-9288-5468394388ff_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customers</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_3536260f-0dd5-43fd-9a95-f59ff1f7c938_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_ef5d75e0-a95c-4a7d-b0ed-6f245888a866_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_ac97b59d-eb7f-489a-8000-810219a01f5f_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_3e1c53d3-7b42-481f-8e38-a254b4a46a62_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForSoftware_b590f61f-1ae7-4359-b839-7a217d7ddf11_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForSoftware" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to internal use-software implementation costs</link:label>
    <link:label id="lab_us-gaap_PaymentsForSoftware_label_en-US" xlink:label="lab_us-gaap_PaymentsForSoftware" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForSoftware" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForSoftware"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForSoftware" xlink:to="lab_us-gaap_PaymentsForSoftware" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_a7f59658-3bb5-419e-94a5-81fc3d16d4e4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_5be9292d-c618-44d1-9e44-5317bfdd3bc1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_bfc943e6-5f64-4d94-ac95-868c2e9d9420_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of noncash transactions</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_25f7801b-e8e4-4806-8d33-7b5c9a9bca6c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dbdf88c9-5557-4674-abe3-ab12868f9e16_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value per common share option (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid_e44fe916-dae7-462f-95e6-42cb45365a5b_terseLabel_en-US" xlink:label="lab_auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future value of minimum lease payments of leases not yet commenced</link:label>
    <link:label id="lab_auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid_label_en-US" xlink:label="lab_auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Liability, to be Paid</link:label>
    <link:label id="lab_auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid_documentation_en-US" xlink:label="lab_auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid" xlink:href="auph-20220930.xsd#auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid" xlink:to="lab_auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_PerformanceShareSandRestrictedStockUnitsRSUsMember_0a37340a-6528-4e92-98c1-bf7274f7c37c_terseLabel_en-US" xlink:label="lab_auph_PerformanceShareSandRestrictedStockUnitsRSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share sand Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_auph_PerformanceShareSandRestrictedStockUnitsRSUsMember_label_en-US" xlink:label="lab_auph_PerformanceShareSandRestrictedStockUnitsRSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share sand Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label id="lab_auph_PerformanceShareSandRestrictedStockUnitsRSUsMember_documentation_en-US" xlink:label="lab_auph_PerformanceShareSandRestrictedStockUnitsRSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share sand Restricted Stock Units (RSUs)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_PerformanceShareSandRestrictedStockUnitsRSUsMember" xlink:href="auph-20220930.xsd#auph_PerformanceShareSandRestrictedStockUnitsRSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_PerformanceShareSandRestrictedStockUnitsRSUsMember" xlink:to="lab_auph_PerformanceShareSandRestrictedStockUnitsRSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_c7d4d9e6-ea40-46ee-8c55-615f9ca16013_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation and other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_30b67477-7e7a-4aa6-9046-c249d5370fa3_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0047f0be-78d6-4076-a57f-36babb44e97f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_AccountsReceivableCreditTerm_e8e367bf-b0b5-47a4-a2a2-c6d2c6ee51ec_terseLabel_en-US" xlink:label="lab_auph_AccountsReceivableCreditTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable standard credit terms (in days)</link:label>
    <link:label id="lab_auph_AccountsReceivableCreditTerm_label_en-US" xlink:label="lab_auph_AccountsReceivableCreditTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Term</link:label>
    <link:label id="lab_auph_AccountsReceivableCreditTerm_documentation_en-US" xlink:label="lab_auph_AccountsReceivableCreditTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_AccountsReceivableCreditTerm" xlink:href="auph-20220930.xsd#auph_AccountsReceivableCreditTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_AccountsReceivableCreditTerm" xlink:to="lab_auph_AccountsReceivableCreditTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_19b14670-0ebf-4065-bac7-24e58d1722f7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Loss Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2d48e50b-5114-4c27-95d0-1098a0981b95_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial recognition of operating lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_5633ffb7-4d8e-4b15-ae80-b2723295079a_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_USAgencySecurityMember_300aef65-d412-4a54-ae75-7e438c1d1bd5_terseLabel_en-US" xlink:label="lab_auph_USAgencySecurityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. agency security</link:label>
    <link:label id="lab_auph_USAgencySecurityMember_label_en-US" xlink:label="lab_auph_USAgencySecurityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Agency Security [Member]</link:label>
    <link:label id="lab_auph_USAgencySecurityMember_documentation_en-US" xlink:label="lab_auph_USAgencySecurityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Agency Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_USAgencySecurityMember" xlink:href="auph-20220930.xsd#auph_USAgencySecurityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_USAgencySecurityMember" xlink:to="lab_auph_USAgencySecurityMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>auph-20220930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:05323eab-3ae1-47f9-a870-5f1cb7d56826,g:99240d06-396b-484e-9f8c-0586e299f202-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.auriniapharma.com/role/COVER" xlink:type="simple" xlink:href="auph-20220930.xsd#COVER"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/COVER" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_49961eef-230f-4203-b417-a2d7e0d8c89d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_3efd966d-3065-49f8-bdce-ef307296ae57" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49961eef-230f-4203-b417-a2d7e0d8c89d" xlink:to="loc_dei_DocumentType_3efd966d-3065-49f8-bdce-ef307296ae57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_b11aa4da-784c-4289-80c1-1ea6b9b4eee2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49961eef-230f-4203-b417-a2d7e0d8c89d" xlink:to="loc_dei_DocumentQuarterlyReport_b11aa4da-784c-4289-80c1-1ea6b9b4eee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_3e32fb5a-7172-4b75-960e-1d620eb12c9a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49961eef-230f-4203-b417-a2d7e0d8c89d" xlink:to="loc_dei_DocumentPeriodEndDate_3e32fb5a-7172-4b75-960e-1d620eb12c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_697c9f9e-4ef4-4e0b-b16b-cf2912464937" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49961eef-230f-4203-b417-a2d7e0d8c89d" xlink:to="loc_dei_DocumentTransitionReport_697c9f9e-4ef4-4e0b-b16b-cf2912464937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_13d3fc29-62e7-4f8f-8558-fe3a27634fd6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49961eef-230f-4203-b417-a2d7e0d8c89d" xlink:to="loc_dei_EntityFileNumber_13d3fc29-62e7-4f8f-8558-fe3a27634fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_9342f8c7-69a8-40c4-8ea3-b2b8c7d4739f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49961eef-230f-4203-b417-a2d7e0d8c89d" xlink:to="loc_dei_EntityRegistrantName_9342f8c7-69a8-40c4-8ea3-b2b8c7d4739f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_bdea9ca7-e5a7-4650-abf1-a4f405decf42" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49961eef-230f-4203-b417-a2d7e0d8c89d" xlink:to="loc_dei_EntityIncorporationStateCountryCode_bdea9ca7-e5a7-4650-abf1-a4f405decf42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_f2bfdff8-d969-4fac-a40d-bede7bc505b2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49961eef-230f-4203-b417-a2d7e0d8c89d" xlink:to="loc_dei_EntityAddressAddressLine1_f2bfdff8-d969-4fac-a40d-bede7bc505b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6f50df09-67ce-43b0-9e06-184f60dc890f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49961eef-230f-4203-b417-a2d7e0d8c89d" xlink:to="loc_dei_EntityTaxIdentificationNumber_6f50df09-67ce-43b0-9e06-184f60dc890f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_7198611b-ce27-4423-aef2-a4c528a322bb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49961eef-230f-4203-b417-a2d7e0d8c89d" xlink:to="loc_dei_EntityAddressCityOrTown_7198611b-ce27-4423-aef2-a4c528a322bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e2c7b89c-b49f-4621-a1f2-c3d2c532682d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49961eef-230f-4203-b417-a2d7e0d8c89d" xlink:to="loc_dei_EntityAddressStateOrProvince_e2c7b89c-b49f-4621-a1f2-c3d2c532682d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_624f46b7-c8a5-4e73-8e3b-b7dcbfe17ce7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49961eef-230f-4203-b417-a2d7e0d8c89d" xlink:to="loc_dei_EntityAddressPostalZipCode_624f46b7-c8a5-4e73-8e3b-b7dcbfe17ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ef0b7c9a-1d03-4c73-a725-3fc09d781e82" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49961eef-230f-4203-b417-a2d7e0d8c89d" xlink:to="loc_dei_CityAreaCode_ef0b7c9a-1d03-4c73-a725-3fc09d781e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_314c59d9-21a7-4015-8399-d191482438bf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49961eef-230f-4203-b417-a2d7e0d8c89d" xlink:to="loc_dei_LocalPhoneNumber_314c59d9-21a7-4015-8399-d191482438bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_ca1c93c5-326b-4d37-a2b9-c059d21f8242" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49961eef-230f-4203-b417-a2d7e0d8c89d" xlink:to="loc_dei_EntityCurrentReportingStatus_ca1c93c5-326b-4d37-a2b9-c059d21f8242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_7ecb9fcf-7a80-4be6-8442-34c338c34f1b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49961eef-230f-4203-b417-a2d7e0d8c89d" xlink:to="loc_dei_EntityInteractiveDataCurrent_7ecb9fcf-7a80-4be6-8442-34c338c34f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_5e19ab52-ba31-4c19-a27c-638b9be84b47" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49961eef-230f-4203-b417-a2d7e0d8c89d" xlink:to="loc_dei_EntityFilerCategory_5e19ab52-ba31-4c19-a27c-638b9be84b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_24e2f813-222e-4c14-964a-cc0274715a1a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49961eef-230f-4203-b417-a2d7e0d8c89d" xlink:to="loc_dei_EntitySmallBusiness_24e2f813-222e-4c14-964a-cc0274715a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_cd23ff0d-507b-4a15-8d41-917f43ae6bab" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49961eef-230f-4203-b417-a2d7e0d8c89d" xlink:to="loc_dei_EntityEmergingGrowthCompany_cd23ff0d-507b-4a15-8d41-917f43ae6bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_3b38461a-9bec-437f-b5d9-814d0eb07d1a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49961eef-230f-4203-b417-a2d7e0d8c89d" xlink:to="loc_dei_EntityShellCompany_3b38461a-9bec-437f-b5d9-814d0eb07d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_0f07cf8f-a889-476f-835f-6e64680228f5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49961eef-230f-4203-b417-a2d7e0d8c89d" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_0f07cf8f-a889-476f-835f-6e64680228f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f4ab31e5-b03a-4dfd-9f7b-b92d617761c3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49961eef-230f-4203-b417-a2d7e0d8c89d" xlink:to="loc_dei_Security12bTitle_f4ab31e5-b03a-4dfd-9f7b-b92d617761c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_0cce0f76-74ee-4cca-b4a2-93d24ebbf7b2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49961eef-230f-4203-b417-a2d7e0d8c89d" xlink:to="loc_dei_TradingSymbol_0cce0f76-74ee-4cca-b4a2-93d24ebbf7b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d1a6a3e8-c42b-4b38-b156-108d8f956806" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49961eef-230f-4203-b417-a2d7e0d8c89d" xlink:to="loc_dei_SecurityExchangeName_d1a6a3e8-c42b-4b38-b156-108d8f956806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_1129b032-9dc6-41af-ad1d-ebdd2bd4ecbf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49961eef-230f-4203-b417-a2d7e0d8c89d" xlink:to="loc_dei_AmendmentFlag_1129b032-9dc6-41af-ad1d-ebdd2bd4ecbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_679358e4-58c5-487e-a184-0e811df814f4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49961eef-230f-4203-b417-a2d7e0d8c89d" xlink:to="loc_dei_DocumentFiscalYearFocus_679358e4-58c5-487e-a184-0e811df814f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_c41e07ba-26dc-4fe5-80c2-66cb21e8a1ba" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49961eef-230f-4203-b417-a2d7e0d8c89d" xlink:to="loc_dei_DocumentFiscalPeriodFocus_c41e07ba-26dc-4fe5-80c2-66cb21e8a1ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f278949e-c72c-4965-ad13-f1640ff59256" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49961eef-230f-4203-b417-a2d7e0d8c89d" xlink:to="loc_dei_EntityCentralIndexKey_f278949e-c72c-4965-ad13-f1640ff59256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_3877d5b3-8cd4-459f-b5b8-5994baec2009" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49961eef-230f-4203-b417-a2d7e0d8c89d" xlink:to="loc_dei_CurrentFiscalYearEndDate_3877d5b3-8cd4-459f-b5b8-5994baec2009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="auph-20220930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_90ebb736-115e-434e-800e-d24651520061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_9669c6d1-c469-4163-8d03-7d2d273753be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_90ebb736-115e-434e-800e-d24651520061" xlink:to="loc_us-gaap_AssetsAbstract_9669c6d1-c469-4163-8d03-7d2d273753be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_50aacae4-3445-4d04-aaea-583f6fe0a84b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9669c6d1-c469-4163-8d03-7d2d273753be" xlink:to="loc_us-gaap_AssetsCurrentAbstract_50aacae4-3445-4d04-aaea-583f6fe0a84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_de3d4ce5-6e20-4e9e-9ad8-6825f7a26b78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_50aacae4-3445-4d04-aaea-583f6fe0a84b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_de3d4ce5-6e20-4e9e-9ad8-6825f7a26b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesCurrent_c1b41b5a-0137-45fe-b414-94ee5bc8ef5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_50aacae4-3445-4d04-aaea-583f6fe0a84b" xlink:to="loc_us-gaap_DebtSecuritiesCurrent_c1b41b5a-0137-45fe-b414-94ee5bc8ef5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_92f22bfa-5dd8-4ed1-ac59-4ef218c658cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_50aacae4-3445-4d04-aaea-583f6fe0a84b" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_92f22bfa-5dd8-4ed1-ac59-4ef218c658cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_247d4921-26be-4479-aa7e-c08e4b831b85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_50aacae4-3445-4d04-aaea-583f6fe0a84b" xlink:to="loc_us-gaap_InventoryNet_247d4921-26be-4479-aa7e-c08e4b831b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_cbdf6067-4a00-41e4-98d9-d24f74844816" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_50aacae4-3445-4d04-aaea-583f6fe0a84b" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_cbdf6067-4a00-41e4-98d9-d24f74844816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_0a098357-1828-4c87-8cad-9ee1f5ccb775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_50aacae4-3445-4d04-aaea-583f6fe0a84b" xlink:to="loc_us-gaap_OtherAssetsCurrent_0a098357-1828-4c87-8cad-9ee1f5ccb775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4c76bfbe-c56b-436b-a92e-8679bad2e2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_50aacae4-3445-4d04-aaea-583f6fe0a84b" xlink:to="loc_us-gaap_AssetsCurrent_4c76bfbe-c56b-436b-a92e-8679bad2e2b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_7c4da061-175f-4d8f-a08c-90409858cbd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9669c6d1-c469-4163-8d03-7d2d273753be" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_7c4da061-175f-4d8f-a08c-90409858cbd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_06a74818-dd09-43b7-ae01-f59024e3437a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7c4da061-175f-4d8f-a08c-90409858cbd7" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_06a74818-dd09-43b7-ae01-f59024e3437a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_cead05ac-5a52-4f3f-9112-27c915914521" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7c4da061-175f-4d8f-a08c-90409858cbd7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_cead05ac-5a52-4f3f-9112-27c915914521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4be31629-005c-474d-ba55-7a87bef5f21a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7c4da061-175f-4d8f-a08c-90409858cbd7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4be31629-005c-474d-ba55-7a87bef5f21a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7bddc472-945e-4791-ab64-8fecbc366669" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7c4da061-175f-4d8f-a08c-90409858cbd7" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7bddc472-945e-4791-ab64-8fecbc366669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_fc015ffd-3ff2-4f8a-aabd-6d18bc94c5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7c4da061-175f-4d8f-a08c-90409858cbd7" xlink:to="loc_us-gaap_Assets_fc015ffd-3ff2-4f8a-aabd-6d18bc94c5dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_a169c9bd-2655-462d-95bd-21f61610669d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_90ebb736-115e-434e-800e-d24651520061" xlink:to="loc_us-gaap_LiabilitiesAbstract_a169c9bd-2655-462d-95bd-21f61610669d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_357d088d-9b61-4a1a-a532-3b3cd3491db3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a169c9bd-2655-462d-95bd-21f61610669d" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_357d088d-9b61-4a1a-a532-3b3cd3491db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_38252070-6ca7-48da-87ad-f0aff9dbaa73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_357d088d-9b61-4a1a-a532-3b3cd3491db3" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_38252070-6ca7-48da-87ad-f0aff9dbaa73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_6ffd4b50-a7dc-4aab-9291-a7439801d282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_357d088d-9b61-4a1a-a532-3b3cd3491db3" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_6ffd4b50-a7dc-4aab-9291-a7439801d282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b3184506-36e0-4344-8840-04fcf3412822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_357d088d-9b61-4a1a-a532-3b3cd3491db3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b3184506-36e0-4344-8840-04fcf3412822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8704e925-0bfc-4825-8411-08eaaaf5b374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a169c9bd-2655-462d-95bd-21f61610669d" xlink:to="loc_us-gaap_LiabilitiesCurrent_8704e925-0bfc-4825-8411-08eaaaf5b374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_2d9dac2b-5171-4fa4-a7e6-52220fca90a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a169c9bd-2655-462d-95bd-21f61610669d" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_2d9dac2b-5171-4fa4-a7e6-52220fca90a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_091f6f9d-d829-41d0-b139-86b09a225ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_2d9dac2b-5171-4fa4-a7e6-52220fca90a8" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_091f6f9d-d829-41d0-b139-86b09a225ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e764582a-1458-495b-b108-91184cf8dad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_2d9dac2b-5171-4fa4-a7e6-52220fca90a8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e764582a-1458-495b-b108-91184cf8dad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1a8f0486-9298-4e98-831e-1e992dce7833" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a169c9bd-2655-462d-95bd-21f61610669d" xlink:to="loc_us-gaap_Liabilities_1a8f0486-9298-4e98-831e-1e992dce7833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e888493f-3787-477f-a89e-3a1c8346f02c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a169c9bd-2655-462d-95bd-21f61610669d" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e888493f-3787-477f-a89e-3a1c8346f02c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_69c70d4a-74e0-4f72-8664-50961ce22b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a169c9bd-2655-462d-95bd-21f61610669d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_69c70d4a-74e0-4f72-8664-50961ce22b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_9e5119b6-45eb-445e-988a-bd7657d7c673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_69c70d4a-74e0-4f72-8664-50961ce22b9c" xlink:to="loc_us-gaap_CommonStockValueOutstanding_9e5119b6-45eb-445e-988a-bd7657d7c673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a2138264-1551-4cb6-95f1-a9d04d279b64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_69c70d4a-74e0-4f72-8664-50961ce22b9c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a2138264-1551-4cb6-95f1-a9d04d279b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7b103156-a3fd-4222-8f82-71d10625d97f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_69c70d4a-74e0-4f72-8664-50961ce22b9c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7b103156-a3fd-4222-8f82-71d10625d97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_edb1c656-9224-4aae-a533-76b662437b65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_69c70d4a-74e0-4f72-8664-50961ce22b9c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_edb1c656-9224-4aae-a533-76b662437b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_198daed7-f024-407c-a735-75d983fabf5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_69c70d4a-74e0-4f72-8664-50961ce22b9c" xlink:to="loc_us-gaap_StockholdersEquity_198daed7-f024-407c-a735-75d983fabf5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7343463-8a53-4591-b5c8-3c39c6fcd450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a169c9bd-2655-462d-95bd-21f61610669d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7343463-8a53-4591-b5c8-3c39c6fcd450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="auph-20220930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_dc34210c-8fd6-4304-9fcf-d3c5c2ae9138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_96997b9d-a140-4c98-9ae7-dd5c034a5eef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dc34210c-8fd6-4304-9fcf-d3c5c2ae9138" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_96997b9d-a140-4c98-9ae7-dd5c034a5eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a42385fe-b001-461c-bc81-445522f69ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dc34210c-8fd6-4304-9fcf-d3c5c2ae9138" xlink:to="loc_us-gaap_CommonStockSharesIssued_a42385fe-b001-461c-bc81-445522f69ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ffc6584b-aa26-4704-917e-7da2b773242a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dc34210c-8fd6-4304-9fcf-d3c5c2ae9138" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ffc6584b-aa26-4704-917e-7da2b773242a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="auph-20220930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_0fe0aa13-5d37-4c51-a44b-7915597bb01b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e78be07f-ccf2-4838-9d82-a9433cd5393d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0fe0aa13-5d37-4c51-a44b-7915597bb01b" xlink:to="loc_us-gaap_StatementTable_e78be07f-ccf2-4838-9d82-a9433cd5393d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_434f56b9-7e96-429d-a3db-5fcb9152ac6d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e78be07f-ccf2-4838-9d82-a9433cd5393d" xlink:to="loc_srt_ProductOrServiceAxis_434f56b9-7e96-429d-a3db-5fcb9152ac6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_11db1404-dea5-45fd-9d1c-ebb40bcf5568" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_434f56b9-7e96-429d-a3db-5fcb9152ac6d" xlink:to="loc_srt_ProductsAndServicesDomain_11db1404-dea5-45fd-9d1c-ebb40bcf5568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_bccea20d-1361-416d-abe2-c767816f9aab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_11db1404-dea5-45fd-9d1c-ebb40bcf5568" xlink:to="loc_us-gaap_ProductMember_bccea20d-1361-416d-abe2-c767816f9aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_c08ff704-21d7-43d2-a933-5396af16e85f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_11db1404-dea5-45fd-9d1c-ebb40bcf5568" xlink:to="loc_us-gaap_LicenseMember_c08ff704-21d7-43d2-a933-5396af16e85f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9db917f2-91fd-4780-a7b7-1e89dda98bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e78be07f-ccf2-4838-9d82-a9433cd5393d" xlink:to="loc_us-gaap_StatementLineItems_9db917f2-91fd-4780-a7b7-1e89dda98bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_acfd923b-67af-436b-bb25-bcf583bae229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9db917f2-91fd-4780-a7b7-1e89dda98bc2" xlink:to="loc_us-gaap_RevenuesAbstract_acfd923b-67af-436b-bb25-bcf583bae229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2a64f894-bb9a-4829-bbff-e1ed6ef8b8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_acfd923b-67af-436b-bb25-bcf583bae229" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2a64f894-bb9a-4829-bbff-e1ed6ef8b8c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_327d0e97-4865-43af-a6be-a38557d37105" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9db917f2-91fd-4780-a7b7-1e89dda98bc2" xlink:to="loc_us-gaap_OperatingExpensesAbstract_327d0e97-4865-43af-a6be-a38557d37105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_ce9d84c0-9ae0-4d3c-80d1-51be4e0edd88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_327d0e97-4865-43af-a6be-a38557d37105" xlink:to="loc_us-gaap_CostOfRevenue_ce9d84c0-9ae0-4d3c-80d1-51be4e0edd88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_63cd6c4f-1220-4984-b36c-e0fe95811103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_327d0e97-4865-43af-a6be-a38557d37105" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_63cd6c4f-1220-4984-b36c-e0fe95811103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f5918434-a384-4cdc-aa41-c94bb301e1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_327d0e97-4865-43af-a6be-a38557d37105" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f5918434-a384-4cdc-aa41-c94bb301e1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_5932e93c-878c-4a4a-bb14-7441a79001a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_327d0e97-4865-43af-a6be-a38557d37105" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_5932e93c-878c-4a4a-bb14-7441a79001a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_17d442e2-4ae3-4fb7-bfff-ccf2e9a6d864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_327d0e97-4865-43af-a6be-a38557d37105" xlink:to="loc_us-gaap_CostsAndExpenses_17d442e2-4ae3-4fb7-bfff-ccf2e9a6d864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c62a5133-58ee-47fd-a0a1-b9e033ea11fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9db917f2-91fd-4780-a7b7-1e89dda98bc2" xlink:to="loc_us-gaap_OperatingIncomeLoss_c62a5133-58ee-47fd-a0a1-b9e033ea11fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_0652e27a-c0c2-4b46-8e49-335c8a27365a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9db917f2-91fd-4780-a7b7-1e89dda98bc2" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_0652e27a-c0c2-4b46-8e49-335c8a27365a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6b7cf79d-dc46-4bcc-ad37-3c9bfa187ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9db917f2-91fd-4780-a7b7-1e89dda98bc2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6b7cf79d-dc46-4bcc-ad37-3c9bfa187ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_22dac452-2c7a-4589-b66b-278875c87789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9db917f2-91fd-4780-a7b7-1e89dda98bc2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_22dac452-2c7a-4589-b66b-278875c87789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8d3c30f5-9721-4f08-89ce-e83acc121712" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9db917f2-91fd-4780-a7b7-1e89dda98bc2" xlink:to="loc_us-gaap_NetIncomeLoss_8d3c30f5-9721-4f08-89ce-e83acc121712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5bafdba0-af47-49af-bcf0-8aa5233b5b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9db917f2-91fd-4780-a7b7-1e89dda98bc2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5bafdba0-af47-49af-bcf0-8aa5233b5b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_b9f35cef-1330-4bdc-8a7d-6eb7c883c621" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5bafdba0-af47-49af-bcf0-8aa5233b5b9d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_b9f35cef-1330-4bdc-8a7d-6eb7c883c621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_1a2070ab-f381-44c8-be6b-6bc549dceae7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9db917f2-91fd-4780-a7b7-1e89dda98bc2" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_1a2070ab-f381-44c8-be6b-6bc549dceae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_4111a5b7-6e71-4ed6-972d-8951f4f481d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9db917f2-91fd-4780-a7b7-1e89dda98bc2" xlink:to="loc_us-gaap_EarningsPerShareBasic_4111a5b7-6e71-4ed6-972d-8951f4f481d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1558927b-a85b-462f-8edc-0ac90df4f828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9db917f2-91fd-4780-a7b7-1e89dda98bc2" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1558927b-a85b-462f-8edc-0ac90df4f828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_98c5825d-5096-4553-b8ad-df1505bc0568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9db917f2-91fd-4780-a7b7-1e89dda98bc2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_98c5825d-5096-4553-b8ad-df1505bc0568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ac3dc0f8-e3f8-47ca-a69b-0cf90cb82bda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9db917f2-91fd-4780-a7b7-1e89dda98bc2" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ac3dc0f8-e3f8-47ca-a69b-0cf90cb82bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical" xlink:type="simple" xlink:href="auph-20220930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_55a9f462-98d6-476c-9712-74f4c272ff4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_d93e7f87-5a4b-4fe1-a30c-6366e84200e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_55a9f462-98d6-476c-9712-74f4c272ff4a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_d93e7f87-5a4b-4fe1-a30c-6366e84200e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" xlink:type="simple" xlink:href="auph-20220930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_4d8c9787-aa55-4d44-9361-17c708a6dd44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_78bf16c7-d5ae-46e5-9ea4-15cca9ec67b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_4d8c9787-aa55-4d44-9361-17c708a6dd44" xlink:to="loc_us-gaap_StatementTable_78bf16c7-d5ae-46e5-9ea4-15cca9ec67b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_849c22f7-3efd-4627-8005-f64fa342aaa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_78bf16c7-d5ae-46e5-9ea4-15cca9ec67b2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_849c22f7-3efd-4627-8005-f64fa342aaa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d5526451-ae00-4906-9ad8-002c4879f05a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_849c22f7-3efd-4627-8005-f64fa342aaa0" xlink:to="loc_us-gaap_EquityComponentDomain_d5526451-ae00-4906-9ad8-002c4879f05a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a8e27a21-4b5e-4c93-a13a-b7ba9f22df0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d5526451-ae00-4906-9ad8-002c4879f05a" xlink:to="loc_us-gaap_CommonStockMember_a8e27a21-4b5e-4c93-a13a-b7ba9f22df0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4873dfee-9f5f-4b84-963a-b1aa662e4747" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d5526451-ae00-4906-9ad8-002c4879f05a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4873dfee-9f5f-4b84-963a-b1aa662e4747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2820e52a-50a4-42a8-8ac4-ed82a9a15af3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d5526451-ae00-4906-9ad8-002c4879f05a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2820e52a-50a4-42a8-8ac4-ed82a9a15af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_937620fb-ee5e-4dba-928c-edd8eec904c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d5526451-ae00-4906-9ad8-002c4879f05a" xlink:to="loc_us-gaap_RetainedEarningsMember_937620fb-ee5e-4dba-928c-edd8eec904c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_49e8f2ce-72c9-41e6-83ec-02497de14e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_78bf16c7-d5ae-46e5-9ea4-15cca9ec67b2" xlink:to="loc_us-gaap_StatementLineItems_49e8f2ce-72c9-41e6-83ec-02497de14e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4522719d-28b8-4c48-b935-9c05740fbfea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49e8f2ce-72c9-41e6-83ec-02497de14e5c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4522719d-28b8-4c48-b935-9c05740fbfea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_db0618dd-d114-468a-99a4-298ca83c3276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4522719d-28b8-4c48-b935-9c05740fbfea" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_db0618dd-d114-468a-99a4-298ca83c3276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_76c774f4-5331-4c2f-b12a-007926cb140f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4522719d-28b8-4c48-b935-9c05740fbfea" xlink:to="loc_us-gaap_StockholdersEquity_76c774f4-5331-4c2f-b12a-007926cb140f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_50045edd-9d9e-4b2f-a22e-7facc886c8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4522719d-28b8-4c48-b935-9c05740fbfea" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_50045edd-9d9e-4b2f-a22e-7facc886c8b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f8e8cf73-82d3-4467-8d33-fb53bf99decb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4522719d-28b8-4c48-b935-9c05740fbfea" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f8e8cf73-82d3-4467-8d33-fb53bf99decb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_39a34695-297f-44fa-acf6-04f629fbcc94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4522719d-28b8-4c48-b935-9c05740fbfea" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_39a34695-297f-44fa-acf6-04f629fbcc94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_ec9e898e-5b9c-4c8f-8c39-02c95076999f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4522719d-28b8-4c48-b935-9c05740fbfea" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_ec9e898e-5b9c-4c8f-8c39-02c95076999f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_41caf01a-287d-470f-b24b-c0abb602c6b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4522719d-28b8-4c48-b935-9c05740fbfea" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_41caf01a-287d-470f-b24b-c0abb602c6b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_1cfb04a1-dc54-41bb-a64e-82cf931db02b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4522719d-28b8-4c48-b935-9c05740fbfea" xlink:to="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_1cfb04a1-dc54-41bb-a64e-82cf931db02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_162112c1-f0e5-45cf-b11b-32561a77f33c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4522719d-28b8-4c48-b935-9c05740fbfea" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_162112c1-f0e5-45cf-b11b-32561a77f33c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_fe4daf12-802e-4ad2-a294-6c8c2cfe99b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4522719d-28b8-4c48-b935-9c05740fbfea" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_fe4daf12-802e-4ad2-a294-6c8c2cfe99b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1b79ab45-0f71-4c4d-ada4-c4f1d7132670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4522719d-28b8-4c48-b935-9c05740fbfea" xlink:to="loc_us-gaap_NetIncomeLoss_1b79ab45-0f71-4c4d-ada4-c4f1d7132670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_068c4da2-34b8-4b34-89bf-350d1a72724d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4522719d-28b8-4c48-b935-9c05740fbfea" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_068c4da2-34b8-4b34-89bf-350d1a72724d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_57b55eea-9134-45f4-947a-deabf8234802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4522719d-28b8-4c48-b935-9c05740fbfea" xlink:to="loc_us-gaap_StockholdersEquity_57b55eea-9134-45f4-947a-deabf8234802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="auph-20220930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_7ac9369a-bd11-4bf9-9637-f71af6cb617d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_9add30af-5b12-4a22-9f46-99feea3e9f45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7ac9369a-bd11-4bf9-9637-f71af6cb617d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_9add30af-5b12-4a22-9f46-99feea3e9f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6fe6813e-64fa-48d6-a589-a2f7be11fa61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_9add30af-5b12-4a22-9f46-99feea3e9f45" xlink:to="loc_us-gaap_NetIncomeLoss_6fe6813e-64fa-48d6-a589-a2f7be11fa61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ea94a338-2dcd-4a1e-914d-3be037a5ba9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_9add30af-5b12-4a22-9f46-99feea3e9f45" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ea94a338-2dcd-4a1e-914d-3be037a5ba9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_c1da9c2a-1642-4094-bd9c-36fdb27cae97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ea94a338-2dcd-4a1e-914d-3be037a5ba9f" xlink:to="loc_us-gaap_Depreciation_c1da9c2a-1642-4094-bd9c-36fdb27cae97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_AcquiredUpfrontLicensePayment_b03a74ab-7ab1-4c92-9330-23f57c397c06" xlink:href="auph-20220930.xsd#auph_AcquiredUpfrontLicensePayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ea94a338-2dcd-4a1e-914d-3be037a5ba9f" xlink:to="loc_auph_AcquiredUpfrontLicensePayment_b03a74ab-7ab1-4c92-9330-23f57c397c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_58def30e-c62a-47dd-9aa5-323926e15d97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ea94a338-2dcd-4a1e-914d-3be037a5ba9f" xlink:to="loc_us-gaap_ShareBasedCompensation_58def30e-c62a-47dd-9aa5-323926e15d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_383ef8e3-ef3c-47be-92c7-b32653a34272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ea94a338-2dcd-4a1e-914d-3be037a5ba9f" xlink:to="loc_us-gaap_InventoryWriteDown_383ef8e3-ef3c-47be-92c7-b32653a34272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_c93236ab-3dd6-4baf-899d-8d7f1142858e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ea94a338-2dcd-4a1e-914d-3be037a5ba9f" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_c93236ab-3dd6-4baf-899d-8d7f1142858e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_be49100f-6754-4847-96e4-6b18a2223975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ea94a338-2dcd-4a1e-914d-3be037a5ba9f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_be49100f-6754-4847-96e4-6b18a2223975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_7ae44370-cc00-407a-a0d4-4ece7544dbba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_be49100f-6754-4847-96e4-6b18a2223975" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_7ae44370-cc00-407a-a0d4-4ece7544dbba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_ec88cb06-8f94-4150-a733-ab9be56d1b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_be49100f-6754-4847-96e4-6b18a2223975" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_ec88cb06-8f94-4150-a733-ab9be56d1b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_0b530f77-1a46-4879-a881-c066e71c7e83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_be49100f-6754-4847-96e4-6b18a2223975" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_0b530f77-1a46-4879-a881-c066e71c7e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_056c1ff9-93af-43f8-b4c5-1ebf40e069b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_be49100f-6754-4847-96e4-6b18a2223975" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_056c1ff9-93af-43f8-b4c5-1ebf40e069b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2b7d1c3f-917e-4740-9ab7-92b1a41f935d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_be49100f-6754-4847-96e4-6b18a2223975" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2b7d1c3f-917e-4740-9ab7-92b1a41f935d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_030f1bc6-0be7-423d-bf81-11612072d95e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_be49100f-6754-4847-96e4-6b18a2223975" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_030f1bc6-0be7-423d-bf81-11612072d95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b103d7b-bb9c-4495-b0d7-99e6f9711cee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_9add30af-5b12-4a22-9f46-99feea3e9f45" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b103d7b-bb9c-4495-b0d7-99e6f9711cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_e0e83cd1-64ce-478c-89cb-f4b979e8ecf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7ac9369a-bd11-4bf9-9637-f71af6cb617d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_e0e83cd1-64ce-478c-89cb-f4b979e8ecf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_fcb4e23d-b599-40ae-8506-47241a6b44c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_e0e83cd1-64ce-478c-89cb-f4b979e8ecf4" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_fcb4e23d-b599-40ae-8506-47241a6b44c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_7a96623e-1667-4e9f-b5d8-46f72314d08f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_e0e83cd1-64ce-478c-89cb-f4b979e8ecf4" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_7a96623e-1667-4e9f-b5d8-46f72314d08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLeaseReceivables_e402691d-817e-40ad-9477-086f57940650" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireLeaseReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_e0e83cd1-64ce-478c-89cb-f4b979e8ecf4" xlink:to="loc_us-gaap_PaymentsToAcquireLeaseReceivables_e402691d-817e-40ad-9477-086f57940650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_dee526ea-b0a3-48a2-bc8a-9be7d319b50c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_e0e83cd1-64ce-478c-89cb-f4b979e8ecf4" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_dee526ea-b0a3-48a2-bc8a-9be7d319b50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_3ddd39bb-baaa-49cf-8514-4e046b3e13d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_e0e83cd1-64ce-478c-89cb-f4b979e8ecf4" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_3ddd39bb-baaa-49cf-8514-4e046b3e13d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForSoftware_3875e8d2-fc43-40d3-b91c-8a41132b77a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForSoftware"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_e0e83cd1-64ce-478c-89cb-f4b979e8ecf4" xlink:to="loc_us-gaap_PaymentsForSoftware_3875e8d2-fc43-40d3-b91c-8a41132b77a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f9bacae9-46e5-40cf-96cd-4aa5ddc3d9a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_e0e83cd1-64ce-478c-89cb-f4b979e8ecf4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f9bacae9-46e5-40cf-96cd-4aa5ddc3d9a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_39b115e8-42db-4c35-a484-42a5e60653a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7ac9369a-bd11-4bf9-9637-f71af6cb617d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_39b115e8-42db-4c35-a484-42a5e60653a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_ea927571-1bc6-452c-b11e-fe68ea32d249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_39b115e8-42db-4c35-a484-42a5e60653a6" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_ea927571-1bc6-452c-b11e-fe68ea32d249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_99e04b38-8616-4b12-9c8c-4e6dc785fb72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_39b115e8-42db-4c35-a484-42a5e60653a6" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_99e04b38-8616-4b12-9c8c-4e6dc785fb72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_78f27c18-5328-4dd6-8eb7-0baf43bd435d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_39b115e8-42db-4c35-a484-42a5e60653a6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_78f27c18-5328-4dd6-8eb7-0baf43bd435d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ffd3f5ce-1bae-47bf-a932-db4875f173f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7ac9369a-bd11-4bf9-9637-f71af6cb617d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ffd3f5ce-1bae-47bf-a932-db4875f173f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cdc21fbc-6639-4c00-ad53-fed940bf0db9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7ac9369a-bd11-4bf9-9637-f71af6cb617d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cdc21fbc-6639-4c00-ad53-fed940bf0db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b6bd6bda-2da7-4a53-9ace-a5855797c27a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7ac9369a-bd11-4bf9-9637-f71af6cb617d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b6bd6bda-2da7-4a53-9ace-a5855797c27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_977d7965-aa75-4911-86bd-256ba623e660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7ac9369a-bd11-4bf9-9637-f71af6cb617d" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_977d7965-aa75-4911-86bd-256ba623e660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInterestReceived_1f533dc0-be6c-4b86-9100-5a6af9400a47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromInterestReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_977d7965-aa75-4911-86bd-256ba623e660" xlink:to="loc_us-gaap_ProceedsFromInterestReceived_1f533dc0-be6c-4b86-9100-5a6af9400a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_1dc0f3ed-623b-4882-b649-7a8b713aeec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_977d7965-aa75-4911-86bd-256ba623e660" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_1dc0f3ed-623b-4882-b649-7a8b713aeec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsIncurred_581cf054-d0ef-4051-b942-4cc156242607" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLeaseObligationsIncurred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_977d7965-aa75-4911-86bd-256ba623e660" xlink:to="loc_us-gaap_CapitalLeaseObligationsIncurred_581cf054-d0ef-4051-b942-4cc156242607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_c77dcf7f-f703-4d2b-9a63-0841a0e3ca05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7ac9369a-bd11-4bf9-9637-f71af6cb617d" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_c77dcf7f-f703-4d2b-9a63-0841a0e3ca05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_226e2258-6d6e-4f2b-8946-b777eccffa11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_c77dcf7f-f703-4d2b-9a63-0841a0e3ca05" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_226e2258-6d6e-4f2b-8946-b777eccffa11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsSummationsAbstract_57afca44-e560-4f79-9c8b-b11240387f00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalCashFlowElementsSummationsAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7ac9369a-bd11-4bf9-9637-f71af6cb617d" xlink:to="loc_us-gaap_AdditionalCashFlowElementsSummationsAbstract_57afca44-e560-4f79-9c8b-b11240387f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7070b397-5d2d-4b26-a8db-e0cbbe193fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsSummationsAbstract_57afca44-e560-4f79-9c8b-b11240387f00" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7070b397-5d2d-4b26-a8db-e0cbbe193fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_468d2911-2f20-4a60-9d9f-cbbbdfd2b18b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsSummationsAbstract_57afca44-e560-4f79-9c8b-b11240387f00" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_468d2911-2f20-4a60-9d9f-cbbbdfd2b18b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_871ac668-613d-41cf-8720-869d5d8276cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsSummationsAbstract_57afca44-e560-4f79-9c8b-b11240387f00" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_871ac668-613d-41cf-8720-869d5d8276cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/OrganizationandDescriptionofBusiness" xlink:type="simple" xlink:href="auph-20220930.xsd#OrganizationandDescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/OrganizationandDescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bf8f97d6-02f3-4262-8ece-1bedb5fb1cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_beb1d13d-94e4-4386-ab0f-5956bb17c960" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bf8f97d6-02f3-4262-8ece-1bedb5fb1cd9" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_beb1d13d-94e4-4386-ab0f-5956bb17c960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="auph-20220930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8fd25279-dbad-4704-a92c-ca9b6898d73e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_bf67275a-5e9b-42ff-94f6-22085fc9742b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8fd25279-dbad-4704-a92c-ca9b6898d73e" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_bf67275a-5e9b-42ff-94f6-22085fc9742b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="auph-20220930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7f12ffe7-3c8b-4384-8a2d-184973891da7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_2187724d-36ad-4ef9-a632-62afdfdbfc14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7f12ffe7-3c8b-4384-8a2d-184973891da7" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_2187724d-36ad-4ef9-a632-62afdfdbfc14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestments" xlink:type="simple" xlink:href="auph-20220930.xsd#CashCashEquivalentsRestrictedCashandShortTermInvestments"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a9d00ced-5618-437e-980d-08fc3220e173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_8feedb8c-d1f0-4055-8900-cffbcd3f61c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a9d00ced-5618-437e-980d-08fc3220e173" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_8feedb8c-d1f0-4055-8900-cffbcd3f61c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/Inventoriesnet" xlink:type="simple" xlink:href="auph-20220930.xsd#Inventoriesnet"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/Inventoriesnet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_1e976e9b-df09-4521-afb8-a471deda72d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_75b28a5d-8f36-4609-8741-1c7d9d6da50c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1e976e9b-df09-4521-afb8-a471deda72d7" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_75b28a5d-8f36-4609-8741-1c7d9d6da50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/PrepaidExpenses" xlink:type="simple" xlink:href="auph-20220930.xsd#PrepaidExpenses"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/PrepaidExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_d67848c8-87be-489a-a14d-9052ac3117ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_PrepaidExpensesTextBlock_3723b2c1-8a7c-4336-9890-8c01e38638ad" xlink:href="auph-20220930.xsd#auph_PrepaidExpensesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_d67848c8-87be-489a-a14d-9052ac3117ab" xlink:to="loc_auph_PrepaidExpensesTextBlock_3723b2c1-8a7c-4336-9890-8c01e38638ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/IntangibleAssets" xlink:type="simple" xlink:href="auph-20220930.xsd#IntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/IntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b62e6f76-594a-446f-881d-9dc07b81f342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_a96591f0-eba6-417e-a6bf-1c16af6c4015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b62e6f76-594a-446f-881d-9dc07b81f342" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_a96591f0-eba6-417e-a6bf-1c16af6c4015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/PropertyandEquipmentnet" xlink:type="simple" xlink:href="auph-20220930.xsd#PropertyandEquipmentnet"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/PropertyandEquipmentnet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e2a41864-ed95-40fc-9e56-5e6fe3a4ed48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_94a92859-5a8f-46da-aefe-a61593a577f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e2a41864-ed95-40fc-9e56-5e6fe3a4ed48" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_94a92859-5a8f-46da-aefe-a61593a577f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/LeaseObligations" xlink:type="simple" xlink:href="auph-20220930.xsd#LeaseObligations"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/LeaseObligations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3b7f0676-56f9-47b3-83b2-6029e07796ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_af975c55-8589-4ea0-8b38-05ae68329218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3b7f0676-56f9-47b3-83b2-6029e07796ec" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_af975c55-8589-4ea0-8b38-05ae68329218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilities" xlink:type="simple" xlink:href="auph-20220930.xsd#AccountsPayableandAccruedLiabilities"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_bad8127b-5c65-4190-9d8c-ddee93341c43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_99b2baff-b943-40e8-9883-58e235d8515e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_bad8127b-5c65-4190-9d8c-ddee93341c43" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_99b2baff-b943-40e8-9883-58e235d8515e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilities" xlink:type="simple" xlink:href="auph-20220930.xsd#DeferredCompensationandOtherNoncurrentLiabilities"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_5198d966-8fa2-4757-96e8-f35961726c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock_a4e36050-9a07-47cc-84c1-45221b792bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5198d966-8fa2-4757-96e8-f35961726c8c" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock_a4e36050-9a07-47cc-84c1-45221b792bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/LicenseandCollaborationAgreement" xlink:type="simple" xlink:href="auph-20220930.xsd#LicenseandCollaborationAgreement"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/LicenseandCollaborationAgreement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e6a932a4-76aa-4769-a0e0-06cb28db965a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_d1d7feec-ae2c-4732-96e9-01d66bca6237" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e6a932a4-76aa-4769-a0e0-06cb28db965a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_d1d7feec-ae2c-4732-96e9-01d66bca6237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/NetLossperCommonShare" xlink:type="simple" xlink:href="auph-20220930.xsd#NetLossperCommonShare"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/NetLossperCommonShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f9913701-95c8-4c7b-917a-6cbe39cf1139" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_64abebe5-fbfc-477d-93f2-1c1951298578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f9913701-95c8-4c7b-917a-6cbe39cf1139" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_64abebe5-fbfc-477d-93f2-1c1951298578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/SharebasedCompensation" xlink:type="simple" xlink:href="auph-20220930.xsd#SharebasedCompensation"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/SharebasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_afed11ac-ef30-4df9-b5df-082df6467535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4dd6c5e5-ffd0-4ad8-933a-d2cf3476c68f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_afed11ac-ef30-4df9-b5df-082df6467535" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4dd6c5e5-ffd0-4ad8-933a-d2cf3476c68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="auph-20220930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0d182e84-b59f-4ed4-a60e-b1d85f89d000" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_f9187996-89cc-4c26-b082-654f32595a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0d182e84-b59f-4ed4-a60e-b1d85f89d000" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_f9187996-89cc-4c26-b082-654f32595a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="auph-20220930.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_5d76b7d9-6fd5-4448-89e7-43dbfffb86e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_883cb822-7205-42c2-872e-80b9f0a0c305" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_5d76b7d9-6fd5-4448-89e7-43dbfffb86e8" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_883cb822-7205-42c2-872e-80b9f0a0c305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/CommitmentandContingencies" xlink:type="simple" xlink:href="auph-20220930.xsd#CommitmentandContingencies"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/CommitmentandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_50b9324b-99b1-4ca1-bfec-f9b2c4a16ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5b2fc710-f9eb-448b-9650-ed1cc5dfb16f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_50b9324b-99b1-4ca1-bfec-f9b2c4a16ad6" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5b2fc710-f9eb-448b-9650-ed1cc5dfb16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/SubsequentEvents" xlink:type="simple" xlink:href="auph-20220930.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_9690a6c1-f8ff-416a-8e0b-de52a425d62b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_fdfc1221-c784-4ab6-a9bd-d8eefd213e55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_9690a6c1-f8ff-416a-8e0b-de52a425d62b" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_fdfc1221-c784-4ab6-a9bd-d8eefd213e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="auph-20220930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6bbf44f9-8e04-4979-9570-d1d0f1853636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9e55b6ab-b10c-41e5-9e0a-3372299b6786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6bbf44f9-8e04-4979-9570-d1d0f1853636" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9e55b6ab-b10c-41e5-9e0a-3372299b6786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_a85dbb31-0d57-40c6-aa79-de96d343d16e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6bbf44f9-8e04-4979-9570-d1d0f1853636" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_a85dbb31-0d57-40c6-aa79-de96d343d16e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_1d03324d-0a7e-4212-9368-db3eece9b97e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6bbf44f9-8e04-4979-9570-d1d0f1853636" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_1d03324d-0a7e-4212-9368-db3eece9b97e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_e7fc6632-29b9-4fc8-8cd8-7138cc145c94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6bbf44f9-8e04-4979-9570-d1d0f1853636" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_e7fc6632-29b9-4fc8-8cd8-7138cc145c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_fd08c172-0a5c-48dc-9057-11804343b41d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6bbf44f9-8e04-4979-9570-d1d0f1853636" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_fd08c172-0a5c-48dc-9057-11804343b41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1a1c9966-5023-4c52-9d24-e2b8b6d99617" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6bbf44f9-8e04-4979-9570-d1d0f1853636" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1a1c9966-5023-4c52-9d24-e2b8b6d99617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0d0400c9-f1d3-4c35-bf40-a41656a79d00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6bbf44f9-8e04-4979-9570-d1d0f1853636" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0d0400c9-f1d3-4c35-bf40-a41656a79d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="auph-20220930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5a18ab14-5623-4452-a6c8-55db124e7b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_538383b8-d829-4683-a115-f27fa43b0921" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5a18ab14-5623-4452-a6c8-55db124e7b1a" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_538383b8-d829-4683-a115-f27fa43b0921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsTables" xlink:type="simple" xlink:href="auph-20220930.xsd#CashCashEquivalentsRestrictedCashandShortTermInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a7890e18-8483-4f9f-b99d-b21ea923ac5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_98245d51-0e1f-4533-8d39-03084859743f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a7890e18-8483-4f9f-b99d-b21ea923ac5f" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_98245d51-0e1f-4533-8d39-03084859743f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/InventoriesnetTables" xlink:type="simple" xlink:href="auph-20220930.xsd#InventoriesnetTables"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/InventoriesnetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_0937a608-01fe-49b7-b875-25418bfe2153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_d6896fab-f446-4487-bbf2-83462b2b519a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0937a608-01fe-49b7-b875-25418bfe2153" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_d6896fab-f446-4487-bbf2-83462b2b519a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/PrepaidExpensesTables" xlink:type="simple" xlink:href="auph-20220930.xsd#PrepaidExpensesTables"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/PrepaidExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_36d042c1-abf0-47a9-9dbb-cd5258ddc8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_88630266-6136-4390-a095-68176ae45aab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_36d042c1-abf0-47a9-9dbb-cd5258ddc8b9" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_88630266-6136-4390-a095-68176ae45aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/IntangibleAssetsTables" xlink:type="simple" xlink:href="auph-20220930.xsd#IntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/IntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bd897a1f-7bbb-4584-8bff-ba1f9c43dc1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_8b71d7f9-d83f-4cd9-99f4-9cd34d68f364" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bd897a1f-7bbb-4584-8bff-ba1f9c43dc1e" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_8b71d7f9-d83f-4cd9-99f4-9cd34d68f364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/PropertyandEquipmentnetTables" xlink:type="simple" xlink:href="auph-20220930.xsd#PropertyandEquipmentnetTables"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/PropertyandEquipmentnetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_29197e8e-8de5-4c2b-aa3d-aad951207554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_bbf44c6e-6740-4455-83bc-260307e77451" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_29197e8e-8de5-4c2b-aa3d-aad951207554" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_bbf44c6e-6740-4455-83bc-260307e77451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/LeaseObligationsTables" xlink:type="simple" xlink:href="auph-20220930.xsd#LeaseObligationsTables"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/LeaseObligationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c7e01c6a-3da3-4fd2-9657-a311d7dcc537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_4a390efc-8db9-4b69-a1f5-3370e0a22d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c7e01c6a-3da3-4fd2-9657-a311d7dcc537" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_4a390efc-8db9-4b69-a1f5-3370e0a22d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_c1d9334d-c278-40b4-b2bc-92d1d58c5ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c7e01c6a-3da3-4fd2-9657-a311d7dcc537" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_c1d9334d-c278-40b4-b2bc-92d1d58c5ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesTables" xlink:type="simple" xlink:href="auph-20220930.xsd#AccountsPayableandAccruedLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_5f0ca30c-c257-4294-adf0-520e078260ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_20ed8346-2a88-46e9-8fbe-053098783a07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5f0ca30c-c257-4294-adf0-520e078260ab" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_20ed8346-2a88-46e9-8fbe-053098783a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/NetLossperCommonShareTables" xlink:type="simple" xlink:href="auph-20220930.xsd#NetLossperCommonShareTables"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/NetLossperCommonShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_50f3b4ba-b955-42bb-98c3-58a6cb85be4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_95531209-a756-480e-9baa-c1d589477291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_50f3b4ba-b955-42bb-98c3-58a6cb85be4f" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_95531209-a756-480e-9baa-c1d589477291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_28c7b696-3e4f-4605-baf7-d8260910a01e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_50f3b4ba-b955-42bb-98c3-58a6cb85be4f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_28c7b696-3e4f-4605-baf7-d8260910a01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/SharebasedCompensationTables" xlink:type="simple" xlink:href="auph-20220930.xsd#SharebasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/SharebasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0fdcec54-a8c6-47b6-97d9-5d48fae8e577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7578be43-2143-422e-bffa-ce94ef4fadf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0fdcec54-a8c6-47b6-97d9-5d48fae8e577" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7578be43-2143-422e-bffa-ce94ef4fadf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b8dbb8bf-eaf1-4acf-944a-48e604c18e19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0fdcec54-a8c6-47b6-97d9-5d48fae8e577" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b8dbb8bf-eaf1-4acf-944a-48e604c18e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_5f0f7d66-e314-4819-8d02-84b89ab1ac61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0fdcec54-a8c6-47b6-97d9-5d48fae8e577" xlink:to="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_5f0f7d66-e314-4819-8d02-84b89ab1ac61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_d2a14ecb-d280-434b-a953-4bd01688e915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0fdcec54-a8c6-47b6-97d9-5d48fae8e577" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_d2a14ecb-d280-434b-a953-4bd01688e915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a4b075be-e270-4d33-9d3c-c978ba0891dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1e596b79-7b5c-4e5a-970c-bfd04862d202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a4b075be-e270-4d33-9d3c-c978ba0891dc" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1e596b79-7b5c-4e5a-970c-bfd04862d202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_02864f94-e3f7-4893-b822-55e615218f01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1e596b79-7b5c-4e5a-970c-bfd04862d202" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_02864f94-e3f7-4893-b822-55e615218f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_b9f78e8d-f95b-4b17-a31b-71db9deec676" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_02864f94-e3f7-4893-b822-55e615218f01" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_b9f78e8d-f95b-4b17-a31b-71db9deec676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_a6575359-87fe-44a1-b5e3-6aef90bb49b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_b9f78e8d-f95b-4b17-a31b-71db9deec676" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_a6575359-87fe-44a1-b5e3-6aef90bb49b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3fa4e998-0da9-414c-8af2-18254449f829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1e596b79-7b5c-4e5a-970c-bfd04862d202" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3fa4e998-0da9-414c-8af2-18254449f829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ae84e254-3e01-470d-a18b-d16c84246af2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3fa4e998-0da9-414c-8af2-18254449f829" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ae84e254-3e01-470d-a18b-d16c84246af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_7a200275-4f52-4dea-833a-a8400a5ce5c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ae84e254-3e01-470d-a18b-d16c84246af2" xlink:to="loc_us-gaap_SalesRevenueNetMember_7a200275-4f52-4dea-833a-a8400a5ce5c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_4ae7b7f9-3771-4f38-a2f0-c259190de12b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1e596b79-7b5c-4e5a-970c-bfd04862d202" xlink:to="loc_srt_MajorCustomersAxis_4ae7b7f9-3771-4f38-a2f0-c259190de12b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_fda99c08-36ab-4f04-8b15-d3b206e69c02" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_4ae7b7f9-3771-4f38-a2f0-c259190de12b" xlink:to="loc_srt_NameOfMajorCustomerDomain_fda99c08-36ab-4f04-8b15-d3b206e69c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_SpecialtyPharmacyOneMember_f4bed16f-812a-4355-904a-b61995c7824e" xlink:href="auph-20220930.xsd#auph_SpecialtyPharmacyOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_fda99c08-36ab-4f04-8b15-d3b206e69c02" xlink:to="loc_auph_SpecialtyPharmacyOneMember_f4bed16f-812a-4355-904a-b61995c7824e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c612800f-acf7-4762-ac64-5b9e02b83f63" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1e596b79-7b5c-4e5a-970c-bfd04862d202" xlink:to="loc_srt_RangeAxis_c612800f-acf7-4762-ac64-5b9e02b83f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c31536a8-52a0-4b7a-950c-7f6597ecc2f4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c612800f-acf7-4762-ac64-5b9e02b83f63" xlink:to="loc_srt_RangeMember_c31536a8-52a0-4b7a-950c-7f6597ecc2f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_eec6ea0e-a280-464e-a5f2-44029d60484c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c31536a8-52a0-4b7a-950c-7f6597ecc2f4" xlink:to="loc_srt_MinimumMember_eec6ea0e-a280-464e-a5f2-44029d60484c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_386531a1-95a6-47c6-bac1-22a9c888ee09" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c31536a8-52a0-4b7a-950c-7f6597ecc2f4" xlink:to="loc_srt_MaximumMember_386531a1-95a6-47c6-bac1-22a9c888ee09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ad5ab528-073e-4f02-8a56-6771e574960b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1e596b79-7b5c-4e5a-970c-bfd04862d202" xlink:to="loc_srt_StatementGeographicalAxis_ad5ab528-073e-4f02-8a56-6771e574960b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7ae61164-2a33-44e6-89d8-78c3b587e617" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_ad5ab528-073e-4f02-8a56-6771e574960b" xlink:to="loc_srt_SegmentGeographicalDomain_7ae61164-2a33-44e6-89d8-78c3b587e617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_2ba2309f-b9fa-4158-8fba-95f084c9b6eb" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7ae61164-2a33-44e6-89d8-78c3b587e617" xlink:to="loc_country_US_2ba2309f-b9fa-4158-8fba-95f084c9b6eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_OutsideUnitedStatesMember_52f6d92f-fcfe-472b-a443-4053c4aa0c87" xlink:href="auph-20220930.xsd#auph_OutsideUnitedStatesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7ae61164-2a33-44e6-89d8-78c3b587e617" xlink:to="loc_auph_OutsideUnitedStatesMember_52f6d92f-fcfe-472b-a443-4053c4aa0c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1e07db2d-70fd-47be-bce2-082e68d2b2af" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1e596b79-7b5c-4e5a-970c-bfd04862d202" xlink:to="loc_srt_ProductOrServiceAxis_1e07db2d-70fd-47be-bce2-082e68d2b2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cf22ef01-9936-4145-8878-dc0eef6aa481" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1e07db2d-70fd-47be-bce2-082e68d2b2af" xlink:to="loc_srt_ProductsAndServicesDomain_cf22ef01-9936-4145-8878-dc0eef6aa481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_MilestoneAchievementMember_8ff05424-070c-4380-829b-a77b154ec473" xlink:href="auph-20220930.xsd#auph_MilestoneAchievementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cf22ef01-9936-4145-8878-dc0eef6aa481" xlink:to="loc_auph_MilestoneAchievementMember_8ff05424-070c-4380-829b-a77b154ec473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_90b4aa32-a532-4044-b6a2-427a1c6848c5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1e596b79-7b5c-4e5a-970c-bfd04862d202" xlink:to="loc_srt_CounterpartyNameAxis_90b4aa32-a532-4044-b6a2-427a1c6848c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b503fca2-09ac-441d-8327-596abd4e1073" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_90b4aa32-a532-4044-b6a2-427a1c6848c5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b503fca2-09ac-441d-8327-596abd4e1073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_OtuskaPharmaceuticalCoLtdMember_7ecd2682-5a7e-4626-9254-6742e10aaf82" xlink:href="auph-20220930.xsd#auph_OtuskaPharmaceuticalCoLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b503fca2-09ac-441d-8327-596abd4e1073" xlink:to="loc_auph_OtuskaPharmaceuticalCoLtdMember_7ecd2682-5a7e-4626-9254-6742e10aaf82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_390ed9eb-eaff-403d-9644-e35b4dac104b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1e596b79-7b5c-4e5a-970c-bfd04862d202" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_390ed9eb-eaff-403d-9644-e35b4dac104b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_e965a585-6f84-4e39-99fa-0db1d7394399" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_390ed9eb-eaff-403d-9644-e35b4dac104b" xlink:to="loc_us-gaap_NumberOfOperatingSegments_e965a585-6f84-4e39-99fa-0db1d7394399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_CashCashEquivalentsAndDebtSecuritiesCurrent_c09836c8-0b9b-4595-869f-e7062f462193" xlink:href="auph-20220930.xsd#auph_CashCashEquivalentsAndDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_390ed9eb-eaff-403d-9644-e35b4dac104b" xlink:to="loc_auph_CashCashEquivalentsAndDebtSecuritiesCurrent_c09836c8-0b9b-4595-869f-e7062f462193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_9380668b-e153-49aa-9490-948cc938244c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_390ed9eb-eaff-403d-9644-e35b4dac104b" xlink:to="loc_us-gaap_RestrictedCash_9380668b-e153-49aa-9490-948cc938244c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_d6acef76-795f-4a29-8afd-47c077e1114d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_390ed9eb-eaff-403d-9644-e35b4dac104b" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_d6acef76-795f-4a29-8afd-47c077e1114d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d0024453-0124-4b74-aef2-a9ac1d5e62d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_390ed9eb-eaff-403d-9644-e35b4dac104b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d0024453-0124-4b74-aef2-a9ac1d5e62d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_9dce3246-3e6f-4856-a1c3-ece588fe396f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_390ed9eb-eaff-403d-9644-e35b4dac104b" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_9dce3246-3e6f-4856-a1c3-ece588fe396f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_AccountsReceivableCreditTerm_d8f9d584-2db7-41fe-bed2-54eaadeb44d1" xlink:href="auph-20220930.xsd#auph_AccountsReceivableCreditTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_390ed9eb-eaff-403d-9644-e35b4dac104b" xlink:to="loc_auph_AccountsReceivableCreditTerm_d8f9d584-2db7-41fe-bed2-54eaadeb44d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_41c64b39-8876-4e44-88fa-e41fa140b25f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_390ed9eb-eaff-403d-9644-e35b4dac104b" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_41c64b39-8876-4e44-88fa-e41fa140b25f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_AcquiredUpfrontLicensePayment_880d4b68-ab8b-4aad-afe2-3ce200337610" xlink:href="auph-20220930.xsd#auph_AcquiredUpfrontLicensePayment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_390ed9eb-eaff-403d-9644-e35b4dac104b" xlink:to="loc_auph_AcquiredUpfrontLicensePayment_880d4b68-ab8b-4aad-afe2-3ce200337610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_19a285cc-57f2-47df-b2f5-5d864f06c549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_390ed9eb-eaff-403d-9644-e35b4dac104b" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_19a285cc-57f2-47df-b2f5-5d864f06c549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_44b04f7c-986b-4381-8b58-b1daf7074e24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_54e16137-407c-4e3d-bd03-19bbe631a5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_44b04f7c-986b-4381-8b58-b1daf7074e24" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_54e16137-407c-4e3d-bd03-19bbe631a5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cae3d3a5-9609-4e44-b63c-62059d6a7b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_54e16137-407c-4e3d-bd03-19bbe631a5a9" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cae3d3a5-9609-4e44-b63c-62059d6a7b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_164df746-9130-46b0-ba7f-3143138e59cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cae3d3a5-9609-4e44-b63c-62059d6a7b2f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_164df746-9130-46b0-ba7f-3143138e59cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_edff2fe0-ed96-4e42-bc48-17ab70953a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_164df746-9130-46b0-ba7f-3143138e59cd" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_edff2fe0-ed96-4e42-bc48-17ab70953a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_722ba192-0821-4194-a580-97e8c0e742c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_164df746-9130-46b0-ba7f-3143138e59cd" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_722ba192-0821-4194-a580-97e8c0e742c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_db9d24b9-3648-4d4e-af78-0a18526d9edc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_164df746-9130-46b0-ba7f-3143138e59cd" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_db9d24b9-3648-4d4e-af78-0a18526d9edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_49f10987-68a3-4156-905c-0c10d82c2b51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_54e16137-407c-4e3d-bd03-19bbe631a5a9" xlink:to="loc_us-gaap_FinancialInstrumentAxis_49f10987-68a3-4156-905c-0c10d82c2b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82f41609-afe9-47e5-8325-4a66274a2884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_49f10987-68a3-4156-905c-0c10d82c2b51" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82f41609-afe9-47e5-8325-4a66274a2884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_CashCashEquivalentsAndRestrictedCashMember_2379e385-7a57-46a2-ab2d-3e9a98c10dcf" xlink:href="auph-20220930.xsd#auph_CashCashEquivalentsAndRestrictedCashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82f41609-afe9-47e5-8325-4a66274a2884" xlink:to="loc_auph_CashCashEquivalentsAndRestrictedCashMember_2379e385-7a57-46a2-ab2d-3e9a98c10dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_USAgencySecurityMember_36d51964-37be-4b05-a601-d4030365af83" xlink:href="auph-20220930.xsd#auph_USAgencySecurityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82f41609-afe9-47e5-8325-4a66274a2884" xlink:to="loc_auph_USAgencySecurityMember_36d51964-37be-4b05-a601-d4030365af83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_0b3b3f1c-8438-4b9d-8a0c-85eaa60f3da5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82f41609-afe9-47e5-8325-4a66274a2884" xlink:to="loc_us-gaap_CertificatesOfDepositMember_0b3b3f1c-8438-4b9d-8a0c-85eaa60f3da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_b944f875-7887-44f7-b37b-e187f19ff31d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82f41609-afe9-47e5-8325-4a66274a2884" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_b944f875-7887-44f7-b37b-e187f19ff31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_4d7cf9fc-9fd7-49cd-a8b5-ee4c6c1b3910" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82f41609-afe9-47e5-8325-4a66274a2884" xlink:to="loc_us-gaap_CommercialPaperMember_4d7cf9fc-9fd7-49cd-a8b5-ee4c6c1b3910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_c16d9167-b304-4762-af73-7466a73a7a41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82f41609-afe9-47e5-8325-4a66274a2884" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_c16d9167-b304-4762-af73-7466a73a7a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBondSecuritiesMember_42763879-1d8d-4721-a864-ab9a733424ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryBondSecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82f41609-afe9-47e5-8325-4a66274a2884" xlink:to="loc_us-gaap_USTreasuryBondSecuritiesMember_42763879-1d8d-4721-a864-ab9a733424ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_YankeeBondMember_f220c02d-1c5d-4913-9db8-a1ec4957e295" xlink:href="auph-20220930.xsd#auph_YankeeBondMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82f41609-afe9-47e5-8325-4a66274a2884" xlink:to="loc_auph_YankeeBondMember_f220c02d-1c5d-4913-9db8-a1ec4957e295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e8b8160c-1dbd-49b7-b1fa-5e7e493a0c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_54e16137-407c-4e3d-bd03-19bbe631a5a9" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e8b8160c-1dbd-49b7-b1fa-5e7e493a0c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_e7698262-b7c6-4b7f-a2ea-2447c54ee1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e8b8160c-1dbd-49b7-b1fa-5e7e493a0c3d" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_e7698262-b7c6-4b7f-a2ea-2447c54ee1ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2ad0da58-d285-4527-a613-3a29f605bf0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_e7698262-b7c6-4b7f-a2ea-2447c54ee1ff" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_2ad0da58-d285-4527-a613-3a29f605bf0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAverageRemainingMaturity1_cc8b0a60-c36c-4b48-ad04-cbd263c966c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAverageRemainingMaturity1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e8b8160c-1dbd-49b7-b1fa-5e7e493a0c3d" xlink:to="loc_us-gaap_DerivativeAverageRemainingMaturity1_cc8b0a60-c36c-4b48-ad04-cbd263c966c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#CashCashEquivalentsRestrictedCashandShortTermInvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9d909e97-2960-41fa-994c-d451a86f5755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments_b850d387-8033-46d5-b1a7-b266ef92b02a" xlink:href="auph-20220930.xsd#auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9d909e97-2960-41fa-994c-d451a86f5755" xlink:to="loc_auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments_b850d387-8033-46d5-b1a7-b266ef92b02a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f0326a8b-63a9-46fb-80ab-a54914db2fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9d909e97-2960-41fa-994c-d451a86f5755" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f0326a8b-63a9-46fb-80ab-a54914db2fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent_110aaebe-be99-497c-ab46-1596e2426397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9d909e97-2960-41fa-994c-d451a86f5755" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent_110aaebe-be99-497c-ab46-1596e2426397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_4fb8481e-1221-4088-9358-21d3f13ec80e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9d909e97-2960-41fa-994c-d451a86f5755" xlink:to="loc_us-gaap_InterestReceivable_4fb8481e-1221-4088-9358-21d3f13ec80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_7890b063-7ff5-4a44-9bcf-86439e08d0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9d909e97-2960-41fa-994c-d451a86f5755" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_7890b063-7ff5-4a44-9bcf-86439e08d0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_53973cdf-b55c-4794-ae6f-4e8af437e21a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable_c65c60ce-b652-4db1-8a51-aa9f73026aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_53973cdf-b55c-4794-ae6f-4e8af437e21a" xlink:to="loc_us-gaap_MarketableSecuritiesTable_c65c60ce-b652-4db1-8a51-aa9f73026aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0cad72cf-6098-4ac4-8e67-4315f0ab2354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_c65c60ce-b652-4db1-8a51-aa9f73026aeb" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0cad72cf-6098-4ac4-8e67-4315f0ab2354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_22e859fa-f0b6-4585-af18-c80de4e9d513" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0cad72cf-6098-4ac4-8e67-4315f0ab2354" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_22e859fa-f0b6-4585-af18-c80de4e9d513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_CashCashEquivalentsAndRestrictedCashMember_7d14e646-96cc-4c8a-b513-a6e772281b19" xlink:href="auph-20220930.xsd#auph_CashCashEquivalentsAndRestrictedCashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_22e859fa-f0b6-4585-af18-c80de4e9d513" xlink:to="loc_auph_CashCashEquivalentsAndRestrictedCashMember_7d14e646-96cc-4c8a-b513-a6e772281b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_6252df43-33f1-4ea6-8a99-2a3e9c60b64c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_22e859fa-f0b6-4585-af18-c80de4e9d513" xlink:to="loc_us-gaap_CertificatesOfDepositMember_6252df43-33f1-4ea6-8a99-2a3e9c60b64c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ShortTermCorporateDebtSecuritiesMember_c57ad559-eceb-4a98-b779-8ddb36cca303" xlink:href="auph-20220930.xsd#auph_ShortTermCorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_22e859fa-f0b6-4585-af18-c80de4e9d513" xlink:to="loc_auph_ShortTermCorporateDebtSecuritiesMember_c57ad559-eceb-4a98-b779-8ddb36cca303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_8c807e6f-9381-49b9-8d38-622ac143fb6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_22e859fa-f0b6-4585-af18-c80de4e9d513" xlink:to="loc_us-gaap_CommercialPaperMember_8c807e6f-9381-49b9-8d38-622ac143fb6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_fc2e542f-d5cf-447a-963f-ebc513a68dce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_22e859fa-f0b6-4585-af18-c80de4e9d513" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_fc2e542f-d5cf-447a-963f-ebc513a68dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBondSecuritiesMember_d090df08-b82b-4542-b2f5-4100a7aaf100" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryBondSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_22e859fa-f0b6-4585-af18-c80de4e9d513" xlink:to="loc_us-gaap_USTreasuryBondSecuritiesMember_d090df08-b82b-4542-b2f5-4100a7aaf100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_YankeeBondMember_60888c53-d8de-4d4a-98db-21e5f975b2d6" xlink:href="auph-20220930.xsd#auph_YankeeBondMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_22e859fa-f0b6-4585-af18-c80de4e9d513" xlink:to="loc_auph_YankeeBondMember_60888c53-d8de-4d4a-98db-21e5f975b2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_45c55731-2447-4353-bc5e-a4e37176e5b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_c65c60ce-b652-4db1-8a51-aa9f73026aeb" xlink:to="loc_us-gaap_MarketableSecuritiesLineItems_45c55731-2447-4353-bc5e-a4e37176e5b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_309e2e1f-e6d2-49c3-b477-43bfc3e29aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_45c55731-2447-4353-bc5e-a4e37176e5b8" xlink:to="loc_us-gaap_HeldToMaturitySecurities_309e2e1f-e6d2-49c3-b477-43bfc3e29aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_590718db-f402-42e6-9927-cf764dd5e351" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_45c55731-2447-4353-bc5e-a4e37176e5b8" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_590718db-f402-42e6-9927-cf764dd5e351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_4adc92e9-cb1f-4d5a-a392-96206645f82a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_45c55731-2447-4353-bc5e-a4e37176e5b8" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_4adc92e9-cb1f-4d5a-a392-96206645f82a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_77288f13-52bd-4ddd-98f4-73cd56aa580e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_45c55731-2447-4353-bc5e-a4e37176e5b8" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_77288f13-52bd-4ddd-98f4-73cd56aa580e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent_c35b8b18-4791-415d-8d44-a255282ba8af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_45c55731-2447-4353-bc5e-a4e37176e5b8" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent_c35b8b18-4791-415d-8d44-a255282ba8af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments_d8a3a43c-862b-4479-84a9-36347b36b072" xlink:href="auph-20220930.xsd#auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_45c55731-2447-4353-bc5e-a4e37176e5b8" xlink:to="loc_auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments_d8a3a43c-862b-4479-84a9-36347b36b072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/InventoriesnetDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#InventoriesnetDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/InventoriesnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8cf4ab80-e5e4-4f6d-9b36-f9e9e3cea71b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_421b8ba5-3e5c-4a6d-8acf-7af72dad61c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8cf4ab80-e5e4-4f6d-9b36-f9e9e3cea71b" xlink:to="loc_us-gaap_InventoryFinishedGoods_421b8ba5-3e5c-4a6d-8acf-7af72dad61c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d01d6a7b-6582-4f1c-9254-cf856b7ebf2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8cf4ab80-e5e4-4f6d-9b36-f9e9e3cea71b" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d01d6a7b-6582-4f1c-9254-cf856b7ebf2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_48c9fd49-0c62-4bb5-a75e-975a2199c580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8cf4ab80-e5e4-4f6d-9b36-f9e9e3cea71b" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_48c9fd49-0c62-4bb5-a75e-975a2199c580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_16b8d201-35ff-488f-9302-a5767cae3118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8cf4ab80-e5e4-4f6d-9b36-f9e9e3cea71b" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_16b8d201-35ff-488f-9302-a5767cae3118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e2759e00-c83b-40b1-93d3-21be4a3236ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8cf4ab80-e5e4-4f6d-9b36-f9e9e3cea71b" xlink:to="loc_us-gaap_InventoryNet_e2759e00-c83b-40b1-93d3-21be4a3236ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/PrepaidExpensesDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#PrepaidExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/PrepaidExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_29e83e1b-2e26-4751-a968-6f1d56d8f494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_PrepaidAssetsCurrent_6cf6d31e-72d4-4d3e-8ef8-969c21e2604d" xlink:href="auph-20220930.xsd#auph_PrepaidAssetsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_29e83e1b-2e26-4751-a968-6f1d56d8f494" xlink:to="loc_auph_PrepaidAssetsCurrent_6cf6d31e-72d4-4d3e-8ef8-969c21e2604d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsCurrent_825bcaab-b68c-4ed5-8f5e-240e1704889c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_29e83e1b-2e26-4751-a968-6f1d56d8f494" xlink:to="loc_us-gaap_DepositsAssetsCurrent_825bcaab-b68c-4ed5-8f5e-240e1704889c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_051ba902-a313-4c72-a800-ed2c8b8cab34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_29e83e1b-2e26-4751-a968-6f1d56d8f494" xlink:to="loc_us-gaap_PrepaidInsurance_051ba902-a313-4c72-a800-ed2c8b8cab34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_b655ba85-9799-4151-91d4-5596b7772e68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_29e83e1b-2e26-4751-a968-6f1d56d8f494" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_b655ba85-9799-4151-91d4-5596b7772e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_354a1170-b288-49e9-894c-9f3f4c687976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_985fb18b-cb78-4739-9cec-0b1facdcba6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_354a1170-b288-49e9-894c-9f3f4c687976" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_985fb18b-cb78-4739-9cec-0b1facdcba6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eac598ae-2a0d-4dda-ad25-a62026453ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_985fb18b-cb78-4739-9cec-0b1facdcba6a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eac598ae-2a0d-4dda-ad25-a62026453ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7fbd94f1-cf9d-44e8-888e-9a60b1d0a709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eac598ae-2a0d-4dda-ad25-a62026453ebb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7fbd94f1-cf9d-44e8-888e-9a60b1d0a709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_9422de61-a54c-42e6-a57f-c6df1db1425d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7fbd94f1-cf9d-44e8-888e-9a60b1d0a709" xlink:to="loc_us-gaap_PatentsMember_9422de61-a54c-42e6-a57f-c6df1db1425d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntellectualPropertyMember_fc06c37d-eb01-411b-b93a-c52186c63616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntellectualPropertyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7fbd94f1-cf9d-44e8-888e-9a60b1d0a709" xlink:to="loc_us-gaap_IntellectualPropertyMember_fc06c37d-eb01-411b-b93a-c52186c63616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_7b3fa0b9-8fa4-4f42-9a47-b2153330eb62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7fbd94f1-cf9d-44e8-888e-9a60b1d0a709" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_7b3fa0b9-8fa4-4f42-9a47-b2153330eb62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4ebcfc16-2991-4d37-865f-0ec9c53b4a29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_985fb18b-cb78-4739-9cec-0b1facdcba6a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4ebcfc16-2991-4d37-865f-0ec9c53b4a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_40716b6f-cc55-4e1a-a854-659c7670de2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4ebcfc16-2991-4d37-865f-0ec9c53b4a29" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_40716b6f-cc55-4e1a-a854-659c7670de2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bb88f03a-8e17-4d67-9336-2ae55ee83131" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4ebcfc16-2991-4d37-865f-0ec9c53b4a29" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bb88f03a-8e17-4d67-9336-2ae55ee83131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ce937958-10c9-4b3b-af1b-3b570e7b5145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4ebcfc16-2991-4d37-865f-0ec9c53b4a29" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ce937958-10c9-4b3b-af1b-3b570e7b5145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/IntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#IntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/IntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_862662b0-c34e-402a-aed4-7dd66f2c8839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_c75cfac0-bf65-4a27-8c37-7d77b0c41d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_862662b0-c34e-402a-aed4-7dd66f2c8839" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_c75cfac0-bf65-4a27-8c37-7d77b0c41d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#PropertyandEquipmentnetDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_49fef564-852e-40a9-9293-d7e28a429542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_90afd21a-7a94-4acc-b530-985083933399" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_49fef564-852e-40a9-9293-d7e28a429542" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_90afd21a-7a94-4acc-b530-985083933399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6bf71091-1c09-44ef-8a75-de45385ec976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_90afd21a-7a94-4acc-b530-985083933399" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6bf71091-1c09-44ef-8a75-de45385ec976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f8464cf-4fd8-4b3a-80ba-1da5698c2bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6bf71091-1c09-44ef-8a75-de45385ec976" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f8464cf-4fd8-4b3a-80ba-1da5698c2bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_028c3cb8-1a27-437d-864f-4c0075a06265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f8464cf-4fd8-4b3a-80ba-1da5698c2bd7" xlink:to="loc_us-gaap_ConstructionInProgressMember_028c3cb8-1a27-437d-864f-4c0075a06265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_4ade8ae8-4e3c-458d-b7df-dd680f485e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f8464cf-4fd8-4b3a-80ba-1da5698c2bd7" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_4ade8ae8-4e3c-458d-b7df-dd680f485e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_991f353b-5172-4f49-9bd0-c332c83d55ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f8464cf-4fd8-4b3a-80ba-1da5698c2bd7" xlink:to="loc_us-gaap_OfficeEquipmentMember_991f353b-5172-4f49-9bd0-c332c83d55ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_dddace0b-b37c-49c8-b1b4-666cbcf2914c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f8464cf-4fd8-4b3a-80ba-1da5698c2bd7" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_dddace0b-b37c-49c8-b1b4-666cbcf2914c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_40bcd1f8-8d47-4829-affa-0b703eabd5a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f8464cf-4fd8-4b3a-80ba-1da5698c2bd7" xlink:to="loc_us-gaap_ComputerEquipmentMember_40bcd1f8-8d47-4829-affa-0b703eabd5a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2819a6d8-d782-4a62-82f4-0ba243800095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_90afd21a-7a94-4acc-b530-985083933399" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2819a6d8-d782-4a62-82f4-0ba243800095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_5bc2c6e4-fa20-4429-bead-f9b1f46a22f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2819a6d8-d782-4a62-82f4-0ba243800095" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_5bc2c6e4-fa20-4429-bead-f9b1f46a22f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0a1ada70-318b-450f-bbfd-7f4ad39020b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2819a6d8-d782-4a62-82f4-0ba243800095" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0a1ada70-318b-450f-bbfd-7f4ad39020b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7608eb10-9044-4e33-bc12-a7f3cf9f2773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2819a6d8-d782-4a62-82f4-0ba243800095" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7608eb10-9044-4e33-bc12-a7f3cf9f2773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#LeaseObligationsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4c5ae916-cdab-4853-8d9c-4c453edf582c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_cdc82de8-5b92-4414-826e-82c7c38442ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4c5ae916-cdab-4853-8d9c-4c453edf582c" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_cdc82de8-5b92-4414-826e-82c7c38442ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_bb6b0118-a653-4493-8598-7abffa94e0c6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_cdc82de8-5b92-4414-826e-82c7c38442ad" xlink:to="loc_srt_StatementGeographicalAxis_bb6b0118-a653-4493-8598-7abffa94e0c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_18552065-5880-4e9d-aa28-ae9ed8677483" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_bb6b0118-a653-4493-8598-7abffa94e0c6" xlink:to="loc_srt_SegmentGeographicalDomain_18552065-5880-4e9d-aa28-ae9ed8677483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_VictoriaBritishColumbiaMember_3e37d73d-34d0-4a88-ad98-04e21e0579ba" xlink:href="auph-20220930.xsd#auph_VictoriaBritishColumbiaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_18552065-5880-4e9d-aa28-ae9ed8677483" xlink:to="loc_auph_VictoriaBritishColumbiaMember_3e37d73d-34d0-4a88-ad98-04e21e0579ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_RockvilleMarylandMember_8eb45e8c-560e-4987-9b10-3ca2c7db00f2" xlink:href="auph-20220930.xsd#auph_RockvilleMarylandMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_18552065-5880-4e9d-aa28-ae9ed8677483" xlink:to="loc_auph_RockvilleMarylandMember_8eb45e8c-560e-4987-9b10-3ca2c7db00f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ff107ab-d6a5-45b2-b58f-22b806245596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_cdc82de8-5b92-4414-826e-82c7c38442ad" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ff107ab-d6a5-45b2-b58f-22b806245596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_1e5fab73-3a26-4a54-a3c0-564ae385a673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ff107ab-d6a5-45b2-b58f-22b806245596" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_1e5fab73-3a26-4a54-a3c0-564ae385a673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_546f88c3-226f-44c0-be2e-510613a27395" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ff107ab-d6a5-45b2-b58f-22b806245596" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_546f88c3-226f-44c0-be2e-510613a27395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_1a7278e5-747d-41b8-9694-9155a703e384" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ff107ab-d6a5-45b2-b58f-22b806245596" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_1a7278e5-747d-41b8-9694-9155a703e384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_f0eee7a0-ca07-4d74-b864-918790dfe337" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ff107ab-d6a5-45b2-b58f-22b806245596" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_f0eee7a0-ca07-4d74-b864-918790dfe337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_LesseeOperatingLeaseNumberOfExtensionOptions_3e195e80-59d1-4b38-8500-47d17b8fda1f" xlink:href="auph-20220930.xsd#auph_LesseeOperatingLeaseNumberOfExtensionOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ff107ab-d6a5-45b2-b58f-22b806245596" xlink:to="loc_auph_LesseeOperatingLeaseNumberOfExtensionOptions_3e195e80-59d1-4b38-8500-47d17b8fda1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_63a6d795-91f7-49af-807d-759861f7de17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ff107ab-d6a5-45b2-b58f-22b806245596" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_63a6d795-91f7-49af-807d-759861f7de17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_LesseeOperatingLeaseLeaseTerminationTerm_399c57f9-79e6-41a6-af8e-3b0283452c2a" xlink:href="auph-20220930.xsd#auph_LesseeOperatingLeaseLeaseTerminationTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ff107ab-d6a5-45b2-b58f-22b806245596" xlink:to="loc_auph_LesseeOperatingLeaseLeaseTerminationTerm_399c57f9-79e6-41a6-af8e-3b0283452c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_aafdcce9-8605-4f79-9381-567fff2bca33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ff107ab-d6a5-45b2-b58f-22b806245596" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_aafdcce9-8605-4f79-9381-567fff2bca33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_54e5663c-9732-4b0b-8578-a5ed4cdebb98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ff107ab-d6a5-45b2-b58f-22b806245596" xlink:to="loc_us-gaap_OperatingLeaseLiability_54e5663c-9732-4b0b-8578-a5ed4cdebb98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_047c8b85-6f80-45d7-a1cb-655ee4a50a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ff107ab-d6a5-45b2-b58f-22b806245596" xlink:to="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_047c8b85-6f80-45d7-a1cb-655ee4a50a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_021e3015-2e75-4c8a-ae36-fb1d450393e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ff107ab-d6a5-45b2-b58f-22b806245596" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_021e3015-2e75-4c8a-ae36-fb1d450393e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_bdbac142-3b43-487c-bb6f-60c91b280169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ff107ab-d6a5-45b2-b58f-22b806245596" xlink:to="loc_us-gaap_OperatingLeaseCost_bdbac142-3b43-487c-bb6f-60c91b280169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCapitalImprovements_ce6ccb2b-28df-4910-9e02-edd689de0f57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForCapitalImprovements"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ff107ab-d6a5-45b2-b58f-22b806245596" xlink:to="loc_us-gaap_PaymentsForCapitalImprovements_ce6ccb2b-28df-4910-9e02-edd689de0f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_ba4427d1-6b94-4feb-8bdc-fede06ee166e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ff107ab-d6a5-45b2-b58f-22b806245596" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_ba4427d1-6b94-4feb-8bdc-fede06ee166e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease_d53104e9-7148-47e1-a4ea-35296513c7f1" xlink:href="auph-20220930.xsd#auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ff107ab-d6a5-45b2-b58f-22b806245596" xlink:to="loc_auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease_d53104e9-7148-47e1-a4ea-35296513c7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid_9ada4fea-7b06-4f24-8f6f-347032b63c4b" xlink:href="auph-20220930.xsd#auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ff107ab-d6a5-45b2-b58f-22b806245596" xlink:to="loc_auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid_9ada4fea-7b06-4f24-8f6f-347032b63c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d6022111-fdbc-4969-bcd0-2a8ea5bf70bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_9874d89e-9002-48b1-9c8c-431a7f62c9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d6022111-fdbc-4969-bcd0-2a8ea5bf70bb" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_9874d89e-9002-48b1-9c8c-431a7f62c9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_4fe9c425-98ff-4c4b-ac79-7ed8eab5be09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d6022111-fdbc-4969-bcd0-2a8ea5bf70bb" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_4fe9c425-98ff-4c4b-ac79-7ed8eab5be09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_944a48ce-af63-4ed0-a5fc-7cda1c26bc30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8cf29a88-f56a-4133-9241-97822133c936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_944a48ce-af63-4ed0-a5fc-7cda1c26bc30" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8cf29a88-f56a-4133-9241-97822133c936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_dfed1755-0cd4-4714-b494-8be8f48d74f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_944a48ce-af63-4ed0-a5fc-7cda1c26bc30" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_dfed1755-0cd4-4714-b494-8be8f48d74f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c5e10366-4cf4-4016-ae75-7ecbe1e7eca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_944a48ce-af63-4ed0-a5fc-7cda1c26bc30" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c5e10366-4cf4-4016-ae75-7ecbe1e7eca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f5504b21-0d06-4869-ae9a-cb7701fdb2de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_944a48ce-af63-4ed0-a5fc-7cda1c26bc30" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f5504b21-0d06-4869-ae9a-cb7701fdb2de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_622ed4d1-3e91-443a-9867-a7a029d5be70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_944a48ce-af63-4ed0-a5fc-7cda1c26bc30" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_622ed4d1-3e91-443a-9867-a7a029d5be70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_7299f054-3205-4824-bd02-af8a423d8875" xlink:href="auph-20220930.xsd#auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_944a48ce-af63-4ed0-a5fc-7cda1c26bc30" xlink:to="loc_auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_7299f054-3205-4824-bd02-af8a423d8875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c89ff4ec-ebb0-4ca7-8dd9-c37c0df04376" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_944a48ce-af63-4ed0-a5fc-7cda1c26bc30" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c89ff4ec-ebb0-4ca7-8dd9-c37c0df04376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_98a9cdb2-a97b-4b93-83f0-17d1abaae4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_944a48ce-af63-4ed0-a5fc-7cda1c26bc30" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_98a9cdb2-a97b-4b93-83f0-17d1abaae4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_bc51a4b9-8850-4c06-81ff-7cbc7623d942" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_944a48ce-af63-4ed0-a5fc-7cda1c26bc30" xlink:to="loc_us-gaap_OperatingLeaseLiability_bc51a4b9-8850-4c06-81ff-7cbc7623d942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="auph-20220930.xsd#LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#AccountsPayableandAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_dbb6cdef-850d-40a0-9787-3303353fd234" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_74b9aaa6-a164-4596-8d3d-e1f4ff6e5465" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_dbb6cdef-850d-40a0-9787-3303353fd234" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_74b9aaa6-a164-4596-8d3d-e1f4ff6e5465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_CommercialRelatedAccrualsCurrent_28bf7ca7-102e-4c1a-8228-3ffaa7aac240" xlink:href="auph-20220930.xsd#auph_CommercialRelatedAccrualsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_dbb6cdef-850d-40a0-9787-3303353fd234" xlink:to="loc_auph_CommercialRelatedAccrualsCurrent_28bf7ca7-102e-4c1a-8228-3ffaa7aac240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_AccruedResearchCurrent_030ab3c7-6b20-4d5e-8087-ab82ba8ef822" xlink:href="auph-20220930.xsd#auph_AccruedResearchCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_dbb6cdef-850d-40a0-9787-3303353fd234" xlink:to="loc_auph_AccruedResearchCurrent_030ab3c7-6b20-4d5e-8087-ab82ba8ef822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_64b4d66f-fa84-4e8a-b161-c51b6eb3563f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_dbb6cdef-850d-40a0-9787-3303353fd234" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_64b4d66f-fa84-4e8a-b161-c51b6eb3563f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_3a9a5cd5-0f1f-4eab-8837-ecc9cae7870c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_dbb6cdef-850d-40a0-9787-3303353fd234" xlink:to="loc_us-gaap_TaxesPayableCurrent_3a9a5cd5-0f1f-4eab-8837-ecc9cae7870c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_be34060e-3a05-4c98-a471-6be3074a9019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_dbb6cdef-850d-40a0-9787-3303353fd234" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_be34060e-3a05-4c98-a471-6be3074a9019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilitiesDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#DeferredCompensationandOtherNoncurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_b7bb75d5-ecf1-4e9a-9afe-c1740cc50ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_da7a79dd-06d1-44ea-8741-153db8eb2597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b7bb75d5-ecf1-4e9a-9afe-c1740cc50ce1" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_da7a79dd-06d1-44ea-8741-153db8eb2597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#LicenseandCollaborationAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ea54fe8b-1230-448b-bb99-d2f8b5d8383b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_ff6e02f7-e5da-4f25-8eba-7f0f53342c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ea54fe8b-1230-448b-bb99-d2f8b5d8383b" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_ff6e02f7-e5da-4f25-8eba-7f0f53342c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_63845c31-6e07-4f56-b5f3-85361ab6a012" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_ff6e02f7-e5da-4f25-8eba-7f0f53342c2c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_63845c31-6e07-4f56-b5f3-85361ab6a012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8c47d957-a91f-4e11-9103-dedc70faa9ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_63845c31-6e07-4f56-b5f3-85361ab6a012" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8c47d957-a91f-4e11-9103-dedc70faa9ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_9a02d7ba-28c3-4814-86ed-886667781e83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8c47d957-a91f-4e11-9103-dedc70faa9ba" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_9a02d7ba-28c3-4814-86ed-886667781e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_bffb4414-e35f-4c25-b70e-60d24bd2ae06" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_ff6e02f7-e5da-4f25-8eba-7f0f53342c2c" xlink:to="loc_srt_CounterpartyNameAxis_bffb4414-e35f-4c25-b70e-60d24bd2ae06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c7f6c0a-1e55-417a-bae4-96c59cd126d7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_bffb4414-e35f-4c25-b70e-60d24bd2ae06" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c7f6c0a-1e55-417a-bae4-96c59cd126d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_OtuskaPharmaceuticalCoLtdMember_211fb543-4dec-4f78-8cdc-9de4bbe2cc4a" xlink:href="auph-20220930.xsd#auph_OtuskaPharmaceuticalCoLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c7f6c0a-1e55-417a-bae4-96c59cd126d7" xlink:to="loc_auph_OtuskaPharmaceuticalCoLtdMember_211fb543-4dec-4f78-8cdc-9de4bbe2cc4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_RiptideBioscienceIncMember_ccd2cbd3-c96d-43bc-98e8-8764b453ed2d" xlink:href="auph-20220930.xsd#auph_RiptideBioscienceIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c7f6c0a-1e55-417a-bae4-96c59cd126d7" xlink:to="loc_auph_RiptideBioscienceIncMember_ccd2cbd3-c96d-43bc-98e8-8764b453ed2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e9293ceb-e6e2-4ba4-a419-195a8d309066" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_ff6e02f7-e5da-4f25-8eba-7f0f53342c2c" xlink:to="loc_srt_RangeAxis_e9293ceb-e6e2-4ba4-a419-195a8d309066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3cba41b4-1dcf-4bb7-b3fa-d862ddcebf04" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e9293ceb-e6e2-4ba4-a419-195a8d309066" xlink:to="loc_srt_RangeMember_3cba41b4-1dcf-4bb7-b3fa-d862ddcebf04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d6584826-750f-4621-8dbd-fd550248ccc9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3cba41b4-1dcf-4bb7-b3fa-d862ddcebf04" xlink:to="loc_srt_MinimumMember_d6584826-750f-4621-8dbd-fd550248ccc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0e03dcc4-a1a4-4c15-a5c1-2529fb96b44a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3cba41b4-1dcf-4bb7-b3fa-d862ddcebf04" xlink:to="loc_srt_MaximumMember_0e03dcc4-a1a4-4c15-a5c1-2529fb96b44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_13f719ec-2730-4b03-a824-22ccf72fa944" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_ff6e02f7-e5da-4f25-8eba-7f0f53342c2c" xlink:to="loc_srt_ProductOrServiceAxis_13f719ec-2730-4b03-a824-22ccf72fa944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1c52c380-dca0-40eb-b557-483be6b659d4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_13f719ec-2730-4b03-a824-22ccf72fa944" xlink:to="loc_srt_ProductsAndServicesDomain_1c52c380-dca0-40eb-b557-483be6b659d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_09825403-7b66-4b99-9eab-952d7cab6315" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1c52c380-dca0-40eb-b557-483be6b659d4" xlink:to="loc_us-gaap_ProductMember_09825403-7b66-4b99-9eab-952d7cab6315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_e90bf5b4-a53c-41b6-8e60-9231d26e7153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1c52c380-dca0-40eb-b557-483be6b659d4" xlink:to="loc_us-gaap_ServiceMember_e90bf5b4-a53c-41b6-8e60-9231d26e7153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ab45cd25-feff-4fc7-b8aa-f8655cb7a7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_ff6e02f7-e5da-4f25-8eba-7f0f53342c2c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ab45cd25-feff-4fc7-b8aa-f8655cb7a7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_6b396efb-86d8-40d2-b86c-a484a7065869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ab45cd25-feff-4fc7-b8aa-f8655cb7a7b5" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_6b396efb-86d8-40d2-b86c-a484a7065869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount_95b769c7-ef50-4315-b1e2-7e3a1f20d6c5" xlink:href="auph-20220930.xsd#auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ab45cd25-feff-4fc7-b8aa-f8655cb7a7b5" xlink:to="loc_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount_95b769c7-ef50-4315-b1e2-7e3a1f20d6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent_e0003e90-695c-4a62-a096-95505a880e30" xlink:href="auph-20220930.xsd#auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ab45cd25-feff-4fc7-b8aa-f8655cb7a7b5" xlink:to="loc_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent_e0003e90-695c-4a62-a096-95505a880e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ResearchAndDevelopmentArrangementContractToPerformMilestonePayments_cf27fc57-743e-4459-98ec-f94f86e8a0f0" xlink:href="auph-20220930.xsd#auph_ResearchAndDevelopmentArrangementContractToPerformMilestonePayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ab45cd25-feff-4fc7-b8aa-f8655cb7a7b5" xlink:to="loc_auph_ResearchAndDevelopmentArrangementContractToPerformMilestonePayments_cf27fc57-743e-4459-98ec-f94f86e8a0f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9416f5dd-c4a5-4827-b105-a7d8406a6e74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ab45cd25-feff-4fc7-b8aa-f8655cb7a7b5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9416f5dd-c4a5-4827-b105-a7d8406a6e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_ae50bf2f-cc43-4246-96b0-6c1ede7292cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ab45cd25-feff-4fc7-b8aa-f8655cb7a7b5" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_ae50bf2f-cc43-4246-96b0-6c1ede7292cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_69373b1f-cb78-4a9f-bdd6-74516c05f0d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ab45cd25-feff-4fc7-b8aa-f8655cb7a7b5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_69373b1f-cb78-4a9f-bdd6-74516c05f0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1bc1a45b-1a7a-45d1-b1df-a71f0fcb8f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5c317077-8b8e-4454-b807-54b11d40112d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1bc1a45b-1a7a-45d1-b1df-a71f0fcb8f8c" xlink:to="loc_us-gaap_NetIncomeLoss_5c317077-8b8e-4454-b807-54b11d40112d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f80d4575-f63d-47aa-963d-1afd67421685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1bc1a45b-1a7a-45d1-b1df-a71f0fcb8f8c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f80d4575-f63d-47aa-963d-1afd67421685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fbdef442-60f9-4d80-beb5-e5c5acd941b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1bc1a45b-1a7a-45d1-b1df-a71f0fcb8f8c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fbdef442-60f9-4d80-beb5-e5c5acd941b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_02baf68a-b8df-40c4-89f6-153bb4eccf8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1bc1a45b-1a7a-45d1-b1df-a71f0fcb8f8c" xlink:to="loc_us-gaap_EarningsPerShareBasic_02baf68a-b8df-40c4-89f6-153bb4eccf8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_fbe910aa-78df-4c4e-8cd5-85d49390d6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1bc1a45b-1a7a-45d1-b1df-a71f0fcb8f8c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_fbe910aa-78df-4c4e-8cd5-85d49390d6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#NetLossperCommonShareAntiDilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_dbf4595b-3e92-40bf-beb4-b9f0bd21e87d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ee5974f1-0b63-48a5-bb53-8be754d7a236" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dbf4595b-3e92-40bf-beb4-b9f0bd21e87d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ee5974f1-0b63-48a5-bb53-8be754d7a236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_736b4420-5050-4ec0-86ba-f1c59886c117" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ee5974f1-0b63-48a5-bb53-8be754d7a236" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_736b4420-5050-4ec0-86ba-f1c59886c117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_752accdf-9b5d-46ef-851d-ef49d6102343" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_736b4420-5050-4ec0-86ba-f1c59886c117" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_752accdf-9b5d-46ef-851d-ef49d6102343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d1cf3257-d8c6-4bf6-87ad-b66fb9b756a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_752accdf-9b5d-46ef-851d-ef49d6102343" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d1cf3257-d8c6-4bf6-87ad-b66fb9b756a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_604c3020-df61-4b57-9fc7-96a7c04605ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_752accdf-9b5d-46ef-851d-ef49d6102343" xlink:to="loc_us-gaap_PerformanceSharesMember_604c3020-df61-4b57-9fc7-96a7c04605ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1d7159cc-8202-42cf-9fc6-944e55aca3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_752accdf-9b5d-46ef-851d-ef49d6102343" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1d7159cc-8202-42cf-9fc6-944e55aca3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_3891de19-6ae9-4bbf-98d3-0c9ee6daed6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_752accdf-9b5d-46ef-851d-ef49d6102343" xlink:to="loc_us-gaap_WarrantMember_3891de19-6ae9-4bbf-98d3-0c9ee6daed6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4ff89b45-9a6c-466f-a84a-54c7e8b297cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ee5974f1-0b63-48a5-bb53-8be754d7a236" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4ff89b45-9a6c-466f-a84a-54c7e8b297cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ac8180ce-8a4c-4493-b441-38d4a0972f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4ff89b45-9a6c-466f-a84a-54c7e8b297cf" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ac8180ce-8a4c-4493-b441-38d4a0972f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#SharebasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ae957521-14c6-4a19-b247-d8b2b5653fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17cfa0f3-7c94-481e-9dac-a790c06b1376" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ae957521-14c6-4a19-b247-d8b2b5653fbf" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17cfa0f3-7c94-481e-9dac-a790c06b1376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_898fc9ab-0a57-4e52-abfb-b6ef2e6bf324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17cfa0f3-7c94-481e-9dac-a790c06b1376" xlink:to="loc_us-gaap_PlanNameAxis_898fc9ab-0a57-4e52-abfb-b6ef2e6bf324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d23cb24b-18e2-4055-a67d-d1b83305134a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_898fc9ab-0a57-4e52-abfb-b6ef2e6bf324" xlink:to="loc_us-gaap_PlanNameDomain_d23cb24b-18e2-4055-a67d-d1b83305134a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_AmendedAndRestatedEquityIncentivePlanMember_014f3825-0ffd-4276-94de-f7b721df69da" xlink:href="auph-20220930.xsd#auph_AmendedAndRestatedEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d23cb24b-18e2-4055-a67d-d1b83305134a" xlink:to="loc_auph_AmendedAndRestatedEquityIncentivePlanMember_014f3825-0ffd-4276-94de-f7b721df69da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c91f8968-78d7-41b6-9625-c2f5d44e0034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17cfa0f3-7c94-481e-9dac-a790c06b1376" xlink:to="loc_us-gaap_AwardTypeAxis_c91f8968-78d7-41b6-9625-c2f5d44e0034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_162430f6-c168-46be-aacc-36a9d9979d66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c91f8968-78d7-41b6-9625-c2f5d44e0034" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_162430f6-c168-46be-aacc-36a9d9979d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_ecdedfca-06a2-4fc0-965e-d5e5600ccc02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_162430f6-c168-46be-aacc-36a9d9979d66" xlink:to="loc_us-gaap_EmployeeStockMember_ecdedfca-06a2-4fc0-965e-d5e5600ccc02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_2528057d-b5ae-44a2-af75-aef1d1ba90ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_162430f6-c168-46be-aacc-36a9d9979d66" xlink:to="loc_us-gaap_PerformanceSharesMember_2528057d-b5ae-44a2-af75-aef1d1ba90ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_PerformanceShareSandRestrictedStockUnitsRSUsMember_1c55613c-b129-4c54-8351-abdb134b827d" xlink:href="auph-20220930.xsd#auph_PerformanceShareSandRestrictedStockUnitsRSUsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_162430f6-c168-46be-aacc-36a9d9979d66" xlink:to="loc_auph_PerformanceShareSandRestrictedStockUnitsRSUsMember_1c55613c-b129-4c54-8351-abdb134b827d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d048bc3b-cfeb-4374-9357-07dd18cd167e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_162430f6-c168-46be-aacc-36a9d9979d66" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d048bc3b-cfeb-4374-9357-07dd18cd167e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_3025acf7-ba54-4390-9310-ef2f1d4fd6d0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17cfa0f3-7c94-481e-9dac-a790c06b1376" xlink:to="loc_srt_TitleOfIndividualAxis_3025acf7-ba54-4390-9310-ef2f1d4fd6d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_99ebf775-5404-488f-99b5-0ca5d40d25a8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_3025acf7-ba54-4390-9310-ef2f1d4fd6d0" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_99ebf775-5404-488f-99b5-0ca5d40d25a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficerMember_084c8cce-c99b-4003-92b8-7731117241ec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_99ebf775-5404-488f-99b5-0ca5d40d25a8" xlink:to="loc_srt_OfficerMember_084c8cce-c99b-4003-92b8-7731117241ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_af9208d8-019b-4258-a1c5-f4fbea364127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17cfa0f3-7c94-481e-9dac-a790c06b1376" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_af9208d8-019b-4258-a1c5-f4fbea364127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63339b48-993d-4e8c-8313-829f9fddc8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_af9208d8-019b-4258-a1c5-f4fbea364127" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63339b48-993d-4e8c-8313-829f9fddc8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_69eea806-0989-493f-9823-48d536f4289e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63339b48-993d-4e8c-8313-829f9fddc8fe" xlink:to="loc_us-gaap_EmployeeStockMember_69eea806-0989-493f-9823-48d536f4289e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_210381bc-1e45-48ed-88bf-c8015ef37d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17cfa0f3-7c94-481e-9dac-a790c06b1376" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_210381bc-1e45-48ed-88bf-c8015ef37d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_79856e54-c213-4928-af33-aa85b089ac64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_210381bc-1e45-48ed-88bf-c8015ef37d8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_79856e54-c213-4928-af33-aa85b089ac64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_91c65629-3143-4607-9e24-b45292cd7c12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_210381bc-1e45-48ed-88bf-c8015ef37d8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_91c65629-3143-4607-9e24-b45292cd7c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_8bf97207-86cb-4c87-b6e7-2fd1bd7a4058" xlink:href="auph-20220930.xsd#auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_210381bc-1e45-48ed-88bf-c8015ef37d8f" xlink:to="loc_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_8bf97207-86cb-4c87-b6e7-2fd1bd7a4058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_074b812d-cc2c-4bd2-b41a-9314e6f853c3" xlink:href="auph-20220930.xsd#auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_210381bc-1e45-48ed-88bf-c8015ef37d8f" xlink:to="loc_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_074b812d-cc2c-4bd2-b41a-9314e6f853c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod_86b3f0da-0b1c-43cf-a212-8347efc304ee" xlink:href="auph-20220930.xsd#auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_210381bc-1e45-48ed-88bf-c8015ef37d8f" xlink:to="loc_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod_86b3f0da-0b1c-43cf-a212-8347efc304ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4c083d4e-a07e-4290-8566-4ecf821ace2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_210381bc-1e45-48ed-88bf-c8015ef37d8f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4c083d4e-a07e-4290-8566-4ecf821ace2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ShareBasedPaymentArrangementUnamortizedExpense_c3766796-8a35-4b6b-8ea6-bd0bef155f96" xlink:href="auph-20220930.xsd#auph_ShareBasedPaymentArrangementUnamortizedExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_210381bc-1e45-48ed-88bf-c8015ef37d8f" xlink:to="loc_auph_ShareBasedPaymentArrangementUnamortizedExpense_c3766796-8a35-4b6b-8ea6-bd0bef155f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_fae8b579-fb8c-4372-a3d0-727726f8687f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_210381bc-1e45-48ed-88bf-c8015ef37d8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_fae8b579-fb8c-4372-a3d0-727726f8687f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a7511f42-16cc-4b1c-9ff9-f763baf80812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_210381bc-1e45-48ed-88bf-c8015ef37d8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a7511f42-16cc-4b1c-9ff9-f763baf80812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e61395d3-4599-47d4-a3c2-5380b3da174f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_210381bc-1e45-48ed-88bf-c8015ef37d8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e61395d3-4599-47d4-a3c2-5380b3da174f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_295f0fdc-f70b-4d50-8b44-e09dabbb943f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_210381bc-1e45-48ed-88bf-c8015ef37d8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_295f0fdc-f70b-4d50-8b44-e09dabbb943f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ac44a4c2-4036-4496-ba88-4ca54b302665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_210381bc-1e45-48ed-88bf-c8015ef37d8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ac44a4c2-4036-4496-ba88-4ca54b302665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_25ba2474-b471-446c-b7de-c2d844c12c91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_210381bc-1e45-48ed-88bf-c8015ef37d8f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_25ba2474-b471-446c-b7de-c2d844c12c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0213f65c-9799-46ae-b1c1-16462948ef2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_210381bc-1e45-48ed-88bf-c8015ef37d8f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0213f65c-9799-46ae-b1c1-16462948ef2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#ShareBasedCompensationWeightedAverageAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8e789c1f-f339-4ec1-943f-90194e9e49ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_ae408952-e08b-49b0-a15e-849f4c5f59ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8e789c1f-f339-4ec1-943f-90194e9e49ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_ae408952-e08b-49b0-a15e-849f4c5f59ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_995c83a3-d75b-4c0d-b131-23c14e0112d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8e789c1f-f339-4ec1-943f-90194e9e49ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_995c83a3-d75b-4c0d-b131-23c14e0112d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5d1168d6-0326-471e-afc7-27156a9e5a85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8e789c1f-f339-4ec1-943f-90194e9e49ee" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5d1168d6-0326-471e-afc7-27156a9e5a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_ea67d5be-eaa7-4e9d-8328-a5cfc4d4c91c" xlink:href="auph-20220930.xsd#auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8e789c1f-f339-4ec1-943f-90194e9e49ee" xlink:to="loc_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_ea67d5be-eaa7-4e9d-8328-a5cfc4d4c91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_14d2bd22-668b-4333-9f8b-926723f09f51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8e789c1f-f339-4ec1-943f-90194e9e49ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_14d2bd22-668b-4333-9f8b-926723f09f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d36d5076-b649-41d3-b6f0-2f63818aee95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8e789c1f-f339-4ec1-943f-90194e9e49ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d36d5076-b649-41d3-b6f0-2f63818aee95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#ShareBasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e52231f9-3ce5-47fc-9e1f-7d8d67808dae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c9366189-49f3-49e6-9258-21c560ee6a82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e52231f9-3ce5-47fc-9e1f-7d8d67808dae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c9366189-49f3-49e6-9258-21c560ee6a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f9220e4f-5e12-4582-b01b-d2d92b0d1524" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c9366189-49f3-49e6-9258-21c560ee6a82" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f9220e4f-5e12-4582-b01b-d2d92b0d1524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_04409893-b99b-4951-95de-5f4c4f9ea072" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c9366189-49f3-49e6-9258-21c560ee6a82" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_04409893-b99b-4951-95de-5f4c4f9ea072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_df4df216-dc70-4ca2-9c5c-ec9f4b767303" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c9366189-49f3-49e6-9258-21c560ee6a82" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_df4df216-dc70-4ca2-9c5c-ec9f4b767303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_9eea2829-2602-40a0-87f1-d52a44f21368" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c9366189-49f3-49e6-9258-21c560ee6a82" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_9eea2829-2602-40a0-87f1-d52a44f21368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_237f59ce-3a3c-4435-bde0-9c16c186bc47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c9366189-49f3-49e6-9258-21c560ee6a82" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_237f59ce-3a3c-4435-bde0-9c16c186bc47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_68943124-9cb3-47d4-9844-d443b7c2cd07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e52231f9-3ce5-47fc-9e1f-7d8d67808dae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_68943124-9cb3-47d4-9844-d443b7c2cd07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5a0a66b8-686a-43d2-ac56-efa23a98d51f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_68943124-9cb3-47d4-9844-d443b7c2cd07" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5a0a66b8-686a-43d2-ac56-efa23a98d51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_49254e5f-5b6d-4090-a0a5-8238f6fe3d40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_68943124-9cb3-47d4-9844-d443b7c2cd07" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_49254e5f-5b6d-4090-a0a5-8238f6fe3d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5e71b14d-1e48-45dd-9384-115cde4843b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_68943124-9cb3-47d4-9844-d443b7c2cd07" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5e71b14d-1e48-45dd-9384-115cde4843b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_797499a4-63e5-400d-a392-7c2c217e717c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_68943124-9cb3-47d4-9844-d443b7c2cd07" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_797499a4-63e5-400d-a392-7c2c217e717c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5b535832-2c03-4392-803c-d29c72dcc85e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_68943124-9cb3-47d4-9844-d443b7c2cd07" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5b535832-2c03-4392-803c-d29c72dcc85e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_48606be8-0eef-4491-96a4-beac2a9fd33f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e2adbf68-0eb9-4db8-8a35-b3fcd16f39ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_48606be8-0eef-4491-96a4-beac2a9fd33f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e2adbf68-0eb9-4db8-8a35-b3fcd16f39ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8f9c844e-d846-4782-b31f-f15022e78f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e2adbf68-0eb9-4db8-8a35-b3fcd16f39ae" xlink:to="loc_us-gaap_AwardTypeAxis_8f9c844e-d846-4782-b31f-f15022e78f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56c4e608-9191-4834-8d17-ea9ad2381fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8f9c844e-d846-4782-b31f-f15022e78f4f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56c4e608-9191-4834-8d17-ea9ad2381fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_PerformanceShareSandRestrictedStockUnitsRSUsMember_8fc5e396-6542-4662-8e27-92e7b99044c5" xlink:href="auph-20220930.xsd#auph_PerformanceShareSandRestrictedStockUnitsRSUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56c4e608-9191-4834-8d17-ea9ad2381fd4" xlink:to="loc_auph_PerformanceShareSandRestrictedStockUnitsRSUsMember_8fc5e396-6542-4662-8e27-92e7b99044c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_b1d50b64-a791-4ef9-9e60-82febd619543" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e2adbf68-0eb9-4db8-8a35-b3fcd16f39ae" xlink:to="loc_srt_TitleOfIndividualAxis_b1d50b64-a791-4ef9-9e60-82febd619543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_302d8f2c-0b1b-421f-9e34-f21dcb7704e4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_b1d50b64-a791-4ef9-9e60-82febd619543" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_302d8f2c-0b1b-421f-9e34-f21dcb7704e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficerMember_e1345ca0-86d7-47a2-b68e-9910a739abb4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_302d8f2c-0b1b-421f-9e34-f21dcb7704e4" xlink:to="loc_srt_OfficerMember_e1345ca0-86d7-47a2-b68e-9910a739abb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf12a7f5-9948-46fa-b373-c6b26447d915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e2adbf68-0eb9-4db8-8a35-b3fcd16f39ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf12a7f5-9948-46fa-b373-c6b26447d915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_6ce5015c-d01f-4101-9b56-3af1fe8385d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf12a7f5-9948-46fa-b373-c6b26447d915" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_6ce5015c-d01f-4101-9b56-3af1fe8385d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5672969a-bfdc-4fea-88d1-ef83ed2b6bda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_6ce5015c-d01f-4101-9b56-3af1fe8385d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5672969a-bfdc-4fea-88d1-ef83ed2b6bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b123a1f3-7faf-44b3-aa68-afa2adb5acce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_6ce5015c-d01f-4101-9b56-3af1fe8385d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b123a1f3-7faf-44b3-aa68-afa2adb5acce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2c7adc74-6c73-48c2-8774-c5a85b3462a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_6ce5015c-d01f-4101-9b56-3af1fe8385d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2c7adc74-6c73-48c2-8774-c5a85b3462a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_84a47f36-6cb5-41d6-be03-c0d460f3987c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_6ce5015c-d01f-4101-9b56-3af1fe8385d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_84a47f36-6cb5-41d6-be03-c0d460f3987c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c1e9b119-363e-4b82-ade5-4d77fcb850ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_6ce5015c-d01f-4101-9b56-3af1fe8385d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c1e9b119-363e-4b82-ade5-4d77fcb850ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b134edce-1f5c-4362-83d5-33e2ec4be27f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf12a7f5-9948-46fa-b373-c6b26447d915" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b134edce-1f5c-4362-83d5-33e2ec4be27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6a8ead5b-6448-48a8-8a36-a41f39c8337e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b134edce-1f5c-4362-83d5-33e2ec4be27f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6a8ead5b-6448-48a8-8a36-a41f39c8337e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0b1cdd2-11b1-4e17-ae1f-238725347541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b134edce-1f5c-4362-83d5-33e2ec4be27f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0b1cdd2-11b1-4e17-ae1f-238725347541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_fa2a255e-3d15-43de-8761-1396ccbfbb71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b134edce-1f5c-4362-83d5-33e2ec4be27f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_fa2a255e-3d15-43de-8761-1396ccbfbb71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fec1fc9b-4396-4860-827f-e27792b10443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b134edce-1f5c-4362-83d5-33e2ec4be27f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fec1fc9b-4396-4860-827f-e27792b10443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cda9b518-89fe-4d83-aeb7-fd66966f1818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b134edce-1f5c-4362-83d5-33e2ec4be27f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cda9b518-89fe-4d83-aeb7-fd66966f1818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_51dadcfc-8825-447b-bdd4-6d34b454daaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a91a964-455a-44c2-858e-17e0c09300bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_51dadcfc-8825-447b-bdd4-6d34b454daaa" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a91a964-455a-44c2-858e-17e0c09300bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d54668a5-ba13-43c1-ad6c-e33b4a5a5546" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a91a964-455a-44c2-858e-17e0c09300bb" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d54668a5-ba13-43c1-ad6c-e33b4a5a5546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8cf5112c-4bb8-4a17-a00d-633f06e5827b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d54668a5-ba13-43c1-ad6c-e33b4a5a5546" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8cf5112c-4bb8-4a17-a00d-633f06e5827b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9710b071-c50e-4327-b108-b11f2d0f467c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8cf5112c-4bb8-4a17-a00d-633f06e5827b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9710b071-c50e-4327-b108-b11f2d0f467c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_841f423e-0eab-49bd-98e2-2666ab2bf5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8cf5112c-4bb8-4a17-a00d-633f06e5827b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_841f423e-0eab-49bd-98e2-2666ab2bf5b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_6bd9c3ee-3a95-4e65-839b-27963c18c919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoriesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8cf5112c-4bb8-4a17-a00d-633f06e5827b" xlink:to="loc_us-gaap_InventoriesMember_6bd9c3ee-3a95-4e65-839b-27963c18c919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_545c9588-a845-44ec-8315-6f49bf9fee94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a91a964-455a-44c2-858e-17e0c09300bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_545c9588-a845-44ec-8315-6f49bf9fee94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5b728db2-ea2d-41c9-8611-795256963849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_545c9588-a845-44ec-8315-6f49bf9fee94" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5b728db2-ea2d-41c9-8611-795256963849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4e2345e7-f322-4a2f-b75d-6410e22802ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_239645eb-66b9-4040-8863-d7d3128b4662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4e2345e7-f322-4a2f-b75d-6410e22802ab" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_239645eb-66b9-4040-8863-d7d3128b4662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_5ea5d0e7-bffc-4f67-9295-0781f4ebdc3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4694ece6-9058-46ee-8682-8470082c23f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_5ea5d0e7-bffc-4f67-9295-0781f4ebdc3e" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4694ece6-9058-46ee-8682-8470082c23f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_c4126f28-b9a6-4352-8167-432eb1dcf468" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4694ece6-9058-46ee-8682-8470082c23f3" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_c4126f28-b9a6-4352-8167-432eb1dcf468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_6a4bd4b5-5583-4eeb-9fc9-489cd9bc275d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_c4126f28-b9a6-4352-8167-432eb1dcf468" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_6a4bd4b5-5583-4eeb-9fc9-489cd9bc275d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_MilestonePaymentMember_1a195e6c-ba25-40f5-b750-3c2ae1ed7116" xlink:href="auph-20220930.xsd#auph_MilestonePaymentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_6a4bd4b5-5583-4eeb-9fc9-489cd9bc275d" xlink:to="loc_auph_MilestonePaymentMember_1a195e6c-ba25-40f5-b750-3c2ae1ed7116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_69ebbadb-7aba-4f14-aca2-7b416ec44758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4694ece6-9058-46ee-8682-8470082c23f3" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_69ebbadb-7aba-4f14-aca2-7b416ec44758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_63a942c1-f931-4637-aa5e-2b246be7eb13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_69ebbadb-7aba-4f14-aca2-7b416ec44758" xlink:to="loc_us-gaap_RelatedPartyDomain_63a942c1-f931-4637-aa5e-2b246be7eb13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_cba11231-6846-4571-b2cc-e9c03f1ca346" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_63a942c1-f931-4637-aa5e-2b246be7eb13" xlink:to="loc_srt_AffiliatedEntityMember_cba11231-6846-4571-b2cc-e9c03f1ca346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_2dad3a02-ad4d-4c92-83bd-6e95878f8061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4694ece6-9058-46ee-8682-8470082c23f3" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_2dad3a02-ad4d-4c92-83bd-6e95878f8061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f989a0ac-ec6d-4a4c-8ce4-0837a3cea50a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2dad3a02-ad4d-4c92-83bd-6e95878f8061" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f989a0ac-ec6d-4a4c-8ce4-0837a3cea50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_cc749583-68e4-4028-913a-e22df04cbbbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f989a0ac-ec6d-4a4c-8ce4-0837a3cea50a" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_cc749583-68e4-4028-913a-e22df04cbbbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_54a44b12-3e17-4da1-bd71-01664886ea64" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4694ece6-9058-46ee-8682-8470082c23f3" xlink:to="loc_srt_CounterpartyNameAxis_54a44b12-3e17-4da1-bd71-01664886ea64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c34f27fa-5f0c-49ee-b573-b695f9c0f5e3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_54a44b12-3e17-4da1-bd71-01664886ea64" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c34f27fa-5f0c-49ee-b573-b695f9c0f5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ILJINMember_97546d40-da65-484d-8d08-d0672d5516c8" xlink:href="auph-20220930.xsd#auph_ILJINMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c34f27fa-5f0c-49ee-b573-b695f9c0f5e3" xlink:to="loc_auph_ILJINMember_97546d40-da65-484d-8d08-d0672d5516c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_3111eaf7-1fd2-4326-87e7-22cf14a97774" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4694ece6-9058-46ee-8682-8470082c23f3" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_3111eaf7-1fd2-4326-87e7-22cf14a97774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_e5a61dd5-b23d-4df1-ad82-c55953ea4db4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_3111eaf7-1fd2-4326-87e7-22cf14a97774" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_e5a61dd5-b23d-4df1-ad82-c55953ea4db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_0680f1ac-c26b-46e0-afc4-c9736ea19fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_3111eaf7-1fd2-4326-87e7-22cf14a97774" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_0680f1ac-c26b-46e0-afc4-c9736ea19fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="auph-20220930.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_fe1c8035-1d10-45d9-a60e-5aef33caed26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_93192e79-6148-4e93-b3cc-816b80a10baf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_fe1c8035-1d10-45d9-a60e-5aef33caed26" xlink:to="loc_us-gaap_SubsequentEventTable_93192e79-6148-4e93-b3cc-816b80a10baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_9f033c81-e84b-415c-a0fb-baf8643f0523" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_93192e79-6148-4e93-b3cc-816b80a10baf" xlink:to="loc_srt_TitleOfIndividualAxis_9f033c81-e84b-415c-a0fb-baf8643f0523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_93f88697-f5f6-4cb1-b2c5-272a323f7235" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_9f033c81-e84b-415c-a0fb-baf8643f0523" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_93f88697-f5f6-4cb1-b2c5-272a323f7235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_NewEmployeesMember_98a52a33-d578-4ded-ba43-2298c29830cb" xlink:href="auph-20220930.xsd#auph_NewEmployeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_93f88697-f5f6-4cb1-b2c5-272a323f7235" xlink:to="loc_auph_NewEmployeesMember_98a52a33-d578-4ded-ba43-2298c29830cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_37ea861b-6862-46ff-8667-6d28352e3784" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_93192e79-6148-4e93-b3cc-816b80a10baf" xlink:to="loc_us-gaap_AwardTypeAxis_37ea861b-6862-46ff-8667-6d28352e3784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89b93056-380d-4380-bb29-977e11a423a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_37ea861b-6862-46ff-8667-6d28352e3784" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89b93056-380d-4380-bb29-977e11a423a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ShareBasedPaymentArrangementInducementOptionMember_6c8ae793-7164-476c-bbd8-3f73838f13d3" xlink:href="auph-20220930.xsd#auph_ShareBasedPaymentArrangementInducementOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89b93056-380d-4380-bb29-977e11a423a8" xlink:to="loc_auph_ShareBasedPaymentArrangementInducementOptionMember_6c8ae793-7164-476c-bbd8-3f73838f13d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c7f816a9-3563-4407-9ca1-f405431ff2e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89b93056-380d-4380-bb29-977e11a423a8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c7f816a9-3563-4407-9ca1-f405431ff2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_93ad8da6-25bd-4a40-bc60-00abfa027261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_93192e79-6148-4e93-b3cc-816b80a10baf" xlink:to="loc_us-gaap_SubsequentEventLineItems_93ad8da6-25bd-4a40-bc60-00abfa027261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNewEmployees_575e4fab-7dcb-4f0d-9ae7-522468d70dad" xlink:href="auph-20220930.xsd#auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNewEmployees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_93ad8da6-25bd-4a40-bc60-00abfa027261" xlink:to="loc_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNewEmployees_575e4fab-7dcb-4f0d-9ae7-522468d70dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f4a75f40-7ebf-4151-aced-d59aa75b052f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_93ad8da6-25bd-4a40-bc60-00abfa027261" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f4a75f40-7ebf-4151-aced-d59aa75b052f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_74f29c41-4f3f-4f30-a3fd-4ed3a682698e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_93ad8da6-25bd-4a40-bc60-00abfa027261" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_74f29c41-4f3f-4f30-a3fd-4ed3a682698e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
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M?@,SV-9PJ>5RK=@<B7X(&VC2SV!CYISL'"C>R:F%?\>/'=?6)G<<NH&C2//
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MU]?7PP8\F:II'CCVI-PA)I^J:B46E6VQ[M)2T^!-%.FJ;9LYT?%;:;VU5EO
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MB"><J7&@>5.VWVAVH%:*>B]VQ(NT=SAENN3KUZ^6;-Q%=_9,(O83\RPO#TW
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M)A]MY>MUL"T0O"\(W0RVJ5G%%_TU(K:WMT^>,!'=2*6/]:/T1S/$J[+0>9+
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KPV%@Z %Z1O.-#2U57]2?I<# P* V_P]-D\;C_VZ#B     !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_01.jpg
<TEXT>
begin 644 image_01.jpg
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M?@,SV-9PJ>5RK=@<B7X(&VC2SV!CYISL'"C>R:F%?\>/'=?6)G<<NH&C2//
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MU]?7PP8\F:II'CCVI-PA)I^J:B46E6VQ[M)2T^!-%.FJ;9LYT?%;:;VU5EO
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MB"><J7&@>5.VWVAVH%:*>B]VQ(NT=SAENN3KUZ^6;-Q%=_9,(O83\RPO#TW
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M)A]MY>MUL"T0O"\(W0RVJ5G%%_TU(K:WMT^>,!'=2*6/]:/T1S/$J[+0>9+
M!_*(/;MWDRN0:$U.HQ]'\RN6+L-.JJ,WS1/<O'YCVN0I-.\7<0HP2W-V>&@H
MC_2.>I<U>%E^0]0\D%E8S1D>+K.7'NKSB\3SY[=PHN\>T_*"@4JIKZN#.A6Z
MUG36J-,NU+7W%'3:26AI:;EX_L*B^0N&#!@(NYM0HT2Q010#E?R<[!RT.U/.
MHS3H5/-=XOMUX]KU-7_]9<$R5W"_P/KU-8(:061X./75'3]&.0]T='4M=CEK
MS@ZD:AYLI?E^+_-PGY&Q#=6JO9A=<_@\'E1NX:DB6;Z"]Y;I"'@:GL.9G^5+
MD@&IJJFA^RK.#Q\^7+U\.6CO7@\WMR4+%\V=-7O.S%D@:9_MVY,2SWZ0\XIH
M^!Q^+.F,^7Q2>8*HK*@@.\.V)F/(X:>AHRD(K/A\/I$\B;.\7Z02*J6AK+04
M.3<TJ+] (US,>W?N1D=&>7EZ0K1%W*\%<^=!U@RQV-DSB2]?O*!VP1"4EDBE
M)#\_7XW%U_6A>>!JRBNV!0[O):^U\.9$7PI*P_LP,##H #UIOKZ^><RX<'-.
M -*\G6A 3MA6F^BJ$GV7K@P,OR9ZTCS@N^<ZVR*(K'FHS(]E!T(A?\I;R\N&
M,3 PR$-_FL_+^\BVD*K2B]]C$^1M$?D^[Q/V9F!@T WZT[Q (%SB?-R<\WU,
M'I3SRSGA<:O.=PIU/LJ5@8&!0'^:!RY>>D9NR>.P_=W8X2_N%6,_!@8&G:%7
MS3<VMDR<%$6TY(E6Q>+L"YISJJ--G7>8,S PJ(=>-0\<.IQ.M.2)*O,6H4^2
M-5K7C8&!057TK?GJ&MZH,6$L*.HY >X3XUH;98\]8&!@T!'ZUCP0'7/?W"+(
MUB+X:EPF_HZ!@4''](#FJVN:1HP.G6@?4E\A8\T !@8&G=(#F@=BXQX$_<.,
KPV%@Z %Z1O.-#2U57]2?I<# P* V_P]-D\;C_VZ#B     !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648618246464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COVER - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Nov. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Aurinia Pharmaceuticals Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">Z4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">#1203-4464 Markham Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1231763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Victoria<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">BC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">V8Z 7X8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">744-2487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,109,703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common shares, no par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AUPH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001600620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648617562848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 86,052<span></span>
</td>
<td class="nump">$ 231,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">290,592<span></span>
</td>
<td class="nump">234,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">41,771<span></span>
</td>
<td class="nump">15,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">25,320<span></span>
</td>
<td class="nump">19,326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">12,159<span></span>
</td>
<td class="nump">11,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">3,808<span></span>
</td>
<td class="nump">796<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">459,702<span></span>
</td>
<td class="nump">513,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">13,049<span></span>
</td>
<td class="nump">11,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,758<span></span>
</td>
<td class="nump">4,418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Acquired intellectual property and other intangible assets, net</a></td>
<td class="nump">6,839<span></span>
</td>
<td class="nump">8,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, net</a></td>
<td class="nump">4,945<span></span>
</td>
<td class="nump">5,383<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">488,293<span></span>
</td>
<td class="nump">543,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">40,123<span></span>
</td>
<td class="nump">34,947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">724<span></span>
</td>
<td class="nump">4,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">918<span></span>
</td>
<td class="nump">1,059<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">41,765<span></span>
</td>
<td class="nump">40,646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Deferred compensation and other non-current liabilities</a></td>
<td class="nump">15,833<span></span>
</td>
<td class="nump">15,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">7,270<span></span>
</td>
<td class="nump">7,680<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">64,868<span></span>
</td>
<td class="nump">64,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 17)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>SHAREHOLDER&#8217;S EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common shares - no par value, unlimited shares authorized, 142,110 and 141,600 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">1,184,020<span></span>
</td>
<td class="nump">1,177,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">79,188<span></span>
</td>
<td class="nump">59,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,527)<span></span>
</td>
<td class="num">(852)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(838,256)<span></span>
</td>
<td class="num">(756,122)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">423,425<span></span>
</td>
<td class="nump">479,091<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 488,293<span></span>
</td>
<td class="nump">$ 543,367<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648620209904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value ($ per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (shares)</a></td>
<td class="nump">142,110,000<span></span>
</td>
<td class="nump">141,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (shares)</a></td>
<td class="nump">142,110,000<span></span>
</td>
<td class="nump">141,600,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648618306592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue, net</a></td>
<td class="nump">$ 55,779<span></span>
</td>
<td class="nump">$ 14,667<span></span>
</td>
<td class="nump">$ 105,595<span></span>
</td>
<td class="nump">$ 22,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of sales</a></td>
<td class="nump">2,447<span></span>
</td>
<td class="nump">254<span></span>
</td>
<td class="nump">4,302<span></span>
</td>
<td class="nump">610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">52,169<span></span>
</td>
<td class="nump">44,645<span></span>
</td>
<td class="nump">148,898<span></span>
</td>
<td class="nump">128,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">10,973<span></span>
</td>
<td class="nump">20,066<span></span>
</td>
<td class="nump">35,118<span></span>
</td>
<td class="nump">39,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (income) expense, net</a></td>
<td class="num">(311)<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">647<span></span>
</td>
<td class="nump">859<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total cost of sales and operating expenses</a></td>
<td class="nump">65,278<span></span>
</td>
<td class="nump">65,020<span></span>
</td>
<td class="nump">188,965<span></span>
</td>
<td class="nump">170,231<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(9,499)<span></span>
</td>
<td class="num">(50,353)<span></span>
</td>
<td class="num">(83,370)<span></span>
</td>
<td class="num">(148,030)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">1,464<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="nump">2,209<span></span>
</td>
<td class="nump">420<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="num">(8,035)<span></span>
</td>
<td class="num">(50,247)<span></span>
</td>
<td class="num">(81,161)<span></span>
</td>
<td class="num">(147,610)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">954<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">973<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(8,989)<span></span>
</td>
<td class="num">(50,255)<span></span>
</td>
<td class="num">(82,134)<span></span>
</td>
<td class="num">(147,644)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on available-for-sale securities, net of tax of nil</a></td>
<td class="nump">326<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(675)<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (8,663)<span></span>
</td>
<td class="num">$ (50,257)<span></span>
</td>
<td class="num">$ (82,809)<span></span>
</td>
<td class="num">$ (147,633)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share ($ per share)</a></td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (0.58)<span></span>
</td>
<td class="num">$ (1.15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share ($ per share)</a></td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (0.58)<span></span>
</td>
<td class="num">$ (1.15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding used in computation of basic loss per share (in shares)</a></td>
<td class="nump">141,856<span></span>
</td>
<td class="nump">128,443<span></span>
</td>
<td class="nump">141,831<span></span>
</td>
<td class="nump">128,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding used in computation of diluted loss per share (in shares)</a></td>
<td class="nump">141,856<span></span>
</td>
<td class="nump">128,443<span></span>
</td>
<td class="nump">141,831<span></span>
</td>
<td class="nump">128,084<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue, net</a></td>
<td class="nump">$ 25,502<span></span>
</td>
<td class="nump">$ 14,638<span></span>
</td>
<td class="nump">$ 75,142<span></span>
</td>
<td class="nump">$ 22,113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License and collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue, net</a></td>
<td class="nump">$ 30,277<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">$ 30,453<span></span>
</td>
<td class="nump">$ 88<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648618238304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax', window );">Unrealized gain on available-for-sale securities, tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648614564912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Shares</div></th>
<th class="th"><div>Additional paid in capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,725,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 407,750<span></span>
</td>
<td class="nump">$ 944,328<span></span>
</td>
<td class="nump">$ 39,383<span></span>
</td>
<td class="num">$ (805)<span></span>
</td>
<td class="num">$ (575,156)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued on exercise of stock options and vesting of performance awards and restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,324,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued on exercise of stock options and vesting of performance awards and restricted stock units</a></td>
<td class="nump">15,352<span></span>
</td>
<td class="nump">$ 22,097<span></span>
</td>
<td class="num">(6,745)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">521,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Exercise of warrants</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">$ 734<span></span>
</td>
<td class="num">(697)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Shared-based compensation</a></td>
<td class="nump">22,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(147,644)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(147,644)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,570,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2021</a></td>
<td class="nump">298,172<span></span>
</td>
<td class="nump">$ 967,159<span></span>
</td>
<td class="nump">54,607<span></span>
</td>
<td class="num">(794)<span></span>
</td>
<td class="num">(722,800)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,396,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2021</a></td>
<td class="nump">332,257<span></span>
</td>
<td class="nump">$ 954,572<span></span>
</td>
<td class="nump">51,022<span></span>
</td>
<td class="num">(792)<span></span>
</td>
<td class="num">(672,545)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued on exercise of stock options and vesting of performance awards and restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,172,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued on exercise of stock options and vesting of performance awards and restricted stock units</a></td>
<td class="nump">9,074<span></span>
</td>
<td class="nump">$ 12,579<span></span>
</td>
<td class="num">(3,505)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Exercise of warrants</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Shared-based compensation</a></td>
<td class="nump">7,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(50,255)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,255)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,570,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2021</a></td>
<td class="nump">$ 298,172<span></span>
</td>
<td class="nump">$ 967,159<span></span>
</td>
<td class="nump">54,607<span></span>
</td>
<td class="num">(794)<span></span>
</td>
<td class="num">(722,800)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">141,600,000<span></span>
</td>
<td class="nump">141,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 479,091<span></span>
</td>
<td class="nump">$ 1,177,051<span></span>
</td>
<td class="nump">59,014<span></span>
</td>
<td class="num">(852)<span></span>
</td>
<td class="num">(756,122)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued on exercise of stock options and vesting of performance awards and restricted stock units (in shares)</a></td>
<td class="nump">77,000<span></span>
</td>
<td class="nump">383,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued on exercise of stock options and vesting of performance awards and restricted stock units</a></td>
<td class="nump">$ 522<span></span>
</td>
<td class="nump">$ 5,064<span></span>
</td>
<td class="num">(4,542)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common shares in conjunction with ESPP program (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common shares in conjunction with ESPP program</a></td>
<td class="nump">1,223<span></span>
</td>
<td class="nump">$ 1,905<span></span>
</td>
<td class="num">(682)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Shared-based compensation</a></td>
<td class="nump">25,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="num">(675)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(675)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (82,134)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(82,134)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Sep. 30, 2022</a></td>
<td class="nump">142,110,000<span></span>
</td>
<td class="nump">142,110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2022</a></td>
<td class="nump">$ 423,425<span></span>
</td>
<td class="nump">$ 1,184,020<span></span>
</td>
<td class="nump">79,188<span></span>
</td>
<td class="num">(1,527)<span></span>
</td>
<td class="num">(838,256)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,892,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td>
<td class="nump">423,768<span></span>
</td>
<td class="nump">$ 1,180,884<span></span>
</td>
<td class="nump">74,004<span></span>
</td>
<td class="num">(1,853)<span></span>
</td>
<td class="num">(829,267)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued on exercise of stock options and vesting of performance awards and restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued on exercise of stock options and vesting of performance awards and restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 3,136<span></span>
</td>
<td class="num">(3,136)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Shared-based compensation</a></td>
<td class="nump">8,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="nump">326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (8,989)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,989)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Sep. 30, 2022</a></td>
<td class="nump">142,110,000<span></span>
</td>
<td class="nump">142,110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2022</a></td>
<td class="nump">$ 423,425<span></span>
</td>
<td class="nump">$ 1,184,020<span></span>
</td>
<td class="nump">$ 79,188<span></span>
</td>
<td class="num">$ (1,527)<span></span>
</td>
<td class="num">$ (838,256)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648617997904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (82,134)<span></span>
</td>
<td class="num">$ (147,644)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization</a></td>
<td class="nump">2,487<span></span>
</td>
<td class="nump">2,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_auph_AcquiredUpfrontLicensePayment', window );">Upfront license and milestone expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">25,398<span></span>
</td>
<td class="nump">22,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="nump">2,464<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other, net</a></td>
<td class="nump">587<span></span>
</td>
<td class="nump">1,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Accounts receivable</a></td>
<td class="num">(26,356)<span></span>
</td>
<td class="num">(9,815)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories, net</a></td>
<td class="num">(8,458)<span></span>
</td>
<td class="num">(5,366)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(3,461)<span></span>
</td>
<td class="num">(6,541)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Non-current assets</a></td>
<td class="num">(830)<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued and other liabilities</a></td>
<td class="nump">875<span></span>
</td>
<td class="nump">1,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="num">(551)<span></span>
</td>
<td class="nump">499<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(89,979)<span></span>
</td>
<td class="num">(131,770)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows used in investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of investments</a></td>
<td class="num">(403,184)<span></span>
</td>
<td class="num">(342,831)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from investments</a></td>
<td class="nump">346,109<span></span>
</td>
<td class="nump">263,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLeaseReceivables', window );">Upfront lease payment</a></td>
<td class="num">(381)<span></span>
</td>
<td class="num">(11,838)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Upfront license payment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Purchase of non-current assets</a></td>
<td class="num">(158)<span></span>
</td>
<td class="num">(268)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForSoftware', window );">Additions to internal use-software implementation costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,198)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(57,614)<span></span>
</td>
<td class="num">(98,383)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options and employee share purchase plan</a></td>
<td class="nump">1,745<span></span>
</td>
<td class="nump">15,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash provided by financing activities</a></td>
<td class="nump">1,745<span></span>
</td>
<td class="nump">15,390<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(145,848)<span></span>
</td>
<td class="num">(214,763)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">231,900<span></span>
</td>
<td class="nump">272,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">86,052<span></span>
</td>
<td class="nump">57,587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromInterestReceived', window );">Cash received for interest</a></td>
<td class="nump">1,705<span></span>
</td>
<td class="nump">671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for taxes</a></td>
<td class="num">(779)<span></span>
</td>
<td class="num">(236)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsIncurred', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="num">(897)<span></span>
</td>
<td class="num">(195)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of noncash transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Initial recognition of operating lease right-of-use asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsSummationsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash, cash equivalents</a></td>
<td class="nump">85,341<span></span>
</td>
<td class="nump">57,587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">711<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 86,052<span></span>
</td>
<td class="nump">$ 57,587<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_AcquiredUpfrontLicensePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired Upfront License Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_AcquiredUpfrontLicensePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsSummationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsSummationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in lease obligation from new lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireLeaseReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of receivables arising from the lease of real estate, equipment or other fixed assets for a specified time in exchange for payment, usually in the form of rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireLeaseReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest received on loans and other debt instruments during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3337-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648620245136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Description of Business</a></td>
<td class="text">Organization and Description of Business<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurinia Pharmaceuticals Inc. (Aurinia or the Company) is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the Company introduced LUPKYNIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (voclosporin), the first U.S. Food and Drug Administration (FDA) approved oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory activities to support the voclosporin development program as well as our other assets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 17, 2021, the Company announced the addition of two novel assets AUR200 and AUR300. AUR200 and AUR300 are currently undergoing pre-clinical development with projected submission of Investigational New Drug Applications (INDs) to the FDA in 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2022, the European Commission (EC) granted marketing authorization of LUPKYNIS to Otsuka Pharmaceutical Co., Ltd. (Otsuka). </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The centralized marketing authorization is valid in all European (EU) member states as well as in Iceland, Liechtenstein, Norway and Northern Ireland.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurinia's head office is located at #1203-4464 Markham Street, Victoria, British Columbia, Canada and its registered office is located at #201, 17873-106 A Avenue, Edmonton, Alberta. Aurinia also has a U.S. commercial office located at 77 Upper Rock Circle Suite 700, Rockville, Maryland, 20850 United States.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurinia is incorporated pursuant to the Business Corporations Act (Alberta). The Company&#8217;s common shares are traded on the Nasdaq Global Market (Nasdaq) under the symbol AUPH.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648619791760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of December&#160;31, 2021 was derived from audited annual consolidated financial statements but does not include all annual disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021. The results of operations for the nine months ended September&#160;30, 2022 are not necessarily indicative of the results to be expected for the full year or any other future periods.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aurinia Pharma U.S., Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). All intercompany balances and transactions have been eliminated in consolidation and operate in one segment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements are presented in U.S. dollars which is the Company's functional currency, therefore, there is no currency translation adjustment upon consolidation as the remeasurement of gains or losses are recorded in the condensed consolidated statements of operations. All assets and liabilities denominated in a foreign currency are remeasured into U.S. dollars at the exchange rate on the balance sheet date. Revenues and expenses are remeasured at the average exchange rate during the period. Foreign exchange gains and losses arising on translation or settlement of a foreign currency denominated monetary item are included in the condensed consolidated statements of operations.</span></div>The Company is devoting the majority of our operational efforts and financial resources towards the commercialization and post approval commitments of our approved drug, LUPKYNIS. The Company is also expending efforts towards our newly acquired assets AUR200 and AUR300. Taking into consideration the Company's cash, cash equivalents, restricted cash and investments of $376.6 million as of September&#160;30, 2022, the Company believes that it has sufficient resources to fund its operations for at least the next few years beyond the date that the unaudited condensed consolidated financial statements are issued.<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as described below, the Company's significant accounting policies have not changed from those previously described in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Restricted cash consists of the 2021 Employee Share Purchase Plan (2021 ESPP) deposits of $0.7&#160;million and $0.3&#160;million as of September&#160;30, 2022 and December&#160;31, 2021, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Customers:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company currently has two main customers for U.S. commercial sales of LUPKYNIS and a collaboration partner for sales of LUPKYNIS in the EU, Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine (collectively, the "Otsuka Territories"). Revenues from the two main customers in the U.S. accounted in total of approximately 48% for the three months ended September&#160;30, 2022 and 74% for the nine months ended September&#160;30, 2022 of the Company's total revenues. Our collaboration partner for sales outside the U.S. accounted for approximately 52% and 26% for the three and nine months ended September&#160;30, 2022 of the Company's total revenues.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late March 2022, we provided a nominal additional discount to both of our two main U.S. customers, applicable for the remainder of the 2022 calendar year, in connection with holding additional amounts of LUPKYNIS on hand due to supply chain concerns. Such discounts, or any future discounts, may result in reduced sales to these customers in subsequent periods and substantial fluctuations in our revenues from period to period. The Company monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances. Global economic conditions and customer specific factors may require the Company to periodically re-evaluate the collectability of its receivables and based on this evaluation the Company could potentially incur credit losses. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenues</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States (and territories), the Company sells LUPKYNIS primarily to specialty pharmacies and specialty distributors. These customers subsequently resell the Company's products to health care providers and patients. Revenues from product sales are recognized when the customer obtains control of our product, which typically occurs upon delivery to the customer. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for discounts and allowances: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's estimates of reserves established for variable consideration are calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant judgment is required in estimating variable consideration. In making these estimates, we consider historical data, including patient mix and inventory sold to our customers that has not yet been dispensed. We use a data aggregator and historical claims to estimate variable consideration for inventory sold to our customers, including specialty pharmacies and specialty distributors, that has not yet been dispensed. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjust these estimates, which could have an effect on earnings in the period of adjustment. As of September&#160;30, 2022, we did not have any material adjustments to estimates based on actual results. These specific adjustments are detailed further in our Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the inception of each arrangement that includes development or commercial sales milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment. Any consideration related to sales-based royalties (and sales-based milestones) will be recognized when the related sales occur. As of September&#160;30, 2022, we recognized $30.0&#160;million for the regulatory milestone related to the EC marketing authorization of LUPKYNIS.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable, net:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accounts receivable are stated at their net realizable value. The Company's accounts receivable represents amounts due to the Company from product sales and from its Otsuka collaboration agreement (Note 12). Milestone payments that have not been invoiced as of the balance sheet date are recorded as unbilled accounts receivable. As of September&#160;30, 2022 and December&#160;31, 2021, accounts receivable, net are $41.8 million and $15.4 million. The accounts receivable, net as of September&#160;30, 2022 includes $28.8 million due from Otsuka related to the achievement of a regulatory milestone in September 2022, for which payment was received on October 31, 2022. </span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing between the recognition of revenue for product sales and the receipt of payment is not significant. Our standard credit terms range from 30 to 45 days. We do not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between the transfer of the promised good to the customer and receipt of payment will be one year or less. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the allowance for doubtful accounts using the current expected credit loss, or CECL, model. Under the CECL model, the allowance for doubtful accounts reflects the net amount expected to be collected from the account receivables. We evaluate the collectability of these cash flows based on the asset&#8217;s amortized cost, the risk of loss even when that risk is remote, losses over an asset&#8217;s contractual life, and other relevant information available to us. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. The allowance for doubtful accounts was $nil as of September&#160;30, 2022 and as of December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Compensation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows ASC Topic 718, Compensation - Stock Compensation (ASC 718), which requires the measurement and recognition of compensation expense, based on estimated fair values, for all share-based awards made to employees and directors. The Company records compensation expense based on the fair value on the grant date using the graded accelerated vesting method for all share-based payments related to stock options, performance awards (PAs), restricted stock units (RSUs) and purchases under the Company's 2021 ESPP. For stock options, forfeitures are estimated based on historical experience at the time of grant and revised in subsequent periods if actual forfeitures differ from those estimates. For RSUs and PAs, forfeitures are accounted for as they occur.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently adopted accounting pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 740): Simplifying the Accounting for Income Taxes, which clarifies and simplifies certain aspects of the accounting for income taxes such as eliminating the exception to the general intraperiod tax allocation principle. The standard is effective for years beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2020. The Company adopted the ASU effective January 1, 2021, with no material impact on the condensed consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, which requires business entities to make annual disclosures about transactions with a government (including government assistance) by analogizing to a grant or contribution accounting model. The required disclosures include the nature of the transaction, the entity's related accounting policy, the financial statement line items affected and the amounts reflected in the current period financial statements, as well as any significant terms and conditions. The guidance is effective for financial statements issued for annual periods beginning after December 15, 2021. The Company adopted the ASU effective January 1, 2022, with no material impact on the condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648619816080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist primarily of cash and cash equivalents, short-term investments, accounts receivable, accounts payable and accrued liabilities. The carrying value of accounts receivable, accounts payable and accrued liabilities approximate their fair value because of their short-term nature. Estimated fair value of available-for-sale securities are generally based on prices obtained from commercial pricing services.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8217;s assumptions about how market participants would price assets and liabilities). As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 1 - Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 2 - Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 3 - Unobservable inputs that reflect the reporting entity&#8217;s own assumptions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the financial assets (cash, cash equivalents, restricted cash and short-term investments) measured at fair value on a recurring basis:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">86,052</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">86,052</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency security</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,904</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,904</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">98,068</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">98,068</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">112,633</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">112,633</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,704</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,704</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bond</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44,553</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44,553</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yankee bond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,730</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,730</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">198,685</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">177,959</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">376,644</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438,624&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,454&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,078&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Level 1 instruments include cash, cash equivalents, restricted cash and commercial paper that are valued using quoted market prices. We estimate the fair values of our investments in corporate debt securities, government and government related securities and certificates of deposits by taking into consideration valuations obtained from third-party pricing services. The fair value of our short-term investments classified within Level 2 is based upon observable inputs that may include benchmark yield curves, reported trades, issuer spreads, benchmark securities and reference data including market research publications. At September&#160;30, 2022, and December&#160;31, 2021, the weighted average remaining contractual maturities of our Level 1 and 2 investments were approximately for 7 months and 8 months, respectively. These investments have an overall rating of A-1, or higher, by Moody&#8217;s, Standard &amp; Poor&#8217;s and Fitch.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No credit loss allowance was recorded as of September&#160;30, 2022, as we do not believe the unrealized loss is a result of a credit loss due to the nature of our investments. We also considered the current and expected future economic and market conditions and determined that the estimate of credit losses was not significantly impacted.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 4, &#8220;Cash, Cash Equivalents, Restricted Cash and Short-Term Investments,&#8221; for the carrying amount and related unrealized gains (losses) by type of investment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648623885552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Restricted Cash and Short-Term Investments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Cash, Cash Equivalents, Restricted Cash and Short-Term Investments</a></td>
<td class="text">Cash, Cash Equivalents, Restricted Cash and Short-Term Investments<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022 and December&#160;31, 2021, the Company had $376.6 million and $466.1 million, respectively of cash, cash equivalents, restricted cash and short-term investments summarized below. As of September&#160;30, 2022, $376.6 million were available-for-sale debt securities which are carried at fair market value. As of December&#160;31, 2021, $446.9 million were classified as available-for-sale and $19.2 million were held-to-maturity. </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.660%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">86,052</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">86,052</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency security</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,900</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,904</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bond</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">98,448</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(380)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">98,068</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">112,833</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">112,633</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,721</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,704</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44,670</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44,553</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yankee bond</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,742</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,730</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash and short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">377,366</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(726)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">376,644</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bond</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446,897&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446,850&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total held to maturity securities at amortized cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash and short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,078&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022 and December&#160;31, 2021, accrued interest receivable from the investments were $0.7 million and $0.1 million, respectively. During the three and nine months ended September&#160;30, 2022, the Company had $0.3 million and $0.7 million unrealized gains and losses on available-for-sale securities, net of tax, respectively, which are included as a component of comprehensive loss on the consolidated statements of operations. Currently, the Company does not intend to sell investments that are in an unrealized loss position, and it is unlikely we will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. We have determined that the gross unrealized losses on our investments at September&#160;30, 2022, were temporary in nature. Realized gains or losses were immaterial during the three and nine months ended September&#160;30, 2022 and 2021.</span></div>The Company's short-term investments as of September&#160;30, 2022 mature at various dates through June 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648620181296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories, net<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories, net</a></td>
<td class="text">Inventories, netInventories are valued under a standard costing methodology on a first-in, first-out basis and are stated at the lower of cost or net realizable value. The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs. Capitalized costs of inventories for LUPKYNIS mainly include third party manufacturing costs, transportation, storage, insurance, and allocated internal labor. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses recoverability of inventory each reporting period to determine any write-down to net realizable value resulting from excess or obsolete inventories. As of September&#160;30, 2022, we have recorded reserves of finished goods inventories of approximately $2.7 million which were primarily related to process validation batches used for FDA approval.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory, net are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,217</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,150</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,953</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,320</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,326&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648619594096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_auph_PrepaidExpensesTextBlock', window );">Prepaid Expenses</a></td>
<td class="text">Prepaid Expenses<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses are as follows:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,725</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,316&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,582</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,852</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,159</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,710&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_PrepaidExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_PrepaidExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648619626560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text">Intangible Assets<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of intangible assets, net of accumulated amortization. </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.424%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,473</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,249)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">224</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intellectual property and reacquired rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,126</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,580)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,546</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software implementation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,873</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,804)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,069</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,472</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12,633)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,839</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.424%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,471&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,176)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intellectual property and reacquired rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,804)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software implementation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,873&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,086)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,470&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,066)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,404&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for the three months ended September&#160;30, 2022 and 2021 was $0.5 million for both periods and for the nine months ended September&#160;30, 2022 and 2021 was $1.6 million for both periods.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648622629088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, net</a></td>
<td class="text">Property and Equipment, net<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net are as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">217</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,978</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">645</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">976</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">251</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,067</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,254</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,309)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(836)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,758</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,418&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648619651888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Obligations<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Lease Obligations</a></td>
<td class="text">Lease Obligations<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has the following lease obligations:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Victoria, British Columbia</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During August 2020, the Company signed a lease for commercial office space in Victoria, British Columbia for a new corporate headquarters that was expected to commence in April 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2020, the Company entered into 18-month facility and furniture leases for its existing corporate head office located in Victoria, British Columbia. The lease terms commenced on January 1, 2021 with an end date of August 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 3, 2022, we provided notice of termination for the lease of the intended new corporate headquarters space in Victoria on the basis that the landlord's work was not completed by the time required under the lease. As a result of the termination, the company expensed $0.3&#160;million of CIP cost that was related to the new corporate headquarters.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2022, the fixed lease term ended for Aurinia's existing corporate headquarters and the Company exercised its right to enter into a month to month lease, of which expenses are incurred in SG&amp;A.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rockville, Maryland</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During March 2020, the Company entered into a lease for its U.S. commercial office in Rockville, Maryland for a total of 30,531 square feet of office space. The lease has a remaining term of approximately 9 years and has an option to extend for two five-year periods after the initial term of 11 years has elapsed and has an option to terminate after seven years. As of September&#160;30, 2022, the Company had a right-of-use asset of $4.9 million and lease liability of $8.2 million included in the condensed consolidated balance sheets. As of December&#160;31, 2021, the Company had a right of use asset of $5.2 million and lease liability of $8.6 million included in the condensed consolidated balance sheets. The Company recorded leasehold improvement incentives in the amount of $2.3&#160;million as additions to the lease liability. The lease term commenced on March 12, 2020. When measuring the lease liability, the Company discounted lease payments using its incremental borrowing rate at March 12, 2020. The incremental borrowing rate applied to the lease liability on March 12, 2020 was 5.2% based on the financial position of the Company, geographical region and term of lease.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Edmonton, Alberta</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Company has a short term lease in Edmonton, Alberta in which expenses are recognized in SG&amp;A. The lease is not material to the Company's financial position.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs variable lease costs under the existing Victoria and Rockville leases. These costs include operation and maintenance costs included in SG&amp;A and are expensed as incurred. The variable lease costs are not material to the Company's financial position.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating lease costs for the three and nine months ended September&#160;30, 2022 and September&#160;30, 2021 are $0.2&#160;million and $0.8&#160;million for both periods respectively.</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the weighted-average remaining lease term and discount rate as of September&#160;30, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term (years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.22%</span></td></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of operating lease liabilities payments for the next five years and thereafter:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Lease Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">263</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,061</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,085</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,110</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,135</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,638</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,292</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: lease imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,104)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,188</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 15, 2020, the Company entered into a collaborative agreement with Lonza to build a dedicated manufacturing facility within Lonza&#8217;s existing small molecule facility in Visp, Switzerland. The dedicated facility (also referred to as "monoplant") will be equipped with state-of-the-art manufacturing equipment to provide cost and production efficiency for the manufacture of voclosporin, while expanding existing capacity and providing supply security to meet future commercial demand.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following U.S. regulatory approval of LUPKYNIS in January 2021, the Company has commenced a capital expenditure payment program for the monoplant totaling approximately CHF 21.0&#160;million. The first capital expenditure payment was made in February 2021 of $11.8&#160;million (CHF 10.5&#160;million) and was treated as an upfront lease payment and recorded under other non-current assets on the condensed consolidated balance sheets. The second payment is not due until the facility fulfills the required operational qualifications which is estimated to be during the first half of 2023. Upon completion of the monoplant, the Company will have the right to maintain sole dedicated use of the monoplant by paying a quarterly fixed facility fee. The Company expects to account for the arrangement as a finance lease under ASC 842. The present value of the minimum lease payments total approximately $73.0&#160;million, beginning April 2023 and expiring in 2030, and are not included in the above table.</span></div>The Company has entered into an equipment and facility finance lease for a backup manufacturing encapsulation site in Beinheim, France that has not yet commenced and is therefore, not included in the above table. As part of the agreement, the Company expects to make payments of approximately $0.9&#160;million prior to lease commencement and the future value of minimum lease payments will total approximately $0.1&#160;million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648621649360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Liabilities</a></td>
<td class="text">Accounts Payable and Accrued Liabilities<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee accruals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,511</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,278&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial accruals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,140</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued R&amp;D projects</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,995</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,411</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40,123</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,947&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648619570336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Compensation and Other Non-current Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock', window );">Deferred Compensation and Other Non-current Liabilities</a></td>
<td class="text">Deferred Compensation and Other Non-current LiabilitiesThe Company recorded other non-current liabilities of $15.8 million and $16.0 million as of September&#160;30, 2022 and December&#160;31, 2021, respectively. The balance as of September&#160;30, 2022 and December&#160;31, 2021 primarily included deferred compensation arrangements whereby certain executive officers as of March 8, 2012 were provided with future potential employee benefit obligations for remaining with the Company, for a certain period of time. These obligations were also contingent on the occurrence of uncertain future events. Other non-current liabilities also include milestone payments deemed probable to be paid in the future.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as noncurrent at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648619651888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreement<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">License and Collaboration Agreement</a></td>
<td class="text">License and Collaboration Agreements<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Otsuka Contract</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 17, 2020, the Company entered into a collaboration and license agreement with Otsuka for the development and commercialization of oral LUPKYNIS in the Otsuka Territories.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the agreement, the Company received an upfront cash payment of $50.0&#160;million for the license agreement and has the potential to receive up to $50.0&#160;million in regulatory related milestones. The Company will provide semi-finished product of LUPKYNIS to Otsuka on a cost-plus basis, and will receive tiered royalties on future sales ranging from 10 to 20 percent (dependent on territory and achievement of sale thresholds) on net product sales by Otsuka, along with additional milestone payments based on the attainment of certain annual sales. In addition, certain collaboration services are to be provided to Otsuka on agreed upon rates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In furtherance of the collaboration and license agreement with Otsuka mentioned above, on August 1, 2022, the Company entered into a commercial supply agreement with Otsuka, formalizing the terms to supply semi-finished goods of LUPKYNIS to Otsuka in the Otsuka Territories, including capacity sharing of the monoplant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2022, the European Commission (EC) granted marketing authorization of LUPKYNIS. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The centralized marketing authorization is valid in all EU member states as well as in Iceland, Liechtenstein, Norway and Northern Ireland.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The approval triggered a $30.0&#160;million milestone to the Company, which was recognized as collaboration revenue in the three and nine months period ended September&#160;30, 2022 and was subsequently received on October 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September&#160;30, 2022, the Company recognized $0.2 million and $0.4 million, respectively, of collaboration service revenue from Otsuka. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Riptide License</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 17, 2021, AUR300 (M2 macrophage modulation via CD206 binding) was secured through a global licensing and research agreement with Riptide Bioscience, Inc. (Riptide), a private company. As part of the agreement, in 2021 the Company paid Riptide an upfront license fee of $6.0&#160;million which was expensed as research and development on the condensed consolidated statements of operations. During the first quarter of 2022, Aurinia paid $4.0&#160;million for the achievement of a one-time milestone. Additional payments are due upon certain development, clinical and regulatory milestones, and royalties will be payable upon commercialization.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648619600256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text">Net Loss per Common Share<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share. The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.683%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,989)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,255)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(82,134)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147,644)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">141,856</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">141,831</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share (expressed in $ per share)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.06)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.39)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.58)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.15)</span></div></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not include the securities in the following table in the computation of the net loss per common share because the effect would have been anti-dilutive during each period:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,299</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested performance awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,098</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,397</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,907&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648620149360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Compensation</a></td>
<td class="text">Share-based Compensation<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Amended and Restated Equity Incentive Plan (the Plan), which was adopted and approved by the Company's shareholders in June 2021, allows for an issuance of up to an aggregate of 23.8 million shares (inclusive of then outstanding awards) and provides for grants of stock options, performance awards, and restricted stock units (RSUs) that may be settled in cash and common shares. Also in June 2021, the Company's shareholders adopted and approved the Company's 2021 ESPP, which allows for the issuance of up to 2.5 million shares. The 2021 ESPP is intended to qualify as an &#8220;employee stock purchase plan&#8221; under Section 423 of the Internal Revenue Code (the Code) but also permits the Company to include the employees, including non-United States employees, in offerings not intended to qualify under Section 423. The purpose of the 2021 ESPP is to provide eligible employees with opportunities to purchase the Company&#8217;s common shares at a discounted price.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2022, the Company modified the 2021 ESPP for the current and future offerings. The new ESPP terms shortened the plan from four (4) purchases over a 24 month Offering Period to two (2) purchases over a 12 month offering period. Additionally, the ESPP now contains a rollover mechanism; that is, if the stock price on the purchase date is less than the offering price (as that is determined under the 2021 ESPP), that offering is then canceled and any participants are rolled into the new 12 month offering period at the lower price.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As a result of the modification, $475&#160;thousand of incremental expense was added to the estimated expense for the November 2022 and May 2023 purchase dates (to be amortized over the new 12 month offering period). Additionally, the originally scheduled purchase date in November 2023 is no longer planned given the new 12 month offering period; therefore, the modification also resulted in a &#8220;repurchase for no consideration&#8221; under ASC 718. The Company recognized an additional $651&#160;thousand of unamortized expense for the cancelled November 2023 purchase, which was recorded during the second quarter of 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to stock options, performance awards and RSUs granted under the Plan, the Company has granted certain stock options and RSUs as inducements material to new employees entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The inducements were granted outside of the Plan during 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plan requires the exercise price of each option not to be less than the closing market price of the Company&#8217;s common shares on the day immediately prior to the date of grant. The board of directors approves the vesting criteria and periods at its discretion. The options issued under the plan are accounted for as equity-settled share-based payments. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used the Black-Scholes option pricing model to estimate the fair value of the options granted. The Company considers historical volatility of its common shares in estimating its future stock price volatility. The risk-free interest rate for the expected life of the options was based on the yield available on government benchmark bonds with an approximate equivalent remaining term at the time of the grant. The expected life is based upon the contractual term, taking into account expected employee exercise and expected post-vesting employment termination behavior. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted average assumptions were used to estimate the fair value of the options granted during the nine months ended September&#160;30, 2022 and September&#160;30, 2021:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annualized volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.01</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of options in years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated forfeiture rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value per common share option</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the option award activity for the nine months ended September&#160;30, 2022:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of shares (in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price $</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,074</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.84</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,809</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.47</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,507)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.63</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,299</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Awards and Restricted Stock Units</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 23, 2020, the Company issued 439,000 PAs to executive management of the Company whose vesting was contingent upon meeting specific performance metrics based on the results for the year ended December 31, 2021. Each PA which vested entitled the participant to receive common shares on the basis of the performance metrics set. On March 18, 2021 performance metrics were set and formally communicated. Therefore, March 18, 2021 was the grant date and the fair value on the grant date was $13.56. The PAs vested in 2022 and the participant was required to achieve at least one of the performance metrics to obtain the portion of the award associated with the metric.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2021, the Company granted approximately 619,000 PAs and RSUs. The grant date for the PAs and RSUs was August 6, 2021 and the fair value on the grant date was $14.42 as this was the date performance measures were set and communicated to employees. The PAs vested on the employee's first anniversary of the grant date and the employee was required to achieve at least one of the performance metrics to obtain the portion of the award associated with the metric. The RSUs had no performance metrics and vested on the one year anniversary of the grant.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the 2022, the Company has granted RSUs and intends to grant RSUs throughout the year under the Plan, as well as inducements for certain new hires as discussed above. The RSUs are fair valued based on the market price of our common shares on the date of the grant.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the PA and RSU activity for the nine months ended September&#160;30, 2022:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of shares (in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price $</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">347</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.33</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,311</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(305)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(255)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.39</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,098</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.04</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Expense</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized share-based compensation expense for the three and nine month periods ended September&#160;30, 2022 and September&#160;30, 2021 as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.683%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,489</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,531</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,201&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,625</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,480</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized under inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">387</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,320</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,092&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,398</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,666&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of September&#160;30, 2022, there was $33.6&#160;million of unrecognized share-based compensation expense related to unvested awards granted which is expected to be recognized over a weighted-average period of approximately 1.4 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648621729328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rates for the three and nine months ended September&#160;30, 2022 and September&#160;30, 2021 differed from the federal statutory rate applied to losses before income taxes primarily as a result of the mix of income, losses and valuation allowances. The Company recognized an income tax expense of approximately $1.0 million for the three and nine months ended September&#160;30, 2022. The Company recognized an income tax expense of approximately $8 thousand and $34 thousand for the three and nine months ended September&#160;30, 2021, respectively. The expense recognized for these periods is a result of income in certain jurisdictions and withholding taxes on foreign income. The Company currently has tax expense in certain jurisdictions that are not offset by tax benefits. The increase from prior periods was due to withholding taxes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Uncertain Tax Positions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was under examination by the Canadian Revenue Agency for years 2017 and 2018. In March 2022, the Company was notified by the Canadian Revenue Agency that the examination is now complete and there were no findings and as a result, there is no additional tax expense or benefit recognized in regards to the audit. There are no outstanding tax audits ongoing at September&#160;30, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648619687264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Transactions</a></td>
<td class="text">Related Party TransactionsILJIN SNT Co., Ltd (ILJIN) was considered to be a related party due to their equity ownership of over 5% as per their public filing. The outstanding related party amount payable to ILJIN was the result of a settlement completed on September 20, 2013 between ILJIN and the Company. During 2021, Aurinia paid ILJIN $6.0&#160;million upon achievement of specific milestones. The amount payable to ILJIN is nil as of September&#160;30, 2022 and December&#160;31, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648619750224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and ContingenciesThe Company may, from time to time, be subject to claims and legal proceedings brought against it in the normal course of business. Such matters are subject to many uncertainties. Management believes the ultimate resolution of such contingencies <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will not have a material adverse effect on the consolidated financial position of the Company. The Company's material commitments and contingencies have not changed in any material manner from those previously described in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021 and the quarterly report for the quarter ended September&#160;30, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Funding Commitments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into agreements with contract research organizations, contract manufacturing organizations and other third parties for services to be provided to the Company. Generally, these agreements provide for termination upon notice, with specified amounts due upon termination based on the timing of termination and the terms of the agreement. The actual amounts and timing of payments under these agreements are uncertain and contingent upon the initiation and completion of services to be provided to the Company.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648619606112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Compensation Committee granted 4 new employees an aggregate of 20,800 inducement stock options and an aggregate of 12,500 inducement RSUs. The options have a per share exercise price of $7.52,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the closing price of Aurinia's common stock on September 30</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 2022. The stock options and RSUs have a grant date of October 3, 2022. The stock options and RSUs were granted as inducements material to the new employees entering employment with Aurinia in accordance with Nasdaq Listing Rule 5635(c)(4).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 17, 2022, Aurinia mutually agreed with Robert Huizinga, PhD RN, CNeph(C), Executive Vice President, Research and Neil Solomons, M.D.,  Chief Medical Officer, to cease their employment with Aurinia, each effective October 31, 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurnia has entered into separation agreements with Dr. Huizinga and Dr. Solomons which will supersede and replace all the severance arrangements between Aurinia and Dr. Huizinga and Dr. Solomons, set forth in their respective employment agreements with Aurinia, dated October 1, 2018 and September 12, 2012, respectively (together, as amended, the Employment Agreements). The terms of the separation agreements are expected to be consistent with the terms of the Employment Agreements, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648614536352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of December&#160;31, 2021 was derived from audited annual consolidated financial statements but does not include all annual disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021. The results of operations for the nine months ended September&#160;30, 2022 are not necessarily indicative of the results to be expected for the full year or any other future periods.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted cash</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Restricted cash consists of the 2021 Employee Share Purchase Plan (2021 ESPP) deposits of $0.7&#160;million and $0.3&#160;million as of September&#160;30, 2022 and December&#160;31, 2021, respectively.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Major Customers</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Customers:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company currently has two main customers for U.S. commercial sales of LUPKYNIS and a collaboration partner for sales of LUPKYNIS in the EU, Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine (collectively, the "Otsuka Territories"). Revenues from the two main customers in the U.S. accounted in total of approximately 48% for the three months ended September&#160;30, 2022 and 74% for the nine months ended September&#160;30, 2022 of the Company's total revenues. Our collaboration partner for sales outside the U.S. accounted for approximately 52% and 26% for the three and nine months ended September&#160;30, 2022 of the Company's total revenues.</span>In late March 2022, we provided a nominal additional discount to both of our two main U.S. customers, applicable for the remainder of the 2022 calendar year, in connection with holding additional amounts of LUPKYNIS on hand due to supply chain concerns. Such discounts, or any future discounts, may result in reduced sales to these customers in subsequent periods and substantial fluctuations in our revenues from period to period. The Company monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances. Global economic conditions and customer specific factors may require the Company to periodically re-evaluate the collectability of its receivables and based on this evaluation the Company could potentially incur credit losses.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Product Revenues</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenues</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States (and territories), the Company sells LUPKYNIS primarily to specialty pharmacies and specialty distributors. These customers subsequently resell the Company's products to health care providers and patients. Revenues from product sales are recognized when the customer obtains control of our product, which typically occurs upon delivery to the customer. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for discounts and allowances: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's estimates of reserves established for variable consideration are calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant judgment is required in estimating variable consideration. In making these estimates, we consider historical data, including patient mix and inventory sold to our customers that has not yet been dispensed. We use a data aggregator and historical claims to estimate variable consideration for inventory sold to our customers, including specialty pharmacies and specialty distributors, that has not yet been dispensed. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjust these estimates, which could have an effect on earnings in the period of adjustment. As of September&#160;30, 2022, we did not have any material adjustments to estimates based on actual results. These specific adjustments are detailed further in our Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the inception of each arrangement that includes development or commercial sales milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be </span></div>included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment. Any consideration related to sales-based royalties (and sales-based milestones) will be recognized when the related sales occur.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts receivable, net</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable, net:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accounts receivable are stated at their net realizable value. The Company's accounts receivable represents amounts due to the Company from product sales and from its Otsuka collaboration agreement (Note 12). Milestone payments that have not been invoiced as of the balance sheet date are recorded as unbilled accounts receivable. As of September&#160;30, 2022 and December&#160;31, 2021, accounts receivable, net are $41.8 million and $15.4 million. The accounts receivable, net as of September&#160;30, 2022 includes $28.8 million due from Otsuka related to the achievement of a regulatory milestone in September 2022, for which payment was received on October 31, 2022. </span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing between the recognition of revenue for product sales and the receipt of payment is not significant. Our standard credit terms range from 30 to 45 days. We do not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between the transfer of the promised good to the customer and receipt of payment will be one year or less. </span>We estimate the allowance for doubtful accounts using the current expected credit loss, or CECL, model. Under the CECL model, the allowance for doubtful accounts reflects the net amount expected to be collected from the account receivables. We evaluate the collectability of these cash flows based on the asset&#8217;s amortized cost, the risk of loss even when that risk is remote, losses over an asset&#8217;s contractual life, and other relevant information available to us. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. The allowance for doubtful accounts was $nil as of September&#160;30, 2022 and as of December&#160;31, 2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Compensation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows ASC Topic 718, Compensation - Stock Compensation (ASC 718), which requires the measurement and recognition of compensation expense, based on estimated fair values, for all share-based awards made to employees and directors. The Company records compensation expense based on the fair value on the grant date using the graded accelerated vesting method for all share-based payments related to stock options, performance awards (PAs), restricted stock units (RSUs) and purchases under the Company's 2021 ESPP. For stock options, forfeitures are estimated based on historical experience at the time of grant and revised in subsequent periods if actual forfeitures differ from those estimates. For RSUs and PAs, forfeitures are accounted for as they occur.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently adopted accounting pronouncements</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently adopted accounting pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 740): Simplifying the Accounting for Income Taxes, which clarifies and simplifies certain aspects of the accounting for income taxes such as eliminating the exception to the general intraperiod tax allocation principle. The standard is effective for years beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2020. The Company adopted the ASU effective January 1, 2021, with no material impact on the condensed consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, which requires business entities to make annual disclosures about transactions with a government (including government assistance) by analogizing to a grant or contribution accounting model. The required disclosures include the nature of the transaction, the entity's related accounting policy, the financial statement line items affected and the amounts reflected in the current period financial statements, as well as any significant terms and conditions. The guidance is effective for financial statements issued for annual periods beginning after December 15, 2021. The Company adopted the ASU effective January 1, 2022, with no material impact on the condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648619597824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the financial assets (cash, cash equivalents, restricted cash and short-term investments) measured at fair value on a recurring basis:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">86,052</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">86,052</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency security</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,904</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,904</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">98,068</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">98,068</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">112,633</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">112,633</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,704</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,704</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bond</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44,553</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44,553</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yankee bond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,730</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,730</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">198,685</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">177,959</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">376,644</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438,624&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,454&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,078&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648619567104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Restricted Cash and Short-Term Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Investments</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.660%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">86,052</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">86,052</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency security</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,900</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,904</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bond</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">98,448</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(380)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">98,068</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">112,833</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">112,633</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,721</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,704</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44,670</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44,553</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yankee bond</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,742</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,730</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash and short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">377,366</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(726)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">376,644</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bond</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446,897&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446,850&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total held to maturity securities at amortized cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash and short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,078&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648619600256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventories, net</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory, net are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,217</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,150</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,953</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,320</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,326&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648619570336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule Of Prepaid Expenses And Other Current Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses are as follows:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,725</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,316&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,582</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,852</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,159</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,710&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648619681664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of intangible assets, net of accumulated amortization. </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.424%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,473</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,249)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">224</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intellectual property and reacquired rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,126</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,580)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,546</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software implementation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,873</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,804)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,069</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,472</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12,633)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,839</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.424%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,471&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,176)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intellectual property and reacquired rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,804)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software implementation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,873&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,086)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,470&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,066)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,404&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648619750224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net are as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">217</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,978</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">645</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">976</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">251</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,067</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,254</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,309)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(836)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,758</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,418&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648621699296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Obligations (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost</a></td>
<td class="text"><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the weighted-average remaining lease term and discount rate as of September&#160;30, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term (years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.22%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of operating lease liabilities payments for the next five years and thereafter:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Lease Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">263</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,061</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,085</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,110</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,135</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,638</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,292</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: lease imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,104)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,188</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648619647168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee accruals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,511</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,278&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial accruals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,140</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued R&amp;D projects</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,995</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,411</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40,123</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,947&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648619707040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Loss Per Share, Basic and Diluted</a></td>
<td class="text">The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.683%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,989)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,255)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(82,134)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147,644)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">141,856</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">141,831</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share (expressed in $ per share)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.06)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.39)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.58)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.15)</span></div></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Loss Per Share</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not include the securities in the following table in the computation of the net loss per common share because the effect would have been anti-dilutive during each period:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,299</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested performance awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,098</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,397</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,907&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648618145616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award Valuation Assumptions</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted average assumptions were used to estimate the fair value of the options granted during the nine months ended September&#160;30, 2022 and September&#160;30, 2021:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annualized volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.01</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of options in years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated forfeiture rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value per common share option</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Option Activity</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the option award activity for the nine months ended September&#160;30, 2022:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of shares (in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price $</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,074</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.84</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,809</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.47</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,507)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.63</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,299</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock', window );">Schedule of Performance Shares Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the PA and RSU activity for the nine months ended September&#160;30, 2022:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of shares (in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price $</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">347</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.33</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,311</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(305)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(255)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.39</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,098</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.04</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Allocation of Share-Based Payments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized share-based compensation expense for the three and nine month periods ended September&#160;30, 2022 and September&#160;30, 2021 as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.683%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,489</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,531</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,201&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,625</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,480</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized under inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">387</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,320</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,092&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,398</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,666&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648614422720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_auph_CashCashEquivalentsAndDebtSecuritiesCurrent', window );">Cash and cash equivalents and investments</a></td>
<td class="nump">$ 376,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 376,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">55,779,000<span></span>
</td>
<td class="nump">$ 14,667,000<span></span>
</td>
<td class="nump">105,595,000<span></span>
</td>
<td class="nump">$ 22,201,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">41,771,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,771,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,414,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_auph_AcquiredUpfrontLicensePayment', window );">Upfront license and milestone expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Upfront license payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">$ (6,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=auph_OtuskaPharmaceuticalCoLtdMember', window );">Otuska</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 28,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=auph_MilestoneAchievementMember', window );">Milestone Achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_auph_AccountsReceivableCreditTerm', window );">Receivable standard credit terms (in days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_auph_AccountsReceivableCreditTerm', window );">Receivable standard credit terms (in days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Revenue Benchmark | Specialty Pharmacy One | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as percent)</a></td>
<td class="nump">48.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Revenue Benchmark | Specialty Pharmacy One | Outside United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as percent)</a></td>
<td class="nump">52.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_AccountsReceivableCreditTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Credit Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_AccountsReceivableCreditTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_AcquiredUpfrontLicensePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired Upfront License Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_AcquiredUpfrontLicensePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_CashCashEquivalentsAndDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents and Debt Securities, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_CashCashEquivalentsAndDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=auph_OtuskaPharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=auph_OtuskaPharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=auph_MilestoneAchievementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=auph_MilestoneAchievementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=auph_SpecialtyPharmacyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=auph_SpecialtyPharmacyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=auph_OutsideUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=auph_OutsideUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648613797936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">$ 376,644<span></span>
</td>
<td class="nump">$ 466,078<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=auph_CashCashEquivalentsAndRestrictedCashMember', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">86,052<span></span>
</td>
<td class="nump">231,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=auph_USAgencySecurityMember', window );">U.S. agency security</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">4,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">98,068<span></span>
</td>
<td class="nump">21,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">112,633<span></span>
</td>
<td class="nump">206,724<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">Treasury bill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">26,704<span></span>
</td>
<td class="nump">2,494<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBondSecuritiesMember', window );">Treasury bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">44,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=auph_YankeeBondMember', window );">Yankee bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">3,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">$ 198,685<span></span>
</td>
<td class="nump">$ 438,624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAverageRemainingMaturity1', window );">Derivative, average remaining maturity</a></td>
<td class="text">7 months<span></span>
</td>
<td class="text">8 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Cash, cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">$ 86,052<span></span>
</td>
<td class="nump">$ 231,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. agency security</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Corporate bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">112,633<span></span>
</td>
<td class="nump">206,724<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Treasury bill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Treasury bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Yankee bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">$ 177,959<span></span>
</td>
<td class="nump">$ 27,454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAverageRemainingMaturity1', window );">Derivative, average remaining maturity</a></td>
<td class="text">7 months<span></span>
</td>
<td class="text">8 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Cash, cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. agency security</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">4,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">98,068<span></span>
</td>
<td class="nump">21,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Treasury bill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">26,704<span></span>
</td>
<td class="nump">2,494<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Treasury bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">44,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Yankee bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">3,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Cash, cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | U.S. agency security</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Corporate bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Treasury bill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Treasury bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Yankee bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAverageRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average remaining period until maturity of the derivative contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAverageRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=auph_CashCashEquivalentsAndRestrictedCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=auph_CashCashEquivalentsAndRestrictedCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=auph_USAgencySecurityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=auph_USAgencySecurityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=auph_YankeeBondMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=auph_YankeeBondMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648614381280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Restricted Cash and Short-Term Investments - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments', window );">Total cash, cash equivalents, restricted cash and short-term investments</a></td>
<td class="nump">$ 376,600<span></span>
</td>
<td class="nump">$ 376,600<span></span>
</td>
<td class="nump">$ 466,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">376,600<span></span>
</td>
<td class="nump">376,600<span></span>
</td>
<td class="nump">446,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent', window );">Total held to maturity securities at amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Unrealized gains on available-for-sale securities</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="num">$ (700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Short Term Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648617835024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Restricted Cash and Short-Term Investments - Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Amortized Cost</a></td>
<td class="nump">$ 377,366<span></span>
</td>
<td class="nump">$ 446,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Unrealized Gains</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Unrealized Losses</a></td>
<td class="num">(726)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Estimated Fair Value</a></td>
<td class="nump">376,644<span></span>
</td>
<td class="nump">446,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent', window );">Total held to maturity securities at amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,228<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments', window );">Total cash, cash equivalents, restricted cash and short-term investments</a></td>
<td class="nump">376,600<span></span>
</td>
<td class="nump">466,078<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=auph_CashCashEquivalentsAndRestrictedCashMember', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Amortized Cost</a></td>
<td class="nump">86,052<span></span>
</td>
<td class="nump">231,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Estimated Fair Value</a></td>
<td class="nump">86,052<span></span>
</td>
<td class="nump">231,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Amortized Cost</a></td>
<td class="nump">4,900<span></span>
</td>
<td class="nump">3,144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Unrealized Gains</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Estimated Fair Value</a></td>
<td class="nump">4,904<span></span>
</td>
<td class="nump">3,140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=auph_ShortTermCorporateDebtSecuritiesMember', window );">Corporate bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Amortized Cost</a></td>
<td class="nump">98,448<span></span>
</td>
<td class="nump">2,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Unrealized Losses</a></td>
<td class="num">(380)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Estimated Fair Value</a></td>
<td class="nump">98,068<span></span>
</td>
<td class="nump">2,591<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Amortized Cost</a></td>
<td class="nump">112,833<span></span>
</td>
<td class="nump">206,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Unrealized Losses</a></td>
<td class="num">(200)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Estimated Fair Value</a></td>
<td class="nump">112,633<span></span>
</td>
<td class="nump">206,724<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">Treasury bill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Amortized Cost</a></td>
<td class="nump">26,721<span></span>
</td>
<td class="nump">2,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Unrealized Losses</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Estimated Fair Value</a></td>
<td class="nump">26,704<span></span>
</td>
<td class="nump">$ 2,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBondSecuritiesMember', window );">Treasury bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Amortized Cost</a></td>
<td class="nump">44,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Unrealized Losses</a></td>
<td class="num">(117)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Estimated Fair Value</a></td>
<td class="nump">44,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=auph_YankeeBondMember', window );">Yankee bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Amortized Cost</a></td>
<td class="nump">3,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Unrealized Losses</a></td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Estimated Fair Value</a></td>
<td class="nump">$ 3,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Short Term Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7A<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953401-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=auph_CashCashEquivalentsAndRestrictedCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=auph_CashCashEquivalentsAndRestrictedCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=auph_ShortTermCorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=auph_ShortTermCorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=auph_YankeeBondMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=auph_YankeeBondMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648622487472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods inventories</a></td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">2,217<span></span>
</td>
<td class="nump">$ 2,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">20,150<span></span>
</td>
<td class="nump">12,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">2,953<span></span>
</td>
<td class="nump">4,543<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 25,320<span></span>
</td>
<td class="nump">$ 19,326<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648622496080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_auph_PrepaidAssetsCurrent', window );">Prepaid assets</a></td>
<td class="nump">$ 5,725<span></span>
</td>
<td class="nump">$ 5,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Prepaid deposits</a></td>
<td class="nump">3,582<span></span>
</td>
<td class="nump">4,762<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">2,852<span></span>
</td>
<td class="nump">1,632<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 12,159<span></span>
</td>
<td class="nump">$ 11,710<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_PrepaidAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Assets, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_PrepaidAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648614390752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">$ 19,472<span></span>
</td>
<td class="nump">$ 19,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(12,633)<span></span>
</td>
<td class="num">(11,066)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">6,839<span></span>
</td>
<td class="nump">8,404<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">1,473<span></span>
</td>
<td class="nump">1,471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,249)<span></span>
</td>
<td class="num">(1,176)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Acquired intellectual property and reacquired rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">15,126<span></span>
</td>
<td class="nump">15,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(9,580)<span></span>
</td>
<td class="num">(8,804)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">5,546<span></span>
</td>
<td class="nump">6,322<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Internal-use software implementation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">2,873<span></span>
</td>
<td class="nump">2,873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,804)<span></span>
</td>
<td class="num">(1,086)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 1,069<span></span>
</td>
<td class="nump">$ 1,787<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648618145488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648614280080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 5,067<span></span>
</td>
<td class="nump">$ 5,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(1,309)<span></span>
</td>
<td class="num">(836)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,758<span></span>
</td>
<td class="nump">4,418<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">393<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">2,978<span></span>
</td>
<td class="nump">2,978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">645<span></span>
</td>
<td class="nump">645<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">976<span></span>
</td>
<td class="nump">976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 251<span></span>
</td>
<td class="nump">$ 262<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648612572800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Obligations - Narrative (Details)<br> $ in Thousands, SFr in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 03, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>ft&#178; </div>
<div>extension_option</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 12, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Capital expenditure payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,800<span></span>
</td>
<td class="nump">SFr 10.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.22%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.22%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForCapitalImprovements', window );">Payments for capital improvements | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 21.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Minimum finance lease liability payments due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease', window );">Expected payments prior to commencement of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid', window );">Future value of minimum lease payments of leases not yet commenced</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=auph_VictoriaBritishColumbiaMember', window );">Victoria, British Columbia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Capital expenditure payments</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=auph_RockvilleMarylandMember', window );">Rockville, Maryland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of property (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_auph_LesseeOperatingLeaseNumberOfExtensionOptions', window );">Number of extension options | extension_option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease extension term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_auph_LesseeOperatingLeaseLeaseTerminationTerm', window );">Lease termination option term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromTenantAllowance', window );">Proceeds from tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not yet Commenced, Liability, to be Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not yet Commenced, Payments Prior To Commencement Of Lease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_LesseeOperatingLeaseLeaseTerminationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Termination Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_LesseeOperatingLeaseLeaseTerminationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_LesseeOperatingLeaseNumberOfExtensionOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number of Extension Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_LesseeOperatingLeaseNumberOfExtensionOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForCapitalImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for acquisition of or capital improvements to properties held for investment (operating, managed, leased) or for use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForCapitalImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromTenantAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromTenantAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=auph_VictoriaBritishColumbiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=auph_VictoriaBritishColumbiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=auph_RockvilleMarylandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=auph_RockvilleMarylandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648617565616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease Obligations - Summary of Components of Leasing Costs and Rent (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term - operating leases (in years)</a></td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate - operating leases</a></td>
<td class="nump">5.22%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648622486384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease Obligations - Schedule of Maturities of Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2022</a></td>
<td class="nump">$ 263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">1,061<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">1,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">1,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">1,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">5,638<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">10,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: lease imputed interest</a></td>
<td class="num">(2,104)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total future minimum lease payments</a></td>
<td class="nump">$ 8,188<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, to be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648614635472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee accruals</a></td>
<td class="nump">$ 16,511<span></span>
</td>
<td class="nump">$ 18,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_auph_CommercialRelatedAccrualsCurrent', window );">Commercial accruals</a></td>
<td class="nump">9,140<span></span>
</td>
<td class="nump">5,916<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_auph_AccruedResearchCurrent', window );">Accrued R&amp;D projects</a></td>
<td class="nump">8,995<span></span>
</td>
<td class="nump">6,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">5,411<span></span>
</td>
<td class="nump">3,527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income taxes payable</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">814<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">$ 40,123<span></span>
</td>
<td class="nump">$ 34,947<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_AccruedResearchCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_AccruedResearchCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_CommercialRelatedAccrualsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercial Related Accruals, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_CommercialRelatedAccrualsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648614655328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Deferred Compensation and Other Non-current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">$ 15,833<span></span>
</td>
<td class="nump">$ 15,950<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648614462784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 17, 2021</div></th>
<th class="th"><div>Dec. 17, 2020</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 15, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,667<span></span>
</td>
<td class="nump">$ 105,595<span></span>
</td>
<td class="nump">$ 22,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,066<span></span>
</td>
<td class="nump">35,118<span></span>
</td>
<td class="nump">39,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,638<span></span>
</td>
<td class="nump">75,142<span></span>
</td>
<td class="nump">$ 22,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">License Agreement Terms | Otuska</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Upfront payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount', window );">Potential regulatory milestone revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_auph_ResearchAndDevelopmentArrangementContractToPerformMilestonePayments', window );">Triggered milestone, payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">License Agreement Terms | Otuska | Service Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">License Agreement Terms | Otuska | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent', window );">Tiered royalty percentages on future sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">License Agreement Terms | Otuska | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent', window );">Tiered royalty percentages on future sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">License Agreement Terms | Riptide Bioscience, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Upfront license fee</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Performance Obligation, Potential Revenue Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Tiered Royalty, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_ResearchAndDevelopmentArrangementContractToPerformMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform, Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_ResearchAndDevelopmentArrangementContractToPerformMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=auph_OtuskaPharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=auph_OtuskaPharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=auph_RiptideBioscienceIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=auph_RiptideBioscienceIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648612476160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (8,989)<span></span>
</td>
<td class="num">$ (50,255)<span></span>
</td>
<td class="num">$ (82,134)<span></span>
</td>
<td class="num">$ (147,644)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding used in computation of basic loss per share (in shares)</a></td>
<td class="nump">141,856<span></span>
</td>
<td class="nump">128,443<span></span>
</td>
<td class="nump">141,831<span></span>
</td>
<td class="nump">128,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding used in computation of diluted loss per share (in shares)</a></td>
<td class="nump">141,856<span></span>
</td>
<td class="nump">128,443<span></span>
</td>
<td class="nump">141,831<span></span>
</td>
<td class="nump">128,084<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share ($ per share)</a></td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (0.58)<span></span>
</td>
<td class="num">$ (1.15)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share ($ per share)</a></td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (0.58)<span></span>
</td>
<td class="num">$ (1.15)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648617726672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share - Anti-Dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">16,397,000<span></span>
</td>
<td class="nump">14,907,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">14,299,000<span></span>
</td>
<td class="nump">12,837,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember', window );">Unvested performance awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">857,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">2,098,000<span></span>
</td>
<td class="nump">201,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,012,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648614095264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 06, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 18, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Oct. 23, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>purchase_period</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>purchase_period</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,092<span></span>
</td>
<td class="nump">$ 25,398<span></span>
</td>
<td class="nump">$ 22,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized share-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized share-based compensation expense weighted average recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods', window );">Number of purchase periods | purchase_period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod', window );">Purchase period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod', window );">Offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_auph_ShareBasedPaymentArrangementUnamortizedExpense', window );">Unamortized expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Unvested performance awards | Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">439,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, weighted average exercise price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=auph_PerformanceShareSandRestrictedStockUnitsRSUsMember', window );">Performance Share sand Restricted Stock Units (RSUs) | Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">619,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,311,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, weighted average exercise price (in usd per share) | $ / shares</a></td>
<td class="nump">$ 14.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Performance shares vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">305,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares forfeited/canceled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=auph_AmendedAndRestatedEquityIncentivePlanMember', window );">Amended and Restated Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Consecutive Offering Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Purchase Periods</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_ShareBasedPaymentArrangementUnamortizedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Payment Arrangement, Unamortized Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_ShareBasedPaymentArrangementUnamortizedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_OfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_OfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=auph_PerformanceShareSandRestrictedStockUnitsRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=auph_PerformanceShareSandRestrictedStockUnitsRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=auph_AmendedAndRestatedEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=auph_AmendedAndRestatedEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648622605200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Weighted Average Assumptions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Annualized volatility(as percent)</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">66.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as percent)</a></td>
<td class="nump">2.01%<span></span>
</td>
<td class="nump">0.38%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options in years</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate', window );">Estimated forfeiture rate (as percent)</a></td>
<td class="nump">12.10%<span></span>
</td>
<td class="nump">8.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend', window );">Dividend rate</a></td>
<td class="nump">$ 0.000<span></span>
</td>
<td class="nump">$ 0.000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value per common share option (in usd per share)</a></td>
<td class="nump">$ 6.60<span></span>
</td>
<td class="nump">$ 6.64<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648614286800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Stock Option Activity (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of shares (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">12,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">3,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(77)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(1,507)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">14,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price $</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in usd per share)</a></td>
<td class="nump">$ 12.26<span></span>
</td>
<td class="nump">$ 12.84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share)</a></td>
<td class="nump">11.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share)</a></td>
<td class="nump">6.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited (in usd per share)</a></td>
<td class="nump">14.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in usd per share)</a></td>
<td class="nump">$ 12.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648613807696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Performance Awards and Restricted Stock Units Activity (Details) - Performance Share sand Restricted Stock Units (RSUs) - Officer - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 06, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Number of shares (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding - Beginning of Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">619<span></span>
</td>
<td class="nump">2,311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Performance shares vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(305)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Performance shares forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(255)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding - End of Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average exercise price $</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, Weighted average exercise price - Beginning of Period (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Performance shares awards, weighted average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 14.42<span></span>
</td>
<td class="nump">11.26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Performance shares vested, Weighted average grant date fair value (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Performance share forfeited, Weighted average exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, Weighted average exercise price - End of Period (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.04<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=auph_PerformanceShareSandRestrictedStockUnitsRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=auph_PerformanceShareSandRestrictedStockUnitsRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_OfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_OfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648617138928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Allocated Share-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 8,320<span></span>
</td>
<td class="nump">$ 7,092<span></span>
</td>
<td class="nump">$ 25,398<span></span>
</td>
<td class="nump">$ 22,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">1,489<span></span>
</td>
<td class="nump">1,038<span></span>
</td>
<td class="nump">3,531<span></span>
</td>
<td class="nump">3,201<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">6,625<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">21,480<span></span>
</td>
<td class="nump">19,189<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InventoriesMember', window );">Capitalized under inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 206<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
<td class="nump">$ 387<span></span>
</td>
<td class="nump">$ 276<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648620223776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="nump">$ 954<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 973<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648614623792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions (Details) - ILJIN - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related parties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=auph_MilestonePaymentMember', window );">Milestone Payment | Affiliated Shareholder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Payments to related party</a></td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=auph_ILJINMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=auph_ILJINMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=auph_MilestonePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=auph_MilestonePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140648614693376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>employee </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,809,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=auph_NewEmployeesMember', window );">New Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNewEmployees', window );">Number of new employees | employee</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=auph_NewEmployeesMember', window );">New Employees | Inducement Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">20,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">$ 7.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=auph_NewEmployeesMember', window );">New Employees | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNewEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Number of New Employees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNewEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=auph_NewEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=auph_NewEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=auph_ShareBasedPaymentArrangementInducementOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=auph_ShareBasedPaymentArrangementInducementOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>auph-20220930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:auph="http://www.auriniapharma.com/20220930"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="auph-20220930.xsd" xlink:type="simple"/>
    <context id="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4297c0d464e7468e8bf8e0d66421c5a2_I20221102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
        </entity>
        <period>
            <instant>2022-11-02</instant>
        </period>
    </context>
    <context id="iea170fa7b20a4b41b108e493dc1948f2_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6469b2d1ea454cb388fc81376000b775_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7047233c039c4e5db5ccb689cf181bd9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id8e7b1e28ca6475699ad1f3389d65b0f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6eb1901eda7949188f64f0ae3e428eaa_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9bad260542ee4aa9ae02bb08274b9038_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic4783d7802784076a6f6bfe42837f76c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i31e4e566879a474d8c808a4b79ad4910_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id181d42e4a034ee68572be022fef93f4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i436b2d2997234350abf975a031f0ec09_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7d4690f8a2eb435883c18b3504cdad69_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5eb0f19f9c074e79a40d0cb3e2ff02f3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic68c4ca008b74f51b6d19d40416666ee_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if36244d95f6d4bd299450825700e832d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i377749222219417c8982b959ba79c8f1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i27eec2a9a9cc4f2ba78ceffaf03f0d83_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i835bd94d3b8a46aea93d75b9c3e1b9f5_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i009b59fb6c994af8b5d17ed41e99cf66_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i588bcb33d7f94f32abdfc4d3a91cd187_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i611a8c2b382345d5bee16ff18c8b7de6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic38f683d1d4d4b88a3ddee342ade79d4_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7eb54bdb3b8e4810b83f9db13ac1682e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i17263ca8130048c8b999c4d7f9352e2e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i11d40396b1dd41869d1b914f4f6d8f92_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i41d70372ff754478b1094be19cf13784_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i12cec0e7fdf24de3b783ef6f7d90a849_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7c9dfc2f3c3741708e7b3da4e03bb444_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibfb50debae134f6a85fce4e5f3651cc7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i787c6a58aafe40fb93dba68bac8a5d88_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibaa74b4b308f463fa84d6d3a382b7c6a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i703ab11d0a9946cf8cc57b8243e5db59_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i114549079e764ecab84b77d1ecf6b9e4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2b49777eb2204f95acb28165c4ffb245_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i02ce71b787ab4ca797b5a9fcbaf61402_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1d1cf1ea09434d15b4be325b80931e8c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i77fa57c5982e468f985e9bcaf10d6a42_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i7443770797b0498c8cdad90152a5c590_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if9ee7fe05eee40f48c092e1b88df007a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibb29a2f97a214b8e9f797f9687616d27_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib52fb1312906471b8f138a9a0ea36fec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2464b25495094609998bc808c8e1f431_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i68fb759408e04e9b9a39503596bd5faa_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icb236f49e0c24418ab0220edb3a611e4_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iaabe0fca9ec24b28814dfdae4e2dd4d3_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i75925341cc3e4f78bacf59fb0684c25d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ied2bf63884594bf3a519994bdc8a9be1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6785021da65c4996946ac6e43914d14e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if864e170575941afb3bbe7afabdecd5a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic9fdb7f1323043c4ad197d9228b4b4b6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i08686fdbde8047d69c05941c654afac6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i533a99201f634a479988a643e020cf8b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i16ed573a0bd841e98023564edf9f9c34_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic873b1cf2e4c4bf98cf80aac069abfdf_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i84a4831b700f48b1833b184774156aeb_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie2b6cee70b84464499f7df7285aed325_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">auph:SpecialtyPharmacyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i92eaeeead41c4c3486efa48480d9b63a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">auph:SpecialtyPharmacyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib9fbd2d01b054439a783e60189d0d151_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">auph:SpecialtyPharmacyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:OutsideUnitedStatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id143a176c2d7418fa9b6975ad686ab0a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">auph:SpecialtyPharmacyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:OutsideUnitedStatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic5a4159b186c46bdae3c4c7db5a48d91_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">auph:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i248fcdd355b64b138d9e8363df09e99f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:OtuskaPharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i16cb885c9c784f19a3fb5c186669134a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i97636c4925384d11aa8a85148d437f88_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0ff9e818dc3248f3a984013c0ec35cb4_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:CashCashEquivalentsAndRestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i45420271e8ea4082b3d52812ce062bcd_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:CashCashEquivalentsAndRestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib5b00f6af1a1489ca4e19effbd717dc7_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:CashCashEquivalentsAndRestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id57531e234234b2b9cb0d8e02f891cfd_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:CashCashEquivalentsAndRestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ibabafbb16aec41b1915f48581e656afd_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:USAgencySecurityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8f27ddb9f76a467b94259faf2e7e0317_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:USAgencySecurityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ifc8d7c6306b94e968ff4f645fa32aea3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:USAgencySecurityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="idda7e1c04624428eb78cb35510f9fa7f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:USAgencySecurityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8a6083a877744937bdaec6596e628a5e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib545381e546241bfb7702079a5b4ae46_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia75ddf3673b0477d801dd590a53168cd_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7a88e33246a947da84b61da9acf16369_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i64fba90d628a47388702c84b97bf7d7a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ifa631ff412fa4ce5999335712a18dd4e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia4bd4b996a4d4872b3fac48673a43a27_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic9f1f2ee39a841c18e4e03be170e2977_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib6d26265caac4b03ac1c32ac9b0d215c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ieafdf4a188174114bc1155f63c1daa4d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i669c0d32fa12413e948255d28b9891a2_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id9a7d157907c4446a83d6762c688bc37_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7d9ec18821a143c0b5342802f48f6311_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i64661310650543b4a59ec68285dc9734_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i119daddb27794e028c6e80587444d5ad_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i879c4a29d0b4430fa56ad47b590225c2_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0c5b7f81c61c4e96ac98e4766d33339a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:YankeeBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id9178f49b5784f9aba75be7f38379650_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:YankeeBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ieb9283d88b424c60b9b3d5353d69a897_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:YankeeBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i20cb6a6c7b9e4a5380a7381cd01eeee6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:YankeeBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="idb5b6a1ae596438681cfbfdf9892f83d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id28bab9c7e1c4295b873580752711af5_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i20e1087e0598412981eb9152d79b6b14_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i565005420cf94f52b9804cec98cee107_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:CashCashEquivalentsAndRestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i615ccd0cba2748fb9fcffb4adcc668be_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:CashCashEquivalentsAndRestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i734f0c5aa1b846b08acb4ccd89a87f39_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:CashCashEquivalentsAndRestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i263f1cbad4dd43fcb51ad6c9abe11101_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:CashCashEquivalentsAndRestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2b5b0fee0d3a410eb5fe646815a1df0d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i37d4bff646e04f7f80b9a75717f9fea4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3a260d1645884811bafbb0ac61e2190b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i64ab53854b6748a49a313e183035fb12_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id6ca842beffc422d80be5664771bc026_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4804d6f12b174250ace2bb6d08b12a0e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i87306c1797ef420a8944c1b4d0ff89c4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3c5de38286e74db18b18df7f49cac2d3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idbdc367dda2942d19a94e15c46320342_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if20a77aa2fc04f8a96554bede25f9d7c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if7fb0798462249e3a2d60ca4407e0eab_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8af1b2c873d0434eaf8b9108131f9009_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i34d4826b176e435f8bd5b0030feb4952_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i59210d4302394347a4104d3d57a6934b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaf503387569145268e73f2bf99c3cba4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i904ede1b4aeb489099791792b04faf0e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i938ca9c21c994394a2ac416a16c72176_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i19c0b5fabb074b7692f8a2ab582c6da6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i477353e441ec446e872a95c69aab7d85_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if1d1a617e2e74074ae1e4ccd6de119b5_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib0a72a6a58e04c6dbc7123f06753286b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia851cc9f46674b05af88b96945f0cb85_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib711a46ca0504a0f83970696c2b2069c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i12201e4c78d14b7fa31409f5abef573b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i43c8446460754675965bbc2c13bac604_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:ShortTermCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0e7b23d46c544fc184d25711658db577_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:ShortTermCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i694749f08fba4701ba5443abefc101e0_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5cb5e9e831f5489cad13f8086d409cfb_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2753c410533a473db311c14ff1da390f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib78726334c604e7abc504057535e595b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i587a5632527b4d8f9fc78a79b55065c0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i762371a552ae4e189fdad22d6c254db5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia8ebc008d0bf419399d57a1954b31411_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i015f087f0bfd4fa583200ee0a162bffe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie438ea390b8846d7831dd0900ee639c1_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia783c0184bda40e8a385452883ad9164_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if39e9f1e69324041b0415ecd8d450952_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ieafc1263da604de4864e371e83bf3ae9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if15808d1e63744299f8008a22843785a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i71d0284de4094b58a61726e34448a7c7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie5e1845517044932807f74d13e17f14f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i344a287699e44b6abf65762731d49159_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib0122d51e9ce4a43a91c77261f282564_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:VictoriaBritishColumbiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie76075ad5fba4197953b1f9074f707fb_D20220803-20220803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:VictoriaBritishColumbiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-03</startDate>
            <endDate>2022-08-03</endDate>
        </period>
    </context>
    <context id="i8217ea002f274269ad63c35be20de5d2_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:RockvilleMarylandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ifdc02d86fd494bcd9c3bbcefc6567c61_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:RockvilleMarylandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ieab7019fc2e44f7281b349abacde0bc3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:RockvilleMarylandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i58c5e7c150d14386a0bf23271f8fcc59_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:RockvilleMarylandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2010334e882c4ffd813f86072931dd35_D20211231-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:RockvilleMarylandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i67061bc27f97417eb92caad1115e4f65_I20200312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:RockvilleMarylandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-12</instant>
        </period>
    </context>
    <context id="ibdd4d5c6c4cc486cb6916357de93b010_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i0218c4022baf4887b278a279993662cb_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="ibf32de36976c4acea4a8d8fcae729345_D20201217-20201217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:OtuskaPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-17</startDate>
            <endDate>2020-12-17</endDate>
        </period>
    </context>
    <context id="i7157bd498212400d9ba95e50a9998561_I20201217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:OtuskaPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-17</instant>
        </period>
    </context>
    <context id="i8cca31f183434cd5ab9525b020f34afc_I20201217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:OtuskaPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-17</instant>
        </period>
    </context>
    <context id="i91f3a2c3fb9444049582457768137f12_I20201217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:OtuskaPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-17</instant>
        </period>
    </context>
    <context id="ie85ef3843f6e45c68cf365c48ec7f1a3_I20220915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:OtuskaPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-15</instant>
        </period>
    </context>
    <context id="i81ca80b01c3949bc93f26e42672ea414_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:OtuskaPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2297b01889a7491d85e8a7f9850e7bfc_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:OtuskaPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia6745a5042314bd3ac418f4f36aac11f_D20210817-20210817">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:RiptideBioscienceIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-17</startDate>
            <endDate>2021-08-17</endDate>
        </period>
    </context>
    <context id="i7e7f455148c3452faa9d3f2b5d9c272f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:RiptideBioscienceIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i00d7e31976534d258d0e07349aba01f3_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i805aaa2562214865ab8c371faa3a53b2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icc8095d666774c36bf30723faadf9ce6_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2e834a4131b9497aa7197b83f5903f9c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i13cbe039556149bf854d1dbc12844c1e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic61229edf4264d52a22130a0c3be9d0a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5279b4da301648499575592309f9f17e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0b1a989842e543fabb7e5905343568bb_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2e55bb773ff34dceb51b86c13030f998_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">auph:AmendedAndRestatedEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5685017490fa48d98ee11fbfaba4943f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i141c5810302b4f94afd3d50f70c69c68_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic9213ee7781c41f3a44fe9ed868b853a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="idc1689ad65c84b429cf133572117af7a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i50399ead67c54ca8bc4d5ef310825018_D20201023-20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-23</startDate>
            <endDate>2020-10-23</endDate>
        </period>
    </context>
    <context id="i300f179e3ff14347817cbe32101e4854_D20210318-20210318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-18</startDate>
            <endDate>2021-03-18</endDate>
        </period>
    </context>
    <context id="i93beb22f8ad34d9c947d6dafa4a95334_D20210806-20210806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">auph:PerformanceShareSandRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-06</startDate>
            <endDate>2021-08-06</endDate>
        </period>
    </context>
    <context id="i6dac794371204eeea2843a0a01c0643c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2b58579e74a9437291aa1de82c974264_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">auph:PerformanceShareSandRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3c18e125ab214150a60e144497c275d2_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">auph:PerformanceShareSandRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iccc401454be24c33a5c889e8fc773573_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">auph:PerformanceShareSandRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic7fef15dae2646efa24f1995243223c6_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i41e86bba83634e53a5535985a6f3f748_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i955689f54f8c4df3a7afd2244253bc6d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib7ac41ae30d34bb5830b64dd0083e341_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib20172c5476e4c24ba772f206955d222_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iaa46d448221541eea1922a7412dadd8d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i950b5dba05e8467bb230db400bb54c89_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i92f1f72ffef04012bdf6f2e23691fde6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i31e34ae4d79d4a16962c6e8ca983e3f6_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i84deabd17e064c569d85797d9b5eda83_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3566507c79934103bc6f40ab688f624a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8ef75c4fe6024db197c096eb57a144ea_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6a603236462942e0951722c7b53081bd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:ILJINMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">auph:MilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i600c866525944e51adcfcdad3efc98eb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:ILJINMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i68a01b7c21f844ae96d03ac2032c0e28_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:ILJINMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie1901be7a6424fe8a7f80634ccb66032_D20220930-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">auph:NewEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-30</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i090a7d0df6ad405a8d7fb3f2f1fc2096_D20220930-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">auph:NewEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">auph:ShareBasedPaymentArrangementInducementOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-30</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6baa5e11e43442d0b6c324d3f77c8f48_D20220930-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">auph:NewEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-30</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>auph:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="extension_option">
        <measure>auph:extension_option</measure>
    </unit>
    <unit id="chf">
        <measure>iso4217:CHF</measure>
    </unit>
    <unit id="purchase_period">
        <measure>auph:purchase_period</measure>
    </unit>
    <unit id="employee">
        <measure>auph:employee</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180L2ZyYWc6MDliZWQ0MjQ0ZjQ3NDIzZGJkZjYxN2FlNzg2YzAzOTcvdGFibGU6OTllYjRiNmM0NTEwNDI3YTgxOWNlODI2YjY2NjE3MWUvdGFibGVyYW5nZTo5OWViNGI2YzQ1MTA0MjdhODE5Y2U4MjZiNjY2MTcxZV8yLTEtMS0xLTY4Nzk1_e2985b45-b58d-4baa-a756-a45ab9bb84f8">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180L2ZyYWc6MDliZWQ0MjQ0ZjQ3NDIzZGJkZjYxN2FlNzg2YzAzOTcvdGFibGU6OTllYjRiNmM0NTEwNDI3YTgxOWNlODI2YjY2NjE3MWUvdGFibGVyYW5nZTo5OWViNGI2YzQ1MTA0MjdhODE5Y2U4MjZiNjY2MTcxZV8zLTEtMS0xLTY4Nzk1_6498d952-52b5-46a6-ad05-09cea9a99a12">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180L2ZyYWc6MDliZWQ0MjQ0ZjQ3NDIzZGJkZjYxN2FlNzg2YzAzOTcvdGFibGU6OTllYjRiNmM0NTEwNDI3YTgxOWNlODI2YjY2NjE3MWUvdGFibGVyYW5nZTo5OWViNGI2YzQ1MTA0MjdhODE5Y2U4MjZiNjY2MTcxZV80LTEtMS0xLTY4Nzk1_be58425b-b66b-4cbb-aa56-44cb03d85b64">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180L2ZyYWc6MDliZWQ0MjQ0ZjQ3NDIzZGJkZjYxN2FlNzg2YzAzOTcvdGFibGU6OTllYjRiNmM0NTEwNDI3YTgxOWNlODI2YjY2NjE3MWUvdGFibGVyYW5nZTo5OWViNGI2YzQ1MTA0MjdhODE5Y2U4MjZiNjY2MTcxZV81LTEtMS0xLTY4Nzk1_79801d84-f635-45fc-862e-9ee6be92fe8a">0001600620</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180L2ZyYWc6MDliZWQ0MjQ0ZjQ3NDIzZGJkZjYxN2FlNzg2YzAzOTcvdGFibGU6OTllYjRiNmM0NTEwNDI3YTgxOWNlODI2YjY2NjE3MWUvdGFibGVyYW5nZTo5OWViNGI2YzQ1MTA0MjdhODE5Y2U4MjZiNjY2MTcxZV82LTEtMS0xLTY4Nzk1_879fad0b-1367-44e6-a652-4d96e89200ab">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGV4dHJlZ2lvbjpmZGQ2ZDhhOGI2ODc0ZjlhOWE3YzBjNWUxNzY4MWI0Ml8yMjg3_b4a89add-b9a3-41af-8f3f-57af906158fc">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGFibGU6MjU0ZmMwNGY2MDlmNGVjZGI1NDEzNmIyZDY1MzVjMTQvdGFibGVyYW5nZToyNTRmYzA0ZjYwOWY0ZWNkYjU0MTM2YjJkNjUzNWMxNF8wLTAtMS0xLTY4Nzk1_eb723448-7bc0-4d51-905c-0ef2d4ce03b1">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGV4dHJlZ2lvbjpmZGQ2ZDhhOGI2ODc0ZjlhOWE3YzBjNWUxNzY4MWI0Ml8yMTI_719a235c-6e6a-460c-9bd6-4796f84ba83d">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGFibGU6YmRiMjgyZGU0MjA1NDcyZGJhNmJhMmNkOTcyZDM4MTcvdGFibGVyYW5nZTpiZGIyODJkZTQyMDU0NzJkYmE2YmEyY2Q5NzJkMzgxN18wLTAtMS0xLTY4Nzk1_f31f458d-efb4-46f5-96cb-89670066240d">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGV4dHJlZ2lvbjpmZGQ2ZDhhOGI2ODc0ZjlhOWE3YzBjNWUxNzY4MWI0Ml8yMjg4_2de15a94-08dc-4017-aefe-decdf332b4d2">001-36421</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGV4dHJlZ2lvbjpmZGQ2ZDhhOGI2ODc0ZjlhOWE3YzBjNWUxNzY4MWI0Ml8yMjg5_1cc75c0e-a778-4df2-8b76-8895f2b2765b">Aurinia Pharmaceuticals Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGFibGU6ZDA0ZDk2YzE2MmY2NDNkN2JmYmQ3ZTFmN2NmODkxYTUvdGFibGVyYW5nZTpkMDRkOTZjMTYyZjY0M2Q3YmZiZDdlMWY3Y2Y4OTFhNV8wLTAtMS0xLTY4Nzk1L3RleHRyZWdpb246ZjFhMTY5YzUyNTQ1NDk1Mjg5OTc3YTUwYWFlNGUzMWZfMTM_7a1057bf-fbbc-4e78-88eb-97c9de202e04">Z4</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGFibGU6ZDA0ZDk2YzE2MmY2NDNkN2JmYmQ3ZTFmN2NmODkxYTUvdGFibGVyYW5nZTpkMDRkOTZjMTYyZjY0M2Q3YmZiZDdlMWY3Y2Y4OTFhNV8yLTAtMS0xLTY4Nzk1L3RleHRyZWdpb246OTE3YmVhMTA1ZmIzNDE3YjljYjIwNWU3NzMzODUyOWZfNA_8babe654-5aba-46c8-85ce-28fc2e1178b1">#1203-4464 Markham Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGFibGU6ZDA0ZDk2YzE2MmY2NDNkN2JmYmQ3ZTFmN2NmODkxYTUvdGFibGVyYW5nZTpkMDRkOTZjMTYyZjY0M2Q3YmZiZDdlMWY3Y2Y4OTFhNV8yLTAtMS0xLTY4Nzk1L3RleHRyZWdpb246OTE3YmVhMTA1ZmIzNDE3YjljYjIwNWU3NzMzODUyOWZfNw_2383dfee-55c6-4f4f-bf34-b74e93414006">Victoria</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGFibGU6ZDA0ZDk2YzE2MmY2NDNkN2JmYmQ3ZTFmN2NmODkxYTUvdGFibGVyYW5nZTpkMDRkOTZjMTYyZjY0M2Q3YmZiZDdlMWY3Y2Y4OTFhNV8yLTAtMS0xLTY4Nzk1L3RleHRyZWdpb246OTE3YmVhMTA1ZmIzNDE3YjljYjIwNWU3NzMzODUyOWZfMTE_c7c59036-e001-4433-b081-0337816883ef">BC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGFibGU6ZDA0ZDk2YzE2MmY2NDNkN2JmYmQ3ZTFmN2NmODkxYTUvdGFibGVyYW5nZTpkMDRkOTZjMTYyZjY0M2Q3YmZiZDdlMWY3Y2Y4OTFhNV8yLTAtMS0xLTY4Nzk1L3RleHRyZWdpb246OTE3YmVhMTA1ZmIzNDE3YjljYjIwNWU3NzMzODUyOWZfMTQ_31482de1-fa2c-4f62-b3ed-da6f9bc66f28">V8Z 7X8</dei:EntityAddressPostalZipCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGFibGU6ZDA0ZDk2YzE2MmY2NDNkN2JmYmQ3ZTFmN2NmODkxYTUvdGFibGVyYW5nZTpkMDRkOTZjMTYyZjY0M2Q3YmZiZDdlMWY3Y2Y4OTFhNV8yLTEtMS0xLTY4Nzk1L3RleHRyZWdpb246MDJiMTQyNmUwMGU1NGU5NTg2ODczOGI2NTk4YTdiNWRfNA_49bdd13d-a67c-43e4-8af5-a8ce7ddc59c7">98-1231763</dei:EntityTaxIdentificationNumber>
    <dei:CityAreaCode
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGV4dHJlZ2lvbjpmZGQ2ZDhhOGI2ODc0ZjlhOWE3YzBjNWUxNzY4MWI0Ml8yMjkw_e6601714-7760-4f11-9ec7-09302dd62bce">(250)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGV4dHJlZ2lvbjpmZGQ2ZDhhOGI2ODc0ZjlhOWE3YzBjNWUxNzY4MWI0Ml8yMjkx_f4d7e338-b177-4128-ae17-92f3490f7558">744-2487</dei:LocalPhoneNumber>
    <dei:EntityCurrentReportingStatus
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGV4dHJlZ2lvbjpmZGQ2ZDhhOGI2ODc0ZjlhOWE3YzBjNWUxNzY4MWI0Ml8yMjg0_4cbf8dcd-5579-4a69-9d10-21d906403174">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGV4dHJlZ2lvbjpmZGQ2ZDhhOGI2ODc0ZjlhOWE3YzBjNWUxNzY4MWI0Ml8yMjg1_c2538e3d-459d-4ca2-93ab-f208822f6801">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGFibGU6MDc5ZjkxNzA5ODRhNDNjMGJjODM4MWQ5YzkyMDUyOGYvdGFibGVyYW5nZTowNzlmOTE3MDk4NGE0M2MwYmM4MzgxZDljOTIwNTI4Zl8wLTAtMS0xLTY4Nzk1_20bf9d8d-5870-4dd0-bd0e-6ea85b61d288">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGFibGU6MDc5ZjkxNzA5ODRhNDNjMGJjODM4MWQ5YzkyMDUyOGYvdGFibGVyYW5nZTowNzlmOTE3MDk4NGE0M2MwYmM4MzgxZDljOTIwNTI4Zl8yLTQtMS0xLTY4Nzk1_9c8f49e9-afdd-4b18-95dd-d4f114a4598c">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGFibGU6MDc5ZjkxNzA5ODRhNDNjMGJjODM4MWQ5YzkyMDUyOGYvdGFibGVyYW5nZTowNzlmOTE3MDk4NGE0M2MwYmM4MzgxZDljOTIwNTI4Zl80LTEtMS0xLTY4Nzk1_95057e11-113e-490c-a05d-9eac8f4f83ee">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGV4dHJlZ2lvbjpmZGQ2ZDhhOGI2ODc0ZjlhOWE3YzBjNWUxNzY4MWI0Ml8yMjg2_75e37ccc-43bd-4c6d-a19d-70484c51d4bf">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i4297c0d464e7468e8bf8e0d66421c5a2_I20221102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGV4dHJlZ2lvbjpmZGQ2ZDhhOGI2ODc0ZjlhOWE3YzBjNWUxNzY4MWI0Ml8xNjQ5MjY3NDQ0MDU1_f6468205-4fc3-4494-b003-89e868e4be54"
      unitRef="shares">142109703</dei:EntityCommonStockSharesOutstanding>
    <dei:Security12bTitle
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGFibGU6MDk1ODE3MTc1OWI4NDUzMDhmNWU1Yzg4NWVmZjgyOGYvdGFibGVyYW5nZTowOTU4MTcxNzU5Yjg0NTMwOGY1ZTVjODg1ZWZmODI4Zl8xLTAtMS0xLTY4Nzk1_2a63b8d9-26b2-4640-9378-33fcf59e3d9c">Common shares, no par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGFibGU6MDk1ODE3MTc1OWI4NDUzMDhmNWU1Yzg4NWVmZjgyOGYvdGFibGVyYW5nZTowOTU4MTcxNzU5Yjg0NTMwOGY1ZTVjODg1ZWZmODI4Zl8xLTEtMS0xLTY4Nzk1_1dab4d97-d4e5-4bc6-b50b-538055a12f73">AUPH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xL2ZyYWc6ZmRkNmQ4YThiNjg3NGY5YTlhN2MwYzVlMTc2ODFiNDIvdGFibGU6MDk1ODE3MTc1OWI4NDUzMDhmNWU1Yzg4NWVmZjgyOGYvdGFibGVyYW5nZTowOTU4MTcxNzU5Yjg0NTMwOGY1ZTVjODg1ZWZmODI4Zl8xLTItMS0xLTY4Nzk1_3b77cab3-b6f1-4567-9923-d39fd07d8f5b">NASDAQ</dei:SecurityExchangeName>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfNC0yLTEtMS02ODc5NQ_662d350c-0fbb-4659-909c-c2527d99e2e6"
      unitRef="usd">86052000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfNC00LTEtMS02ODc5NQ_06a69c63-6432-4e9c-9536-d01d9baf30f9"
      unitRef="usd">231900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfNS0yLTEtMS02ODc5NQ_a3fec716-46b7-4cef-b116-f07e5531f385"
      unitRef="usd">290592000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfNS00LTEtMS02ODc5NQ_b5990155-ebcb-4270-a36a-12d10acdd078"
      unitRef="usd">234178000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfNi0yLTEtMS02ODc5NQ_ba39803d-6071-400f-99f8-296a7b7076db"
      unitRef="usd">41771000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfNi00LTEtMS02ODc5NQ_eb273425-3ae0-4861-b2dd-b8d24163a253"
      unitRef="usd">15414000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfNy0yLTEtMS02ODc5NQ_59893fd4-b411-4bb7-9bf5-0dbeb231dd97"
      unitRef="usd">25320000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfNy00LTEtMS02ODc5NQ_24d038ca-1a28-4c91-a23e-2b5f5339da5e"
      unitRef="usd">19326000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfOC0yLTEtMS02ODc5NQ_13cb65e9-e1f1-45b2-955d-295a21395a1f"
      unitRef="usd">12159000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfOC00LTEtMS02ODc5NQ_8587d2c8-e381-4634-b9ed-28f341d77071"
      unitRef="usd">11710000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfOS0yLTEtMS03NjE3Mg_c7f76ecc-5ed8-43c6-9ae1-5512e36f8e12"
      unitRef="usd">3808000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfOS00LTEtMS03NjE3Mg_c7caa5b5-f89b-49bf-90b7-4bdd38b6a68f"
      unitRef="usd">796000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfOS0yLTEtMS02ODc5NQ_9a43d5ac-b820-4857-950d-4ae00a623e34"
      unitRef="usd">459702000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfOS00LTEtMS02ODc5NQ_afb31def-1bdf-462d-a613-aeb1b5227f92"
      unitRef="usd">513324000</us-gaap:AssetsCurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMTMtMi0xLTEtNjg3OTU_40275d7a-1c89-4e5e-9327-c4a4ba14186b"
      unitRef="usd">13049000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMTMtNC0xLTEtNjg3OTU_751f6121-45f6-48c7-866e-321e6aefde44"
      unitRef="usd">11838000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMTQtMi0xLTEtNjg3OTU_496b733a-abbc-4a67-a9b2-39e62f8fbe75"
      unitRef="usd">3758000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMTQtNC0xLTEtNjg3OTU_ebee8a9e-d2f9-4a26-85ad-156b5baded1f"
      unitRef="usd">4418000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMTUtMi0xLTEtNjg3OTU_43d45e2f-a508-45ad-a698-c1d817259b93"
      unitRef="usd">6839000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMTUtNC0xLTEtNjg3OTU_c6a6e266-572e-426d-b6d1-151143ad217e"
      unitRef="usd">8404000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMTYtMi0xLTEtNjg3OTU_a1ce61cf-ab81-4eb0-90cc-de9bb544a6f8"
      unitRef="usd">4945000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMTYtNC0xLTEtNjg3OTU_9b62d272-4c70-489a-aae3-297dbd1d8acc"
      unitRef="usd">5383000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMTctMi0xLTEtNjg3OTU_4a73fd77-b359-4b6d-b04e-c049e5e59c16"
      unitRef="usd">488293000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMTctNC0xLTEtNjg3OTU_55f5ae56-8698-4452-a2dd-57f61f6d4401"
      unitRef="usd">543367000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMjEtMi0xLTEtNjg3OTU_90ff1f26-ac8a-46b0-9ef4-66a2f3c55f2f"
      unitRef="usd">40123000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMjEtNC0xLTEtNjg3OTU_7024a41a-97b4-42b2-850d-49071c0db43b"
      unitRef="usd">34947000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMjItMi0xLTEtNjg3OTU_08be742a-0557-4a50-8ffb-cf8a3d5750b8"
      unitRef="usd">724000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMjItNC0xLTEtNjg3OTU_e2571848-5f1e-419e-8643-62e718d08817"
      unitRef="usd">4640000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMjMtMi0xLTEtNjg3OTU_fb566ef1-9b03-41bc-a911-885211907edc"
      unitRef="usd">918000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMjMtNC0xLTEtNjg3OTU_94d9bd6e-301b-46e6-b5df-914e449b3d48"
      unitRef="usd">1059000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMjQtMi0xLTEtNjg3OTU_a313b7c5-7dcd-424b-b1fa-bfbf3d89dea0"
      unitRef="usd">41765000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMjQtNC0xLTEtNjg3OTU_f853965e-4100-49f9-980e-079c978db5bd"
      unitRef="usd">40646000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMjctMi0xLTEtNjg3OTU_16c1fd81-dbe3-4ae3-9129-c7585ea41b96"
      unitRef="usd">15833000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMjctNC0xLTEtNjg3OTU_056d96f1-34a0-4869-a5de-2b4c93ad5f0c"
      unitRef="usd">15950000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMjgtMi0xLTEtNjg3OTU_d6e69e7d-a146-45e5-b670-b685a8949a82"
      unitRef="usd">7270000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMjgtNC0xLTEtNjg3OTU_41a42514-6876-4e55-9f77-b392e47002a9"
      unitRef="usd">7680000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMjktMi0xLTEtNjg3OTU_6992fe4b-ac2a-4624-9564-cece607094cb"
      unitRef="usd">64868000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMjktNC0xLTEtNjg3OTU_09e54f13-885b-454f-b513-9dd1af8ef775"
      unitRef="usd">64276000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzAtMi0xLTEtNjg3OTU_a0f8f6a7-b5a2-4063-9c2e-729db481726d"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzAtNC0xLTEtNjg3OTU_6b977572-73cf-457b-bfdf-9e506f21d643"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzItMC0xLTEtNjg3OTUvdGV4dHJlZ2lvbjo3NzBjOTRiYjJlMWE0NzNlOWIyNzY4OTEwZTVlZWY5Yl8yMA_22e1a25f-0e51-49c4-b1a6-bf5ac229b7bd"
      unitRef="usdPerShare">0</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzItMC0xLTEtNjg3OTUvdGV4dHJlZ2lvbjo3NzBjOTRiYjJlMWE0NzNlOWIyNzY4OTEwZTVlZWY5Yl8yMA_bf763934-c40a-4fdc-8ce7-544fe6b13d0e"
      unitRef="usdPerShare">0</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzItMC0xLTEtNjg3OTUvdGV4dHJlZ2lvbjo3NzBjOTRiYjJlMWE0NzNlOWIyNzY4OTEwZTVlZWY5Yl82Mw_2f0d46a8-6fb1-4bf7-aa13-5318cf50a72d"
      unitRef="shares">142110000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzItMC0xLTEtNjg3OTUvdGV4dHJlZ2lvbjo3NzBjOTRiYjJlMWE0NzNlOWIyNzY4OTEwZTVlZWY5Yl82Mw_4a40b82e-36a7-4f09-be91-93dc69d072de"
      unitRef="shares">142110000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzItMC0xLTEtNjg3OTUvdGV4dHJlZ2lvbjo3NzBjOTRiYjJlMWE0NzNlOWIyNzY4OTEwZTVlZWY5Yl83MA_a55f13dd-f09f-4773-805f-f7b174332b4f"
      unitRef="shares">141600000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzItMC0xLTEtNjg3OTUvdGV4dHJlZ2lvbjo3NzBjOTRiYjJlMWE0NzNlOWIyNzY4OTEwZTVlZWY5Yl83MA_f6af4d5d-016a-42e3-a175-39dcbcfa890e"
      unitRef="shares">141600000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValueOutstanding
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzItMi0xLTEtNjg3OTU_32a101b5-758f-45a3-8419-9dafe1091e00"
      unitRef="usd">1184020000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzItNC0xLTEtNjg3OTU_e95f341d-2eac-48f2-86ce-759f65e2e843"
      unitRef="usd">1177051000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzMtMi0xLTEtNjg3OTU_cb8426c0-839e-458a-8a1b-f946183cb4e9"
      unitRef="usd">79188000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzMtNC0xLTEtNjg3OTU_fb2f15bc-bd67-4748-9378-c846a2006dd1"
      unitRef="usd">59014000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzQtMi0xLTEtNjg3OTU_27e4104f-9332-4733-ac46-f2c4697d588c"
      unitRef="usd">-1527000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzQtNC0xLTEtNjg3OTU_c782c557-cab1-446e-86fc-168bc10ebfe0"
      unitRef="usd">-852000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzUtMi0xLTEtNjg3OTU_8292cbd5-e944-45e7-9512-99098da8e355"
      unitRef="usd">-838256000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzUtNC0xLTEtNjg3OTU_f7cf510a-0f05-466e-a77c-d618fc0af3da"
      unitRef="usd">-756122000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzYtMi0xLTEtNjg3OTU_b5d2e340-525a-44cc-9cc2-e2d33d173388"
      unitRef="usd">423425000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzYtNC0xLTEtNjg3OTU_f4c3a5ab-278b-43f0-87d5-b8b8870b4250"
      unitRef="usd">479091000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzctMi0xLTEtNjg3OTU_96bea594-120e-4f38-980f-11653735304b"
      unitRef="usd">488293000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xNi9mcmFnOjBhMjE2YWRjM2E2NzQ2MTY4OTI5OWRjZWFiNWQzYjgxL3RhYmxlOjhhYWNiNDYzZTE2NDQyZTZiZTg0MWIxNmExNjI5NGQ4L3RhYmxlcmFuZ2U6OGFhY2I0NjNlMTY0NDJlNmJlODQxYjE2YTE2Mjk0ZDhfMzctNC0xLTEtNjg3OTU_43794912-6b75-4fae-801b-4344294116f2"
      unitRef="usd">543367000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6469b2d1ea454cb388fc81376000b775_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfNS0yLTEtMS02ODc5NQ_9e65c100-b232-4d1d-834a-6fd79b0c32c7"
      unitRef="usd">25502000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7047233c039c4e5db5ccb689cf181bd9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfNS00LTEtMS02ODc5NQ_3ce3b094-5735-4540-b83b-3d75c4884949"
      unitRef="usd">14638000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id8e7b1e28ca6475699ad1f3389d65b0f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfNS02LTEtMS02ODc5NQ_de4ccda9-d15d-417b-b86a-b0aa7cce4e61"
      unitRef="usd">75142000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6eb1901eda7949188f64f0ae3e428eaa_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfNS04LTEtMS02ODc5NQ_4810740c-c917-48b1-aa2e-7f261b324763"
      unitRef="usd">22113000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9bad260542ee4aa9ae02bb08274b9038_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfNi0yLTEtMS02ODc5NQ_ca431cb7-132c-4ccd-a7bc-b126f6e329a7"
      unitRef="usd">30277000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic4783d7802784076a6f6bfe42837f76c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfNi00LTEtMS02ODc5NQ_04a3c6f8-bc45-4128-8202-a4a61b0679f1"
      unitRef="usd">29000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i31e4e566879a474d8c808a4b79ad4910_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfNi02LTEtMS02ODc5NQ_a7c7a217-3066-4e40-b66f-ef1e0efba75f"
      unitRef="usd">30453000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id181d42e4a034ee68572be022fef93f4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfNi04LTEtMS02ODc5NQ_6c66b28f-b882-408b-998f-c900bdf4f04a"
      unitRef="usd">88000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfNy0yLTEtMS02ODc5NQ_164a71c7-96a6-44f7-b443-8ef780d46748"
      unitRef="usd">55779000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfNy00LTEtMS02ODc5NQ_c42ff336-8dc9-43a8-913f-faf46f689184"
      unitRef="usd">14667000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfNy02LTEtMS02ODc5NQ_dd81ac05-7ad8-403c-b13b-cc1403b35b54"
      unitRef="usd">105595000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfNy04LTEtMS02ODc5NQ_1b1f11ce-52d7-4082-9586-10c0d7670257"
      unitRef="usd">22201000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfOS0yLTEtMS02ODc5NQ_dfb04afb-bdd7-49a5-ad78-4b2930b47cfd"
      unitRef="usd">2447000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfOS00LTEtMS02ODc5NQ_5d78ff74-8a50-4d4a-81a4-a9a1bc347d65"
      unitRef="usd">254000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfOS02LTEtMS02ODc5NQ_6933a87c-61e1-4a89-b069-5199f39a724b"
      unitRef="usd">4302000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfOS04LTEtMS02ODc5NQ_1502c1a1-40dc-43a4-b233-b12bf76bec77"
      unitRef="usd">610000</us-gaap:CostOfRevenue>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTAtMi0xLTEtNjg3OTU_9f20c9c5-deb4-4e4c-a3b7-3208add48954"
      unitRef="usd">52169000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTAtNC0xLTEtNjg3OTU_f5c760bf-3c08-43ff-b03a-d0117188a5d4"
      unitRef="usd">44645000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTAtNi0xLTEtNjg3OTU_73733aef-2bc3-4222-a75c-f487b0642b49"
      unitRef="usd">148898000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTAtOC0xLTEtNjg3OTU_933cab8f-2ec2-4b2f-9c9e-763a4556e9f3"
      unitRef="usd">128772000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTEtMi0xLTEtNjg3OTU_377ab3a5-37b9-41e2-88a4-3b9727e7d827"
      unitRef="usd">10973000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTEtNC0xLTEtNjg3OTU_128d6edf-9194-4569-9b9e-e12dd31bafd1"
      unitRef="usd">20066000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTEtNi0xLTEtNjg3OTU_d1c8ce1b-0840-417a-be2f-568daf52edd0"
      unitRef="usd">35118000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTEtOC0xLTEtNjg3OTU_116b84af-2c92-47ef-861c-674b49d516a4"
      unitRef="usd">39990000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTMtMi0xLTEtNjg3OTU_e31948d3-4fc9-4aae-b55f-2f50beb8232b"
      unitRef="usd">311000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTMtNC0xLTEtNjg3OTU_8643bddf-4eae-462f-a870-0af5076703ab"
      unitRef="usd">-55000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTMtNi0xLTEtNjg3OTU_a45cd1f0-7e20-4a91-b928-d0e40fcbf6ed"
      unitRef="usd">-647000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTMtOC0xLTEtNjg3OTU_e45f1013-e5e4-45a3-a5fe-01da78d26710"
      unitRef="usd">-859000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:CostsAndExpenses
      contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTQtMi0xLTEtNjg3OTU_6b81aa24-0c5e-4aea-8965-3110ca879a87"
      unitRef="usd">65278000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTQtNC0xLTEtNjg3OTU_b94eb6f3-95b2-4783-8a9a-3f9ad2081dda"
      unitRef="usd">65020000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTQtNi0xLTEtNjg3OTU_e9a5871f-1631-4eb3-ad9e-a4cf3a13c48f"
      unitRef="usd">188965000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTQtOC0xLTEtNjg3OTU_53b72284-a70a-46ac-aa87-456625540fb9"
      unitRef="usd">170231000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTUtMi0xLTEtNjg3OTU_70f5ff8e-a88f-4224-a332-81b944f01629"
      unitRef="usd">-9499000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTUtNC0xLTEtNjg3OTU_5d251d21-f1db-4b26-a6a4-0d04f4d73cd4"
      unitRef="usd">-50353000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTUtNi0xLTEtNjg3OTU_0ae75d90-6e75-465c-935f-0a3dadec8f21"
      unitRef="usd">-83370000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTUtOC0xLTEtNjg3OTU_919ff696-3f67-4070-ac6b-2f6438d566a1"
      unitRef="usd">-148030000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTYtMi0xLTEtNjg3OTU_926f56bb-83c0-4caf-9919-264b1681849e"
      unitRef="usd">1464000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTYtNC0xLTEtNjg3OTU_8f7bd871-f702-4101-9543-bacc054d34e4"
      unitRef="usd">106000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTYtNi0xLTEtNjg3OTU_6a0df447-eb65-441b-9fcf-9f54a429d93d"
      unitRef="usd">2209000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTYtOC0xLTEtNjg3OTU_9a8c9b86-22be-4738-aa2c-16e47356cdc5"
      unitRef="usd">420000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTctMi0xLTEtNjg3OTU_4db5d862-c5d1-47d4-9fb1-bdde710000a8"
      unitRef="usd">-8035000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTctNC0xLTEtNjg3OTU_a1cb2137-760d-4087-b792-568ee096d59e"
      unitRef="usd">-50247000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTctNi0xLTEtNjg3OTU_8dd833cc-ae0a-4759-867c-f58503553d32"
      unitRef="usd">-81161000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTctOC0xLTEtNjg3OTU_70a05b6a-7a82-4e09-a9a4-ff988e1ebc5f"
      unitRef="usd">-147610000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTgtMi0xLTEtNjg3OTU_7a0e4cdc-ad8c-48c5-abd5-2b72d0c5ce70"
      unitRef="usd">954000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTgtNC0xLTEtNjg3OTU_78e60b59-49fb-4f6a-8960-eec1cb2796d8"
      unitRef="usd">8000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTgtNi0xLTEtNjg3OTU_67818103-59ea-48ff-9499-e72a896784db"
      unitRef="usd">973000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTgtOC0xLTEtNjg3OTU_21a7213c-d782-43a3-88e5-9a1e335ad4a1"
      unitRef="usd">34000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTktMi0xLTEtNjg3OTU_c73fa4d2-b2f1-4f6c-96c7-2e75599b0882"
      unitRef="usd">-8989000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTktNC0xLTEtNjg3OTU_2fae839c-b95b-444a-84b6-a6af98b12e20"
      unitRef="usd">-50255000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTktNi0xLTEtNjg3OTU_9e9b5b58-b094-4198-bfd4-b7dc5a6aab4b"
      unitRef="usd">-82134000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMTktOC0xLTEtNjg3OTU_d38cd7d1-808f-4cc4-aac9-b23f911b005b"
      unitRef="usd">-147644000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjEtMC0xLTEtNjg3OTUvdGV4dHJlZ2lvbjpjODJlYTUwNDQzZDI0ZDZmOTkxNjFhYTc1ZTg1ZmRhNl83NQ_8699fd76-fdcf-4a25-94ed-af4ff415ce00"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjEtMC0xLTEtNjg3OTUvdGV4dHJlZ2lvbjpjODJlYTUwNDQzZDI0ZDZmOTkxNjFhYTc1ZTg1ZmRhNl83NQ_a3bace4b-78ad-454b-b87f-f2d8245c8c3d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjEtMC0xLTEtNjg3OTUvdGV4dHJlZ2lvbjpjODJlYTUwNDQzZDI0ZDZmOTkxNjFhYTc1ZTg1ZmRhNl83NQ_c06a3897-48c5-4583-a599-079f5ea26587"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjEtMC0xLTEtNjg3OTUvdGV4dHJlZ2lvbjpjODJlYTUwNDQzZDI0ZDZmOTkxNjFhYTc1ZTg1ZmRhNl83NQ_f542165e-d5be-40d1-ad4d-d4c69d074b87"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjEtMi0xLTEtNjg3OTU_4f4c0b6f-2c35-4011-afbc-dfad02816ebd"
      unitRef="usd">326000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjEtNC0xLTEtNjg3OTU_3e598ad0-b400-447c-a6e8-817029cb40af"
      unitRef="usd">-2000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjEtNi0xLTEtNjg3OTU_b5cabf12-abf1-43c3-9d26-2c9fd625ee4d"
      unitRef="usd">-675000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjEtOC0xLTEtNjg3OTU_ffd69119-5b0f-471b-ba02-c12401e4189b"
      unitRef="usd">11000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjItMi0xLTEtNjg3OTU_6b10f586-6774-48be-83eb-57746a9bd407"
      unitRef="usd">-8663000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjItNC0xLTEtNjg3OTU_8e5b2269-3605-4e92-8f9c-eb07d73efdd9"
      unitRef="usd">-50257000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjItNi0xLTEtNjg3OTU_50041993-9cee-453a-be31-64041ec63900"
      unitRef="usd">-82809000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjItOC0xLTEtNjg3OTU_a7e3f44e-e1f0-4866-bccb-22ff0c6d3d62"
      unitRef="usd">-147633000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjMtMi0xLTEtNjg3OTU_ae38e2c4-7756-406c-8771-fcba4ca02e5f"
      unitRef="usdPerShare">-0.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjMtMi0xLTEtNjg3OTU_daf9800f-993b-4772-bc88-a8a4111d49e1"
      unitRef="usdPerShare">-0.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjMtNC0xLTEtNjg3OTU_dc254853-dc60-4e33-8b3f-4d8fff6e5e85"
      unitRef="usdPerShare">-0.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjMtNC0xLTEtNjg3OTU_fff8f429-aedf-400d-bf81-ee2f2631205d"
      unitRef="usdPerShare">-0.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjMtNi0xLTEtNjg3OTU_b4968c48-c79b-4a8c-b05a-6bf21069c9ed"
      unitRef="usdPerShare">-0.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjMtNi0xLTEtNjg3OTU_b5a8a608-e110-43a1-88aa-f81c58ffd49b"
      unitRef="usdPerShare">-0.58</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjMtOC0xLTEtNjg3OTU_31ffa586-e0ed-48c8-8aaa-ba9f30bfa8d6"
      unitRef="usdPerShare">-1.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjMtOC0xLTEtNjg3OTU_e5084b12-23ad-44fc-97c9-46969cd8e562"
      unitRef="usdPerShare">-1.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjQtMi0xLTEtNjg3OTU_7332c26b-4c28-41c2-a66b-242e73af1578"
      unitRef="shares">141856000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjQtMi0xLTEtNjg3OTU_c33d077b-fa58-4487-8c99-79c51376595c"
      unitRef="shares">141856000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjQtNC0xLTEtNjg3OTU_9ac42c5a-ca34-4075-a9aa-d906013a561f"
      unitRef="shares">128443000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjQtNC0xLTEtNjg3OTU_d466ad19-a69b-4c0b-b2ce-342866f78249"
      unitRef="shares">128443000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjQtNi0xLTEtNjg3OTU_37a95419-36d0-4d38-adae-31253d4a387d"
      unitRef="shares">141831000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjQtNi0xLTEtNjg3OTU_c8fedb66-8dc5-4220-98a3-c77d43e50d1b"
      unitRef="shares">141831000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjQtOC0xLTEtNjg3OTU_32e2352f-c254-43ba-94ae-4e53c4979b68"
      unitRef="shares">128084000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18xOS9mcmFnOmRmN2FiYTc1ZDVmNjQ2MmQ4YTlmNjNjMjNmMzVhOTc0L3RhYmxlOjAxMGJjMTc3MjU5ZjQ4NzY5Mjc2ZmQ3ZWRiNWUyZWI0L3RhYmxlcmFuZ2U6MDEwYmMxNzcyNTlmNDg3NjkyNzZmZDdlZGI1ZTJlYjRfMjQtOC0xLTEtNjg3OTU_ce59f9bd-4250-40e5-baa7-145a84bf684d"
      unitRef="shares">128084000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7d4690f8a2eb435883c18b3504cdad69_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMi0yLTEtMS02ODc5NQ_a898face-8030-4c5c-86cb-d524e692d2af"
      unitRef="shares">141892000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i7d4690f8a2eb435883c18b3504cdad69_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMi00LTEtMS02ODc5NQ_79c62ff9-519c-4d6d-944b-359434aeaed0"
      unitRef="usd">1180884000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5eb0f19f9c074e79a40d0cb3e2ff02f3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMi02LTEtMS02ODc5NQ_3db9be0a-23e4-43fc-9651-39fa8fef7ea3"
      unitRef="usd">74004000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic68c4ca008b74f51b6d19d40416666ee_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMi04LTEtMS02ODc5NQ_dc494a88-8ccd-4b2e-976a-9f2ee0203fa4"
      unitRef="usd">-1853000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if36244d95f6d4bd299450825700e832d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMi0xMC0xLTEtNjg3OTU_6de3aff4-bec7-453c-8566-4d9659eab1d6"
      unitRef="usd">-829267000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i377749222219417c8982b959ba79c8f1_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMi0xMi0xLTEtNjg3OTU_a731e6bc-dea1-404d-ab39-8c709cee4d99"
      unitRef="usd">423768000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i27eec2a9a9cc4f2ba78ceffaf03f0d83_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMy0yLTEtMS02ODc5NQ_f7e55753-f923-47b7-b7f5-ceb1e918cc63"
      unitRef="shares">218000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i27eec2a9a9cc4f2ba78ceffaf03f0d83_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMy00LTEtMS02ODc5NQ_956c9ca6-aedd-4e39-95d0-376bc1ea448a"
      unitRef="usd">3136000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i835bd94d3b8a46aea93d75b9c3e1b9f5_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMy02LTEtMS02ODc5NQ_502d6d60-ea6c-48c1-9564-a5656741826c"
      unitRef="usd">-3136000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMy0xMi0xLTEtNjg3OTU_77813bf9-840f-4e5d-b4d8-db91199a2a1d"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i835bd94d3b8a46aea93d75b9c3e1b9f5_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfNS02LTEtMS02ODc5NQ_8f3c317a-1af3-4fdd-98c1-0b7d03e38413"
      unitRef="usd">8320000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfNS0xMi0xLTEtNjg3OTU_42157d27-24cd-474b-9e3b-051a770c3882"
      unitRef="usd">8320000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i009b59fb6c994af8b5d17ed41e99cf66_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfNi04LTEtMS02ODc5NQ_0362e098-1c37-434b-8cbe-43125e6f65c1"
      unitRef="usd">326000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfNi0xMi0xLTEtNjg3OTU_47ade82e-f3e9-4f5e-9236-5e5c0d371870"
      unitRef="usd">326000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i588bcb33d7f94f32abdfc4d3a91cd187_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfNy0xMC0xLTEtNjg3OTU_fe0b8e6c-3ddc-4e1f-8a5f-d0036bc7ab26"
      unitRef="usd">-8989000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfNy0xMi0xLTEtNjg3OTU_9b611fdd-5dc3-4fa5-b920-dacc6fdaa991"
      unitRef="usd">-8989000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i611a8c2b382345d5bee16ff18c8b7de6_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfOC0yLTEtMS02ODc5NQ_2a283fbc-4f53-43a4-94a6-4e9016d9dfda"
      unitRef="shares">142110000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i611a8c2b382345d5bee16ff18c8b7de6_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfOC00LTEtMS02ODc5NQ_e72b17df-930e-4599-bcc1-8ea91a9c0f2c"
      unitRef="usd">1184020000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic38f683d1d4d4b88a3ddee342ade79d4_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfOC02LTEtMS02ODc5NQ_812c33c7-b03a-4033-b426-8259af7ccce2"
      unitRef="usd">79188000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7eb54bdb3b8e4810b83f9db13ac1682e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfOC04LTEtMS02ODc5NQ_52785b08-3b85-4a9a-8fcd-60ac1a78b890"
      unitRef="usd">-1527000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i17263ca8130048c8b999c4d7f9352e2e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfOC0xMC0xLTEtNjg3OTU_b25e0e30-5770-479e-85ba-244b54f4e61b"
      unitRef="usd">-838256000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfOC0xMi0xLTEtNjg3OTU_0c5c79c7-c3d7-4de0-9434-4d4a0e0581d3"
      unitRef="usd">423425000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i11d40396b1dd41869d1b914f4f6d8f92_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTItMi0xLTEtNjg3OTU_0e1af857-d3f1-423c-9e96-984269deedc2"
      unitRef="shares">128396000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i11d40396b1dd41869d1b914f4f6d8f92_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTItNC0xLTEtNjg3OTU_e1fbb94e-f525-4c06-8016-8c44a2d196c8"
      unitRef="usd">954572000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i41d70372ff754478b1094be19cf13784_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTItNi0xLTEtNjg3OTU_6ef07f1c-741c-4cd5-a1ca-57f21fec8a67"
      unitRef="usd">51022000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i12cec0e7fdf24de3b783ef6f7d90a849_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTItOC0xLTEtNjg3OTU_dcbba2c0-9a4e-44de-a819-0f26a4b86f29"
      unitRef="usd">-792000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7c9dfc2f3c3741708e7b3da4e03bb444_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTItMTAtMS0xLTY4Nzk1_42a8bdd9-7303-48ef-8e4b-8fcb7314df3d"
      unitRef="usd">-672545000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibfb50debae134f6a85fce4e5f3651cc7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTItMTItMS0xLTY4Nzk1_5212ad11-6ee2-47a8-bc42-838603fc3e3f"
      unitRef="usd">332257000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i787c6a58aafe40fb93dba68bac8a5d88_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTMtMi0xLTEtNjg3OTU_78d6e3fa-92db-48a3-ad6c-b6952af3e5ab"
      unitRef="shares">1172000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i787c6a58aafe40fb93dba68bac8a5d88_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTMtNC0xLTEtNjg3OTU_fc192957-fb08-418f-8eb4-fb6759e20b53"
      unitRef="usd">12579000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ibaa74b4b308f463fa84d6d3a382b7c6a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTMtNi0xLTEtNjg3OTU_6d5bb23c-e318-4ab0-bd31-06c15d6753ff"
      unitRef="usd">-3505000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTMtMTItMS0xLTY4Nzk1_430dae3d-6433-4117-ad31-5d95218852e5"
      unitRef="usd">9074000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i787c6a58aafe40fb93dba68bac8a5d88_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTQtMi0xLTEtNjg3OTU_a9edf8df-f430-4188-9958-d6a9160624ad"
      unitRef="shares">2000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="i787c6a58aafe40fb93dba68bac8a5d88_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTQtNC0xLTEtNjg3OTU_775176ff-a02b-4eda-bb93-4fc80d69a56c"
      unitRef="usd">8000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="ibaa74b4b308f463fa84d6d3a382b7c6a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTQtNi0xLTEtNjg3OTU_30dd5054-1c16-4ded-8390-63b8bc6b5b1d"
      unitRef="usd">-2000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTQtMTItMS0xLTY4Nzk1_38cef964-60b1-472d-bde2-25fc84024cba"
      unitRef="usd">6000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibaa74b4b308f463fa84d6d3a382b7c6a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTUtNi0xLTEtNjg3OTU_c97aa9f9-5f45-4e84-9557-5b555e919fa4"
      unitRef="usd">7092000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTUtMTItMS0xLTY4Nzk1_7b961efb-e931-4bf1-a314-e244d91944f9"
      unitRef="usd">7092000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i703ab11d0a9946cf8cc57b8243e5db59_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTYtOC0xLTEtNjg3OTU_ef70cf10-9cb9-441c-9960-5afa1de534c1"
      unitRef="usd">-2000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTYtMTItMS0xLTY4Nzk1_9ff9de2a-7f50-4ca7-8d15-aa4954b4f732"
      unitRef="usd">-2000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i114549079e764ecab84b77d1ecf6b9e4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTctMTAtMS0xLTY4Nzk1_e358ae8c-2117-4ad7-bf1f-0d3bf7e4478e"
      unitRef="usd">-50255000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTctMTItMS0xLTY4Nzk1_0e729ced-4451-4780-807d-74c66a52c207"
      unitRef="usd">-50255000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2b49777eb2204f95acb28165c4ffb245_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTgtMi0xLTEtNjg3OTU_b2466e67-10e0-461d-b352-0dbbcf5061e4"
      unitRef="shares">129570000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2b49777eb2204f95acb28165c4ffb245_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTgtNC0xLTEtNjg3OTU_1af1afd6-7d20-482f-86d4-23f8299a7905"
      unitRef="usd">967159000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i02ce71b787ab4ca797b5a9fcbaf61402_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTgtNi0xLTEtNjg3OTU_87c2ae0d-794f-4e6b-9a83-ee7e66df95ec"
      unitRef="usd">54607000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1d1cf1ea09434d15b4be325b80931e8c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTgtOC0xLTEtNjg3OTU_b8e2b47b-dc54-4cf8-aedc-70fc1dd6a74a"
      unitRef="usd">-794000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i77fa57c5982e468f985e9bcaf10d6a42_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTgtMTAtMS0xLTY4Nzk1_5492085c-376a-49e4-9fc3-7da9efdcf8bf"
      unitRef="usd">-722800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7443770797b0498c8cdad90152a5c590_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMTgtMTItMS0xLTY4Nzk1_8c820c97-9ca1-413b-9e6d-b47d235440f1"
      unitRef="usd">298172000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if9ee7fe05eee40f48c092e1b88df007a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjItMi0xLTEtNjg3OTU_cb8428bc-6c82-4fa7-bf24-683868155d8d"
      unitRef="shares">141600000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if9ee7fe05eee40f48c092e1b88df007a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjItNC0xLTEtNjg3OTU_c912fcd3-b213-483d-8d81-bff366a425ca"
      unitRef="usd">1177051000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibb29a2f97a214b8e9f797f9687616d27_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjItNi0xLTEtNjg3OTU_cf8e6501-da6d-4eab-b8fc-26bf5e021745"
      unitRef="usd">59014000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib52fb1312906471b8f138a9a0ea36fec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjItOC0xLTEtNjg3OTU_53cffa24-b76f-44a1-b900-fd5262d6a9ff"
      unitRef="usd">-852000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2464b25495094609998bc808c8e1f431_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjItMTAtMS0xLTY4Nzk1_b434fadd-b9b9-4fb1-80a9-183f7f05ddcd"
      unitRef="usd">-756122000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjItMTItMS0xLTY4Nzk1_ba9b1549-4e3d-4ed0-a575-1baf5d532ea9"
      unitRef="usd">479091000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i68fb759408e04e9b9a39503596bd5faa_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjMtMi0xLTEtNjg3OTU_dde94886-a5bb-4112-a941-cb72149b8f3e"
      unitRef="shares">383000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i68fb759408e04e9b9a39503596bd5faa_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjMtNC0xLTEtNjg3OTU_8ccec8b0-e877-45fb-9e13-076d86e3fb53"
      unitRef="usd">5064000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="icb236f49e0c24418ab0220edb3a611e4_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjMtNi0xLTEtNjg3OTU_6fa1e6f4-baea-4168-84c9-8a2cfd007f11"
      unitRef="usd">-4542000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjMtMTItMS0xLTY4Nzk1_677d976f-1042-4c6a-9a69-5041f55d8703"
      unitRef="usd">522000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i68fb759408e04e9b9a39503596bd5faa_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjQtMi0xLTEtNjg3OTU_c483bb97-1bf8-47a1-aa5b-2c6b58aa5210"
      unitRef="shares">127000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i68fb759408e04e9b9a39503596bd5faa_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjQtNC0xLTEtNjg3OTU_30420317-a0ce-4f96-a063-117bd4ac57a2"
      unitRef="usd">1905000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="icb236f49e0c24418ab0220edb3a611e4_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjQtNi0xLTEtNjg3OTU_6e46c3fe-e448-4c42-8484-dce2fc6b3c4d"
      unitRef="usd">-682000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjQtMTItMS0xLTY4Nzk1_ebaf7db4-fdea-47da-a301-49420b64892b"
      unitRef="usd">1223000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icb236f49e0c24418ab0220edb3a611e4_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjUtNi0xLTEtNjg3OTU_47788ec8-d93b-4766-baa0-380d04faba6b"
      unitRef="usd">25398000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjUtMTItMS0xLTY4Nzk1_0694180e-d1fc-43e0-aa55-41f468d3715b"
      unitRef="usd">25398000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iaabe0fca9ec24b28814dfdae4e2dd4d3_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjYtOC0xLTEtNjg3OTU_bc881302-defb-4373-82da-776ada61b3d8"
      unitRef="usd">-675000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjYtMTItMS0xLTY4Nzk1_40ce01ec-0588-4e70-98c9-a242bce7da94"
      unitRef="usd">-675000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i75925341cc3e4f78bacf59fb0684c25d_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjctMTAtMS0xLTY4Nzk1_25b8b42f-153b-4eca-baec-671dbb409753"
      unitRef="usd">-82134000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjctMTItMS0xLTY4Nzk1_0406b82d-b8ad-4cc3-9772-263b932e007e"
      unitRef="usd">-82134000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i611a8c2b382345d5bee16ff18c8b7de6_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjgtMi0xLTEtNjg3OTU_bc84aca0-0053-4e43-90a0-8513c77e3f6b"
      unitRef="shares">142110000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i611a8c2b382345d5bee16ff18c8b7de6_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjgtNC0xLTEtNjg3OTU_9392d85e-9733-4ad5-a65d-2e145c33246f"
      unitRef="usd">1184020000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic38f683d1d4d4b88a3ddee342ade79d4_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjgtNi0xLTEtNjg3OTU_ad3136ac-50f3-4c7a-87e7-da6bf08461e7"
      unitRef="usd">79188000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7eb54bdb3b8e4810b83f9db13ac1682e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjgtOC0xLTEtNjg3OTU_530bc1ee-dfd1-4b91-a625-74187470ae25"
      unitRef="usd">-1527000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i17263ca8130048c8b999c4d7f9352e2e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjgtMTAtMS0xLTY4Nzk1_4e35a265-50d5-436a-84d5-ae8f637ee4b3"
      unitRef="usd">-838256000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMjgtMTItMS0xLTY4Nzk1_b41c1428-580b-4d8d-831e-43e0edaa7b76"
      unitRef="usd">423425000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ied2bf63884594bf3a519994bdc8a9be1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzItMi0xLTEtNjg3OTU_b3825332-eaf2-41b4-8801-816c27f16a33"
      unitRef="shares">126725000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ied2bf63884594bf3a519994bdc8a9be1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzItNC0xLTEtNjg3OTU_98eb7918-cf97-4e24-9ce3-0e9b78d6556f"
      unitRef="usd">944328000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6785021da65c4996946ac6e43914d14e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzItNi0xLTEtNjg3OTU_a44a19e0-37f2-4d4d-82d4-180b24e52bfe"
      unitRef="usd">39383000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if864e170575941afb3bbe7afabdecd5a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzItOC0xLTEtNjg3OTU_d95c27e7-39e8-43c6-b3ca-5b6659d00d74"
      unitRef="usd">-805000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic9fdb7f1323043c4ad197d9228b4b4b6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzItMTAtMS0xLTY4Nzk1_770ae3c5-7c53-47a3-b455-c0ed81d30c14"
      unitRef="usd">-575156000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i08686fdbde8047d69c05941c654afac6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzItMTItMS0xLTY4Nzk1_e4951347-0f48-4bf0-a4e7-6c7fc745e2d2"
      unitRef="usd">407750000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i533a99201f634a479988a643e020cf8b_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzMtMi0xLTEtNjg3OTU_10189998-0c06-42bd-8060-d140d7180350"
      unitRef="shares">2324000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i533a99201f634a479988a643e020cf8b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzMtNC0xLTEtNjg3OTU_22b27618-3617-42c5-b6df-1864746cde22"
      unitRef="usd">22097000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i16ed573a0bd841e98023564edf9f9c34_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzMtNi0xLTEtNjg3OTU_0b2d9b9a-cdb9-43d6-91f8-3af81bcc079f"
      unitRef="usd">-6745000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzMtMTItMS0xLTY4Nzk1_91f65d2f-870e-44dd-8437-56015afeae27"
      unitRef="usd">15352000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i533a99201f634a479988a643e020cf8b_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzQtMi0xLTEtNjg3OTU_98fc1a72-7f54-4154-8515-989d951b935f"
      unitRef="shares">521000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="i533a99201f634a479988a643e020cf8b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzQtNC0xLTEtNjg3OTU_fa520eaa-95b2-477f-8dd4-1e8906dd8902"
      unitRef="usd">734000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="i16ed573a0bd841e98023564edf9f9c34_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzQtNi0xLTEtNjg3OTU_e0c5a1b3-225c-4a1d-be29-6b59d09a4e11"
      unitRef="usd">-697000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzQtMTItMS0xLTY4Nzk1_79e951df-2157-4a7e-a40e-87a9722cb11b"
      unitRef="usd">37000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i16ed573a0bd841e98023564edf9f9c34_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzUtNi0xLTEtNjg3OTU_da2527f8-252f-4687-929a-506608ccb25e"
      unitRef="usd">22666000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzUtMTItMS0xLTY4Nzk1_8ceb0b82-ce7e-4c68-bf56-f188d2630046"
      unitRef="usd">22666000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic873b1cf2e4c4bf98cf80aac069abfdf_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzYtOC0xLTEtNjg3OTU_18699567-c755-46d3-bc45-ac5fa63fee49"
      unitRef="usd">11000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzYtMTItMS0xLTY4Nzk1_d3438b1a-61d4-4536-a291-4da6c69ded73"
      unitRef="usd">11000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i84a4831b700f48b1833b184774156aeb_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzctMTAtMS0xLTY4Nzk1_3d7ceb99-0913-4a65-a497-b094e454314b"
      unitRef="usd">-147644000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzctMTItMS0xLTY4Nzk1_1782ff43-24d4-4241-860d-6185ab8c770a"
      unitRef="usd">-147644000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2b49777eb2204f95acb28165c4ffb245_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzgtMi0xLTEtNjg3OTU_98a814a4-8187-4724-b444-9397faf0083b"
      unitRef="shares">129570000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2b49777eb2204f95acb28165c4ffb245_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzgtNC0xLTEtNjg3OTU_556f768e-f9fc-46be-924f-7f9f846c1719"
      unitRef="usd">967159000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i02ce71b787ab4ca797b5a9fcbaf61402_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzgtNi0xLTEtNjg3OTU_c22c65a8-ceb0-453b-91e2-18fc1f56a5db"
      unitRef="usd">54607000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1d1cf1ea09434d15b4be325b80931e8c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzgtOC0xLTEtNjg3OTU_4a8bdab1-f419-48bb-8193-b80cd55020cd"
      unitRef="usd">-794000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i77fa57c5982e468f985e9bcaf10d6a42_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzgtMTAtMS0xLTY4Nzk1_19ad1ed6-dd35-4128-aa57-58f3aadb8fed"
      unitRef="usd">-722800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7443770797b0498c8cdad90152a5c590_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yMi9mcmFnOmFlZmJiZGQ0MjBhMjQ1Yzc4MmRjZDllOGQzMDdmZTcwL3RhYmxlOjZmOWEwOGFjNGRhODQxMTlhMTJmMjQ1NWU2NGZjZTYwL3RhYmxlcmFuZ2U6NmY5YTA4YWM0ZGE4NDExOWExMmYyNDU1ZTY0ZmNlNjBfMzgtMTItMS0xLTY4Nzk1_6e80abb3-bf50-428d-a94c-e8605c7094b9"
      unitRef="usd">298172000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfNC0yLTEtMS02ODc5NQ_9e9b5b58-b094-4198-bfd4-b7dc5a6aab4b"
      unitRef="usd">-82134000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfNC00LTEtMS02ODc5NQ_e5a51ba3-bbb7-408b-ae56-4b84b30ce5ee"
      unitRef="usd">-147644000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfNi0yLTEtMS02ODc5NQ_2bbdc4a1-3849-462b-b4b2-0e73a8e0c0a8"
      unitRef="usd">2487000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfNi00LTEtMS02ODc5NQ_598c8b86-c1c2-4d4d-b1e2-229203dd1543"
      unitRef="usd">2030000</us-gaap:Depreciation>
    <auph:AcquiredUpfrontLicensePayment
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfOC0yLTEtMS02ODc5NQ_72ea9212-8f08-4750-ad11-e61d631d70c8"
      unitRef="usd">0</auph:AcquiredUpfrontLicensePayment>
    <auph:AcquiredUpfrontLicensePayment
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfOC00LTEtMS02ODc5NQ_4eb2a69f-57f4-4884-8264-eed324b5f639"
      unitRef="usd">10000000</auph:AcquiredUpfrontLicensePayment>
    <us-gaap:ShareBasedCompensation
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfOS0yLTEtMS02ODc5NQ_e03d50bf-ee58-41a3-a490-c46e29de530c"
      unitRef="usd">25398000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfOS00LTEtMS02ODc5NQ_1f5e8134-4edb-41dd-acb8-c09b28ee5a2f"
      unitRef="usd">22666000</us-gaap:ShareBasedCompensation>
    <us-gaap:InventoryWriteDown
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMTAtMi0xLTEtNzYzNzU_7a886649-27ef-4086-8255-ddc61d46ad43"
      unitRef="usd">2464000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMTAtNC0xLTEtNzYzNzU_0a5072d2-e212-41a3-bcfe-65d52f6d5852"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMTAtMi0xLTEtNjg3OTU_00273193-17eb-47c0-82e8-48e5cf4e18b7"
      unitRef="usd">-587000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMTAtNC0xLTEtNjg3OTU_74ea01dc-ea90-4675-bee0-476288d75097"
      unitRef="usd">-1005000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMTItMi0xLTEtNjg3OTU_30421dc1-a222-41ac-9a8e-a8b1304895e1"
      unitRef="usd">26356000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMTItNC0xLTEtNjg3OTU_536ecb61-58c1-4a34-903d-b92c23fcdeb8"
      unitRef="usd">9815000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMTMtMi0xLTEtNjg3OTU_4d0a3222-eff1-42e1-93e6-5cdf11b3257f"
      unitRef="usd">8458000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMTMtNC0xLTEtNjg3OTU_4c2ebaae-b68e-4de2-aa5b-b8ab76c1a65b"
      unitRef="usd">5366000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMTQtMi0xLTEtNjg3OTU_90fe5ab1-79e5-48d5-b758-0ce084cbc585"
      unitRef="usd">3461000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMTQtNC0xLTEtNjg3OTU_617f2fd3-928c-4332-979d-4f065894969a"
      unitRef="usd">6541000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMTUtMi0xLTEtNjg3OTU_d1b35d22-2471-4b50-ac6e-826f855ecde4"
      unitRef="usd">830000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMTUtNC0xLTEtNjg3OTU_0298ebb2-20d8-4ba1-b08c-efef461fe507"
      unitRef="usd">-247000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMTYtMi0xLTEtNjg3OTU_24c4dbb5-b0c9-4800-94b9-3ca826d3a558"
      unitRef="usd">875000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMTYtNC0xLTEtNjg3OTU_8de71cd8-ba9b-4b78-bfcd-bcb526ae68d9"
      unitRef="usd">1149000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMTctMi0xLTEtNjg3OTU_fa13faba-ffc4-4896-b1a7-a91d0920d0e6"
      unitRef="usd">-551000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMTctNC0xLTEtNjg3OTU_b3af62e0-ff66-44a4-adf0-782565436ae4"
      unitRef="usd">499000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMTgtMi0xLTEtNjg3OTU_4308c792-2a69-4a53-b3e7-b5d45fdcb413"
      unitRef="usd">-89979000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMTgtNC0xLTEtNjg3OTU_cc793040-49cc-4f32-96ca-2b689f3bf228"
      unitRef="usd">-131770000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMjAtMi0xLTEtNjg3OTU_feed88b1-27de-42cf-9f8f-25a6a438dd52"
      unitRef="usd">403184000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMjAtNC0xLTEtNjg3OTU_24e94a65-954f-4932-bd12-3a8d480d3e03"
      unitRef="usd">342831000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMjEtMi0xLTEtNjg3OTU_53a3492e-d886-46fb-8d7f-de77abcf9da3"
      unitRef="usd">346109000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMjEtNC0xLTEtNjg3OTU_8e8912ec-479f-4652-a270-94ca76d40cf3"
      unitRef="usd">263752000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireLeaseReceivables
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMjItMi0xLTEtNjg3OTU_ee15854e-fbf8-4cb8-b037-271fd2bf4e64"
      unitRef="usd">381000</us-gaap:PaymentsToAcquireLeaseReceivables>
    <us-gaap:PaymentsToAcquireLeaseReceivables
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMjItNC0xLTEtNjg3OTU_769e0faa-e3ad-4536-b51d-00d8df11a188"
      unitRef="usd">11838000</us-gaap:PaymentsToAcquireLeaseReceivables>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMjMtMi0xLTEtNjg3OTU_fa752700-75b3-4ea1-a917-7aec767343db"
      unitRef="usd">0</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMjMtNC0xLTEtNjg3OTU_b1eb9f8a-c896-47e0-b7be-9153695372d2"
      unitRef="usd">6000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMjQtMi0xLTEtNjg3OTU_a7ad90d2-4c70-4f0a-870c-6ba630e160d0"
      unitRef="usd">158000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMjQtNC0xLTEtNjg3OTU_ddf240ec-1b7f-4835-83bc-fabf2f7307eb"
      unitRef="usd">268000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsForSoftware
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMjUtMi0xLTEtNjg3OTU_78b03456-8a9e-49d9-b45f-ddfed3bdfbab"
      unitRef="usd">0</us-gaap:PaymentsForSoftware>
    <us-gaap:PaymentsForSoftware
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMjUtNC0xLTEtNjg3OTU_4e1e5ac2-4049-4917-a3ea-53fb8254d168"
      unitRef="usd">1198000</us-gaap:PaymentsForSoftware>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMjctMi0xLTEtNjg3OTU_0472d18e-1903-41dc-bcfb-5b4e885d3423"
      unitRef="usd">-57614000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMjctNC0xLTEtNjg3OTU_607cbd72-db9f-4104-a45b-0dc37d9dc757"
      unitRef="usd">-98383000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMjktMi0xLTEtNjg3OTU_0716ed7c-8658-4442-8916-e425d3cc56b7"
      unitRef="usd">1745000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMjktNC0xLTEtNjg3OTU_b15db537-2d40-408c-a1e6-e02455192474"
      unitRef="usd">15353000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMzAtMi0xLTEtNjg3OTU_7d5b155c-2cb1-41c5-b01d-f28669dbe178"
      unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMzAtNC0xLTEtNjg3OTU_b9ac990e-8da8-4e83-9669-df8f4fc9f73b"
      unitRef="usd">37000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMzItMi0xLTEtNjg3OTU_3480d14c-e15f-45ac-9d85-99aede1b2553"
      unitRef="usd">1745000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMzItNC0xLTEtNjg3OTU_78260ae0-bad4-44eb-8add-53ce1a6a0379"
      unitRef="usd">15390000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMzMtMi0xLTEtNjg3OTU_b74c0b5f-86a2-4f04-8ee2-aa8e97366d60"
      unitRef="usd">-145848000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMzMtNC0xLTEtNjg3OTU_9d806e2b-8ae1-4649-b7cb-acab8c414b8d"
      unitRef="usd">-214763000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMzQtMi0xLTEtNjg3OTU_b1c6c519-251b-4f56-8a4f-4043905523e8"
      unitRef="usd">231900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i08686fdbde8047d69c05941c654afac6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMzQtNC0xLTEtNjg3OTU_ffefb36d-6e28-40b5-905d-cc1144600eb6"
      unitRef="usd">272350000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMzUtMi0xLTEtNjg3OTU_dbb15f7c-ec3b-402a-b9e6-fd014f4cdcc9"
      unitRef="usd">86052000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7443770797b0498c8cdad90152a5c590_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMzUtNC0xLTEtNjg3OTU_d257afc6-4f5e-43e1-bfd8-00f995efa708"
      unitRef="usd">57587000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ProceedsFromInterestReceived
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMzgtMi0xLTEtNjg3OTU_81632bbd-6eaa-4fef-90aa-4f9a958031ff"
      unitRef="usd">1705000</us-gaap:ProceedsFromInterestReceived>
    <us-gaap:ProceedsFromInterestReceived
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMzgtNC0xLTEtNjg3OTU_ead4370b-1ab8-452f-9176-23eab2c95913"
      unitRef="usd">671000</us-gaap:ProceedsFromInterestReceived>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMzktMi0xLTEtNjg3OTU_b22d06cb-e209-4401-b303-75f272f3c961"
      unitRef="usd">779000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfMzktNC0xLTEtNjg3OTU_e20fba65-088e-40b1-8eab-bd437ce44f25"
      unitRef="usd">236000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfNDAtMi0xLTEtNjg3OTU_a73bc878-9e01-4130-a634-6e2d1bbe6f92"
      unitRef="usd">897000</us-gaap:CapitalLeaseObligationsIncurred>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfNDAtNC0xLTEtNjg3OTU_d8be57ec-b20b-4749-9db2-8d1ab70d32ff"
      unitRef="usd">195000</us-gaap:CapitalLeaseObligationsIncurred>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfNDItMi0xLTEtNjg3OTU_07e61505-6c5d-4ad1-9b19-b7571d364b9b"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfNDItNC0xLTEtNjg3OTU_1cd60ae4-c663-43bd-81b8-d3c15a71ad0c"
      unitRef="usd">419000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfNDUtMi0xLTEtNjg3OTU_67f23f59-207f-4427-bcd6-0ec28e0e198e"
      unitRef="usd">85341000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7443770797b0498c8cdad90152a5c590_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfNDUtNC0xLTEtNjg3OTU_3422233a-e79f-4a86-9851-20432149e22c"
      unitRef="usd">57587000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfNDYtMi0xLTEtNjg3OTU_26851756-f81f-4cac-9123-c98d54689fbd"
      unitRef="usd">711000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i7443770797b0498c8cdad90152a5c590_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfNDYtNC0xLTEtNjg3OTU_e86c4a86-41c9-4548-8197-a848a016f862"
      unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfNDctMi0xLTEtNjg3OTU_1723823c-b1cd-497a-a8cc-2b556e2815d5"
      unitRef="usd">86052000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7443770797b0498c8cdad90152a5c590_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18yNS9mcmFnOjE5NGUzMjgyYjdmMTQ1ZjM5OTk3MTBjMTViNWQ5ODhkL3RhYmxlOmEyYjY4MmVjNzgyMzRjNWI5ZjliMDI3OWRhZmQ5Y2I1L3RhYmxlcmFuZ2U6YTJiNjgyZWM3ODIzNGM1YjlmOWIwMjc5ZGFmZDljYjVfNDctNC0xLTEtNjg3OTU_00b9d9b0-e2ab-4118-a157-aaf41dcb25b4"
      unitRef="usd">57587000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zMS9mcmFnOjU2ZWFkNGVjZTMzNzQ5MTQ4YzE3MzUyNWE1MzI4ODI3L3RleHRyZWdpb246NTZlYWQ0ZWNlMzM3NDkxNDhjMTczNTI1YTUzMjg4MjdfMTQ1Nw_db3b31e8-a326-4090-b716-e093e6fb536a">Organization and Description of Business&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aurinia Pharmaceuticals Inc. (Aurinia or the Company) is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the Company introduced LUPKYNIS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (voclosporin), the first U.S. Food and Drug Administration (FDA) approved oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory activities to support the voclosporin development program as well as our other assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 17, 2021, the Company announced the addition of two novel assets AUR200 and AUR300. AUR200 and AUR300 are currently undergoing pre-clinical development with projected submission of Investigational New Drug Applications (INDs) to the FDA in 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 15, 2022, the European Commission (EC) granted marketing authorization of LUPKYNIS to Otsuka Pharmaceutical Co., Ltd. (Otsuka). &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The centralized marketing authorization is valid in all European (EU) member states as well as in Iceland, Liechtenstein, Norway and Northern Ireland.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aurinia's head office is located at #1203-4464 Markham Street, Victoria, British Columbia, Canada and its registered office is located at #201, 17873-106 A Avenue, Edmonton, Alberta. Aurinia also has a U.S. commercial office located at 77 Upper Rock Circle Suite 700, Rockville, Maryland, 20850 United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aurinia is incorporated pursuant to the Business Corporations Act (Alberta). The Company&#x2019;s common shares are traded on the Nasdaq Global Market (Nasdaq) under the symbol AUPH.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNC9mcmFnOjYyZDEzNWYzOTgxNDRmYmZiOTQ1NGQ1YmRjYWFiMTVjL3RleHRyZWdpb246NjJkMTM1ZjM5ODE0NGZiZmI5NDU0ZDViZGNhYWIxNWNfMjgxNA_d1a6a86c-d195-4422-8363-e2635de46a3d">Summary of Significant Accounting Policies &lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of December&#160;31, 2021 was derived from audited annual consolidated financial statements but does not include all annual disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021. The results of operations for the nine months ended September&#160;30, 2022 are not necessarily indicative of the results to be expected for the full year or any other future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aurinia Pharma U.S., Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). All intercompany balances and transactions have been eliminated in consolidation and operate in one segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated financial statements are presented in U.S. dollars which is the Company's functional currency, therefore, there is no currency translation adjustment upon consolidation as the remeasurement of gains or losses are recorded in the condensed consolidated statements of operations. All assets and liabilities denominated in a foreign currency are remeasured into U.S. dollars at the exchange rate on the balance sheet date. Revenues and expenses are remeasured at the average exchange rate during the period. Foreign exchange gains and losses arising on translation or settlement of a foreign currency denominated monetary item are included in the condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;The Company is devoting the majority of our operational efforts and financial resources towards the commercialization and post approval commitments of our approved drug, LUPKYNIS. The Company is also expending efforts towards our newly acquired assets AUR200 and AUR300. Taking into consideration the Company's cash, cash equivalents, restricted cash and investments of $376.6 million as of September&#160;30, 2022, the Company believes that it has sufficient resources to fund its operations for at least the next few years beyond the date that the unaudited condensed consolidated financial statements are issued.&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other than as described below, the Company's significant accounting policies have not changed from those previously described in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted cash&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: Restricted cash consists of the 2021 Employee Share Purchase Plan (2021 ESPP) deposits of $0.7&#160;million and $0.3&#160;million as of September&#160;30, 2022 and December&#160;31, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Major Customers:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company currently has two main customers for U.S. commercial sales of LUPKYNIS and a collaboration partner for sales of LUPKYNIS in the EU, Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine (collectively, the "Otsuka Territories"). Revenues from the two main customers in the U.S. accounted in total of approximately 48% for the three months ended September&#160;30, 2022 and 74% for the nine months ended September&#160;30, 2022 of the Company's total revenues. Our collaboration partner for sales outside the U.S. accounted for approximately 52% and 26% for the three and nine months ended September&#160;30, 2022 of the Company's total revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In late March 2022, we provided a nominal additional discount to both of our two main U.S. customers, applicable for the remainder of the 2022 calendar year, in connection with holding additional amounts of LUPKYNIS on hand due to supply chain concerns. Such discounts, or any future discounts, may result in reduced sales to these customers in subsequent periods and substantial fluctuations in our revenues from period to period. The Company monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances. Global economic conditions and customer specific factors may require the Company to periodically re-evaluate the collectability of its receivables and based on this evaluation the Company could potentially incur credit losses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the United States (and territories), the Company sells LUPKYNIS primarily to specialty pharmacies and specialty distributors. These customers subsequently resell the Company's products to health care providers and patients. Revenues from product sales are recognized when the customer obtains control of our product, which typically occurs upon delivery to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reserves for discounts and allowances: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's estimates of reserves established for variable consideration are calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant judgment is required in estimating variable consideration. In making these estimates, we consider historical data, including patient mix and inventory sold to our customers that has not yet been dispensed. We use a data aggregator and historical claims to estimate variable consideration for inventory sold to our customers, including specialty pharmacies and specialty distributors, that has not yet been dispensed. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjust these estimates, which could have an effect on earnings in the period of adjustment. As of September&#160;30, 2022, we did not have any material adjustments to estimates based on actual results. These specific adjustments are detailed further in our Annual Report on Form 10-K for the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; At the inception of each arrangement that includes development or commercial sales milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment. Any consideration related to sales-based royalties (and sales-based milestones) will be recognized when the related sales occur. As of September&#160;30, 2022, we recognized $30.0&#160;million for the regulatory milestone related to the EC marketing authorization of LUPKYNIS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts receivable, net:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Accounts receivable are stated at their net realizable value. The Company's accounts receivable represents amounts due to the Company from product sales and from its Otsuka collaboration agreement (Note 12). Milestone payments that have not been invoiced as of the balance sheet date are recorded as unbilled accounts receivable. As of September&#160;30, 2022 and December&#160;31, 2021, accounts receivable, net are $41.8 million and $15.4 million. The accounts receivable, net as of September&#160;30, 2022 includes $28.8 million due from Otsuka related to the achievement of a regulatory milestone in September 2022, for which payment was received on October 31, 2022. &lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The timing between the recognition of revenue for product sales and the receipt of payment is not significant. Our standard credit terms range from 30 to 45 days. We do not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between the transfer of the promised good to the customer and receipt of payment will be one year or less. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the allowance for doubtful accounts using the current expected credit loss, or CECL, model. Under the CECL model, the allowance for doubtful accounts reflects the net amount expected to be collected from the account receivables. We evaluate the collectability of these cash flows based on the asset&#x2019;s amortized cost, the risk of loss even when that risk is remote, losses over an asset&#x2019;s contractual life, and other relevant information available to us. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. The allowance for doubtful accounts was $nil as of September&#160;30, 2022 and as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Share-Based Compensation: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows ASC Topic 718, Compensation - Stock Compensation (ASC 718), which requires the measurement and recognition of compensation expense, based on estimated fair values, for all share-based awards made to employees and directors. The Company records compensation expense based on the fair value on the grant date using the graded accelerated vesting method for all share-based payments related to stock options, performance awards (PAs), restricted stock units (RSUs) and purchases under the Company's 2021 ESPP. For stock options, forfeitures are estimated based on historical experience at the time of grant and revised in subsequent periods if actual forfeitures differ from those estimates. For RSUs and PAs, forfeitures are accounted for as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 740): Simplifying the Accounting for Income Taxes, which clarifies and simplifies certain aspects of the accounting for income taxes such as eliminating the exception to the general intraperiod tax allocation principle. The standard is effective for years beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2020. The Company adopted the ASU effective January 1, 2021, with no material impact on the condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, which requires business entities to make annual disclosures about transactions with a government (including government assistance) by analogizing to a grant or contribution accounting model. The required disclosures include the nature of the transaction, the entity's related accounting policy, the financial statement line items affected and the amounts reflected in the current period financial statements, as well as any significant terms and conditions. The guidance is effective for financial statements issued for annual periods beginning after December 15, 2021. The Company adopted the ASU effective January 1, 2022, with no material impact on the condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNC9mcmFnOjYyZDEzNWYzOTgxNDRmYmZiOTQ1NGQ1YmRjYWFiMTVjL3RleHRyZWdpb246NjJkMTM1ZjM5ODE0NGZiZmI5NDU0ZDViZGNhYWIxNWNfMjgxNQ_4caa8f32-de66-4ec1-9c2c-f98568bd08d3">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of December&#160;31, 2021 was derived from audited annual consolidated financial statements but does not include all annual disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021. The results of operations for the nine months ended September&#160;30, 2022 are not necessarily indicative of the results to be expected for the full year or any other future periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNC9mcmFnOjYyZDEzNWYzOTgxNDRmYmZiOTQ1NGQ1YmRjYWFiMTVjL3RleHRyZWdpb246NjJkMTM1ZjM5ODE0NGZiZmI5NDU0ZDViZGNhYWIxNWNfMTQ5MQ_50af2f18-3db9-4955-87c9-7eabc98aa3fb"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <auph:CashCashEquivalentsAndDebtSecuritiesCurrent
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNC9mcmFnOjYyZDEzNWYzOTgxNDRmYmZiOTQ1NGQ1YmRjYWFiMTVjL3RleHRyZWdpb246NjJkMTM1ZjM5ODE0NGZiZmI5NDU0ZDViZGNhYWIxNWNfMjYwMw_10d136df-c3a2-48c3-b024-70e263437060"
      unitRef="usd">376600000</auph:CashCashEquivalentsAndDebtSecuritiesCurrent>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNy9mcmFnOmNmMzVlY2YyZmU1ZjRmNDY5MWZmNTM0YmZkMzFhYjBkL3RleHRyZWdpb246Y2YzNWVjZjJmZTVmNGY0NjkxZmY1MzRiZmQzMWFiMGRfMzU2MQ_24254e40-c0d1-404c-996d-3be0be48c4ae">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted cash&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: Restricted cash consists of the 2021 Employee Share Purchase Plan (2021 ESPP) deposits of $0.7&#160;million and $0.3&#160;million as of September&#160;30, 2022 and December&#160;31, 2021, respectively.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCash
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNy9mcmFnOmNmMzVlY2YyZmU1ZjRmNDY5MWZmNTM0YmZkMzFhYjBkL3RleHRyZWdpb246Y2YzNWVjZjJmZTVmNGY0NjkxZmY1MzRiZmQzMWFiMGRfMzM3_7a16d4e0-2cb4-4ca8-99e2-18ecde2ea393"
      unitRef="usd">700000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNy9mcmFnOmNmMzVlY2YyZmU1ZjRmNDY5MWZmNTM0YmZkMzFhYjBkL3RleHRyZWdpb246Y2YzNWVjZjJmZTVmNGY0NjkxZmY1MzRiZmQzMWFiMGRfMzQ0_7f4bc93b-2a77-4867-9b77-9935aacd583d"
      unitRef="usd">300000</us-gaap:RestrictedCash>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNy9mcmFnOmNmMzVlY2YyZmU1ZjRmNDY5MWZmNTM0YmZkMzFhYjBkL3RleHRyZWdpb246Y2YzNWVjZjJmZTVmNGY0NjkxZmY1MzRiZmQzMWFiMGRfMzU2Mw_81da4183-199b-4370-84a2-3da97676ef41">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Major Customers:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company currently has two main customers for U.S. commercial sales of LUPKYNIS and a collaboration partner for sales of LUPKYNIS in the EU, Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine (collectively, the "Otsuka Territories"). Revenues from the two main customers in the U.S. accounted in total of approximately 48% for the three months ended September&#160;30, 2022 and 74% for the nine months ended September&#160;30, 2022 of the Company's total revenues. Our collaboration partner for sales outside the U.S. accounted for approximately 52% and 26% for the three and nine months ended September&#160;30, 2022 of the Company's total revenues.&lt;/span&gt;In late March 2022, we provided a nominal additional discount to both of our two main U.S. customers, applicable for the remainder of the 2022 calendar year, in connection with holding additional amounts of LUPKYNIS on hand due to supply chain concerns. Such discounts, or any future discounts, may result in reduced sales to these customers in subsequent periods and substantial fluctuations in our revenues from period to period. The Company monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances. Global economic conditions and customer specific factors may require the Company to periodically re-evaluate the collectability of its receivables and based on this evaluation the Company could potentially incur credit losses.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie2b6cee70b84464499f7df7285aed325_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNy9mcmFnOmNmMzVlY2YyZmU1ZjRmNDY5MWZmNTM0YmZkMzFhYjBkL3RleHRyZWdpb246Y2YzNWVjZjJmZTVmNGY0NjkxZmY1MzRiZmQzMWFiMGRfMzU5Ng_96a60ccd-48a8-4143-8aae-5678ab2b58d0"
      unitRef="number">0.48</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i92eaeeead41c4c3486efa48480d9b63a_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNy9mcmFnOmNmMzVlY2YyZmU1ZjRmNDY5MWZmNTM0YmZkMzFhYjBkL3RleHRyZWdpb246Y2YzNWVjZjJmZTVmNGY0NjkxZmY1MzRiZmQzMWFiMGRfNTQ5NzU1ODE3NTA4_fcaa2b79-e53c-48ac-be89-51855e28e114"
      unitRef="number">0.74</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib9fbd2d01b054439a783e60189d0d151_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNy9mcmFnOmNmMzVlY2YyZmU1ZjRmNDY5MWZmNTM0YmZkMzFhYjBkL3RleHRyZWdpb246Y2YzNWVjZjJmZTVmNGY0NjkxZmY1MzRiZmQzMWFiMGRfNTQ5NzU1ODE3ODY4_98c3ffb4-ceba-41c0-9b23-7049f1c53c64"
      unitRef="number">0.52</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id143a176c2d7418fa9b6975ad686ab0a_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNy9mcmFnOmNmMzVlY2YyZmU1ZjRmNDY5MWZmNTM0YmZkMzFhYjBkL3RleHRyZWdpb246Y2YzNWVjZjJmZTVmNGY0NjkxZmY1MzRiZmQzMWFiMGRfNTQ5NzU1ODE3ODc2_d616c7fb-14c7-4a21-bd5a-406abb8e084a"
      unitRef="number">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNy9mcmFnOmNmMzVlY2YyZmU1ZjRmNDY5MWZmNTM0YmZkMzFhYjBkL3RleHRyZWdpb246Y2YzNWVjZjJmZTVmNGY0NjkxZmY1MzRiZmQzMWFiMGRfMzI5ODUzNDg5MjgxOA_5bd63648-33d8-40af-bdd1-9e7504fc1655">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the United States (and territories), the Company sells LUPKYNIS primarily to specialty pharmacies and specialty distributors. These customers subsequently resell the Company's products to health care providers and patients. Revenues from product sales are recognized when the customer obtains control of our product, which typically occurs upon delivery to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reserves for discounts and allowances: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's estimates of reserves established for variable consideration are calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant judgment is required in estimating variable consideration. In making these estimates, we consider historical data, including patient mix and inventory sold to our customers that has not yet been dispensed. We use a data aggregator and historical claims to estimate variable consideration for inventory sold to our customers, including specialty pharmacies and specialty distributors, that has not yet been dispensed. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjust these estimates, which could have an effect on earnings in the period of adjustment. As of September&#160;30, 2022, we did not have any material adjustments to estimates based on actual results. These specific adjustments are detailed further in our Annual Report on Form 10-K for the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; At the inception of each arrangement that includes development or commercial sales milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be &lt;/span&gt;&lt;/div&gt;included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment. Any consideration related to sales-based royalties (and sales-based milestones) will be recognized when the related sales occur.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic5a4159b186c46bdae3c4c7db5a48d91_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNy9mcmFnOmNmMzVlY2YyZmU1ZjRmNDY5MWZmNTM0YmZkMzFhYjBkL3RleHRyZWdpb246Y2YzNWVjZjJmZTVmNGY0NjkxZmY1MzRiZmQzMWFiMGRfNTQ5NzU1ODIyODEy_8d13aa73-9a06-4eac-8a01-e024c062d4ef"
      unitRef="usd">30000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNy9mcmFnOmNmMzVlY2YyZmU1ZjRmNDY5MWZmNTM0YmZkMzFhYjBkL3RleHRyZWdpb246Y2YzNWVjZjJmZTVmNGY0NjkxZmY1MzRiZmQzMWFiMGRfMzU2NA_59812e18-705c-4a2f-93c7-a006d50c8136">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts receivable, net:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Accounts receivable are stated at their net realizable value. The Company's accounts receivable represents amounts due to the Company from product sales and from its Otsuka collaboration agreement (Note 12). Milestone payments that have not been invoiced as of the balance sheet date are recorded as unbilled accounts receivable. As of September&#160;30, 2022 and December&#160;31, 2021, accounts receivable, net are $41.8 million and $15.4 million. The accounts receivable, net as of September&#160;30, 2022 includes $28.8 million due from Otsuka related to the achievement of a regulatory milestone in September 2022, for which payment was received on October 31, 2022. &lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The timing between the recognition of revenue for product sales and the receipt of payment is not significant. Our standard credit terms range from 30 to 45 days. We do not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between the transfer of the promised good to the customer and receipt of payment will be one year or less. &lt;/span&gt;We estimate the allowance for doubtful accounts using the current expected credit loss, or CECL, model. Under the CECL model, the allowance for doubtful accounts reflects the net amount expected to be collected from the account receivables. We evaluate the collectability of these cash flows based on the asset&#x2019;s amortized cost, the risk of loss even when that risk is remote, losses over an asset&#x2019;s contractual life, and other relevant information available to us. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. The allowance for doubtful accounts was $nil as of September&#160;30, 2022 and as of December&#160;31, 2021</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNy9mcmFnOmNmMzVlY2YyZmU1ZjRmNDY5MWZmNTM0YmZkMzFhYjBkL3RleHRyZWdpb246Y2YzNWVjZjJmZTVmNGY0NjkxZmY1MzRiZmQzMWFiMGRfMTY4MQ_dbc0d206-73ea-4c0c-b7bb-c3b0769a26f1"
      unitRef="usd">41800000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNy9mcmFnOmNmMzVlY2YyZmU1ZjRmNDY5MWZmNTM0YmZkMzFhYjBkL3RleHRyZWdpb246Y2YzNWVjZjJmZTVmNGY0NjkxZmY1MzRiZmQzMWFiMGRfMTY4OA_99670b5f-66a3-42f1-8812-9adccdb48d9c"
      unitRef="usd">15400000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="i248fcdd355b64b138d9e8363df09e99f_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNy9mcmFnOmNmMzVlY2YyZmU1ZjRmNDY5MWZmNTM0YmZkMzFhYjBkL3RleHRyZWdpb246Y2YzNWVjZjJmZTVmNGY0NjkxZmY1MzRiZmQzMWFiMGRfNjA0NzMxMzk2Nzc1MA_1cee654d-7375-440e-a8fa-a1d47d9679d3"
      unitRef="usd">28800000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <auph:AccountsReceivableCreditTerm
      contextRef="i16cb885c9c784f19a3fb5c186669134a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNy9mcmFnOmNmMzVlY2YyZmU1ZjRmNDY5MWZmNTM0YmZkMzFhYjBkL3RleHRyZWdpb246Y2YzNWVjZjJmZTVmNGY0NjkxZmY1MzRiZmQzMWFiMGRfMTg0MQ_e0f6bf25-9751-451d-a2da-c886458dc9cc">P30D</auph:AccountsReceivableCreditTerm>
    <auph:AccountsReceivableCreditTerm
      contextRef="i97636c4925384d11aa8a85148d437f88_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNy9mcmFnOmNmMzVlY2YyZmU1ZjRmNDY5MWZmNTM0YmZkMzFhYjBkL3RleHRyZWdpb246Y2YzNWVjZjJmZTVmNGY0NjkxZmY1MzRiZmQzMWFiMGRfMTg0Nw_6a60ffd9-3664-4312-a666-ed61ffb31c33">P45D</auph:AccountsReceivableCreditTerm>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNy9mcmFnOmNmMzVlY2YyZmU1ZjRmNDY5MWZmNTM0YmZkMzFhYjBkL3RleHRyZWdpb246Y2YzNWVjZjJmZTVmNGY0NjkxZmY1MzRiZmQzMWFiMGRfMjczOQ_305492cf-8b10-41da-bcba-59ee8cf23ebc"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNy9mcmFnOmNmMzVlY2YyZmU1ZjRmNDY5MWZmNTM0YmZkMzFhYjBkL3RleHRyZWdpb246Y2YzNWVjZjJmZTVmNGY0NjkxZmY1MzRiZmQzMWFiMGRfMjczOQ_c69438a3-e2ef-4df3-b2d8-a137088871f7"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY18zNy9mcmFnOmNmMzVlY2YyZmU1ZjRmNDY5MWZmNTM0YmZkMzFhYjBkL3RleHRyZWdpb246Y2YzNWVjZjJmZTVmNGY0NjkxZmY1MzRiZmQzMWFiMGRfMzU2NQ_71701bde-6c4f-44f8-8146-f090983a6f91">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Share-Based Compensation: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows ASC Topic 718, Compensation - Stock Compensation (ASC 718), which requires the measurement and recognition of compensation expense, based on estimated fair values, for all share-based awards made to employees and directors. The Company records compensation expense based on the fair value on the grant date using the graded accelerated vesting method for all share-based payments related to stock options, performance awards (PAs), restricted stock units (RSUs) and purchases under the Company's 2021 ESPP. For stock options, forfeitures are estimated based on historical experience at the time of grant and revised in subsequent periods if actual forfeitures differ from those estimates. For RSUs and PAs, forfeitures are accounted for as they occur.&lt;/span&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180MC9mcmFnOjFjZTg3YzQyYmFmYjQ2YmZhMzJlYzVmYTYzZGI0MzY0L3RleHRyZWdpb246MWNlODdjNDJiYWZiNDZiZmEzMmVjNWZhNjNkYjQzNjRfMTQ2MQ_c027534c-3bf8-463c-89e8-727a37690123">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 740): Simplifying the Accounting for Income Taxes, which clarifies and simplifies certain aspects of the accounting for income taxes such as eliminating the exception to the general intraperiod tax allocation principle. The standard is effective for years beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2020. The Company adopted the ASU effective January 1, 2021, with no material impact on the condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, which requires business entities to make annual disclosures about transactions with a government (including government assistance) by analogizing to a grant or contribution accounting model. The required disclosures include the nature of the transaction, the entity's related accounting policy, the financial statement line items affected and the amounts reflected in the current period financial statements, as well as any significant terms and conditions. The guidance is effective for financial statements issued for annual periods beginning after December 15, 2021. The Company adopted the ASU effective January 1, 2022, with no material impact on the condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RleHRyZWdpb246ZWI2YmU1NzM2MDExNDA3NTg2OTg3Zjc2YzRmMDUwOWFfMzA1NA_08985075-d69b-4e47-91ff-917edcdef018">Fair Value Measurements&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial instruments consist primarily of cash and cash equivalents, short-term investments, accounts receivable, accounts payable and accrued liabilities. The carrying value of accounts receivable, accounts payable and accrued liabilities approximate their fair value because of their short-term nature. Estimated fair value of available-for-sale securities are generally based on prices obtained from commercial pricing services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company&#x2019;s assumptions about how market participants would price assets and liabilities). As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 1 - Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 2 - Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 3 - Unobservable inputs that reflect the reporting entity&#x2019;s own assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the financial assets (cash, cash equivalents, restricted cash and short-term investments) measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;86,052&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;86,052&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency security&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,904&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,904&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;98,068&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;98,068&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;112,633&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;112,633&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Treasury bill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;26,704&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;26,704&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Treasury bond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;44,553&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;44,553&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Yankee bond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,730&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,730&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;198,685&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;177,959&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;376,644&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Treasury bill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;438,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's Level 1 instruments include cash, cash equivalents, restricted cash and commercial paper that are valued using quoted market prices. We estimate the fair values of our investments in corporate debt securities, government and government related securities and certificates of deposits by taking into consideration valuations obtained from third-party pricing services. The fair value of our short-term investments classified within Level 2 is based upon observable inputs that may include benchmark yield curves, reported trades, issuer spreads, benchmark securities and reference data including market research publications. At September&#160;30, 2022, and December&#160;31, 2021, the weighted average remaining contractual maturities of our Level 1 and 2 investments were approximately for 7 months and 8 months, respectively. These investments have an overall rating of A-1, or higher, by Moody&#x2019;s, Standard &amp;amp; Poor&#x2019;s and Fitch.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No credit loss allowance was recorded as of September&#160;30, 2022, as we do not believe the unrealized loss is a result of a credit loss due to the nature of our investments. We also considered the current and expected future economic and market conditions and determined that the estimate of credit losses was not significantly impacted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 4, &#x201c;Cash, Cash Equivalents, Restricted Cash and Short-Term Investments,&#x201d; for the carrying amount and related unrealized gains (losses) by type of investment.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RleHRyZWdpb246ZWI2YmU1NzM2MDExNDA3NTg2OTg3Zjc2YzRmMDUwOWFfMzA1NQ_4f687540-50c8-4d56-8eae-335fab36b322">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the financial assets (cash, cash equivalents, restricted cash and short-term investments) measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;86,052&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;86,052&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency security&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,904&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,904&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;98,068&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;98,068&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;112,633&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;112,633&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Treasury bill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;26,704&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;26,704&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Treasury bond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;44,553&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;44,553&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Yankee bond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,730&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,730&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;198,685&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;177,959&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;376,644&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Treasury bill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;438,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0ff9e818dc3248f3a984013c0ec35cb4_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfMy0yLTEtMS02ODc5NQ_0f58a6a8-e9e9-429a-aa29-637c80e7ba2c"
      unitRef="usd">86052000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i45420271e8ea4082b3d52812ce062bcd_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfMy00LTEtMS02ODc5NQ_35f2d719-f00b-4580-836a-bed530bac936"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib5b00f6af1a1489ca4e19effbd717dc7_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfMy02LTEtMS02ODc5NQ_f6912df7-c7b7-45b8-8d6a-b558024cdfbb"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id57531e234234b2b9cb0d8e02f891cfd_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfMy04LTEtMS02ODc5NQ_1fd7da1e-5ddd-4efc-bb55-a86846f4ffb8"
      unitRef="usd">86052000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibabafbb16aec41b1915f48581e656afd_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfNC0yLTEtMS02ODc5NQ_13c04e29-a57b-497c-9cb8-2719aa54c08a"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8f27ddb9f76a467b94259faf2e7e0317_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfNC00LTEtMS02ODc5NQ_89cac281-f637-4451-bfa2-c0ab79444141"
      unitRef="usd">4904000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifc8d7c6306b94e968ff4f645fa32aea3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfNC02LTEtMS02ODc5NQ_27d4de28-2cfa-4350-9cb4-034d91f6eb60"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idda7e1c04624428eb78cb35510f9fa7f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfNC04LTEtMS02ODc5NQ_f2f30ae7-f227-4d1c-b2d2-34505b65ee1d"
      unitRef="usd">4904000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8a6083a877744937bdaec6596e628a5e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfNS0yLTEtMS02ODc5NQ_3dc4d6c9-40bd-4ff0-8539-bffc73f98f7a"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib545381e546241bfb7702079a5b4ae46_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfNS00LTEtMS02ODc5NQ_e31a10ac-d6e8-4db3-9970-89b1796d3832"
      unitRef="usd">98068000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia75ddf3673b0477d801dd590a53168cd_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfNS02LTEtMS02ODc5NQ_f543e973-f658-4cd5-b208-b555dd24ddb1"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7a88e33246a947da84b61da9acf16369_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfNS04LTEtMS02ODc5NQ_8487c157-3d10-48fb-98e6-d50c4d3756a0"
      unitRef="usd">98068000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i64fba90d628a47388702c84b97bf7d7a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfNi0yLTEtMS02ODc5NQ_918ecd8b-7aa0-48cc-9553-eb81d8bdbdd4"
      unitRef="usd">112633000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifa631ff412fa4ce5999335712a18dd4e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfNi00LTEtMS02ODc5NQ_6cc77c21-200b-45f0-b28b-062c97f8080d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia4bd4b996a4d4872b3fac48673a43a27_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfNi02LTEtMS02ODc5NQ_70bea9e4-3d7d-428d-9805-f88de570bc8a"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic9f1f2ee39a841c18e4e03be170e2977_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfNi04LTEtMS02ODc5NQ_a7dc80df-e5c8-4055-8e9b-b10793e8d540"
      unitRef="usd">112633000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib6d26265caac4b03ac1c32ac9b0d215c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfNy0yLTEtMS02ODc5NQ_e7be56ae-b592-4c21-b4db-b0f66b8011db"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ieafdf4a188174114bc1155f63c1daa4d_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfNy00LTEtMS02ODc5NQ_7a7dade0-a3cc-44e9-803a-f16cd9805969"
      unitRef="usd">26704000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i669c0d32fa12413e948255d28b9891a2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfNy02LTEtMS02ODc5NQ_23311e05-fa7e-409b-8d96-9edb4d5bc170"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id9a7d157907c4446a83d6762c688bc37_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfNy04LTEtMS02ODc5NQ_60301726-6033-453f-ac78-3db82bb672e3"
      unitRef="usd">26704000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7d9ec18821a143c0b5342802f48f6311_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfOC0yLTEtMS02ODc5NQ_f04f8a1b-06a8-4567-8fe3-5cbb4998a35e"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i64661310650543b4a59ec68285dc9734_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfOC00LTEtMS02ODc5NQ_d1e4a774-6ef4-4de4-8d86-c6e40fcd9f8f"
      unitRef="usd">44553000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i119daddb27794e028c6e80587444d5ad_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfOC02LTEtMS02ODc5NQ_618838dd-f137-4b56-9e27-b43f86bee238"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i879c4a29d0b4430fa56ad47b590225c2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfOC04LTEtMS02ODc5NQ_9b1aa131-159b-4344-aa31-de4bc8905a32"
      unitRef="usd">44553000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0c5b7f81c61c4e96ac98e4766d33339a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfOS0yLTEtMS02ODc5NQ_3162cad1-d375-45f1-9bb4-12d9102b0fa6"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id9178f49b5784f9aba75be7f38379650_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfOS00LTEtMS02ODc5NQ_85fb6444-a11d-41af-983a-63192cc8cee6"
      unitRef="usd">3730000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ieb9283d88b424c60b9b3d5353d69a897_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfOS02LTEtMS02ODc5NQ_713e2211-180e-427c-bccc-9a621363ce5a"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i20cb6a6c7b9e4a5380a7381cd01eeee6_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfOS04LTEtMS02ODc5NQ_e3957fc1-06db-44e0-ba2a-8e97f7ab840f"
      unitRef="usd">3730000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idb5b6a1ae596438681cfbfdf9892f83d_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfMTAtMi0xLTEtNjg3OTU_a6687f8a-df76-42a0-8b76-95a0127c2707"
      unitRef="usd">198685000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id28bab9c7e1c4295b873580752711af5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfMTAtNC0xLTEtNjg3OTU_cf4d65dc-a9b9-4cfb-9c5b-095e832631e2"
      unitRef="usd">177959000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i20e1087e0598412981eb9152d79b6b14_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfMTAtNi0xLTEtNjg3OTU_82bc9610-4a27-492c-9d64-b2fcc3f06c11"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOjNmZDFmODlkODNkZjRkMmE5MTAxYzM5ZjIxYTNhYzU2L3RhYmxlcmFuZ2U6M2ZkMWY4OWQ4M2RmNGQyYTkxMDFjMzlmMjFhM2FjNTZfMTAtOC0xLTEtNjg3OTU_ab8fc484-1320-4b5a-aeaa-18cc1c125635"
      unitRef="usd">376644000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i565005420cf94f52b9804cec98cee107_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfMy0yLTEtMS02ODc5NQ_1da3ebaf-d65d-4761-82e0-a969812f3c96"
      unitRef="usd">231900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i615ccd0cba2748fb9fcffb4adcc668be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfMy00LTEtMS02ODc5NQ_bc5d9569-72cd-4c08-ba9f-4cf55fedcb20"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i734f0c5aa1b846b08acb4ccd89a87f39_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfMy02LTEtMS02ODc5NQ_9f53e8a0-0c92-4e8f-bb79-888846adca74"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i263f1cbad4dd43fcb51ad6c9abe11101_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfMy04LTEtMS02ODc5NQ_e040f6d8-a34b-44a0-888f-59f5312ac468"
      unitRef="usd">231900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2b5b0fee0d3a410eb5fe646815a1df0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfNC0yLTEtMS02ODc5NQ_ce7d2fc1-8f2c-486e-bfc4-0327812a1ee9"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i37d4bff646e04f7f80b9a75717f9fea4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfNC00LTEtMS02ODc5NQ_dbfd7c18-517a-411f-a5b2-03fe77de7b1b"
      unitRef="usd">3140000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3a260d1645884811bafbb0ac61e2190b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfNC02LTEtMS02ODc5NQ_823df57a-f73f-4d33-9eab-4bac48419769"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i64ab53854b6748a49a313e183035fb12_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfNC04LTEtMS02ODc5NQ_942c4a9a-42e8-4bd1-9e89-6893c7891c2d"
      unitRef="usd">3140000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id6ca842beffc422d80be5664771bc026_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfNS0yLTEtMS02ODc5NQ_fa25dab5-d465-4cb8-8261-1480494f8535"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4804d6f12b174250ace2bb6d08b12a0e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfNS00LTEtMS02ODc5NQ_55f4450f-69d9-4034-b5b8-d156fee80e8d"
      unitRef="usd">21820000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i87306c1797ef420a8944c1b4d0ff89c4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfNS02LTEtMS02ODc5NQ_7f076051-86d7-4c13-b943-fbc61dedc865"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3c5de38286e74db18b18df7f49cac2d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfNS04LTEtMS02ODc5NQ_1eb3da97-d273-415b-afe5-1a50df6525c1"
      unitRef="usd">21820000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idbdc367dda2942d19a94e15c46320342_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfNi0yLTEtMS02ODc5NQ_a4e3750c-1a4a-4c4a-a67b-fd00882246fa"
      unitRef="usd">206724000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if20a77aa2fc04f8a96554bede25f9d7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfNi00LTEtMS02ODc5NQ_656b7ace-ef5d-49c3-9748-0ec1c4198d4f"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if7fb0798462249e3a2d60ca4407e0eab_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfNi02LTEtMS02ODc5NQ_f65052b6-faa8-48a5-bfe2-9b8774b38666"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8af1b2c873d0434eaf8b9108131f9009_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfNi04LTEtMS02ODc5NQ_48c7015d-35df-4d44-8a19-056043ee5542"
      unitRef="usd">206724000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i34d4826b176e435f8bd5b0030feb4952_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfNy0yLTEtMS02ODc5NQ_02e5b54e-9708-474f-ad1c-1adc032f77e8"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i59210d4302394347a4104d3d57a6934b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfNy00LTEtMS02ODc5NQ_d1a643eb-9f6c-4cb7-bc3f-4cb774ffd556"
      unitRef="usd">2494000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iaf503387569145268e73f2bf99c3cba4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfNy02LTEtMS02ODc5NQ_1dfaacd5-97ea-4de5-b692-9ba0604c74d5"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i904ede1b4aeb489099791792b04faf0e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfNy04LTEtMS02ODc5NQ_934e28aa-7604-4138-81ce-6cf38c1c0278"
      unitRef="usd">2494000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i938ca9c21c994394a2ac416a16c72176_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfOC0yLTEtMS02ODc5NQ_539f0880-1737-489e-8571-b0e46bc2f259"
      unitRef="usd">438624000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i19c0b5fabb074b7692f8a2ab582c6da6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfOC00LTEtMS02ODc5NQ_889a28db-b709-4bc4-b8e6-81936370381c"
      unitRef="usd">27454000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i477353e441ec446e872a95c69aab7d85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfOC02LTEtMS02ODc5NQ_8b14add2-c433-4f66-b7ab-cc0610a7db73"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RhYmxlOmFiNDUxMWNjN2Q4YTQ0ZjY5ZTA5ZGYwYjRiOTQzMzQ4L3RhYmxlcmFuZ2U6YWI0NTExY2M3ZDhhNDRmNjllMDlkZjBiNGI5NDMzNDhfOC04LTEtMS02ODc5NQ_00c64c1a-8a25-4a6f-80d1-e2a7aee3081d"
      unitRef="usd">466078000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeAverageRemainingMaturity1
      contextRef="if1d1a617e2e74074ae1e4ccd6de119b5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RleHRyZWdpb246ZWI2YmU1NzM2MDExNDA3NTg2OTg3Zjc2YzRmMDUwOWFfMjE5OTAyMzI1ODc0Mg_0e3ee853-fe6b-4045-af9e-afc7cc5ed9db">P7M</us-gaap:DerivativeAverageRemainingMaturity1>
    <us-gaap:DerivativeAverageRemainingMaturity1
      contextRef="ib0a72a6a58e04c6dbc7123f06753286b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RleHRyZWdpb246ZWI2YmU1NzM2MDExNDA3NTg2OTg3Zjc2YzRmMDUwOWFfMjE5OTAyMzI1ODc0Mg_1132c95e-fa13-4e45-ac18-1534489b700e">P7M</us-gaap:DerivativeAverageRemainingMaturity1>
    <us-gaap:DerivativeAverageRemainingMaturity1
      contextRef="ia851cc9f46674b05af88b96945f0cb85_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RleHRyZWdpb246ZWI2YmU1NzM2MDExNDA3NTg2OTg3Zjc2YzRmMDUwOWFfNTQ5NzU1ODE3Mjkx_43f50693-824b-4035-bc78-318ee7e808ce">P8M</us-gaap:DerivativeAverageRemainingMaturity1>
    <us-gaap:DerivativeAverageRemainingMaturity1
      contextRef="ib711a46ca0504a0f83970696c2b2069c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180My9mcmFnOmViNmJlNTczNjAxMTQwNzU4Njk4N2Y3NmM0ZjA1MDlhL3RleHRyZWdpb246ZWI2YmU1NzM2MDExNDA3NTg2OTg3Zjc2YzRmMDUwOWFfNTQ5NzU1ODE3Mjkx_e525f9c3-8960-4bb2-8156-5ad275892543">P8M</us-gaap:DerivativeAverageRemainingMaturity1>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RleHRyZWdpb246M2I2NmFlYjhmZDQxNDIxMmJiYjRkN2Q3NTQ3NTRiYjJfMTMwNw_896c34bc-d3fd-4575-be9c-dcf465a8cb51">Cash, Cash Equivalents, Restricted Cash and Short-Term Investments&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022 and December&#160;31, 2021, the Company had $376.6 million and $466.1 million, respectively of cash, cash equivalents, restricted cash and short-term investments summarized below. As of September&#160;30, 2022, $376.6 million were available-for-sale debt securities which are carried at fair market value. As of December&#160;31, 2021, $446.9 million were classified as available-for-sale and $19.2 million were held-to-maturity. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;86,052&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;86,052&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency security&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,900&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,904&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;98,448&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;98,068&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;112,833&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;112,633&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Treasury bill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;26,721&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;26,704&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Treasury bond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;44,670&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;44,553&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Yankee bond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,742&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,730&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;377,366&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(726)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;376,644&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Treasury bill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total held to maturity securities at amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022 and December&#160;31, 2021, accrued interest receivable from the investments were $0.7 million and $0.1 million, respectively. During the three and nine months ended September&#160;30, 2022, the Company had $0.3 million and $0.7 million unrealized gains and losses on available-for-sale securities, net of tax, respectively, which are included as a component of comprehensive loss on the consolidated statements of operations. Currently, the Company does not intend to sell investments that are in an unrealized loss position, and it is unlikely we will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. We have determined that the gross unrealized losses on our investments at September&#160;30, 2022, were temporary in nature. Realized gains or losses were immaterial during the three and nine months ended September&#160;30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;The Company's short-term investments as of September&#160;30, 2022 mature at various dates through June 2023.</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <auph:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RleHRyZWdpb246M2I2NmFlYjhmZDQxNDIxMmJiYjRkN2Q3NTQ3NTRiYjJfMTA4_b282e28c-6aad-43a0-9b00-cea734aaab7e"
      unitRef="usd">376600000</auph:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments>
    <auph:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RleHRyZWdpb246M2I2NmFlYjhmZDQxNDIxMmJiYjRkN2Q3NTQ3NTRiYjJfMTE1_9bb8aa69-57bb-4f9b-a7fc-956e0515be96"
      unitRef="usd">466100000</auph:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RleHRyZWdpb246M2I2NmFlYjhmZDQxNDIxMmJiYjRkN2Q3NTQ3NTRiYjJfMzcz_5e6f8d7e-b0ee-4aae-9137-6cfd953185ee"
      unitRef="usd">376600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RleHRyZWdpb246M2I2NmFlYjhmZDQxNDIxMmJiYjRkN2Q3NTQ3NTRiYjJfNDY1_01672470-c976-41d3-8460-d971e982a33b"
      unitRef="usd">446900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RleHRyZWdpb246M2I2NmFlYjhmZDQxNDIxMmJiYjRkN2Q3NTQ3NTRiYjJfNTEw_0f084000-198d-47e0-963c-4455deaed013"
      unitRef="usd">19200000</us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RleHRyZWdpb246M2I2NmFlYjhmZDQxNDIxMmJiYjRkN2Q3NTQ3NTRiYjJfMTMwNg_5251ef9e-0071-478b-b5f6-64f2fc2891ce">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;86,052&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;86,052&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency security&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,900&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,904&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;98,448&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;98,068&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;112,833&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;112,633&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Treasury bill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;26,721&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;26,704&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Treasury bond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;44,670&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;44,553&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Yankee bond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,742&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,730&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;377,366&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(726)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;376,644&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Treasury bill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total held to maturity securities at amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:HeldToMaturitySecurities
      contextRef="id57531e234234b2b9cb0d8e02f891cfd_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMi0yLTEtMS02ODc5NQ_292380e1-2a0b-4b54-a167-d5d554ec7b4d"
      unitRef="usd">86052000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="id57531e234234b2b9cb0d8e02f891cfd_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMi00LTEtMS02ODc5NQ_fdf4a2cf-f4fe-4883-a8b3-f5d11a69c18b"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="id57531e234234b2b9cb0d8e02f891cfd_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMi02LTEtMS02ODc5NQ_e9284e29-627c-4b38-b5b4-ecda05fce5da"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="id57531e234234b2b9cb0d8e02f891cfd_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMi04LTEtMS02ODc5NQ_e7e8b5a1-e30b-46f5-8d6e-796692d9e606"
      unitRef="usd">86052000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i12201e4c78d14b7fa31409f5abef573b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMy0yLTEtMS02ODc5NQ_3d78ac5a-b748-40b3-be54-fb6aa0fd5673"
      unitRef="usd">4900000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i12201e4c78d14b7fa31409f5abef573b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMy00LTEtMS02ODc5NQ_6009cb0e-ee76-4512-a214-0d6d6e3f1f9b"
      unitRef="usd">4000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i12201e4c78d14b7fa31409f5abef573b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMy02LTEtMS02ODc5NQ_b7156f0c-ed55-4c9f-b8ce-ee5c62f4c450"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i12201e4c78d14b7fa31409f5abef573b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMy04LTEtMS02ODc5NQ_95ccb73f-a2b3-4eb7-9ff1-b5300d16d98e"
      unitRef="usd">4904000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i43c8446460754675965bbc2c13bac604_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfNC0yLTEtMS02ODc5NQ_155c3f9e-6d16-4436-8c23-3c4cb701bf3b"
      unitRef="usd">98448000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i43c8446460754675965bbc2c13bac604_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfNC00LTEtMS02ODc5NQ_f2df411a-329c-4b29-af03-ca8ca2bdfa3f"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i43c8446460754675965bbc2c13bac604_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfNC02LTEtMS02ODc5NQ_4cfd8961-74ea-4471-9c3f-5141b7a484bf"
      unitRef="usd">380000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i43c8446460754675965bbc2c13bac604_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfNC04LTEtMS02ODc5NQ_8200aec7-5e42-44a5-a802-fab1f394e0dd"
      unitRef="usd">98068000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="ic9f1f2ee39a841c18e4e03be170e2977_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfNS0yLTEtMS02ODc5NQ_057b2520-e009-42df-a96b-6f161b8095c1"
      unitRef="usd">112833000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="ic9f1f2ee39a841c18e4e03be170e2977_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfNS00LTEtMS02ODc5NQ_8db69ca7-f7ee-4d26-8381-d16936cef70b"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="ic9f1f2ee39a841c18e4e03be170e2977_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfNS02LTEtMS02ODc5NQ_0ff6fd58-6471-48a7-976c-948240f2f6cc"
      unitRef="usd">200000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ic9f1f2ee39a841c18e4e03be170e2977_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfNS04LTEtMS02ODc5NQ_aeb3c0c2-47ff-4b6e-9ad0-9fa4d3a43bd7"
      unitRef="usd">112633000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="id9a7d157907c4446a83d6762c688bc37_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfNi0yLTEtMS02ODc5NQ_c8a388e3-f323-4c5f-9f2e-4481a5111076"
      unitRef="usd">26721000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="id9a7d157907c4446a83d6762c688bc37_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfNi00LTEtMS02ODc5NQ_5a10dd7b-e5f4-40f6-b3e2-062bc2b38f1f"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="id9a7d157907c4446a83d6762c688bc37_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfNi02LTEtMS02ODc5NQ_dc08edf0-dc07-41b3-a082-782f75b7dd04"
      unitRef="usd">17000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="id9a7d157907c4446a83d6762c688bc37_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfNi04LTEtMS02ODc5NQ_6688f986-1a6d-4f2a-b004-6546fe683683"
      unitRef="usd">26704000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i879c4a29d0b4430fa56ad47b590225c2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfNy0yLTEtMS02ODc5NQ_e93b5f19-fa0e-45fb-be64-f0609e935958"
      unitRef="usd">44670000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i879c4a29d0b4430fa56ad47b590225c2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfNy00LTEtMS02ODc5NQ_e6024505-6829-42e1-b97d-cba8e94b0ad7"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i879c4a29d0b4430fa56ad47b590225c2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfNy02LTEtMS02ODc5NQ_6ef3e60b-2ecc-497e-b5bd-1d6cd414b512"
      unitRef="usd">117000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i879c4a29d0b4430fa56ad47b590225c2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfNy04LTEtMS02ODc5NQ_5b9d3e61-4404-4b2b-a26d-fe8024ee28dd"
      unitRef="usd">44553000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i20cb6a6c7b9e4a5380a7381cd01eeee6_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfOC0yLTEtMS02ODc5NQ_f74cbc3e-e80e-48b2-a6f7-c24eae84cdb1"
      unitRef="usd">3742000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i20cb6a6c7b9e4a5380a7381cd01eeee6_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfOC00LTEtMS02ODc5NQ_1c99b2c0-ee6a-4e2c-9f1a-fa1beca708a0"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i20cb6a6c7b9e4a5380a7381cd01eeee6_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfOC02LTEtMS02ODc5NQ_f5dcefa6-5cd2-4447-adde-0ec440b638e9"
      unitRef="usd">12000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i20cb6a6c7b9e4a5380a7381cd01eeee6_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfOC04LTEtMS02ODc5NQ_7b16b480-e8b0-4fd3-ac8d-8462b77c1d08"
      unitRef="usd">3730000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfOS0yLTEtMS02ODc5NQ_e9e1b46d-7af4-4891-a5b8-1ea71033832b"
      unitRef="usd">377366000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfOS00LTEtMS02ODc5NQ_c44f819e-e063-4ef2-bbb3-f9d94d09a593"
      unitRef="usd">4000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfOS02LTEtMS02ODc5NQ_21b8d7da-51c2-4cde-8ee0-ad375ff46e27"
      unitRef="usd">726000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfOS04LTEtMS02ODc5NQ_ad2365d4-7121-402e-bb7f-a2d3729fe70d"
      unitRef="usd">376644000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i263f1cbad4dd43fcb51ad6c9abe11101_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTUtMi0xLTEtNjg3OTU_3160bbe2-e915-4d71-bd5e-bb073ef2db01"
      unitRef="usd">231900000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i263f1cbad4dd43fcb51ad6c9abe11101_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTUtNC0xLTEtNjg3OTU_c4af9328-203d-4d08-a9c2-57493cbe7294"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i263f1cbad4dd43fcb51ad6c9abe11101_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTUtNi0xLTEtNjg3OTU_d36fa762-9d74-4708-80ae-7d5356ef2b3a"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i263f1cbad4dd43fcb51ad6c9abe11101_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTUtOC0xLTEtNjg3OTU_42789cfc-a373-4a72-b49b-432dd3ec5440"
      unitRef="usd">231900000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i64ab53854b6748a49a313e183035fb12_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTYtMi0xLTEtNjg3OTU_2cdd382c-f619-45a2-8037-c0a6b29f2cf6"
      unitRef="usd">3144000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i64ab53854b6748a49a313e183035fb12_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTYtNC0xLTEtNjg3OTU_304c4be7-16d3-4818-a5b5-be415f493fa4"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i64ab53854b6748a49a313e183035fb12_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTYtNi0xLTEtNjg3OTU_dab8ce03-2a52-4a13-ab6d-60b1dd87bca1"
      unitRef="usd">4000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i64ab53854b6748a49a313e183035fb12_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTYtOC0xLTEtNjg3OTU_a8f30e72-702d-4a79-992c-dc0b20892842"
      unitRef="usd">3140000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i0e7b23d46c544fc184d25711658db577_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTctMi0xLTEtNjg3OTU_d517519b-a15e-406b-a732-cf0962901419"
      unitRef="usd">2592000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i0e7b23d46c544fc184d25711658db577_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTctNC0xLTEtNjg3OTU_78e30e68-b8de-45f4-af31-8a5dafc8d579"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i0e7b23d46c544fc184d25711658db577_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTctNi0xLTEtNjg3OTU_7e3246bc-dee0-48ea-8015-66a3c1995b91"
      unitRef="usd">1000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i0e7b23d46c544fc184d25711658db577_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTctOC0xLTEtNjg3OTU_10538dd6-ef3f-4610-aaec-9e946b38a0fd"
      unitRef="usd">2591000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i8af1b2c873d0434eaf8b9108131f9009_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTgtMi0xLTEtNjg3OTU_80286073-e2ca-4d27-9e63-d59721a7fbc1"
      unitRef="usd">206764000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i8af1b2c873d0434eaf8b9108131f9009_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTgtNC0xLTEtNjg3OTU_37cd595b-dda7-4a6b-b4ba-116fd25c51d7"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i8af1b2c873d0434eaf8b9108131f9009_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTgtNi0xLTEtNjg3OTU_afcfaa68-d614-46c4-a3f9-22408ed1b3e3"
      unitRef="usd">40000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i8af1b2c873d0434eaf8b9108131f9009_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTgtOC0xLTEtNjg3OTU_60b2e566-0e3f-4d41-943b-168e77caa70e"
      unitRef="usd">206724000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i904ede1b4aeb489099791792b04faf0e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTktMi0xLTEtNjg3OTU_b31385c0-c4b8-49a5-883f-bc58446406a6"
      unitRef="usd">2497000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i904ede1b4aeb489099791792b04faf0e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTktNC0xLTEtNjg3OTU_fc6041de-c124-4a40-8e9b-ba8661720b21"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i904ede1b4aeb489099791792b04faf0e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTktNi0xLTEtNjg3OTU_e9bddc5a-e208-4774-bb9b-f58dd64d7a45"
      unitRef="usd">2000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i904ede1b4aeb489099791792b04faf0e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMTktOC0xLTEtNjg3OTU_49ea8984-c1f6-44a7-94ae-bf0bdffd7b87"
      unitRef="usd">2495000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMjItMi0xLTEtNjg3OTU_6687bdf2-2fb9-41ac-87f9-1c6e26f53498"
      unitRef="usd">446897000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMjItNC0xLTEtNjg3OTU_935476cc-9a1d-4a71-9f64-855f4dd9d7c1"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMjItNi0xLTEtNjg3OTU_6bcdf914-cdfc-4a11-80f2-bfc0b7c35d66"
      unitRef="usd">47000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMjItOC0xLTEtNjg3OTU_cb69bee1-79c1-4757-9e5e-002fa5e29bb6"
      unitRef="usd">446850000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMjMtOC0xLTEtNjg3OTU_34089a43-d35e-475e-a4c0-c9f56a7e820f"
      unitRef="usd">19228000</us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent>
    <auph:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RhYmxlOjA1YzM1NzYyMGFhNDRiN2FhY2YzM2RkMjFhZjMzY2UxL3RhYmxlcmFuZ2U6MDVjMzU3NjIwYWE0NGI3YWFjZjMzZGQyMWFmMzNjZTFfMjQtOC0xLTEtNjg3OTU_21b7fa22-00b5-4f89-a44b-7d0f3508228b"
      unitRef="usd">466078000</auph:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments>
    <us-gaap:InterestReceivable
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RleHRyZWdpb246M2I2NmFlYjhmZDQxNDIxMmJiYjRkN2Q3NTQ3NTRiYjJfNjEx_9d5a7087-0cf3-402f-a925-1c6d51015b47"
      unitRef="usd">700000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RleHRyZWdpb246M2I2NmFlYjhmZDQxNDIxMmJiYjRkN2Q3NTQ3NTRiYjJfNjE4_21fc23e6-5b08-49f0-a154-bb8dd7139507"
      unitRef="usd">100000</us-gaap:InterestReceivable>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RleHRyZWdpb246M2I2NmFlYjhmZDQxNDIxMmJiYjRkN2Q3NTQ3NTRiYjJfNTQ5NzU1ODE3MjE2_73ee6758-7b6e-447c-bf3c-de96fba404ac"
      unitRef="usd">300000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY180Ni9mcmFnOjNiNjZhZWI4ZmQ0MTQyMTJiYmI0ZDdkNzU0NzU0YmIyL3RleHRyZWdpb246M2I2NmFlYjhmZDQxNDIxMmJiYjRkN2Q3NTQ3NTRiYjJfNzAx_c27bd659-e4b4-42d6-a805-f33ba0a4e5ce"
      unitRef="usd">-700000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181Mi9mcmFnOjU2OTY2MzQ4ZGVmZDRmY2U4ZjdiOWRjZDdkZWNkMWE5L3RleHRyZWdpb246NTY5NjYzNDhkZWZkNGZjZThmN2I5ZGNkN2RlY2QxYTlfMTEzNw_5d4d993a-0e60-455b-9ecf-b9f665433822">Inventories, netInventories are valued under a standard costing methodology on a first-in, first-out basis and are stated at the lower of cost or net realizable value. The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs. Capitalized costs of inventories for LUPKYNIS mainly include third party manufacturing costs, transportation, storage, insurance, and allocated internal labor. &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses recoverability of inventory each reporting period to determine any write-down to net realizable value resulting from excess or obsolete inventories. As of September&#160;30, 2022, we have recorded reserves of finished goods inventories of approximately $2.7 million which were primarily related to process validation batches used for FDA approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventory, net are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,217&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20,150&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,953&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;25,320&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:InventoryFinishedGoods
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181Mi9mcmFnOjU2OTY2MzQ4ZGVmZDRmY2U4ZjdiOWRjZDdkZWNkMWE5L3RleHRyZWdpb246NTY5NjYzNDhkZWZkNGZjZThmN2I5ZGNkN2RlY2QxYTlfNTQ5NzU1ODE1Nzgz_3fc43d79-9600-433d-9694-aa9baf313b9d"
      unitRef="usd">2700000</us-gaap:InventoryFinishedGoods>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181Mi9mcmFnOjU2OTY2MzQ4ZGVmZDRmY2U4ZjdiOWRjZDdkZWNkMWE5L3RleHRyZWdpb246NTY5NjYzNDhkZWZkNGZjZThmN2I5ZGNkN2RlY2QxYTlfMTEzOA_2a9a15b5-bb3a-4b79-8c16-517d9ea852fd">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventory, net are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,217&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20,150&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,953&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;25,320&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181Mi9mcmFnOjU2OTY2MzQ4ZGVmZDRmY2U4ZjdiOWRjZDdkZWNkMWE5L3RhYmxlOjcxMjkyNjYwMzQ4YzQyODZhYmY3MzI0MTRlYTg0YjNlL3RhYmxlcmFuZ2U6NzEyOTI2NjAzNDhjNDI4NmFiZjczMjQxNGVhODRiM2VfMS0yLTEtMS02ODc5NQ_e4b86337-11f2-441b-b3f6-9baba78df695"
      unitRef="usd">2217000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181Mi9mcmFnOjU2OTY2MzQ4ZGVmZDRmY2U4ZjdiOWRjZDdkZWNkMWE5L3RhYmxlOjcxMjkyNjYwMzQ4YzQyODZhYmY3MzI0MTRlYTg0YjNlL3RhYmxlcmFuZ2U6NzEyOTI2NjAzNDhjNDI4NmFiZjczMjQxNGVhODRiM2VfMS00LTEtMS02ODc5NQ_4e6c673f-dc72-413e-a6fd-d66de0aa627f"
      unitRef="usd">2217000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181Mi9mcmFnOjU2OTY2MzQ4ZGVmZDRmY2U4ZjdiOWRjZDdkZWNkMWE5L3RhYmxlOjcxMjkyNjYwMzQ4YzQyODZhYmY3MzI0MTRlYTg0YjNlL3RhYmxlcmFuZ2U6NzEyOTI2NjAzNDhjNDI4NmFiZjczMjQxNGVhODRiM2VfMi0yLTEtMS02ODc5NQ_31704ada-2a3b-482c-857d-0a60e82dce22"
      unitRef="usd">20150000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181Mi9mcmFnOjU2OTY2MzQ4ZGVmZDRmY2U4ZjdiOWRjZDdkZWNkMWE5L3RhYmxlOjcxMjkyNjYwMzQ4YzQyODZhYmY3MzI0MTRlYTg0YjNlL3RhYmxlcmFuZ2U6NzEyOTI2NjAzNDhjNDI4NmFiZjczMjQxNGVhODRiM2VfMi00LTEtMS02ODc5NQ_8a3af0c2-889b-44af-a728-0eb1c8c46b36"
      unitRef="usd">12566000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181Mi9mcmFnOjU2OTY2MzQ4ZGVmZDRmY2U4ZjdiOWRjZDdkZWNkMWE5L3RhYmxlOjcxMjkyNjYwMzQ4YzQyODZhYmY3MzI0MTRlYTg0YjNlL3RhYmxlcmFuZ2U6NzEyOTI2NjAzNDhjNDI4NmFiZjczMjQxNGVhODRiM2VfMy0yLTEtMS02ODc5NQ_30fe7b80-8827-4d77-ac15-861edef0b965"
      unitRef="usd">2953000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181Mi9mcmFnOjU2OTY2MzQ4ZGVmZDRmY2U4ZjdiOWRjZDdkZWNkMWE5L3RhYmxlOjcxMjkyNjYwMzQ4YzQyODZhYmY3MzI0MTRlYTg0YjNlL3RhYmxlcmFuZ2U6NzEyOTI2NjAzNDhjNDI4NmFiZjczMjQxNGVhODRiM2VfMy00LTEtMS02ODc5NQ_1c36d2ac-5729-4e33-882a-513fbe66ab8b"
      unitRef="usd">4543000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181Mi9mcmFnOjU2OTY2MzQ4ZGVmZDRmY2U4ZjdiOWRjZDdkZWNkMWE5L3RhYmxlOjcxMjkyNjYwMzQ4YzQyODZhYmY3MzI0MTRlYTg0YjNlL3RhYmxlcmFuZ2U6NzEyOTI2NjAzNDhjNDI4NmFiZjczMjQxNGVhODRiM2VfNC0yLTEtMS02ODc5NQ_3a7b3d95-4cce-4e61-a522-ce80a8702d67"
      unitRef="usd">25320000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181Mi9mcmFnOjU2OTY2MzQ4ZGVmZDRmY2U4ZjdiOWRjZDdkZWNkMWE5L3RhYmxlOjcxMjkyNjYwMzQ4YzQyODZhYmY3MzI0MTRlYTg0YjNlL3RhYmxlcmFuZ2U6NzEyOTI2NjAzNDhjNDI4NmFiZjczMjQxNGVhODRiM2VfNC00LTEtMS02ODc5NQ_5c692dce-f250-4e68-bbf4-59ff63f06a37"
      unitRef="usd">19326000</us-gaap:InventoryNet>
    <auph:PrepaidExpensesTextBlock
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181NS9mcmFnOmJiMmEzNjE0M2Q2MzQ1YTBiYmNlNTNmNjgxMmUwNzkxL3RleHRyZWdpb246YmIyYTM2MTQzZDYzNDVhMGJiY2U1M2Y2ODEyZTA3OTFfMTA4_ce07956f-bf6b-4374-b794-277dcdc327fc">Prepaid Expenses&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,725&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,582&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,852&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,159&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</auph:PrepaidExpensesTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181NS9mcmFnOmJiMmEzNjE0M2Q2MzQ1YTBiYmNlNTNmNjgxMmUwNzkxL3RleHRyZWdpb246YmIyYTM2MTQzZDYzNDVhMGJiY2U1M2Y2ODEyZTA3OTFfMTA3_3f468894-31ee-4161-a959-90345fb7dc29">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,725&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,582&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,852&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,159&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <auph:PrepaidAssetsCurrent
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181NS9mcmFnOmJiMmEzNjE0M2Q2MzQ1YTBiYmNlNTNmNjgxMmUwNzkxL3RhYmxlOmVkYTQ2NmYxNDMwMTQ0OTQ5MGY5OWJlYTE0YWM3NDVkL3RhYmxlcmFuZ2U6ZWRhNDY2ZjE0MzAxNDQ5NDkwZjk5YmVhMTRhYzc0NWRfMi0yLTEtMS02ODc5NQ_22498e45-b99b-4cbd-82bf-4809c895ea0e"
      unitRef="usd">5725000</auph:PrepaidAssetsCurrent>
    <auph:PrepaidAssetsCurrent
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181NS9mcmFnOmJiMmEzNjE0M2Q2MzQ1YTBiYmNlNTNmNjgxMmUwNzkxL3RhYmxlOmVkYTQ2NmYxNDMwMTQ0OTQ5MGY5OWJlYTE0YWM3NDVkL3RhYmxlcmFuZ2U6ZWRhNDY2ZjE0MzAxNDQ5NDkwZjk5YmVhMTRhYzc0NWRfMi00LTEtMS02ODc5NQ_feac2aa8-ab73-494c-91ed-eb316511ebdd"
      unitRef="usd">5316000</auph:PrepaidAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181NS9mcmFnOmJiMmEzNjE0M2Q2MzQ1YTBiYmNlNTNmNjgxMmUwNzkxL3RhYmxlOmVkYTQ2NmYxNDMwMTQ0OTQ5MGY5OWJlYTE0YWM3NDVkL3RhYmxlcmFuZ2U6ZWRhNDY2ZjE0MzAxNDQ5NDkwZjk5YmVhMTRhYzc0NWRfMy0yLTEtMS02ODc5NQ_8f6c97c1-04b4-441b-86a6-d20b5c0785a4"
      unitRef="usd">3582000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181NS9mcmFnOmJiMmEzNjE0M2Q2MzQ1YTBiYmNlNTNmNjgxMmUwNzkxL3RhYmxlOmVkYTQ2NmYxNDMwMTQ0OTQ5MGY5OWJlYTE0YWM3NDVkL3RhYmxlcmFuZ2U6ZWRhNDY2ZjE0MzAxNDQ5NDkwZjk5YmVhMTRhYzc0NWRfMy00LTEtMS02ODc5NQ_7fae2a7b-f87a-4c27-8ee5-a89f9f5303ca"
      unitRef="usd">4762000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:PrepaidInsurance
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181NS9mcmFnOmJiMmEzNjE0M2Q2MzQ1YTBiYmNlNTNmNjgxMmUwNzkxL3RhYmxlOmVkYTQ2NmYxNDMwMTQ0OTQ5MGY5OWJlYTE0YWM3NDVkL3RhYmxlcmFuZ2U6ZWRhNDY2ZjE0MzAxNDQ5NDkwZjk5YmVhMTRhYzc0NWRfNC0yLTEtMS02ODc5NQ_3a7e27b5-25b1-42df-9313-956afd7bfc3d"
      unitRef="usd">2852000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181NS9mcmFnOmJiMmEzNjE0M2Q2MzQ1YTBiYmNlNTNmNjgxMmUwNzkxL3RhYmxlOmVkYTQ2NmYxNDMwMTQ0OTQ5MGY5OWJlYTE0YWM3NDVkL3RhYmxlcmFuZ2U6ZWRhNDY2ZjE0MzAxNDQ5NDkwZjk5YmVhMTRhYzc0NWRfNC00LTEtMS02ODc5NQ_20724876-45cd-4083-b72a-60129a0d82e5"
      unitRef="usd">1632000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181NS9mcmFnOmJiMmEzNjE0M2Q2MzQ1YTBiYmNlNTNmNjgxMmUwNzkxL3RhYmxlOmVkYTQ2NmYxNDMwMTQ0OTQ5MGY5OWJlYTE0YWM3NDVkL3RhYmxlcmFuZ2U6ZWRhNDY2ZjE0MzAxNDQ5NDkwZjk5YmVhMTRhYzc0NWRfNi0yLTEtMS02ODc5NQ_04b46fe0-295c-478b-b55d-7caa14236198"
      unitRef="usd">12159000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181NS9mcmFnOmJiMmEzNjE0M2Q2MzQ1YTBiYmNlNTNmNjgxMmUwNzkxL3RhYmxlOmVkYTQ2NmYxNDMwMTQ0OTQ5MGY5OWJlYTE0YWM3NDVkL3RhYmxlcmFuZ2U6ZWRhNDY2ZjE0MzAxNDQ5NDkwZjk5YmVhMTRhYzc0NWRfNi00LTEtMS02ODc5NQ_c49b98e9-1439-488b-a5a0-4c9af051d83e"
      unitRef="usd">11710000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RleHRyZWdpb246Y2I2NGE2MTQwYTlkNDViOGI5ZGM2MTc2NTU3YTBmN2ZfMjgz_08cc33bd-e485-4ec1-afcc-206e086d99bc">Intangible Assets&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the carrying amount of intangible assets, net of accumulated amortization. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,473&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,249)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;224&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intellectual property and reacquired rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,126&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9,580)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,546&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software implementation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,873&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,804)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,069&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19,472&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(12,633)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,839&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intellectual property and reacquired rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,804)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software implementation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,086)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,066)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense for the three months ended September&#160;30, 2022 and 2021 was $0.5 million for both periods and for the nine months ended September&#160;30, 2022 and 2021 was $1.6 million for both periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RleHRyZWdpb246Y2I2NGE2MTQwYTlkNDViOGI5ZGM2MTc2NTU3YTBmN2ZfMjg0_3fd534f3-7788-40ea-bd34-cc8ab8d1af3a">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the carrying amount of intangible assets, net of accumulated amortization. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,473&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,249)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;224&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intellectual property and reacquired rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,126&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9,580)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,546&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software implementation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,873&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,804)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,069&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19,472&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(12,633)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,839&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intellectual property and reacquired rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,804)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software implementation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,086)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,066)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i694749f08fba4701ba5443abefc101e0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmQ4ZDFmZGFjYzJjNTQwZjU5YWI5MGNkZTMzYjE2MWZkL3RhYmxlcmFuZ2U6ZDhkMWZkYWNjMmM1NDBmNTlhYjkwY2RlMzNiMTYxZmRfMi0yLTEtMS02ODc5NQ_3f9c4b7d-a49d-4680-86f9-3fca5964cfe8"
      unitRef="usd">1473000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i694749f08fba4701ba5443abefc101e0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmQ4ZDFmZGFjYzJjNTQwZjU5YWI5MGNkZTMzYjE2MWZkL3RhYmxlcmFuZ2U6ZDhkMWZkYWNjMmM1NDBmNTlhYjkwY2RlMzNiMTYxZmRfMi00LTEtMS02ODc5NQ_85faf7c7-a47b-429c-8cbb-346e647d0506"
      unitRef="usd">1249000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i694749f08fba4701ba5443abefc101e0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmQ4ZDFmZGFjYzJjNTQwZjU5YWI5MGNkZTMzYjE2MWZkL3RhYmxlcmFuZ2U6ZDhkMWZkYWNjMmM1NDBmNTlhYjkwY2RlMzNiMTYxZmRfMi02LTEtMS02ODc5NQ_d5fd3868-9bc6-4592-acb4-84d3425c36e5"
      unitRef="usd">224000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5cb5e9e831f5489cad13f8086d409cfb_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmQ4ZDFmZGFjYzJjNTQwZjU5YWI5MGNkZTMzYjE2MWZkL3RhYmxlcmFuZ2U6ZDhkMWZkYWNjMmM1NDBmNTlhYjkwY2RlMzNiMTYxZmRfMy0yLTEtMS02ODc5NQ_f15f0895-921f-491e-b06e-211cd4fef072"
      unitRef="usd">15126000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5cb5e9e831f5489cad13f8086d409cfb_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmQ4ZDFmZGFjYzJjNTQwZjU5YWI5MGNkZTMzYjE2MWZkL3RhYmxlcmFuZ2U6ZDhkMWZkYWNjMmM1NDBmNTlhYjkwY2RlMzNiMTYxZmRfMy00LTEtMS02ODc5NQ_12fa4cb0-7802-4245-86d8-632c4c61ea11"
      unitRef="usd">9580000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5cb5e9e831f5489cad13f8086d409cfb_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmQ4ZDFmZGFjYzJjNTQwZjU5YWI5MGNkZTMzYjE2MWZkL3RhYmxlcmFuZ2U6ZDhkMWZkYWNjMmM1NDBmNTlhYjkwY2RlMzNiMTYxZmRfMy02LTEtMS02ODc5NQ_ba5e17f5-a221-4f70-a410-77c1525c9e88"
      unitRef="usd">5546000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2753c410533a473db311c14ff1da390f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmQ4ZDFmZGFjYzJjNTQwZjU5YWI5MGNkZTMzYjE2MWZkL3RhYmxlcmFuZ2U6ZDhkMWZkYWNjMmM1NDBmNTlhYjkwY2RlMzNiMTYxZmRfNC0yLTEtMS02ODc5NQ_ca8af901-d722-4f04-8fea-decc205c1ed2"
      unitRef="usd">2873000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2753c410533a473db311c14ff1da390f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmQ4ZDFmZGFjYzJjNTQwZjU5YWI5MGNkZTMzYjE2MWZkL3RhYmxlcmFuZ2U6ZDhkMWZkYWNjMmM1NDBmNTlhYjkwY2RlMzNiMTYxZmRfNC00LTEtMS02ODc5NQ_e6b0aee1-56bb-4969-aeaf-82b400fc065a"
      unitRef="usd">1804000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2753c410533a473db311c14ff1da390f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmQ4ZDFmZGFjYzJjNTQwZjU5YWI5MGNkZTMzYjE2MWZkL3RhYmxlcmFuZ2U6ZDhkMWZkYWNjMmM1NDBmNTlhYjkwY2RlMzNiMTYxZmRfNC02LTEtMS02ODc5NQ_f199ab17-edf8-41ac-a225-9c48d9878222"
      unitRef="usd">1069000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmQ4ZDFmZGFjYzJjNTQwZjU5YWI5MGNkZTMzYjE2MWZkL3RhYmxlcmFuZ2U6ZDhkMWZkYWNjMmM1NDBmNTlhYjkwY2RlMzNiMTYxZmRfNS0yLTEtMS02ODc5NQ_717535fe-7141-42b1-b2d4-1cecd1a5805d"
      unitRef="usd">19472000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmQ4ZDFmZGFjYzJjNTQwZjU5YWI5MGNkZTMzYjE2MWZkL3RhYmxlcmFuZ2U6ZDhkMWZkYWNjMmM1NDBmNTlhYjkwY2RlMzNiMTYxZmRfNS00LTEtMS02ODc5NQ_0f28b44f-2b09-4afd-86c4-268a82f3b9a5"
      unitRef="usd">12633000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmQ4ZDFmZGFjYzJjNTQwZjU5YWI5MGNkZTMzYjE2MWZkL3RhYmxlcmFuZ2U6ZDhkMWZkYWNjMmM1NDBmNTlhYjkwY2RlMzNiMTYxZmRfNS02LTEtMS02ODc5NQ_2730ee3c-3e43-43ed-95e7-456eb0089aef"
      unitRef="usd">6839000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib78726334c604e7abc504057535e595b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmRhN2UzZGM1ZDg5NDQ2OWFiMzAwYzVkZjc2MDU4N2NiL3RhYmxlcmFuZ2U6ZGE3ZTNkYzVkODk0NDY5YWIzMDBjNWRmNzYwNTg3Y2JfMi0yLTEtMS02ODc5NQ_f048f570-32b0-4c17-950b-2bba73b2ca5f"
      unitRef="usd">1471000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib78726334c604e7abc504057535e595b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmRhN2UzZGM1ZDg5NDQ2OWFiMzAwYzVkZjc2MDU4N2NiL3RhYmxlcmFuZ2U6ZGE3ZTNkYzVkODk0NDY5YWIzMDBjNWRmNzYwNTg3Y2JfMi00LTEtMS02ODc5NQ_b35546f6-1ada-4411-8c66-e01f361dedc5"
      unitRef="usd">1176000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib78726334c604e7abc504057535e595b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmRhN2UzZGM1ZDg5NDQ2OWFiMzAwYzVkZjc2MDU4N2NiL3RhYmxlcmFuZ2U6ZGE3ZTNkYzVkODk0NDY5YWIzMDBjNWRmNzYwNTg3Y2JfMi02LTEtMS02ODc5NQ_81b3ac90-3e27-47d8-b84a-ecc6a97bcb94"
      unitRef="usd">295000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i587a5632527b4d8f9fc78a79b55065c0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmRhN2UzZGM1ZDg5NDQ2OWFiMzAwYzVkZjc2MDU4N2NiL3RhYmxlcmFuZ2U6ZGE3ZTNkYzVkODk0NDY5YWIzMDBjNWRmNzYwNTg3Y2JfMy0yLTEtMS02ODc5NQ_21160a41-1416-46ee-98a9-241e7b276670"
      unitRef="usd">15126000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i587a5632527b4d8f9fc78a79b55065c0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmRhN2UzZGM1ZDg5NDQ2OWFiMzAwYzVkZjc2MDU4N2NiL3RhYmxlcmFuZ2U6ZGE3ZTNkYzVkODk0NDY5YWIzMDBjNWRmNzYwNTg3Y2JfMy00LTEtMS02ODc5NQ_a0a51aa0-1920-4366-9a85-ffc29bec23aa"
      unitRef="usd">8804000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i587a5632527b4d8f9fc78a79b55065c0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmRhN2UzZGM1ZDg5NDQ2OWFiMzAwYzVkZjc2MDU4N2NiL3RhYmxlcmFuZ2U6ZGE3ZTNkYzVkODk0NDY5YWIzMDBjNWRmNzYwNTg3Y2JfMy02LTEtMS02ODc5NQ_cd5aed9e-3e9e-4a6b-98b8-2ad1459adb54"
      unitRef="usd">6322000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i762371a552ae4e189fdad22d6c254db5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmRhN2UzZGM1ZDg5NDQ2OWFiMzAwYzVkZjc2MDU4N2NiL3RhYmxlcmFuZ2U6ZGE3ZTNkYzVkODk0NDY5YWIzMDBjNWRmNzYwNTg3Y2JfNC0yLTEtMS02ODc5NQ_219a56f4-5381-444a-86c7-88db614f77f0"
      unitRef="usd">2873000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i762371a552ae4e189fdad22d6c254db5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmRhN2UzZGM1ZDg5NDQ2OWFiMzAwYzVkZjc2MDU4N2NiL3RhYmxlcmFuZ2U6ZGE3ZTNkYzVkODk0NDY5YWIzMDBjNWRmNzYwNTg3Y2JfNC00LTEtMS02ODc5NQ_45044935-9898-4836-81ca-d9ed4958e3ed"
      unitRef="usd">1086000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i762371a552ae4e189fdad22d6c254db5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmRhN2UzZGM1ZDg5NDQ2OWFiMzAwYzVkZjc2MDU4N2NiL3RhYmxlcmFuZ2U6ZGE3ZTNkYzVkODk0NDY5YWIzMDBjNWRmNzYwNTg3Y2JfNC02LTEtMS02ODc5NQ_ae9ee208-5679-4936-9784-6e80ac617475"
      unitRef="usd">1787000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmRhN2UzZGM1ZDg5NDQ2OWFiMzAwYzVkZjc2MDU4N2NiL3RhYmxlcmFuZ2U6ZGE3ZTNkYzVkODk0NDY5YWIzMDBjNWRmNzYwNTg3Y2JfNS0yLTEtMS02ODc5NQ_e7f1a310-adc6-46b2-b836-8ba52454f1e1"
      unitRef="usd">19470000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmRhN2UzZGM1ZDg5NDQ2OWFiMzAwYzVkZjc2MDU4N2NiL3RhYmxlcmFuZ2U6ZGE3ZTNkYzVkODk0NDY5YWIzMDBjNWRmNzYwNTg3Y2JfNS00LTEtMS02ODc5NQ_f67669d8-1252-47f5-829d-bce3e6f3e0a9"
      unitRef="usd">11066000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RhYmxlOmRhN2UzZGM1ZDg5NDQ2OWFiMzAwYzVkZjc2MDU4N2NiL3RhYmxlcmFuZ2U6ZGE3ZTNkYzVkODk0NDY5YWIzMDBjNWRmNzYwNTg3Y2JfNS02LTEtMS02ODc5NQ_fbb396bf-b673-44e6-84cd-294b8b1565b7"
      unitRef="usd">8404000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RleHRyZWdpb246Y2I2NGE2MTQwYTlkNDViOGI5ZGM2MTc2NTU3YTBmN2ZfMTk2_630c461a-6744-4e2e-b086-0b2f4dd9b9db"
      unitRef="usd">500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RleHRyZWdpb246Y2I2NGE2MTQwYTlkNDViOGI5ZGM2MTc2NTU3YTBmN2ZfMTk2_7c38ddcf-41d2-40a9-9833-97bc14e2202c"
      unitRef="usd">500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RleHRyZWdpb246Y2I2NGE2MTQwYTlkNDViOGI5ZGM2MTc2NTU3YTBmN2ZfMjU5_05092861-082a-4e8c-84d1-297232da3a62"
      unitRef="usd">1600000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY181OC9mcmFnOmNiNjRhNjE0MGE5ZDQ1YjhiOWRjNjE3NjU1N2EwZjdmL3RleHRyZWdpb246Y2I2NGE2MTQwYTlkNDViOGI5ZGM2MTc2NTU3YTBmN2ZfMjU5_ff1c458b-c487-4b10-ae22-41edf4777654"
      unitRef="usd">1600000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182MS9mcmFnOmIwYTY5ZGVmZmJiODRkZmFhZjFiNDc3NmM0YTc4Yjk1L3RleHRyZWdpb246YjBhNjlkZWZmYmI4NGRmYWFmMWI0Nzc2YzRhNzhiOTVfODE_7846d576-4958-435f-a51a-32fa3ed1b2d3">Property and Equipment, net&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;217&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,978&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;645&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;976&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;251&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,067&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,254&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,309)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(836)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,758&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182MS9mcmFnOmIwYTY5ZGVmZmJiODRkZmFhZjFiNDc3NmM0YTc4Yjk1L3RleHRyZWdpb246YjBhNjlkZWZmYmI4NGRmYWFmMWI0Nzc2YzRhNzhiOTVfODI_bdc50715-10b2-4bc9-b700-e0ede4cbc6b3">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;217&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,978&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;645&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;976&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;251&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,067&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,254&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,309)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(836)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,758&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia8ebc008d0bf419399d57a1954b31411_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182MS9mcmFnOmIwYTY5ZGVmZmJiODRkZmFhZjFiNDc3NmM0YTc4Yjk1L3RhYmxlOjMwYmVkOGNmZjg1ODRmOGZiOTlhYjViZDkwZmRhNmEzL3RhYmxlcmFuZ2U6MzBiZWQ4Y2ZmODU4NGY4ZmI5OWFiNWJkOTBmZGE2YTNfMS0yLTEtMS02ODc5NQ_1b33c370-a9ef-42f2-a394-220084b54074"
      unitRef="usd">217000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i015f087f0bfd4fa583200ee0a162bffe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182MS9mcmFnOmIwYTY5ZGVmZmJiODRkZmFhZjFiNDc3NmM0YTc4Yjk1L3RhYmxlOjMwYmVkOGNmZjg1ODRmOGZiOTlhYjViZDkwZmRhNmEzL3RhYmxlcmFuZ2U6MzBiZWQ4Y2ZmODU4NGY4ZmI5OWFiNWJkOTBmZGE2YTNfMS00LTEtMS02ODc5NQ_427360e6-e034-4583-85bd-b72b99120805"
      unitRef="usd">393000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie438ea390b8846d7831dd0900ee639c1_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182MS9mcmFnOmIwYTY5ZGVmZmJiODRkZmFhZjFiNDc3NmM0YTc4Yjk1L3RhYmxlOjMwYmVkOGNmZjg1ODRmOGZiOTlhYjViZDkwZmRhNmEzL3RhYmxlcmFuZ2U6MzBiZWQ4Y2ZmODU4NGY4ZmI5OWFiNWJkOTBmZGE2YTNfMi0yLTEtMS02ODc5NQ_ef48536e-8c58-45e2-ad2c-38c53f765e95"
      unitRef="usd">2978000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia783c0184bda40e8a385452883ad9164_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182MS9mcmFnOmIwYTY5ZGVmZmJiODRkZmFhZjFiNDc3NmM0YTc4Yjk1L3RhYmxlOjMwYmVkOGNmZjg1ODRmOGZiOTlhYjViZDkwZmRhNmEzL3RhYmxlcmFuZ2U6MzBiZWQ4Y2ZmODU4NGY4ZmI5OWFiNWJkOTBmZGE2YTNfMi00LTEtMS02ODc5NQ_4eef1e40-a7ce-4aee-aa0b-f21fbf6e3afb"
      unitRef="usd">2978000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if39e9f1e69324041b0415ecd8d450952_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182MS9mcmFnOmIwYTY5ZGVmZmJiODRkZmFhZjFiNDc3NmM0YTc4Yjk1L3RhYmxlOjMwYmVkOGNmZjg1ODRmOGZiOTlhYjViZDkwZmRhNmEzL3RhYmxlcmFuZ2U6MzBiZWQ4Y2ZmODU4NGY4ZmI5OWFiNWJkOTBmZGE2YTNfMy0yLTEtMS02ODc5NQ_9919cc9f-425c-4842-8b6b-047ee6903bb6"
      unitRef="usd">645000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ieafc1263da604de4864e371e83bf3ae9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182MS9mcmFnOmIwYTY5ZGVmZmJiODRkZmFhZjFiNDc3NmM0YTc4Yjk1L3RhYmxlOjMwYmVkOGNmZjg1ODRmOGZiOTlhYjViZDkwZmRhNmEzL3RhYmxlcmFuZ2U6MzBiZWQ4Y2ZmODU4NGY4ZmI5OWFiNWJkOTBmZGE2YTNfMy00LTEtMS02ODc5NQ_2deb5c2a-4280-44d8-841c-5349c61f1be2"
      unitRef="usd">645000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if15808d1e63744299f8008a22843785a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182MS9mcmFnOmIwYTY5ZGVmZmJiODRkZmFhZjFiNDc3NmM0YTc4Yjk1L3RhYmxlOjMwYmVkOGNmZjg1ODRmOGZiOTlhYjViZDkwZmRhNmEzL3RhYmxlcmFuZ2U6MzBiZWQ4Y2ZmODU4NGY4ZmI5OWFiNWJkOTBmZGE2YTNfNC0yLTEtMS02ODc5NQ_fe914c6d-693b-4ac1-862f-dfc7ebdaf7ae"
      unitRef="usd">976000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i71d0284de4094b58a61726e34448a7c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182MS9mcmFnOmIwYTY5ZGVmZmJiODRkZmFhZjFiNDc3NmM0YTc4Yjk1L3RhYmxlOjMwYmVkOGNmZjg1ODRmOGZiOTlhYjViZDkwZmRhNmEzL3RhYmxlcmFuZ2U6MzBiZWQ4Y2ZmODU4NGY4ZmI5OWFiNWJkOTBmZGE2YTNfNC00LTEtMS02ODc5NQ_43f95113-4ce0-4fc4-b4a1-e7cc0b904172"
      unitRef="usd">976000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie5e1845517044932807f74d13e17f14f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182MS9mcmFnOmIwYTY5ZGVmZmJiODRkZmFhZjFiNDc3NmM0YTc4Yjk1L3RhYmxlOjMwYmVkOGNmZjg1ODRmOGZiOTlhYjViZDkwZmRhNmEzL3RhYmxlcmFuZ2U6MzBiZWQ4Y2ZmODU4NGY4ZmI5OWFiNWJkOTBmZGE2YTNfNS0yLTEtMS02ODc5NQ_67353fe9-88c6-4082-aaa3-daa6ab1ec6db"
      unitRef="usd">251000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i344a287699e44b6abf65762731d49159_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182MS9mcmFnOmIwYTY5ZGVmZmJiODRkZmFhZjFiNDc3NmM0YTc4Yjk1L3RhYmxlOjMwYmVkOGNmZjg1ODRmOGZiOTlhYjViZDkwZmRhNmEzL3RhYmxlcmFuZ2U6MzBiZWQ4Y2ZmODU4NGY4ZmI5OWFiNWJkOTBmZGE2YTNfNS00LTEtMS02ODc5NQ_78535d9d-803e-4c74-b7a9-45175e61fa78"
      unitRef="usd">262000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182MS9mcmFnOmIwYTY5ZGVmZmJiODRkZmFhZjFiNDc3NmM0YTc4Yjk1L3RhYmxlOjMwYmVkOGNmZjg1ODRmOGZiOTlhYjViZDkwZmRhNmEzL3RhYmxlcmFuZ2U6MzBiZWQ4Y2ZmODU4NGY4ZmI5OWFiNWJkOTBmZGE2YTNfNi0yLTEtMS02ODc5NQ_76eb6285-2148-4329-9275-34f4b93ab2d0"
      unitRef="usd">5067000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182MS9mcmFnOmIwYTY5ZGVmZmJiODRkZmFhZjFiNDc3NmM0YTc4Yjk1L3RhYmxlOjMwYmVkOGNmZjg1ODRmOGZiOTlhYjViZDkwZmRhNmEzL3RhYmxlcmFuZ2U6MzBiZWQ4Y2ZmODU4NGY4ZmI5OWFiNWJkOTBmZGE2YTNfNi00LTEtMS02ODc5NQ_d82d2596-6c51-4445-9cec-24b4b2084721"
      unitRef="usd">5254000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182MS9mcmFnOmIwYTY5ZGVmZmJiODRkZmFhZjFiNDc3NmM0YTc4Yjk1L3RhYmxlOjMwYmVkOGNmZjg1ODRmOGZiOTlhYjViZDkwZmRhNmEzL3RhYmxlcmFuZ2U6MzBiZWQ4Y2ZmODU4NGY4ZmI5OWFiNWJkOTBmZGE2YTNfNy0yLTEtMS02ODc5NQ_119568d9-d383-4be5-afe8-5d0df0d29156"
      unitRef="usd">1309000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182MS9mcmFnOmIwYTY5ZGVmZmJiODRkZmFhZjFiNDc3NmM0YTc4Yjk1L3RhYmxlOjMwYmVkOGNmZjg1ODRmOGZiOTlhYjViZDkwZmRhNmEzL3RhYmxlcmFuZ2U6MzBiZWQ4Y2ZmODU4NGY4ZmI5OWFiNWJkOTBmZGE2YTNfNy00LTEtMS02ODc5NQ_67850c58-56b4-4b85-83a0-05aa213547ce"
      unitRef="usd">836000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182MS9mcmFnOmIwYTY5ZGVmZmJiODRkZmFhZjFiNDc3NmM0YTc4Yjk1L3RhYmxlOjMwYmVkOGNmZjg1ODRmOGZiOTlhYjViZDkwZmRhNmEzL3RhYmxlcmFuZ2U6MzBiZWQ4Y2ZmODU4NGY4ZmI5OWFiNWJkOTBmZGE2YTNfOC0yLTEtMS02ODc5NQ_482fd5bd-2a92-4e4b-851f-6cb424aac17d"
      unitRef="usd">3758000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182MS9mcmFnOmIwYTY5ZGVmZmJiODRkZmFhZjFiNDc3NmM0YTc4Yjk1L3RhYmxlOjMwYmVkOGNmZjg1ODRmOGZiOTlhYjViZDkwZmRhNmEzL3RhYmxlcmFuZ2U6MzBiZWQ4Y2ZmODU4NGY4ZmI5OWFiNWJkOTBmZGE2YTNfOC00LTEtMS02ODc5NQ_1a5c222c-a76a-4883-aefb-78b7ed89dde3"
      unitRef="usd">4418000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfNTA4NQ_2f5ae9bc-eb13-4f2d-8774-754418f3b68b">Lease Obligations&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has the following lease obligations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Victoria, British Columbia&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During August 2020, the Company signed a lease for commercial office space in Victoria, British Columbia for a new corporate headquarters that was expected to commence in April 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fourth quarter of 2020, the Company entered into 18-month facility and furniture leases for its existing corporate head office located in Victoria, British Columbia. The lease terms commenced on January 1, 2021 with an end date of August 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 3, 2022, we provided notice of termination for the lease of the intended new corporate headquarters space in Victoria on the basis that the landlord's work was not completed by the time required under the lease. As a result of the termination, the company expensed $0.3&#160;million of CIP cost that was related to the new corporate headquarters.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 1, 2022, the fixed lease term ended for Aurinia's existing corporate headquarters and the Company exercised its right to enter into a month to month lease, of which expenses are incurred in SG&amp;amp;A.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rockville, Maryland&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During March 2020, the Company entered into a lease for its U.S. commercial office in Rockville, Maryland for a total of 30,531 square feet of office space. The lease has a remaining term of approximately 9 years and has an option to extend for two five-year periods after the initial term of 11 years has elapsed and has an option to terminate after seven years. As of September&#160;30, 2022, the Company had a right-of-use asset of $4.9 million and lease liability of $8.2 million included in the condensed consolidated balance sheets. As of December&#160;31, 2021, the Company had a right of use asset of $5.2 million and lease liability of $8.6 million included in the condensed consolidated balance sheets. The Company recorded leasehold improvement incentives in the amount of $2.3&#160;million as additions to the lease liability. The lease term commenced on March 12, 2020. When measuring the lease liability, the Company discounted lease payments using its incremental borrowing rate at March 12, 2020. The incremental borrowing rate applied to the lease liability on March 12, 2020 was 5.2% based on the financial position of the Company, geographical region and term of lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Edmonton, Alberta&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, the Company has a short term lease in Edmonton, Alberta in which expenses are recognized in SG&amp;amp;A. The lease is not material to the Company's financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurs variable lease costs under the existing Victoria and Rockville leases. These costs include operation and maintenance costs included in SG&amp;amp;A and are expensed as incurred. The variable lease costs are not material to the Company's financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The operating lease costs for the three and nine months ended September&#160;30, 2022 and September&#160;30, 2021 are $0.2&#160;million and $0.8&#160;million for both periods respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the weighted-average remaining lease term and discount rate as of September&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Lease Term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.22%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of operating lease liabilities payments for the next five years and thereafter:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Lease Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;263&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,061&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,085&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,110&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,135&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,638&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,292&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: lease imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,188&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 15, 2020, the Company entered into a collaborative agreement with Lonza to build a dedicated manufacturing facility within Lonza&#x2019;s existing small molecule facility in Visp, Switzerland. The dedicated facility (also referred to as "monoplant") will be equipped with state-of-the-art manufacturing equipment to provide cost and production efficiency for the manufacture of voclosporin, while expanding existing capacity and providing supply security to meet future commercial demand.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following U.S. regulatory approval of LUPKYNIS in January 2021, the Company has commenced a capital expenditure payment program for the monoplant totaling approximately CHF 21.0&#160;million. The first capital expenditure payment was made in February 2021 of $11.8&#160;million (CHF 10.5&#160;million) and was treated as an upfront lease payment and recorded under other non-current assets on the condensed consolidated balance sheets. The second payment is not due until the facility fulfills the required operational qualifications which is estimated to be during the first half of 2023. Upon completion of the monoplant, the Company will have the right to maintain sole dedicated use of the monoplant by paying a quarterly fixed facility fee. The Company expects to account for the arrangement as a finance lease under ASC 842. The present value of the minimum lease payments total approximately $73.0&#160;million, beginning April 2023 and expiring in 2030, and are not included in the above table.&lt;/span&gt;&lt;/div&gt;The Company has entered into an equipment and facility finance lease for a backup manufacturing encapsulation site in Beinheim, France that has not yet commenced and is therefore, not included in the above table. As part of the agreement, the Company expects to make payments of approximately $0.9&#160;million prior to lease commencement and the future value of minimum lease payments will total approximately $0.1&#160;million.</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ib0122d51e9ce4a43a91c77261f282564_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfMzI5ODUzNDg5OTUxMw_4cabe27d-e635-4110-b23c-d6443a41a297">P18M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ie76075ad5fba4197953b1f9074f707fb_D20220803-20220803"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfNjA0NzMxMzk2NzIzNg_906873e4-1c70-47c3-ab43-a8b39db26846"
      unitRef="usd">300000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i8217ea002f274269ad63c35be20de5d2_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfMTQ4MA_88508329-924f-4e77-ad96-39a7406aa1e3"
      unitRef="sqft">30531</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i8217ea002f274269ad63c35be20de5d2_I20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfMTU2MA_b6b8ad8e-3b87-4871-8f4c-adc761c8af82">P9Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <auph:LesseeOperatingLeaseNumberOfExtensionOptions
      contextRef="i8217ea002f274269ad63c35be20de5d2_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfMTU5NQ_561546a4-afeb-4d87-bc22-3615c47e68cb"
      unitRef="extension_option">2</auph:LesseeOperatingLeaseNumberOfExtensionOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i8217ea002f274269ad63c35be20de5d2_I20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfNTA4Mw_3c52e5d6-5ce0-43bb-a01f-ea07ad290ec0">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i8217ea002f274269ad63c35be20de5d2_I20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfMTY0MA_f7428842-4528-40eb-ad9f-cc7e3e076d6c">P11Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <auph:LesseeOperatingLeaseLeaseTerminationTerm
      contextRef="ifdc02d86fd494bcd9c3bbcefc6567c61_D20200301-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfMTY5Mg_6f7f160a-2190-4f54-8e08-de2d0e8498af">P7Y</auph:LesseeOperatingLeaseLeaseTerminationTerm>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ieab7019fc2e44f7281b349abacde0bc3_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfMTc0Ng_d2671925-1487-4ff5-bf01-db3d6b779bef"
      unitRef="usd">4900000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="ieab7019fc2e44f7281b349abacde0bc3_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfMTc3Mg_94d72b14-c86a-420c-b159-9ecc62e1494e"
      unitRef="usd">8200000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i58c5e7c150d14386a0bf23271f8fcc59_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfMTg4MA_25844fc8-9946-4a5b-90f4-25464cd906f3"
      unitRef="usd">5200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="i58c5e7c150d14386a0bf23271f8fcc59_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfMTkwNg_987efbb4-2bd8-4807-9e43-06be09b5bc3e"
      unitRef="usd">8600000</us-gaap:OperatingLeaseLiability>
    <us-gaap:PaymentsForProceedsFromTenantAllowance
      contextRef="i2010334e882c4ffd813f86072931dd35_D20211231-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfMjAzNQ_aca3994c-e5f6-4525-a610-32bce41787d2"
      unitRef="usd">-2300000</us-gaap:PaymentsForProceedsFromTenantAllowance>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i67061bc27f97417eb92caad1115e4f65_I20200312"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfMjMzMw_2ec5a935-1045-4fe0-bdb4-000b6facaa16"
      unitRef="number">0.052</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseCost
      contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfMjk5Ng_1d9cb948-776c-4a31-aeee-e4e5b6f28756"
      unitRef="usd">200000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfMjk5Ng_279a15c6-4d14-4cd8-b01a-ec64afb8d289"
      unitRef="usd">200000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfMzAwMw_52c9d97d-90c7-40b9-9292-9449df0374f3"
      unitRef="usd">800000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfMzAwMw_c8123bca-09f7-454b-b966-64414fd5ec05"
      unitRef="usd">800000</us-gaap:OperatingLeaseCost>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfNTA4NA_55f75ea0-1acd-440a-a090-c3a360c928fd">&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the weighted-average remaining lease term and discount rate as of September&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Lease Term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.22%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RhYmxlOjcwMzc0Y2JhYWUwMzQ2ZWJiZDQ1YjZiMmRiZGFlZjQwL3RhYmxlcmFuZ2U6NzAzNzRjYmFhZTAzNDZlYmJkNDViNmIyZGJkYWVmNDBfMi0yLTEtMS02ODc5NQ_2abb25dd-d984-4e6a-a3e7-22ab2806a4a8">P8Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RhYmxlOjcwMzc0Y2JhYWUwMzQ2ZWJiZDQ1YjZiMmRiZGFlZjQwL3RhYmxlcmFuZ2U6NzAzNzRjYmFhZTAzNDZlYmJkNDViNmIyZGJkYWVmNDBfMi00LTEtMS02ODc5NQ_fbb8c3ad-87bf-43c4-b74a-f5cd1a412990"
      unitRef="number">0.0522</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfNTA4MA_10be816a-a992-4413-be64-fb3627824bb4">&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of operating lease liabilities payments for the next five years and thereafter:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Lease Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;263&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,061&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,085&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,110&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,135&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,638&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,292&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: lease imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,188&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RhYmxlOjU1ZjYwNzA1YWMzYjRkNzk5ZjFkNTFmMWI0Y2YxYmYyL3RhYmxlcmFuZ2U6NTVmNjA3MDVhYzNiNGQ3OTlmMWQ1MWYxYjRjZjFiZjJfMS0yLTEtMS02ODc5NQ_36eb41db-451d-4917-8d02-80f35182f9f4"
      unitRef="usd">263000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RhYmxlOjU1ZjYwNzA1YWMzYjRkNzk5ZjFkNTFmMWI0Y2YxYmYyL3RhYmxlcmFuZ2U6NTVmNjA3MDVhYzNiNGQ3OTlmMWQ1MWYxYjRjZjFiZjJfMi0yLTEtMS02ODc5NQ_c84a48f1-86fb-49fe-b927-554e5dbab94f"
      unitRef="usd">1061000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RhYmxlOjU1ZjYwNzA1YWMzYjRkNzk5ZjFkNTFmMWI0Y2YxYmYyL3RhYmxlcmFuZ2U6NTVmNjA3MDVhYzNiNGQ3OTlmMWQ1MWYxYjRjZjFiZjJfMy0yLTEtMS02ODc5NQ_befec823-b04e-4fbf-986f-36929b733447"
      unitRef="usd">1085000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RhYmxlOjU1ZjYwNzA1YWMzYjRkNzk5ZjFkNTFmMWI0Y2YxYmYyL3RhYmxlcmFuZ2U6NTVmNjA3MDVhYzNiNGQ3OTlmMWQ1MWYxYjRjZjFiZjJfNC0yLTEtMS02ODc5NQ_b55e9fa1-3451-47aa-b325-8c9482b7f33b"
      unitRef="usd">1110000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RhYmxlOjU1ZjYwNzA1YWMzYjRkNzk5ZjFkNTFmMWI0Y2YxYmYyL3RhYmxlcmFuZ2U6NTVmNjA3MDVhYzNiNGQ3OTlmMWQ1MWYxYjRjZjFiZjJfNS0yLTEtMS02ODc5NQ_3b71b346-cc45-4535-8f63-547b5d3c3b75"
      unitRef="usd">1135000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <auph:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RhYmxlOjU1ZjYwNzA1YWMzYjRkNzk5ZjFkNTFmMWI0Y2YxYmYyL3RhYmxlcmFuZ2U6NTVmNjA3MDVhYzNiNGQ3OTlmMWQ1MWYxYjRjZjFiZjJfNi0yLTEtMS02ODc5NQ_774094d1-bf82-43fb-81be-33796d9f215a"
      unitRef="usd">5638000</auph:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RhYmxlOjU1ZjYwNzA1YWMzYjRkNzk5ZjFkNTFmMWI0Y2YxYmYyL3RhYmxlcmFuZ2U6NTVmNjA3MDVhYzNiNGQ3OTlmMWQ1MWYxYjRjZjFiZjJfNy0yLTEtMS02ODc5NQ_932dfafa-0ef4-49aa-8553-137ca1c9c0b0"
      unitRef="usd">10292000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RhYmxlOjU1ZjYwNzA1YWMzYjRkNzk5ZjFkNTFmMWI0Y2YxYmYyL3RhYmxlcmFuZ2U6NTVmNjA3MDVhYzNiNGQ3OTlmMWQ1MWYxYjRjZjFiZjJfOC0yLTEtMS02ODc5NQ_644c9f15-8b33-4141-8f21-fd193de19dd3"
      unitRef="usd">2104000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RhYmxlOjU1ZjYwNzA1YWMzYjRkNzk5ZjFkNTFmMWI0Y2YxYmYyL3RhYmxlcmFuZ2U6NTVmNjA3MDVhYzNiNGQ3OTlmMWQ1MWYxYjRjZjFiZjJfOS0yLTEtMS02ODc5NQ_e229ccb5-16d7-42c1-b3b6-eb3554c6ab5d"
      unitRef="usd">8188000</us-gaap:OperatingLeaseLiability>
    <us-gaap:PaymentsForCapitalImprovements
      contextRef="ibdd4d5c6c4cc486cb6916357de93b010_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfMzkyOA_f6b1cf3f-4d6d-4b5e-a66e-d841c50de924"
      unitRef="chf">21000000</us-gaap:PaymentsForCapitalImprovements>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i0218c4022baf4887b278a279993662cb_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfMzk5OQ_06129fa9-bc5e-43f5-8829-a6b8553cfd48"
      unitRef="usd">11800000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i0218c4022baf4887b278a279993662cb_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfNDAwNw_e48e55dc-90d3-4584-b116-a55315708e0a"
      unitRef="chf">10500000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfNDYwOA_8e8d7f34-66dc-4e15-b621-759741b35ad9"
      unitRef="usd">73000000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <auph:LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfNDk2OQ_740a985d-4af0-4974-90e2-0cde0b4b4545"
      unitRef="usd">900000</auph:LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease>
    <auph:LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182NC9mcmFnOjAyNzViMDdiMGIwNjQ5ZmViZDBkN2U1Zjc1ODJhYjhlL3RleHRyZWdpb246MDI3NWIwN2IwYjA2NDlmZWJkMGQ3ZTVmNzU4MmFiOGVfNTA3Mg_bff0ebad-e2eb-48d9-8554-e6bb032c79fc"
      unitRef="usd">100000</auph:LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182Ny9mcmFnOmU4MWNhODY5MzI5YjQ4N2ZiZDUxZDNkZmZiZTNmOGRhL3RleHRyZWdpb246ZTgxY2E4NjkzMjliNDg3ZmJkNTFkM2RmZmJlM2Y4ZGFfMTA1_0daf5d1c-ffa0-45f3-8bc2-405327be7ea4">Accounts Payable and Accrued Liabilities&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,511&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,140&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued R&amp;amp;D projects&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,995&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,411&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;66&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;40,123&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182Ny9mcmFnOmU4MWNhODY5MzI5YjQ4N2ZiZDUxZDNkZmZiZTNmOGRhL3RleHRyZWdpb246ZTgxY2E4NjkzMjliNDg3ZmJkNTFkM2RmZmJlM2Y4ZGFfMTA2_189e39b2-7737-43e9-9fe3-d1c5e5802b3f">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,511&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,140&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued R&amp;amp;D projects&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,995&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,411&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;66&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;40,123&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182Ny9mcmFnOmU4MWNhODY5MzI5YjQ4N2ZiZDUxZDNkZmZiZTNmOGRhL3RhYmxlOjY1NTgxMjdmODk0NDQwYjdiYTE3NWExOWExOTQzNTg0L3RhYmxlcmFuZ2U6NjU1ODEyN2Y4OTQ0NDBiN2JhMTc1YTE5YTE5NDM1ODRfMi0yLTEtMS02ODc5NQ_31531be6-fa35-40a2-b287-2d7afc179bfa"
      unitRef="usd">16511000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182Ny9mcmFnOmU4MWNhODY5MzI5YjQ4N2ZiZDUxZDNkZmZiZTNmOGRhL3RhYmxlOjY1NTgxMjdmODk0NDQwYjdiYTE3NWExOWExOTQzNTg0L3RhYmxlcmFuZ2U6NjU1ODEyN2Y4OTQ0NDBiN2JhMTc1YTE5YTE5NDM1ODRfMi00LTEtMS02ODc5NQ_b2e3ea0a-66fd-4154-af8e-75a82439697b"
      unitRef="usd">18278000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <auph:CommercialRelatedAccrualsCurrent
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182Ny9mcmFnOmU4MWNhODY5MzI5YjQ4N2ZiZDUxZDNkZmZiZTNmOGRhL3RhYmxlOjY1NTgxMjdmODk0NDQwYjdiYTE3NWExOWExOTQzNTg0L3RhYmxlcmFuZ2U6NjU1ODEyN2Y4OTQ0NDBiN2JhMTc1YTE5YTE5NDM1ODRfMy0yLTEtMS02ODc5NQ_dc277bda-003b-49f0-b05b-fa7633cd7426"
      unitRef="usd">9140000</auph:CommercialRelatedAccrualsCurrent>
    <auph:CommercialRelatedAccrualsCurrent
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182Ny9mcmFnOmU4MWNhODY5MzI5YjQ4N2ZiZDUxZDNkZmZiZTNmOGRhL3RhYmxlOjY1NTgxMjdmODk0NDQwYjdiYTE3NWExOWExOTQzNTg0L3RhYmxlcmFuZ2U6NjU1ODEyN2Y4OTQ0NDBiN2JhMTc1YTE5YTE5NDM1ODRfMy00LTEtMS02ODc5NQ_afaeacdb-6d2d-47f8-a6c4-87fd54a30f8e"
      unitRef="usd">5916000</auph:CommercialRelatedAccrualsCurrent>
    <auph:AccruedResearchCurrent
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182Ny9mcmFnOmU4MWNhODY5MzI5YjQ4N2ZiZDUxZDNkZmZiZTNmOGRhL3RhYmxlOjY1NTgxMjdmODk0NDQwYjdiYTE3NWExOWExOTQzNTg0L3RhYmxlcmFuZ2U6NjU1ODEyN2Y4OTQ0NDBiN2JhMTc1YTE5YTE5NDM1ODRfNC0yLTEtMS02ODc5NQ_cac803de-4033-4ce3-8cd8-e43bd34f9238"
      unitRef="usd">8995000</auph:AccruedResearchCurrent>
    <auph:AccruedResearchCurrent
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182Ny9mcmFnOmU4MWNhODY5MzI5YjQ4N2ZiZDUxZDNkZmZiZTNmOGRhL3RhYmxlOjY1NTgxMjdmODk0NDQwYjdiYTE3NWExOWExOTQzNTg0L3RhYmxlcmFuZ2U6NjU1ODEyN2Y4OTQ0NDBiN2JhMTc1YTE5YTE5NDM1ODRfNC00LTEtMS02ODc5NQ_d8cde40a-aee1-435a-962c-b8a2ac33caed"
      unitRef="usd">6412000</auph:AccruedResearchCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182Ny9mcmFnOmU4MWNhODY5MzI5YjQ4N2ZiZDUxZDNkZmZiZTNmOGRhL3RhYmxlOjY1NTgxMjdmODk0NDQwYjdiYTE3NWExOWExOTQzNTg0L3RhYmxlcmFuZ2U6NjU1ODEyN2Y4OTQ0NDBiN2JhMTc1YTE5YTE5NDM1ODRfNS0yLTEtMS02ODc5NQ_8e9e14eb-f3a1-48fb-aa03-2679b4bff5ce"
      unitRef="usd">5411000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182Ny9mcmFnOmU4MWNhODY5MzI5YjQ4N2ZiZDUxZDNkZmZiZTNmOGRhL3RhYmxlOjY1NTgxMjdmODk0NDQwYjdiYTE3NWExOWExOTQzNTg0L3RhYmxlcmFuZ2U6NjU1ODEyN2Y4OTQ0NDBiN2JhMTc1YTE5YTE5NDM1ODRfNS00LTEtMS02ODc5NQ_0c02072d-6059-4d5f-bbd0-f0997f1c9142"
      unitRef="usd">3527000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182Ny9mcmFnOmU4MWNhODY5MzI5YjQ4N2ZiZDUxZDNkZmZiZTNmOGRhL3RhYmxlOjY1NTgxMjdmODk0NDQwYjdiYTE3NWExOWExOTQzNTg0L3RhYmxlcmFuZ2U6NjU1ODEyN2Y4OTQ0NDBiN2JhMTc1YTE5YTE5NDM1ODRfNi0yLTEtMS02ODc5NQ_b845daf9-5710-4969-9c11-8de1cfcce787"
      unitRef="usd">66000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182Ny9mcmFnOmU4MWNhODY5MzI5YjQ4N2ZiZDUxZDNkZmZiZTNmOGRhL3RhYmxlOjY1NTgxMjdmODk0NDQwYjdiYTE3NWExOWExOTQzNTg0L3RhYmxlcmFuZ2U6NjU1ODEyN2Y4OTQ0NDBiN2JhMTc1YTE5YTE5NDM1ODRfNi00LTEtMS02ODc5NQ_ee1f5f28-90d0-4f79-912a-92998602a50c"
      unitRef="usd">814000</us-gaap:TaxesPayableCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182Ny9mcmFnOmU4MWNhODY5MzI5YjQ4N2ZiZDUxZDNkZmZiZTNmOGRhL3RhYmxlOjY1NTgxMjdmODk0NDQwYjdiYTE3NWExOWExOTQzNTg0L3RhYmxlcmFuZ2U6NjU1ODEyN2Y4OTQ0NDBiN2JhMTc1YTE5YTE5NDM1ODRfNy0yLTEtMS02ODc5NQ_e417ebb8-b16f-41a1-b813-e86877459264"
      unitRef="usd">40123000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY182Ny9mcmFnOmU4MWNhODY5MzI5YjQ4N2ZiZDUxZDNkZmZiZTNmOGRhL3RhYmxlOjY1NTgxMjdmODk0NDQwYjdiYTE3NWExOWExOTQzNTg0L3RhYmxlcmFuZ2U6NjU1ODEyN2Y4OTQ0NDBiN2JhMTc1YTE5YTE5NDM1ODRfNy00LTEtMS02ODc5NQ_d5d747f4-5c3d-4707-8b50-658dee628c98"
      unitRef="usd">34947000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183MC9mcmFnOjUwNTdmMzM4NTZkMTRjMzViNTE1N2M3NTQ4ZDU3NzU0L3RleHRyZWdpb246NTA1N2YzMzg1NmQxNGMzNWI1MTU3Yzc1NDhkNTc3NTRfNjA4_3df413ab-5913-4c3d-80ac-13c0b5af3e83">Deferred Compensation and Other Non-current LiabilitiesThe Company recorded other non-current liabilities of $15.8 million and $16.0 million as of September&#160;30, 2022 and December&#160;31, 2021, respectively. The balance as of September&#160;30, 2022 and December&#160;31, 2021 primarily included deferred compensation arrangements whereby certain executive officers as of March 8, 2012 were provided with future potential employee benefit obligations for remaining with the Company, for a certain period of time. These obligations were also contingent on the occurrence of uncertain future events. Other non-current liabilities also include milestone payments deemed probable to be paid in the future.</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183MC9mcmFnOjUwNTdmMzM4NTZkMTRjMzViNTE1N2M3NTQ4ZDU3NzU0L3RleHRyZWdpb246NTA1N2YzMzg1NmQxNGMzNWI1MTU3Yzc1NDhkNTc3NTRfMTE2_662589bf-7438-4f45-9f38-be6a0dcaaac6"
      unitRef="usd">15800000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183MC9mcmFnOjUwNTdmMzM4NTZkMTRjMzViNTE1N2M3NTQ4ZDU3NzU0L3RleHRyZWdpb246NTA1N2YzMzg1NmQxNGMzNWI1MTU3Yzc1NDhkNTc3NTRfMTIz_b4c79447-6a4c-48f1-9506-3f9673f192d0"
      unitRef="usd">16000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183My9mcmFnOjU1ZDc2NmJjNDc3ZjRhZjk4YjlmMjk3ZWFkM2RkMjM2L3RleHRyZWdpb246NTVkNzY2YmM0NzdmNGFmOThiOWYyOTdlYWQzZGQyMzZfMzAwNw_269ca0bc-d293-4540-a3ab-be14ab1a5448">License and Collaboration Agreements&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Otsuka Contract&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 17, 2020, the Company entered into a collaboration and license agreement with Otsuka for the development and commercialization of oral LUPKYNIS in the Otsuka Territories.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the agreement, the Company received an upfront cash payment of $50.0&#160;million for the license agreement and has the potential to receive up to $50.0&#160;million in regulatory related milestones. The Company will provide semi-finished product of LUPKYNIS to Otsuka on a cost-plus basis, and will receive tiered royalties on future sales ranging from 10 to 20 percent (dependent on territory and achievement of sale thresholds) on net product sales by Otsuka, along with additional milestone payments based on the attainment of certain annual sales. In addition, certain collaboration services are to be provided to Otsuka on agreed upon rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In furtherance of the collaboration and license agreement with Otsuka mentioned above, on August 1, 2022, the Company entered into a commercial supply agreement with Otsuka, formalizing the terms to supply semi-finished goods of LUPKYNIS to Otsuka in the Otsuka Territories, including capacity sharing of the monoplant.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 15, 2022, the European Commission (EC) granted marketing authorization of LUPKYNIS. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The centralized marketing authorization is valid in all EU member states as well as in Iceland, Liechtenstein, Norway and Northern Ireland.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The approval triggered a $30.0&#160;million milestone to the Company, which was recognized as collaboration revenue in the three and nine months period ended September&#160;30, 2022 and was subsequently received on October 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September&#160;30, 2022, the Company recognized $0.2 million and $0.4 million, respectively, of collaboration service revenue from Otsuka. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Riptide License&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 17, 2021, AUR300 (M2 macrophage modulation via CD206 binding) was secured through a global licensing and research agreement with Riptide Bioscience, Inc. (Riptide), a private company. As part of the agreement, in 2021 the Company paid Riptide an upfront license fee of $6.0&#160;million which was expensed as research and development on the condensed consolidated statements of operations. During the first quarter of 2022, Aurinia paid $4.0&#160;million for the achievement of a one-time milestone. Additional payments are due upon certain development, clinical and regulatory milestones, and royalties will be payable upon commercialization.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="ibf32de36976c4acea4a8d8fcae729345_D20201217-20201217"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183My9mcmFnOjU1ZDc2NmJjNDc3ZjRhZjk4YjlmMjk3ZWFkM2RkMjM2L3RleHRyZWdpb246NTVkNzY2YmM0NzdmNGFmOThiOWYyOTdlYWQzZGQyMzZfNDg0_13c16ae0-f594-4db4-bc2e-a88e152eef87"
      unitRef="usd">50000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <auph:ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount
      contextRef="i7157bd498212400d9ba95e50a9998561_I20201217"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183My9mcmFnOjU1ZDc2NmJjNDc3ZjRhZjk4YjlmMjk3ZWFkM2RkMjM2L3RleHRyZWdpb246NTVkNzY2YmM0NzdmNGFmOThiOWYyOTdlYWQzZGQyMzZfNTUy_70f10401-63b8-495e-af6c-9d7c2a66c216"
      unitRef="usd">50000000</auph:ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount>
    <auph:ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent
      contextRef="i8cca31f183434cd5ab9525b020f34afc_I20201217"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183My9mcmFnOjU1ZDc2NmJjNDc3ZjRhZjk4YjlmMjk3ZWFkM2RkMjM2L3RleHRyZWdpb246NTVkNzY2YmM0NzdmNGFmOThiOWYyOTdlYWQzZGQyMzZfNjU2_9cdd850f-2d81-4f8d-a8b9-090835d12a47"
      unitRef="number">0.10</auph:ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent>
    <auph:ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent
      contextRef="i91f3a2c3fb9444049582457768137f12_I20201217"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183My9mcmFnOjU1ZDc2NmJjNDc3ZjRhZjk4YjlmMjk3ZWFkM2RkMjM2L3RleHRyZWdpb246NTVkNzY2YmM0NzdmNGFmOThiOWYyOTdlYWQzZGQyMzZfNjYy_7533e1ff-0546-4bb5-8640-1bb7fb8729b9"
      unitRef="number">0.20</auph:ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent>
    <auph:ResearchAndDevelopmentArrangementContractToPerformMilestonePayments
      contextRef="ie85ef3843f6e45c68cf365c48ec7f1a3_I20220915"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183My9mcmFnOjU1ZDc2NmJjNDc3ZjRhZjk4YjlmMjk3ZWFkM2RkMjM2L3RleHRyZWdpb246NTVkNzY2YmM0NzdmNGFmOThiOWYyOTdlYWQzZGQyMzZfNzU5Mg_3e5bbcce-d2c1-4df9-94cc-5606b95397c7"
      unitRef="usd">30000000</auph:ResearchAndDevelopmentArrangementContractToPerformMilestonePayments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81ca80b01c3949bc93f26e42672ea414_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183My9mcmFnOjU1ZDc2NmJjNDc3ZjRhZjk4YjlmMjk3ZWFkM2RkMjM2L3RleHRyZWdpb246NTVkNzY2YmM0NzdmNGFmOThiOWYyOTdlYWQzZGQyMzZfNjA0NzMxMzk2MjA3Ng_9f45fc79-9d09-4036-a460-e3036d2e51bf"
      unitRef="usd">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2297b01889a7491d85e8a7f9850e7bfc_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183My9mcmFnOjU1ZDc2NmJjNDc3ZjRhZjk4YjlmMjk3ZWFkM2RkMjM2L3RleHRyZWdpb246NTVkNzY2YmM0NzdmNGFmOThiOWYyOTdlYWQzZGQyMzZfODc5NjA5MzAzNDEzNA_f88c884f-2460-4e39-8142-d957072d26d3"
      unitRef="usd">400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ia6745a5042314bd3ac418f4f36aac11f_D20210817-20210817"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183My9mcmFnOjU1ZDc2NmJjNDc3ZjRhZjk4YjlmMjk3ZWFkM2RkMjM2L3RleHRyZWdpb246NTVkNzY2YmM0NzdmNGFmOThiOWYyOTdlYWQzZGQyMzZfMjU4Mg_6b44f803-3e47-4b08-b5bc-9fa9a3f6763d"
      unitRef="usd">6000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7e7f455148c3452faa9d3f2b5d9c272f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183My9mcmFnOjU1ZDc2NmJjNDc3ZjRhZjk4YjlmMjk3ZWFkM2RkMjM2L3RleHRyZWdpb246NTVkNzY2YmM0NzdmNGFmOThiOWYyOTdlYWQzZGQyMzZfMjczNQ_dbb7603c-408a-4533-9454-2faa532654eb"
      unitRef="usd">4000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RleHRyZWdpb246ODQ4N2ZlZmEwNzdmNDdmMzliYzMwNjRkYTA1ZjE5ZDJfNjEz_a89df5f4-5759-478e-bf5e-4a316385e950">Net Loss per Common Share&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share. The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(8,989)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50,255)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(82,134)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(147,644)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;141,856&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;141,831&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per common share (expressed in $ per share)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(0.06)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(0.58)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.15)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not include the securities in the following table in the computation of the net loss per common share because the effect would have been anti-dilutive during each period:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,299&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested performance awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,098&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,397&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RleHRyZWdpb246ODQ4N2ZlZmEwNzdmNDdmMzliYzMwNjRkYTA1ZjE5ZDJfNjE0_d6b94c93-4e7e-4e8c-a0a3-fbec4a0b5005">The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(8,989)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50,255)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(82,134)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(147,644)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;141,856&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;141,831&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per common share (expressed in $ per share)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(0.06)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(0.58)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.15)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfMi0yLTEtMS02ODc5NQ_c73fa4d2-b2f1-4f6c-96c7-2e75599b0882"
      unitRef="usd">-8989000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfMi00LTEtMS02ODc5NQ_2fae839c-b95b-444a-84b6-a6af98b12e20"
      unitRef="usd">-50255000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfMi02LTEtMS02ODc5NQ_b1df6359-2567-40fb-80aa-bdf327e8d662"
      unitRef="usd">-82134000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfMi04LTEtMS02ODc5NQ_8e151243-12ca-443e-9333-2b7dd5992450"
      unitRef="usd">-147644000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfMy0yLTEtMS02ODc5NQ_2f6f4577-4aae-498f-bc00-db2290c5958c"
      unitRef="shares">141856000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfMy0yLTEtMS02ODc5NQ_8de6666d-c0cc-4c47-9325-47629ca2234f"
      unitRef="shares">141856000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfMy00LTEtMS02ODc5NQ_4ac79ce8-694a-4ae4-9a02-65d155ae1c8c"
      unitRef="shares">128443000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfMy00LTEtMS02ODc5NQ_c8bf3ac4-84c1-4291-a588-bcce36602e4d"
      unitRef="shares">128443000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfMy02LTEtMS02ODc5NQ_37a95419-36d0-4d38-adae-31253d4a387d"
      unitRef="shares">141831000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfMy02LTEtMS02ODc5NQ_c8fedb66-8dc5-4220-98a3-c77d43e50d1b"
      unitRef="shares">141831000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfMy04LTEtMS02ODc5NQ_32e2352f-c254-43ba-94ae-4e53c4979b68"
      unitRef="shares">128084000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfMy04LTEtMS02ODc5NQ_ce59f9bd-4250-40e5-baa7-145a84bf684d"
      unitRef="shares">128084000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfNC0yLTEtMS02ODc5NQ_b7599d8e-c50e-4a95-a92e-d7c623250ed7"
      unitRef="usdPerShare">-0.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfNC0yLTEtMS02ODc5NQ_e6a46748-e86b-40eb-828c-108ede09c663"
      unitRef="usdPerShare">-0.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfNC00LTEtMS02ODc5NQ_4fce060b-700a-419b-8641-047039f2aeaa"
      unitRef="usdPerShare">-0.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfNC00LTEtMS02ODc5NQ_e4f4c6c0-8b7b-407c-aae6-bfccf6800823"
      unitRef="usdPerShare">-0.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfNC02LTEtMS02ODc5NS90ZXh0cmVnaW9uOjQ2M2I1YTViM2JjNjQ2NzBhNGJkNTgyYTc1YjdiOWRlXzQ_a1f5937a-b012-468b-9e86-4e5a1d1d1bf6"
      unitRef="usdPerShare">-0.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfNC02LTEtMS02ODc5NS90ZXh0cmVnaW9uOjQ2M2I1YTViM2JjNjQ2NzBhNGJkNTgyYTc1YjdiOWRlXzQ_ecea9620-3dde-456d-a067-e863ad066b8a"
      unitRef="usdPerShare">-0.58</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfNC04LTEtMS02ODc5NS90ZXh0cmVnaW9uOmVmYjA4ZmFmYmZmODRlOWY4MmY5M2I1MDJiNzM2YmMzXzQ_ac7df738-dd03-492e-b4b2-0f8f821c250c"
      unitRef="usdPerShare">-1.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOmU5NjM2ZTZhMGY0MDQ5ZjNhZDY1ZWZjNmM3MzVlOWE2L3RhYmxlcmFuZ2U6ZTk2MzZlNmEwZjQwNDlmM2FkNjVlZmM2YzczNWU5YTZfNC04LTEtMS02ODc5NS90ZXh0cmVnaW9uOmVmYjA4ZmFmYmZmODRlOWY4MmY5M2I1MDJiNzM2YmMzXzQ_fa406006-2a74-469b-ab4e-23069c25d9a1"
      unitRef="usdPerShare">-1.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RleHRyZWdpb246ODQ4N2ZlZmEwNzdmNDdmMzliYzMwNjRkYTA1ZjE5ZDJfNjEy_21f2f967-5b7a-40e5-a702-9f2f4040aaf8">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not include the securities in the following table in the computation of the net loss per common share because the effect would have been anti-dilutive during each period:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,299&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested performance awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,098&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,397&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i00d7e31976534d258d0e07349aba01f3_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOjlhYTAzNjE0MGE5NzQ4OTg4Y2EwMWQyYWMxMDkxMTQxL3RhYmxlcmFuZ2U6OWFhMDM2MTQwYTk3NDg5ODhjYTAxZDJhYzEwOTExNDFfMi0yLTEtMS02ODc5NQ_35b4d04f-3399-449a-a435-332dcf2f6432"
      unitRef="shares">14299000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i805aaa2562214865ab8c371faa3a53b2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOjlhYTAzNjE0MGE5NzQ4OTg4Y2EwMWQyYWMxMDkxMTQxL3RhYmxlcmFuZ2U6OWFhMDM2MTQwYTk3NDg5ODhjYTAxZDJhYzEwOTExNDFfMi00LTEtMS02ODc5NQ_c9f6ceaf-bf51-4f37-bccb-5081bf49561f"
      unitRef="shares">12837000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icc8095d666774c36bf30723faadf9ce6_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOjlhYTAzNjE0MGE5NzQ4OTg4Y2EwMWQyYWMxMDkxMTQxL3RhYmxlcmFuZ2U6OWFhMDM2MTQwYTk3NDg5ODhjYTAxZDJhYzEwOTExNDFfMy0yLTEtMS02ODc5NQ_4fb58457-8b03-4b4c-be16-211b93125a44"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2e834a4131b9497aa7197b83f5903f9c_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOjlhYTAzNjE0MGE5NzQ4OTg4Y2EwMWQyYWMxMDkxMTQxL3RhYmxlcmFuZ2U6OWFhMDM2MTQwYTk3NDg5ODhjYTAxZDJhYzEwOTExNDFfMy00LTEtMS02ODc5NQ_7698d05f-8f30-4dce-8440-e8a491427374"
      unitRef="shares">857000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i13cbe039556149bf854d1dbc12844c1e_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOjlhYTAzNjE0MGE5NzQ4OTg4Y2EwMWQyYWMxMDkxMTQxL3RhYmxlcmFuZ2U6OWFhMDM2MTQwYTk3NDg5ODhjYTAxZDJhYzEwOTExNDFfNC0yLTEtMS02ODc5NQ_c153ee83-406f-4d35-9f1b-3823b543f965"
      unitRef="shares">2098000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic61229edf4264d52a22130a0c3be9d0a_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOjlhYTAzNjE0MGE5NzQ4OTg4Y2EwMWQyYWMxMDkxMTQxL3RhYmxlcmFuZ2U6OWFhMDM2MTQwYTk3NDg5ODhjYTAxZDJhYzEwOTExNDFfNC00LTEtMS02ODc5NQ_9cd5ba7d-9b7c-478c-a1a3-814ce8409a94"
      unitRef="shares">201000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5279b4da301648499575592309f9f17e_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOjlhYTAzNjE0MGE5NzQ4OTg4Y2EwMWQyYWMxMDkxMTQxL3RhYmxlcmFuZ2U6OWFhMDM2MTQwYTk3NDg5ODhjYTAxZDJhYzEwOTExNDFfNS0yLTEtMS02ODc5NQ_a119d7cc-9dcf-4291-b57b-961d106c9b69"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0b1a989842e543fabb7e5905343568bb_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOjlhYTAzNjE0MGE5NzQ4OTg4Y2EwMWQyYWMxMDkxMTQxL3RhYmxlcmFuZ2U6OWFhMDM2MTQwYTk3NDg5ODhjYTAxZDJhYzEwOTExNDFfNS00LTEtMS02ODc5NQ_450e58ad-d4db-4267-a64a-a98d86b5765b"
      unitRef="shares">1012000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOjlhYTAzNjE0MGE5NzQ4OTg4Y2EwMWQyYWMxMDkxMTQxL3RhYmxlcmFuZ2U6OWFhMDM2MTQwYTk3NDg5ODhjYTAxZDJhYzEwOTExNDFfNi0yLTEtMS02ODc5NQ_e81c354e-40f3-4b22-91f5-424465bdca7b"
      unitRef="shares">16397000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183Ni9mcmFnOjg0ODdmZWZhMDc3ZjQ3ZjM5YmMzMDY0ZGEwNWYxOWQyL3RhYmxlOjlhYTAzNjE0MGE5NzQ4OTg4Y2EwMWQyYWMxMDkxMTQxL3RhYmxlcmFuZ2U6OWFhMDM2MTQwYTk3NDg5ODhjYTAxZDJhYzEwOTExNDFfNi00LTEtMS02ODc5NQ_34032153-94c3-4f49-ad5f-92cb0e524df8"
      unitRef="shares">14907000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfNTc4Nw_5136c0db-83ce-4041-b9a2-450f4984cba0">Share-based Compensation&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's Amended and Restated Equity Incentive Plan (the Plan), which was adopted and approved by the Company's shareholders in June 2021, allows for an issuance of up to an aggregate of 23.8 million shares (inclusive of then outstanding awards) and provides for grants of stock options, performance awards, and restricted stock units (RSUs) that may be settled in cash and common shares. Also in June 2021, the Company's shareholders adopted and approved the Company's 2021 ESPP, which allows for the issuance of up to 2.5 million shares. The 2021 ESPP is intended to qualify as an &#x201c;employee stock purchase plan&#x201d; under Section 423 of the Internal Revenue Code (the Code) but also permits the Company to include the employees, including non-United States employees, in offerings not intended to qualify under Section 423. The purpose of the 2021 ESPP is to provide eligible employees with opportunities to purchase the Company&#x2019;s common shares at a discounted price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2022, the Company modified the 2021 ESPP for the current and future offerings. The new ESPP terms shortened the plan from four (4) purchases over a 24 month Offering Period to two (2) purchases over a 12 month offering period. Additionally, the ESPP now contains a rollover mechanism; that is, if the stock price on the purchase date is less than the offering price (as that is determined under the 2021 ESPP), that offering is then canceled and any participants are rolled into the new 12 month offering period at the lower price.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As a result of the modification, $475&#160;thousand of incremental expense was added to the estimated expense for the November 2022 and May 2023 purchase dates (to be amortized over the new 12 month offering period). Additionally, the originally scheduled purchase date in November 2023 is no longer planned given the new 12 month offering period; therefore, the modification also resulted in a &#x201c;repurchase for no consideration&#x201d; under ASC 718. The Company recognized an additional $651&#160;thousand of unamortized expense for the cancelled November 2023 purchase, which was recorded during the second quarter of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In addition to stock options, performance awards and RSUs granted under the Plan, the Company has granted certain stock options and RSUs as inducements material to new employees entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The inducements were granted outside of the Plan during 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Plan requires the exercise price of each option not to be less than the closing market price of the Company&#x2019;s common shares on the day immediately prior to the date of grant. The board of directors approves the vesting criteria and periods at its discretion. The options issued under the plan are accounted for as equity-settled share-based payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company used the Black-Scholes option pricing model to estimate the fair value of the options granted. The Company considers historical volatility of its common shares in estimating its future stock price volatility. The risk-free interest rate for the expected life of the options was based on the yield available on government benchmark bonds with an approximate equivalent remaining term at the time of the grant. The expected life is based upon the contractual term, taking into account expected employee exercise and expected post-vesting employment termination behavior. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following weighted average assumptions were used to estimate the fair value of the options granted during the nine months ended September&#160;30, 2022 and September&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Annualized volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.01&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life of options in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated forfeiture rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value per common share option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.60&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the option award activity for the nine months ended September&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of shares (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price $&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding - December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,074&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.84&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,809&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11.25&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.47&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,507)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14.63&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding - September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,299&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.26&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Performance Awards and Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 23, 2020, the Company issued 439,000 PAs to executive management of the Company whose vesting was contingent upon meeting specific performance metrics based on the results for the year ended December 31, 2021. Each PA which vested entitled the participant to receive common shares on the basis of the performance metrics set. On March 18, 2021 performance metrics were set and formally communicated. Therefore, March 18, 2021 was the grant date and the fair value on the grant date was $13.56. The PAs vested in 2022 and the participant was required to achieve at least one of the performance metrics to obtain the portion of the award associated with the metric.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 6, 2021, the Company granted approximately 619,000 PAs and RSUs. The grant date for the PAs and RSUs was August 6, 2021 and the fair value on the grant date was $14.42 as this was the date performance measures were set and communicated to employees. The PAs vested on the employee's first anniversary of the grant date and the employee was required to achieve at least one of the performance metrics to obtain the portion of the award associated with the metric. The RSUs had no performance metrics and vested on the one year anniversary of the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the 2022, the Company has granted RSUs and intends to grant RSUs throughout the year under the Plan, as well as inducements for certain new hires as discussed above. The RSUs are fair valued based on the market price of our common shares on the date of the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the PA and RSU activity for the nine months ended September&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of shares (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price $&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding - December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;347&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13.33&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,311&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11.26&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(305)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14.17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(255)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.39&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding - September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,098&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11.04&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized share-based compensation expense for the three and nine month periods ended September&#160;30, 2022 and September&#160;30, 2021 as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,489&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,531&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,625&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21,480&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized under inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;206&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;387&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,320&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;25,398&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of September&#160;30, 2022, there was $33.6&#160;million of unrecognized share-based compensation expense related to unvested awards granted which is expected to be recognized over a weighted-average period of approximately 1.4 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i2e55bb773ff34dceb51b86c13030f998_D20210601-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfMjIy_b866e602-4f8a-4d50-89ce-8f0ff4a8c309"
      unitRef="shares">23800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i5685017490fa48d98ee11fbfaba4943f_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfNTYy_b739828a-4710-4c19-8064-3787c823299e"
      unitRef="shares">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <auph:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods
      contextRef="i141c5810302b4f94afd3d50f70c69c68_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfMTE1Mg_7278e8f8-4702-4f20-9b47-c8524be54565"
      unitRef="purchase_period">4</auph:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods>
    <auph:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod
      contextRef="i141c5810302b4f94afd3d50f70c69c68_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfNTc4OA_f517359d-fe07-41ab-b75a-08c53e3f1d16">P24M</auph:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod>
    <auph:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods
      contextRef="ic9213ee7781c41f3a44fe9ed868b853a_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfMTIwNA_133f152e-4884-4658-a796-a84ffaf5af0f"
      unitRef="purchase_period">2</auph:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods>
    <auph:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod
      contextRef="ic9213ee7781c41f3a44fe9ed868b853a_D20220401-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfNTc5Mg_b5c2c45e-83c5-40c6-b4b5-0a1dd9ebfa4d">P12M</auph:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod>
    <auph:ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod
      contextRef="ic9213ee7781c41f3a44fe9ed868b853a_D20220401-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfNTc4Mw_8891bb6c-80a3-4a05-9da6-0feb6c804b92">P12M</auph:ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idc1689ad65c84b429cf133572117af7a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfMTU5Mw_3612dbd1-bda4-4673-a83e-b57047263298"
      unitRef="usd">475000</us-gaap:AllocatedShareBasedCompensationExpense>
    <auph:ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod
      contextRef="idc1689ad65c84b429cf133572117af7a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfNTc4OQ_a4eead4e-9ce3-4f6f-a674-0fb9ae5dd3cd">P12M</auph:ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod>
    <auph:ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod
      contextRef="idc1689ad65c84b429cf133572117af7a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfNTc4NA_08db3686-61c0-457d-9f6c-bc4ecb7cb171">P12M</auph:ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod>
    <auph:ShareBasedPaymentArrangementUnamortizedExpense
      contextRef="idc1689ad65c84b429cf133572117af7a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfMjAyNQ_2d2700c0-bda7-4967-9c2b-567b25e89243"
      unitRef="usd">651000</auph:ShareBasedPaymentArrangementUnamortizedExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfNTc5Mw_d2712560-228b-46fc-84ba-e31a07c7be72">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following weighted average assumptions were used to estimate the fair value of the options granted during the nine months ended September&#160;30, 2022 and September&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Annualized volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.01&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life of options in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated forfeiture rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value per common share option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.60&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmU5ZDk0M2U2ODViMTRlMDc5ODUyOGQ0ZDYwNDIwN2QwL3RhYmxlcmFuZ2U6ZTlkOTQzZTY4NWIxNGUwNzk4NTI4ZDRkNjA0MjA3ZDBfMS0yLTEtMS02ODc5NQ_9c5eb342-a00e-4a03-a7bd-45334bbaf031"
      unitRef="number">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmU5ZDk0M2U2ODViMTRlMDc5ODUyOGQ0ZDYwNDIwN2QwL3RhYmxlcmFuZ2U6ZTlkOTQzZTY4NWIxNGUwNzk4NTI4ZDRkNjA0MjA3ZDBfMS00LTEtMS02ODc5NQ_8f34046a-fcbd-4787-a409-b945674c9495"
      unitRef="number">0.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmU5ZDk0M2U2ODViMTRlMDc5ODUyOGQ0ZDYwNDIwN2QwL3RhYmxlcmFuZ2U6ZTlkOTQzZTY4NWIxNGUwNzk4NTI4ZDRkNjA0MjA3ZDBfMi0yLTEtMS02ODc5NQ_5f5b2a4b-9321-4038-9f31-a01ef46ca99c"
      unitRef="number">0.0201</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmU5ZDk0M2U2ODViMTRlMDc5ODUyOGQ0ZDYwNDIwN2QwL3RhYmxlcmFuZ2U6ZTlkOTQzZTY4NWIxNGUwNzk4NTI4ZDRkNjA0MjA3ZDBfMi00LTEtMS02ODc5NQ_756667ba-6706-4e99-8564-707b42b0aaa0"
      unitRef="number">0.0038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmU5ZDk0M2U2ODViMTRlMDc5ODUyOGQ0ZDYwNDIwN2QwL3RhYmxlcmFuZ2U6ZTlkOTQzZTY4NWIxNGUwNzk4NTI4ZDRkNjA0MjA3ZDBfMy0yLTEtMS02ODc5NQ_8628180a-a62d-44d6-905c-0ca8d3d3d448">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmU5ZDk0M2U2ODViMTRlMDc5ODUyOGQ0ZDYwNDIwN2QwL3RhYmxlcmFuZ2U6ZTlkOTQzZTY4NWIxNGUwNzk4NTI4ZDRkNjA0MjA3ZDBfMy00LTEtMS02ODc5NQ_840b1ae5-9cf9-40b6-9001-d4df1fc72ab2">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <auph:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmU5ZDk0M2U2ODViMTRlMDc5ODUyOGQ0ZDYwNDIwN2QwL3RhYmxlcmFuZ2U6ZTlkOTQzZTY4NWIxNGUwNzk4NTI4ZDRkNjA0MjA3ZDBfNC0yLTEtMS02ODc5NQ_cf9bcd7c-380c-48f0-ae6d-11f739b3af2f"
      unitRef="number">0.121</auph:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate>
    <auph:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmU5ZDk0M2U2ODViMTRlMDc5ODUyOGQ0ZDYwNDIwN2QwL3RhYmxlcmFuZ2U6ZTlkOTQzZTY4NWIxNGUwNzk4NTI4ZDRkNjA0MjA3ZDBfNC00LTEtMS02ODc5NQ_53039eb5-ba15-4702-a736-5eab31af9213"
      unitRef="number">0.089</auph:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmU5ZDk0M2U2ODViMTRlMDc5ODUyOGQ0ZDYwNDIwN2QwL3RhYmxlcmFuZ2U6ZTlkOTQzZTY4NWIxNGUwNzk4NTI4ZDRkNjA0MjA3ZDBfNS0yLTEtMS02ODc5NQ_b7d4a8a8-1074-4d1e-8743-34b1976688be"
      unitRef="usd">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmU5ZDk0M2U2ODViMTRlMDc5ODUyOGQ0ZDYwNDIwN2QwL3RhYmxlcmFuZ2U6ZTlkOTQzZTY4NWIxNGUwNzk4NTI4ZDRkNjA0MjA3ZDBfNS00LTEtMS02ODc5NQ_9f4ec4d6-12b9-4573-bad1-a345344c6402"
      unitRef="usd">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmU5ZDk0M2U2ODViMTRlMDc5ODUyOGQ0ZDYwNDIwN2QwL3RhYmxlcmFuZ2U6ZTlkOTQzZTY4NWIxNGUwNzk4NTI4ZDRkNjA0MjA3ZDBfNi0yLTEtMS02ODc5NQ_e2d15d61-65ab-4638-b6e0-210136495cd9"
      unitRef="usdPerShare">6.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmU5ZDk0M2U2ODViMTRlMDc5ODUyOGQ0ZDYwNDIwN2QwL3RhYmxlcmFuZ2U6ZTlkOTQzZTY4NWIxNGUwNzk4NTI4ZDRkNjA0MjA3ZDBfNi00LTEtMS02ODc5NQ_3d0c34d9-af9c-4665-8bd8-dd94fd346adb"
      unitRef="usdPerShare">6.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfNTc4NQ_ea6d8a2c-d452-4ea2-965c-4d81304591c7">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the option award activity for the nine months ended September&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of shares (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price $&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding - December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,074&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.84&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,809&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11.25&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.47&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,507)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14.63&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding - September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,299&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.26&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjdjMTA5YjA2Njc5MTQ5NTVhMmFjMzA2OTVjZDQ3ZDVlL3RhYmxlcmFuZ2U6N2MxMDliMDY2NzkxNDk1NWEyYWMzMDY5NWNkNDdkNWVfMi0yLTEtMS02ODc5NQ_81f48d5a-b424-425d-8078-43937686ba79"
      unitRef="shares">12074000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ib46a6c6687af4fd9a8a0a685adc3371b_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjdjMTA5YjA2Njc5MTQ5NTVhMmFjMzA2OTVjZDQ3ZDVlL3RhYmxlcmFuZ2U6N2MxMDliMDY2NzkxNDk1NWEyYWMzMDY5NWNkNDdkNWVfMi00LTEtMS02ODc5NQ_7c0477b0-8f1c-4662-bcd8-2c69e8868011"
      unitRef="usdPerShare">12.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjdjMTA5YjA2Njc5MTQ5NTVhMmFjMzA2OTVjZDQ3ZDVlL3RhYmxlcmFuZ2U6N2MxMDliMDY2NzkxNDk1NWEyYWMzMDY5NWNkNDdkNWVfMy0yLTEtMS02ODc5NQ_65622d42-c9fd-450a-83fe-7da3a425d771"
      unitRef="shares">3809000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjdjMTA5YjA2Njc5MTQ5NTVhMmFjMzA2OTVjZDQ3ZDVlL3RhYmxlcmFuZ2U6N2MxMDliMDY2NzkxNDk1NWEyYWMzMDY5NWNkNDdkNWVfMy00LTEtMS02ODc5NQ_ce3785ee-cca1-4810-9db9-44da4d2d0970"
      unitRef="usdPerShare">11.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjdjMTA5YjA2Njc5MTQ5NTVhMmFjMzA2OTVjZDQ3ZDVlL3RhYmxlcmFuZ2U6N2MxMDliMDY2NzkxNDk1NWEyYWMzMDY5NWNkNDdkNWVfNC0yLTEtMS02ODc5NQ_21a01c79-c0b4-440f-88d7-6651f0ab6ab4"
      unitRef="shares">77000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjdjMTA5YjA2Njc5MTQ5NTVhMmFjMzA2OTVjZDQ3ZDVlL3RhYmxlcmFuZ2U6N2MxMDliMDY2NzkxNDk1NWEyYWMzMDY5NWNkNDdkNWVfNC00LTEtMS02ODc5NQ_e5fd7bd9-5235-41be-b0f9-2f84b43277cf"
      unitRef="usdPerShare">6.47</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjdjMTA5YjA2Njc5MTQ5NTVhMmFjMzA2OTVjZDQ3ZDVlL3RhYmxlcmFuZ2U6N2MxMDliMDY2NzkxNDk1NWEyYWMzMDY5NWNkNDdkNWVfNS0yLTEtMS02ODc5NQ_3e09209b-da7f-4e2f-91f2-2399078f2932"
      unitRef="shares">1507000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjdjMTA5YjA2Njc5MTQ5NTVhMmFjMzA2OTVjZDQ3ZDVlL3RhYmxlcmFuZ2U6N2MxMDliMDY2NzkxNDk1NWEyYWMzMDY5NWNkNDdkNWVfNS00LTEtMS02ODc5NQ_e4ef5fac-40f6-4a33-b924-c3165f0acfa9"
      unitRef="usdPerShare">14.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjdjMTA5YjA2Njc5MTQ5NTVhMmFjMzA2OTVjZDQ3ZDVlL3RhYmxlcmFuZ2U6N2MxMDliMDY2NzkxNDk1NWEyYWMzMDY5NWNkNDdkNWVfNi0yLTEtMS02ODc5NQ_8b2f687e-0d89-43b1-9694-c28452d5dad6"
      unitRef="shares">14299000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjdjMTA5YjA2Njc5MTQ5NTVhMmFjMzA2OTVjZDQ3ZDVlL3RhYmxlcmFuZ2U6N2MxMDliMDY2NzkxNDk1NWEyYWMzMDY5NWNkNDdkNWVfNi00LTEtMS02ODc5NQ_6a09d391-39d2-4e3c-baae-9aa1017da235"
      unitRef="usdPerShare">12.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i50399ead67c54ca8bc4d5ef310825018_D20201023-20201023"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfMzk2MQ_a7570dad-7a4d-4534-af79-32da5bea7221"
      unitRef="shares">439000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i300f179e3ff14347817cbe32101e4854_D20210318-20210318"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfNDQxMw_0cf7b650-7fe1-4352-ab6f-2108aa8ad0bf"
      unitRef="usdPerShare">13.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i93beb22f8ad34d9c947d6dafa4a95334_D20210806-20210806"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfNDYxNA_6748dda3-df4b-4ed8-9341-3a1502471f4f"
      unitRef="shares">619000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i93beb22f8ad34d9c947d6dafa4a95334_D20210806-20210806"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfNDcyNw_70b31072-1d4b-497e-b0b1-2dd9ab0752b8"
      unitRef="usdPerShare">14.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i6dac794371204eeea2843a0a01c0643c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfNTA3MA_a10b57f9-e830-4717-b810-7b9b456d9b98">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfNTc5MQ_53a2bcf5-e92d-42dd-97b9-66cfb2c0db87">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the PA and RSU activity for the nine months ended September&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of shares (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price $&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding - December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;347&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13.33&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,311&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11.26&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(305)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14.17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(255)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.39&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding - September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,098&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11.04&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i2b58579e74a9437291aa1de82c974264_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjNhMzdlNTlkNDg4YjQ4ZmRiNzkzNmE5MDdiMDJiMjBiL3RhYmxlcmFuZ2U6M2EzN2U1OWQ0ODhiNDhmZGI3OTM2YTkwN2IwMmIyMGJfMi0yLTEtMS02ODc5NQ_6fa2ad18-fd92-48db-b7f1-028f023836ba"
      unitRef="shares">347000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i2b58579e74a9437291aa1de82c974264_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjNhMzdlNTlkNDg4YjQ4ZmRiNzkzNmE5MDdiMDJiMjBiL3RhYmxlcmFuZ2U6M2EzN2U1OWQ0ODhiNDhmZGI3OTM2YTkwN2IwMmIyMGJfMi00LTEtMS02ODc5NQ_5e860032-9a0e-4b1f-814f-a88849c7f8f9"
      unitRef="usdPerShare">13.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i3c18e125ab214150a60e144497c275d2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjNhMzdlNTlkNDg4YjQ4ZmRiNzkzNmE5MDdiMDJiMjBiL3RhYmxlcmFuZ2U6M2EzN2U1OWQ0ODhiNDhmZGI3OTM2YTkwN2IwMmIyMGJfMy0yLTEtMS02ODc5NQ_48aa4325-bbcc-40d8-bb35-c8d54d3d3c86"
      unitRef="shares">2311000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3c18e125ab214150a60e144497c275d2_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjNhMzdlNTlkNDg4YjQ4ZmRiNzkzNmE5MDdiMDJiMjBiL3RhYmxlcmFuZ2U6M2EzN2U1OWQ0ODhiNDhmZGI3OTM2YTkwN2IwMmIyMGJfMy00LTEtMS02ODc5NQ_a29b8d04-4700-4eda-a4ff-7b93d8440e60"
      unitRef="usdPerShare">11.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i3c18e125ab214150a60e144497c275d2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjNhMzdlNTlkNDg4YjQ4ZmRiNzkzNmE5MDdiMDJiMjBiL3RhYmxlcmFuZ2U6M2EzN2U1OWQ0ODhiNDhmZGI3OTM2YTkwN2IwMmIyMGJfNC0yLTEtMS02ODc5NQ_f791e65e-45bd-4f30-bdcc-115ac0d4c31d"
      unitRef="shares">305000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3c18e125ab214150a60e144497c275d2_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjNhMzdlNTlkNDg4YjQ4ZmRiNzkzNmE5MDdiMDJiMjBiL3RhYmxlcmFuZ2U6M2EzN2U1OWQ0ODhiNDhmZGI3OTM2YTkwN2IwMmIyMGJfNC00LTEtMS02ODc5NQ_ab4daf32-a54e-4475-b534-fcaddeb7e490"
      unitRef="usdPerShare">14.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i3c18e125ab214150a60e144497c275d2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjNhMzdlNTlkNDg4YjQ4ZmRiNzkzNmE5MDdiMDJiMjBiL3RhYmxlcmFuZ2U6M2EzN2U1OWQ0ODhiNDhmZGI3OTM2YTkwN2IwMmIyMGJfNS0yLTEtMS02ODc5NQ_ac058427-ba1c-45f4-b28c-cd4592ada0b5"
      unitRef="shares">255000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i3c18e125ab214150a60e144497c275d2_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjNhMzdlNTlkNDg4YjQ4ZmRiNzkzNmE5MDdiMDJiMjBiL3RhYmxlcmFuZ2U6M2EzN2U1OWQ0ODhiNDhmZGI3OTM2YTkwN2IwMmIyMGJfNS00LTEtMS02ODc5NQ_c3e8e264-3559-4eb9-a7ac-e7ac5280b339"
      unitRef="usdPerShare">12.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="iccc401454be24c33a5c889e8fc773573_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjNhMzdlNTlkNDg4YjQ4ZmRiNzkzNmE5MDdiMDJiMjBiL3RhYmxlcmFuZ2U6M2EzN2U1OWQ0ODhiNDhmZGI3OTM2YTkwN2IwMmIyMGJfNi0yLTEtMS02ODc5NQ_8892e87e-3c56-438e-b7d0-2caeecd3be4a"
      unitRef="shares">2098000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="iccc401454be24c33a5c889e8fc773573_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOjNhMzdlNTlkNDg4YjQ4ZmRiNzkzNmE5MDdiMDJiMjBiL3RhYmxlcmFuZ2U6M2EzN2U1OWQ0ODhiNDhmZGI3OTM2YTkwN2IwMmIyMGJfNi00LTEtMS02ODc5NQ_b2f1bccb-7d8e-4f03-ab22-1d476402cdd3"
      unitRef="usdPerShare">11.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfNTc4Ng_6a782ad5-b363-4f74-bb35-40cbbd92aa10">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized share-based compensation expense for the three and nine month periods ended September&#160;30, 2022 and September&#160;30, 2021 as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,489&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,531&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,625&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21,480&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized under inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;206&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;387&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,320&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;25,398&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic7fef15dae2646efa24f1995243223c6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmE1NTE3MjI0NGUzMjRkZmM5NzlhMzRjNDhhMWIxZjRmL3RhYmxlcmFuZ2U6YTU1MTcyMjQ0ZTMyNGRmYzk3OWEzNGM0OGExYjFmNGZfMi0yLTEtMS02ODc5NQ_4c72b30e-332f-49cc-bc91-aae936927f88"
      unitRef="usd">1489000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i41e86bba83634e53a5535985a6f3f748_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmE1NTE3MjI0NGUzMjRkZmM5NzlhMzRjNDhhMWIxZjRmL3RhYmxlcmFuZ2U6YTU1MTcyMjQ0ZTMyNGRmYzk3OWEzNGM0OGExYjFmNGZfMi00LTEtMS02ODc5NQ_a99195d9-6ee3-4afe-8049-762ad897728b"
      unitRef="usd">1038000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i955689f54f8c4df3a7afd2244253bc6d_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmE1NTE3MjI0NGUzMjRkZmM5NzlhMzRjNDhhMWIxZjRmL3RhYmxlcmFuZ2U6YTU1MTcyMjQ0ZTMyNGRmYzk3OWEzNGM0OGExYjFmNGZfMi02LTEtMS02ODc5NQ_5f861c07-1e0a-454f-bdd2-f0cfe01c6c78"
      unitRef="usd">3531000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib7ac41ae30d34bb5830b64dd0083e341_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmE1NTE3MjI0NGUzMjRkZmM5NzlhMzRjNDhhMWIxZjRmL3RhYmxlcmFuZ2U6YTU1MTcyMjQ0ZTMyNGRmYzk3OWEzNGM0OGExYjFmNGZfMi04LTEtMS02ODc5NQ_d645e456-f9d6-494c-9be0-6b7103963c5b"
      unitRef="usd">3201000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib20172c5476e4c24ba772f206955d222_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmE1NTE3MjI0NGUzMjRkZmM5NzlhMzRjNDhhMWIxZjRmL3RhYmxlcmFuZ2U6YTU1MTcyMjQ0ZTMyNGRmYzk3OWEzNGM0OGExYjFmNGZfMy0yLTEtMS02ODc5NQ_259e0b5c-b88f-4247-bba5-1ca9813c86de"
      unitRef="usd">6625000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iaa46d448221541eea1922a7412dadd8d_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmE1NTE3MjI0NGUzMjRkZmM5NzlhMzRjNDhhMWIxZjRmL3RhYmxlcmFuZ2U6YTU1MTcyMjQ0ZTMyNGRmYzk3OWEzNGM0OGExYjFmNGZfMy00LTEtMS02ODc5NQ_5ad26f0f-ab50-46b7-80f6-b039bba3d2d1"
      unitRef="usd">6000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i950b5dba05e8467bb230db400bb54c89_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmE1NTE3MjI0NGUzMjRkZmM5NzlhMzRjNDhhMWIxZjRmL3RhYmxlcmFuZ2U6YTU1MTcyMjQ0ZTMyNGRmYzk3OWEzNGM0OGExYjFmNGZfMy02LTEtMS02ODc5NQ_f6c62b59-4eb1-4ba0-97d5-c622e5c511c7"
      unitRef="usd">21480000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i92f1f72ffef04012bdf6f2e23691fde6_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmE1NTE3MjI0NGUzMjRkZmM5NzlhMzRjNDhhMWIxZjRmL3RhYmxlcmFuZ2U6YTU1MTcyMjQ0ZTMyNGRmYzk3OWEzNGM0OGExYjFmNGZfMy04LTEtMS02ODc5NQ_0c053a3b-6df4-409b-a84e-fced33243b05"
      unitRef="usd">19189000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i31e34ae4d79d4a16962c6e8ca983e3f6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmE1NTE3MjI0NGUzMjRkZmM5NzlhMzRjNDhhMWIxZjRmL3RhYmxlcmFuZ2U6YTU1MTcyMjQ0ZTMyNGRmYzk3OWEzNGM0OGExYjFmNGZfNC0yLTEtMS02ODc5NQ_2b235d5a-5fd5-457d-9e9a-0f9584b83bb5"
      unitRef="usd">206000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i84deabd17e064c569d85797d9b5eda83_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmE1NTE3MjI0NGUzMjRkZmM5NzlhMzRjNDhhMWIxZjRmL3RhYmxlcmFuZ2U6YTU1MTcyMjQ0ZTMyNGRmYzk3OWEzNGM0OGExYjFmNGZfNC00LTEtMS02ODc5NQ_e6fcb77d-4983-41b0-bcd9-5ecced913e2b"
      unitRef="usd">54000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3566507c79934103bc6f40ab688f624a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmE1NTE3MjI0NGUzMjRkZmM5NzlhMzRjNDhhMWIxZjRmL3RhYmxlcmFuZ2U6YTU1MTcyMjQ0ZTMyNGRmYzk3OWEzNGM0OGExYjFmNGZfNC02LTEtMS02ODc5NQ_b8128654-120c-4bd7-a9cb-2bcf0da5698a"
      unitRef="usd">387000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8ef75c4fe6024db197c096eb57a144ea_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmE1NTE3MjI0NGUzMjRkZmM5NzlhMzRjNDhhMWIxZjRmL3RhYmxlcmFuZ2U6YTU1MTcyMjQ0ZTMyNGRmYzk3OWEzNGM0OGExYjFmNGZfNC04LTEtMS02ODc5NQ_57183706-0cee-433a-9aae-9c556f8fbe18"
      unitRef="usd">276000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmE1NTE3MjI0NGUzMjRkZmM5NzlhMzRjNDhhMWIxZjRmL3RhYmxlcmFuZ2U6YTU1MTcyMjQ0ZTMyNGRmYzk3OWEzNGM0OGExYjFmNGZfNS0yLTEtMS02ODc5NQ_9d8ba67d-de9a-468c-814d-f74540b93ab1"
      unitRef="usd">8320000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmE1NTE3MjI0NGUzMjRkZmM5NzlhMzRjNDhhMWIxZjRmL3RhYmxlcmFuZ2U6YTU1MTcyMjQ0ZTMyNGRmYzk3OWEzNGM0OGExYjFmNGZfNS00LTEtMS02ODc5NQ_ec7359b4-1d06-4e0e-9a76-efdba30ae05e"
      unitRef="usd">7092000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmE1NTE3MjI0NGUzMjRkZmM5NzlhMzRjNDhhMWIxZjRmL3RhYmxlcmFuZ2U6YTU1MTcyMjQ0ZTMyNGRmYzk3OWEzNGM0OGExYjFmNGZfNS02LTEtMS02ODc5NQ_1a3eda00-d1ca-4dfb-a339-cdcb6dd61e97"
      unitRef="usd">25398000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RhYmxlOmE1NTE3MjI0NGUzMjRkZmM5NzlhMzRjNDhhMWIxZjRmL3RhYmxlcmFuZ2U6YTU1MTcyMjQ0ZTMyNGRmYzk3OWEzNGM0OGExYjFmNGZfNS04LTEtMS02ODc5NQ_9bfa44ed-27b7-4766-87fd-b32e65026f82"
      unitRef="usd">22666000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="iea170fa7b20a4b41b108e493dc1948f2_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfNTYwNA_ff3635ed-62c3-4f90-b853-d34a99933b4e"
      unitRef="usd">33600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY183OS9mcmFnOjhlNzkwNmNlYTNhMjQzOWJhY2IyMzAwYzVkYTA2NmM3L3RleHRyZWdpb246OGU3OTA2Y2VhM2EyNDM5YmFjYjIzMDBjNWRhMDY2YzdfNTc3NA_02099802-d2fb-45bc-8064-db3ab612c6fe">P1Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY184Mi9mcmFnOjMxOTEwNWVjOTFlODQwOWNiOGU3NDQ0ZGZhM2ZmNjk5L3RleHRyZWdpb246MzE5MTA1ZWM5MWU4NDA5Y2I4ZTc0NDRkZmEzZmY2OTlfMTAyMQ_59f70ea8-8865-41af-8b56-d67226ce24ee">Income Taxes&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective tax rates for the three and nine months ended September&#160;30, 2022 and September&#160;30, 2021 differed from the federal statutory rate applied to losses before income taxes primarily as a result of the mix of income, losses and valuation allowances. The Company recognized an income tax expense of approximately $1.0 million for the three and nine months ended September&#160;30, 2022. The Company recognized an income tax expense of approximately $8 thousand and $34 thousand for the three and nine months ended September&#160;30, 2021, respectively. The expense recognized for these periods is a result of income in certain jurisdictions and withholding taxes on foreign income. The Company currently has tax expense in certain jurisdictions that are not offset by tax benefits. The increase from prior periods was due to withholding taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Uncertain Tax Positions&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company was under examination by the Canadian Revenue Agency for years 2017 and 2018. In March 2022, the Company was notified by the Canadian Revenue Agency that the examination is now complete and there were no findings and as a result, there is no additional tax expense or benefit recognized in regards to the audit. There are no outstanding tax audits ongoing at September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY184Mi9mcmFnOjMxOTEwNWVjOTFlODQwOWNiOGU3NDQ0ZGZhM2ZmNjk5L3RleHRyZWdpb246MzE5MTA1ZWM5MWU4NDA5Y2I4ZTc0NDRkZmEzZmY2OTlfNTQ5NzU1ODE1MDYx_16822bc4-41cd-419a-b116-2bb4a8e21b70"
      unitRef="usd">1000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY184Mi9mcmFnOjMxOTEwNWVjOTFlODQwOWNiOGU3NDQ0ZGZhM2ZmNjk5L3RleHRyZWdpb246MzE5MTA1ZWM5MWU4NDA5Y2I4ZTc0NDRkZmEzZmY2OTlfNTQ5NzU1ODE1MDYx_c5fea533-9251-4506-90c4-79cddabf16e8"
      unitRef="usd">1000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i436b2d2997234350abf975a031f0ec09_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY184Mi9mcmFnOjMxOTEwNWVjOTFlODQwOWNiOGU3NDQ0ZGZhM2ZmNjk5L3RleHRyZWdpb246MzE5MTA1ZWM5MWU4NDA5Y2I4ZTc0NDRkZmEzZmY2OTlfNTQ5NzU1ODE1MTM3_95bfe8fb-7a15-4267-a190-62384ee2953d"
      unitRef="usd">8000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0959e4ba6b30437abd59307d516ff778_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY184Mi9mcmFnOjMxOTEwNWVjOTFlODQwOWNiOGU3NDQ0ZGZhM2ZmNjk5L3RleHRyZWdpb246MzE5MTA1ZWM5MWU4NDA5Y2I4ZTc0NDRkZmEzZmY2OTlfNTQ5NzU1ODE1MTQz_722f454f-d1c2-4f29-9d7e-43db4be8a975"
      unitRef="usd">34000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY184NS9mcmFnOjcwNWQ0OTNjZWM2OTRjMmQ4OTMxOTk1OTBhMTVhNDI5L3RleHRyZWdpb246NzA1ZDQ5M2NlYzY5NGMyZDg5MzE5OTU5MGExNWE0MjlfNDM4_c1ede05f-460a-414e-9d58-1316c07de90a">Related Party TransactionsILJIN SNT Co., Ltd (ILJIN) was considered to be a related party due to their equity ownership of over 5% as per their public filing. The outstanding related party amount payable to ILJIN was the result of a settlement completed on September 20, 2013 between ILJIN and the Company. During 2021, Aurinia paid ILJIN $6.0&#160;million upon achievement of specific milestones. The amount payable to ILJIN is nil as of September&#160;30, 2022 and December&#160;31, 2021.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="i6a603236462942e0951722c7b53081bd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY184NS9mcmFnOjcwNWQ0OTNjZWM2OTRjMmQ4OTMxOTk1OTBhMTVhNDI5L3RleHRyZWdpb246NzA1ZDQ5M2NlYzY5NGMyZDg5MzE5OTU5MGExNWE0MjlfMzQ1_a043d8ab-3b30-4742-b920-d7bc15c2cb17"
      unitRef="usd">6000000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i600c866525944e51adcfcdad3efc98eb_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY184NS9mcmFnOjcwNWQ0OTNjZWM2OTRjMmQ4OTMxOTk1OTBhMTVhNDI5L3RleHRyZWdpb246NzA1ZDQ5M2NlYzY5NGMyZDg5MzE5OTU5MGExNWE0MjlfNDIw_aa3c34c3-9beb-45c7-8ead-42932dd63dc5"
      unitRef="usd">0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i68a01b7c21f844ae96d03ac2032c0e28_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY184NS9mcmFnOjcwNWQ0OTNjZWM2OTRjMmQ4OTMxOTk1OTBhMTVhNDI5L3RleHRyZWdpb246NzA1ZDQ5M2NlYzY5NGMyZDg5MzE5OTU5MGExNWE0MjlfNDIw_fd775a7f-91a1-4e55-9e3e-27815a4de38e"
      unitRef="usd">0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY184OC9mcmFnOmMzZWEwMWNlNzU1NzRmMmFiNDQ3NGNiODY4NTY5NTQ5L3RleHRyZWdpb246YzNlYTAxY2U3NTU3NGYyYWI0NDc0Y2I4Njg1Njk1NDlfMTIwMg_866fc7cf-3632-4fc5-8298-00ae4d4c4f2f">Commitments and ContingenciesThe Company may, from time to time, be subject to claims and legal proceedings brought against it in the normal course of business. Such matters are subject to many uncertainties. Management believes the ultimate resolution of such contingencies &lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;will not have a material adverse effect on the consolidated financial position of the Company. The Company's material commitments and contingencies have not changed in any material manner from those previously described in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021 and the quarterly report for the quarter ended September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Funding Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company enters into agreements with contract research organizations, contract manufacturing organizations and other third parties for services to be provided to the Company. Generally, these agreements provide for termination upon notice, with specified amounts due upon termination based on the timing of termination and the terms of the agreement. The actual amounts and timing of payments under these agreements are uncertain and contingent upon the initiation and completion of services to be provided to the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="if5bd943c4ac64248977ce4014afc6830_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY185MS9mcmFnOmY4ZGFlZTY3MmRhOTQ5OTQ4MWMyNzIyMTQzNmNlZTAwL3RleHRyZWdpb246ZjhkYWVlNjcyZGE5NDk5NDgxYzI3MjIxNDM2Y2VlMDBfMTUyMQ_397ef8a4-0d0b-4c4e-8ea9-4ed163dda99a">Subsequent Events&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s Compensation Committee granted 4 new employees an aggregate of 20,800 inducement stock options and an aggregate of 12,500 inducement RSUs. The options have a per share exercise price of $7.52,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the closing price of Aurinia's common stock on September 30&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, 2022. The stock options and RSUs have a grant date of October 3, 2022. The stock options and RSUs were granted as inducements material to the new employees entering employment with Aurinia in accordance with Nasdaq Listing Rule 5635(c)(4).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 17, 2022, Aurinia mutually agreed with Robert Huizinga, PhD RN, CNeph(C), Executive Vice President, Research and Neil Solomons, M.D.,  Chief Medical Officer, to cease their employment with Aurinia, each effective October 31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aurnia has entered into separation agreements with Dr. Huizinga and Dr. Solomons which will supersede and replace all the severance arrangements between Aurinia and Dr. Huizinga and Dr. Solomons, set forth in their respective employment agreements with Aurinia, dated October 1, 2018 and September 12, 2012, respectively (together, as amended, the Employment Agreements). The terms of the separation agreements are expected to be consistent with the terms of the Employment Agreements, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <auph:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNewEmployees
      contextRef="ie1901be7a6424fe8a7f80634ccb66032_D20220930-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY185MS9mcmFnOmY4ZGFlZTY3MmRhOTQ5OTQ4MWMyNzIyMTQzNmNlZTAwL3RleHRyZWdpb246ZjhkYWVlNjcyZGE5NDk5NDgxYzI3MjIxNDM2Y2VlMDBfNjc_2fa4a765-16ff-416d-b4a0-f17ed71c6a53"
      unitRef="employee">4</auph:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNewEmployees>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i090a7d0df6ad405a8d7fb3f2f1fc2096_D20220930-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY185MS9mcmFnOmY4ZGFlZTY3MmRhOTQ5OTQ4MWMyNzIyMTQzNmNlZTAwL3RleHRyZWdpb246ZjhkYWVlNjcyZGE5NDk5NDgxYzI3MjIxNDM2Y2VlMDBfMTAw_abb6c555-7eb2-49ff-ad5c-7d8d846d00e0"
      unitRef="shares">20800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i6baa5e11e43442d0b6c324d3f77c8f48_D20220930-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY185MS9mcmFnOmY4ZGFlZTY3MmRhOTQ5OTQ4MWMyNzIyMTQzNmNlZTAwL3RleHRyZWdpb246ZjhkYWVlNjcyZGE5NDk5NDgxYzI3MjIxNDM2Y2VlMDBfMTQ4_3cde9f86-4e0d-41b5-864f-f724cfb3a87e"
      unitRef="shares">12500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i090a7d0df6ad405a8d7fb3f2f1fc2096_D20220930-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY185MS9mcmFnOmY4ZGFlZTY3MmRhOTQ5OTQ4MWMyNzIyMTQzNmNlZTAwL3RleHRyZWdpb246ZjhkYWVlNjcyZGE5NDk5NDgxYzI3MjIxNDM2Y2VlMDBfMjE1_6b4d61c9-d4c7-40cc-a787-bbf183798010"
      unitRef="usdPerShare">7.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <auph:ResearchAndDevelopmentArrangementContractToPerformMilestonePayments
      contextRef="ie85ef3843f6e45c68cf365c48ec7f1a3_I20220915"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIwYjhkNDNlYmJmYzRkYjQ4OWE2N2Y3YTlkOWQ1OWVjL3NlYzoyMGI4ZDQzZWJiZmM0ZGI0ODlhNjdmN2E5ZDlkNTllY185Ny9mcmFnOjZmYTcyOTY2N2EzZTRkYjRiYzg4YTE1MDM1YmUzYjU4L3RleHRyZWdpb246NmZhNzI5NjY3YTNlNGRiNGJjODhhMTUwMzViZTNiNThfNTQ5NzU1ODE3MjU0_3e5bbcce-d2c1-4df9-94cc-5606b95397c7"
      unitRef="usd">30000000</auph:ResearchAndDevelopmentArrangementContractToPerformMilestonePayments>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>78
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MB;4AT;"&@(,"<( 6ZC+6@7XF5T$HR&T:S82R@>$:CD/;;J_+J T.#6T(=UK
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M^0#>SZ74NQOS \41]O!?4$L#!!0    ( ",Q8U70/!3F:@8  +X:   8
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MW!.+?@//-\*[%AN>0V$^539\Y>74M_P.0E7("WJ6+VCP!49\MYE@\3/P!6H
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M!3VQ2]M>@)I[ 865JCP\A%^70I,31#F$U<Y=&CGMW#4^^+@@O^S\P?+[*"V
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MC7WUM$<$17F.2XX GIRCKL2F_DL2-XI9LDY1U6:H:B&J6H2E)KO>%>>TQVF
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M@5:'?H77%)A!/O'E&0?@U 8B68#!4-E#I,WK10N]%,'8,%[M<?4A?9MRB6K
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M8OW6".I%8^^$U:PKCB.D3SP(24L2/ 1+OUY=_O+?'][-F1&))0BUA0D>(P!
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MMR\!.'I]GCSE='4<6[;XA6AR"[I>XRMY'JZDIU\E-HSV9&#6. S5\_=/";J
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M5"=9W$KV.OXFP7M1#=ET'+%X',??H#?M-)UZ>M/?U_2-M&FA25G+_G.[M,[
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M.JB;AB;^1M8Y=3G_63^\8X1KT,#XBHN"SPNXP"9[81 !]A4L.K.OM'4N4L2
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M;"]W;W)K<VAE971S+W-H965T,30N>&ULK55;;]LV%/XK!UHQ)(!J72W+F6W
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MCH[*&M!^+J79"39 ]X^8_P502P,$%     @ (S%C5;#;%SMB"0  ,A@  !D
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MO7?K94DT7DGV@Q:FG 2#  I<D0TS]W+["1L_7<>72Z;]+VSKVLQVS#?:2-Z
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M>S00-KYWXL*;.KPQ9L;C]AP^"SP1R3(!SN<&EYYVP0KZ1^?9WU!+ P04
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MT&UE6\X-0</LAFI"Y7JMEWE/.Z1^MP';MI5QQ""M_(06N)Z%A%]T]LH.R2-
M-"DR;=.J+LFP+5BI O&^)D-XOE5I!:K ! . .7*070<4$T65Z95N>+13O^5+
M6AM#^9(HMZI=;=0.*X] B6+,4[!$082%0:IL!)+[Q<I4!0361AQ-CCL+$7.W
M4$J*> (E4$S$YT:PN,)?Q>B[NTH<Q0<F17$SJ=6&J(%)"*DLT^0C$/_>F\K:
ME<C"0,.A=0%TPE2("Q)5* @NM2U>^=C51 COS(;*!*L [,Z[V[LGHU0$'^?*
M$ANE?[U3AB<=2=L*1?- ^&@"QE-I@/?QV _L!&CK<UA*P9JW,0]_;>%+G>HM
M9RWP@"WA)$-P-?YX#!WB#(U!2H &#6$6C(>R:&U:&GM2I%PMQN+%Y&R*QU5M
M20D,05P9+J,(6?6=ZHIJ"D$3-!R'UNF":TD[I.74)P!?+*$ L9$-^XB$B9MD
MB"^2*F0AD<H"G-+_@BAVV7-6'A\B0640@7POJ-G-:@)MSYWE0+6$G%!6  M-
M@V$JD_?6*#'ELSH0FQ1ZSLJH\0-(?2[SD/OZ(-L\:E2G$\&%Y4%:BQ1B>.8P
ME2ZNWXFS:![T"SK$IM6Z9+2H;G9 B!>S:31P8UWN@-WWD><=832$I-6N7_]I
M14.>SYY+/0%2?:<2$>79FNN[$I167Z@'T4.-R#"90;-N7*H,!?MPB9TX244M
MJU/FL17$5*.!$I0BO^[RM*+B1&;Y1]P]DL=2,IHUY4S^2=I,?A-_UZ ]!G\!
MO\1TEDR/TF-D/>^B_H((0-7I2IT*E8DF_+C7:L#TL%VS$9\;(WYOQQB%-HUJ
M 0?<=V5233779ZR54#+=-)9S7?/1-$Q9:5Y96@>[M!ML"[NYS]>?)B5FB%U=
M%"K3@!#1!0G$H:IYZ3LV-M2#L*S@5WJ60?/45=37^%[&FW&K/(*IT>P2W[)Q
M4''-H_)/5<\HLLO+;+U+W<V (EQ_*$N2NWR9Y"X3;N4&]Z3MT6RO5][Z_8(=
MQE5MFYKV-I?IS<EUBJZ,4/#P$FX,(_H5)E&;_GC*2FHC;F5>=]"V&C<,&"[5
MAKP5&] )F2L%,6^K'"D@IZZ<4K#;=P<XV:S)]0/OFWK=+V,[(7Y%H^W-R<HH
MQ3T/M;;"D-)M&J"TP*TN>J 'NE/L>\0:*MQKE2/KW$J=2VIV\'A-&;ODH%FJ
M,MT0S4"!,FL:('(/>?^[!XN\ IQH."H,PI?S"0IG6[E@8*='CU1#/76K5[UM
M-*/*3[N]FB(<XI VY WC1&6S(<=.2M?-=C%%).Q>H^-S)RU/>VG!5WB?XI=J
M(V\1"5Z_%;4;=S3\CH\.*#D#&+F&9'"V:!&EI.")]J,,ZB=?H*9\6:+T19D9
MVVOGLWB[QV:+'CR.7OJ7W)@LRI*:7RH//?*=A>)G,9OAY\LCY(F#,,+K,$CF
M^+O<IU 7K*6X5Q(DGP9A<S7IKBZ[[@%47"G-3&;I41R0]'EPCM_WFMIKVI71
MJS (>=WP9_%AAQ=RQR!4VI!](6;!+/1_DSTO.>:O/[P" +:'N"],_H2)\&A#
MY3\!_>4A1WRJ^9YVH-U6MJO3V%+^N<^8O43_0GSN;71/Q'N5-BM$WJ> ;!R>
M33 0V,TGXB\-8Y+Q/#P7413$4WC)R\S$T=G9,2"9G(D/'GEZ%HVG(1Y'DV"6
M["UWP*)H,H[/S_UZ\8S:^:ZJ+WI5?;>1]N7M*V^D/Y?B,\H"=QP)"PR'1;Y)
M\I/D?!R&H;A:\,8)H*0UGU1@(=F<\@SK&%H6VJJU@4OIB_("KFDLYXI"*7YG
MP5EJUP8=2:%(W[V<Y[NXW0:;Z-OX_X$C G%)%?EJT31/I EE&^C 18@KUJZ_
M)[-0(A49=;#T0A%M6R,/:8KJ%A"@'R6Z-A'-&SX<&LJI!^/]3H_>4JM,RV)W
MFLJV1K4M[9[$.VEW*=E7?9*SG[G*_4$T[T64!-.9SY/DS 85!$&7I_:!\5TG
M]SZ<*H&J5D )12)7$GFH*M53N&!*M>3ND$=0$UR5[80FOJVM4LT9B L5]_ \
MG1%=U.L:Z\S&#T]MNHS<*VR <A;M^-IVH=[H'AXMB_J#V-KA>C\"[B28Q(+=
MHVWG)WX_1$;:FJ@UX$'?_1QD;5?\P%O-ZNV 7Q$0VEB24H*^QDIS/RC;0XYT
M]?9_[%@RBB'?R(SV7H>6()V'1I-.'/:/&3LXE'EX!-/?M?B]29DU9U!LD0>,
MW[B-J>HU:H/;)9O]#9$D)^;Y_@Z'J-7NB6B'L^&-@_3-=&TII<DENK4>"E0L
M=PS+AHEO?\- YSN/;!#<H9;MF6*+)-D$P/]5J4U0-U'WDB!)NCH;CY,HXCH[
M$W]XYAPEX93+:30HL_&4GL9!<OY\D45-/Y_36E$03H;G^Y?-9OZ18X'^7B?M
MS]L_! #;E _2'>+=5NP'&TMBFG>Y?0G%2/# @Y]HA?Y'I7W?[/K2W15:",6%
MB-;,D"CR:LN%'[",)W-N0<9A0C EXVD2\7^,[O0: 0)DQP*E'Y[._?%:ANY=
MTV<A[B-FXQD:HQDG[9C$A0(I/(+4=W*K7=,9^^C3Y2V6Q4Y-T1'\3$PG(IF?
MB?AL)JZ?0_N%F(^3F!K1,[@TQG\\'2?L6V2*&5KM!1?YAU"/_2&33_1)$LRZ
M@WP^W?D1EQN5MTF^+IOTUIS M*G)]RPH(MT^R)\G])9I#F?;/<Y)&T;-Z2.T
M&M;$*)CX?C\X].'LM/>ELU!FS=]SJ6?#7LU_].R>=I^,%_Y+Z6ZX_]Z,=F5-
M![^Y6F%J&)Q-1]C[\C=<?^.J+7\W75;.505?;I2$:VD WJ^JRK4WM$#W(?WB
MWU!+ P04    "  C,6-5$C.H0^,#  !Z"0  &0   'AL+W=O<FMS:&5E=',O
M<VAE970R,BYX;6RE5DMOW#80_BL#->AIL=(^DKCN[@*VTZ(^!##LI#T4/7"E
MD<2&(E5R9.WFUW=(2FL9\:-(#_:2U,PWW[PXW/3&?G$U(L&A4=IMDYJH/4]3
ME]?8"#<W+6K^4AK;".*MK5+76A1%4&I4NLRR=VDCI$YVFW!V8W<;TY&2&F\L
MN*YIA#U>HC+]-EDDX\&MK&KR!^ENTXH*[Y ^MS>6=^D)I9 -:B>-!HOE-KE8
MG%^NO7P0^%UB[R9K\)[LC?GB-]?%-LD\(528DT<0_'./5ZB4!V(:_PR8R<FD
M5YRN1_1?@^_LRUXXO#+J#UE0O4W.$BBP%)VB6]/_AH,_;SU>;I0+_Z&/LJM5
M GGGR#2#,C-HI(Z_XC#$8:)PECVCL!P4EH%W-!18?A D=AMK>K!>FM'\(K@:
MM)F<U#XI=V3YJV0]VEWKW#0(G\0!W28E1O3G:3YH7T;MY3/:/\%'HZEV\(LN
ML'BLGS*3$YWE2.=R^2+@';9S6&4S6&;+Y0MXJY-[JX"W>M4]^"!=KHSK+,*?
M%WM'E@OBKZ=<CHCKIQ%]DYR[5N2X3;@+'-I[3'8__K!XE_W\ M_UB>_Z)?17
MT_'?M>%3C8!EB:'L@3@"5A"?<R,#\3>J+2((78!F&&AB(M$G$C@-A,T>[2D7
M0?";XP44DDU85BFM:0)NB05:H<"1H(Z,/0:[(-I6298C YP%QT3VR%009"1-
M@71K)=\-4AU!.!#<]8Z["TP9D!MY\,NH,!MA/+%[H3H1NUSQ-2-TCFX>(G!E
MFE9HYH"YJ;3\R@R$GM@$//#]YM #,T5K#DR D F\6<PS-JF4A_V^H/UO"F=L
MT'3.V_-_;U;KAX/OHK28^9BVL2C4,1(<[4\(#N!\V**5IG @'^=CH"\UY&B)
M+W_XN[/2%3)<MC$KO:2Z-JJ0NAK2&R/)-^7H_^,(Y9VUJ(D]KSG]T] \:X=J
M02"XC+3QO$K'<VQ_#+I[U%A*&@J![?'08JA0J%QG[.'H6\_6B@Y];7[#>0Z?
M]6C:7R,WQLEH>LK<(W0<<LN,!5_3L1@]$2\DM"@DY_P6[U&SG8L*=7X,03ZB
ML(XSLW@?0L:+LSE<:_@H;%Z'(II%C(DA=E66OI=>P0^QH9#@!T[2Z_? P6\5
M4BP<EN$(]AC""*74WOV8PTD;S@:Y@ "B*$(<N-,?U; =XSXM)^D'>"4LQYIC
M["F)CM5#9A@QY@_XS<"7AAYC'V5\T53&'[$S3[384Y=N.IF'#=HJ3'W'/G>:
MXF@\G9X>%A=QGCZ(QU<)YZ&2G&R%):MF\_=O$[!QTL<-F39,U[TAGM5A6?/C
M"*T7X.^E,31NO('3<VOW+U!+ P04    "  C,6-5@8C0GNX"  "1!@  &0
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M,:BL ^VOI32M80_HOHOF_P)02P,$%     @ (S%C56,Q&4S/ P  *@D  !D
M  !X;"]W;W)K<VAE971S+W-H965T,C@N>&ULS59;;]LV%/XK!VI16(!F210M
MR:EM($G3K< *!''281CV0,NT140259*.F_WZ'5*VK+9.GO:P!\ODX7?N'R^S
MO52/NN3<P+>Z:O3<*XUI+\)0%R6OF1[+EC>XLI&J9@:G:AOJ5G&V=DIU%9(H
M2L.:B<9;S)SL5BUF<F<JT?!;!7I7UTP]7_%*[N=>[!T%=V);&BL(%[.6;?F2
MFX?V5N$L[*VL1<T;+60#BF_FWF5\<44MW@&^"+[7@S'83%92/MK)I_7<BVQ
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MT/- -;VH$8RL7/VOI*%NXI8YM6]4UH#VUU*:O6 #M#^$V3]02P,$%     @
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M96[&.4H;8/QK(?1N8Q-T?Q#)7U!+ P04    "  C,6-5L=J0W-,#  "N"
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MFM)\D]O?<)^/(YC)4KM_V.Y]0P^R1AM9[1<3@XJ+]LEV^SK\S()XOR!VO-M
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M8?,C+\UTD*ET<$8XD@M![=9G^X(X/KR7]GDX?M6)-OOMK*#.YVCXJ@,"ZC.
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MDAYW^J.1 Y_P 3[)ZD6$;^P^BN.^$>+]32>&2DUW"_C"[=>'(B<%%RHUW3&
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MY3(^*>10J>F. 7)\JG(9OUL&TXE2K(D^P-8.,F.*9,2KE_+QPQC/VA1K,#X
MD$]00>.3H@^5FKZM#J!/0%5!$PQ7T*!-] $"J01C4D["8"D?%S3>!V@*L D
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MI<7/+0W7E.<"ZO\-8_+Q(G_3KGJS<OD_4$L#!!0    ( ",Q8U7\"/=5H (
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MD!73MZ+Y"AL_L>7+!5/NBYHV-L8>RE=*BVH#-@HJRML_>=JLPQ8@'+P!P!L
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M 'U_Q;EZ.C%;#MT6T^P_4$L#!!0    ( ",Q8U5 F<2EG@(  .<'   9
M>&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;*U5WV_3,!#^5ZPPH4V"YN<**VFD
MMBFPAZ%IU> !\> FU\::8P?;;09_/;:3AF[+J@KVDMB7^[[/=^?<Q347=[(
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MVV6A)S$(XZ"_KSA7NXT1Z&9[\@=02P,$%     @ (S%C56KQ7-3' P  W1,
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M<,9X44"^/L\R\792!-CN4#3Y#U!+ P04    "  C,6-5RNWE;8@#  ">#
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MPP7@"+@.4,]GC,GUA9Z@/$\:_P-02P,$%     @ (S%C5;&>-.SV"   'F<
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MNCBSS:6NGT&8 ?I_S+G:=,P$544^_@]02P,$%     @ (S%C53."F3W[ P
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M@YY) -S?4RH>!])!<U2Z_ ]02P,$%     @ (S%C5=;-<GV- @  NP<  !D
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M33QGAB_E5-HG6M>^H79.*ZEXT8#U#0K"ZC?>-'G8 6B>;H#? /SG@/ 50-
M@K<JA T@?*O"60.PH;MU[#9Q"58XC@1?(V&\-9M9V.Q;M,X78>8[F2FA3XG&
MJ?B&I;P =(\W(-%Q @H3*D_09_0P2]#QT0DZ0H2A^YQ7$K-,1J[2H@;JIHW
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M X$T!O@^$4)O)\9!?:L*_P)02P,$%     @ (S%C516XG,EG P  Y \  !D
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MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
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MM]UKVY[2/%TJXC[JY?HH=@MJFS+/Q[9M(6:29L>WZ8YO G[]#5!+ P04
M"  C,6-5]4F2S $"  !>)   &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QSS=I+;J- %(7AK5@L(.7[(DDKSJ@GF4;9 '+*#\4VB**59/=M.0/GH![T
M)*HS0@7B\HO!)P0\/.=#-^W[4]GMA[+X.!Y.9=7LIFGXE5)9[_*Q*S?]D$_G
M(YM^/';3>3ENT]"MW[IM3KI<MFG\/J-Y?/@^<_'R.>3_F=AO-OMU_MVO_QSS
M:?K'X/3>CV]EE_/4+%ZZ<9NG59,^#M?=)5TV<G.>W"R>7E?-^/0J3:H=I!"D
M]8,,@JQ^D$.0UP\*"(KZ02T$M?6#;B'HMG[0'03=U0^ZAZ#[^D&R1!F7!$DS
MK FT%N1:"+P6!%L(Q!8D6PC,%D1;"-069%L(W!:$6PCD%J1;".P6Q%L(]%;4
M6PGT5M1;"?36V<,V@=Z*>BN!WHIZ*X'>BGHK@=Z*>BN!WHIZ*X'>BGHK@=Z*
M>BN!WH9Z&X'>AGH;@=Z&>AN!WC9[64*@MZ'>1J"WH=Y&H+>AWD:@MZ'>1J"W
MH=Y&H+>AWD:@MZ/>3J"WH]Y.H+>CWDZ@MZ/>3J"WSUYV$^CMJ+<3Z.VHMQ/H
M[:BW$^CMJ+<3Z.VHMQ/H':AW$.@=J'<0Z!VH=Q#H':AW$.@=J'<0Z!VSCY4$
M>@?J'01Z!^H=!'H'ZAT$>@?J'01ZMZAW2Z!WBWJW/ZEWF3X/N5Q[OM9X_9^D
M>CJ?FZ^7ORR_=LYNP@7G!+\3/?X%4$L#!!0    ( ",Q8U763,"2X $  .,C
M   3    6T-O;G1E;G1?5'EP97-=+GAM;,W:RT[#,! %T%^)LD6-ZU=YB+(!
MMM %/V"2"8V:Q)9MH/P]3@J50*6B*A)WTZBU/7?BD<ZJEP]OCD*V[MH^S/-E
MC.Z"L5 NJ3.AL([ZM%);WYF8OOHGYDRY,D_$Q'0Z8Z7M(_5Q$H<:^=7E#=7F
MN8W9[3K]'!K;SW-/;<BSZ\W&(6N>&^?:IC0QK;.7OOJ6,OE(*-+)<4]8-BZ<
MI TYVYDPK/P<\''N_H6\;RK*%L;'.].E76S=LA#?6@K%_A([>K1UW914V?*Y
M2T>*X#R9*BR)8M<6FZ(G^Y-CNF':?/*C\\<R^P+3SH6W+J2)>3H\[G,DP^F)
M2X7(QV;_*VX34^FCWX^&:5=4_3([7>^K]:MQ'H&-C^/O^.N,M_4/[$. ]"%!
M^E @?6B0/F8@?9R"]'$&TL<Y2!]\BM((BJ@<A52.8BI'096CJ,I16.4HKG(4
M6#F*K )%5H$BJT"15:#(*E!D%2BR"A19!8JL D56@2*K1)%5HL@J4625*+)*
M%%DEBJP215:)(JM$D56BR*I09%4HLBH4616*K I%5H4BJT*15:'(JE!D52BR
M:A19-8JL&D56C2*K1I%5H\BJ4635*+)J%%DUBJPS%%EG_RGKH[6K/XX?GT5G
MFOXSGXW_[;EZ!U!+ 0(4 Q0    ( ",Q8U4'04UB@0   +$    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ (S%C5=U%
MCBGO    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ (S%C59E<G",0!@  G"<  !,              ( !S0$
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  C,6-5L>/_\ML%  #.
M'@  &               @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ (S%C5= \%.9J!@  OAH  !@              ("!'PX
M 'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( ",Q8U6:AV?E
MB (  (\&   8              " @;\4  !X;"]W;W)K<VAE971S+W-H965T
M,RYX;6Q02P$"% ,4    "  C,6-5P\3);O4&  !:(P  &
M@(%]%P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ (S%C
M54V+W?K" @  ^P<  !@              ("!J!X  'AL+W=O<FMS:&5E=',O
M<VAE970U+GAM;%!+ 0(4 Q0    ( ",Q8U7<7"&VR0D  ,A/   8
M      " @: A  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M"  C,6-5#IPH$OH'  #;(P  &               @(&?*P  >&PO=V]R:W-H
M965T<R]S:&5E=#<N>&UL4$L! A0#%     @ (S%C55H5U6QX!0  @@L  !@
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M970Q,BYX;6Q02P$"% ,4    "  C,6-5V2J <)$"  "X!0  &0
M    @(%.7@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (
M ",Q8U7V9+BT7@,   <(   9              " @19A  !X;"]W;W)K<VAE
M971S+W-H965T,30N>&UL4$L! A0#%     @ (S%C50L&&!.X @  +P8  !D
M             ("!JV0  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"
M% ,4    "  C,6-5L-L7.V()   R&   &0              @(&:9P  >&PO
M=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( ",Q8U4TU:+4LP(
M %4&   9              " @3-Q  !X;"]W;W)K<VAE971S+W-H965T,3<N
M>&UL4$L! A0#%     @ (S%C57DEGPLU P  G@<  !D              ("!
M'70  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  C,6-5
M_/^X@Q0&  " #@  &0              @(&)=P  >&PO=V]R:W-H965T<R]S
M:&5E=#$Y+GAM;%!+ 0(4 Q0    ( ",Q8U6*?;=HZ ,  /H(   9
M      " @=1]  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%
M  @ (S%C5>R$N2ZR"P  5!\  !D              ("!\X$  'AL+W=O<FMS
M:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    "  C,6-5$C.H0^,#  !Z"0
M&0              @('<C0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+
M 0(4 Q0    ( ",Q8U6!B-">[@(  )$&   9              " @?:1  !X
M;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ (S%C59*UKN<0
M!   A@D  !D              ("!&Y4  'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6Q02P$"% ,4    "  C,6-53K^(_BD$  "%"0  &0
M@(%BF0  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( ",Q
M8U7\<1X5G0T  ',G   9              " @<*=  !X;"]W;W)K<VAE971S
M+W-H965T,C8N>&UL4$L! A0#%     @ (S%C5;,1A2*R P  (PD  !D
M         ("!EJL  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
M    "  C,6-58S$93,\#   J"0  &0              @(%_KP  >&PO=V]R
M:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( ",Q8U6= QG)E (  )<%
M   9              " @86S  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL
M4$L! A0#%     @ (S%C577U\-NL @  U04  !D              ("!4+8
M 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    "  C,6-57L],
MS3 #  !5!P  &0              @($SN0  >&PO=V]R:W-H965T<R]S:&5E
M=#,Q+GAM;%!+ 0(4 Q0    ( ",Q8U67DT2)OP(  !P&   9
M  " @9J\  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @
M(S%C50=WZ#]  P  GP<  !D              ("!D+\  'AL+W=O<FMS:&5E
M=',O<VAE970S,RYX;6Q02P$"% ,4    "  C,6-5FC*-,L,"   L!@  &0
M            @($'PP  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4
M Q0    ( ",Q8U6QVI#<TP,  *X(   9              " @0'&  !X;"]W
M;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ (S%C5>6>,M7B!
M!@T  !D              ("!"\H  'AL+W=O<FMS:&5E=',O<VAE970S-BYX
M;6Q02P$"% ,4    "  C,6-5)S60ZYL&  !W-0  &0              @($D
MSP  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( ",Q8U7K
M8!IV( H  $)D   9              " @?;5  !X;"]W;W)K<VAE971S+W-H
M965T,S@N>&UL4$L! A0#%     @ (S%C53;'+?AH P  $@L  !D
M     ("!3>   'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ",Q8U5 F<2EG@(  .<'   9              "
M@67T  !X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ (S%C
M56KQ7-3' P  W1,  !D              ("!.O<  'AL+W=O<FMS:&5E=',O
M<VAE970T-2YX;6Q02P$"% ,4    "  C,6-5;24\(F@)   A;0  &0
M        @($X^P  >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0
M   ( ",Q8U6UOZYG2P(  !@%   9              " @=<$ 0!X;"]W;W)K
M<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ (S%C5>&&?+_* @  ^P<
M !D              ("!60<! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q0
M2P$"% ,4    "  C,6-5C)6=YN,"  !5"   &0              @(%:"@$
M>&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( ",Q8U6ZTPLO
M1 (  # %   9              " @70- 0!X;"]W;W)K<VAE971S+W-H965T
M-3 N>&UL4$L! A0#%     @ (S%C55IEK: 1!P  K4@  !D
M ("![P\! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    "  C
M,6-5RNWE;8@#  ">#   &0              @($W%P$ >&PO=V]R:W-H965T
M<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( ",Q8U5C#'VEF@,  %L2   9
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M970U-RYX;6Q02P$"% ,4    "  C,6-5,X*9/?L#   V%0  &0
M    @($N,P$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    (
M ",Q8U76S7)]C0(  +L'   9              " @6 W 0!X;"]W;W)K<VAE
M971S+W-H965T-3DN>&UL4$L! A0#%     @ (S%C53&PU?S2 @  80D  !D
M             ("!)#H! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"
M% ,4    "  C,6-5%;B<R6<#  #D#P  &0              @($M/0$ >&PO
M=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( ",Q8U63OA_33 ,
M .H4   -              "  <M  0!X;"]S='EL97,N>&UL4$L! A0#%
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K 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !% $4 VA(  (U. 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>201</ContextCount>
  <ElementCount>251</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>59</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - COVER</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/COVER</Role>
      <ShortName>COVER</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/OrganizationandDescriptionofBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Short-Term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestments</Role>
      <ShortName>Cash, Cash Equivalents, Restricted Cash and Short-Term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Inventories, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/Inventoriesnet</Role>
      <ShortName>Inventories, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Prepaid Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/PrepaidExpenses</Role>
      <ShortName>Prepaid Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Property and Equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/PropertyandEquipmentnet</Role>
      <ShortName>Property and Equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Lease Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/LeaseObligations</Role>
      <ShortName>Lease Obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Accounts Payable and Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilities</Role>
      <ShortName>Accounts Payable and Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Deferred Compensation and Other Non-current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilities</Role>
      <ShortName>Deferred Compensation and Other Non-current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - License and Collaboration Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/LicenseandCollaborationAgreement</Role>
      <ShortName>License and Collaboration Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Net Loss per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/NetLossperCommonShare</Role>
      <ShortName>Net Loss per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Share-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/SharebasedCompensation</Role>
      <ShortName>Share-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Related-Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related-Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Commitment and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/CommitmentandContingencies</Role>
      <ShortName>Commitment and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/FairValueMeasurements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Short-Term Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsTables</Role>
      <ShortName>Cash, Cash Equivalents, Restricted Cash and Short-Term Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestments</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Inventories, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/InventoriesnetTables</Role>
      <ShortName>Inventories, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/Inventoriesnet</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Prepaid Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/PrepaidExpensesTables</Role>
      <ShortName>Prepaid Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/PrepaidExpenses</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/IntangibleAssets</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Property and Equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/PropertyandEquipmentnetTables</Role>
      <ShortName>Property and Equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/PropertyandEquipmentnet</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Lease Obligations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/LeaseObligationsTables</Role>
      <ShortName>Lease Obligations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/LeaseObligations</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesTables</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilities</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Net Loss per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/NetLossperCommonShareTables</Role>
      <ShortName>Net Loss per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/NetLossperCommonShare</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Share-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/SharebasedCompensationTables</Role>
      <ShortName>Share-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/SharebasedCompensation</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Short-Term Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsNarrativeDetails</Role>
      <ShortName>Cash, Cash Equivalents, Restricted Cash and Short-Term Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Short-Term Investments - Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails</Role>
      <ShortName>Cash, Cash Equivalents, Restricted Cash and Short-Term Investments - Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Inventories, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/InventoriesnetDetails</Role>
      <ShortName>Inventories, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/InventoriesnetTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Prepaid Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/PrepaidExpensesDetails</Role>
      <ShortName>Prepaid Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/PrepaidExpensesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Intangible Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/IntangibleAssetsNarrativeDetails</Role>
      <ShortName>Intangible Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Property and Equipment, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails</Role>
      <ShortName>Property and Equipment, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/PropertyandEquipmentnetTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Lease Obligations - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails</Role>
      <ShortName>Lease Obligations - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Lease Obligations - Summary of Components of Leasing Costs and Rent (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails</Role>
      <ShortName>Lease Obligations - Summary of Components of Leasing Costs and Rent (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Lease Obligations - Schedule of Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails</Role>
      <ShortName>Lease Obligations - Schedule of Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Accounts Payable and Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Deferred Compensation and Other Non-current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilitiesDetails</Role>
      <ShortName>Deferred Compensation and Other Non-current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilities</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - License and Collaboration Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails</Role>
      <ShortName>License and Collaboration Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/LicenseandCollaborationAgreement</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Net Loss per Common Share - Schedule of Earnings Per Share, Basic and Diluted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails</Role>
      <ShortName>Net Loss per Common Share - Schedule of Earnings Per Share, Basic and Diluted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Net Loss per Common Share - Anti-Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails</Role>
      <ShortName>Net Loss per Common Share - Anti-Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Share-based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails</Role>
      <ShortName>Share-based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Share-Based Compensation - Weighted Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails</Role>
      <ShortName>Share-Based Compensation - Weighted Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Share-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Share-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Share-Based Compensation - Performance Awards and Restricted Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails</Role>
      <ShortName>Share-Based Compensation - Performance Awards and Restricted Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Share-Based Compensation - Allocated Share-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails</Role>
      <ShortName>Share-Based Compensation - Allocated Share-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/IncomeTaxes</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Related-Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related-Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/RelatedPartyTransactions</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="auph-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/SubsequentEvents</ParentRole>
      <Position>61</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="auph-20220930.htm">auph-20220930.htm</File>
    <File>auph-20220930.xsd</File>
    <File>auph-20220930_cal.xml</File>
    <File>auph-20220930_def.xml</File>
    <File>auph-20220930_lab.xml</File>
    <File>auph-20220930_pre.xml</File>
    <File>auph-2022q3exx311.htm</File>
    <File>auph-2022q3exx312.htm</File>
    <File>auph-2022q3exx321.htm</File>
    <File>auph-2022q3exx322.htm</File>
    <File>exhibit1024separationagree.htm</File>
    <File>exhibit1025separationagree.htm</File>
    <File>exhibit1026separationagree.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="678">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>83
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "auph-20220930.htm": {
   "axisCustom": 0,
   "axisStandard": 21,
   "contextCount": 201,
   "dts": {
    "calculationLink": {
     "local": [
      "auph-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "auph-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "auph-20220930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "auph-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "auph-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "auph-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 420,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 22,
   "keyStandard": 229,
   "memberCustom": 17,
   "memberStandard": 40,
   "nsprefix": "auph",
   "nsuri": "http://www.auriniapharma.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - COVER",
     "role": "http://www.auriniapharma.com/role/COVER",
     "shortName": "COVER",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Fair Value Measurements",
     "role": "http://www.auriniapharma.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Short-Term Investments",
     "role": "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestments",
     "shortName": "Cash, Cash Equivalents, Restricted Cash and Short-Term Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Inventories, net",
     "role": "http://www.auriniapharma.com/role/Inventoriesnet",
     "shortName": "Inventories, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "auph:PrepaidExpensesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Prepaid Expenses",
     "role": "http://www.auriniapharma.com/role/PrepaidExpenses",
     "shortName": "Prepaid Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "auph:PrepaidExpensesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Intangible Assets",
     "role": "http://www.auriniapharma.com/role/IntangibleAssets",
     "shortName": "Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Property and Equipment, net",
     "role": "http://www.auriniapharma.com/role/PropertyandEquipmentnet",
     "shortName": "Property and Equipment, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Lease Obligations",
     "role": "http://www.auriniapharma.com/role/LeaseObligations",
     "shortName": "Lease Obligations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Accounts Payable and Accrued Liabilities",
     "role": "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilities",
     "shortName": "Accounts Payable and Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Deferred Compensation and Other Non-current Liabilities",
     "role": "http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilities",
     "shortName": "Deferred Compensation and Other Non-current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - License and Collaboration Agreement",
     "role": "http://www.auriniapharma.com/role/LicenseandCollaborationAgreement",
     "shortName": "License and Collaboration Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Net Loss per Common Share",
     "role": "http://www.auriniapharma.com/role/NetLossperCommonShare",
     "shortName": "Net Loss per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Share-based Compensation",
     "role": "http://www.auriniapharma.com/role/SharebasedCompensation",
     "shortName": "Share-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Income Taxes",
     "role": "http://www.auriniapharma.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Related-Party Transactions",
     "role": "http://www.auriniapharma.com/role/RelatedPartyTransactions",
     "shortName": "Related-Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Commitment and Contingencies",
     "role": "http://www.auriniapharma.com/role/CommitmentandContingencies",
     "shortName": "Commitment and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Subsequent Events",
     "role": "http://www.auriniapharma.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.auriniapharma.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Short-Term Investments (Tables)",
     "role": "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsTables",
     "shortName": "Cash, Cash Equivalents, Restricted Cash and Short-Term Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Inventories, net (Tables)",
     "role": "http://www.auriniapharma.com/role/InventoriesnetTables",
     "shortName": "Inventories, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Prepaid Expenses (Tables)",
     "role": "http://www.auriniapharma.com/role/PrepaidExpensesTables",
     "shortName": "Prepaid Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Intangible Assets (Tables)",
     "role": "http://www.auriniapharma.com/role/IntangibleAssetsTables",
     "shortName": "Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Property and Equipment, net (Tables)",
     "role": "http://www.auriniapharma.com/role/PropertyandEquipmentnetTables",
     "shortName": "Property and Equipment, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Lease Obligations (Tables)",
     "role": "http://www.auriniapharma.com/role/LeaseObligationsTables",
     "shortName": "Lease Obligations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)",
     "role": "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesTables",
     "shortName": "Accounts Payable and Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Net Loss per Common Share (Tables)",
     "role": "http://www.auriniapharma.com/role/NetLossperCommonShareTables",
     "shortName": "Net Loss per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Share-based Compensation (Tables)",
     "role": "http://www.auriniapharma.com/role/SharebasedCompensationTables",
     "shortName": "Share-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)",
     "role": "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "auph:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Short-Term Investments - Narrative (Details)",
     "role": "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsNarrativeDetails",
     "shortName": "Cash, Cash Equivalents, Restricted Cash and Short-Term Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "ib46a6c6687af4fd9a8a0a685adc3371b_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HeldToMaturitySecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Short-Term Investments - Investments (Details)",
     "role": "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails",
     "shortName": "Cash, Cash Equivalents, Restricted Cash and Short-Term Investments - Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HeldToMaturitySecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Inventories, net (Details)",
     "role": "http://www.auriniapharma.com/role/InventoriesnetDetails",
     "shortName": "Inventories, net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "auph:PrepaidAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Prepaid Expenses (Details)",
     "role": "http://www.auriniapharma.com/role/PrepaidExpensesDetails",
     "shortName": "Prepaid Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "auph:PrepaidAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)",
     "role": "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails",
     "shortName": "Intangible Assets - Schedule of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AmortizationOfIntangibleAssets",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Intangible Assets - Narrative (Details)",
     "role": "http://www.auriniapharma.com/role/IntangibleAssetsNarrativeDetails",
     "shortName": "Intangible Assets - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AmortizationOfIntangibleAssets",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Property and Equipment, net (Details)",
     "role": "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails",
     "shortName": "Property and Equipment, net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "i0218c4022baf4887b278a279993662cb_D20210201-20210228",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeasePrincipalPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Lease Obligations - Narrative (Details)",
     "role": "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails",
     "shortName": "Lease Obligations - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "i0218c4022baf4887b278a279993662cb_D20210201-20210228",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeasePrincipalPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Lease Obligations - Summary of Components of Leasing Costs and Rent (Details)",
     "role": "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails",
     "shortName": "Lease Obligations - Summary of Components of Leasing Costs and Rent (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Lease Obligations - Schedule of Maturities of Lease Liabilities (Details)",
     "role": "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails",
     "shortName": "Lease Obligations - Schedule of Maturities of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Accounts Payable and Accrued Liabilities (Details)",
     "role": "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails",
     "shortName": "Accounts Payable and Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)",
     "role": "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Deferred Compensation and Other Non-current Liabilities (Details)",
     "role": "http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilitiesDetails",
     "shortName": "Deferred Compensation and Other Non-current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - License and Collaboration Agreement (Details)",
     "role": "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails",
     "shortName": "License and Collaboration Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "ibf32de36976c4acea4a8d8fcae729345_D20201217-20201217",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Net Loss per Common Share - Schedule of Earnings Per Share, Basic and Diluted (Details)",
     "role": "http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails",
     "shortName": "Net Loss per Common Share - Schedule of Earnings Per Share, Basic and Diluted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Net Loss per Common Share - Anti-Dilutive Securities (Details)",
     "role": "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails",
     "shortName": "Net Loss per Common Share - Anti-Dilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Share-based Compensation - Narrative (Details)",
     "role": "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails",
     "shortName": "Share-based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Share-Based Compensation - Weighted Average Assumptions (Details)",
     "role": "http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails",
     "shortName": "Share-Based Compensation - Weighted Average Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "ib46a6c6687af4fd9a8a0a685adc3371b_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Share-Based Compensation - Stock Option Activity (Details)",
     "role": "http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails",
     "shortName": "Share-Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "ib46a6c6687af4fd9a8a0a685adc3371b_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "i2b58579e74a9437291aa1de82c974264_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Share-Based Compensation - Performance Awards and Restricted Stock Units Activity (Details)",
     "role": "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails",
     "shortName": "Share-Based Compensation - Performance Awards and Restricted Stock Units Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "i2b58579e74a9437291aa1de82c974264_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Share-Based Compensation - Allocated Share-Based Compensation Expense (Details)",
     "role": "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails",
     "shortName": "Share-Based Compensation - Allocated Share-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "ic7fef15dae2646efa24f1995243223c6_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Income Taxes (Details)",
     "role": "http://www.auriniapharma.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "ied2bf63884594bf3a519994bdc8a9be1_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY",
     "role": "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "ied2bf63884594bf3a519994bdc8a9be1_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "i600c866525944e51adcfcdad3efc98eb_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DueToRelatedPartiesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Related-Party Transactions (Details)",
     "role": "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related-Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "i600c866525944e51adcfcdad3efc98eb_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DueToRelatedPartiesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.auriniapharma.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "ie1901be7a6424fe8a7f80634ccb66032_D20220930-20220930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "auph:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNewEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Organization and Description of Business",
     "role": "http://www.auriniapharma.com/role/OrganizationandDescriptionofBusiness",
     "shortName": "Organization and Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220930.htm",
      "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 59,
   "tag": {
    "auph_AccountsReceivableCreditTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Credit Term",
        "label": "Accounts Receivable, Credit Term",
        "terseLabel": "Receivable standard credit terms (in days)"
       }
      }
     },
     "localname": "AccountsReceivableCreditTerm",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "auph_AccruedResearchCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Research, Current",
        "label": "Accrued Research, Current",
        "terseLabel": "Accrued R&amp;D projects"
       }
      }
     },
     "localname": "AccruedResearchCurrent",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "auph_AcquiredUpfrontLicensePayment": {
     "auth_ref": [],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired Upfront License Payment",
        "label": "Acquired Upfront License Payment",
        "terseLabel": "Upfront license and milestone expense"
       }
      }
     },
     "localname": "AcquiredUpfrontLicensePayment",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "auph_AmendedAndRestatedEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended and Restated Equity Incentive Plan",
        "label": "Amended and Restated Equity Incentive Plan [Member]",
        "terseLabel": "Amended and Restated Equity Incentive Plan"
       }
      }
     },
     "localname": "AmendedAndRestatedEquityIncentivePlanMember",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "auph_CashCashEquivalentsAndDebtSecuritiesCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents and Debt Securities, Current",
        "label": "Cash, Cash Equivalents and Debt Securities, Current",
        "terseLabel": "Cash and cash equivalents and investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndDebtSecuritiesCurrent",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "auph_CashCashEquivalentsAndRestrictedCashMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents And Restricted Cash Member",
        "label": "Cash, Cash Equivalents And Restricted Cash [Member]",
        "terseLabel": "Cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsAndRestrictedCashMember",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails",
      "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Short Term Investments",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Short Term Investments",
        "terseLabel": "Total cash, cash equivalents, restricted cash and short-term investments",
        "totalLabel": "Total cash, cash equivalents, restricted cash and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails",
      "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "auph_CommercialRelatedAccrualsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Related Accruals, Current",
        "label": "Commercial Related Accruals, Current",
        "terseLabel": "Commercial accruals"
       }
      }
     },
     "localname": "CommercialRelatedAccrualsCurrent",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "auph_ILJINMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ILJIN",
        "label": "ILJIN [Member]",
        "terseLabel": "ILJIN"
       }
      }
     },
     "localname": "ILJINMember",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not yet Commenced, Liability, to be Paid",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Liability, to be Paid",
        "terseLabel": "Future value of minimum lease payments of leases not yet commenced"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not yet Commenced, Payments Prior To Commencement Of Lease",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Payments Prior To Commencement Of Lease",
        "terseLabel": "Expected payments prior to commencement of lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "auph_LesseeOperatingLeaseLeaseTerminationTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Termination Term",
        "label": "Lessee, Operating Lease, Lease Termination Term",
        "terseLabel": "Lease termination option term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseTerminationTerm",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, to be Paid, After Year Four",
        "label": "Lessee, Operating Lease, Liability, to be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "auph_LesseeOperatingLeaseNumberOfExtensionOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number of Extension Options",
        "label": "Lessee, Operating Lease, Number of Extension Options",
        "terseLabel": "Number of extension options"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfExtensionOptions",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "auph_MilestoneAchievementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Achievement",
        "label": "Milestone Achievement [Member]",
        "terseLabel": "Milestone Achievement"
       }
      }
     },
     "localname": "MilestoneAchievementMember",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "auph_MilestonePaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment",
        "label": "Milestone Payment [Member]",
        "terseLabel": "Milestone Payment"
       }
      }
     },
     "localname": "MilestonePaymentMember",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "auph_NewEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Employees",
        "label": "New Employees [Member]",
        "terseLabel": "New Employees"
       }
      }
     },
     "localname": "NewEmployeesMember",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "auph_OtuskaPharmaceuticalCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Otuska Pharmaceutical Co., Ltd.",
        "label": "Otuska Pharmaceutical Co., Ltd. [Member]",
        "terseLabel": "Otuska"
       }
      }
     },
     "localname": "OtuskaPharmaceuticalCoLtdMember",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails",
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "auph_OutsideUnitedStatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outside United States",
        "label": "Outside United States [Member]",
        "terseLabel": "Outside United States"
       }
      }
     },
     "localname": "OutsideUnitedStatesMember",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "auph_PerformanceShareSandRestrictedStockUnitsRSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Share sand Restricted Stock Units (RSUs)",
        "label": "Performance Share sand Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Performance Share sand Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "PerformanceShareSandRestrictedStockUnitsRSUsMember",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails",
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "auph_PrepaidAssetsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.auriniapharma.com/role/PrepaidExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Assets, Current",
        "label": "Prepaid Assets, Current",
        "terseLabel": "Prepaid assets"
       }
      }
     },
     "localname": "PrepaidAssetsCurrent",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/PrepaidExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "auph_PrepaidExpensesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Expenses",
        "label": "Prepaid Expenses [Text Block]",
        "terseLabel": "Prepaid Expenses"
       }
      }
     },
     "localname": "PrepaidExpensesTextBlock",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/PrepaidExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Performance Obligation, Potential Revenue Amount",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Performance Obligation, Potential Revenue Amount",
        "terseLabel": "Potential regulatory milestone revenue"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Tiered Royalty, Percent",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Tiered Royalty, Percent",
        "verboseLabel": "Tiered royalty percentages on future sales"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "auph_ResearchAndDevelopmentArrangementContractToPerformMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform, Milestone Payments",
        "label": "Research And Development Arrangement, Contract To Perform, Milestone Payments",
        "terseLabel": "Triggered milestone, payments"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformMilestonePayments",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "auph_RiptideBioscienceIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Riptide Bioscience, Inc.",
        "label": "Riptide Bioscience, Inc. [Member]",
        "terseLabel": "Riptide Bioscience, Inc."
       }
      }
     },
     "localname": "RiptideBioscienceIncMember",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "auph_RockvilleMarylandMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rockville, Maryland",
        "label": "Rockville, Maryland [Member]",
        "terseLabel": "Rockville, Maryland"
       }
      }
     },
     "localname": "RockvilleMarylandMember",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Consecutive Offering Period",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Consecutive Offering Period",
        "terseLabel": "Offering period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate",
        "terseLabel": "Estimated forfeiture rate (as percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNewEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number of New Employees",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number of New Employees",
        "terseLabel": "Number of new employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNewEmployees",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Purchase Periods",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Purchase Periods",
        "terseLabel": "Number of purchase periods"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period",
        "terseLabel": "Purchase period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "auph_ShareBasedPaymentArrangementInducementOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Payment Arrangement, Inducement Option",
        "label": "Share-Based Payment Arrangement, Inducement Option [Member]",
        "terseLabel": "Inducement Stock Option"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementInducementOptionMember",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "auph_ShareBasedPaymentArrangementUnamortizedExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Payment Arrangement, Unamortized Expense",
        "label": "Share-Based Payment Arrangement, Unamortized Expense",
        "terseLabel": "Unamortized expense"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementUnamortizedExpense",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "auph_ShortTermCorporateDebtSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-Term Corporate Debt Securities",
        "label": "Short-Term Corporate Debt Securities [Member]",
        "terseLabel": "Corporate bond"
       }
      }
     },
     "localname": "ShortTermCorporateDebtSecuritiesMember",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "auph_SpecialtyPharmacyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specialty Pharmacy One",
        "label": "Specialty Pharmacy One [Member]",
        "terseLabel": "Specialty Pharmacy One"
       }
      }
     },
     "localname": "SpecialtyPharmacyOneMember",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "auph_USAgencySecurityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "U.S. Agency Security",
        "label": "U.S. Agency Security [Member]",
        "terseLabel": "U.S. agency security"
       }
      }
     },
     "localname": "USAgencySecurityMember",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "auph_VictoriaBritishColumbiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Victoria, British Columbia",
        "label": "Victoria, British Columbia [Member]",
        "terseLabel": "Victoria, British Columbia"
       }
      }
     },
     "localname": "VictoriaBritishColumbiaMember",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "auph_YankeeBondMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Yankee Bond",
        "label": "Yankee Bond [Member]",
        "terseLabel": "Yankee bond"
       }
      }
     },
     "localname": "YankeeBondMember",
     "nsuri": "http://www.auriniapharma.com/20220930",
     "presentation": [
      "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails",
      "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/COVER"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/COVER"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/COVER"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/COVER"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/COVER"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/COVER"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/COVER"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/COVER"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/COVER"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/COVER"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/COVER"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/COVER"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/COVER"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/COVER"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/COVER"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/COVER"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/COVER"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/COVER"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/COVER"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/COVER"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/COVER"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/COVER"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/COVER"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/COVER"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/COVER"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/COVER"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/COVER"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/COVER"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/COVER"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r280",
      "r408",
      "r409",
      "r412",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Shareholder"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r45",
      "r47",
      "r96",
      "r97",
      "r237",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails",
      "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails",
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r148",
      "r266",
      "r270",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r236",
      "r243",
      "r282",
      "r283",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r451",
      "r502",
      "r506",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails",
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r236",
      "r243",
      "r282",
      "r283",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r451",
      "r502",
      "r506",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails",
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r148",
      "r266",
      "r270",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OfficerMember": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officer [Member]",
        "terseLabel": "Officer"
       }
      }
     },
     "localname": "OfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails",
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r145",
      "r218",
      "r219",
      "r266",
      "r268",
      "r453",
      "r501",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails",
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r145",
      "r218",
      "r219",
      "r266",
      "r268",
      "r453",
      "r501",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails",
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r212",
      "r217",
      "r218",
      "r219",
      "r220",
      "r236",
      "r243",
      "r272",
      "r282",
      "r283",
      "r317",
      "r318",
      "r319",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r451",
      "r502",
      "r506",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails",
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r212",
      "r217",
      "r218",
      "r219",
      "r220",
      "r236",
      "r243",
      "r272",
      "r282",
      "r283",
      "r317",
      "r318",
      "r319",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r451",
      "r502",
      "r506",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails",
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r46",
      "r47",
      "r96",
      "r97",
      "r237",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails",
      "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails",
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r146",
      "r147",
      "r266",
      "r269",
      "r504",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails",
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r146",
      "r147",
      "r266",
      "r269",
      "r504",
      "r515",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails",
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r149",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails",
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.auriniapharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails",
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.auriniapharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.",
        "label": "Accounts and Other Receivables, Net, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as noncurrent at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Noncurrent [Text Block]",
        "terseLabel": "Deferred Compensation and Other Non-current Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued liabilities",
        "totalLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails",
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accounts Payable and Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r12",
      "r208"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r21",
      "r51",
      "r53",
      "r54",
      "r489",
      "r511",
      "r512"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r50",
      "r54",
      "r61",
      "r62",
      "r63",
      "r99",
      "r100",
      "r101",
      "r363",
      "r405",
      "r507",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive (Loss) Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalCashFlowElementsSummationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Cash Flow Elements, Summations [Abstract]",
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets"
       }
      }
     },
     "localname": "AdditionalCashFlowElementsSummationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r328",
      "r329",
      "r330",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r285",
      "r332",
      "r333"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Shared-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r322"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails",
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r25",
      "r154",
      "r179",
      "r181",
      "r182"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r82",
      "r198",
      "r203"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/IntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of property (in sqft)"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r15",
      "r92",
      "r134",
      "r137",
      "r143",
      "r177",
      "r223",
      "r224",
      "r225",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r360",
      "r364",
      "r380",
      "r415",
      "r417",
      "r471",
      "r487"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r7",
      "r35",
      "r92",
      "r177",
      "r223",
      "r224",
      "r225",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r360",
      "r364",
      "r380",
      "r415",
      "r417"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r373"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Financial assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r159",
      "r162",
      "r187",
      "r473"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Available-for-sale debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r310",
      "r312",
      "r313",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails",
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.auriniapharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r367",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalLeaseObligationsIncurred": {
     "auth_ref": [
      "r87",
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in lease obligation from new lease.",
        "label": "Lease Obligation Incurred",
        "negatedTerseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "CapitalLeaseObligationsIncurred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r10",
      "r84"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash, cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r85",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r79",
      "r84",
      "r89"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "terseLabel": "Cash, cash equivalents and restricted cash",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r79",
      "r381"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of noncash transactions"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails",
      "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails",
      "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r42",
      "r475",
      "r493"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 17)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r221",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CommitmentandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r99",
      "r100",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value ($ per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r17",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "terseLabel": "Common stock, outstanding (shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Common shares - no par value, unlimited shares authorized, 142,110 and 141,600 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r57",
      "r59",
      "r60",
      "r68",
      "r479",
      "r497"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "auth_ref": [
      "r199",
      "r201",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.",
        "label": "Computer Software, Intangible Asset [Member]",
        "terseLabel": "Internal-use software implementation costs"
       }
      }
     },
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r128",
      "r129",
      "r148",
      "r378",
      "r379",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r128",
      "r129",
      "r148",
      "r378",
      "r379",
      "r513",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r128",
      "r129",
      "r148",
      "r378",
      "r379",
      "r513",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r126",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Major Customers"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r128",
      "r129",
      "r148",
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk (as percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r128",
      "r129",
      "r148",
      "r378",
      "r379",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bond"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r72",
      "r92",
      "r177",
      "r223",
      "r224",
      "r225",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r380"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total cost of sales and operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r127",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss)",
        "terseLabel": "Unrealized gains on available-for-sale securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading), classified as current.",
        "label": "Debt Securities, Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "DebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent": {
     "auth_ref": [
      "r159",
      "r161",
      "r167",
      "r473"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current.",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Current",
        "terseLabel": "Total held to maturity securities at amortized cost"
       }
      }
     },
     "localname": "DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails",
      "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Schedule Of Prepaid Expenses And Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/PrepaidExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DepositsAssetsCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/PrepaidExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.",
        "label": "Deposits Assets, Current",
        "terseLabel": "Prepaid deposits"
       }
      }
     },
     "localname": "DepositsAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/PrepaidExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r82",
      "r206"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAverageRemainingMaturity1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average remaining period until maturity of the derivative contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Average Remaining Maturity",
        "terseLabel": "Derivative, average remaining maturity"
       }
      }
     },
     "localname": "DerivativeAverageRemainingMaturity1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r287",
      "r288",
      "r323",
      "r324",
      "r326",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Share-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SharebasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r95",
      "r226",
      "r228",
      "r229",
      "r233",
      "r234",
      "r235",
      "r409",
      "r474",
      "r494"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Due to related parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r69",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r112",
      "r114",
      "r116",
      "r117",
      "r118",
      "r122",
      "r123",
      "r371",
      "r372",
      "r480",
      "r498"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic loss per share ($ per share)",
        "totalLabel": "Basic loss per share ($ per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r69",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r114",
      "r116",
      "r117",
      "r118",
      "r122",
      "r123",
      "r371",
      "r372",
      "r480",
      "r498"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted loss per share ($ per share)",
        "totalLabel": "Diluted loss per share ($ per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/NetLossperCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee accruals"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized share-based compensation expense weighted average recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r325"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized share-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r61",
      "r62",
      "r63",
      "r99",
      "r100",
      "r101",
      "r103",
      "r109",
      "r111",
      "r125",
      "r178",
      "r246",
      "r248",
      "r328",
      "r329",
      "r330",
      "r343",
      "r344",
      "r370",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r388",
      "r405",
      "r507",
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r373",
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r238",
      "r241",
      "r242",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r374",
      "r424",
      "r425",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r238",
      "r273",
      "r274",
      "r279",
      "r281",
      "r374",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r238",
      "r241",
      "r242",
      "r273",
      "r274",
      "r279",
      "r281",
      "r374",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r238",
      "r241",
      "r242",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r374",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r238",
      "r241",
      "r242",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r424",
      "r425",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r402"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, to be Paid",
        "terseLabel": "Minimum finance lease liability payments due"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r392",
      "r397"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "terseLabel": "Capital expenditure payments"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r168",
      "r172",
      "r174",
      "r175",
      "r176",
      "r180",
      "r183",
      "r184",
      "r185",
      "r186",
      "r188",
      "r189",
      "r190",
      "r191",
      "r240",
      "r245",
      "r369",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails",
      "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r13",
      "r202"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedTerseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r199",
      "r200",
      "r202",
      "r204",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r202",
      "r455"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Value"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r199",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r202",
      "r454"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Acquired intellectual property and other intangible assets, net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_HeldToMaturitySecurities": {
     "auth_ref": [
      "r156",
      "r163",
      "r179",
      "r184"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "HeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain": {
     "auth_ref": [
      "r165",
      "r170"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss": {
     "auth_ref": [
      "r166",
      "r171"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss",
        "negatedTerseLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesFairValue": {
     "auth_ref": [
      "r164",
      "r169",
      "r473"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Fair Value",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r65",
      "r134",
      "r136",
      "r139",
      "r142",
      "r144",
      "r468",
      "r476",
      "r481",
      "r499"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r210",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r93",
      "r340",
      "r341",
      "r342",
      "r345",
      "r347",
      "r349",
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r94",
      "r110",
      "r111",
      "r133",
      "r339",
      "r346",
      "r348",
      "r500"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax (benefit) expense",
        "verboseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.auriniapharma.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "negatedTerseLabel": "Cash paid for taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable, accrued and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventories, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Net changes in operating assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r81",
      "r397"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Receivables",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/IntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntellectualPropertyMember": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.",
        "label": "Intellectual Property [Member]",
        "terseLabel": "Acquired intellectual property and reacquired rights"
       }
      }
     },
     "localname": "IntellectualPropertyMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivable": {
     "auth_ref": [
      "r18"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.",
        "label": "Interest Receivable",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.",
        "label": "Inventories [Member]",
        "terseLabel": "Capitalized under inventories"
       }
      }
     },
     "localname": "InventoriesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/Inventoriesnet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r26"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods inventories"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/InventoriesnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r26",
      "r193"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/InventoriesnetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/InventoriesnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r4",
      "r32",
      "r417"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.auriniapharma.com/role/InventoriesnetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories, net",
        "totalLabel": "Total inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.auriniapharma.com/role/InventoriesnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r28",
      "r193"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/InventoriesnetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/InventoriesnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r27",
      "r193"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/InventoriesnetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/InventoriesnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r192"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Inventory write-down"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r173",
      "r469",
      "r483",
      "r514",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Short-Term Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease, Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Lessee, Operating Lease, Liability, Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r402"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r402"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r402"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r402"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r402"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r402"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r402"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: lease imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease extension term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Lease Obligations"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r38",
      "r92",
      "r138",
      "r177",
      "r223",
      "r224",
      "r225",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r361",
      "r364",
      "r365",
      "r380",
      "r415",
      "r416"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r24",
      "r92",
      "r177",
      "r380",
      "r417",
      "r472",
      "r491"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r40",
      "r92",
      "r177",
      "r223",
      "r224",
      "r225",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r361",
      "r364",
      "r365",
      "r380",
      "r415",
      "r416",
      "r417"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAgreementTermsMember": {
     "auth_ref": [
      "r337",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "License Agreement Terms [Member]",
        "terseLabel": "License Agreement Terms"
       }
      }
     },
     "localname": "LicenseAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License and collaboration revenue"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Marketable Securities [Line Items]",
        "terseLabel": "Marketable Securities [Line Items]"
       }
      }
     },
     "localname": "MarketableSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in marketable security.",
        "label": "Marketable Securities [Table]",
        "terseLabel": "Marketable Securities [Table]"
       }
      }
     },
     "localname": "MarketableSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows used in investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r79",
      "r80",
      "r83"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows used in operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r55",
      "r58",
      "r63",
      "r66",
      "r83",
      "r92",
      "r102",
      "r104",
      "r105",
      "r106",
      "r107",
      "r110",
      "r111",
      "r115",
      "r134",
      "r136",
      "r139",
      "r142",
      "r144",
      "r177",
      "r223",
      "r224",
      "r225",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r372",
      "r380",
      "r477",
      "r495"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently adopted accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r134",
      "r136",
      "r139",
      "r142",
      "r144"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r396",
      "r403"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total lease liabilities",
        "verboseLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails",
      "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r390"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r400",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate - operating leases",
        "verboseLabel": "Incremental borrowing rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails",
      "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r399",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term - operating leases (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/OrganizationandDescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r34",
      "r417"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r358",
      "r359",
      "r362"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Unrealized gain (loss) on available-for-sale securities, net of tax of nil"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax": {
     "auth_ref": [
      "r48",
      "r49",
      "r52"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax",
        "terseLabel": "Unrealized gain on available-for-sale securities, tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r56",
      "r59",
      "r61",
      "r62",
      "r64",
      "r67",
      "r246",
      "r382",
      "r387",
      "r388",
      "r478",
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Unrealized gain (loss) on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r39",
      "r417"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Deferred compensation and other non-current liabilities",
        "verboseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "negatedLabel": "Other (income) expense, net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]",
        "terseLabel": "Patents"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForCapitalImprovements": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for acquisition of or capital improvements to properties held for investment (operating, managed, leased) or for use.",
        "label": "Payments for Capital Improvements",
        "terseLabel": "Payments for capital improvements"
       }
      }
     },
     "localname": "PaymentsForCapitalImprovements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromTenantAllowance": {
     "auth_ref": [
      "r74",
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.",
        "label": "Payments for (Proceeds from) Tenant Allowance",
        "negatedTerseLabel": "Proceeds from tenant improvements"
       }
      }
     },
     "localname": "PaymentsForProceedsFromTenantAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForSoftware": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.",
        "label": "Payments for Software",
        "negatedTerseLabel": "Additions to internal use-software implementation costs"
       }
      }
     },
     "localname": "PaymentsForSoftware",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireLeaseReceivables": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the purchase of receivables arising from the lease of real estate, equipment or other fixed assets for a specified time in exchange for payment, usually in the form of rent.",
        "label": "Payments to Acquire Lease Receivables",
        "negatedTerseLabel": "Upfront lease payment"
       }
      }
     },
     "localname": "PaymentsToAcquireLeaseReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r160"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedTerseLabel": "Purchase of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherInvestments": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investments classified as other.",
        "label": "Payments to Acquire Other Investments",
        "negatedTerseLabel": "Upfront license payment"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherProductiveAssets": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.",
        "label": "Payments to Acquire Other Productive Assets",
        "negatedLabel": "Purchase of non-current assets"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r75",
      "r355",
      "r356",
      "r357"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "terseLabel": "Upfront license fee"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Unvested performance awards"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails",
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r310",
      "r312",
      "r313",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r310",
      "r312",
      "r313",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r5",
      "r33",
      "r196",
      "r197"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.auriniapharma.com/role/PrepaidExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses",
        "totalLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.auriniapharma.com/role/PrepaidExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r6",
      "r195",
      "r197"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/PrepaidExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/PrepaidExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromInterestReceived": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest received on loans and other debt instruments during the current period.",
        "label": "Proceeds from Interest Received",
        "terseLabel": "Cash received for interest"
       }
      }
     },
     "localname": "ProceedsFromInterestReceived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r77",
      "r327"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options and employee share purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product revenue, net",
        "verboseLabel": "Product Sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r211",
      "r518",
      "r519",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/PropertyandEquipmentnet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r11",
      "r207"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails",
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r209",
      "r417",
      "r484",
      "r492"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/PropertyandEquipmentnetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r280",
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "auth_ref": [
      "r408",
      "r412"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Related Party Transaction, Amounts of Transaction",
        "terseLabel": "Payments to related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r280",
      "r408",
      "r409",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r280",
      "r408",
      "r412",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r406",
      "r407",
      "r409",
      "r413",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related-Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r337",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "auth_ref": [
      "r336",
      "r338"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned",
        "terseLabel": "Upfront payments received"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r337",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r335",
      "r452",
      "r533"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r10",
      "r89",
      "r470",
      "r488"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r10",
      "r84",
      "r89",
      "r470",
      "r488"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Unvested restricted units",
        "verboseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails",
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.auriniapharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r248",
      "r417",
      "r490",
      "r510",
      "r512"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r99",
      "r100",
      "r101",
      "r103",
      "r109",
      "r111",
      "r178",
      "r328",
      "r329",
      "r330",
      "r343",
      "r344",
      "r370",
      "r507",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "verboseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r131",
      "r132",
      "r135",
      "r140",
      "r141",
      "r145",
      "r146",
      "r148",
      "r265",
      "r266",
      "r453"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues",
        "verboseLabel": "Total revenue, net"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails",
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r91",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Product Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r267",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "License and Collaboration Agreement"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r398",
      "r403"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Initial recognition of operating lease right-of-use asset"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r128",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue Benchmark"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/NetLossperCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Allocation of Share-Based Payments"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SharebasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Loss Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/NetLossperCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r373",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r199",
      "r201",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r199",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r9",
      "r29",
      "r30",
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventories, net"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/InventoriesnetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails",
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r410",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r337",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r284",
      "r286",
      "r288",
      "r289",
      "r290",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r310",
      "r312",
      "r313",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails",
      "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails",
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r293",
      "r308",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SharebasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Award Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SharebasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Service Revenue"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Performance shares forfeited (in shares)",
        "terseLabel": "Shares forfeited/canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails",
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Performance share forfeited, Weighted average exercise price (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails",
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted, weighted average exercise price (in usd per share)",
        "verboseLabel": "Performance shares awards, weighted average grant date fair value (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails",
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding - End of Period (in shares)",
        "periodStartLabel": "Outstanding - Beginning of Period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding, Weighted average exercise price - End of Period (in usd per share)",
        "periodStartLabel": "Outstanding, Weighted average exercise price - Beginning of Period (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted average exercise price $"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Performance shares vested (in shares)",
        "terseLabel": "Performance shares vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails",
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Performance shares vested, Weighted average grant date fair value (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate (as percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend": {
     "auth_ref": [
      "r318"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend",
        "terseLabel": "Dividend rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Annualized volatility(as percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails",
      "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails",
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "terseLabel": "Number of shares (in thousands)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails",
      "http://www.auriniapharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Fair value per common share option (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r294",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of shares (in thousands)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r294",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in usd per share)",
        "terseLabel": "Beginning balance (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average exercise price $"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r310",
      "r312",
      "r313",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails",
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.auriniapharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails",
      "http://www.auriniapharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r291",
      "r314",
      "r315",
      "r316",
      "r317",
      "r320",
      "r331",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares.",
        "label": "Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]",
        "terseLabel": "Schedule of Performance Shares Activity"
       }
      }
     },
     "localname": "ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SharebasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life of options in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r90",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r44",
      "r61",
      "r62",
      "r63",
      "r99",
      "r100",
      "r101",
      "r103",
      "r109",
      "r111",
      "r125",
      "r178",
      "r246",
      "r248",
      "r328",
      "r329",
      "r330",
      "r343",
      "r344",
      "r370",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r388",
      "r405",
      "r507",
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r125",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of preferred stock and warrants for common stock issued.",
        "label": "Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r43",
      "r239",
      "r246",
      "r247",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Exercise of warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r16",
      "r17",
      "r246",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common shares in conjunction with ESPP program (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r17",
      "r246",
      "r248",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Shares issued on exercise of stock options and vesting of performance awards and restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r16",
      "r17",
      "r246",
      "r248"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common shares in conjunction with ESPP program"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r44",
      "r246",
      "r248"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Shares issued on exercise of stock options and vesting of performance awards and restricted stock units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r17",
      "r22",
      "r23",
      "r92",
      "r157",
      "r177",
      "r380",
      "r417"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "SHAREHOLDER\u2019S EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r389",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r418",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r153",
      "r155",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r168",
      "r172",
      "r174",
      "r175",
      "r176",
      "r240",
      "r245",
      "r369",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails",
      "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryBillSecuritiesMember": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government.",
        "label": "US Treasury Bill Securities [Member]",
        "terseLabel": "Treasury bill"
       }
      }
     },
     "localname": "USTreasuryBillSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails",
      "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryBondSecuritiesMember": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities greater than ten and as long as thirty years, are interest bearing, and are backed by the full faith and credit of the United States government.",
        "label": "US Treasury Bond Securities [Member]",
        "terseLabel": "Treasury bond"
       }
      }
     },
     "localname": "USTreasuryBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails",
      "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r113",
      "r118"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding used in computation of diluted loss per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r112",
      "r118"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Weighted-average common shares outstanding used in computation of basic loss per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "44",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5558-128473"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r534": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r535": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r536": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r537": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r538": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r539": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r540": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r541": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r542": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r543": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r544": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r545": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r546": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r547": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3337-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>84
<FILENAME>0001628280-22-027931-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-027931-xbrl.zip
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MP/&:Z1VGOVDJ^QP(4IK%;OM=L+'=W %92]=*@LR,,RA/XJ""84@12STG*B7
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MM$*=IXGAKU.0:)J],G.0@]9N#O[.Y>%;X XGJ\ ]''S^Y[C>^N=XNU4_W6G
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M[8;Y46_0TW:G=F:ZM7/3'(3)QE8\*_T=X>$0#BOE?83RWIDQQMY8YK7,/ M
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M*0#NZ!Y)\B((':3/#&8B8SSPS J)X!\P4DHSL%AD:44N$WD?WTK$D:IPQ&?
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MOD@+_\_9"&_'@1YHE4M3"7^+CA"79GTS%H$*JSR+$9A1-C)O&21(*IID9T%
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M0;^:C-_5H-_3DU%>JDF^KOTT>SP=^B,\^#2LO>+;0OCV6RO&9TT*S&E.=))
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MS8ITRT*ZIC7%1<NUCR\_[GU\\8=VQB@%EG"-J23HJ.P82DEB#&4PFG)Q=G0
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MX5E_6J?@Z6#X?"K#1?__V9C%IVTMY6MA ZOU\K"*D@@LD/0B(&X#0<:17+=
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M ; .)6D!\'H <(D!!B:359(B$Q1'7 $ :FPC4D$P(8$".F9; &P!L 7 FP3
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MV\>G>T?'8K<#'DT3CC_WN/'CZZ+<8DJY@6D2R)F<#^A=0)JZA+C&QFLCHL4
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MS=<&CHEKP61$VN=POXC '0/UB,'O+"DIHA%Y%[-1>I798U7R97EYD07<\)B
MIQ(LQU%;I@475&MF@R&2/Q4OJE#DR5!DCC0!E2&1@P>J?"[Y$B.R%CN4*$DN
MR<AL<M>AR)LJ^;*,S&@GI9:/%TM556V7Y^1$B9EH0!FD891C3AS\$]$'';C
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M:I2N0+ME71GN7@HY^/?D<2H)N$8"&""'X4%11SCR.N?-4.R1(P)\QNB]I)$
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M2H:ND2&Q\V4?2T)-L@8Y#^+#60)775,#@I2+(3.? M>YTOV"VIQ72W'^XYY
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MZQ4/5+0L*L']((/QN&9_SY?JX(M"N*/NY*KC)XX_\TALC,WC=6!>7'L\LED
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M-\>X*( <& Q1:/+A9G(]V6BSU0W;%Q._=<&A)NK3[/T5^YEN?^SU"RHQN.R
M?[#];ER-4O4O;B(:VP=XGS!/I(T8)6$XRGP'.4\CLEI'(FB,*>=H"7Q;QY:I
MFLXK<U;6W/,C?WM!4X>]B1"" .;?[B-NB@CE C>:$@IJ$(RS1D2!K3%&"TD*
M%^X&*2NV=#U"Q,:_9\]A9\J&_YJ\VYB2W*?)_+N3O>:WLWV%$\' ]I!D#IQ_
MD[L8)NF1"<I3*Z6G1-Y)]@#G+[79[)?5"BZ\A<'5%E=%[XU)#]1![+10 G=H
M<!BGC5"O-.@$T1P;D&RNBJ:IZ*0]&H#K.&@-RO9#Q24GX@Q^2S9W_=Z9;9<!
MJ:G/,X#)'M2R@!5]98&S7M\X#T0%;.J,X&OO+2,)9HPS[H.PS@@J' A[8IDT
M+Q;\SXV/3R7YS>+EOA;O=@9?^LO)<(B^-S$^^D;WC0]!"YP0#9H@GG0 ]'0&
M88,U$X%0RU5NJC ?T #1NM_T&V"^EGJ6G.&<8U 93;E02FK"5"+TE:;_+@CW
M#F5C%R!., ;N2D)8<(FX<P)I"4X8<4XEIX$<.;.V21?(QDDYN+5_A)C[L4[B
M*F,.>S9.R3MLQ;)?;H:LC"Y@9?MQ<-AKA\$_\PG=.)RB6HD^[FR,9P!=[=XD
M"I0]]W''PP51%H"Z''8?]^ :YC#.Y*:3J([M@O?6+N^Q4?O<G5YQ?7K(5>8/
M_/8G<(6RXOTX;#.);%W%W,PD K $^ SGOFGV_CF;BGY6-3N.FY7=+^_G,N4_
MP)&9WN=^:>MY%+=&!_!FM3)L26_QT*8UW\;]NA?>9KW4>W"_)HTOX2J=HM':
MM,WW9>-ZT.N%P36F]5I/;7T<_+O24WQP:(NN<[,]+]^P8(";?5')G8C+L_AA
MU.^=1'BD7+"I-1@4/7D__/'/V@$(4=G-OG\<BZ[L=C0\A&&]\)<G4[%16Q0V
MO#:;XJ7>.M.VC(+]+&4WO$EKD#NNE3%?"U3LPS?0@6*H!L.,&#F8?AKA"_@O
M'/+9 T7LAO7:OUO1'P)K'PQC[F;?Z/5/;0FM\#%K(1S;+XY]H;#JXF$HZ.NT
M>_RPWSHX*/35WF^A4XN8F.8LR<B%E]HG)H7G.GK@#I9-%CJ)>%*GJ3XQ)RO5
MD?GEZ<+Y-U$_V&=1..=]1(%Z(),A&62X]TA(+('K,Z-RY)/=[A-=6'% V2MK
M/&4+X]RL.2^H'W0+S8+?KEJ9?NG$3I YTXHRQ-L%\<R0.SP<3!:(,C\)-RZ>
MY;L-1FX0_S,"$6A?"D#!K7;\L'>I)P-]PS#^<1PE63R<-X[C7 !O,G7WP0!-
MO-788>*9X<9YPQ(%-*!2T6@YX>,%%W5EP>7F.-V-RR\??HV-]]9@D!M-AJ;]
M5>G_8G=A"XZI_ZJ?']/ZT19K'.R;Q$7R>6M4P"87T)+(<HE19/ QT"B(2[F)
MY'SYFP?G1E!J%$B'UL8J;@CXM5%;E0SXMU&YY!<NR%7R\0+R4:3.'FV)^OG6
M>6/[PWEC:S]I[;7F"=$L%3PR@S3A% 4C5"X/0&5@63[F-]%-Y.-J1L1ZX<\M
M<M*FUJ (694L?>/Z3J2K -/W7+3[VCH9YGCA>+'S<6W97LF!F+B :I(.L_7M
M*\.X]H\Z!6;MP8LXM ?9&(5)(^^?+5O[ U1>UERKF]7TGZ4ECWZ4^2=8L=[H
MX!!XZ$&[YX":EFYIP<\!>/ICKCCK/D[&\O=6;^!;.4%DO?:YZS=J_QA_\\]U
MN.1)O_43N'N11 ,6[Z9VWT4K>$JN&,@B!61RITNK7!//.<5XWT4N*Q475F!.
M&>$N,.LYT8FGW#C2$Y(*<"18EXM<Q8>;P7'"B)N]+?^?4:L?_RHC-:"-&0\K
MJGQ-;L/1-PY463K.D\8,L<@5X@YKY(3SR"1K+#@Y2K)<'^Y6IGS!AW.K^.Z@
M9,,7PML-5]:>QU$PD(Q0'@R?B@T#Q:)#X6].^\OWRK;:<,!&;7O4G\1)4JL/
M>OB?$4@ST%XXKN1W6_D(T+A"=.^U'!854 5!N/:,"YJL-0&(G1/!>*IHFK7:
M[+;4QL5>WH=R>"JA7"R4_CQO;7%.2<P\T#5M$1>,@?\F.,J3(AB5@D>WMLGO
MO)PZ$^+- =&(<C;>A8,'R'@1O)V&;'-4-8QB&3:=1& OR?%ZS8.1R'M6QE@]
M73^[6#<K%[<N%K**9:XBO:[<%EY>>S8/8\9]NW%KR[OL6<Z>HF>YDE7/\BN#
M^MX2'W-J"]PSYR+\?6B7IBLY:[0FP'L QX3.WH^]PWH!O%_@7UWLYD3S[5VX
MQH?3QH_=7W"OLUG@W=DN]B^V]SIP3 ;>[9R>WF[MGM=/&T?PO,TMLG>4[_LG
M.,X?SO>M-B&)O*-0Y8IH2H,:)!$1MXQ(!EZL$7@VSQ'#!( E%([@R(T%I]=R
MHF ^L(C.6C>;Y]B(P]J_>X,BZE7$V@'\BI%_0'+CK?=>#:?B=SL R2X84BMC
M;RC6&]N30?+E(.7EFIAC])G*%T>Y,SCA9ZM8U9F> 7_,%J^\829A/X$\@3]2
MKH27ONG%]8!?C8; M@JW9*/V=RNOEUUV $[+6+\=/\[83)09[CD!I A=PA>9
MZ.5EDO7%[S!]^'SM 6A@)H>N>._YXS9J+]8]?E;]BZG(?*U\B65J)?\:D(#W
M@W2&^YSU'!4 0=0>66P92B["#& G,!9SD*"5=8S+Y +ED5#C/)8,_A!XPEB&
M64C(ZS+=/-69.8T]A6X/[&OQ^V@0I[L0@&?YB5<-DNSNH3AS'>'ON&/P3JBQ
M&)UN&X85ZBS/Q0;HUJHT:R<;DICJ8:N'E?1NEWUL4;([='A_^#7,HXJC+6'[
M^&:Q;'=YM:[PD"XR,QA>?]8:^!<CNEH#U\BKG/5RW#[<8=S>5JV]Q6/RCX(:
M]$9PC3!8K\5?'H;C$N<,=FC_^:S2=.D:=RV LN1REGGS8X;L]G%X7X-)*OE[
M%OFKQ.P&,7N&0O%CAV>I"J UQA[?<]2'O^V\U2RN]]@ZJ?=[^64IGW<->[C'
M^B#W3@OA5))><>6QQ90Y[F1(7AHRWIUY0]97%D1X8?@T&X\"&2Y;'N3 Z$K4
MS'MH,*JLF=?Y)AI'=;K7A',^[>+Z]A>Q=]0XW-O>)7"=HT:GSNKGW]OY66=K
MYNTUCVG]?*_=Z'PXA7N=-K;;G3K]>-PX^MZ&9Z:[Y_Z\\>.;V&WNI?I\,7VO
M6+(\4.1HRKN,\CXYF$Y$HQ+"&(>UID4C16WFEA;G6.33:,@K%[I_FQCWV *B
MJXEQB]_Z7AC'I*.!&J,HXTQ@ZY)1PF)&$HX>FW%RSACC2(5Q2X!QLW5!:;)1
M,^.1,\(ASKE%&LP4LM(FHQVAD>*\(7B=BOENL17(K0[(543N82#WH!7$"N1>
M%>3H;%<D$I)DPB JI$(<)Y>+D5KD0F)411VDS$2.KA,VG[A=@=SJ@%S%Y!X&
M<M@($[FSTC',F;(N", Q%021*2FEQTR.5$QN>4".S_6Y)8)0SA"AW@*38Q$9
MQABB3@683D.YR&4^N5J7?.E1[AD6HY8Q'OEC-O'JVG2KJLWWTS4N*D?WZ0-V
M5Y%O,K=;Y=0VBI2ZG51DC@UV+F:VR"*KD/')D'&^C1%-,N62/8A;&Q$W.B'G
M,4;!46JP%T9HOZSB,LXMG).:2F">46!TB!+^!QB(O4?<<P6FE K$E:3&6TH9
M3]F4DG4M%K527?E.6$O4T>K-&*E[MF1:C#J/C[A6J+,LJ#,;BN76*^.C1M)P
M(/ V<F3 K" I A'"1N(?8*9>2& J5O/BXN*U2WD_--(\EZVAAB KM$:YE V3
M$M/(0ZY.K]?!%[S=2%6&8ED,Q5-X,T\0M:X,Q;)H_FPXFREK!"<&,9D[>0>F
MD0W@V3!"!0O<,JW"L@I,92A>7%R\3C$X*9$.'GP8F#QDM&7(*Y6W.PL<B!M[
M,XQ4WDQEI%[*FWF"58?*2"T+ZLPN1S :*1,T(4\%1YPYB\"MR;M"!5@9HXR3
M>ED%IC)2+RXN/@J3C M@GP1P&AP%<M8J1+BPFKLD]<2;P7I^]6J)O)EWEDD_
MOW?Z'_%7WN _WHC]ORYV5SUL8]73Y#&\J8;W3YO*]38:WC\@T6M2QN%I5W;H
MM:D0L^4CQK1D:CEP93ENM1R-/^86:YP2Q@0=D1<X5Y\Q EE#(PK*2\K FL2@
M;B :2R (8W91B<%CQ"!*RZ7B&D4M7280#FFJ/<JMI4/$QDM95&;%=UBP>V@R
MS*.@=#42 M^4(7W:=,&W84@?D$QX'7X^;NVI,J3/C*!SZX_)1RRQ0\"E+.+$
MN-PXB2#,%68F41NM?9@A?2E!J SI$XA!Y(E[Z3'23F5#JCRR-DKDDO?@AF.L
M:6%(V?RFQ\J0WO,:-[[NO=[XSA9U<7768GA6R$E[Y')595N>&52NKD'];?#>
M_W>(?>=[U_XPHYVC+[1./Y/=YO=6G?YYU(#?&^>_'S8^_0GO>7"VV_1D]RBT
M=GY\;?]_YU_V+4G",&61PX0B+K5#!EA^#B5;$N#_+LD'&:87DZ+*,+VV#$4?
MK9$4(Q9"1%S(@"R6*GN+S 8LI=,V6S6A[V/5RO+,E?%X">/Q=([)(Y>1*K5_
M5K7G-ZI]YWMG]VB+[W4^=G8[>YV=[:]PSUU>[^R*# ?U[3];C?-Z;A]P7I@.
MKT)23*,0,$,\QP4==Q3AI).FQ%.!;\JI7 (9J@C(ZTM1LAP<8RP1M8H# 0'/
MV#H>$658&I"A8"Q9VR0;9+Y$PIV,1[%F^-]%J=Y%S1NF1<U?I,KU%MRZJ)#<
M^AG_SEV'6KD11=DU+(:RJUBN*5X\W'Q1['=< /MLGY)$DP%:(1S0U6(5VRI,
MD8$_<\RQM4G/%K1>B:KSS4M5W@.PB&YO..X27%: 'TP%95)]NZR=7;3?*>I6
M3XIR7\C.I*O4]66X7?1V-"CO (PG^F'MM#=JA]JA_9F_C;G;WK"%)N):"V7#
MGVC]X;C:_&^/J]6],C6W%=V@YJ$%E:O*T+=5AJ959>BE*V+9F&WC6A4XOEK@
MN*ID7%4R?M,E9I=NZ?CO(1#?6N^DZ#_X'.EN=\H??WP)G^7+Y+IGHC .*C)B
ME!2,!RITP!$KQHUU%I/$;@GLSGE'C_2)MCHP/<-WD#]\U#X$G^@\-P.J?_H@
M&N?P7,T#ODL_G-;AN-T?]5_U[>-?]>:77[/^_<Z/CW"?.H7O3G>;QZRQ?2!V
MM@^/X'J__G_VWKVY;1SI%_XJK)S99Y,J44N"X"UY3ZH\<9+C?<9R)G%F*ODG
M!0*@Q40B-:1D1_GT;S= 2M3-EGRE;-;69&6)!$&@^]?W!MA7_2^_WEZ<G+[]
MV3M\MZY7J^-&5%@T-ATG#$T*.VTRZKCP)Q$<K"^/.@2+7#HD7!>WW)N2EGWJ
M,?8$P.HVRF "RV6,$1>L#)L&GLNB@#N^'3/F,->)R!6NQ!:L&@]6*Z7;8>QQ
MR6(\,!$;2SL^5FU'IFL%=A33T/5L["]".H'CW[2T85_;=35.M_N<GLL">W6-
M9*YX T\_9!<L%]?3])Y*I>!MZ'.<!U;H"L_S?)]RQXMBQ_*) Q IXI!+KP'Z
M7)S\E,+\)?.L1<==T'&U^Q*-(S>@KF\&$<;L(LK-2-J>26P["K'&G5&*>E-
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MPB/0R@@5<:!234/KEK.W'A!X%DM4=>GJ0D7JNL)5=9E^4RS-62W%4^1'K"C
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M>#3*QEM6^B,_4+3-IDL+6_NWGU>S&;$SL#YRR7Z8+(;)OF2#"S8MGOUGD8Z
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M_GR?D77]ECP.9-U=K=V K U2;UMDO0]D73EE5%C<H2(T61QR0%;/-8-(!*8
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MS$\N>[E6N;XOXOZP=J]S!"5697E6O^J*P>?C>5-F_=6+:H_+]-JBAHU #.=
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M]JGD_W&RS^UF9NP+^VQHCA9VPF#7XX%:$GYH$FXE0"U]B'1HL(<G.[?LTTJ
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M.T?S&QF5WR#5@[ 3^N&*/-^C^KE])KA;2A]I),&M?[?GMF-W?-]Z$(J[S6+
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MDXQ5E*XY4PK7T_'SO ABG@JU3 +OD3Q,UL7XR@F9KEP9@?=+P$H.R&</A_K
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M6K*<;T($##]4N=$G@^N&<P'0Y/1=U@5SBLU"0+VU+*-RALT/5&7VK.'<!-$
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MO=G:&>SNM)J[._X7:O1Z*6]TR/UJ[R^3" 7<F9DF4J;5$VH#07V?X<]LJAI
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M;!WAKLI$MEXNCVSM#R)O!G^-TTGP^_\!4$L#!!0    ( ",Q8U4'?4TS:0X
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M5[R15WDDF:ICCIPOLZDL!$OU2^:JQ,(0?MT&H65U:?E.9*W2^(YDLM9ZY;=
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M;W.C!3W:RZ1=+!3FQ_7_U<5Z%R;5 7^%\T4W3@O,]1>$^>H/+GURE%.6!$N
MPYJ<L('"-ZXT17-6F4B!'4^M7>*M  ]OMZ0%O78GP[9IQZLK4(1.,F::/*/)
MJX ,/&H+FM8E1.^TMZV=T"]1;$(0\\T19,O5[C.H+D$Q)IR'@#6X+RZ"3]J
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M=5<[DV/HO(B HG#MLS8*6U/CKK*/AV="7H:/-=2F((A^TIUA7C/AY+@AWR!
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MU+$/H^0V3D"OD2 QA5S40AN9@?"196&3UU); GT2=-G</-DC6S;10A=U,V&
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M277@\:?1F(#]/*I"6C2EG8.+0>OB':UNGC9J^MZQ2#QG*+PK(I2B1/M&H/<
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MDFM!'GJP0;,@C(&ZOZKF+;%783DM.C21> ?>SK)%["U6<5U?TGJ%(Z(#<L*
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MR),F(\=DQT"DR&PM:J+!<!"MZT&NA^RT2-*!-NYR)K1=.O[ NK!A/OM,O_V
MS_N3-+H83M]6OQO':1;*+04J+@R3Z,QE*6Y 95F)(FO#55#8^J!C4XRGQ:-.
M-;3DB&SGP].;@&OKL%[,L1;"E60I:<6T=XG%6K7+\A1$E)X+VSI\^BZ*4Z;%
MQE)>HO@&Z>]7*]XS^-2?PN!ZI$HOH4TIRLBDSZ5V.^<L()<,:Y!*R,B+:1YC
M>"^BTR)$0^DO(<?NT2'7CO6O+*8%YN<7V(N@M719,!MK('=!,IYB3JP@@;.(
MPMK69LE#F$Z+($TUL(0B[8]'+X_M1M/_PNFL\#JASPO ;\;]T?C]:/'[^KO7
M9?8/>MDHP35Y8T[H6CH)16TE!TP9&:P1*KG;N:B;GH5LC.DTF'1(12TAW&X-
M0]<=Q]54>3_Z&=] /_<"9*#9 <Q%;FF>2,U\H7U6:<>5C.0 ZMB47W<@/$$Z
M[::&)>S9N<7G<I',FQ+FY&5&STP,DFDM")NT2%^22\K3.@NM:__< V=?*8+=
MG]+O+NU#IP1.QM/>NWJ1/4O=Q]&',7SZV$\PF"66D+T>N1">@35DPNN@F#?!
M,U<CPB!HY&FMD"MZRS7.T$_?^'(O@$.E^S73[JBUE!L&D<Q 7;+G.J1YR.<Z
MH#;)XGN( JN [#=?KZ&B1EU)>6\4$-X8R:UAQM>S0 R9 4C"B@&SM\YIO]85
MSG&I?D6^W;XUOXEP6_> ^\]^HD_[\'-MTC+Y^&PTN#B/?9@'9BM4+CN5R7+)
MA P\@<HT5C*-I4!N7(CKW=W>^YK]V8P-]3#J1(@-(T9GR-Z.TI^?^X,!_@KC
MKP.X:LOB,6J#/C%C.3(=O&.A%KM0"6CORI'S(M=2[(H7/'J5MA#<RKG:0:I"
M/]&BAH23R$<DJ/T#J[@_C'&VBNV2L;#FHYLE+FPSE-OY"]*5;&V=7^1JB>RQ
MB%)T2!"5+-+UUGW);G[86Z17C-/'LV%^CI]Q,)HEO9R-QS#\,'O-(JK\_>@-
MCLMH?/[+:/QZ^A''U\J^ Q$NU;*T!4O-NDF.10_ BK?&I.C Q=8QW2UP[^K#
M[H"AIAF1=F<:?0'C(>:>C2I8+)'Y6@1&\RQK>&5BH+T&1PN$;W[-TW0 ^S]6
MV3MW;[O5AR- \TUX^Y',?ZZGX]^RK=Z,:H'A/@S>TM.&%WAV7B]:>\%$9P.)
M&(OALS;J+ J4S*$"423/-IGU]O2]X'U"E#Y6%K1V)G88XOL^CC&_'7V%P?3K
M(EX .><* V<VF'19M0MXL"P8PPW9T1P5[YK1RX!]I^[^]-HP06;+L?S:'^!D
M.AKB5:I7(A.R)..8TXJ< &T""QX3*T&3+-$#+UWQ\@Z8[USL5G\=E!Z8+]@U
MYFX!]H_^]..S"T)YCN,77]+@(O>''VH$+_TOOX<OO:"%+29GEG2]H/"2Y"6X
M8>"RU]R"1=<ZN&T+F$^(C/M29@=I/8MY\'YTEO[GHC^NF8NY5G7Z/*]DWP,T
M/!99FU?6>"VI:6VVD=;K)#"CDT&FTIAM#X)Z@MQJJZB&&4#W2^C%E^I]8<\&
MY5049=XH#$)A,6=+JZX1-G%3>-Z/TST'] 09U$Y!'60-?:NDNHN!.;N)+<4B
MEX6\'I.A1EP8YC$"<X47HY262;8NX]0._;Z"( [.Q@,I_-"!%0WD?[W"I_*D
M 248"<#1R(UET91Z":FL@&B!B]:]>)H /WR]YOV2KMUQYI;*[Z#(R"X2O%9"
M;(U!=%05NLD #E,W^@ $:D?A';5_M%3V2;L<C&,0R(S2* 0+@BO29DZ.%X [
M 1*G3.$'ZE>?"H,W47H'S)W?75_=5=<" %?=)H'+[&A+JL68F?8U(M%B9MY;
M:YWS M>+T]HDNG<UG$?E<&VKX-O1P(VTT_ 2LH;(/*N70SC^!./IU]J>\#*4
MK90XBUI%96JA;K)GHN/(+,]2QRP!>8N8WF7O?J+68!-5-+P2J7C>XJ<+D@-<
M(^UMB(L0U35 -@P$7AO8_@.#=]?A:%\*:!PCO#Y8F5RQB0,3: S3P@&+@)H%
MFTQ(64B[7N>.XV;)/3'$!R+))G)O'0'P>GHQ^1/>S$+Z$EY,:RCFL]&KZ2)\
M4@I1HJE'U1E3+4?CF4\YL9!1QX@R);U>0/$#+]IO_&E'NAEU)-CF\4TU)R;C
MS_W1)/5K2MS+89K#2BG+%+-B*=C,M(JIWK02-F=UU$9AEGDM?:]^Q\FINI$X
M6Z_[U2R:K6 89% )(T.+M980: 9:!":" 9\5#]RVL!JO7OB$3<7MA-XP9.$*
MQ)R Z\!H:0%^>_7^;;PMA7];?3M(KHLIO$A*282@MML0N?9RB-&QVD>>96]E
MSH2S\+7B20ZMP'O,K[;ZVT1@C?7V*TGJ_.)\T3?%&J^]M,S59L7:2L%\CIF5
M; R7VJ>4UKI5?T!S-UZZYSUV6[&/6LBL\<'+K_#E&A".7&6RQ1@((J%.PC P
M23!I9"@Q6'(-UCHO?DAYUU_Z")6WM<P:S[QYO,WK\3L<?^ZGR]5$J.)$("M;
M.L5K+47%P$O-)!G9Q<F: ]IBZ5SV[B=L"NVLBH:!=-?P3$@0<T231<[A&J :
MVD@K@>S?8MI=1W<5WDC W2P,R\ E(Y/RG.4$!(Z3U1&-J5VM5$0;K0FYX>JP
M+ZW?8V;M2^D;R+6#2[<YL,66%+PTF@;EHK4TO!!80(@L&)E=@FB5:)V3>0/
M?K?T1DJYVVUX2XEVT%9I/JXK7XW'8LAN 5-[EHIH:8^RG 6I1)86G3"M;U%O
M #@%]6XOT3VFS?^&TU>CR80LH5K-:S1\1Y_CV7#:?]X?7-0PZW>8+FI1!Q+)
M]AGT6[RE53+]K@.\E5?O4S#%!8_*>^UJ[9,H=1 I8M!1">AM\;X=VU[1L_.=
M9U]F76"^S,JH32=G*9.O2\T&[@\_U(S*&;175W&MNA0?HC8L@"6&6EMHQ]+
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M06LT!A*HU+Y(S#V 3HP3[83?0=?W/Z#>P2^N4Y0/(J,(S *&&GE!8'Q6C*>
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M#4>EPD *R;S2#DM27..##F!'V+[S<X^Z[:"0\-E@]C>8EP]M4694)^Y5ULB
M.V1:!L[(T+;UPJ9X*2"AC(W-T/60/1G^=:BPAE6%;\V2Q?"_">?W(9R/QM-J
MU"Z@)N6L=<$R#XJD$6UD'L&RF'G$(HPIP6ZXNJWSWB?#G*YUTD59X6TE]>)_
M+OK3KR^'D^GXHOYR,LM;>_\1AI=7@9-_UD/@R<OA?/4M@#X:%UB)OJZ^3C)0
MF3,GG9-D*%COCN9L;L.Q/1E^'S5I[DX.]U@FQQ_8__"1-IJSSSB&#SC[\#GM
M/+] ?_R?,+C 'C@C1-&2"9NJF4T&3"B%Y.*LBE \]\=S.-5Z\-^GUZ.@W=WY
MYX]W_OTG3FC@5^L,6J&"R8II$P+3+FM:9Y)D1GD>50;A]./9G&Z.[?OL.0;2
MW)T<X7@GQR^C<<'^]:'*8 HO.='$YY'I;,C'B5HSY"%#C#%H]7CFQYWA?9\B
M1T*=)?<IA[LHG'VI4_[J!$GT(&D-FN:XYLK6#"[RTVJ+<IW Z*BXM+9U*GM+
M_-^)OB_E+V%RNR#GRV3QY6/[;33\/-NF9B.8O!]-:^G+;Y\_&TVFOXVF_X73
MMYA&'X;U*.): "^)VT20VM4+3R=HE#:QZ#*R)+/7.@F9@N@J8+K+@3TY[A\?
M799,BITC.3L;Y>6LI_UL_JOZ=Z+'I5#%&G*#7+7Y+" CITB0?Z2M#*2@TKQU
MUGY'^'V:' ^!ELR7G=NI?DNQ?%#NDU6"O\RN%"X5X$4QEX*N_1F0D467&+C
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M-M><52,#/8(+?0"]?M)E/M;7*_[VGYOL00N\$=_7KY1IOR^(3"(?49VQB@4
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M3>GNM<I[O]7JC[/Z&(:<LUAZ*^$3!]</ >8XVGY0*_;GR&\:UT&=:W01D31
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M:/H"+ONC0G[:Y7]<D0.23_^2+54+^4HT"^G&W1(R%B&($Y R1@!*0@E2/V"
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M%K!*QROOY\)I6HQN*)PY#)\4,K%W<)>AQZ[ G4^/78_E5)JS;=$#1A@6W!>
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MY ,#K]_69%WM)JMX8.W/29:?\[+*\&0YAY@T-:-O<*MN$_Y>*^RU&H\RM]A
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M@7DF$&OY<^/EG9;-'JM6UB;KA7T?=+/O!,A.>-"[/<#=KW^UAWIMPJ!T(_;
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M>JJ>AC9->$A)$@*_JJM- @D(%@0D,)4B)@1S[=&4K\ER*FBWLO[HT)HQ\L6
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M+X]>P/>B_.>*^%Y^^ ;N04L7LU;?3</S'ZJY0[?44\:I^JB_LC]F(M49DU(
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M>,1_\M.\>]:3*CQT"-V,VP@#,[#%Z\L Z(C'^U( (@:_W0CFL%D 5Z680AZ
M*U2.F0#.S?E9UVJ]F;U:/2V-R7EDZ\WS!_-YWO\QKV8<E5CB' /$RA3 M-2
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M)8VXR6_M[RY,W][FV0^I2+;5L=-1#:,?$,=6S?/MT +0V_3)+5] B6V(1*8
MR4L)H%9VQV^CSG2N2Y1SD6/B5_CYI(^I&9OW[^Y_?O?^W==W;[[X%GD^Q<_-
MGMR(RL#&8T^Z07@3>K2/5L+YM(>12S=?5/&T9//E1P-Y#=>K1[7>/-OXJLW]
M4EH'Y]%Z-A_49D;24DC(,,@R:B8X(ARP7&.@6,%$JA26S"NLM*^SJ<WT3M;Z
M7%UU@MXE2^7+8MB'<,%(21A* :2( ZA*@S M(4B1($Q)C;C,?2AHHR$\ @?M
M. B[&=E8N UL;3LQ[^I0V$V-W)L=<A]ZD/.GAG2 )!8K9%]7XQ)".BA]P@7I
M\DX@#21[G-N):!,-/O+%_%N]N:G>-;GL<J85Q$(7 LB<00!3G@%>4 W,ME K
M56:*,AC .7NE6Z<),3[C;%W2L"ZUHU?KA#U8;]A&^HO%DVP*2&Z^J^3!*/6T
M;@ZPS)ZGH:<-)JZY-D!NUB<&WF/E*UFX=C(FG8P1:23=P(C%)'FEMW'))-U4
M/^&3='PMD.=&Z[E06Z/6DJ1RQ51N/$# F,@!-/^SKJ$"7&G,N-9(^R4ZGNUE
M:CYA(^3.5_'DMSD+I)N%N!F>@>U"B\Q6P 'H97LAB$5P<[:/<0EN^M0\(;CI
M?3ALOA^DWS2GWNVG*C0K4R8$0"DTVT&6(D!3(H$H!2H0$8QBKSE_L:>IS?LF
MP&K5!#/Z3?K+:+I-_"@8C7A9N+T$W%VJ=-'& ]B$J^A$L@N7^QG5-EQ5]]@^
M7'\AS$88UV)MO8W7JOG]W;*FVMJ1;#6D6S.!:%XB60!!D :P,']BHE"@A"5*
M>5KR5!8!^Q/'[B>Z3_EP(T^>*_AN!B8FEN.8FT[BY*=.YK_8S5U#L;>3NV7;
MBV=L/)&*9'I<>QW5$'E"<6R6?%_W3_?].M\LU$?];BGG/^;RB2W^-M]\_ZP6
MS<[H^_SQZZH)9'N]>F#SY2SG95ZF-@,0E@Q ;B^UTC(#2E&,,JXMP8)K)K!G
MWU-S=FKQ[='(3H'DMT94CT1AWP'H-U8#PSJPP0I"U"O%.!";&[*/?7L<+3$Y
M$(K]G.70)@((1<\QRG27?,]?5S^K3VPN[[69]W]7;/W6?)(S9LP1YYP"1G0&
MH(0<< TAX%B33%&12RB=R4;]^Y^<N3(+AV)60@]NS0#8^PW4"& .?K)[@8EJ
MJ\&=K4G&56*UN$MJ/1*K2&(U&19\#]+380=A)$+4H0;#CS8U',I>2M6 9L>C
M6PW7^8"*]89FXM<)W]O]5UUFIYQAHO)4Z1*4C!N7M] "4(A24+!"<9A"691E
MK!KA9R68VDKRI:4&:Y(N5\M$[67!5OM'@/6]^P]5U3/31IZJM5ZM'VJF!&;C
M?YLG3&N;]5QL3&O-ZT_+>5 >K=>XNFW[!QVMH<\;KQ<1;QYI=4BV2HQ3/[P7
MOQ%JAY_O?PI\8=?A\:D9WM_0R,EGIYD!]DCCZW?69@Y4;U=KK>;&&+Q;-CK,
M(,]5GJ492 7+;?2&L< H30',4B@$8JHHO>)G1Y1]HK9;=W+^/\(:XX6Q#^,S
MUP1\"=)NVA16@&I)S?@S"F@!;2D)6X@>4H;RM#LG_W-^"X?'[ -_#9_VUN/J
MZ,OX<WP0CHOXQ ;Y3Y.;>)J0V%X?; P$.W*D+0IUY=P:APDD)X8/WDNG)P9(
M_N=(4 P?DF@IBC>($)JD6%/#??FNU.:]_=JMG)8.%$,J!2PR@*6RBYF@@)5%
M 3!4$F:%R*GVRAJXU-'4?)!6SJ06-.DD]:)8O8JMV[H0 [&!C7@86 $IAOU(
M1$LJO-#-R&F$_<J>)@Y>>3YP"R6^*_ED;U#J.Q-KIM:;YZ_&@E6LIENO?GX^
M^!=;LV.&L(:IRC$H=$H U+($C)0Y* 1#A4UTSID3%_--4DS-I'1*V$.F5MBD
MEC;95^3.>CN'__Q;K8ZGU0D;.$=7=>CA&-KI'&HD_/W&6Y",Y0$&R3"N+W<+
M3"=>V4V-A9G1X[J5V[1ACJ0H$<T HS0%D!<0,.-; 4U4B;E21$(G>K5K'4W-
M&-X:-W<14#<+%@.F@8W4:7W907*RKR$1R<A<[&94.W)-V6-3<?5Y_V"VO[(_
MY@]/#VW<.-6""8D($#PM 11FYC.E.,@*F&,!&<X*[AJJ=M#RU.9[*YQ[S-DA
M3OVS^B;M!Y[&K5P1X^4O:GM#!-AA>Z/%=YU58S]ZZ_P#@6NP$$\/3_6Z7A^G
MV#.9M?JNEM7\A[(<B _*UA7\H#8?]5?VQTPA6F!!(*!%00',90I8@1"0 DK)
M,YAF?EEQGOU/;0;OB9^LZO-5L:] LC"R>Z[AG@/BN+0/!_/0*_X>PLT)]H'L
M22-\6]VT)@BP&QBC0T1O( R\6$Z"9^_C^@YAT)RX%('-A'(.5-_OE]+^9L^4
M?["%/4W^O(UE.?_O#=O4S.Y ,FR\D5022T@@.* :8T"$@I1F4F;2ZQ3G%F&F
M9@UW4B?"R.M+-'##J+A9P;&P'M@DUC00-ORJ_L.>I'?)W@CT/#4&]5T,K*,Q
M(-P@RLCT"+>#=LJ=$*'-F(;V?O.*K=?/\^6W.L9IAK-428%RP)A-NLYJDD]A
M-GY0Y:24@I6%5Y"04Z]3,YU6VKO::M;D"ZW0,2SH,=RWF,H;0'PYF\@V22=U
M$SPYM)&[@-*@UNRXSPF8K0LPN-FG2R_?<M+\JCFOFDDELC*C"D@JD-G#0@*H
MD!"@@A8ESIGDD/A0TAVT[F581N"@^VK[2&X_5>[ \SE*#H!DI//C5K+8)\9'
M"D<])N[:?H&SX2.USA\('S\4-E/-[DY5G]BSO5[J/CF<*Z88E0!GJF8!+P#/
M\\S\0C1$B!8B%SX.PID^IN8.M*<:&RMI\MB(ZC=KSP'I-G=OA&?@&5Q+E[3B
M#3"1>[2/-)W/]3#JI.Y1\7AJ]ST:3*QBONRVW;FT!*8I1+J0I;:L2QA I#1@
M.6.@5!RA@I0LTR*,0^6H)Z?/^*5I'>LY[\V7<HRIVU0/A&@T%A1K [L);[-
MH]*_7E8^'K')<0=C<YA<4/ ,7<FE)\-F^6=5*?.2=>Q?JQ]JL:K9V_:"?%^M
MEO6E\==5F\KP=K6NCWZKKZ;'EC)#J+),"YD#7 @"((,<D!3:H]>R$%"B(G,K
MLQ=5JJFY"IU2]>YW3ZU#@K).,YM4W>I66YM&N[O$ZN=)@A)WK-T,UN@C.+"-
M&W/PO UD5+ CV=0X,HUJAJ/">&RYXS8>6BWURP-;+'Y^JN9+556S$D$F<XP
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MO4[-$'U1=2;B7?*MD;Z>.^Q ?C\+Y(:]FQ&*CNC =NB7/0P/)>[\GP&NB;Q
MBF2+W/H<U1QYP7!LD?Q>#C-*GYN;TK=&<AO?;_-]_S;??'_U5&U6#VK]YH\V
M;_B^JI3YO_S*_IA))12$. <$E;9H#Q> \X(#5N1<98P7BFH_'IL *7PFV#AL
M-@T'9'OU'$">&3(4C&M8<IB#$LH<0+-P (Z1!D6>BH(7*669\EDM!AZ(,=:.
M5@5/JK\0\-V6BX$A'7CQ:*5/K&E+.OF3WXT"2:>!S0+MR"LZ)1*C1;S%Y 8(
M(RTM(1*,NM#< -'QLG-+4Z&)I.U)L(V*.KF60%F1(Y(C8]XR6^.G8&:ER0J
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M-7)DNX/:IY'N+B_Y<W^\6AESY/@MGSP_H>^VEBOJ5WI1VR!NBL.61B.E.*O
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M_'4(+I::=W@US.#\EUK(KZN_LDU-2;Z+2-@> <]*PG,*BQQ@@2" $%' D)*
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M<Z?= '>S']%A'-B6;!&T.[_FL&-/Y+O$"#W L8<72I%)(OK[?!%*""<8+A%
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M"J1:40 I(V:6:@;R@NB<"XB9=.(ZN=3!U"9J*V.]MV_%] I0OPAD_\2- <_
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M/?PLM _Z;B9X($P'MK&MU$DM=K(GXUU;9J"RUG?OY_&,9P!@D:RC3\^CFK\
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ML^*#4E#]H%X$(A81.M_/Z)6$>M4]5TZH_X51R<=W]?-*KFA.<PD$LJ&C4&:
M*@A!6628:RD+ST+0MPHT.>/2!=M\U!TY>7=J5"7W6Y+R]MJA#7[TLSXWCZ&;
MD1IS9 :V91$HY <LX1H+Z)?EDG^A$HVQP(O$)A^KU*.E,WF[6/W^P:!@_OBN
MSB>8+[^9?M_.EVPI[)_%9OZCOL0\4R6"US&N"H%2(PB@I! P08UWAXC(%35_
MS[U"_&\5:')V^NFQ.PM9)'(WT8W'LVQ43#:[0N6^452WCIZ;A1YS3(:^4;6
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MGT*@5^&S] '];X36_ZV4><E6,WJM?JC%ZM&Z$.TE8.?]IQ#KE"N B:QKBR#
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M3!:,#PX42PH<!N*&B/2G65GI2P,$7%]U+Q28WE%P!">[0,)K<NB7I,(VC/]
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M%6B7-"AG$0)W"A@ZSC,YRZJHH^1_Q\+[(:'CP&,+AG:%B;/*@K--),617.
MPF3R@0I9-HXE <:D*#BZP&.;&HU;2^^'BX[CCVV8VH=C2=M8AMGK><9O_Q._
M3XJPSBN/D*R@#7BCJ[J34+A1K!3MA6Z1FW]CV?T0T7TD\AAFCIW3</:<<JGI
M+LJ/G+591PDN905*^QHJB0ZT]RH&3$2(/PH0=ZV\'R8ZCD(V86DS6/S+S[?X
M^(;^X,C"[-]>O/SMP\L7])L/;]^\?O'LX\L7OSQ[\^RWYR\__/WERX\?KF]C
MWZKM![_:LJ3[<5LXLM[[= 6?0CB9;%+CZA7RMKR:SL,\3>D>69Q5>%T SS-R
M,*TD#X/KFF:KD"X3AD">I]%<DZP-O^?HE;"*&U!L%ST[?SA;K\[_Y/(@/H:N
M0]7,^1K/5BM<KRYW:8Q/)G-RJVK&.3=T+FH^D,TB"RNMEA$;[_(Z!>-4DP^&
MA',5U(#=(]Y)UZG?JM*+36@60@ID@$NER #/3$$(&,@>E\449,&I^U['#L?,
M#4+&A<XQDMT)DF/8W %6GH?5Y_K?E__G=/HUS&@GJ_=(6YFF->;Z%\_F^?H?
M7/E)NK)E5HD,=H."@4(RVWS(#HP3NM@@3+2N,::.(K@'[!T%F,58TNL JB\P
MKK=!QBF>LW&2.!F6M=2?<6G),"Q8+4T%7B'JF!P6?9]+?@@$=Q(R3E^-X:!U
M/+<[@,RSE&H!YXJ.P=OU9UR^QX0$_SC#U6^X/M^4%T6(6(@OF="OD*Z#D+2O
M;0($=\EHEU+KFW$?PL;IS3$<I-I+HP.(O9Y_):H7R^^TA8E0-BLO.)#N))M3
M64_<L0B).53121[=?5D%AR#IZOKC=.X8#C '\[8#7+Q;XDF8YI??3G"^P@O]
M&7,QS)#J#(RN7$Y\\2[[ZI04JYQ2CM\7*CP$(#L)&:>[QW!(.9[;'4!FHQ2O
M\6;" O-.:@O<"5*&R5EP*63PB+SHE**UK17*;2K&:0(R'%B.Y','2+E.O$K6
MQ$)*,>E:\2'IE^ %@C/6QY %BGA?N/EHSWZ<YA\#VBD'<_=P:"S68=80&K\M
MYND&1VQ2.3##@5M=B",U*8^Y!)XIPCY953'?5S5Q.$INT]*#K]0P!'0DLSO0
M)U<TXN5F)LP$NB6Y@YR9KRTK+ 1D'(KV3"B42MK6KO5.0GJ(VAPKX[NOH ,9
MW@%JWBT7)[A<?W\W"\26>:ZQI9,:EJ_F>L*0F0X)=- "5)$%/.<"A$V>:\^5
M%JT?8NZCIP>5TQA#S=C? 91>3>?3-;Z9?L7\FN0R_S2-,]QRC7:C(DINA ?&
M= )E5888M*[UBS9BT47<6\)Q")CNIZB'T$QC.#4400> >DM'(]2JZ#<85OB^
M-K!_6WY?G6UH8F/.25D!7M6W0>LYA&@4N((I)FGH_UI;S/<2U$/@IO4-UTP
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MUMUKCZ-XW/+]#N [A&1[P?&S>?Y'6"[#?+VZX]R^.R?OYL]/>"J1J< A)ZU
M\1@A&(5D)J7B)<^1B4'LVB-H'K?\_\FQ_%32[0#-E^7:JX^+.Y[#-P<Y$N-S
M?<_"^6HC^?=(C%]-U[B=(W+&G?>8%I_FFZ]L&#7A1G N$H?"L(X5236@PB-(
MH0T/UA8I6[_M#+VG<6NKG_(T=(6.#D[+/BT9)@55#H4+<$P@J%#'WPBOP"27
M2 F@][%U=L4^=(U<V_V4L&TNI@Z@=[V!$H_6AZ@TL%*+V)/*$')0D%3AV7(I
MC&T=OGU\;ZKA:KZ?$DR',[X#U-S[:L:,(_J# *DJ5Z)4X'PL(#7+I'R%%:IU
M.ZKCWS+_6SP\-1/+D4]0+^=M.F3O>$C3-FJ-&,!SVH#218%7-M3I<K$X(16I
MW3Z>,H<KW![Y+?,Q(F@*I%'J#)\_^_#W5V_>_F.8H>277W_"JL([MM2^F/!Y
M6'U^-5O\>=G'W8;DI?$!8N8UE[[XFOML@6Z]4$R*AMO!QG+OH*>!]52_^6ZY
M^#HESOWR_7?R5U[/+UJ)/TOKZ==-.&I7X]P+KOB0LV2A@(Z\=J47 FKM,'A?
MZ)Q)I']H'81L0WDG^6?'(FV';?;48NW J+MND9J"QG&)4"NK0-4B]E!;[091
M;$3.2S"MVRX>X H,!:TQ$'"O@_ 8<72 I6L1GAJ>F:?I#*]MZ>-B3PY?<!.#
M5T%*!R*G3-SD2"8(>4HR(I,VZ%J)-63,K]$^QDV$ZP#9HX.CBX*%%TAKI^F&
MKY/$<_!)!.!&$3M9G0R:?0)I2H["IH"^=47>U?7'5;;CXV'12#0C:M[J?$R>
M)7+1:,W?3XC+-2]_,S_]7?C^9=,5E\E@58A@0ZQ!)D]GMO;'%;)HFZ2WB9F'
M/)J'EQE7O76#I<;RZ.!./V]V>OU%9J)=QB(90AV6!,K6U-$0-$@AO3#(=6ZN
MNG93,FY:;S? :RBN#D#W>OZ56+I8?O_'<KK&%XL_YQ/I)!:'$F@?B780B2DB
M68A2&"UK%PC;.@1XFXIQ,W2[ ]N18NH :)O'O3JGB+AV;6S7)'DZ&X;4M,RU
MDULDH]=YG\%E6SA7PFF'C?%V)S'CYMIV![LV0CMV&NC' 2M4+SBW38NX8%M$
MY3EC!8RM"4%.6? &%9C('7ECI,UMZYCA_M2-FV/;'4P'$FL7;NSMO1''<?JU
MUINO)C:@4M(R2*EV)F V0&"9-D8_0QM4.<;A2ZBO$-1;86L;'#P(MT-%TK-F
M/#<Y:JXO)N=29 9<\34[4M>^U5)"B#ZB-IG'FY[M #"[0E!OM:Y/!+-#1=(S
MS-XM\21,SX='3UC4DA5K@8<ZLM)9#\$Y#N2JU\$?R:)KG87W$$V]E;,^$=B.
M$$S/>+LP:4^7FW%;JQ6N5Q.F3>*EOF'6T>>J=LR/*FG@&(MBR(R/K:L!]R2M
MMU+5)T+?\6+J&83/4EJ<DOG\+GRO1L.S>:8_69X2@=,0I[.S AL1;>9)%K*#
M;1V.KACX$(FK(M(9Y,5+W3J7XS!*>RM0?2*(-A=B!U&:>YCYIO[S^=:^3QC=
M!CPF RRB!25DAECH/N#<<,&LR%ZWCMKL35QO):A/I3,;B*H##.[_@CYQD3.9
M;82XJ:557D-DF9CHT11O.4_8&H3[4S>NW=A!'L) @NQ@'.0=.ZO^V>H1S$5&
M1G/*'(Q*]7)PJ<[3CE!4]-:CPU1:6YUM*.^DZ>(3Y24.*=8.].WVN;R6"IX]
MI_\:EG_@9N#OE7+ODJ+"S=6AO0?% H+3K$[>$8H'$Y5*K;&Z%V%=YC$.BIC%
MT.+KQW,BOI+BSZM7Q/@ZC(EL[%_#NN[I^]NR<Y\V>&.$1.#&D*U#]Q/M.#M0
MIE@AN<K,M<YA?#21728H/BED!Q5KCRIU8Y%??25 Q83Q/(/;^(4LY%KD8X$Y
M4[3UBAG=NA+T0:*Z-%A'5:5'B:TC-7IS7YOHVAEG-W\QR8A:&"2KB05)CF@0
M$%-MQTH>8Y;<1\U:MWMXD*AQ(Y\]PO$HL?4.1^)T/JU,Q6VP5V9R/7TDGS"$
M ,JG0B9+[1.,3)DHD<L\N,6YD[)QXYW= O,H 1Z+SJ; K*,_%V7])\EC(IW5
MZ+* DA0=,98E1,^)64%Q+D6T-K3. ]I!QK@1S8X@=ZAH^M%^^S-S4GP,M?[A
M;)*$8G2 O-ED1P6=<Y+9A]:IW_M3-VZCO X@.9 @^PUOOIK.PSSMSUS2_9S3
M"04E<@25I(:@W&9&DD;#:I9RZZRA-I2/ZP@]=7AS2+'VX(M?#3;L['B-P0NK
M+8?-(YG2(M5N9@BU)!B#%%DHW_J*?XBH+L.:@R+EOAC1T6+K#(?;MI/G>UE-
MO">;.$H'SO":3L\%^$27D4*3DW6ZQ.8U-_?1TV6$<BST'26L#H"W/SLGUA5A
M$W>@I2"^U=(.A]$"BZ$H&;-JGW*T/W5=AB>?$I0#";(#@[-NJ_ZW=L#Z&F;5
MT7M/1O1RFLCUJG_Q;)ZO_\&5GSSK47H['2;-3FMCMI??TN<P_X3OR:IZ60J2
M$$K)LF@R^'FL8_IL+!"\%)"C(I>R<"M+:VW[M#L<-W0ZF ';,4Q^]$,T23D)
M7F("8R3YJ;5V)60MR9K*7K%86(ZMC>"C"!XW"-LGQ!\EQ&[&H!VWY6ABIO\$
M$#E84(%VZP.=V:"=UM;;)&SK"KCA<3M8)+=3W#Y&B+WT3CT].9EM6!EFYZQ\
M/2^+Y9<S85XD4%J;K3=DY@6K07GBK*.M@M FAIK28$SSB7W[D39N '<P) XA
MF Z\N*L>Z>LY?9<.TUEF N8)+UK*G!A$-.2'1F>@YI6##B84TOPLJ-8/!??1
M,W+;RB$ <$]\X"AI=("LLZK]C^$;KNJ$"/(R)YRH+Q(S$!O(2W5.0#3*@PTN
M6BX#8FJ-I]M4C)QD_ 0H.I+S_;QI;NM:-NE2;^-L^NDLZO'ZK'PO3[3CJ3"M
M(#,LH)CF$'WM]I82UT8H85AK/#U TLA//$\ KI8RZ0EI9]RZ:$IS_M@ZSSOB
M8"^FJS1;K$Z7>,'21"Q-Q1:R)9@$E44D4]-(8$[QP%"FP%KG<QQ+\[ACO 9U
M&9Y,E!W<L^^GGSX3$W]?G>5'O8WK,)W7 .YYZ.G58GE7"9\0!H70#DPV"*K0
M5IU7!J*U%E,J)?#6W:*/('=<^^]I<;481\@=X/ERL-@YQU^>W6FK#Z=?OMQX
M]] VE!24 M2&T=ZLKV]FL;[8"L6DLX6U=H,?0]^XL^$&4[&#B:@#^&V#2C="
M2<_6S\-R^9T.U]FD.LLLB]);T%EDXIXP$%R.@"S%B-S+@D,\]3Q(V-@=H8?"
MQ8X[OJV0.D#>K<#FS7"F,BZ+:JR+(HAC@=CFLR] NXFYT'W"7>M1L0_1-';7
MZ"?"6U/1= "UX\+JCJZ(9 P9%%S2N>(U =_2MIWQ66<GK$G-)\4-_C8R8(?I
M)U2*3R/49J_20XP&>[O\%.;3_]I\+,SS"UREY723Y+<HOYRNR&Q>K:YO9+^A
M8'M]M]TXL,=OH]$@L*L+/R=L+F;3?'98YOG=E3V]+5NW)\PN#,U+(,?BBK?9
M !.%G!UA!#C<Y#Q@CKI$GG+K=_\FA!_=C_H8(BZ=QH\DS%_HNW],(D:>ZY'T
M"A4HZ<B(B:R ]MK$R&WRS1_Z6N]A7*/TZ?%\J]WUF)AH9FT,H:LW-^#R^Z)\
MF'Z:3\LTA?EZV_^,K/AWQ*A4,S0/T-9[?KF=OCYD*XTT]NUE+F#KR/;4@JR(
M' /=ZI8I"%XD2,%'X[S+5K;N9'4W-4?G1MS'V2NGHQ@KK Z@T4<ZJJ70.2D&
M"!U.E^2M$JW=I/TH&]DY;X.26WD1[872M<IZ%:;+37CA5PQ5*Y_U%#A 0^W^
M4#N%M >AC?3/Q4J7=]65.&/A)&RT(*L?0W>5 A=$!NZ4M])YGIL7F]Y'S[$Z
M:->W+U$NN+-U(#=(4P\2%@_!2 %&A))+CB7QUKT%[B5H7(W3#!<W=4X[(72M
M:AYTZ,DO_/!YL5Q_Q.67JQU.#M!&!Z_5< !VD^TVTFE7OO\"XYHL];,QZI?-
MHRZ0''QF+&$&;;@C)%L$[U@&YDJ2Q&+DMGUO^7VI:S'(:[O2Z_EVK<M66K=6
MG>?GN*QODQ^7H98_G+7LV.7#N(+D.;D$F9<ZST)K<)XQ2*7$E&4Q/+6?_3#,
M7L:>3C((4G>-"AL="%VKZRMC-.:X/D0)W_A".]5Z'VD-%>9FE-R.S >.WIIJ
M]^?"?"VIYA!*=!"4Y;1RL"*WS_N\DYQFLPUWH=GJ*%S0&5R1!I2A_3JK./!D
ML\\FA_8=S^ZC9WS5U (3=XXM/%8"7>N3ZY-2#K+J;GZBG4:YE[A&*N7%5B+/
M%ZOU:IMW.OTOS-NUZ8[9- B[>;5<0"P;ZY1+CN0?$93S 4*=_>:9%B%)SFUH
M'0@ZDN2CIDC?$,GEB9!6R"@2)P?+)KKVZ5AXNF+!)<91.B-=R \AZ=X5QM4R
M3PF3:V.BFS"\:Q7TFCXT_S2M8TC.6A0>9-3<^$9+L^8^\AIIH;\M%OG/Z6Q&
M.+JYW@XP12/0%&M >Q5 *5/ .4Y@RHG9Z'B1JG5BV*,(/-[XN6N%2_@';[2O
MQCS&0#=P;6D;3"QT W-3<PL5X^UGG#Y(UKA*:C@4W3:.VDJH:P7U;KDX(3_S
M>SCS>D^J?WJ@\W77IUK:3'L0VTAKG:_U;E8?9JXL>-FC4 3%G5& V=?F@26!
M1TV0(^2A# JS<HU/Z8-$-:AFW;W KD- 1\L+ISWHX HY"IGN?<(WG02NO0S:
MVO)D#.A.7[7%SXXZUV'DU+6RNEDS=XB6NO6-=NKI?O(:Z:7-(E?Z5D5;F*D7
MG2F^]L*1X,AT!L.$1V:M-]@Z7'*=@F,USAND2Q:OE]Y<\01"\5:G&M+4CO:'
M@9R VN*-Z8#&2>$%;ZUC[J=H7*URA/1OJI"&C.]::=P8!QEV3LH\0)'L]=UV
MRN7QVVAE")TMN#J?HQEF5Y+Z0G9<V @Z&;K"N*]9^_4E(B-Z*15/JO7+W3WD
M'%TXM\?@T)WWJX\BAE)JG7;M=XX.O',2M$,A=7::-Q^Y>2"I(YM$C9!TJYKN
M">36M8J[#.!]J9&T\Y3W&[.:C]1WCU^DG?([<H-/H DU]RY[8\"5(.@FUIN)
ML0Z*U-YP*TQR PSJ>2I->.LXG<>$=YZP2XE<,2<42L-TG;+,+/$G)7 J\?IN
M)7BT7L3F+YC--]&O]GP,^A[2GD\KZZ[UZIMIJ@\3I&F>+V9T3!9G78.??5KB
M)AOT(/_SH6\V]$<?17XC)?D>O^+\%&L#KMIPN<+S']/UY^>GJ_7B"RXOHQ^F
M]FP-"JRI0XBL\1 8,F F1>%R]$:W[@^Y)VG'ER'?N\SE.<D\VX*8(*!(Q (I
MZJGUP'@V)J;:2*BU3MR7MG%5W1 8NEV1/("4NM9FO^'ZS6*U(H>?S*@OB_F'
MSW6 U0$J;/>'VNFM/0AMI*Q>AN5\.O]4>U!O%KE 5O&>2\LX>)T<J$2.B><V
M  $+I4^%<]FZ^O(N6HY51S>_>XELH^BG(VHHL51DVPQ>%E$?L;SFPCMM6\?6
M[B1F7(73! <W-4P;QG>M4C;[BF%UW3,[1*?<\:6&Y85[D-HJ[>K".GY;KB[V
M'F>UZ=XFS>:2G/,)>I=)Q@4SYR$!%LE Y>+K3.4"S(E<C#)6R]:O_\=1?*R&
MVGOU7ZZN?GF<ZAB-I.MQ*KGV#LF.CI,,D$4JDJR"9)K/%C^2Y)'SO9X.GS=U
MXE.*NFO->:7%[&$Y89?_>LMTL#N(:I;BOOW^CHP=EKD3Z!1AR1>HC]\0#$.(
M/#M=7"V\:-VFX1YRFO5NWA5W+IX[Z[VI(RWI^D_"0*3# T:K(H7V.IC6[P7W
MT3-VBGL;3-S9P_E8"72M1K9Z\UU8KK]_7 ;2ING@S(@[O]5.P>Q';K-(U.[%
M+J.FV9IHLP=3L@:EE",\H 4E<RRE1&>PM?_S$$W'QYYV?W]GW9B3*3HAP I&
MVQ=)U(95"(Y%7UA@23;ON/P(\L:.0#7$SNW0TS!"ZEI3U5#.=%/^N(E';[I<
MX/S0[C3W?*UA/?6>)#?25Y?+;:H_KZZWXV[4!  I5 3O(Z<K+'"(!1,4'T52
M@9N06Y?_/HK HSLL[K/8Y3G1491D.:/]8Z3SZ(@Q1C,@5R4E\DXB-ZU]P,=1
M.'+O[<&P=:N)XG!RZUJ_?3B-*_P_I_2]EU\/[2%QZQLMNVO=1UXC#79SD<MY
M&<:S8!*'X@H9\@0@<,@B9-0B**&S:=]1Z@Y:CI\O=OV[5YR*7!(7@D.R=7!L
MB :"CQFR0RQ9<(FZM3UU)S%C3WIJ@(/;\\-:,+YS';)/"[SAN_J-UMUOK"Y_
M)L:B5/$5C80@7[L&:\L@\\P*=UH:V=J8&J[+WR]A-5V]+3<6^'[VZY7L1SH5
MT83:&IDE.HNHP2,+(*45@BY^8UWK/>]'6;==_AZ#DIO::P"A=-(&_78S]X>:
MO9]M>A*<SC%*#BQK<IQ9,G6<EJ?+P)LLR9'FS<.@Q] [<J?^86#Y9 +L :R+
M><*:Z;-Y<)JN_GA.-$S7]7<38I64M>4="Q9!"2[ 2^,@1XF8T$=OFV/Q;G)&
M[K<_$-0:L;\#)#V0.W93J:,MR=0&BH(V JK43ADI.[!<NI2XTLFW;FKY. KW
MPIOZP? VH) Z@&#M"H<7G5FV*=QGDVYK%O=60Y?,7.)6T+G29$ZXG&I3%@N<
M.Z9(0T?%6P\:V8NPO0"G?S# M1=)!SB[3,:XFJ[Q]F3;??_U1J=/OV(M1#^W
M"WC@R==J!,V$!)4T:?,L%*"(+IKL:TE"ZT#(X\G<"X/F!\/@T.+J )&_X9]7
MF+=<S.FWZ:PY]VZ?BF6F&$L>"L]U?U(#,9A!4-QH0P9K;IY9\E@:]\*B_<&P
M.*B@NH[C[>P<_W%3O75(T.Z^SPW<[GX7T4_1]%X'[D+D"K2I.DF13@J&3#)-
M'B<7"FWDK:N#AFQZ_R%]QGPZP[?E8I6SWE*DDZ^4U6TYG]_.W]=&P"2F3YNX
MT48*5][,I*/_C^0>.4&FJG$2 N<:BK ED 7!O&@]=+CI!CINJO\8W-VZ>T<3
M<M?*\-"N](?KRR-7'+\A_X!:]S'-SJWS##GYP8K 1T9 ;93@,T3!,7@A0]*M
M4RJ>KBW_9>?URV]?"<,[H736'&C_!926$ER6'IADQ SMK9*MMWXO06.GZ Z"
MF9OZLYU(NM:'UUO)'Z[E=GYGJ([W VNDNWJ<TV9M,,P!XP7)_8@6HK,:A%;<
MQ8*"ZR$F@PS4]_[20+A8Y/FV=\+UNS\;YTT)$<CW,C4IBK8=BP GE1%11,U]
M:^MW7]K&UT0ML'*WZ=90,EUKH9NMMP]60[L_-%B?_ $5T;%MT*7)3-6FY2'6
M.2PV>/ Y1DA9"^UR3BZVKAD?J5O^D<M?S6XWD@ECZLQL.D[2,PC,:S".6Q-0
MZ=#+@(%.%.!38O16[>932KMKY7FS0_@Q1MS.+PW7X7] _?G(#NW9>1O(E+>1
M\*=T'5\8:R\^^C.?E,R)M\ZX>-(^_U>B0227-;Z9?L5;R]ZP+ERTM=F,A^PD
M^3@IT^GT18%/62HR/8HTK1,%#B#SAYH#\ B4W1//&T2"7:NX.UKM'V,GWO?!
MP6<$#*CW'N[T+CSW%AV"RZAKN7&$$&2F7W+M]\*LUJW/]7B3 JZ,K*YOA\D@
M&*M8#:;KVITZ@3!,,HO6*MWZG>)AJGJ?"O 8K.P]%> PF72MH&XVVS]<,]WQ
MI>'F @RHBV[TAT\6&4\F@,RAAF-S[5VG+03)Z9K**>GF'09;3P>@KU6'X\8]
MJP)Y#U@2U"Y_H&+M_,>+KGGR#%D0(C=_'[Z#E*[F 3Q&WK?G 1S/Z@[2@W:-
M-3A_??W^:UC7AX7O-[:8>*X]QC,D81TH%A5$04K1T]ZR=DFGT+IR[P RQRU
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M(6KA@%F)U1(2X((V8,A01FV5-ZR%6WDG >/.]QG<(&C#^+'1@Y]N;F%K1]N
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MB*/[KYV4T6PDX4 @^VV6-U5+S&_^3/17S[[5?YMX%WRB\Q^"MQ%4K!.19&'
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M<OTUZUS_R4]A.4V!1#(]OUAA/N !>)L/MWL>/H @&CT>O__IZU>Z/"8>E([
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MFM; <6S*ZJ3.M<O .FQ91P0,H8[H]I0[ROJX2Z>25%;)\_12@C(TD>.VP(^
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M\#$NN ^ 5;/Z5",=C_WN_U:<M^;S\Q-QWJ?/ORTW:[Q=21JE-V"T$J",H;0
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M-?183;_C7::<XD4)B< PU"V),8-W*$ 88T(4L>C8^N#<BK!Q[Q:' UI[K70
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M730'*E:Z\ZKN_AU12R7BB8SGG3=#F0C#SL6,7:F$IV_*!F&H&*%EY 6-_$/
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MP6IN7;#><X,0(1C)G-VD:A:+<"S*/F9%I$(%$U*%W(<1N$P93^<L3ZW.!6:
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MQHDEK6:K13XI?2<FU+=;824_G>LY:?C[DX8;Y"14;'9ZPL2$"/:^(O;B9G#
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MW&E!)8EI!(\T42GD#ZN\W)I QB-N#-4S%$GI'8=QEW0:>,; &!A2NLP.8Z!
M)#1D<A#+H#M8PK@FTT1$"3$%_BSZ3[GFI1*<0"J,A)2/U<-4V 0F:'(>.0-1
M;PZF*0;3G$ W1L+9LAM>#0;;+P>#G,0B@R@C8!91K0( 01R:]5*[R&+@$XH5
M)UQ'LF"@$Y"S%,(JH$X@!^40>,0L8EG*!2A+/)A'0P/NF2MEJRA12!  )"J
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M$$EAU[M\X1/,\M=_$.H^33W] U!+ P04    "  D,6-5HJ*9OJ\$  #/%
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M6]#IZ?0OHM,_QM./2CHH^U-VE((6132[!!,$B-*0WS!R;+(WY[/.6G0QP@:
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M(; 2B"<G-)YQ?[%WP, (&-/WAK!SO$2@)@=I0=]SB7C;KI%O!Y[7EB344/$
M:K8KTT&EHM)L7]7ZJOJ$EE>ZXEW"GS)FG>0"((C46!?5<I453V1WUZWAFB7D
M]\=Y>)<3 O^\1(*S[$8F:Z^T@O0!TZ,M/>X'?A,(%SQ07/]IQ$^\MXW9[Y7B
MUR)V\>'R#+E0ZEE1FE2+AH>R395]2@-3!2:):@!S.=@'G!X:L\("85E.Q3TR
M0 3D;;#T<K"7Y*)P6SB "&$)R&H$*HHT!CE%1&3G#OT<+PQ=@3R9[@/;AKQ.
M'7]OQ";A>["N:%LI?<,RDIJ\9?Z=@RT6UM-KF&+CJ<A))'K(>O]4A>$7F*;0
M1'!IH:<QP3 G4N*B0M^HB(HG>_L//SWRK\\3ZZV+3;LJQ(J2FE=$: 0&-$T+
M8MZJ0@1'LE3BY.%SJ3^#O8=+Y_T]N(8P7$MKZ)SU':W,:[=SU62SL$CXAJ@[
MW0-!]/3."Z)^TD30=V[K#896>M,;_(ER<S@BD]QJF'RM"4!&'<,Z4;AQY&IF
MYE87'%'#SUK!X88]1];,TTOF>CX&)I@F"%HF68$2# X:.6SA"PX)5_A;QQ,D
M_,N2C&6!3<.#V6#9GB:9ABA38B4P,;+N:S*52<:1))_35!'BQ0C4FN4N M_9
MF*FC!)_@#(C=6\CXA*)A,1Z233J!I<M97&/"C:P!2BM\M'.*36NCKY"[PQO
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M>T^7A!Y6?@<'#HHGN+"X0(T52LA.6EJ7X:!3U!N^FLRR<N5]>]MR'^3'W:_
M=8A=7_T^GA(\9"MD1H?&$/HB+H1YE5-6."?72R\3;EWK$N\"/C)J51+[N=PQ
M7@I/<9F4P?WF*M$/M/!(NIU]H_#FYC#@%3JLX9A[+$[!#7DI8,$5:="5X87
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M%[?\"<@AU FYBK(/V70R<WO!TRG(-U"@=0>?Y? 2:%5F'#$&JA,;=)4O#L;
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MO:/@\;C*K^&O63,O?OK_4$L#!!0    ( "0Q8U4=2.OC?AX  #3'   >
M97AH:6)I=#$P,C5S97!A<F%T:6]N86=R964N:'1M[3UK4]M(MM_OK^@E.UFH
M,@;SAF12Q8!GPFZ&4,!,:CY-M:6VW1-9K6U).-Y??\^C6P^_@$S AI!*);8E
MM;I/GS[OQ]M_G'X\N?[CHBWZV2 2%[_]].'L1*RL;VQ\VC[9V#B]/A7OKW_]
M('::FRUQ;66<ZDR;6$8;&^WS%;'2S[+D:&-C.!PVA]M-8WL;UY<;.-3.1F1,
MJIIA%JZ\>XN_P+]*AN_^[^T_UM?%J0GR@8HS$5@E,Q6*/-5Q3WP*5?I9K*^[
MNTY,,K*ZU\_$UN;6EOAD[&=](_EZIK-(O?/CO-W@[V\WZ"5O.R8<O7L;ZANA
MPQ]7=%=UME5W^V!_5QWL='=V9?>@L]U2>ZV=P_VMH+7W9PLFN0&W\S-I-HK4
MCRL#':_W%;[_:/^@N7.09&^&.LSZ1ZW-S1]6:K=FZDNV+B/=BX]HPG"U:V!Y
M[G)@(F./7FW2GS=X9;TK!SH:'?WK6@]4*L[54%R:@8S_U4@!R.NILKK+-Z;Z
M?^JHM04OIZ]#-R$8)]*Q\A/D*;6_]'5'9Z*UV=S:?;N!#U36]>ZM'O2$C#*
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MJ:U,?_LW!O[TE]X&Z BL/D/JJY&W 3;%HN 2V+\2/:Z(S2"*"",[3)!F^'G
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M@?(9 QVOG@2YIP!Y)04\*X8"_B*1=_*W.S"/,FV\(--*(-./((C&78Y&H)
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M-UC"\R++X>$K#M]RKO40V 7HGR@*E(C\(.:HE _0%GF7 ;X/@"3"U1@GV,^
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MR,B=E9$4F7:FGA^$[@?14"1 :-=;.QML ./U78Q]:)E95DJT]M98)0S3H+2
MT%[OX_H2$^EK, "%/#I-V7 Z-LP)MUM-@HTV#0R!L '/M/B;/MKJ;X$ZL=>O
M=D%I_Y@!,M/W"ZE]L.-'V165 Z#!SB[H[HL&^U%E9<ZN12&5 =\-O\-@178%
MI,P:K3#"CRPGGCB9KR /I0\B9C:^SP<TH(+HA&]O-IP>G?>""#,$,R5<' 5P
M)$ +8SG/;>BI=P#96,JB#_O<Z[.;,C7(8&796D2/T9', 203K)'FV+IH]IH-
M9_#?;0$Q'FDOQD4.*=WVXD207&_,9U=?"?L%N?X?FX;YE^9U/")[>%6=UB]Z
M\4KHQ=8G@=[VBI:<@WB*G,-YC(&R'&UO;^[L'6X>'!WN8R &D7$;V"6^"!6A
M$CV%< %5MW=3WAH*T/\MA?87;:28CSBK^5LZ&#!(\2Z.)LU6+%],B]\GXJ(=
M$7C<3SPM$\1=P-4>",K +E^_.M@['=C?FQ$(SX!O1T='FX<[AYN'AP<')'-,
MR6C#(BY=H9071.;*5&S]^OKF:L,)-XI=9NDFC"9U06$6]7LOZ5Y,;ZL\AZAC
MFB.2)7$E"JKJ?=J,\=P,4O,L%C=%%GUFG_*O].4M];K7WI[![I= +#5ZQ1VM
M],'"-A0W-GG34R,RVD VBQ&684"?#E!60B\G6$>H%2082VVCH&9+Y<\-I];>
M_N:8#15?P LU)D5G:PSR)M\TIP :E(./MXU(#))E$8K!#39-L9T8;F(;O.\_
MAA,=%73X98J<#\W0%>G1A/0>'S#U-BH5);\1->.F&D=.Q3B0I*WR[CTV+?;7
M#[?O/_U\RZZNV__^^>+#>9O=M']I7Y]=PJ=//_S0OEYA6,RL$%"K9R%CBJ9Q
MP0.5^CUF?F]4S"B(&" Q:F #4TSV/\9*CC 0T-03J(IIU$V>&(F<9BP!/$T"
MMT!@8;5J?=$GU X5Q]0$I]5R^0Q9TY0%+!K$PQ4P\0;R1>*)L,*P@H0E8MY2
MZRGE-U%(7P3 E1  KS$"+)TL<F%M^CX,QJ49D]7+)0W_R6SCT)A_3SPFV;!?
MM)87I+5(2UE>AIJC*)"9F!LD?-TN8DU?)#XFPH=V67U!EQTM8^G*\\ #B:1T
M,A/S:&,$:T]6U5TF3;0OP3HON!GZ31$SR?_IPKY<Q163_,=]#'I5[4(V1;,1
M7+F/&FXT+*VE4&(3JUIJ'WH^S-CZSD85?4M"^.1[?3#/2T3C]XFJ_Q$B#]SX
M%N-,&G$8Q_T5'M(E5PE"24=BU+W(N3+U5,SR*=DXR*W.>?09G3E6AJ[R,PAT
ME*X\5F<)HWITET<NM@<%IRCA<F",5.BD,K;<'LA?NI@0ONCO.&\:+:^H_LU]
MX1NSCL[M>%@)YE=;!Y^IE+*IRX'+Y<:]^/OAWG;C>*?5/-[#Z@.3Y6JT+ZTT
MIW"-"^<"Y &IEU0RFC FFZZWCGS$@9=ZTQ2T0UARS-X!/UA$>:.%5$*[X0G*
M6HNNZ73C#[,ME[78>DX&=^KU>%+V;PXX L!J[9-=<;>!BI<S9)/+9[XF]-<%
MH*T$4>C\E41A9^^@<7RXU]S>_E-$P9,#RLYB!8!68%YY"A*:>QUL):>$U?WM
M?WCZ@$2!F<-BT>.O1<TE+I8X?@Q^PC*V_A#,1_E5Q=UH)N[^-JW^&I9]@_E+
M&[WBZHP@4;T6!:(;P*UR9+A:OQP=T$8(.7I09/^CJK&M!*#C1Q")"3LL:^UL
M$A_'%$B!&I1O3E'E@COIT(43?12"O1=1OV#ON5)2P[WK']^_]U0_XBEEW*-)
MP4EWL D14@RX]S*[$P-?;'EGQX\+^S[F>-I=I;Q$+)ZG4 A6%'U7JYO3\<;M
M>!R])Z5PC]P=@)2+C)AIQS=^J13KZ7"-WJ<J'<8^:JH&-<;#+*ALR,QR0XW'
M%11:K8TZTVQ@: KFK2&8;8'E!U2@Q4I&L?@&*I&D*ED)[04ABQ2ZR<XB+(D!
M\$XP:YH<-#QP<M">P&\OD7/!]NX^_\BY93Q5YH#X  7]=*9"_\[/#[3YK!:Y
M^LV2#^?3M=D0QM7*8RI",][)@:@"+7RUUOJA.Z6Z?[ :7VG"^DB\G1BI8C[R
M!-'6)C>FX\Z(7-.\</'K$P$N[$S7^:YAX /DA^-O(JYM7(,.HQ]@H7YZQ6->
MG,3DX5M(&;LYY0:6&#DGHU0]5G:%2%@71&F3+FGB#K'3Q2/6^?3416D0_$N0
M,![../VU)[!S'>ZAS#:OR="3S6U&G*E0#S!=6R41%<FEB: TQ<?HWZ4HLSEO
MKC_Q+^PB2Q,Q6BY:^OOX?\N)!B$ [_/3+=O,@ZY05PWV*1?*9BF9_+>; KZ+
MWF0QK?O)U_*T%)QNWC\[_\_EIU\_MB]^;/_4OKRE3HEGY^?MJUN*:7S4S)?&
M0?G!L%!0L%Q1_Z#U4TUX#[K,V(LB-34]O>QE8[FP(Y)1!#ZP.]!3@?4JF8S"
M\M)N7%/:T)I7'J/'&_O6!S:@@.&:-C^7/<U2[T-CS609-)AS1B754%,W$9FH
M-BE)35ZIO4&7#483!9_F3B53DX49:F,T87T\^IQFPT3$/>% 6IF,>G ,C1"<
M4='(,L5@MTHM02J1"R(5#U51 BT.7CZP>V8KE:$TA<:/8%,;WC&!4(A+&'1*
MWL.R'?"9/0I@K=CQ,A @EH.QL=]723R8[&BZ")5F3!1@]?]L8!*PK-^7:ZMG
M=:Y=(.@>JC%M+U@SW-V=$_CTD#:[#UM7S:+ZDBT]CCQ[WYW-=QY^/(%T2FA_
MW?[8/KMI/\:($[0=GP&2FDOU\%L:1*:+W'/.[%.2P[!Q\B("BXP?72S$,#C>
M(?HIU[V0S>XZN1RS2V*KWH8MC6N.%*L2U7L7.]:]\%"TCS2[Q<:?D3KG,L58
M+\N,HGG'DY*BG6IP;K X0V7,^KI1'\1\'J!"U%@'7>34=Z S8@D?-G!@] JC
M9N8U4/<;]ISH8U#40E#W04;2I]R*,.3F2<TF-4"PGYLW30)"8R%0*+*>Z7?E
M$M%DD)D#B.=S=L@FX)-^&C;?!S\)2XVQIGC/U!;/J!JOZ=\ RQ08I(<_K,-R
M$I/0DYCV#0LD!D%.^J*H@2F*YB//J3)?2J!#ZX[K8491+_6?=$EEK%SJ*7XD
M.Y"I'Y]@>3_<+CXPW2^C3-M>6KYW@JW&GO*B5%2P_3-6\A[V>:$S(A=H9R%O
M>)F:CZXS&OIW^9"M5P8BPQX&@XRN4'T(;(=L<ORQ[U;01LNGS9+%JH%Y75/"
M3AI!O)P0E,%+D^KS& ?$QH;47\C%%N%R)BU05$??A P-./$EXF74%K1::!9%
MI:F606TAI";S3ID[HDNE_F T82R]06A+8.=K>)L/6<D<5. \ "6GG$OK\4=J
MW,NHO8!I6(_S:KAI^OG--ZV%P/$U%>965Y_ZA$,?6MV\IZ>9YA[W_GJW 4)6
M4[_$H:A)M&[X2%W;IPW?Y"X-59;VL),2<#+LS8'5W<(8-7A-DIDN?KXR7(6D
M5%Y%^J8S."'L=$"F5TNIL'8=?8U]K;KJ"8P(3[7ILZE+G+()+<9>G)N*Y)TP
M_WL#P]0RF -10-IO4QX!QBZ4[)2&O==+)F3*_@ G!GBUM@4@D*+",JE@ RT3
M#YMI3H+M)&J=:P57Z/ZG>X%&^^1+:R>N2G*\]+*[=RX.[Y<45.]+X!;LFC $
MYA8O)E!B537LV26F/=L)G W:-K@H\RPU0;*YI\2^6>684F2TC0;K"V.LIC:B
MP..MA\D6R9EH=^GZDMH\MXSUY8 &0,KY<GX?<WZ=[^;A"E1M/RF<=FP#:GM+
M%2L?X*<+>I+6*HD$F.&#<%]ZCK[0H'DT*$0:4]FFL#T(L6ZJ<<\2PF'5$$ ^
M5/N5] 5M,NKU1.TWD?@8' VD8<1BK.9*HK7/KR2G)E>*FE_,FH5-IA!&TO.*
M2.5'Q^[DYE93L9_N'KMYZ0G<4G!=W,;E  <&/Z/">A[V6GZA ]^6#I"8@!ED
M]C#>:Y^U[,IH0]@!L:0LMV#+;*Q*, 2J9TZ?"G0[KUKYP A;F@@T8L\EI]T?
M=N^>(2LU66W-.$L7)@-/9(FHESD:F8PE*K%M0U+\V\:)%(9MFZI(/KF/%C"]
M_FNNY)U,!,)Z2+6M@W34\6"1"B!%#09H,T'#"YKW3'Q0U5.]9MWH"-@)>!-I
MG;##-8FQZCEDZ:8N12U!ITO6%J?6>L-R5>L<?@JWLBI#7H.UI_EDTJA7;JM9
MJ9P@$_17P5<DDOO24\Y:0<_=AQ8N>LK-C_H#^DD^XQ-=[>QT!AD+>+= HZNF
M[E'"=%L<"#Z]O!+ CN YTWH;&&HKZZTWZ=(PSGY;&S$W/=:,><*F7C:<F%'T
MI8JQO97IG6F-6FC$#*2*,)K,Y53J+,)6E0,!\WMVVQP8!^%C1]IVMKDEM"+%
MP+"J1!LA^TS#'AKE<?O(_DC&=QZ#/(=V)&Z_4T$X;0U#0$DMCR@4  2^O, W
M@.]X+=H_[^X ,3D6:!RE6X& ^<]^8Q+YWU+&=KNL[A]^Q#,#P^%/;M-FNE&>
MV6[6N&-8TL'HPT:_$:DM_B!BU\RKGY5)'$1_NNMCO@. '/;XA>4-4EBM@28^
MA/XW*C4QE=4!_I1)80S'GK,UZEW%C,RDB[ &;F!K-?.T/=BO<7W NL\ 9R+R
MBDSMA7[N+;MD$1@ 0S!H'4YRW$2P')K AQ3%&';+ORS,WK-N@+WQS7RI7V\D
MJ;9X\< !O"61S)JWEP-6]IQ<62<+%@1?!)C((TDR:()%\)/*:D)U[FV/&Q#,
M@*#$MJD5^EK@*+Y$/09PW/_NHAX?QFV?NN">1!5B7&4E)E*S<F=!-RU;C"6V
MOF=JG 5,M#LNH%H_OQO7&KJGG..9W*YJX*6,,]KZ19^;B'./19<\$QC&,09.
M6Z=_3-JE_4(ZA/OD2A0%'=!02Y24280E6%S7/3\^O1& G=KJ1!A+X6,].B*1
MXL[X0VI;;=X"HJEH,C:V'&.>(9N4UN7 &@^4U)]]T .]O"-00*KF-FG%"A9J
MQ+8.N5>XZ<-L&KX*;+$3"3+%X @H'P9-PVKM#N"AR$A3I-/>@5QOZ'EG1'9Q
M]*J/'.*ZB6%A(?3IX)R?-1X:T%MK TF:)BX#Q0+\!O@5"6%$\2K:IS$E'\S$
MLD0JTWJS"D0JD?WX[X&AP <KV7@FLC<8 QM]W_ A04&;&5!\#"..,I7;/!&#
M-R;GS<P]I"*&/I'<3S7/G6.!Z)MV+5.I,K4)2JH%<$P+2WHH.LRM-OUTD<K3
M$S_F%>4:1PY C.F%2SZ&J8_AL:6>?<FH5M/$YL39BE-X\#!/TK81J1IF36;A
M^?>8N"@=5K6 I[-45*%&X@MEYAF/:VATU'E6VE#8\&?;#D*1SS8E6Q1F QJ]
MO4Q),R0+>6)+8\49TYEU%!L\+!60:16CW?HYTXDI_"K8"HK#0_W;V*< 5K4<
M5ZKFT:<&4!2]-R4[T]4<"U,RGQWAK?-PDZD: LJ%V8-N#\*^"= $FFQJ68['
M%\"A,"$$+@MXENG06R(J_ZZUS4^C;NQV+*IQ/-3!\@K3Y%.C-!!;T8W\1NCY
M14& [)/&B $3<_:3D1,J'DE,EW1+)YTZ1JI60#IYWB>5$;#<<"F 3=:=B!L-
M9)P[F%)LHFT# :<Q5D*O9E*'45.CJ<YZ?/IL_%LI=M(KL2BR44^2F'I[UV;:
M"'0"7*DL*"^!\$$)SUC'GA=^H;59K?B^UVAC51Y@FE-V]F&B^CLRU;9N ';*
MJ[H7P=X40R'J-C\W0$66G?MULBZ!?ZD2/L:WM&S8;%F$9IG'2;?+N!/3SE(/
MA?JT4F& 6WNIY0JQV%1,G @O:3C-=0+2UC4*2L: /,N9DS>24B/?^J,$FAK+
MJ(H-%T8X<$X8D$=3S'6A:[PPAXE"BGE8Z/B9\;RVDP>B+/>]78(=LZ8T@"-H
MK3VS8:!T:= J$A+%!::*J"S%1"'@D'>8-'/Q S,"8Y.U.9"^V@-XE4JMZ:R2
M1DS6@WN'*W@<XU'#B_"<["%7?6;0OZ"(=$"VY<KF_T6B0PUVDK&%Y#NQ=2!]
MHXW&$R0?/18T.]N@R2P$)C$G(\AR@<,FCR[&!["SO5S 6$S9BR<BB8]ID3#/
M;E_8;@'6=8**^28F'/)<BQ/WX13#:1(^.I$I+9@>.JV_9!_>0/DVP'CL6^B%
MYK+U,.P=-_=;Q^AD*&#V1>Q>;/T/3=/PJ(@GKQT?-8^W9U^&)?IK6S2V&1]6
MH$$4_-?:[EKE(Z$R\"<[^1?6JH,%*\./+\+,?ZI;Q&];K;+\3O-P/_B-DI'<
MCW]%SYOO<ORG*?RR,J45[YGKPFLGW0O+QUE9O[K+PY+@VHQJ*_<5$ZJHV191
MW'L!</Q5[.'13MWOW$M_\+UYZ8_=<*XO"K+Q!Z+:]X@@AU^'(%N=+![!GWXQ
M2-[^/U!+ 0(4 Q0    ( ",Q8U5(-0#H8:0! %1[$P 1              "
M 0    !A=7!H+3(P,C(P.3,P+FAT;5!+ 0(4 Q0    ( ",Q8U4'?4TS:0X
M -R>   1              "  9"D 0!A=7!H+3(P,C(P.3,P+GAS9%!+ 0(4
M Q0    ( ",Q8U6U='3PVQH  $W^   5              "  2BS 0!A=7!H
M+3(P,C(P.3,P7V-A;"YX;6Q02P$"% ,4    "  C,6-5HFXJD.5!   BV (
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M,#(R<3-E>'@S,3$N:'1M4$L! A0#%     @ (S%C58-JICUD"   ]2H  !4
M             ( !8$P# &%U<&@M,C R,G$S97AX,S$R+FAT;5!+ 0(4 Q0
M   ( "0Q8U6BHIF^KP0  ,\4   5              "  ?=4 P!A=7!H+3(P
M,C)Q,V5X>#,R,2YH=&U02P$"% ,4    "  D,6-5F:C3T+0$  #7%   %0
M            @ '960, 875P:"TR,#(R<3-E>'@S,C(N:'1M4$L! A0#%
M  @ )#%C5?7*.%*<,@  0 T! !X              ( !P%X# &5X:&EB:70Q
M,#(T<V5P87)A=&EO;F%G<F5E+FAT;5!+ 0(4 Q0    ( "0Q8U4=2.OC?AX
M #3'   >              "  9B1 P!E>&AI8FET,3 R-7-E<&%R871I;VYA
M9W)E92YH=&U02P$"% ,4    "  D,6-5*X2B1;(>  "$R   '@
M    @ %2L , 97AH:6)I=#$P,C9S97!A<F%T:6]N86=R964N:'1M4$L%!@
0   -  T >@,  $#/ P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
